ticlopidine has been researched along with Acute Coronary Syndrome in 1291 studies
Ticlopidine: An effective inhibitor of platelet aggregation commonly used in the placement of STENTS in CORONARY ARTERIES.
ticlopidine : A thienopyridine that is 4,5,6,7-tetrahydrothieno[3,2-c]pyridine in which the hydrogen attached to the nitrogen is replaced by an o-chlorobenzyl group.
Acute Coronary Syndrome: An episode of MYOCARDIAL ISCHEMIA that generally lasts longer than a transient anginal episode that ultimately may lead to MYOCARDIAL INFARCTION.
| Excerpt | Relevance | Reference |
|---|---|---|
| " We studied the platelet inhibitory effect of crushed clopidogrel in patients with acute coronary syndrome (ACS) and its relative efficacy compared with integral clopidogrel, crushed and integral ticagrelor." | 9.69 | Randomized, Double-Blind, Active Comparator Pharmacodynamic Study of Platelet Inhibition with Crushed and Integral Formulations of Clopidogrel and Ticagrelor in Acute Coronary Syndrome. ( Alex, AG; Attumalil, TV; Dave, RG; Geevar, T; George, P; Gowri, SM; Joseph, G; Mony, PK; Nair, SC; Perla, HT; Thomson, VS, 2023) |
| "Discontinuing aspirin after short-term dual antiplatelet therapy (DAPT) was evaluated as a bleeding reduction strategy." | 9.34 | Effect of Ticagrelor Monotherapy vs Ticagrelor With Aspirin on Major Bleeding and Cardiovascular Events in Patients With Acute Coronary Syndrome: The TICO Randomized Clinical Trial. ( Ahn, CM; Cho, DK; Cho, JY; Cho, S; Cho, YH; Choi, D; Her, AY; Hong, BK; Hong, MK; Hong, SJ; Jang, Y; Jeon, DW; Kim, BK; Kim, JS; Kim, YH; Ko, YG; Kwon, H; Nam, CM; Shin, DH; Suh, Y; Yoo, SY; Yun, KH, 2020) |
| "Clopidogrel is used to pretreat patients with non-ST elevation acute coronary syndromes (NSTE-ACS), but prasugrel provides better platelet inhibition with improved outcome." | 9.27 | Switching from clopidogrel to prasugrel to protect early invasive treatment in acute coronary syndromes: Results of the switch over trial. ( Attanasio, C; Caravita, L; Cattaneo, M; Femia, EA; Galvani, M; Ottani, F, 2018) |
| "A dual pathway antithrombotic therapy approach combining low-dose rivaroxaban with a P2Y12 inhibitor for the treatment of patients with acute coronary syndromes had similar risk of clinically significant bleeding as aspirin and a P2Y12 inhibitor." | 9.24 | Clinically significant bleeding with low-dose rivaroxaban versus aspirin, in addition to P2Y12 inhibition, in acute coronary syndromes (GEMINI-ACS-1): a double-blind, multicentre, randomised trial. ( Ardissino, D; Bahit, MC; Bode, C; Bueno, H; Claeys, MJ; Cornel, JH; Gibson, CM; Goto, S; Güray, Ü; Husted, S; James, SK; Kiss, RG; Montalescot, G; Mundl, H; Nicolau, JC; Ohman, EM; Park, DW; Plotnikov, A; Povsic, TJ; Rockhold, F; Roe, MT; Steg, PG; Strony, J; Sun, X; Tendera, M; Welsh, RC; White, J, 2017) |
| "In patients with ischemic heart disease and type 2 diabetes mellitus in 4-6 weeks after acute coronary syndrome (ACS) on stable dual antiplatelet therapy (DAPT) with aspirin and clopidogrel co-adminstrated with rosuvastatin residual platelet reactivity on adenosine diphosphate was higher than in patients receiving atorvastatin." | 9.24 | [IMPACT OF ATORVASTATIN AND ROSUVASTATIN ON RESIDUAL ON-CLOPIDOGREL TREATMENT PLATELET REACTIVITY IN PATIENTS WITH ISCHEMIC HEART DISEASE AND TYPE 2 DIABETES MELLITUS AFTER ACUTE CORONARY SYNDROME]. ( Kochubiei, O; Ovrakh, T; Serik, S, 2017) |
| " clopidogrel in acute coronary syndrome (ACS) was only evaluated using TRITON-TIMI 38 event rates." | 9.24 | Prasugrel vs. clopidogrel in contemporary Western European patients with acute coronary syndromes receiving drug-eluting stents: Comparative cost-effectiveness analysis from the BASKET-PROVE cohorts. ( Coslovsky, M; Galatius, S; Jabbari, R; Kaiser, C; Pfisterer, M; Wein, B, 2017) |
| "In smokers, a double-dose clopidogrel regimen reduced major cardiovascular events and stent thrombosis after percutaneous coronary intervention, with no increase in major bleeding." | 9.24 | Double-Dose Versus Standard-Dose Clopidogrel According to Smoking Status Among Patients With Acute Coronary Syndromes Undergoing Percutaneous Coronary Intervention. ( Bossard, M; Faxon, DP; Fox, KAA; Gao, P; Granger, CB; Jolly, SS; Mehta, SR; Montalescot, G; Natarajan, MK; Niemela, K; Steg, PG; Tanguay, JF; Widimsky, P; Yusuf, S, 2017) |
| "Enhanced clopidogrel responsiveness was associated with an increased risk of bleeding and entry-site complication." | 9.24 | The Prognostic Value of ADP-Induced Platelet Aggregation for Bleeding Complications in Low - Intermediate Risk Patients with Acute Coronary Syndrome Taking Clopidogrel After Percutaneous Coronary Intervention. ( Dong, T; Jin, L; Liao, H; Yan, H; Yu, H; Zhang, B; Zou, X, 2017) |
| "The purpose of this study was to investigate outcomes of patients treated with prasugrel or clopidogrel after percutaneous coronary intervention (PCI) in a nationwide acute coronary syndrome (ACS) registry." | 9.22 | Comparison of prasugrel and clopidogrel-treated patients with acute coronary syndrome undergoing percutaneous coronary intervention: A propensity score-matched analysis of the Acute Myocardial Infarction in Switzerland (AMIS)-Plus Registry. ( Bernheim, AM; Eberli, FR; Erne, P; Kurz, DJ; Pedrazzini, G; Radovanovic, D; Roffi, M; Seifert, B; Windecker, S, 2016) |
| "The Targeted Platelet Inhibition to Clarify the Optimal Strategy to Medically Manage Acute Coronary Syndromes trial enrolled 9326 participants with ACS, who received aspirin plus clopidogrel or prasugrel." | 9.22 | Ascertainment, classification, and impact of neoplasm detection during prolonged treatment with dual antiplatelet therapy with prasugrel vs. clopidogrel following acute coronary syndrome. ( Armstrong, PW; Beaven, AW; Blackwell, KL; Cyr, DD; Eckart, D; Fox, KA; Houterloot, L; Morse, MA; Ohman, EM; Onken, JE; Prabhakaran, D; Ready, NE; Roe, MT; Schulte, PJ; Strickler, JH; White, HD; Winters, KJ; Wiviott, SD; Zafar, SY; Zamoryakhin, D, 2016) |
| "Dual antiplatelet therapy (DAPT), the combination of aspirin and a P2Y12 inhibitor, given for 12 months remains the standard of care after presentation with acute coronary syndrome (ACS) because it has been shown to be associated with a significant reduction in ischemic events compared with aspirin monotherapy." | 9.22 | A randomized trial to compare the safety of rivaroxaban vs aspirin in addition to either clopidogrel or ticagrelor in acute coronary syndrome: The design of the GEMINI-ACS-1 phase II study. ( Bode, C; Gibson, CM; James, S; Mundl, H; Ohman, EM; Plotnikov, A; Povsic, TJ; Roe, MT; Steg, PG; Welsh, R, 2016) |
| "Medically managed patients with ACS in the Targeted Platelet Inhibition to Clarify the Optimal Strategy to Medically Manage Acute Coronary Syndromes (TRILOGY ACS) trial were randomised to clopidogrel versus prasugrel (plus aspirin), stratified by prior clopidogrel use." | 9.22 | Effect of prior clopidogrel use on outcomes in medically managed acute coronary syndrome patients. ( Armstrong, PW; Boden, WE; Chin, CT; Corbalán, R; Dalby, AJ; Fox, KA; Gottlieb, S; Leiva-Pons, JL; Neely, B; Neely, ML; Ohman, EM; Prabhakaran, D; Roe, MT; Schiele, F; White, HD; Winters, KJ, 2016) |
| "This study suggests that impaired response to both intravenous and oral aspirin is frequent in comatose patients resuscitated from OHCA." | 9.22 | Impaired biological response to aspirin in therapeutic hypothermia comatose patients resuscitated from out-of-hospital cardiac arrest. ( Bal Dit Sollier, C; Deye, N; Dillinger, JG; Drouet, L; Henry, P; Llitjos, JF; Megarbane, B; Sideris, G; Voicu, S, 2016) |
| "Ticagrelor reduced cardiovascular events compared with clopidogrel in PLATO without increasing overall major bleeding." | 9.22 | Impact of glycoprotein IIb/IIIa inhibitors on the efficacy and safety of ticagrelor compared with clopidogrel in patients with acute coronary syndromes: Analysis from the Platelet Inhibition and Patient Outcomes (PLATO) Trial. ( Bansilal, S; Becker, RC; Cannon, CP; Harrington, RA; Himmelmann, A; Husted, S; James, SK; Katus, HA; Lopes, RD; Neely, B; Shimada, YJ; Steg, PG; Storey, RF; Wallentin, L; Wiviott, SD, 2016) |
| "There are a number of economic evaluation studies of clopidogrel for patients with non-ST-segment elevation acute coronary syndrome (NSTEACS) published from the perspective of multiple countries in recent years." | 9.22 | A Cost-Effectiveness Analysis of Clopidogrel for Patients with Non-ST-Segment Elevation Acute Coronary Syndrome in China. ( Chen, C; Chen, EZ; Cui, M; Tan, SC; Tu, CC; Wang, XL, 2016) |
| "The CHAMPION PHOENIX (A Clinical Trial Comparing Cangrelor to Clopidogrel Standard Therapy in Subjects Who Require Percutaneous Coronary Intervention) trial demonstrated that cangrelor significantly reduced periprocedural ischemic events in all-comer percutaneous coronary intervention with a modest increase in mild and moderate bleeding." | 9.22 | Efficacy and Safety of Cangrelor in Preventing Periprocedural Complications in Patients With Stable Angina and Acute Coronary Syndromes Undergoing Percutaneous Coronary Intervention: The CHAMPION PHOENIX Trial. ( Abnousi, F; Abtan, J; Bhatt, DL; Deliargyris, EN; Gibson, CM; Hamm, CW; Harrington, RA; Mahaffey, KW; Prats, J; Price, MJ; Steg, PG; Stone, GW; White, HD, 2016) |
| "The Elderly-ACS 2 study is a multicenter, randomized, parallel-group, open-label trial designed to demonstrate the superiority of a strategy of dual antiplatelet treatment using a reduced 5-mg daily dose of prasugrel over a standard strategy with a daily clopidogrel dose of 75mg in patients older than 74years with ACS (either ST- or non-ST-elevation myocardial infarction) undergoing early percutaneous revascularization." | 9.22 | A comparison of reduced-dose prasugrel and standard-dose clopidogrel in elderly patients with acute coronary syndromes undergoing early percutaneous revascularization: Design and rationale of the randomized Elderly-ACS 2 study. ( Bossi, I; Cacucci, M; Cavallini, C; Corrada, E; De Servi, S; Di Ascenzo, L; Ferrario, M; Ferri, LA; Gandolfo, N; Grosseto, D; Mariani, M; Moffa, N; Morici, N; Petronio, AS; Ravera, A; Savonitto, S; Sganzerla, P; Sibilio, G; Tondi, S; Tortorella, G; Toso, A, 2016) |
| "BACKGROUND The aim of this study was to observe the effects of genetic polymorphism of CYP2C19 on inhibitory effects of ticagrelor (Tic) and clopidogrel (Clo) towards post-percutaneous coronary intervention (PCI) platelet aggregation (IPA) and major cardiovascular events (MACE) in patients with acute coronary syndromes (ACS)." | 9.22 | Genetic Polymorphism of CYP2C19 and Inhibitory Effects of Ticagrelor and Clopidogrel Towards Post-Percutaneous Coronary Intervention (PCI) Platelet Aggregation in Patients with Acute Coronary Syndromes. ( Bian, S; Dong, P; Yang, X, 2016) |
| "To explore the effect of Shexiang baoxin pills on clopidogrel resistance in patients with acute coronary syndrome (ACS)." | 9.22 | Effect of Shexiang baoxin pills on clopidogrel resistance in patients with acute coronary syndrome. ( Liu, N; Zhang, H; Zhang, J; Zhang, L, 2016) |
| "PLATO (n = 18,624) was a multicentre, double-blind, randomized trial in ACS, that showed a 16% reduction in cardiovascular death (CV-death), myocardial infarction (MI) and stroke with ticagrelor compared with clopidogrel, without significant increase in overall major bleeding." | 9.20 | Cardiovascular events in acute coronary syndrome patients with peripheral arterial disease treated with ticagrelor compared with clopidogrel: Data from the PLATO Trial. ( Becker, RC; Emanuelsson, H; Hiatt, WR; Horrow, J; Husted, S; James, SK; Mahaffey, KW; Patel, MR; Steg, PG; Storey, RF; Wallentin, L; Wojdyla, DM, 2015) |
| "MULTIPRAC demonstrated a steady increase in prasugrel use over time without an increase in bleeding rates compared to clopidogrel." | 9.20 | MULTInational non-interventional study of patients with ST-segment elevation myocardial infarction treated with PRimary Angioplasty and Concomitant use of upstream antiplatelet therapy with prasugrel or clopidogrel--the European MULTIPRAC Registry. ( Clemmensen, P; Danchin, N; Goedicke, J; Goldstein, P; Grieco, N; Ince, H; Ramos, Y; Schmitt, J, 2015) |
| "To investigate the cost effectiveness of ticagrelor versus clopidogrel in patients with acute coronary syndromes (ACS) in the Platelet Inhibition and Patient Outcomes (PLATO) study who were scheduled for non-invasive management." | 9.20 | Health economic analysis of ticagrelor in patients with acute coronary syndromes intended for non-invasive therapy. ( Cannon, CP; Henriksson, M; James, S; Janzon, M; Mellström, C; Nicolau, JC; Storey, RF; Wallentin, L, 2015) |
| "The aim of this study was the identification of the optimal cutoff value of high residual platelet reactivity (HRPR) assessed by light transmission aggregometry (LTA) in the responsiveness to clopidogrel and stent thrombosis 2-acute coronary syndrome (RECLOSE 2-ACS) patient cohort to discriminate patients with and without major adverse cardiac events (MACE) and cardiac death at 2 years." | 9.20 | Residual platelet reactivity to predict long-term clinical outcomes after clopidogrel loading in patients with acute coronary syndromes: comparison of different cutoff values by light transmission aggregometry from the responsiveness to clopidogrel and st ( Abbate, R; Antoniucci, D; Cantini, G; Capodanno, D; Carrabba, N; De Luca, G; Gensini, GF; Giusti, B; Gori, AM; Marcucci, R; Marrani, M; Migliorini, A; Paniccia, R; Parodi, G; Valenti, R, 2015) |
| "401 acute coronary syndrome (ACS) patients received either a 300 mg loading dose following 75 mg maintenance dose daily or a 75mg maintenance dose daily of clopidogrel." | 9.20 | Genetic polymorphisms of CYP2C19 2 and ABCB1 C3435T affect the pharmacokinetic and pharmacodynamic responses to clopidogrel in 401 patients with acute coronary syndrome. ( Hu, ZL; Huang, XH; Li, J; Shen, CL; Wang, BN; Wang, XQ, 2015) |
| "In the PLATO trial, ticagrelor was superior to clopidogrel in reducing cardiovascular events among patients with acute coronary syndrome (ACS) at the expense of increased nonfatal bleeding." | 9.20 | Ticagrelor versus clopidogrel in Asian patients with acute coronary syndrome: A retrospective analysis from the Platelet Inhibition and Patient Outcomes (PLATO) Trial. ( Becker, RC; Clare, RM; Gao, R; Held, C; Himmelmann, A; James, SK; Kang, HJ; Lim, ST; Santoso, A; Wallentin, L; Yu, CM, 2015) |
| "Prasugrel is more effective than clopidogrel in reducing platelet aggregation in acute coronary syndromes." | 9.20 | High Platelet Reactivity in Patients with Acute Coronary Syndromes Undergoing Percutaneous Coronary Intervention: Randomised Controlled Trial Comparing Prasugrel and Clopidogrel. ( Banya, W; Booth, J; Dalby, M; Davidson, SJ; Droppa, M; Flather, M; Gawaz, M; Geisler, T; Karathanos, A; Müller, K; Stables, RH; Tavlaki, E; Yanez-Lopez, M; Zaman, A, 2015) |
| "Few data on the relative efficacy and safety of new P2Y12inhibitors such as prasugrel and ticagrelor in Japanese, Taiwanese and South Korean patients with acute coronary syndromes (ACS) exist." | 9.20 | Ticagrelor vs. clopidogrel in Japanese, Korean and Taiwanese patients with acute coronary syndrome -- randomized, double-blind, phase III PHILO study. ( Emanuelsson, H; Goto, S; Huang, CH; Kimura, T; Park, SJ, 2015) |
| " In the Platelet Inhibition and Patient Outcomes (PLATO) trial, ticagrelor versus clopidogrel reduced the primary endpoint of death from vascular causes, myocardial infarction, or stroke after ACS, but increased the incidence of dyspnea, which may lead clinicians to withhold ticagrelor from COPD patients." | 9.20 | Ticagrelor Versus Clopidogrel in Patients With Acute Coronary Syndromes and Chronic Obstructive Pulmonary Disease: An Analysis From the Platelet Inhibition and Patient Outcomes (PLATO) Trial. ( Andell, P; Cannon, CP; Cyr, DD; Erlinge, D; Himmelmann, A; Husted, S; James, SK; Keltai, M; Koul, S; Santoso, A; Steg, PG; Storey, RF; Wallentin, L, 2015) |
| "Dual antiplatelet therapy with acetylsalicylic acid in combination with a more potent P2Y12- inhibitor (ticagrelor or prasugrel) is recommended in patients with acute coronary syndrome without ST-segment elevation (NSTE-ACS) to prevent atherothrombotic complications." | 9.20 | Ticagrelor or prasugrel versus clopidogrel in elderly patients with an acute coronary syndrome: Optimization of antiplatelet treatment in patients 70 years and older--rationale and design of the POPular AGE study. ( Bergmeijer, TO; de Boer, MJ; de Vrey, E; Deneer, VH; Groenemeijer, BE; Heestermans, AA; Ishak, M; Janssen, PW; Jukema, JW; Kelder, JC; Qaderdan, K; ten Berg, JM; van't Hof, AW; Vos, GJ; Voskuil, M, 2015) |
| "The goal of this study was to determine whether there is a relationship between aspirin dose and the potent antiplatelet agent prasugrel in the TRITON-TIMI 38 (Trial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet Inhibition With Prasugrel-Thrombolysis In Myocardial Infarction 38) study." | 9.19 | Discharge aspirin dose and clinical outcomes in patients with acute coronary syndromes treated with prasugrel versus clopidogrel: an analysis from the TRITON-TIMI 38 study (trial to assess improvement in therapeutic outcomes by optimizing platelet inhibit ( Antman, EM; Braunwald, E; Cannon, CP; Kohli, P; Murphy, SA; Udell, JA; Wiviott, SD, 2014) |
| "This study aimed to investigate the impact of ticagrelor on adenosine plasma concentration (APC) in acute coronary syndrome (ACS) patients." | 9.19 | Ticagrelor increases adenosine plasma concentration in patients with an acute coronary syndrome. ( Bonello, L; Camoin-Jau, L; Condo, J; Dignat-George, F; Frere, C; Fromonot, J; Gariboldi, V; Guieu, R; Helal, O; Kipson, N; Laine, M; Mancini, J; Paganelli, F; Thuny, F, 2014) |
| "Ticagrelor outperforms clopidogrel in preventing cardiovascular events in acute coronary syndrome." | 9.19 | Administration of a loading dose has no additive effect on platelet aggregation during the switch from ongoing clopidogrel treatment to ticagrelor in patients with acute coronary syndrome. ( Caiazzo, G; De Rosa, S; Giampà, S; Gulletta, E; Indolfi, C; Micieli, M; Mongiardo, A; Palella, E; Spaccarotella, C; Torella, D, 2014) |
| "Ticagrelor reduces thrombotic events compared with clopidogrel in patients with acute coronary syndrome, but may also increase bleeding complications." | 9.19 | Coronary artery bypass grafting-related bleeding complications in real-life acute coronary syndrome patients treated with clopidogrel or ticagrelor. ( Albertsson, P; Dellborg, M; Hansson, EC; Jeppsson, A; Rexius, H, 2014) |
| "To evaluate the cost-effectiveness of treating patients with acute coronary syndromes (ACS) for 12 months with ticagrelor compared with generic clopidogrel in Sweden and Denmark." | 9.19 | Ticagrelor treatment in patients with acute coronary syndrome is cost-effective in Sweden and Denmark. ( Henriksson, M; Janzon, M; Nikolic, E; Ohna, A; Wallentin, L, 2014) |
| "The aim of this study was to assess the relationship between sex and clinical outcomes and treatment-related complications in patients with ST-elevation or non-ST-elevation acute coronary syndromes (ACS) randomized to treatment with ticagrelor or clopidogrel in the PLATelet inhibition and patient Outcomes (PLATO) trial." | 9.19 | The efficacy of ticagrelor is maintained in women with acute coronary syndromes participating in the prospective, randomized, PLATelet inhibition and patient Outcomes (PLATO) trial. ( Bach, RG; Becker, RC; Budaj, A; Heras, M; Himmelmann, A; Horrow, J; Husted, S; James, SK; Katus, HA; Lassila, R; Morais, J; Nicolau, JC; Steg, PG; Storey, RF; Wallentin, L; Wojdyla, D, 2014) |
| " The randomised, double-blind, TRIPLET trial included a pre-defined comparison of HPR in acute coronary syndrome (ACS) patients undergoing percutaneous coronary intervention (PCI) following a placebo/600-mg clopidogrel loading dose (LD) immediately before a subsequent prasugrel 60-mg or 30-mg LD." | 9.19 | Transferring from clopidogrel loading dose to prasugrel loading dose in acute coronary syndrome patients. High on-treatment platelet reactivity analysis of the TRIPLET trial. ( Angiolillo, DJ; Cardillo, TE; Diodati, JG; Duvvuru, S; Effron, MB; Fisher, HN; Henneges, C; Jakubowski, JA; Lipkin, FR; Saucedo, JF; Sundseth, SS; Walker, JR, 2014) |
| " clopidogrel in the non-ST-elevation acute coronary syndrome (NSTE-ACS) subgroup of the PLATO trial, in the total cohort, and in the subgroups managed with and without revascularization within 10 days of randomization." | 9.19 | Ticagrelor vs. clopidogrel in patients with non-ST-elevation acute coronary syndrome with or without revascularization: results from the PLATO trial. ( Cannon, CP; Cornel, JH; Harrington, RA; Himmelmann, A; Husted, S; James, SK; Lindholm, D; Maya, J; Steg, PG; Stevens, SR; Storey, RF; Varenhorst, C; Wallentin, L, 2014) |
| " clopidogrel in patients with acute coronary syndromes managed medically without revascularization." | 9.19 | Impact of smoking status on platelet function and clinical outcomes with prasugrel vs. clopidogrel in patients with acute coronary syndromes managed without revascularization: Insights from the TRILOGY ACS trial. ( Armstrong, PW; Clemmensen, P; Cornel, JH; Fox, KA; Gurbel, PA; Neely, B; Ohman, EM; Prabhakaran, D; Roe, MT; Sritara, P; White, HD; Zamoryakhin, D, 2014) |
| "To describe specific causes of death and evaluate whether bleeding events and infection contributed to mortality in all ticagrelor-treated and clopidogrel-treated patients with acute coronary syndromes." | 9.19 | Causes of mortality with ticagrelor compared with clopidogrel in acute coronary syndromes. ( Alström, U; Bertilsson, M; Braun, OÖ; Cannon, CP; Held, C; Himmelmann, A; James, SK; Mahaffey, KW; Scirica, BM; Storey, RF; Varenhorst, C; Wallentin, L, 2014) |
| "Patients with acute coronary syndrome (ACS) undergoing percutaneous coronary intervention (PCI) commonly receive a clopidogrel LD prior to angiography." | 9.19 | Switching patients from clopidogrel to prasugrel in acute coronary syndrome: impact of the clopidogrel loading dose on platelet reactivity. ( Chen, F; Drenning, D; Lhermusier, T; Lipinski, MJ; Marso, S; Torguson, R; Waksman, R, 2014) |
| "We observed no interaction between vorapaxar and clopidogrel after non-ST-segment elevation acute coronary syndromes on efficacy or safety outcomes, supporting a complementary role of protease-activated receptor 1 and P2Y12 antagonism." | 9.19 | Vorapaxar with or without clopidogrel after non-ST-segment elevation acute coronary syndromes: results from the thrombin receptor antagonist for clinical event reduction in acute coronary syndrome trial. ( Armstrong, PW; Aylward, PE; Chen, E; Cornel, JH; Harrington, RA; Held, C; Huang, Z; Jennings, LK; Lokhnygina, Y; Mahaffey, KW; Moliterno, DJ; Strony, J; Tricoci, P; Van de Werf, F; Wallentin, L; White, HD, 2014) |
| "Clopidogrel is recommended in patients with acute coronary syndrome (ACS) managed with PCI, but its effect on PCI-related myonecrosis in contemporary patients has not been quantified." | 9.17 | Quantification of the effect of clopidogrel on enzymatic infarct size related to a percutaneous coronary intervention in patients with acute coronary syndromes: insights from the CHAMPION percutaneous coronary intervention trial. ( Bhatt, DL; Dauerman, HL; Gibson, CM; Goodman, SG; Gruberg, L; Herrmann, HC; Leonardi, S; Lincoff, AM; Lokhnygina, Y; Lopes, RD; Mahaffey, KW; McLaurin, BT; Parikh, KH; Stebbins, A; Stone, GW; Todd, M; White, HD, 2013) |
| "Whether an additional clopidogrel load in patients receiving chronic clopidogrel therapy and undergoing percutaneous coronary intervention (PCI) for acute coronary syndrome (ACS) is associated with clinical benefit has not been well characterized." | 9.17 | Efficacy of clopidogrel reloading in patients with acute coronary syndrome undergoing percutaneous coronary intervention during chronic clopidogrel therapy (from the Antiplatelet therapy for Reduction of MYocardial Damage during Angioplasty [ARMYDA-8 RELO ( Barbato, E; Colonna, G; D'Ambrosio, A; Di Sciascio, G; Mangiacapra, F; Montinaro, A; Pasceri, V; Patti, G; Ricottini, E; Vizzi, V; Wijns, W, 2013) |
| "The PLATO trial showed that ticagrelor was superior to clopidogrel for the prevention of cardiovascular death, myocardial infarction, or stroke in a broad population of patients with acute coronary syndromes." | 9.17 | Health-related quality of life of ticagrelor versus clopidogrel in patients with acute coronary syndromes-results from the PLATO trial. ( Andersson, D; Bergström, G; Bernfort, L; Janzon, M; Kaul, P; Lamm, CJ; Levin, LÅ; Storey, RF; Wallentin, L, 2013) |
| "A total of 9326 medically managed patients with acute coronary syndromes from the Targeted Platelet Inhibition to Clarify the Optimal Strategy to Medically Manage Acute Coronary Syndromes (TRILOGY ACS) trial (<75 years of age, n=7243; ≥75 years of age, n=2083) were randomized to prasugrel (10 mg/d; 5 mg/d for those ≥75 or <75 years of age and <60 kg in weight) or clopidogrel (75 mg/d) plus aspirin for ≤30 months." | 9.17 | Elderly patients with acute coronary syndromes managed without revascularization: insights into the safety of long-term dual antiplatelet therapy with reduced-dose prasugrel versus standard-dose clopidogrel. ( Ardissino, D; Armstrong, PW; Aylward, PE; Bassand, JP; Boden, WE; Dalby, AJ; Fox, KA; Goodman, SG; Gottlieb, S; Hochman, JS; Martinez, F; McGuire, DK; Ohman, EM; Prabhakaran, D; Roe, MT; Stevens, SR; White, HD; Winters, KJ, 2013) |
| "Ticagrelor compared with clopidogrel reduces the incidence of stent thrombosis in patients with acute coronary syndromes, with consistent benefit across a broad range of patient, stent, and treatment characteristics." | 9.17 | Stent thrombosis with ticagrelor versus clopidogrel in patients with acute coronary syndromes: an analysis from the prospective, randomized PLATO trial. ( Emanuelsson, H; Harrington, RA; James, SK; Katus, HA; Lewis, BS; Mahaffey, KW; Maurer, G; Meier, B; Steg, PG; Storey, RF; Wallentin, L; Wojdyla, DM, 2013) |
| "Among patients who had angiography who took prasugrel there were fewer cardiovascular deaths, myocardial infarctions, or strokes than in those who took clopidogrel." | 9.17 | Prasugrel versus clopidogrel for patients with unstable angina or non-ST-segment elevation myocardial infarction with or without angiography: a secondary, prespecified analysis of the TRILOGY ACS trial. ( Armstrong, PW; Bhatt, DL; Boden, WE; Clemmensen, P; Fox, KA; Hafley, G; Hamm, C; Leiva-Pons, J; Lokhnygina, Y; Menozzi, A; Nicolau, JC; Ohman, EM; Oto, A; Pavlides, G; Prabhakaran, D; Roe, MT; Ruzyllo, W; White, HD; Widimsky, P; Winters, KJ; Wiviott, SD, 2013) |
| "Adding a prasugrel loading dose (LD) to a clopidogrel LD could be desirable because clopidogrel may fail to provide adequate levels of platelet inhibition in patients with acute coronary syndrome undergoing percutaneous coronary intervention." | 9.17 | Effect on platelet reactivity from a prasugrel loading dose after a clopidogrel loading dose compared with a prasugrel loading dose alone: Transferring From Clopidogrel Loading Dose to Prasugrel Loading Dose in Acute Coronary Syndrome Patients (TRIPLET): ( Angiolillo, DJ; Cardillo, TE; Diodati, JG; Effron, MB; Fisher, HN; French, JK; Fung, AY; Henneges, C; Saucedo, JF, 2013) |
| "The aim of this study was to evaluate the cost-effectiveness of ticagrelor and generic clopidogrel as add-on therapy to acetylsalicylic acid (ASA) in patients with acute coronary syndrome (ACS), from a Swiss perspective." | 9.17 | Cost-effectiveness of ticagrelor and generic clopidogrel in patients with acute coronary syndrome in Switzerland. ( Gasche, D; Greiner, RA; Meier, B; Ulle, T, 2013) |
| " Clopidogrel in the patients with acute coronary syndromes (ACS) undergoing percutaneous coronary intervention (PCI) by measuring inhibition of platelet aggregation after loading and maintenance dose of both the drugs." | 9.17 | A comparative evaluation of prasugrel and clopidogrel in patients with acute coronary syndrome undergoing percutaneous coronary intervention. ( Alexander, T; Babu, PR; Dani, S; Dasbiswas, A; Hiremath, S; Nayak, R; Patel, T; Pathak, K; Prakash, VS; Rao, MS; Singh, DP; Srivastava, A; Tyagi, S; Vijayvergiya, R; Yadav, MK, 2013) |
| " The aim of the study was to assess the antiplatelet activity and safety of a combined antiplatelet treatment with indobufen and clopidogrel in acute coronary syndrome (ACS) patients with hypersensitivity to aspirin, undergoing coronary stenting." | 9.17 | Clopidogrel plus indobufen in acute coronary syndrome patients with hypersensitivity to aspirin undergoing percutaneous coronary intervention. ( Acconcia, MC; Barillà, F; Dominici, T; Gaudio, C; Mangieri, E; Paravati, V; Pellicano, M; Pulcinelli, FM; Tanzilli, G; Torromeo, C, 2013) |
| " clopidogrel in patients with acute coronary syndromes (ACS) are well documented in the PLATelet inhibition and patient Outcomes trial (PLATO)." | 9.17 | Cost-effectiveness of treating acute coronary syndrome patients with ticagrelor for 12 months: results from the PLATO study. ( Hauch, O; Henriksson, M; Janzon, M; Nikolic, E; Wallentin, L, 2013) |
| "On average, acute coronary syndrome patients treated with prasugrel experience fewer ischemic complications, but more bleeding, than those receiving clopidogrel." | 9.17 | Selecting antiplatelet therapy at the time of percutaneous intervention for an acute coronary syndrome: weighing the benefits and risks of prasugrel versus clopidogrel. ( Cohen, DJ; Jones, PG; Li, Y; Salisbury, AC; Spertus, JA; Wang, K, 2013) |
| "Little is known about the efficacy of proton pump inhibitors compared with H(2) receptor antagonists in preventing adverse upper gastrointestinal complications in patients with acute coronary syndrome (ACS) or ST elevation myocardial infarction (STEMI) receiving aspirin, clopidogrel, and enoxaparin or thrombolytics." | 9.16 | Esomeprazole compared with famotidine in the prevention of upper gastrointestinal bleeding in patients with acute coronary syndrome or myocardial infarction. ( Chan, K; Chu, WM; Keung, KK; Kng, C; Kwan, A; Lam, KF; Lau, YK; Li, A; Ng, FH; Tunggal, P; Wong, BC, 2012) |
| "The efficacy of clopidogrel therapy in patients with an acute coronary syndrome (ACS) has been established using the clopidogrel hydrogen sulfate (CHS) formulation." | 9.16 | Antiplatelet efficacy of long-term treatment with clopidogrel besylate in patients with a history of acute coronary syndrome: comparison with clopidogrel hydrogen sulfate. ( Dimitriou, AA; Goudevenos, IA; Kalantzi, KI; Ntalas, IV; Tselepis, AD; Tsoumani, ME, 2012) |
| "The efficacy of clopidogrel therapy in patients with an acute coronary syndrome (ACS) has been established using the clopidogrel hydrogen sulfate (CHS) formulation." | 9.16 | Effect of clopidogrel besylate on platelet reactivity in patients with acute coronary syndromes. Comparison with clopidogrel hydrogen sulfate. ( Dimitriou, AA; Goudevenos, IA; Kalantzi, KI; Ntalas, IV; Tselepis, AD; Tsoumani, ME, 2012) |
| "Clopidogrel use prior to coronary artery bypass graft surgery in patients presenting with acute coronary syndromes is associated with a greater incidence of procedural related morbidity." | 9.16 | Bleeding-associated outcomes with preoperative clopidogrel use in on- and off-pump coronary artery bypass. ( Becker, RC; Berger, JS; Frye, CB; Harshaw, Q; Herout, PM; Steinhubl, SR, 2012) |
| "We evaluated treatment effects of ticagrelor versus clopidogrel in patients with acute coronary syndrome with and without a history of prior stroke or TIA in the PLATelet inhibition and patient Outcomes (PLATO) trial." | 9.16 | Ticagrelor versus clopidogrel in patients with acute coronary syndromes and a history of stroke or transient ischemic attack. ( Becker, RC; Husted, S; James, SK; Keltai, M; Khurmi, NS; Lopes, RD; Lopez-Sendon, JL; Mahaffey, KW; Maya, J; Morais, J; Nicolau, JC; Pais, P; Raev, D; Stevens, SR; Storey, RF, 2012) |
| "The study aimed to compare the antiplatelet action of ticagrelor with prasugrel in acute coronary syndrome (ACS) patients with high on-treatment platelet reactivity (HTPR) while on clopidogrel after percutaneous coronary intervention (PCI)." | 9.16 | Ticagrelor versus prasugrel in acute coronary syndrome patients with high on-clopidogrel platelet reactivity following percutaneous coronary intervention: a pharmacodynamic study. ( Alexopoulos, D; Damelou, A; Davlouros, P; Galati, A; Hahalis, G; Kassimis, G; Makris, G; Mavronasiou, E; Theodoropoulos, KC; Tsigkas, G; Xanthopoulou, I, 2012) |
| "It remains unclear whether concomitant use of omeprazole attenuates platelet function as compared with that of famotidine in patients with acute coronary syndromes (ACS) who receive clopidogrel." | 9.16 | Influence of omeprazole and famotidine on the antiplatelet effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes: a prospective, randomized, multicenter study. ( Endo, T; Fukui, K; Hibi, K; Himeno, H; Kimura, K; Morita, S; Sugano, T; Tsukahara, K; Umemura, S; Yano, H, 2012) |
| "Among patients with unstable angina or myocardial infarction without ST-segment elevation, prasugrel did not significantly reduce the frequency of the primary end point, as compared with clopidogrel, and similar risks of bleeding were observed." | 9.16 | Prasugrel versus clopidogrel for acute coronary syndromes without revascularization. ( Ardissino, D; Armstrong, PW; Aylward, PE; Bhatt, DL; Boden, WE; Brown, EB; Cinteză, M; Clemmensen, P; Corbalan, R; Cornel, JH; Dalby, AJ; Fox, KA; Gasparovic, V; Goodman, SG; Gottlieb, S; Goudev, AR; Gurbel, PA; Hamm, C; Hochman, JS; Huber, K; Leiva-Pons, JL; Lokhnygina, Y; Martinez, F; McGuire, DK; McLendon, RC; Merkely, B; Nicolau, JC; Ohman, EM; Oto, A; Parkhomenko, A; Pavlides, G; Prabhakaran, D; Roe, MT; Ruzyllo, W; Topacio, GO; Tseng, CD; White, HD; Winters, KJ, 2012) |
| " In the PLATO trial, ticagrelor compared to clopidogrel in patients with acute coronary syndromes (ACS) reduced the primary composite end point of vascular death, myocardial infarction and stroke, without increasing overall rates of major bleeding." | 9.16 | Prior smoking status, clinical outcomes, and the comparison of ticagrelor with clopidogrel in acute coronary syndromes-insights from the PLATelet inhibition and patient Outcomes (PLATO) trial. ( Becker, RC; Cornel, JH; Goodman, SG; Harrington, R; Horrow, J; Husted, S; James, S; Katus, H; Santoso, A; Steg, G; Storey, RF; Sun, JL; Vintila, M; Wallentin, L, 2012) |
| "The significant clinical benefit and overall safety of ticagrelor compared with clopidogrel in acute coronary syndrome patients in the PLATO cohort were not found to depend on age." | 9.16 | Ticagrelor versus clopidogrel in elderly patients with acute coronary syndromes: a substudy from the prospective randomized PLATelet inhibition and patient Outcomes (PLATO) trial. ( Bach, RG; Becker, RC; Cannon, CP; Heras, M; Horrow, J; Husted, S; James, S; Katus, H; Lopes, RD; Mahaffey, KW; Morais, J; Storey, RF; Wallentin, L; Wojdyla, D, 2012) |
| "In large clinical trials enrolling patients with acute coronary syndromes, a high loading dose of clopidogrel (600 mg) has been found to be more effective compared to a low loading dose (300 mg)." | 9.15 | Comparison of adverse cardiovascular events and bleeding complications of loading dose of clopidogrel 300 mg versus 600 mg in stable patients undergoing elective percutaneous intervention (from the CADICE study). ( Aboodi, MS; Delgado, JA; Fernandez, A; Granada, JF; Milewski, K; Rodríguez, A, 2011) |
| " We investigated the effects of cilostazol 200 mg, in addition to aspirin 100 mg and clopidogrel 75 mg, on carotid intima-media thickness (IMT) progression during a 2-year follow-up period in patients with acute coronary syndrome (ACS) requiring stent implantation." | 9.15 | Cilostazol reduces the progression of carotid intima-media thickness without increasing the risk of bleeding in patients with acute coronary syndrome during a 2-year follow-up. ( Ahn, CM; Hong, SJ; Kim, JS; Lim, DS; Park, JH, 2011) |
| "Routine early eptifibatide use, compared with delayed provisional use, may be associated with lower 30-day ischemic risk in non-ST-elevation acute coronary syndrome patients also treated with clopidogrel before angiography." | 9.15 | Upstream clopidogrel use and the efficacy and safety of early eptifibatide treatment in patients with acute coronary syndrome: an analysis from the Early Glycoprotein IIb/IIIa Inhibition in Patients with Non-ST-Segment Elevation Acute Coronary Syndrome (E ( Armstrong, PW; Braunwald, E; Califf, RM; Giugliano, RP; Harrington, RA; James, SK; Montalescot, G; Newby, LK; Tricoci, P; Van de Werf, F; Wang, TY; White, JA; Zeymer, U, 2011) |
| "Abciximab reduced the combined endpoint of death, myocardial infarction (MI) and target vessel revascularization in patients with non-ST-segment elevation acute coronary syndromes (NSTE-ACS) undergoing percutaneous coronary intervention (PCI) with stent implantation after a 600-mg loading dose of clopidogrel." | 9.15 | Influence of abciximab on evolution of left ventricular function in patients with non-ST-segment elevation acute coronary syndromes undergoing PCI after clopidogrel pretreatment: lessons from the ISAR-REACT 2 trial. ( Birkmeier, KA; Byrne, RA; Dommasch, M; Dotzer, F; Kastrati, A; Kufner, S; Mehilli, J; Ndrepepa, G; Schömig, A; Schulz, S; Tiroch, K, 2011) |
| "Omeprazole, usually used in the antiplatelet therapy during percutaneous coronary intervention (PCI) in acute coronary syndrome (ACS), has been reported to increase ischemic events in retrospective studies." | 9.15 | Omeprazole affects clopidogrel efficacy but not ischemic events in patients with acute coronary syndrome undergoing elective percutaneous coronary intervention. ( Chen, JS; Chen, L; Chen, YD; Guo, YS; Huang, TT; Liu, HB; Ren, YH; Sun, ZJ; Wang, CY; Wang, Y; Xie, YJ; Zhao, M, 2011) |
| "The aim of this study was to determine whether ticagrelor increased the risk of ventricular pauses compared with clopidogrel and whether these pauses were associated with any clinical bradycardic events in patients presenting with acute coronary syndromes." | 9.15 | The incidence of bradyarrhythmias and clinical bradyarrhythmic events in patients with acute coronary syndromes treated with ticagrelor or clopidogrel in the PLATO (Platelet Inhibition and Patient Outcomes) trial: results of the continuous electrocardiogr ( Cannon, CP; Emanuelsson, H; Harrington, RA; Husted, S; James, S; Katus, H; Michelson, EL; Pais, P; Raev, D; Scirica, BM; Spinar, J; Steg, PG; Storey, RF; Wallentin, L, 2011) |
| "After an acute coronary syndrome, patients remain at risk of recurrent ischaemic events, despite contemporary treatment, including aspirin and clopidogrel." | 9.15 | Dabigatran vs. placebo in patients with acute coronary syndromes on dual antiplatelet therapy: a randomized, double-blind, phase II trial. ( Budaj, A; Granger, CB; Khder, Y; Oldgren, J; Roberts, J; Siegbahn, A; Tijssen, JG; Van de Werf, F; Wallentin, L, 2011) |
| "In patients with acute coronary syndrome initially intended for non-invasive management, the benefits of ticagrelor over clopidogrel were consistent with those from the overall PLATO results, indicating the broad benefits of P2Y12 inhibition with ticagrelor regardless of intended management strategy." | 9.15 | Ticagrelor versus clopidogrel in patients with acute coronary syndromes intended for non-invasive management: substudy from prospective randomised PLATelet inhibition and patient Outcomes (PLATO) trial. ( Cannon, CP; Cornel, JH; Harrington, RA; Horrow, J; Husted, S; James, SK; Katus, H; Morais, J; Roe, MT; Steg, PG; Stevens, S; Storey, RF; Wallentin, L, 2011) |
| "Residual platelet reactivity (RPR) after clopidogrel loading, measured by the VerifyNow assay, has been shown to predict 12-month clinical events in patients with acute coronary syndromes." | 9.15 | Residual platelet reactivity after clopidogrel loading in patients with ST-elevation myocardial infarction undergoing an unexpectedly delayed primary percutaneous coronary intervention. - Impact on intracoronary thrombus burden and myocardial perfusion-. ( Archontakis, S; Gafou, A; Kalogeras, KI; Kariori, MG; Moldovan, C; Papaioannou, TG; Stefanadis, C; Tzamalis, P; Vavuranakis, M; Vrachatis, DA, 2011) |
| "The aim of this study is to investigate the relationship between the duration of clopidogrel use and the inflammation process after acute coronary syndrome in patients who received bare metal stent (BMS) or drug eluting stent (DES)." | 9.15 | The effect of the duration of clopidogrel use on hsCRP levels after stenting the target vessel in patients with acute coronary syndrome. ( Akbulut, M; Bilen, MN; Bulut, M; Cekici, Y; Celik, A; Korkmaz, H, 2011) |
| " On-clopidogrel platelet reactivity was investigated in patients with previous angiographically confirmed STh, myocardial infarction (MI), and controls." | 9.15 | Relationship between clopidogrel-induced platelet P2Y12 inhibition and stent thrombosis or myocardial infarction after percutaneous coronary intervention-a case-control study. ( Erlinge, D; James, S; Koul, S; Lagerqvist, B; Siegbahn, A; Varenhorst, C; Wallentin, L, 2011) |
| "The Platelet Inhibition and Patient Outcomes (PLATO) trial showed that ticagrelor reduced the risk for cardiovascular events in patients with acute coronary syndromes compared to clopidogrel but was associated with increased incidence of dyspnea." | 9.15 | Pulmonary function in patients with acute coronary syndrome treated with ticagrelor or clopidogrel (from the Platelet Inhibition and Patient Outcomes [PLATO] pulmonary function substudy). ( Becker, RC; Cannon, CP; Cools, F; Emanuelsson, H; Harrington, RA; Husted, S; James, SK; Katus, HA; Khurmi, NS; Lim, ST; Steg, PG; Storey, RF; Wallentin, L, 2011) |
| "To examine if tirofiban may improve the prognosis in aged acute coronary syndrome (ACS) patients received percutaneous coronary intervention (PCI)." | 9.15 | [Tirofiban improved the prognosis of senior acute coronary syndrome patients received percutaneous coronary intervention]. ( Chen, R; Gao, L; Gao, W; Li, LJ; Lu, CY; Tian, JW; Xue, Q; Zhai, JY; Zhang, YX; Zhou, SH, 2011) |
| "We compared the effects of a 600- versus a 300-mg LD of clopidogrel on inhibition of platelet aggregation, myonecrosis, and clinical outcomes in patients with NSTEACS undergoing an early invasive management strategy." | 9.14 | Randomized trial comparing 600- with 300-mg loading dose of clopidogrel in patients with non-ST elevation acute coronary syndrome undergoing percutaneous coronary intervention: results of the Platelet Responsiveness to Aspirin and Clopidogrel and Troponin ( Brieger, D; Chew, DP; Dick, R; Eccleston, D; Eikelboom, JW; Ferguson, L; French, J; Hockings, B; Rankin, J; Thom, J; Walters, D; Whelan, A; Yong, G, 2009) |
| "In this prospective study, 1,212 patients with acute coronary syndromes were randomly assigned to receive either standard dual-antiplatelet treatment with aspirin and clopidogrel (n = 608) or triple-antiplatelet therapy with the addition of a 6-month course of cilostazol (n = 604) after successful PCI." | 9.14 | Cilostazol in addition to aspirin and clopidogrel improves long-term outcomes after percutaneous coronary intervention in patients with acute coronary syndromes: a randomized, controlled study. ( Han, Y; Jing, Q; Li, Y; Shu, Q; Tang, X; Wang, D; Wang, S; Wang, Z, 2009) |
| "The effect of atorvastatin 10 mg vs 40 mg in clopidogrel resistance and clinical events after coronary stenting was compared in patients with acute coronary syndrome (ACS)." | 9.14 | Comparison of low vs moderate dose of atorvastatin in clopidogrel resistance after coronary stenting in Korean patients with acute coronary syndrome. ( Ahn, CM; Hong, SJ; Kim, KA; Kim, YH; Lim, DS; Park, JS; Park, JY; Park, SM; Shim, WJ, 2009) |
| "Prasugrel is a novel thienopyridine that reduces new or recurrent myocardial infarctions (MIs) compared with clopidogrel in patients with acute coronary syndrome undergoing percutaneous coronary intervention." | 9.14 | Effect of the novel thienopyridine prasugrel compared with clopidogrel on spontaneous and procedural myocardial infarction in the Trial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet Inhibition with Prasugrel-Thrombolysis in Myocardi ( Antman, EM; Bonaca, MP; Bramucci, E; Braunwald, E; McCabe, CH; Morrow, DA; Murphy, SA; Nicolau, JC; Ruff, CT; Scirica, BM; White, HD; Wiviott, SD, 2009) |
| "This study sought to evaluate the impact of upstream clopidogrel in patients with non-ST-segment elevation acute coronary syndromes (NSTE-ACS) requiring coronary artery bypass grafting (CABG) from the ACUITY (Acute Catheterization and Urgent Intervention Triage strategY) trial." | 9.14 | Outcomes following pre-operative clopidogrel administration in patients with acute coronary syndromes undergoing coronary artery bypass surgery: the ACUITY (Acute Catheterization and Urgent Intervention Triage strategY) trial. ( Cox, DA; Dyke, C; Ebrahimi, R; Feit, F; Gersh, BJ; Lincoff, AM; Manoukian, SV; Mehran, R; Moses, JW; Ohman, EM; Stone, GW; Ware, JH; White, HD, 2009) |
| " Apixaban, an oral direct factor Xa inhibitor, is a novel anticoagulant that may reduce these events but also poses a risk of bleeding." | 9.14 | Apixaban, an oral, direct, selective factor Xa inhibitor, in combination with antiplatelet therapy after acute coronary syndrome: results of the Apixaban for Prevention of Acute Ischemic and Safety Events (APPRAISE) trial. ( Alexander, JH; Becker, RC; Bhatt, DL; Cools, F; Crea, F; Dellborg, M; Fox, KA; Goodman, SG; Harrington, RA; Huber, K; Husted, S; Lewis, BS; Lopez-Sendon, J; Mohan, P; Montalescot, G; Ruda, M; Ruzyllo, W; Verheugt, F; Wallentin, L, 2009) |
| "To observe the effects of upstream versus downstream application of tirofiban on platelet aggregation and clinical outcomes (major adverse cardiovascular event, MACE) in patients with high-risk non-ST-segment elevation acute coronary syndromes (NSTE-ACS) undergoing percutaneous coronary intervention (PCI)." | 9.14 | [Effects of upstream tirofiban versus downstream tirofiban on platelet aggregation and clinical outcomes in patients with high-risk acute coronary syndromes undergoing percutaneous coronary interventions]. ( Cheng, WJ; Guo, YH; Li, YP; Liu, T; Liu, YY; Ma, HY; Shi, DM; Xie, Y; Zhao, YX; Zhou, YJ, 2009) |
| "Prasugrel led to a significant reduction in ischemic cardiovascular events among patients with acute coronary syndrome (ACS) undergoing percutaneous coronary intervention (PCI) with stent implantation compared to clopidogrel." | 9.14 | Effect of prasugrel versus clopidogrel on outcomes among patients with acute coronary syndrome undergoing percutaneous coronary intervention without stent implantation: a TRial to assess Improvement in Therapeutic Outcomes by optimizing platelet inhibitio ( Antman, EM; Braunwald, E; Buros, JL; Gibson, CM; Pride, YB; Tariq, MU; Wiviott, SD; Zorkun, C, 2009) |
| "In patients who have an acute coronary syndrome with or without ST-segment elevation, treatment with ticagrelor as compared with clopidogrel significantly reduced the rate of death from vascular causes, myocardial infarction, or stroke without an increase in the rate of overall major bleeding but with an increase in the rate of non-procedure-related bleeding." | 9.14 | Ticagrelor versus clopidogrel in patients with acute coronary syndromes. ( Becker, RC; Budaj, A; Cannon, CP; Emanuelsson, H; Freij, A; Harrington, RA; Held, C; Horrow, J; Husted, S; James, S; Katus, H; Mahaffey, KW; Scirica, BM; Skene, A; Steg, PG; Storey, RF; Thorsén, M; Wallentin, L, 2009) |
| "Our aim was to determine whether a 600-mg loading dose of clopidogrel compared with 300 mg results in improved clinical outcomes in patients with ST-segment elevation myocardial infarction (STEMI) undergoing primary percutaneous coronary intervention (PCI)." | 9.14 | Role of clopidogrel loading dose in patients with ST-segment elevation myocardial infarction undergoing primary angioplasty: results from the HORIZONS-AMI (harmonizing outcomes with revascularization and stents in acute myocardial infarction) trial. ( Aoki, J; Brodie, BR; Caixeta, A; Dangas, G; Dudek, D; Guagliumi, G; Kornowski, R; Mehran, R; Parise, H; Peruga, JZ; Rabbani, LE; Stone, GW; Witzenbichler, B, 2009) |
| "Co-administration of pantoprazole may enhance the antiplatelet effect of enteric-coated aspirin in patients with acute coronary syndrome undergoing PCI." | 9.14 | Pantoprazole may enhance antiplatelet effect of enteric-coated aspirin in patients with acute coronary syndrome. ( Bielis, L; Boinska, J; Budzyński, J; Kasprzak, M; Koziński, M; Kubica, J; Marciniak, A; Plazuk, W; Rość, D; Siller-Matula, J, 2009) |
| "Compared with the approved dose regimen of clopidogrel (300-mg loading dose [LD], 75-mg maintenance dose [MD]), prasugrel has been demonstrated to reduce ischaemic events in patients with acute coronary syndrome (ACS) undergoing percutaneous coronary intervention (PCI)." | 9.14 | Prasugrel compared with high-dose clopidogrel in acute coronary syndrome. The randomised, double-blind ACAPULCO study. ( Bal dit Sollier, C; Barthélémy, O; Beygui, F; Cohen, R; Collet, JP; Drouet, L; Henry, P; Lim, P; Luo, J; Marshall, D; Meuleman, C; Montalescot, G; Petitjean, H; Sideris, G, 2010) |
| "Variation in and irreversibility of platelet inhibition with clopidogrel has led to controversy about its optimum dose and timing of administration in patients with acute coronary syndromes." | 9.14 | Comparison of ticagrelor with clopidogrel in patients with a planned invasive strategy for acute coronary syndromes (PLATO): a randomised double-blind study. ( Ardissino, D; Becker, RC; Cannon, CP; Emanuelsson, H; Harrington, RA; Husted, S; James, S; Katus, H; Keltai, M; Khurmi, NS; Kontny, F; Lewis, BS; Steg, PG; Storey, RF; Wallentin, L; Wojdyla, D, 2010) |
| "The current clinical study is designed to confirm superior inhibition of platelet aggregation with prasugrel versus clopidogrel in the treatment of Asian subjects with acute coronary syndrome (ACS) undergoing percutaneous coronary intervention (PCI)." | 9.14 | Prasugrel versus clopidogrel in Asian patients with acute coronary syndromes: design and rationale of a multi-dose, pharmacodynamic, phase 3 clinical trial. ( Boonbaichaiyapruck, S; Ge, J; Goh, YS; Hong, BK; Hou, CJ; Pinton, P; Zhu, J, 2010) |
| "To observe the impact of various application time of aspirin and clopidogrel on the circadian rhythm changes of platelet aggregation in patients with acute coronary syndrome." | 9.14 | [Impact of application time of aspirin and clopidogrel on platelet aggregation in patients with acute coronary syndrome]. ( Cui, W; Li, Z; Liu, F; Liu, J; Lu, JC; Ren, XJ; Xie, RQ; Yang, XC; Zheng, HM, 2010) |
| " We evaluated the immediate and early outcomes in patients with high-risk non-ST elevation acute coronary syndrome (NSTE ACS) who received tirofiban with conventional therapy compared to patients who received only conventional therapy (a combination of aspirin, clopidogrel, low-molecular-weight heparin with or without beta-blockers and angiotensin-converting enzyme inhibitors)." | 9.14 | Randomised controlled trial evaluating the role of tirofiban in high-risk non-ST elevation acute coronary syndromes: an East Indian perspective. ( Basak, S; Bhattacharya, R; Das Baksi, S; Dutta, D; Gangopadhyay, S; Pani, A; Sarkar, RN, 2010) |
| "ticagrelor, when compared with clopidogrel, reduced ischaemic events in ACS patients irrespective of diabetic status and glycaemic control, without an increase in major bleeding events." | 9.14 | Ticagrelor vs. clopidogrel in patients with acute coronary syndromes and diabetes: a substudy from the PLATelet inhibition and patient Outcomes (PLATO) trial. ( Angiolillo, DJ; Cornel, JH; Erlinge, D; Husted, S; James, S; Kontny, F; Maya, J; Nicolau, JC; Spinar, J; Stevens, SR; Storey, RF; Wallentin, L, 2010) |
| "In acute coronary syndrome patients with chronic kidney disease, ticagrelor compared with clopidogrel significantly reduces ischemic end points and mortality without a significant increase in major bleeding but with numerically more non-procedure-related bleeding." | 9.14 | Ticagrelor versus clopidogrel in acute coronary syndromes in relation to renal function: results from the Platelet Inhibition and Patient Outcomes (PLATO) trial. ( Aylward, P; Buck, KK; Budaj, A; Cannon, CP; Cornel, JH; Harrington, RA; Horrow, J; James, S; Katus, H; Keltai, M; Lewis, BS; Parikh, K; Storey, RF; Szummer, K; Wallentin, L; Wojdyla, D, 2010) |
| " 25,086 individuals with acute coronary syndromes and intended early PCI were randomly assigned to double-dose (600 mg on day 1, 150 mg on days 2-7, then 75 mg daily) versus standard-dose (300 mg on day 1 then 75 mg daily) clopidogrel, and high-dose (300-325 mg daily) versus low-dose (75-100 mg daily) aspirin." | 9.14 | Double-dose versus standard-dose clopidogrel and high-dose versus low-dose aspirin in individuals undergoing percutaneous coronary intervention for acute coronary syndromes (CURRENT-OASIS 7): a randomised factorial trial. ( Ajani, AE; Avezum, A; Bassand, JP; Budaj, A; Chrolavicius, S; Di Pasquale, G; Eikelboom, JW; Faxon, DP; Fox, KA; Gao, P; Granger, CB; Jolly, SS; Joyner, CD; Macaya, C; Mehta, SR; Montalescot, G; Niemela, K; Rupprecht, HJ; Steg, PG; Tanguay, JF; White, HD; Widimsky, P; Yusuf, S, 2010) |
| "In patients with an acute coronary syndrome who were referred for an invasive strategy, there was no significant difference between a 7-day, double-dose clopidogrel regimen and the standard-dose regimen, or between higher-dose aspirin and lower-dose aspirin, with respect to the primary outcome of cardiovascular death, myocardial infarction, or stroke." | 9.14 | Dose comparisons of clopidogrel and aspirin in acute coronary syndromes. ( Afzal, R; Bassand, JP; Chrolavicius, S; Diaz, R; Eikelboom, JW; Fox, KA; Granger, CB; Jolly, S; Joyner, CD; Mehta, SR; Pogue, J; Rupprecht, HJ; Widimsky, P; Yusuf, S, 2010) |
| "The PLATO (PLATelet inhibition and patient Outcomes) PLATELET substudy aimed to compare the antiplatelet effects of clopidogrel and ticagrelor in patients with acute coronary syndromes." | 9.14 | Inhibitory effects of ticagrelor compared with clopidogrel on platelet function in patients with acute coronary syndromes: the PLATO (PLATelet inhibition and patient Outcomes) PLATELET substudy. ( Angiolillo, DJ; Becker, RC; Cannon, CP; Desai, B; Ecob, R; Emanuelsson, H; Husted, S; Patil, SB; Storey, RF; Wallentin, L, 2010) |
| "The objective was to evaluate the pharmacodynamic response of switching patients on maintenance phase clopidogrel therapy after an acute coronary syndrome (ACS) to prasugrel." | 9.14 | Increased platelet inhibition after switching from maintenance clopidogrel to prasugrel in patients with acute coronary syndromes: results of the SWAP (SWitching Anti Platelet) study. ( Angiolillo, DJ; Costigan, TM; Deraad, R; Effron, MB; Frelinger, AL; Gurbel, PA; Jakubowski, JA; Ojeh, CK; Saucedo, JF, 2010) |
| "Aspirin and clopidogrel are recommended for patients with acute coronary syndromes (ACS) or undergoing coronary stenting." | 9.14 | Ticagrelor versus clopidogrel in patients with ST-elevation acute coronary syndromes intended for reperfusion with primary percutaneous coronary intervention: A Platelet Inhibition and Patient Outcomes (PLATO) trial subgroup analysis. ( Ardissino, D; Becker, RC; Cannon, CP; Emanuelsson, H; Finkelstein, A; Harrington, RA; Husted, S; James, S; Katus, H; Kilhamn, J; Olofsson, S; Steg, PG; Storey, RF; Wallentin, L; Weaver, WD, 2010) |
| "In data we published earlier, there is a correlation between platelet aggregation in patients with acute coronary syndrome (ACS) who are receiving aspirin and elevated hsCRP-level." | 9.13 | The antiplatelet effect of atorvastatin in patients with acute coronary syndrome depends on the hs-CRP level. ( Kasyanova, O; Shpektor, A; Vasilieva, E, 2008) |
| "In the TRITON-TIMI 38 trial, greater platelet inhibition with prasugrel reduced the first occurrence of the primary endpoint (cardiovascular death, MI, or stroke) compared with clopidogrel in patients with an acute coronary syndrome (ACS) undergoing planned percutaneous coronary intervention." | 9.13 | Reduction in recurrent cardiovascular events with prasugrel compared with clopidogrel in patients with acute coronary syndromes from the TRITON-TIMI 38 trial. ( Antman, EM; Braunwald, E; Huber, K; Lopez-Sendon, J; McCabe, CH; Morocutti, G; Murphy, SA; Weerakkody, G; Wiviott, SD, 2008) |
| "Antiplatelet therapy with clopidogrel and acetylsalicylic acid (ASA) reduces major cardiovascular events in patients with ST and non-ST-segment-elevation acute coronary syndromes (ACS)." | 9.13 | Design and rationale of CURRENT-OASIS 7: a randomized, 2 x 2 factorial trial evaluating optimal dosing strategies for clopidogrel and aspirin in patients with ST and non-ST-elevation acute coronary syndromes managed with an early invasive strategy. ( Bassand, JP; Chrolavicius, S; Diaz, R; Fox, KA; Granger, CB; Jolly, S; Mehta, SR; Rupprecht, HJ; Widimsky, P; Yusuf, S, 2008) |
| "This prospective registered study was conducted to investigate the impact of statins (pravastatin, fluvastatin, atorvastatin) on clopidogrel platelet inhibition in patients with acute coronary syndrome (ACS) or stable angina." | 9.13 | [Impact of statins on clopidogrel platelet inhibition in patients with acute coronary syndrome or stable angina]. ( Shen, J; Zhang, Q; Zhang, RY, 2008) |
| "This post-hoc analysis suggests that in acute coronary syndrome patients, as long as clopidogrel is administered before or within 30 min of PCI treatment with bivalirudin alone is similarly effective to heparin plus a GP IIb/IIIa inhibitor in suppressing 30-day ischemic events with significantly less bleeding." | 9.13 | Influence of timing of clopidogrel treatment on the efficacy and safety of bivalirudin in patients with non-ST-segment elevation acute coronary syndromes undergoing percutaneous coronary intervention: an analysis of the ACUITY (Acute Catheterization and U ( Bertrand, ME; Chew, D; Cox, DA; Desmet, W; Feit, F; Lincoff, AM; Manoukian, SV; Mehran, R; Ohman, EM; Pollack, CV; Steinhubl, SR; Stone, GW; Ware, JH, 2008) |
| "We investigated how does troponin level (TnT) affect the benefit achieved by abciximab in patients with acute coronary syndromes (ACS) undergoing percutaneous coronary intervention (PCI) after pretreatment with a high loading dose of clopidogrel." | 9.13 | Troponin level and efficacy of abciximab in patients with acute coronary syndromes undergoing early intervention after clopidogrel pretreatment. ( Berger, PB; Bruskina, O; Dirschinger, J; Dotzer, F; Iijima, R; Kastrati, A; Mehilli, J; Ndrepepa, G; Neumann, FJ; Schömig, A; Schulz, S; ten Berg, J, 2008) |
| "Unresponsiveness to clopidogrel or aspirin has been reported in patients with acute coronary syndrome (ACS)." | 9.13 | Variable responsiveness to clopidogrel and aspirin among patients with acute coronary syndrome as assessed by platelet function tests. ( Einav, Y; Fefer, P; Hod, H; Lubetsky, A; Matetzky, S; Savion, N; Shenkman, B; Varon, D, 2008) |
| "The aim of this study is to investigate whether the benefit of abciximab in patients with non-ST-segment elevation acute coronary syndromes (NSTE-ACSs) undergoing percutaneous coronary intervention (PCI) after pre-treatment with 600 mg clopidogrel is sustained at 1 year." | 9.13 | One-year clinical outcomes with abciximab vs. placebo in patients with non-ST-segment elevation acute coronary syndromes undergoing percutaneous coronary intervention after pre-treatment with clopidogrel: results of the ISAR-REACT 2 randomized trial. ( Berger, PB; Bruskina, O; Dirschinger, J; Dotzer, F; Kastrati, A; Mehilli, J; Ndrepepa, G; Neumann, FJ; Pache, J; Schömig, A; Seyfarth, M; ten Berg, J, 2008) |
| "In the PROVE IT-TIMI 22 study, 4162 patients with an acute coronary syndrome within the preceding 10 days were randomly assigned in a 1:1 fashion to pravastatin 40 mg or atorvastatin 80 mg daily." | 9.13 | High-dose atorvastatin does not negatively influence clinical outcomes among clopidogrel treated acute coronary syndrome patients--a Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis in Myocardial Infarction 22 (PROVE IT-TIMI 22) a ( Cannon, CP; Giugliano, GR; Lotfi, A; Murphy, SA; Schweiger, MJ, 2008) |
| "Our goal was to compare the safety and initial efficacy of AZD6140, the first reversible oral adenosine diphosphate receptor antagonist, with clopidogrel in patients with non-ST-segment elevation acute coronary syndromes (NSTE-ACS)." | 9.12 | Safety, tolerability, and initial efficacy of AZD6140, the first reversible oral adenosine diphosphate receptor antagonist, compared with clopidogrel, in patients with non-ST-segment elevation acute coronary syndrome: primary results of the DISPERSE-2 tri ( Cannon, CP; Emanuelsson, H; Harrington, RA; Husted, S; Peters, G; Scirica, BM; Storey, RF, 2007) |
| " clopidogRel in non-ST-segment Elevation myocardial infarction)-2, we compared the antiplatelet effects of AZD6140 and clopidogrel and assessed the effects of AZD6140 in clopidogrel-pretreated patients." | 9.12 | Inhibition of platelet aggregation by AZD6140, a reversible oral P2Y12 receptor antagonist, compared with clopidogrel in patients with acute coronary syndromes. ( Cannon, CP; Emanuelsson, H; Grande, P; Gurbel, P; Harrington, RA; Heptinstall, S; Husted, S; Peters, G; Storey, RF; Wickens, M; Wilcox, RG, 2007) |
| "Dual-antiplatelet therapy with aspirin and a thienopyridine is a cornerstone of treatment to prevent thrombotic complications of acute coronary syndromes and percutaneous coronary intervention." | 9.12 | Prasugrel versus clopidogrel in patients with acute coronary syndromes. ( Antman, EM; Ardissino, D; Braunwald, E; De Servi, S; Gibson, CM; Gottlieb, S; McCabe, CH; Montalescot, G; Murphy, SA; Neumann, FJ; Riesmeyer, J; Ruzyllo, W; Weerakkody, G; Wiviott, SD, 2007) |
| " The Clopidogrel in Unstable angina to prevent Recurrent Events (CURE) trial demonstrated the effectiveness of clopidogrel plus acetylsalicylic acid (ASA) compared with ASA alone in reducing cardiovascular events in patients with acute coronary syndromes and, in addition, patients undergoing percutaneous coronary intervention in the Percutaneous Coronary Intervention in CURE (PCI-CURE) trial." | 9.12 | Cost-effectiveness of clopidogrel in acute coronary syndromes in Canada: a long-term analysis based on the CURE trial. ( Kolm, P; Mehta, SR; O'Brien, JA; Veledar, E; Weintraub, WS; Yuan, Y, 2007) |
| "To evaluate the interaction of atorvastatin or pravastatin with clopidogrel on platelet activation and aggregation function in patients with acute coronary syndromes (ACS) undergoing coronary stenting." | 9.12 | [The antiplatelet effect of clopidogrel is not attenuated by statin treatment in patients with acute coronary syndromes undergone coronary stenting]. ( Han, YL; Kang, J; Li, CY; Li, Y; Yan, CH, 2007) |
| "It is unknown whether pretreatment with clopidogrel in acute coronary syndrome (ACS) managed invasively, is superior to a strategy of administering clopidogrel in the cardiac catheterization laboratory at the time of percutaneous coronary intervention (PCI)." | 8.95 | Meta-analysis of clopidogrel pretreatment in acute coronary syndrome patients undergoing invasive strategy. ( Mukherjee, D; Naidu, SS; Nairooz, R; Pothineni, NV; Raina, S; Rochlani, Y; Sardar, P; Shavelle, DM; Valgimigli, M, 2017) |
| "A review of the literature was conducted for clinical trials evaluating the antiplatelet P2Y12 receptor antagonists, clopidogrel, prasugrel, and ticagrelor, as well as the guidelines for the management of acute coronary syndrome (ACS) or myocardial infarction." | 8.93 | Developments in Oral Antiplatelet Agents for the Treatment of Acute Coronary Syndromes: Clopidogrel, Prasugrel, and Ticagrelor. ( Roffman, DS, 2016) |
| "Dual antiplatelet therapy (DAPT) with aspirin combined with either a thienopyridine (clopidogrel or prasugrel) or acyclopentyl-triazolo-pyrimidine (ticagrelor) plays a vital role in the management of acute coronary syndrome (ACS) especially in those undergoing percutaneous coronary intervention (PCI) but even those being managed medically." | 8.93 | Prasugrel hydrochloride for the treatment of acute coronary syndrome patients. ( Gershlick, AH; Gunarathne, A; Hussain, S, 2016) |
| "Prasugrel has similar effects as clopidogrel in terms of all causes of death, MI, and stroke in ACS patients." | 8.91 | Novel oral P2Y12 inhibitor prasugrel vs. clopidogrel in patients with acute coronary syndrome: evidence based on 6 studies. ( Chen, K; Chu, H; Jia, M; Li, L; Li, Z, 2015) |
| "Literature archives (Pubmed, EMBASE, Cochrane) and main scientific sessions abstracts were scanned for randomized trials comparing new ADP antagonists with clopidogrel in patients with acute coronary syndromes or stable angina." | 8.90 | Benefits from new ADP antagonists as compared with clopidogrel in patients with stable angina or acute coronary syndrome undergoing invasive management: a meta-analysis of randomized trials. ( Barbieri, L; Cassetti, E; De Luca, G; Galasso, G; Marino, P; Piccolo, R; Schaffer, A; Sinigaglia, F; Verdoia, M, 2014) |
| " These P2Y12 inhibitors might be superior to clopidogrel for reducing ischemic events in patients with coronary artery disease (CAD)." | 8.90 | Impact of new oral or intravenous P2Y12 inhibitors and clopidogrel on major ischemic and bleeding events in patients with coronary artery disease: a meta-analysis of randomized trials. ( Fan, JY; Jin, C; Meng, J; Tang, XF; Yang, YJ; Yuan, JQ, 2014) |
| "Patients presenting with acute coronary syndrome (ACS) are treated with dual antiplatelet agents, including aspirin and clopidogrel, to prevent mortality and recurrent ischemia." | 8.90 | Should clopidogrel be discontinued before coronary artery bypass grafting for patients with acute coronary syndrome? A systematic review and meta-analysis. ( Ang, SC; Bannon, PG; Cao, C; Indraratna, P; Manganas, C; Park, J; Yan, TD, 2014) |
| "Aspirin is a cornerstone of therapy in the treatment of patients with acute coronary syndromes (ACS)." | 8.89 | Clopidogrel, prasugrel, or ticagrelor? a practical guide to use of antiplatelet agents in patients with acute coronary syndromes. ( Dinicolantonio, JJ; Norgard, NB, 2013) |
| "Dual antiplatelet therapy (DAPT) with aspirin and a P2Y12 receptor antagonist is the standard of care in acute coronary syndromes." | 8.89 | Triple versus dual antiplatelet therapy in acute coronary syndromes: adding cilostazol to aspirin and clopidogrel? ( Bangalore, S; Dinicolantonio, JJ; Lavie, CJ; Meier, P; Niazi, AK; O'Keefe, JH, 2013) |
| " In the large Phase III trial, PLATO, ticagrelor significantly reduced the composite of cardiovascular death, myocardial infarction, or stroke as well as cardiovascular and all-cause mortality compared with clopidogrel in patients presenting with acute coronary syndromes." | 8.89 | Ticagrelor for acute coronary syndromes. ( Bansilal, S; Bonaca, MP; Sabatine, MS, 2013) |
| "Dual antiplatelet therapy with aspirin plus a P2Y(12) receptor inhibitor is the cornerstone of treatment for patients with acute coronary syndrome and in those undergoing percutaneous coronary intervention." | 8.89 | Switching antiplatelet regimens: alternatives to clopidogrel in patients with acute coronary syndrome undergoing PCI: a review of the literature and practical considerations for the interventional cardiologist. ( Angiolillo, DJ; Azmoon, S, 2013) |
| "Until a few years ago, the mainstay of anti-platelet therapy in patients with acute coronary syndrome (ACS) was the combination of aspirin and clopidogrel, a P2Y12 receptor inhibitor." | 8.89 | A critical overview on ticagrelor in acute coronary syndromes. ( Austin, D; Buffon, A; De Servi, S; Kozinski, M; Kubica, J; Kunadian, V; Navarese, EP; Obonska, K; Rychter, M; Sukiennik, A, 2013) |
| "Ticagrelor, an oral P2Y(12) receptor antagonist used as part of dual antiplatelet therapy in the treatment of acute coronary syndromes (ACS), has many favorable characteristics when compared with the more frequently used P2Y(12) receptor antagonist clopidogrel." | 8.88 | Review of ticagrelor in the management of acute coronary syndromes. ( Burgess, S; Juergens, CP; Mallard, TA, 2012) |
| "Although some patients suffer from dyspnea when administered with ticagrelor, there is no evidence of any untoward effects on the cardiovascular or pulmonary systems." | 8.88 | Safety profile and bleeding risk of ticagrelor compared with clopidogrel. ( Lincoff, AM; May, CH, 2012) |
| "To evaluate the association of clopidogrel pretreatment vs no treatment with mortality and major bleeding after PCI." | 8.88 | Association of clopidogrel pretreatment with mortality, cardiovascular events, and major bleeding among patients undergoing percutaneous coronary intervention: a systematic review and meta-analysis. ( Barthélémy, O; Bellemain-Appaix, A; Bernasconi, F; Beygui, F; Collet, JP; Cucherat, M; Jacq, L; Montalescot, G; O'Connor, SA; Silvain, J, 2012) |
| "Clopidogrel use is associated with a significant decrease in major adverse cardiac events when used in patients with non-ST elevation acute coronary syndromes (NSTE-ACS), and guidelines give a class I level of evidence A recommendation for the use of clopidogrel in these patients." | 8.87 | Early clopidogrel use in non-ST elevation acute coronary syndrome and subsequent coronary artery bypass grafting. ( Burke, MA; Fintel, DJ; Lee, R, 2011) |
| "Current guidelines from the National Institute for Clinical Excellence (NICE) recommend antiplatelet therapy comprising aspirin plus either clopidogrel or prasugrel for patients with acute coronary syndrome (ACS)." | 8.87 | Ticagrelor for acute coronary syndrome? ( , 2011) |
| " In clinical trials the antiplatelet agent reduced significantly vascular mortality and death from any cause when compared to clopidogrel in patients with acute coronary syndrome." | 8.87 | [Ticagrelor: a novel antiplatelet agent for patients with acute coronary syndrome]. ( Hinneburg, I, 2011) |
| " The phase 3 PLATelet Inhibition and Patient Outcomes (PLATO) trial (NCT00391872) evaluated ticagrelor compared with clopidogrel in 18 624 patients with acute coronary syndromes (ACS), and demonstrated a significant reduction in the risk of death from vascular causes/myocardial infarction (MI)/stroke with ticagrelor (9." | 8.87 | Evaluating the risk-benefit profile of the direct-acting P2Y(12) inhibitor ticagrelor in acute coronary syndromes. ( Husted, S, 2011) |
| "The platelet ADP receptor antagonist clopidogrel is recommended for the treatment of patients with acute coronary syndrome and/or percutaneous coronary intervention." | 8.86 | Clopidogrel in acute coronary syndrome: implications of recent study findings. ( Bode, C; Duerschmied, D; Moser, M, 2010) |
| "To update the previous systematic review of the use of clopidogrel in combination with aspirin for patients with non-ST-elevation acute coronary syndrome (NSTE-ACS), investigating the optimal duration of treatment and effects of withdrawal from treatment." | 8.85 | The effect of different treatment durations of clopidogrel in patients with non-ST-segment elevation acute coronary syndromes: a systematic review and value of information analysis. ( Burch, J; Craigs, C; Golder, S; Palmer, S; Rogowski, W; Woolacott, N, 2009) |
| " In patients with ACS, inhibition of platelet activation beyond that produced by clopidogrel 600 mg has been associated with an increased bleeding risk." | 8.84 | Benefits and risks of clopidogrel use in patients with coronary artery disease: evidence from randomized studies and registries. ( Kala, P; Motovska, Z, 2008) |
| "Bleeding is a major adverse event during clopidogrel treatment in patients with acute coronary syndrome (ACS)." | 8.31 | miR-6076 rs1463411 polymorphisms are associated with bleeding during clopidogrel treatment in patients with acute coronary syndrome. ( Chen, BL; Dai, W; Mo, ZZ; Peng, YY; Tang, J; Wang, G; Yuan, Z; Zhang, W; Zhou, WL, 2023) |
| " A total of 477 patients receiving double antiaggregation therapy with aspirin and clopidogrel, after suffering a first event, were followed for 1 year to record relapse, as a surrogate end point to measure their therapeutic response, as defined by presenting with an acute coronary event (unstable angina, ST-segment-elevation myocardial infarction, or non-ST-segment-elevation myocardial infarction), stent thrombosis/restenosis, or cardiac mortality." | 8.12 | Clinical and Pharmacological Parameters Determine Relapse During Clopidogrel Treatment of Acute Coronary Syndrome. ( Martínez-Quintana, E; Medina-Gil, JM; Rodríguez-González, F; Saavedra-Santana, P; Santana-Mateos, M; Tugores, A, 2022) |
| "Pharmacogenetics is a potential driver of the "East Asian paradox," in which East Asian acute coronary syndrome (ACS) patients receiving dual antiplatelet therapy (DAPT) with clopidogrel following percutaneous coronary intervention (PCI) demonstrate higher levels of platelet reactivity on treatment than Western patients, yet have lower ischemic risk and higher bleeding risk at comparable doses." | 8.12 | Effect of CYP2C19 status on platelet reactivity in Taiwanese acute coronary syndrome patients switching to prasugrel from clopidogrel: Switch Study. ( Cheng, LC; Chu, PH; Huang, CL; Kuo, FY; Lan, WR; Lee, CH; Lee, WL; Lin, WS; Liu, PY; Lo, PH; Lu, TM; Su, CH; Tsukiyama, S; Wang, YC; Yang, WC; Yin, WH, 2022) |
| "The PLATelet inhibition and patient Outcomes (PLATO) trial (NCT00391872) demonstrated that ticagrelor compared to clopidogrel significantly reduced the rate of death from cardiovascular causes, myocardial infarction or stroke in patients with acute coronary syndrome (ACS)." | 8.02 | Cost-Effectiveness of Ticagrelor Compared with Clopidogrel in Patients with Acute Coronary Syndrome from Vietnamese Healthcare Payers' Perspective. ( Cong Luu, T; Le Phuong, T; Manh Pham, H; Mellstrom, C; Quang Nguyen, T; Thi Thu Nguyen, T; Van Do, D; Van Hoang, S, 2021) |
| "The positive interaction of ticagrelor with the metabolism of adenosine has been claimed for the large antithrombotic and antiischemic benefits of this antiplatelet agent in acute coronary syndromes (ACS)." | 7.96 | Impact of the rs73598374 polymorphism of the adenosine deaminase gene on platelet reactivity and long-term outcomes among patients with acute coronary syndrome treated with ticagrelor. ( De Luca, G; Fierro, N; Gioscia, R; Nardin, M; Negro, F; Pergolini, P; Rolla, R; Sagazio, E; Tonon, F; Verdoia, M, 2020) |
| "To study the comparative efficacy and safety of clopidogrel and ticagrelor in the "double" antiplatelet therapy (DATT) in patients with acute coronary syndrome (ACS) after percutaneous coronary intervention (PCI) in the early and late periods in real clinical practice, and to assess adherence to treatment." | 7.91 | [Double antiplatelet therapy in patients with acute coronary syndrome after percutaneous coronary intervention: individual efficacy and hemorrhagic safety of P2Y12 blockers of ticagrelor and clopidogrel in actual clinical practice]. ( Koroleva, LY; Korotaeva, ES; Kovaleva, GV; Kuzmenko, EA; Nosov, VP, 2019) |
| "The objective of this study is to evaluate the effects of cytochrome P450 2C19 (CYP2C19) polymorphism on adverse cardiovascular events (MACE) in Hakka patients with acute coronary syndrome (ACS) receiving clopidogrel who had undergone coronary drug-eluting stent placement after percutaneous coronary intervention (PCI) in southern China." | 7.88 | Effect of cytochrome P450 2C19 polymorphism on adverse cardiovascular events after drug-eluting stent implantation in a large Hakka population with acute coronary syndrome receiving clopidogrel in southern China. ( He, X; Hou, J; Li, B; Li, C; Liu, Z; Wu, H; Yang, M; Zhang, Q; Zhao, P; Zhong, M; Zhong, W; Zhong, Z, 2018) |
| "The main objective of our study was to investigate the association of CYP2C19*2 and CYP2C19*3 loss-of-function and CYP2C19*17 gain-of-function variants of CYP2C19 gene with Clopidogrel resistance in a sample of Moroccan Acute Coronary Syndromes patients." | 7.88 | A synergic effect between CYP2C19*2, CYP2C19*3 loss-of-function and CYP2C19*17 gain-of-function alleles is associated with Clopidogrel resistance among Moroccan Acute Coronary Syndromes patients. ( Akoudad, H; Habbal, R; Hassani Idrissi, H; Hmimech, W; Khorb, NE; Nadifi, S, 2018) |
| "PROMETHEUS was a multicentre observational study that compared clopidogrel vs prasugrel in acute coronary syndrome patients who underwent PCI (n = 19,914)." | 7.88 | Associations Between Complex PCI and Prasugrel or Clopidogrel Use in Patients With Acute Coronary Syndrome Who Undergo PCI: From the PROMETHEUS Study. ( Aquino, M; Baber, U; Baker, BA; Chandrasekhar, J; Dangas, G; DeFranco, A; Effron, MB; Farhan, S; Ge, Z; Henry, TD; Kapadia, S; Keller, S; Kini, AS; Mehran, R; Muhlestein, JB; Pocock, S; Rao, S; Sartori, S; Sorrentino, S; Strauss, C; Toma, C; Vogel, B; Weintraub, W; Weiss, S, 2018) |
| "The clinical significance of the laboratory-based phenomenon of clopidogrel hypo-responsiveness and platelet reactivity associated with acute myocardial infarction, despite chronic clopidogrel therapy, is largely unknown." | 7.88 | Acute myocardial infarction occurring while on chronic clopidogrel therapy ('clopidogrel failure') is associated with high incidence of clopidogrel poor responsiveness and stent thrombosis. ( Asher, E; Beigel, R; Fefer, P; Matetzky, S; Mazin, I; Regev, E, 2018) |
| " Patients receiving ticagrelor or clopidogrel were further subdivided according to basic bleeding risk." | 7.88 | Impact of Baseline Bleeding Risk on Efficacy and Safety of Ticagrelor versus Clopidogrel in Chinese Patients with Acute Coronary Syndrome Undergoing Percutaneous Coronary Intervention. ( Han, YL; Li, J; Li, Y; Wang, HY; Xu, XM, 2018) |
| "A complete set of fifty-nine demographic, clinical, genetic data was available of 603 patients with acute coronary syndromes enrolled in the prospective GEPRESS study, which showed that HPR after 1month of clopidogrel treatment independently predicted adverse cardiovascular events in patients with Syntax Score >14." | 7.85 | Prediction of high on-treatment platelet reactivity in clopidogrel-treated patients with acute coronary syndromes. ( Buscema, M; Calabrò, P; Capodanno, D; Cattaneo, M; De Carlo, M; de Servi, S; Della Riva, D; Femia, EA; Genereux, P; Grossi, E; Maffeo, D; Palmerini, T; Palmieri, C; Piscione, F; Podda, GM; Toso, A, 2017) |
| "Diabetes mellitus (DM) is associated with enhanced platelet reactivity and impaired response to oral antiplatelet therapy, including clopidogrel." | 7.85 | Impact of Diabetes Mellitus on the Pharmacodynamic Effects of Ticagrelor Versus Clopidogrel in Troponin-Negative Acute Coronary Syndrome Patients Undergoing Ad Hoc Percutaneous Coronary Intervention. ( Angiolillo, DJ; Carlson, GF; Dangas, G; Franchi, F; Khan, ND; Mehran, R; Raveendran, G; Rollini, F; Sweeny, JM; Teng, R; Waksman, R; Zhao, Y, 2017) |
| "Clopidogrel resistance in patients with acute coronary syndrome (ACS) is one of the key causes of recurrent cardiovascular disease (CVD) events after percutaneous coronary intervention (PCI)." | 7.85 | Associations between P2RY12 gene polymorphisms and risks of clopidogrel resistance and adverse cardiovascular events after PCI in patients with acute coronary syndrome. ( Huang, Y; Li, M; Shi, X; Wang, H; Xuan, L; Zhang, N; Zhou, T, 2017) |
| "In this retrospective study, we compared ticagrelor (180mg loading dose 90mg twice daily thereafter), clopidogrel (300mg loading dose, 75mg or 150mg daily thereafter) for the prevention of cardiovascular events in 273 high-risk patients admitted to coronary care unit with acute coronary syndrome." | 7.85 | Efficacy and safety of ticagrelor versus clopidogrel with different dosage in high-risk patients with acute coronary syndrome. ( Gao, Y; Guan, QG; Guo, L; Jia, DL; Li, YZ; Qi, GX; Sun, YX; Tian, W; Xin, YG; Xu, F; Yu, HJ; Zhang, HS; Zhang, XG; Zhang, YL, 2017) |
| "To evaluate the incremental cost-effectiveness ratio (ICER) of the use of ticagrelor as a substitute for clopidogrel for secondary prevention of acute coronary syndrome in Chile." | 7.85 | Latin American Clinical Epidemiology Network Series - Paper 8: Ticagrelor was cost-effective vs. clopidogrel in acute coronary syndrome in Chile. ( Bustos, L; De la Puente, C; Lanas, F; Vallejos, C; Velasquez, M; Zaror, C, 2017) |
| "Although aspirin-clopidogrel combination is more useful for acute coronary syndrome (ACS), the renal safety of this combination had not been established." | 7.83 | Short Communication: Evaluation of nephrotoxicity by aspirin-clopidogrel combination therapy in patients with acute coronary syndrome. ( Baber, M; HamidAkash, MS; Hussain, SB; Irfan, M; Qadir, MI; Rehman, A, 2016) |
| "Despite the growing use of clopidogrel, limited data exist regarding the prognostic significance of chronic clopidogrel therapy in patients sustaining acute coronary syndrome (ACS)." | 7.83 | Prior chronic clopidogrel therapy is associated with increased adverse events and early stent thrombosis. ( Asher, E; Atar, S; Beigel, R; Fefer, P; Hammerman, H; Herscovici, R; Matetzky, S; Mazin, I; Polak, A; Regev, E; Sabbag, A; Shlomo, N; Zahger, D, 2016) |
| "Ticagrelor can lower the resting heart rate of patients and cause bradyarrhythmias in the 12th month after PCI." | 7.83 | Ticagrelor vs. clopidogrel in non-ST-elevation acute coronary syndromes. ( Dong, C; Liu, X; Ren, C; Ren, Q; Zhang, X, 2016) |
| "We observed a potential late treatment effect for prasugrel versus clopidogrel for a reduced risk of ischemic stroke in medically managed patients with ACS aged <75 years." | 7.83 | Time-Varying Effects of Prasugrel Versus Clopidogrel on the Long-Term Risks of Stroke After Acute Coronary Syndromes: Results From the TRILOGY ACS Trial. ( Armstrong, PW; Chin, CT; Corbalán, R; Fox, KA; Magnus Ohman, E; Neely, B; Prabhakaran, D; Roe, MT; White, HD; Winters, KJ, 2016) |
| "Guidelines recommend prasugrel or ticagrelor instead of clopidogrel in patients with acute coronary syndromes (ACS) undergoing percutaneous coronary interventions (PCI)." | 7.83 | Clopidogrel, prasugrel or ticagrelor in patients with acute coronary syndromes undergoing percutaneous coronary intervention. ( Ajani, AE; Andrianopoulos, N; Brennan, A; Clark, DJ; Duffy, SJ; Eccleston, D; Farouque, O; Lefkovits, J; Oqueli, E; Ramchand, J; Reid, CM; Yip, T; Yudi, MB, 2016) |
| "Results of a study of bleeding events and other inhospital outcomes with the use of clopidogrel versus prasugrel in patients with acute coronary syndrome (ACS) managed with percutaneous coronary intervention (PCI) are reported." | 7.83 | Comparative resource utilization and costs for patients with acute coronary syndrome managed with percutaneous coronary intervention and treated with clopidogrel or prasugrel. ( Bae, JP; Effron, MB; Ernst, FR; Faries, DE; Lieu, HD; Lipkin, C; Moretz, C; Zhao, Z, 2016) |
| "To observe the relationship between ATP-binding cassette subfamily B member 1 (ABCB1) and cytochrome P450 (CYP)2C19 polymorphisms and the effect of clopidogrel post percutaneous coronary intervention in patients with coronary artery disease." | 7.83 | [Relationship between ATP-binding cassette subfamily B member 1 and cytochrome P450 2C19 polymorphisms and the effect of clopidogrel post percutaneous coronary intervention in patients with acute coronary syndrome]. ( Fu, ZH; Han, BS; Li, DY; Ren, YH; Song, YQ; Xue, Q; Yi, J; Zhou, CF, 2016) |
| "The goal of this study was to explore the polymorphisms of CYP2C19 (CYP2C19*2, CYP2C19*3) in patients with acute coronary syndrome (ACS) undergoing percutaneous coronary intervention (PCI) on clopidogrel therapy in Zhengzhou city for guidance on clinical medication and reduction in the incidence of thromboembolic events." | 7.83 | CYP2C19 polymorphisms in acute coronary syndrome patients undergoing clopidogrel therapy in Zhengzhou population. ( Guo, YM; Li, HZ; Li, Z; Sun, HL; Zhang, L; Zhao, ZC, 2016) |
| "The efficacy and safety of ticagrelor compared with clopidogrel in acute coronary syndrome has not previously been evaluated in an Eastern Asian population, which is recognized to have a different response to P2Y12 antagonists compared with the Caucasian population in real-life situations." | 7.83 | Efficacy and safety of ticagrelor versus clopidogrel in acute coronary syndrome in Taiwan: A multicenter retrospective pilot study. ( Chao, TH; Chen, IC; Chen, Y; Cheng, CL; Fang, CC; Lee, CH; Li, YH; Lin, CC; Lin, CY; Yu, CL, 2016) |
| "Ticagrelor reduces ischaemic events and mortality in acute coronary syndrome (ACS) vs." | 7.83 | Outcomes in patients treated with ticagrelor or clopidogrel after acute myocardial infarction: experiences from SWEDEHEART registry. ( Erlinge, D; James, SK; Jernberg, T; Lagerqvist, B; Omerovic, E; Renlund, H; Sahlén, A; Varenhorst, C; Wallentin, L, 2016) |
| " We report a case of clopidogrel-induced severe neutropenia in a patient treated with coronary stent and safety of alternative treatment with ticagrelor." | 7.81 | Ticagrelor as an alternative in clopidogrel-associated neutropenia. ( Belalcazar-Portacio, A; Keough, LA; Ramanathan, KB; Shah, R, 2015) |
| "High-post clopidogrel platelet reactivity in acute coronary syndrome (ACS) patients is associated with adverse outcomes and may be related to clopidogrel dosing." | 7.81 | Evaluation of platelet response to different clopidogrel dosing regimens in patients with acute coronary syndrome in clinical practice. ( Beigel, R; Fefer, P; Gannot, S; Hod, H; Matetzky, S; Rosenberg, N; Savion, N; Shechter, M; Varon, D, 2015) |
| "To investigate whether an intensified antiplatelet regimen could improve prognosis in stable or non-ST elevation in acute coronary syndrome (ACS) patients exhibiting high on-treatment platelet reactivity (HTPR) on clopidogrel and treated with percutaneous coronary intervention (PCI)." | 7.81 | Tailored antiplatelet therapy to improve prognosis in patients exhibiting clopidogrel low-response prior to percutaneous coronary intervention for stable angina or non-ST elevation acute coronary syndrome. ( Clemmensen, P; Engstrøm, T; Helqvist, S; Holmvang, L; Johansson, PI; Jørgensen, E; Kelbæk, H; Kollslid, R; Lønborg, JT; Paarup Dridi, N; Pedersen, F; Qayyum, A; Radu, MD; Saunamäki, K, 2015) |
| "Treatment with warfarin in combination with clopidogrel has been shown to reduce the incidence of major bleeding as compared to triple antithrombotic therapy (TT; warfarin, clopidogrel and aspirin)." | 7.81 | Concomitant use of warfarin and ticagrelor as an alternative to triple antithrombotic therapy after an acute coronary syndrome. ( Bico, B; Braun, OÖ; Chaudhry, U; Gustav Smith, J; Jovinge, S; Koul, S; Scherstén, F; Svensson, PJ; Tydén, P; van der Pals, J; Wagner, H, 2015) |
| "In acute coronary syndrome (ACS), inflammation and redox response are associated with increased residual platelet reactivity (RPR) on clopidogrel therapy." | 7.81 | Inflammatory and antioxidant pattern unbalance in "clopidogrel-resistant" patients during acute coronary syndrome. ( Abbate, R; Caruso, R; Cecchettini, A; Citti, L; Cozzi, L; Giusti, B; Gori, AM; Marcucci, R; Parodi, G; Parodi, O; Parolini, M; Rocchiccioli, S; Romagnuolo, I, 2015) |
| "To investigate the contributions of CYP2C19 polymorphisms to the various clopidogrel responses tested by thrombelastography (TEG) in Chinese patients with the acute coronary syndrome (ACS)." | 7.81 | CYP2C19*2 and Other Allelic Variants Affecting Platelet Response to Clopidogrel Tested by Thrombelastography in Patients with Acute Coronary Syndrome. ( Liu, J; Lu, Y; Nie, XY; Shi, LW; Wang, WM; Zhang, Y, 2015) |
| "Greater antithrombotic potency new antiplatelet agents have been added such as prasugrel (PR) and ticagrelor to the traditional use of clopidogrel (CL) in the treatment of acute coronary syndrome (ACS)." | 7.81 | [Clopidogrel versus prasugrel in acute coronary syndrome treated with coronary angioplasty]. ( Conde, D; Cura, F; Elissamburu, P; Filipini, E; Lalor, N; Nau, G; Rodríguez, L; Trivi, M, 2015) |
| "To compare healthcare costs between clopidogrel and prasugrel over 30-day and 365-day periods after discharge from the hospital or emergency room (ER) in patients treated with prasugrel who were hospitalized or had an ER visit for an acute coronary syndrome (ACS) event." | 7.81 | Economic outcomes with prasugrel versus clopidogrel in acute coronary syndrome patients: observations from prasugrel users and matched clopidogrel users. ( Crivera, C; Dea, K; Germain, G; Laliberté, F; Lefebvre, P; Lynch, SM; Ma, YW; Olson, WH; Schein, J, 2015) |
| " We aimed to evaluate the effect of DAPT duration with clopidogrel and aspirin on the recurrence of ischaemic events and bleeding in a large, unselected ACS population." | 7.80 | Duration of dual antiplatelet treatment with clopidogrel and aspirin in patients with acute coronary syndrome. ( Hasvold, P; Held, C; James, S; Jensevik, K; Jernberg, T; Lagerqvist, B; Sundström, A; Varenhorst, C, 2014) |
| "We aimed to investigate the association of aspirin and/or clopidogrel low response with -455G/A polymorphism of β-fibrinogen in patients with acute coronary syndrome (ACS)." | 7.80 | Impact of -455G/a polymorphism of the β-fibrinogen gene on platelet aggregation in patients with acute coronary syndrome. ( Bakirci, EM; Borekci, A; Kalkan, K; Karakoyun, S; Sevimli, S; Topcu, S; Vançelik, S, 2014) |
| "Clopidogrel therapy is the standard of care in patients with acute coronary syndrome (ACS) and stent implantation." | 7.80 | Diagnostic accuracy of mean platelet volume in prediction of clopidogrel resistance in patients with acute coronary syndrome. ( Akdeniz, B; Aytemiz, F; Badak, O; Barış, N; Göldeli, O; Ozpelit, E; Uzel, H, 2014) |
| "Switching patients with ACS who have HPR to treatment with prasugrel reduces thrombotic and bleeding events to a level similar to that of those without HPR; however, there is a higher risk of both thrombotic and bleeding complications with high-dose clopidogrel." | 7.80 | Optimizing P2Y12 receptor inhibition in patients with acute coronary syndrome on the basis of platelet function testing: impact of prasugrel and high-dose clopidogrel. ( Aradi, D; Faluközy, J; Horváth, IG; Komócsi, A; Kónyi, A; Magyari, B; Pintér, T; Tornyos, A; Veress, G; Vorobcsuk, A, 2014) |
| "To evaluate the effect of drug interaction between omeprazol and clopidogrel in hospital readmission of patients with acute coronary syndrome (ACS)." | 7.80 | [Effect of drug interaction between clopidogrel and omeprazole in hospital readmision of patients by a recurrent acute coronary syndrome: a case-control study]. ( Amariles, P; Angulo, NY; Betancourth, PM; Ceballos, M; Holguín, H, 2014) |
| "The aim of this study was to assess antiplatelet effect of prasugrel in acute coronary syndrome (ACS) patients with high on-treatment platelet reactivity (HTPR) on clopidogrel, undergoing percutaneous coronary intervention (PCI)." | 7.80 | Prasugrel overcomes high on-clopidogrel platelet reactivity in the acute phase of acute coronary syndrome and maintains its antiplatelet potency at 30-day follow-up. ( De Servi, S; Fabiszak, T; Kasprzak, M; Koziński, M; Kubica, J; Navarese, EP; Obońska, K; Rość, D; Siller-Matula, JM; Stankowska, K; Stolarek, W, 2014) |
| "Ticagrelor is the first reversibly binding oral P2Y12 receptor antagonist designed to reduce clinical thrombotic events in patients with acute coronary syndrome (ACS)." | 7.80 | Direct healthcare costs and cost-effectiveness of acute coronary syndrome secondary prevention with ticagrelor compared to clopidogrel: economic evaluation from the public payer's perspective in Poland based on the PLATO trial results. ( Budaj, A; Macioch, T; Niewada, M; Pawęska, J; Perkowski, P, 2014) |
| "To compare 30 and 90 day real-world acute myocardial infarction (AMI) and bleeding related rehospitalization rates in acute coronary syndrome (ACS) patients receiving percutaneous coronary intervention (PCI; ACS-PCI) treated with clopidogrel or prasugrel." | 7.80 | Real-world observations with prasugrel compared to clopidogrel in acute coronary syndrome patients treated with percutaneous coronary intervention in the United States. ( Bae, JP; Effron, MB; Ernst, FR; Faries, DE; Lieu, HD; Lipkin, C; Moretz, C; Zhao, Z, 2014) |
| "To assess the cost-effectiveness relationship of Ticagrelor versus Clopidogrel for the management of acute coronary syndrome in Spain." | 7.80 | [Long-term cost-effectiveness of ticagrelor versus clopidogrel in acute coronary syndrome in Spain]. ( Mateo-Carrasco, H; Molina-Cuadrado, E; Nieto-Guindo, P; Rodríguez-Gómez, P, 2014) |
| "Current guidelines recommend a combination of clopidogrel and aspirin for management of patients who have experienced an acute coronary syndrome (ACS)." | 7.80 | Prasugrel vs. clopidogrel in acute coronary syndrome patients treated with prasugrel. ( Crivera, C; Dea, K; Fields, LE; Germain, G; Laliberté, F; Lefebvre, P; Lynch, SM; Ma, YW; Olson, WH; Schein, JR, 2014) |
| "This study established a population pharmacokinetics-pharmacodynamics model of clopidogrel in patients with acute coronary syndrome." | 7.80 | [Population pharmacokinetics and pharmacodynamics of clopidogrel in patients with acute coronary syndrome]. ( Ding, XL; Gao, J; Hang, YF; Jiang, B; Miao, LY; Xie, C; Xue, L, 2014) |
| " Patients displaying low on-treatment platelet reactivity (LPR) and/or at high risk of bleeding were switched to clopidogrel 75 mg and tested again 15 days later." | 7.79 | Switching acute coronary syndrome patients from prasugrel to clopidogrel. ( Abtan, J; Barthélémy, O; Beygui, F; Brugier, D; Cayla, G; Collet, JP; Kerneis, M; Martin, R; Montalescot, G; O'Connor, SA; Silvain, J; Vignalou, JB, 2013) |
| "Coexisting polymorphisms of different genes affected clopidogrel responsiveness and clinical outcome more than single polymorphism in Chinese patients with acute coronary syndrome undergoing percutaneous coronary intervention." | 7.79 | Effects of coexisting polymorphisms of CYP2C19 and P2Y12 on clopidogrel responsiveness and clinical outcome in patients with acute coronary syndromes undergoing stent-based coronary intervention. ( Chen, J; Chen, JL; Gao, RL; Han, YL; Qiao, SB; Tang, XF; Wang, J; Wu, Y; Wu, YJ; Xu, B; Yang, YJ; Yuan, JQ; Zhang, JH, 2013) |
| " The PLATO trial compared ticagrelor and aspirin to clopidogrel and aspirin in patients with acute coronary syndromes (ACS)." | 7.79 | Lifetime cost-effectiveness analysis of ticagrelor in patients with acute coronary syndromes based on the PLATO trial: a Singapore healthcare perspective. ( Chin, CT; Chua, TS; Matchar, DB; Mellstrom, C, 2013) |
| "Aim of this multicenter retrospective study was assessment of effect of intracoronary administration of tirofiban loading dose in troponin positive patients with acute coronary syndrome (ACS)." | 7.79 | [Effect of intracoronary and intravenous administration of tirofiban loading dose in patients underwent percutaneous coronary interventions because of acute coronary syndrome]. ( Arystanova, AZh; Balli, M; Batyraliev, TA; Fettser, DV; Kagliian, KÉ; Samko, AN; Serchelik, A; Sidorenko, BA; Tekin, K; Turkmen, S, 2013) |
| "The novel P2Y12 antagonist ticagrelor inhibits adenosine diphosphate (ADP)-induced platelet aggregation more potently than clopidogrel and reduces the incidence of myocardial infarction and total death in patients with an acute coronary syndrome (ACS)." | 7.79 | Ticagrelor improves peripheral arterial function in patients with a previous acute coronary syndrome. ( Erlinge, D; Larsson, J; Ohman, J; Salmi, H; Torngren, K, 2013) |
| "The PLATO (Platelet Inhibition and Patient Outcomes) randomized trial (NCT00391872) in patients with acute coronary syndromes (ACS) reported that ticagrelor (in addition to aspirin) reduced the rate of the composite end point of myocardial infarction (MI), stroke, or cardiovascular death compared with clopidogrel (in addition to aspirin) by 16% over 12 months (P < 0." | 7.79 | Cost-effectiveness of 12-month treatment with ticagrelor compared with clopidogrel in the management of acute coronary syndromes. ( Adena, M; Aylward, P; Chim, L; De Abreu Lourenço, R; Liew, D, 2013) |
| "Treatment with clopidogrel, a selective platelet P2Y12 receptor antagonist, reduces risk of recurrent ischemic events in patients with acute coronary syndrome (ACS), by limiting platelet aggregation and activation." | 7.79 | Plasma and whole blood clot strength measured by thrombelastography in patients treated with clopidogrel during acute coronary syndromes. ( Kreutz, RP; Lu, D; Owens, J, 2013) |
| "Clopidogrel could decrease mortality and improve cardiovascular outcomes without increasing risk of bleeding in ACS patients with CKD." | 7.79 | Effects of clopidogrel on mortality, cardiovascular and bleeding outcomes in patients with chronic kidney disease - data from Taiwan acute coronary syndrome full spectrum registry. ( Chang, SC; Chiang, FT; Hsin, HT; Hwang, JJ; Kuo, CT; Lai, WT; Li, AH; Lin, TH; Wang, CL, 2013) |
| "To investigate the relationship between cytochrome P450 (CYP) 2C19 genetic polymorphism and clopidogrel resistance(CR) in patients with acute coronary syndrome(ACS), and to assess the effects of genetic polymorphism at CYP2C19 (681G>A) on the prognosis of ACS patients." | 7.79 | [The effects of cytochrome P450 2C19 genetic polymorphism on clopidogrel resistance and recent prognosis of patients with acute coronary syndrome]. ( Chen, PA; Lei, XM; Li, GL; Li, SN; Liu, Z; Luo, Y, 2013) |
| "High on clopidogrel platelet reactivity (HPR) has been associated with adverse outcomes following acute coronary syndromes (ACS)." | 7.79 | Suboptimal response to clopidogrel and the effect of prasugrel in acute coronary syndromes. ( Harding, SA; Johnston, LR; La Flamme, AC; Larsen, PD; Michel, JM; Simmonds, MB, 2013) |
| "Patients with acute coronary syndrome undergoing percutaneous coronary intervention (PCI) commonly receive a loading dose of either clopidogrel or prasugrel, in addition to aspirin." | 7.79 | Safety of reloading prasugrel in addition to clopidogrel loading in patients with acute coronary syndrome undergoing percutaneous coronary intervention. ( Chen, F; Kent, KM; Kitabata, H; Loh, JP; Pendyala, LK; Pichard, AD; Satler, LF; Suddath, WO; Torguson, R; Waksman, R, 2013) |
| "In the TRITON-TIMI 38 trial, patients with an acute coronary syndrome (ACS) undergoing percutaneous coronary intervention (PCI) were treated with prasugrel or clopidogrel." | 7.79 | Prasugrel vs clopidogrel in patients with acute coronary syndrome undergoing percutaneous coronary intervention: a model-based cost-effectiveness analysis for Germany, Sweden, the Netherlands, and Turkey. ( Bakhai, A; Barrett, A; Davies, A; Graham-Clarke, P; Schmitt, C; Sculpher, M, 2013) |
| "The present study was performed to compare the influence of cytochrome P459 2C19 (CYP2C19) *2 and *17 genetic variants on the platelet response to clopidogrel and prasugrel maintenance therapy and to assess the relation between platelet reactivity and bleeding complications." | 7.79 | Effect of CYP2C19*2 and *17 genetic variants on platelet response to clopidogrel and prasugrel maintenance dose and relation to bleeding complications. ( Alessi, MC; Beguin, S; Bonnet, JL; Camoin, L; Cohen, W; Cuisset, T; Gaborit, B; Grosdidier, C; Lambert, M; Loosveld, M; Morange, PE; Moro, PJ; Pankert, M; Quilici, J; Saut, N, 2013) |
| "We sought to compare the 1-year risk of re-hospitalization for acute coronary syndrome (ACS) between patients taking clopidogrel with proton pump inhibitors (PPIs) vs." | 7.78 | One-year clinical outcome in patients with acute coronary syndrome treated with concomitant use of clopidogrel and proton pump inhibitors: results from a regional cohort study. ( Branzi, A; De Palma, R; Marino, M; Marzocchi, A; Ortolani, P, 2012) |
| "Our study indicated no statistically significant increase in the risk of rehospitalization for acute coronary syndrome due to concurrent use of clopidogrel and PPIs in an Asian population with higher prevalence of CYP2C19 intermediate and poor metabolizers." | 7.78 | Cardiovascular outcomes associated with concomitant use of clopidogrel and proton pump inhibitors in patients with acute coronary syndrome in Taiwan. ( Bai, CH; Gau, CS; Lin, CF; Shen, LJ; Wu, FL, 2012) |
| "Guidelines stipulate that clopidogrel should be interrupted ≥ 5 days prior to elective coronary artery bypass graft (CABG) surgery to reduce the risk of bleeding unless the need for revascularization and/or the net benefit of the clopidogrel outweighs the potential risks of bleeding." | 7.78 | Coronary artery bypass graft surgery in acute coronary syndrome: incidence, cost impact, and acute clopidogrel interruption. ( Bell, K; Gdovin, J; Graham, J; Jing, Y; Johnston, SS, 2012) |
| "Recent concerns about clopidogrel and proton pump inhibitor (PPI) co-administration in patients following an acute coronary syndrome (ACS) led us to investigate our practice." | 7.78 | Reducing co-administration of clopidogrel and proton pump inhibitors in acute coronary syndromes. ( Kavvoura, F; Rowlands, DB; Schofield, R; Silva, A; Vassiliou, V, 2012) |
| " We aimed to determine the relationship between high on-treatment platelet reactivity (HTPR) and ST-elevation myocardial infarction (STEMI) following a 600 mg loading dose (LD) of clopidogrel." | 7.78 | Biological efficacy of a 600 mg loading dose of clopidogrel in ST-elevation myocardial infarction. ( Armero, S; Barragan, P; Berbis, J; Bessereau, J; Bonello, C; Bonello, L; Camillieri, E; Camoin-Jau, L; Dignat-George, F; Jacquin, L; Laine, M; Paganelli, F, 2012) |
| "One-year treatment with clopidogrel in addition to aspirin is a cost-effective treatment option for secondary prevention in patients with acute coronary syndrome without ST-segment elevation in Greece." | 7.78 | Economic evaluation of clopidogrel in acute coronary syndrome patients without ST-segment elevation in Greece: a cost-utility analysis. ( Fragoulakis, V; Kourlaba, G; Maniadakis, N, 2012) |
| "A total of 10,101 patients aged 18 years or older with a diagnosis of acute coronary syndrome (ACS) made during a hospitalization or emergency department visit between 2001 and 2008 and who had their first clopidogrel prescription within 90 days after their ACS diagnosis were included in the study." | 7.78 | Effect of the clopidogrel-proton pump inhibitor drug interaction on adverse cardiovascular events in patients with acute coronary syndrome. ( Bhurke, SM; Bursac, Z; Franks, AM; Li, C; Martin, BC; Said, Q, 2012) |
| "High platelet reactivity (HPR) after clopidogrel treatment is linked to an increased risk of periprocedural myocardial infarction (PMI)." | 7.78 | Association of CYP2C19 genotype with periprocedural myocardial infarction after uneventful stent implantation in Chinese patients receiving clopidogrel pretreatment. ( Ge, J; Qian, J; Sun, A; Wang, Q; Wu, H, 2012) |
| "In conclusion, the present study showed that initial clopidogrel response in patients with acute coronary syndrome is not a reliable predictor of response to maintenance therapy and their values for prediction of clinical outcome are likely to be different." | 7.78 | Comparison between initial and chronic response to clopidogrel therapy after coronary stenting for acute coronary syndrome and influence on clinical outcomes. ( Alessi, MC; Bonnet, JL; Cuisset, T; Fourcade, L; Gaborit, B; Gil, JM; Grosdidier, C; Loosveld, M; Morange, PE; Moro, PJ; Quilici, J, 2012) |
| "To detect the single nucleotide polymorphisms of clopidogrel metabolism related genes (CYP2C19, ABCB1 and PON1) in Chinese patients with acute coronary syndrome (ACS) by genotype analysis." | 7.78 | [Clopidogrel metabolism related gene polymorphisms in Chinese patients with acute coronary syndrome]. ( Bai, Y; Chen, T; Feng, GX; Liang, Y; Liu, X; Wang, XY; Yang, YJ; Yang, YM; Zhu, J, 2012) |
| "The purpose of this study is to evaluate the efficacy and safety of ticagrelor and clopidogrel in patients with acute coronary syndrome undergoing coronary artery bypass graft surgery (CABG), as a post-randomization strategy." | 7.77 | Ticagrelor versus clopidogrel in patients with acute coronary syndromes undergoing coronary artery bypass surgery: results from the PLATO (Platelet Inhibition and Patient Outcomes) trial. ( Asenblad, N; Bassand, JP; Becker, RC; Cannon, CP; Claeys, MJ; Harrington, RA; Held, C; Horrow, J; Husted, S; James, SK; Mahaffey, KW; Nicolau, JC; Scirica, BM; Storey, RF; Vintila, M; Wallentin, L; Ycas, J, 2011) |
| "Recent guidelines recommend use of aspirin and either clopidogrel or prasugrel for at least 12 months following use of drug-eluting or bare metal stents in patients with acute coronary syndromes (ACS) undergoing percutaneous coronary intervention (PCI)." | 7.77 | Factors associated with clopidogrel use, adherence, and persistence in patients with acute coronary syndromes undergoing percutaneous coronary intervention. ( Anderson, J; Bae, JP; Fu, H; Lenarz, L; McCollam, P; Zettler, M; Zhao, Z; Zhu, B, 2011) |
| "Clopidogrel reduces long-term ischemic events in patients with acute coronary syndrome or stable angina (SA) undergoing percutaneous coronary intervention (PCI)." | 7.77 | Relationship between peripheral arterial reactive hyperemia and residual platelet reactivity after 600 mg clopidogrel. ( Barbato, E; Bartunek, J; Cuisset, T; De Bruyne, B; Dierickx, K; Hamilos, M; Mangiacapra, F; Meeus, P; Muller, O; Ntalianis, A; Sarno, G; Trana, C; Wijns, W, 2011) |
| "Guidelines support clopidogrel therapy in medically-treated or percutaneous coronary intervention (PCI) patients after hospitalization for acute coronary syndrome (ACS)." | 7.77 | Incidence of death and recurring acute coronary syndrome after stopping clopidogrel therapy in a large commercially-insured population in the US. ( Chang, CL; Cziraky, MJ; Devecchis Wygant, G; Hauch, O; Stephenson, JJ, 2011) |
| "Clopidogrel has been widely used to prevent recurrent ischemia in patients with acute coronary syndrome (ACS)." | 7.77 | Clinical, pharmacokinetic, and pharmacogenetic determinants of clopidogrel resistance in Korean patients with acute coronary syndrome. ( Chung, HS; Han, JY; Kim, HJ; Kim, SR; Lee, SY; Park, KJ, 2011) |
| " Triple therapy (OAC, clopidogrel plus aspirin) was associated with four times higher risk of any bleeding than OAC plus aspirin, adj." | 7.77 | Efficacy and safety of clopidogrel after PCI with stenting in patients on oral anticoagulants with acute coronary syndrome. ( Hofman-Bang, C; Lagerqvist, B; Lindbäck, J; Persson, J; Samnegard, A; Stenestrand, U, 2011) |
| "Results of a study of the association between early discontinuation of clopidogrel therapy and rehospitalization rates among patients with acute coronary syndrome (ACS) are reported." | 7.77 | Effect of early clopidogrel discontinuation on rehospitalization in acute coronary syndrome: results from two distinct patient populations. ( Curkendall, S; Ernst, FR; Johnston, S; Mozaffari, E; Stemkowski, S, 2011) |
| "The clinical safety and efficacy of clopidogrel reloading in patients receiving long-term clopidogrel therapy who present with acute coronary syndromes and undergo percutaneous coronary intervention have not yet been evaluated." | 7.77 | Safety and efficacy of clopidogrel reloading in patients on chronic clopidogrel therapy who present with an acute coronary syndrome and undergo percutaneous coronary intervention. ( Ben-Dor, I; Gaglia, MA; Gonzalez, M; Mahmoudi, M; Maluenda, G; Pichard, AD; Sardi, G; Satler, LF; Suddath, WO; Syed, AI; Torguson, R; Wakabayashi, K; Waksman, R; Xue, Z, 2011) |
| "To test the hypothesis that HRPR after clopidogrel loading is an independent prognostic marker of risk of long-term thrombotic events in patients with acute coronary syndromes (ACS) undergoing an invasive procedure and antithrombotic treatment adjusted according to the results of platelet function tests." | 7.77 | High residual platelet reactivity after clopidogrel loading and long-term cardiovascular events among patients with acute coronary syndromes undergoing PCI. ( Abbate, R; Antoniucci, D; Buonamici, P; Gensini, GF; Giusti, B; Gori, AM; Marcucci, R; Migliorini, A; Parodi, G; Valenti, R, 2011) |
| "The antiplatelet agent clopidogrel is an effective drug for the prevention of thrombotic events in patients with acute coronary syndrome and in those undergoing percutaneous coronary intervention with the deployment of a coronary stent." | 7.77 | [Stent thrombosis and clopidogrel response variability: is the genetic test useful in clinical practice?]. ( Ardissino, D; Conte, G; Demola, MA; Giacalone, R; Mantovani, F; Marziliano, N; Notarangelo, MF, 2011) |
| "Of 1381 patients admitted with hip fractures, 114 were receiving regular clopidogrel therapy with a median age of 83." | 7.77 | Perioperative management of clopidogrel therapy: the effects on in-hospital cardiac morbidity in older patients with hip fractures. ( Collyer, TC; Corcoran, T; Kilshaw, L; Reynolds, HC; Truyens, E, 2011) |
| "In patients with acute coronary syndromes and planned percutaneous coronary intervention, the Trial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet Inhibition With Prasugrel-Thrombolysis in Myocardial Infarction 38 (TRITON-TIMI 38) demonstrated that treatment with prasugrel versus clopidogrel was associated with reduced rates of cardiovascular death, MI, or stroke and an increased risk of major bleeding." | 7.76 | Cost-effectiveness of prasugrel versus clopidogrel in patients with acute coronary syndromes and planned percutaneous coronary intervention: results from the trial to assess improvement in therapeutic outcomes by optimizing platelet inhibition with Prasug ( Antman, E; Arnold, SV; Braunwald, E; Cohen, DJ; Mahoney, EM; Proskorovsky, I; Wang, K; Wiviott, S, 2010) |
| "Current guidelines recommend pretreatment with a loading dose of clopidogrel before percutaneous coronary intervention (PCI) to reduce the incidence of periprocedural myocardial infarctions in patients undergoing PCI." | 7.76 | Efficacy of high-dose clopidogrel treatment (600 mg) less than two hours before percutaneous coronary intervention in patients with non-ST-segment elevation acute coronary syndromes. ( Bergman, G; Fakorede, F; Feldman, DN; Minutello, RM; Moussa, I; Wong, SC, 2010) |
| "This was a retrospective cohort study of 2017 patients with acute coronary syndrome discharged on clopidogrel from an integrated health care delivery system." | 7.76 | Adverse events after stopping clopidogrel in post-acute coronary syndrome patients: Insights from a large integrated healthcare delivery system. ( Clarke, CL; Go, AS; Ho, PM; Magid, DJ; Peterson, ED; Rumsfeld, JS; Sedrakyan, A; Shetterly, SM; Tsai, TT; Wang, TY, 2010) |
| "We initiated this study to investigate the utility of s-TEG in assessing the response to clopidogrel in patients presenting with acute coronary syndromes (ACS) and to compare these results with established clopidogrel monitoring techniques." | 7.76 | Individualised assessment of response to clopidogrel in patients presenting with acute coronary syndromes: a role for short thrombelastography? ( Amoah, V; Cotton, JM; Curzen, N; Dunmore, S; Hobson, AR; Nevill, AM; Raghuraman, RP; Rajendra, R; Smallwood, A; Vickers, J; Worrall, AM, 2010) |
| "In the PLATO trial of ticagrelor versus clopidogrel for treatment of acute coronary syndromes, ticagrelor reduced the composite outcome of cardiovascular death, myocardial infarction, and stroke, but increased events of major bleeding related to non-coronary artery bypass graft (CABG)." | 7.76 | Effect of CYP2C19 and ABCB1 single nucleotide polymorphisms on outcomes of treatment with ticagrelor versus clopidogrel for acute coronary syndromes: a genetic substudy of the PLATO trial. ( Armstrong, M; Barratt, BJ; Becker, RC; Horrow, J; Husted, S; James, S; Katus, H; Shah, SH; Steg, PG; Storey, RF; Wallentin, L, 2010) |
| "to reveal the frequency of clopidogrel resistance in patients with acute coronary syndrome (ACS) and its impact on prognosis in these patients." | 7.76 | [Clopidogrel resistance in patients with acute coronary syndrome]. ( Dobrovol'skiĭ, AB; Frolova, NS; Ruda, MIa; Shakhnovich, RM; Sirotkina, OV, 2010) |
| "In patients presenting with ACS and receiving clopidogrel treatment after angiography (before or within 30 min of PCI), peri-procedural bivalirudin monotherapy suppresses acute and long-term adverse events to a similar extent as does UFH plus GP IIb/IIIa inhibitors, while significantly lowering the risk of bleeding complications." | 7.76 | Efficacy and safety of bivalirudin in patients receiving clopidogrel therapy after diagnostic angiography for percutaneous coronary intervention in acute coronary syndromes. ( Bergman, G; Feldman, DN; Minutello, RM; Moussa, I; Wong, SC, 2010) |
| "Current guidelines recommend dual antiplatelet therapy using aspirin and clopidogrel for non-ST elevation acute coronary syndromes (ACS)." | 7.75 | Efficacy and safety of prasugrel compared with clopidogrel in patients with acute coronary syndromes: results of TRITON-TIMI 38 trials. ( De Servi, S; Mariani, G; Mariani, M, 2009) |
| "To assess the prognosis of patients presenting with an acute coronary syndrome (ACS) despite chronic clopidogrel therapy (CCT)." | 7.75 | Prognosis of patients suffering an acute coronary syndrome while already under chronic clopidogrel therapy. ( Bonello, L; De Labriolle, A; Kent, KM; Lemesle, G; Pichard, AD; Roy, P; Satler, LF; Steinberg, DH; Suddath, WO; Torguson, R; Waksman, R, 2009) |
| " The objective of this study is to assess the relationship between response to clopidogrel and post-treatment platelet reactivity (PPR) and 1-year major adverse cardiovascular events (MACE) in patients with non-ST segment elevation acute coronary syndrome (NSTEACS)." | 7.75 | Post-treatment platelet reactivity predicts long-term adverse events better than the response to clopidogrel in patients with non-ST-segment elevation acute coronary syndrome. ( Alonso Orcajo, N; Alonso Rodríguez, D; Carbonell de Blas, R; Cuellas Ramón, C; de Miguel Castro, A; Diego Nieto, A; Fernández Vázquez, F; Pascual Vicente, C; Pérez de Prado, A; Samaniego Lampón, B, 2009) |
| "To assess outcomes of patients taking clopidogrel with or without a proton pump inhibitor (PPI) after hospitalization for acute coronary syndrome (ACS)." | 7.75 | Risk of adverse outcomes associated with concomitant use of clopidogrel and proton pump inhibitors following acute coronary syndrome. ( Fihn, SD; Ho, PM; Jesse, RL; Maddox, TM; Peterson, ED; Rumsfeld, JS; Wang, L, 2009) |
| "Randomized trials have established efficacy of clopidogrel in various types of acute coronary syndromes (ACS)." | 7.75 | Temporal trends and patterns of early clopidogrel use across the spectrum of acute coronary syndromes. ( DeYoung, JP; Fox, KA; Gallo, R; Goodman, SG; Gore, JM; Grondin, FR; Rao, RV; Rose, B; Spencer, FA; Yan, AT; Yan, RT, 2009) |
| " The present study was designed to assess the predictive value of adenosine diphosphate (ADP)-induced platelet aggregation (ADP-Ag) and the Platelet Reactivity Index of vasodilator-stimulated phosphoprotein for the occurrence of stent thrombosis in patients admitted for non-ST-elevation acute coronary syndrome undergoing percutaneous coronary intervention." | 7.75 | Predictive values of post-treatment adenosine diphosphate-induced aggregation and vasodilator-stimulated phosphoprotein index for stent thrombosis after acute coronary syndrome in clopidogrel-treated patients. ( Alessi, MC; Bali, L; Bonnet, JL; Castelli, C; Cuisset, T; Frere, C; Gaborit, B; Morange, PE; Poyet, R; Quilici, J, 2009) |
| "There are limited contemporary data on the early use of clopidogrel or glycoprotein (Gp) IIb/IIIa inhibitors, alone versus combination therapies, in non-ST-elevation acute coronary syndrome (NSTE-ACS)." | 7.75 | Underutilization of clopidogrel and glycoprotein IIb/IIIa inhibitors in non-ST-elevation acute coronary syndrome patients: the Canadian global registry of acute coronary events (GRACE) experience. ( Banihashemi, B; Goodman, SG; Gyenes, G; Kornder, JM; Mehta, SR; Montalescot, G; Steg, PG; Welsh, RC; Wong, GC; Yan, AT; Yan, RT, 2009) |
| "To observe and assess the effect of different dosages of aspirin on inflammatory biomarkers, hemorheology (platelet aggregation rate) and clinical prognosis in patients with acute coronary syndrome (ACS)." | 7.75 | [The effect of different dosage of aspirin on inflammatory biomarkers and prognosis in acute coronary syndrome.]. ( Hu, DY; Li, RJ; Liang, YQ; Ren, WL; Song, LF; Xu, YY; Yin, ZN, 2009) |
| "635 Non ST Elevation Acute Coronary Syndrome (NSTE ACS) patients were included and received loading doses of 250 mg aspirin and 600 mg clopidogrel." | 7.75 | Relationship between aspirin and clopidogrel responses in acute coronary syndrome and clinical predictors of non response. ( Alessi, MC; Bali, L; Bonnet, JL; Camoin, L; Cuisset, T; Frere, C; Juhan-Vague, I; Lambert, M; Morange, PE; Quilici, J, 2009) |
| "The purpose of our multicenter study was to examine the impact of pre-operative administration of clopidogrel on reoperation rates, incidence of life-threatening bleeding, inpatient length of stay, and other bleeding-related outcomes in acute coronary syndrome (ACS) patients requiring cardiopulmonary bypass (coronary artery bypass graft surgery [CABG]) in a broad cross section of U." | 7.74 | Impact of clopidogrel in patients with acute coronary syndromes requiring coronary artery bypass surgery: a multicenter analysis. ( Becker, RC; Berger, JS; Edwards, FH; Frye, CB; Harshaw, Q; Steinhubl, SR, 2008) |
| "Patients with acute coronary syndrome without ST-segment elevation receiving clopidogrel in addition to acetylsalicylic acid (ASA) showed a 20% risk reduction in comparison to patients receiving ASA monotherapy (CURE trial)." | 7.74 | Long-term cost-effectiveness of clopidogrel in patients with acute coronary syndrome without ST-segment elevation in Germany. ( Brüggenjürgen, B; Ehlken, B; Lindgren, P; Rupprecht, HJ; Willich, SN, 2007) |
| "This study sought to assess whether patients with acute coronary syndromes (ACS) undergoing PCI would receive additional benefit from higher-than-standard (300 mg) loading doses of clopidogrel." | 7.74 | Clopidogrel loading doses and outcomes of patients undergoing percutaneous coronary intervention for acute coronary syndromes. ( Bae, JP; Griffin, B; He, J; Kereiakes, DJ; McCollam, P; Wang, C, 2007) |
| "The combination of aspirin, clopidogrel, and enoxaparin (combination therapy) is the standard treatment for acute coronary syndrome but is associated with gastrointestinal bleeding." | 7.74 | Gastrointestinal bleeding in patients receiving a combination of aspirin, clopidogrel, and enoxaparin in acute coronary syndrome. ( Chang, CM; Chu, WM; Lam, KF; Lau, YK; Ng, FH; Wong, BC; Wong, SY, 2008) |
| "Rate of all-cause mortality or acute myocardial infarction (AMI) after stopping treatment with clopidogrel." | 7.74 | Incidence of death and acute myocardial infarction associated with stopping clopidogrel after acute coronary syndrome. ( Fihn, SD; Ho, PM; Jesse, RA; Larsen, GC; Magid, DJ; Peterson, ED; Rumsfeld, JS; Wang, L, 2008) |
| "Preoperative continuous administration of clopidogrel did not increase the risk of hemorrhagic complications in patients with acute coronary syndrome undergoing isolated off-pump coronary artery bypass surgery." | 7.74 | Effects of continuous administration of clopidogrel before off-pump coronary artery bypass grafting in patients with acute coronary syndrome. ( Lee, S; Song, SW; Yi, G; Yoo, KJ; Youn, YN, 2008) |
| " This study was conducted to analyze, in 603 patients with non-ST elevation acute coronary syndromes, the effect of CYP3A4, CYP3A5, and CYP2C19 gene polymorphisms on clopidogrel response and post-treatment platelet reactivity assessed by adenosine diphosphate (ADP)-induced platelet aggregation, vasodilator-stimulated phosphoprotein phosphorylation index, and ADP-induced P-selectin expression." | 7.74 | Effect of cytochrome p450 polymorphisms on platelet reactivity after treatment with clopidogrel in acute coronary syndrome. ( Alessi, MC; Bonnet, JL; Camoin-Jau, L; Cuisset, T; Faille, D; Frere, C; Juhan-Vague, I; Lambert, M; Morange, PE; Quilici, J; Saut, N, 2008) |
| " The primary efficacy endpoint was the incidence of major adverse cardiovascular events (MACE) at 24 weeks, defined as a composite of cardiovascular death, nonfatal myocardial infarction, and nonfatal ischemic stroke." | 6.79 | Efficacy and safety of adjusted-dose prasugrel compared with clopidogrel in Japanese patients with acute coronary syndrome: the PRASFIT-ACS study. ( Isshiki, T; Kimura, T; Kitagawa, K; Miyazaki, S; Nakamura, M; Nanto, S; Nishikawa, M; Ogawa, H; Saito, S; Takayama, M; Yokoi, H, 2014) |
| "Fatal bleeding was low and did not differ between groups." | 6.76 | Bleeding complications with the P2Y12 receptor antagonists clopidogrel and ticagrelor in the PLATelet inhibition and patient Outcomes (PLATO) trial. ( Bassand, JP; Becker, RC; Budaj, A; Cornel, JH; French, J; Harrington, RA; Held, C; Horrow, J; Husted, S; James, SK; Lassila, R; Lopez-Sendon, J; Mahaffey, KW; Storey, RF; Wallentin, L; Wojdyla, DM, 2011) |
| "Cilostazol 100 mg b." | 6.75 | Effect of cilostazol on platelet aggregation in patients with non-ST elevation acute coronary syndrome. ( Ahluwalia, J; Bhalla, A; Malhotra, S; Pandhi, P; Pattanaik, S; Sharma, YP, 2010) |
| "Antiplatelet therapy is essential treatment for acute coronary syndromes (ACS)." | 6.74 | Comparison of ticagrelor, the first reversible oral P2Y(12) receptor antagonist, with clopidogrel in patients with acute coronary syndromes: Rationale, design, and baseline characteristics of the PLATelet inhibition and patient Outcomes (PLATO) trial. ( Akerblom, A; Becker, R; Cannon, CP; Emanuelsson, H; Harrington, R; Husted, S; James, S; Katus, H; Skene, A; Steg, PG; Storey, RF; Wallentin, L, 2009) |
| "Recurrent ischemic events occurred even during routine use of 75 mg clopidogrel in addition to aspirin, that indicated a potentially insufficient maintenance dosage of clopidogrel." | 6.74 | A high maintenance dose of clopidogrel improves short-term clinical outcomes in patients with acute coronary syndrome undergoing drug-eluting stent implantation. ( Han, YL; Jing, QM; Li, Y; Ma, YY; Wang, B; Wang, DM; Wang, G; Wang, SL; Wang, ZL; Xu, K, 2009) |
| " A review of data regarding aspirin use for secondary prevention of events in ACS demonstrated that low aspirin doses (75 to 160 mg/day) are consistently favored for short- and long-term use because of the lack of a dose-response relationship between increasing aspirin dose and improved efficacy, and a higher incidence of gastrointestinal bleeding with increasing aspirin dose." | 6.49 | Aspirin, clopidogrel, and ticagrelor in acute coronary syndromes. ( Berger, JS, 2013) |
| " Combined major adverse cardiovascular event (stroke, MI, and death) was not different in the two groups (OR 1." | 6.47 | Safety of clopidogrel being continued until the time of coronary artery bypass grafting in patients with acute coronary syndrome: a meta-analysis of 34 studies. ( Athanasiou, T; Malik, IS; Nijjer, SS; Watson, G, 2011) |
| " In the forth communication we consider data of randomized studies in which efficacy and safety of clopidogrel in combination with has acetylsalicylic acid (ASA) been assessed in comparison with (ASA) in various acute coronary syndromes (ACS), as well as before, during, and after percutaneous coronary interventions (PCI)." | 6.45 | [Thienopyridines in the treatment and prevention of cardiovascular diseases. Part IV. therapeutic application of clopidogrel in combination with acetylsalicylic acid in acute coronary syndromes and percutaneous coronary interventions]. ( Avsar, O; Batyraliev, TA; Fettser, DV; Islek, M; Preobrazhenskiĭ, DV; Sidorenko, BA; Vural, A, 2009) |
| " Coupled with the results from previous multicentre trials, these two studies provide a guide for the early and long-term use of clopidogrel in the whole spectrum of ACS." | 6.44 | Clinical use of clopidogrel in acute coronary syndrome. ( Chow, WH; Hwang, JJ; Javier, S; Kwok, OH; Mak, KH; Piyamitr, S; Suryawan, R; Tri Ho, HQ; Zambahari, R, 2007) |
| " Aspirin and the thienopyridines, clopidogrel, and ticlopidine, are the most widely used oral antiplatelet agents in patients with non-ST-segment elevation myocardial infarction undergoing percutaneous coronary intervention." | 6.24 | Antiplatelet therapy in percutaneous coronary intervention: integration of prasugrel into clinical practice. ( Giugliano, RP; Thomas, D, 2009) |
| " This modified dosage regimen has been established in studies conducted in Japan; however, the efficacy and safety of switching from clopidogrel to prasugrel DAPT among Taiwanese patients remain to be explored." | 5.72 | Prasugrel switching from clopidogrel after percutaneous coronary intervention for acute coronary syndrome in Taiwanese patients: an analysis of safety and efficacy. ( Cheng, LC; Chu, PH; Huang, CL; Kuo, FY; Lan, WR; Lee, CH; Lee, WL; Lin, WS; Liu, PY; Lo, PH; Lu, TM; Nikolajsen, C; Rafael, V; Su, CH; Tsukiyama, S; Wang, YC; Yang, WC; Yin, WH, 2022) |
| " We studied the platelet inhibitory effect of crushed clopidogrel in patients with acute coronary syndrome (ACS) and its relative efficacy compared with integral clopidogrel, crushed and integral ticagrelor." | 5.69 | Randomized, Double-Blind, Active Comparator Pharmacodynamic Study of Platelet Inhibition with Crushed and Integral Formulations of Clopidogrel and Ticagrelor in Acute Coronary Syndrome. ( Alex, AG; Attumalil, TV; Dave, RG; Geevar, T; George, P; Gowri, SM; Joseph, G; Mony, PK; Nair, SC; Perla, HT; Thomson, VS, 2023) |
| " The impact of LOF alleles on the pharmacodynamic response to half-dose prasugrel in patients with non-ST-elevation acute coronary syndrome (NSTE-ACS) undergoing percutaneous coronary intervention (PCI) is unknown." | 5.56 | Pharmacodynamic study of prasugrel or clopidogrel in non-ST-elevation acute coronary syndrome with CYP2C19 genetic variants undergoing percutaneous coronary intervention (PRAISE-GENE trial). ( Ann, SH; Cho, YR; Guo, LZ; Jin, C; Jin, E; Kim, MH; Kim, SJ; Lee, MS; Park, JS; Shin, ES, 2020) |
| "In patients undergoing drug-eluting stent implantation for non-complex lesions, the benefits of 1-month DAPT followed by aspirin monotherapy for a composite of ischaemic and bleeding outcomes were found in patients with stable CAD, but not in those with ACS." | 5.51 | Impact of one-month DAPT followed by aspirin monotherapy in patients undergoing percutaneous coronary intervention according to clinical presentation: a post hoc analysis of the randomised One-Month DAPT trial. ( Ahn, CM; Cho, JY; Choi, D; Hong, MK; Hong, SJ; Jang, Y; Kim, BK; Kim, JS; Ko, YG; Lee, SJ; Lee, YJ; Yun, KH, 2022) |
| " However, a substantial number of patients do not respond to clopidogrel despite a standardized dosage regimen, and this is directly associated with poor prognosis." | 5.46 | Effects of four novel genetic polymorphisms on clopidogrel efficacy in Chinese acute coronary syndromes patients. ( Cao, S; Chen, BL; Fan, L; Liu, M; Liu, ZQ; Xiao, FY; Zhang, W; Zhou, G; Zhou, HH, 2017) |
| "Aspirin has been regarded as the drug of first choice in the prevention of thromboembolic diseases." | 5.46 | Evidences about combination use of acetylsalicylic acid (aspirin) and clopidogrel in acute coronary syndrome. ( Velázquez de Campos, O, 2017) |
| "The primary end point was recurrence of ACS or death >30days after the index event." | 5.46 | Clopidogrel, prasugrel, or ticagrelor use and clinical outcome in patients with acute coronary syndrome: A nationwide long-term registry analysis from 2009 to 2014. ( Geroldinger, A; Heinze, G; Reichardt, B; Sheikh Rezaei, S; Wolzt, M, 2017) |
| "7, p NS], and in adverse cardiac or cerebrovascular events (MACCE) (5 vs." | 5.42 | Safety and efficacy of in-hospital clopidogrel-to-prasugrel switching in patients with acute coronary syndrome. An analysis from the 'real world'. ( Almendro-Delia, M; Blanco Ponce, E; Caballero-Garcia, A; Cruz-Fernandez, MJ; Garcia-Rubira, JC; Gomez-Domínguez, R; Gonzalez-Matos, C; Hidalgo-Urbano, R; Lobo-Gonzalez, M, 2015) |
| "Kounis syndrome is the concurrence of acute coronary syndrome with allergic reactions, such as anaphylaxis or anaphylactoid reactions." | 5.42 | An Extraordinary Case Associated with an Allergic Reaction to Clopidogrel: Coronary Artery Spasm or Kounis Syndrome? ( Bin, H; Liping, Z; Qiming, F, 2015) |
| " However, it is unclear whether antiplatelet monotherapy with ticagrelor alone versus ticagrelor plus aspirin reduces the incidence of clinically relevant bleeding without increasing the risk of major adverse cardiovascular and cerebrovascular events (MACCEs) in ACS patients undergoing percutaneous coronary intervention (PCI) with DES implantation guided by either intravascular ultrasound (IVUS) or angiography who have completed a 1-month course of DAPT with aspirin plus ticagrelor." | 5.41 | Comparison of one-month versus twelve-month dual antiplatelet therapy after implantation of drug-eluting stents guided by either intravascular ultrasound or angiography in patients with acute coronary syndrome: rationale and design of prospective, multice ( Chen, F; Chen, SL; Gao, DS; Gao, XF; Ge, Z; Han, YL; He, YQ; Kan, J; Kong, XQ; Li, F; Lin, S; Liu, ZZ; Qian, XS; Qu, H; Shao, YB; Tao, L; Tian, NL; Wang, Y; Wang, ZZ; Wen, SY; Xia, Y; Xiao, PX; Yang, Q; Yang, S; Ye, F; Zeng, HS; Zhang, JJ; Zuo, GF, 2021) |
| "Discontinuing aspirin after short-term dual antiplatelet therapy (DAPT) was evaluated as a bleeding reduction strategy." | 5.34 | Effect of Ticagrelor Monotherapy vs Ticagrelor With Aspirin on Major Bleeding and Cardiovascular Events in Patients With Acute Coronary Syndrome: The TICO Randomized Clinical Trial. ( Ahn, CM; Cho, DK; Cho, JY; Cho, S; Cho, YH; Choi, D; Her, AY; Hong, BK; Hong, MK; Hong, SJ; Jang, Y; Jeon, DW; Kim, BK; Kim, JS; Kim, YH; Ko, YG; Kwon, H; Nam, CM; Shin, DH; Suh, Y; Yoo, SY; Yun, KH, 2020) |
| "Clopidogrel is used to pretreat patients with non-ST elevation acute coronary syndromes (NSTE-ACS), but prasugrel provides better platelet inhibition with improved outcome." | 5.27 | Switching from clopidogrel to prasugrel to protect early invasive treatment in acute coronary syndromes: Results of the switch over trial. ( Attanasio, C; Caravita, L; Cattaneo, M; Femia, EA; Galvani, M; Ottani, F, 2018) |
| "Current guidelines recommend dual antiplatelet therapy (DAPT) of aspirin plus a P2Y12 inhibitor for at least 12 months after implantation of drug-eluting stents (DES) in patients with acute coronary syndrome." | 5.27 | 6-month versus 12-month or longer dual antiplatelet therapy after percutaneous coronary intervention in patients with acute coronary syndrome (SMART-DATE): a randomised, open-label, non-inferiority trial. ( Bae, JH; Cho, DK; Cho, JH; Choi, JH; Choi, KH; Choi, SH; Choi, WG; Doh, JH; Gwon, HC; Hahn, JY; Jeong, JO; Kim, BO; Kim, DI; Kim, J; Kim, SH; Lee, JB; Lee, JM; Lee, WS; Oh, JH; Park, HK; Park, JS; Park, TK; Song, YB; Suh, IW; Yang, JH, 2018) |
| "The purpose of this study was to test whether different results between Cangrelor versus standard therapy to acHieve optimal Management of Platelet InhibitiON (CHAMPION) PCI/PLATFORM and PHOENIX trials are due in part to different definitions of percutaneous coronary intervention (PCI)-related myocardial infarction (MI)." | 5.27 | Implications of different criteria for percutaneous coronary intervention-related myocardial infarction on study results of three large phase III clinical trials: The CHAMPION experience. ( Abnousi, F; Bhatt, DL; Gibson, CM; Hamm, CW; Harrington, RA; Leonardi, S; Lopes, RD; Mahaffey, KW; Mangum, S; Menozzi, A; Prats, J; Price, MJ; Steg, PG; Stone, GW; Todd, M; White, HD; Wilson, M, 2018) |
| "A dual pathway antithrombotic therapy approach combining low-dose rivaroxaban with a P2Y12 inhibitor for the treatment of patients with acute coronary syndromes had similar risk of clinically significant bleeding as aspirin and a P2Y12 inhibitor." | 5.24 | Clinically significant bleeding with low-dose rivaroxaban versus aspirin, in addition to P2Y12 inhibition, in acute coronary syndromes (GEMINI-ACS-1): a double-blind, multicentre, randomised trial. ( Ardissino, D; Bahit, MC; Bode, C; Bueno, H; Claeys, MJ; Cornel, JH; Gibson, CM; Goto, S; Güray, Ü; Husted, S; James, SK; Kiss, RG; Montalescot, G; Mundl, H; Nicolau, JC; Ohman, EM; Park, DW; Plotnikov, A; Povsic, TJ; Rockhold, F; Roe, MT; Steg, PG; Strony, J; Sun, X; Tendera, M; Welsh, RC; White, J, 2017) |
| "In 6763 medically managed non-ST-segment elevation ACS patients randomized in TRILOGY ACS (Targeted Platelet Inhibition to Clarify the Optimal Strategy to Medically Manage Acute Coronary Syndromes) (prasugrel versus clopidogrel), we examined relationships between categories of peak troponin/upper limit of normal (ULN) ratio within 48 hours of the index ACS event (≈4." | 5.24 | Relationship Between Peak Troponin Values and Long-Term Ischemic Events Among Medically Managed Patients With Acute Coronary Syndromes. ( Brown, EB; Cyr, DD; Goldstein, SA; Hamm, CW; Lüscher, TF; Neely, M; Newby, LK; Ohman, EM; Roe, MT; White, HD, 2017) |
| "Newer P2Y12 blockers (prasugrel and ticagrelor) demonstrated significant ischaemic benefit over clopidogrel after acute coronary syndrome (ACS)." | 5.24 | Benefit of switching dual antiplatelet therapy after acute coronary syndrome: the TOPIC (timing of platelet inhibition after acute coronary syndrome) randomized study. ( Alessi, MC; Bassez, C; Bonnet, G; Bonnet, JL; Cuisset, T; Deffarges, S; Deharo, P; Fourcade, L; Johnson, TW; Lambert, M; Morange, PE; Mouret, JP; Quilici, J; Verdier, V, 2017) |
| "In patients with ischemic heart disease and type 2 diabetes mellitus in 4-6 weeks after acute coronary syndrome (ACS) on stable dual antiplatelet therapy (DAPT) with aspirin and clopidogrel co-adminstrated with rosuvastatin residual platelet reactivity on adenosine diphosphate was higher than in patients receiving atorvastatin." | 5.24 | [IMPACT OF ATORVASTATIN AND ROSUVASTATIN ON RESIDUAL ON-CLOPIDOGREL TREATMENT PLATELET REACTIVITY IN PATIENTS WITH ISCHEMIC HEART DISEASE AND TYPE 2 DIABETES MELLITUS AFTER ACUTE CORONARY SYNDROME]. ( Kochubiei, O; Ovrakh, T; Serik, S, 2017) |
| "The PLATelet inhibition and patient Outcomes (PLATO) trial showed that treatment with ticagrelor reduced the rate of death due to vascular causes, myocardial infarction and stroke when compared to clopidogrel in patients with ST-elevation or non-ST-elevation acute coronary syndrome (ACS)." | 5.24 | Platelet-related biomarkers and their response to inhibition with aspirin and p2y ( Angiolillo, DJ; Becker, RC; Cannon, CP; Himmelmann, A; Huber, K; James, SK; Katus, HA; Lowenstern, A; Morais, J; Neely, M; Siegbahn, A; Steg, PG; Storey, RF; Sun, JL; Wallentin, L, 2017) |
| " clopidogrel in acute coronary syndrome (ACS) was only evaluated using TRITON-TIMI 38 event rates." | 5.24 | Prasugrel vs. clopidogrel in contemporary Western European patients with acute coronary syndromes receiving drug-eluting stents: Comparative cost-effectiveness analysis from the BASKET-PROVE cohorts. ( Coslovsky, M; Galatius, S; Jabbari, R; Kaiser, C; Pfisterer, M; Wein, B, 2017) |
| " However, the greatest anti-ischaemic benefit of potent antiplatelet drugs over the less potent clopidogrel occurs early, while most excess bleeding events arise during chronic treatment." | 5.24 | Guided de-escalation of antiplatelet treatment in patients with acute coronary syndrome undergoing percutaneous coronary intervention (TROPICAL-ACS): a randomised, open-label, multicentre trial. ( Aradi, D; Dézsi, CA; Felix, SB; Geisler, T; Gross, L; Hadamitzky, M; Holdt, L; Huber, K; Huczek, Z; Jacobshagen, C; Kiss, RG; Klopotowski, M; Koltowski, L; Komócsi, A; Massberg, S; Mehilli, J; Merkely, B; Neumann, FJ; Orban, M; Parma, R; Rieber, J; Schwinger, RHG; Sibbing, D; Trenk, D, 2017) |
| "In smokers, a double-dose clopidogrel regimen reduced major cardiovascular events and stent thrombosis after percutaneous coronary intervention, with no increase in major bleeding." | 5.24 | Double-Dose Versus Standard-Dose Clopidogrel According to Smoking Status Among Patients With Acute Coronary Syndromes Undergoing Percutaneous Coronary Intervention. ( Bossard, M; Faxon, DP; Fox, KAA; Gao, P; Granger, CB; Jolly, SS; Mehta, SR; Montalescot, G; Natarajan, MK; Niemela, K; Steg, PG; Tanguay, JF; Widimsky, P; Yusuf, S, 2017) |
| "Enhanced clopidogrel responsiveness was associated with an increased risk of bleeding and entry-site complication." | 5.24 | The Prognostic Value of ADP-Induced Platelet Aggregation for Bleeding Complications in Low - Intermediate Risk Patients with Acute Coronary Syndrome Taking Clopidogrel After Percutaneous Coronary Intervention. ( Dong, T; Jin, L; Liao, H; Yan, H; Yu, H; Zhang, B; Zou, X, 2017) |
| "Thienopyridine plus aspirin beyond 1 year after coronary stenting reduces myocardial infarction (MI) risk and increases bleeding risk in comparison with aspirin alone." | 5.24 | Myocardial Infarction Risk After Discontinuation of Thienopyridine Therapy in the Randomized DAPT Study (Dual Antiplatelet Therapy). ( Cutlip, DE; D'Agostino, RB; Hsieh, WH; Kereiakes, DJ; Massaro, JM; Mauri, L; Stefanescu Schmidt, AC; Yeh, RW, 2017) |
| "The purpose of this study was to investigate outcomes of patients treated with prasugrel or clopidogrel after percutaneous coronary intervention (PCI) in a nationwide acute coronary syndrome (ACS) registry." | 5.22 | Comparison of prasugrel and clopidogrel-treated patients with acute coronary syndrome undergoing percutaneous coronary intervention: A propensity score-matched analysis of the Acute Myocardial Infarction in Switzerland (AMIS)-Plus Registry. ( Bernheim, AM; Eberli, FR; Erne, P; Kurz, DJ; Pedrazzini, G; Radovanovic, D; Roffi, M; Seifert, B; Windecker, S, 2016) |
| "The TaRgeted platelet Inhibition to cLarify the Optimal strateGy to medicallY manage Acute Coronary Syndromes (TRILOGY ACS) trial randomized 9326 patients planned for medical management to prasugrel or clopidogrel." | 5.22 | Frailty is associated with worse outcomes in non-ST-segment elevation acute coronary syndromes: Insights from the TaRgeted platelet Inhibition to cLarify the Optimal strateGy to medicallY manage Acute Coronary Syndromes (TRILOGY ACS) trial. ( Alexander, KP; Armstrong, PW; Cyr, DD; Fox, KA; Hochman, JS; Ohman, EM; Prabhakaran, D; Roe, MT; Westerhout, CM; White, HD; Winters, KJ, 2016) |
| "We examined the effects of cytochrome P450 2C19 (CYP2C19) polymorphisms on the efficacy and safety of prasugrel and clopidogrel in a post hoc analysis of the PRASugrel compared with clopidogrel For Japanese patIenTs with acute coronary syndrome (ACS) undergoing percutaneous coronary intervention (PCI) (PRASFIT-ACS) study." | 5.22 | Effects of CYP2C19 allelic variants on inhibition of platelet aggregation and major adverse cardiovascular events in Japanese patients with acute coronary syndrome: The PRASFIT-ACS study. ( Ikeda, Y; Isshiki, T; Kimura, T; Kitagawa, K; Miyazaki, S; Nakamura, M; Nanto, S; Nishikawa, M; Ogawa, H; Saito, S; Takayama, M; Tanaka, Y; Yokoi, H, 2016) |
| "The Targeted Platelet Inhibition to Clarify the Optimal Strategy to Medically Manage Acute Coronary Syndromes trial enrolled 9326 participants with ACS, who received aspirin plus clopidogrel or prasugrel." | 5.22 | Ascertainment, classification, and impact of neoplasm detection during prolonged treatment with dual antiplatelet therapy with prasugrel vs. clopidogrel following acute coronary syndrome. ( Armstrong, PW; Beaven, AW; Blackwell, KL; Cyr, DD; Eckart, D; Fox, KA; Houterloot, L; Morse, MA; Ohman, EM; Onken, JE; Prabhakaran, D; Ready, NE; Roe, MT; Schulte, PJ; Strickler, JH; White, HD; Winters, KJ; Wiviott, SD; Zafar, SY; Zamoryakhin, D, 2016) |
| "We analyzed data from the randomized TRILOGY ACS (TaRgeted platelet Inhibition to cLarify the Optimal strateGy to medically manage Acute Coronary Syndromes) trial of aspirin plus prasugrel or clopidogrel following ACS." | 5.22 | Spontaneous MI After Non-ST-Segment Elevation Acute Coronary Syndrome Managed Without Revascularization: The TRILOGY ACS Trial. ( Ardissino, D; Armstrong, PW; Bhatt, DL; Fox, KA; Goodman, SG; Hamm, CW; Leonardi, S; Lopes, RD; Martinez, F; Neely, B; Neely, ML; Nicolau, JC; Ohman, EM; Prabhakaran, D; Roe, MT; White, HD; Winters, KJ, 2016) |
| "Dual antiplatelet therapy (DAPT), the combination of aspirin and a P2Y12 inhibitor, given for 12 months remains the standard of care after presentation with acute coronary syndrome (ACS) because it has been shown to be associated with a significant reduction in ischemic events compared with aspirin monotherapy." | 5.22 | A randomized trial to compare the safety of rivaroxaban vs aspirin in addition to either clopidogrel or ticagrelor in acute coronary syndrome: The design of the GEMINI-ACS-1 phase II study. ( Bode, C; Gibson, CM; James, S; Mundl, H; Ohman, EM; Plotnikov, A; Povsic, TJ; Roe, MT; Steg, PG; Welsh, R, 2016) |
| "Medically managed patients with ACS in the Targeted Platelet Inhibition to Clarify the Optimal Strategy to Medically Manage Acute Coronary Syndromes (TRILOGY ACS) trial were randomised to clopidogrel versus prasugrel (plus aspirin), stratified by prior clopidogrel use." | 5.22 | Effect of prior clopidogrel use on outcomes in medically managed acute coronary syndrome patients. ( Armstrong, PW; Boden, WE; Chin, CT; Corbalán, R; Dalby, AJ; Fox, KA; Gottlieb, S; Leiva-Pons, JL; Neely, B; Neely, ML; Ohman, EM; Prabhakaran, D; Roe, MT; Schiele, F; White, HD; Winters, KJ, 2016) |
| " In contrast to overall PLATO results, but similar to PLATO-US cohort, PHILO revealed numerical inferiority of ticagrelor with regard to death, myocardial infarction, stroke, and bleeding over clopidogrel." | 5.22 | Inferiority of ticagrelor in the PHILO trial: Play of chance in East Asians or nightmare confirmation of PLATO-USA? ( Bekbossynova, M; Kim, MH; Pya, Y; Serebruany, VL; Tomek, A, 2016) |
| "This study suggests that impaired response to both intravenous and oral aspirin is frequent in comatose patients resuscitated from OHCA." | 5.22 | Impaired biological response to aspirin in therapeutic hypothermia comatose patients resuscitated from out-of-hospital cardiac arrest. ( Bal Dit Sollier, C; Deye, N; Dillinger, JG; Drouet, L; Henry, P; Llitjos, JF; Megarbane, B; Sideris, G; Voicu, S, 2016) |
| "Ticagrelor reduced cardiovascular events compared with clopidogrel in PLATO without increasing overall major bleeding." | 5.22 | Impact of glycoprotein IIb/IIIa inhibitors on the efficacy and safety of ticagrelor compared with clopidogrel in patients with acute coronary syndromes: Analysis from the Platelet Inhibition and Patient Outcomes (PLATO) Trial. ( Bansilal, S; Becker, RC; Cannon, CP; Harrington, RA; Himmelmann, A; Husted, S; James, SK; Katus, HA; Lopes, RD; Neely, B; Shimada, YJ; Steg, PG; Storey, RF; Wallentin, L; Wiviott, SD, 2016) |
| "Eighty-three acute coronary syndrome (ACS) patients undergoing percutaneous coronary intervention (PCI) with planned GPI use were randomized to receive high-dose bolus tirofiban, double-bolus eptifibatide, or abciximab followed by a 12-hour infusion." | 5.22 | A randomized trial assessing the impact of three different glycoprotein IIb/IIIa antagonists on glycoprotein IIb/IIIa platelet receptor inhibition and clinical endpoints in patients with acute coronary syndromes. ( French, JK; Gupta, R; Holmes, LE; Juergens, CP; Luu, J; Rajendran, S, 2016) |
| "Policosanol reduced platelet reactivity to a similar extent as high maintenance dose of clopidogrel without increasing bleeding rate." | 5.22 | Safety and efficacy of policosanol in patients with high on-treatment platelet reactivity after drug-eluting stent implantation: two-year follow-up results. ( Guo, L; Han, Y; Li, Y; Liu, X; Wang, X; Wang, Y; Xu, K; Zang, H; Zhao, W, 2016) |
| "There are a number of economic evaluation studies of clopidogrel for patients with non-ST-segment elevation acute coronary syndrome (NSTEACS) published from the perspective of multiple countries in recent years." | 5.22 | A Cost-Effectiveness Analysis of Clopidogrel for Patients with Non-ST-Segment Elevation Acute Coronary Syndrome in China. ( Chen, C; Chen, EZ; Cui, M; Tan, SC; Tu, CC; Wang, XL, 2016) |
| "The CHAMPION PHOENIX (A Clinical Trial Comparing Cangrelor to Clopidogrel Standard Therapy in Subjects Who Require Percutaneous Coronary Intervention) trial demonstrated that cangrelor significantly reduced periprocedural ischemic events in all-comer percutaneous coronary intervention with a modest increase in mild and moderate bleeding." | 5.22 | Efficacy and Safety of Cangrelor in Preventing Periprocedural Complications in Patients With Stable Angina and Acute Coronary Syndromes Undergoing Percutaneous Coronary Intervention: The CHAMPION PHOENIX Trial. ( Abnousi, F; Abtan, J; Bhatt, DL; Deliargyris, EN; Gibson, CM; Hamm, CW; Harrington, RA; Mahaffey, KW; Prats, J; Price, MJ; Steg, PG; Stone, GW; White, HD, 2016) |
| "Simultaneous prescription of clopidogrel and low-dose aspirin is recommended for the treatment of acute coronary syndrome because of improvements in efficacy and patient compliance." | 5.22 | Pharmacokinetics and relative bioavailability of fixed-dose combination of clopidogrel and aspirin versus coadministration of individual formulations in healthy Korean men. ( Choi, HK; Choi, YK; Ghim, JL; Jung, JA; Shon, J, 2016) |
| "The Elderly-ACS 2 study is a multicenter, randomized, parallel-group, open-label trial designed to demonstrate the superiority of a strategy of dual antiplatelet treatment using a reduced 5-mg daily dose of prasugrel over a standard strategy with a daily clopidogrel dose of 75mg in patients older than 74years with ACS (either ST- or non-ST-elevation myocardial infarction) undergoing early percutaneous revascularization." | 5.22 | A comparison of reduced-dose prasugrel and standard-dose clopidogrel in elderly patients with acute coronary syndromes undergoing early percutaneous revascularization: Design and rationale of the randomized Elderly-ACS 2 study. ( Bossi, I; Cacucci, M; Cavallini, C; Corrada, E; De Servi, S; Di Ascenzo, L; Ferrario, M; Ferri, LA; Gandolfo, N; Grosseto, D; Mariani, M; Moffa, N; Morici, N; Petronio, AS; Ravera, A; Savonitto, S; Sganzerla, P; Sibilio, G; Tondi, S; Tortorella, G; Toso, A, 2016) |
| "BACKGROUND The aim of this study was to observe the effects of genetic polymorphism of CYP2C19 on inhibitory effects of ticagrelor (Tic) and clopidogrel (Clo) towards post-percutaneous coronary intervention (PCI) platelet aggregation (IPA) and major cardiovascular events (MACE) in patients with acute coronary syndromes (ACS)." | 5.22 | Genetic Polymorphism of CYP2C19 and Inhibitory Effects of Ticagrelor and Clopidogrel Towards Post-Percutaneous Coronary Intervention (PCI) Platelet Aggregation in Patients with Acute Coronary Syndromes. ( Bian, S; Dong, P; Yang, X, 2016) |
| "To explore the effect of Shexiang baoxin pills on clopidogrel resistance in patients with acute coronary syndrome (ACS)." | 5.22 | Effect of Shexiang baoxin pills on clopidogrel resistance in patients with acute coronary syndrome. ( Liu, N; Zhang, H; Zhang, J; Zhang, L, 2016) |
| "PLATO (n = 18,624) was a multicentre, double-blind, randomized trial in ACS, that showed a 16% reduction in cardiovascular death (CV-death), myocardial infarction (MI) and stroke with ticagrelor compared with clopidogrel, without significant increase in overall major bleeding." | 5.20 | Cardiovascular events in acute coronary syndrome patients with peripheral arterial disease treated with ticagrelor compared with clopidogrel: Data from the PLATO Trial. ( Becker, RC; Emanuelsson, H; Hiatt, WR; Horrow, J; Husted, S; James, SK; Mahaffey, KW; Patel, MR; Steg, PG; Storey, RF; Wallentin, L; Wojdyla, DM, 2015) |
| "Dual antiplatelet treatment (DAPT) with clopidogrel and aspirin represents common approach in prevention of thromboembolic events in patients with acute coronary syndrome undergoing percutaneous coronary intervention (PCI)." | 5.20 | Monitoring the efficacy of ADP inhibitor treatment in patients with acute STEMI post-PCI by VASP-P flow cytometry assay. ( Duraj, L; Fedor, M; Fedorová, J; Kovář, F; Kubisz, P; Mokáň, M; Samoš, M; Šimonová, R; Škorňová, I; Staško, J, 2015) |
| "MULTIPRAC demonstrated a steady increase in prasugrel use over time without an increase in bleeding rates compared to clopidogrel." | 5.20 | MULTInational non-interventional study of patients with ST-segment elevation myocardial infarction treated with PRimary Angioplasty and Concomitant use of upstream antiplatelet therapy with prasugrel or clopidogrel--the European MULTIPRAC Registry. ( Clemmensen, P; Danchin, N; Goedicke, J; Goldstein, P; Grieco, N; Ince, H; Ramos, Y; Schmitt, J, 2015) |
| "To investigate the cost effectiveness of ticagrelor versus clopidogrel in patients with acute coronary syndromes (ACS) in the Platelet Inhibition and Patient Outcomes (PLATO) study who were scheduled for non-invasive management." | 5.20 | Health economic analysis of ticagrelor in patients with acute coronary syndromes intended for non-invasive therapy. ( Cannon, CP; Henriksson, M; James, S; Janzon, M; Mellström, C; Nicolau, JC; Storey, RF; Wallentin, L, 2015) |
| "The aim of this study was the identification of the optimal cutoff value of high residual platelet reactivity (HRPR) assessed by light transmission aggregometry (LTA) in the responsiveness to clopidogrel and stent thrombosis 2-acute coronary syndrome (RECLOSE 2-ACS) patient cohort to discriminate patients with and without major adverse cardiac events (MACE) and cardiac death at 2 years." | 5.20 | Residual platelet reactivity to predict long-term clinical outcomes after clopidogrel loading in patients with acute coronary syndromes: comparison of different cutoff values by light transmission aggregometry from the responsiveness to clopidogrel and st ( Abbate, R; Antoniucci, D; Cantini, G; Capodanno, D; Carrabba, N; De Luca, G; Gensini, GF; Giusti, B; Gori, AM; Marcucci, R; Marrani, M; Migliorini, A; Paniccia, R; Parodi, G; Valenti, R, 2015) |
| "401 acute coronary syndrome (ACS) patients received either a 300 mg loading dose following 75 mg maintenance dose daily or a 75mg maintenance dose daily of clopidogrel." | 5.20 | Genetic polymorphisms of CYP2C19 2 and ABCB1 C3435T affect the pharmacokinetic and pharmacodynamic responses to clopidogrel in 401 patients with acute coronary syndrome. ( Hu, ZL; Huang, XH; Li, J; Shen, CL; Wang, BN; Wang, XQ, 2015) |
| "In the PLATO trial, ticagrelor was superior to clopidogrel in reducing cardiovascular events among patients with acute coronary syndrome (ACS) at the expense of increased nonfatal bleeding." | 5.20 | Ticagrelor versus clopidogrel in Asian patients with acute coronary syndrome: A retrospective analysis from the Platelet Inhibition and Patient Outcomes (PLATO) Trial. ( Becker, RC; Clare, RM; Gao, R; Held, C; Himmelmann, A; James, SK; Kang, HJ; Lim, ST; Santoso, A; Wallentin, L; Yu, CM, 2015) |
| "Prasugrel is more effective than clopidogrel in reducing platelet aggregation in acute coronary syndromes." | 5.20 | High Platelet Reactivity in Patients with Acute Coronary Syndromes Undergoing Percutaneous Coronary Intervention: Randomised Controlled Trial Comparing Prasugrel and Clopidogrel. ( Banya, W; Booth, J; Dalby, M; Davidson, SJ; Droppa, M; Flather, M; Gawaz, M; Geisler, T; Karathanos, A; Müller, K; Stables, RH; Tavlaki, E; Yanez-Lopez, M; Zaman, A, 2015) |
| "Few data on the relative efficacy and safety of new P2Y12inhibitors such as prasugrel and ticagrelor in Japanese, Taiwanese and South Korean patients with acute coronary syndromes (ACS) exist." | 5.20 | Ticagrelor vs. clopidogrel in Japanese, Korean and Taiwanese patients with acute coronary syndrome -- randomized, double-blind, phase III PHILO study. ( Emanuelsson, H; Goto, S; Huang, CH; Kimura, T; Park, SJ, 2015) |
| "Previous studies evaluating correlates of stent thrombosis (ST) have included mostly patients with bare metal stents and early-generation drug-eluting stents (DES) and have not systematically evaluated the role of intravascular ultrasound-guided stenting and high platelet reactivity on clopidogrel." | 5.20 | Fixed and Modifiable Correlates of Drug-Eluting Stent Thrombosis From a Large All-Comers Registry: Insights From ADAPT-DES. ( Brodie, BR; Garg, A; Kirtane, AJ; Maehara, A; Mehran, R; Metzger, DC; Neumann, FJ; Parvataneni, R; Rinaldi, MJ; Stone, GW; Stuckey, TD; Weisz, G; Witzenbichler, B, 2015) |
| " In the Platelet Inhibition and Patient Outcomes (PLATO) trial, ticagrelor versus clopidogrel reduced the primary endpoint of death from vascular causes, myocardial infarction, or stroke after ACS, but increased the incidence of dyspnea, which may lead clinicians to withhold ticagrelor from COPD patients." | 5.20 | Ticagrelor Versus Clopidogrel in Patients With Acute Coronary Syndromes and Chronic Obstructive Pulmonary Disease: An Analysis From the Platelet Inhibition and Patient Outcomes (PLATO) Trial. ( Andell, P; Cannon, CP; Cyr, DD; Erlinge, D; Himmelmann, A; Husted, S; James, SK; Keltai, M; Koul, S; Santoso, A; Steg, PG; Storey, RF; Wallentin, L, 2015) |
| "Dual antiplatelet therapy with acetylsalicylic acid in combination with a more potent P2Y12- inhibitor (ticagrelor or prasugrel) is recommended in patients with acute coronary syndrome without ST-segment elevation (NSTE-ACS) to prevent atherothrombotic complications." | 5.20 | Ticagrelor or prasugrel versus clopidogrel in elderly patients with an acute coronary syndrome: Optimization of antiplatelet treatment in patients 70 years and older--rationale and design of the POPular AGE study. ( Bergmeijer, TO; de Boer, MJ; de Vrey, E; Deneer, VH; Groenemeijer, BE; Heestermans, AA; Ishak, M; Janssen, PW; Jukema, JW; Kelder, JC; Qaderdan, K; ten Berg, JM; van't Hof, AW; Vos, GJ; Voskuil, M, 2015) |
| "In the Antagonize P2Y12 Treatment Inhibitors by Transfusion of Platelets in an Urgent or Delayed Timing After Acute Coronary Syndrome or Percutaneous Coronary Intervention Presentation-Acute Coronary Syndrome (APTITUDE-ACS) study, patients presenting with acute coronary syndrome or for elective percutaneous coronary intervention, receiving loading doses of clopidogrel (600 mg, n=13 or 900 mg, n=12), prasugrel 60 mg (n=10), or ticagrelor 180 mg (n=10) were included." | 5.20 | Efficacy of ex vivo autologous and in vivo platelet transfusion in the reversal of P2Y12 inhibition by clopidogrel, prasugrel, and ticagrelor: the APTITUDE study. ( Abtan, J; Amour, J; Barthélémy, O; Brugier, D; Collet, JP; Kerneis, M; Leprince, P; Martin, R; Mercadier, A; Montalescot, G; O'Connor, SA; Silvain, J, 2015) |
| "Diabetic patients with an acute coronary syndrome undergoing percutaneous coronary intervention frequently exhibit high platelet reactivity while on clopidogrel." | 5.20 | VERifyNow in DIabetes high-on-treatment platelet reactivity: a pharmacodynamic study on switching from clopidogrel to prasugrel. ( Acosta Martínez, J; Cubero Gómez, JM; Díaz De La Llera, LS; Fernández-Quero, M; Guisado Rasco, A; Mendias Benítez, C; Sánchez González, Á; Villa Gil-Ortega, M, 2015) |
| "Dual antiplatelet therapy consisting of clopidogrel in addition to aspirin has previously been the standard of care for patients with acute coronary syndromes (ACS) but international guidelines have been evolving over the last 4 years with the introduction of prasugrel and ticagrelor." | 5.19 | Evolving pattern of platelet P2Y12 inhibition in patients with acute coronary syndromes. ( Ecob, R; Hossain, R; Joshi, RR; Judge, HM; Karunakaran, A; Morton, AC; Storey, RF; Wales, C; Walker, JV, 2014) |
| "The goal of this study was to determine whether there is a relationship between aspirin dose and the potent antiplatelet agent prasugrel in the TRITON-TIMI 38 (Trial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet Inhibition With Prasugrel-Thrombolysis In Myocardial Infarction 38) study." | 5.19 | Discharge aspirin dose and clinical outcomes in patients with acute coronary syndromes treated with prasugrel versus clopidogrel: an analysis from the TRITON-TIMI 38 study (trial to assess improvement in therapeutic outcomes by optimizing platelet inhibit ( Antman, EM; Braunwald, E; Cannon, CP; Kohli, P; Murphy, SA; Udell, JA; Wiviott, SD, 2014) |
| "This study aimed to investigate the impact of ticagrelor on adenosine plasma concentration (APC) in acute coronary syndrome (ACS) patients." | 5.19 | Ticagrelor increases adenosine plasma concentration in patients with an acute coronary syndrome. ( Bonello, L; Camoin-Jau, L; Condo, J; Dignat-George, F; Frere, C; Fromonot, J; Gariboldi, V; Guieu, R; Helal, O; Kipson, N; Laine, M; Mancini, J; Paganelli, F; Thuny, F, 2014) |
| "Ticagrelor outperforms clopidogrel in preventing cardiovascular events in acute coronary syndrome." | 5.19 | Administration of a loading dose has no additive effect on platelet aggregation during the switch from ongoing clopidogrel treatment to ticagrelor in patients with acute coronary syndrome. ( Caiazzo, G; De Rosa, S; Giampà, S; Gulletta, E; Indolfi, C; Micieli, M; Mongiardo, A; Palella, E; Spaccarotella, C; Torella, D, 2014) |
| "Ticagrelor reduces thrombotic events compared with clopidogrel in patients with acute coronary syndrome, but may also increase bleeding complications." | 5.19 | Coronary artery bypass grafting-related bleeding complications in real-life acute coronary syndrome patients treated with clopidogrel or ticagrelor. ( Albertsson, P; Dellborg, M; Hansson, EC; Jeppsson, A; Rexius, H, 2014) |
| "To evaluate the cost-effectiveness of treating patients with acute coronary syndromes (ACS) for 12 months with ticagrelor compared with generic clopidogrel in Sweden and Denmark." | 5.19 | Ticagrelor treatment in patients with acute coronary syndrome is cost-effective in Sweden and Denmark. ( Henriksson, M; Janzon, M; Nikolic, E; Ohna, A; Wallentin, L, 2014) |
| "The aim of this study was to assess the relationship between sex and clinical outcomes and treatment-related complications in patients with ST-elevation or non-ST-elevation acute coronary syndromes (ACS) randomized to treatment with ticagrelor or clopidogrel in the PLATelet inhibition and patient Outcomes (PLATO) trial." | 5.19 | The efficacy of ticagrelor is maintained in women with acute coronary syndromes participating in the prospective, randomized, PLATelet inhibition and patient Outcomes (PLATO) trial. ( Bach, RG; Becker, RC; Budaj, A; Heras, M; Himmelmann, A; Horrow, J; Husted, S; James, SK; Katus, HA; Lassila, R; Morais, J; Nicolau, JC; Steg, PG; Storey, RF; Wallentin, L; Wojdyla, D, 2014) |
| " The randomised, double-blind, TRIPLET trial included a pre-defined comparison of HPR in acute coronary syndrome (ACS) patients undergoing percutaneous coronary intervention (PCI) following a placebo/600-mg clopidogrel loading dose (LD) immediately before a subsequent prasugrel 60-mg or 30-mg LD." | 5.19 | Transferring from clopidogrel loading dose to prasugrel loading dose in acute coronary syndrome patients. High on-treatment platelet reactivity analysis of the TRIPLET trial. ( Angiolillo, DJ; Cardillo, TE; Diodati, JG; Duvvuru, S; Effron, MB; Fisher, HN; Henneges, C; Jakubowski, JA; Lipkin, FR; Saucedo, JF; Sundseth, SS; Walker, JR, 2014) |
| " clopidogrel in the non-ST-elevation acute coronary syndrome (NSTE-ACS) subgroup of the PLATO trial, in the total cohort, and in the subgroups managed with and without revascularization within 10 days of randomization." | 5.19 | Ticagrelor vs. clopidogrel in patients with non-ST-elevation acute coronary syndrome with or without revascularization: results from the PLATO trial. ( Cannon, CP; Cornel, JH; Harrington, RA; Himmelmann, A; Husted, S; James, SK; Lindholm, D; Maya, J; Steg, PG; Stevens, SR; Storey, RF; Varenhorst, C; Wallentin, L, 2014) |
| " clopidogrel in patients with acute coronary syndromes managed medically without revascularization." | 5.19 | Impact of smoking status on platelet function and clinical outcomes with prasugrel vs. clopidogrel in patients with acute coronary syndromes managed without revascularization: Insights from the TRILOGY ACS trial. ( Armstrong, PW; Clemmensen, P; Cornel, JH; Fox, KA; Gurbel, PA; Neely, B; Ohman, EM; Prabhakaran, D; Roe, MT; Sritara, P; White, HD; Zamoryakhin, D, 2014) |
| "To describe specific causes of death and evaluate whether bleeding events and infection contributed to mortality in all ticagrelor-treated and clopidogrel-treated patients with acute coronary syndromes." | 5.19 | Causes of mortality with ticagrelor compared with clopidogrel in acute coronary syndromes. ( Alström, U; Bertilsson, M; Braun, OÖ; Cannon, CP; Held, C; Himmelmann, A; James, SK; Mahaffey, KW; Scirica, BM; Storey, RF; Varenhorst, C; Wallentin, L, 2014) |
| "In TRITON-TIMI 38, patients with acute coronary syndromes were treated with prasugrel or clopidogrel, with aspirin, for a median of 14." | 5.19 | An analysis of TRITON-TIMI 38, based on the 12 month recommended length of therapy in the European label for prasugrel. ( Costigan, T; Iqbal, K; Lopez-Sendon, J; Ramos, Y; Widimsky, P; Wilcox, R, 2014) |
| "Patients with acute coronary syndrome (ACS) undergoing percutaneous coronary intervention (PCI) commonly receive a clopidogrel LD prior to angiography." | 5.19 | Switching patients from clopidogrel to prasugrel in acute coronary syndrome: impact of the clopidogrel loading dose on platelet reactivity. ( Chen, F; Drenning, D; Lhermusier, T; Lipinski, MJ; Marso, S; Torguson, R; Waksman, R, 2014) |
| "In the PRATO-ACS trial, 504 consecutive statin-naïve non-ST-elevation acute coronary syndrome patients scheduled for early invasive strategy and pretreated with high-dose clopidogrel were randomly assigned to rosuvastatin (40 mg on admission followed by 20 mg/d; statin group, n = 252) or no statin treatment (control group, n = 252)." | 5.19 | Early high-dose rosuvastatin and cardioprotection in the protective effect of rosuvastatin and antiplatelet therapy on contrast-induced acute kidney injury and myocardial damage in patients with acute coronary syndrome (PRATO-ACS) study. ( Badia, T; Bellandi, F; Leoncini, M; Maioli, M; Toso, A; Tropeano, F; Villani, S, 2014) |
| "We observed no interaction between vorapaxar and clopidogrel after non-ST-segment elevation acute coronary syndromes on efficacy or safety outcomes, supporting a complementary role of protease-activated receptor 1 and P2Y12 antagonism." | 5.19 | Vorapaxar with or without clopidogrel after non-ST-segment elevation acute coronary syndromes: results from the thrombin receptor antagonist for clinical event reduction in acute coronary syndrome trial. ( Armstrong, PW; Aylward, PE; Chen, E; Cornel, JH; Harrington, RA; Held, C; Huang, Z; Jennings, LK; Lokhnygina, Y; Mahaffey, KW; Moliterno, DJ; Strony, J; Tricoci, P; Van de Werf, F; Wallentin, L; White, HD, 2014) |
| "Clopidogrel is recommended in patients with acute coronary syndrome (ACS) managed with PCI, but its effect on PCI-related myonecrosis in contemporary patients has not been quantified." | 5.17 | Quantification of the effect of clopidogrel on enzymatic infarct size related to a percutaneous coronary intervention in patients with acute coronary syndromes: insights from the CHAMPION percutaneous coronary intervention trial. ( Bhatt, DL; Dauerman, HL; Gibson, CM; Goodman, SG; Gruberg, L; Herrmann, HC; Leonardi, S; Lincoff, AM; Lokhnygina, Y; Lopes, RD; Mahaffey, KW; McLaurin, BT; Parikh, KH; Stebbins, A; Stone, GW; Todd, M; White, HD, 2013) |
| "Whether an additional clopidogrel load in patients receiving chronic clopidogrel therapy and undergoing percutaneous coronary intervention (PCI) for acute coronary syndrome (ACS) is associated with clinical benefit has not been well characterized." | 5.17 | Efficacy of clopidogrel reloading in patients with acute coronary syndrome undergoing percutaneous coronary intervention during chronic clopidogrel therapy (from the Antiplatelet therapy for Reduction of MYocardial Damage during Angioplasty [ARMYDA-8 RELO ( Barbato, E; Colonna, G; D'Ambrosio, A; Di Sciascio, G; Mangiacapra, F; Montinaro, A; Pasceri, V; Patti, G; Ricottini, E; Vizzi, V; Wijns, W, 2013) |
| "High residual platelet reactivity (RPR) on clopidogrel treatment has been associated with increased risk for ischemic events during follow-up in patients with acute coronary syndromes." | 5.17 | Incidence and outcome of high on-treatment platelet reactivity in patients with non-ST elevation acute coronary syndromes undergoing percutaneous coronary intervention (from the VIP [VerifyNow and Inhibition of Platelet Reactivity] study). ( Campo, G; De Palma, R; Guastaroba, P; Guiducci, V; Magnavacchi, P; Manari, A; Marino, M; Marzocchi, A; Saia, F; Sangiorgio, P; Taglieri, N; Tondi, S; Valgimigli, M; Varani, E, 2013) |
| " Across the baseline ST-segment depression strata, there was a consistent treatment benefit with ticagrelor versus clopidogrel on vascular death/myocardial infarction." | 5.17 | Quantitative ST-depression in acute coronary syndromes: the PLATO electrocardiographic substudy. ( Armstrong, PW; Fu, Y; Harrington, RA; James, S; Katus, H; Storey, RF; Wallentin, L; Westerhout, CM, 2013) |
| "The PLATO trial showed that ticagrelor was superior to clopidogrel for the prevention of cardiovascular death, myocardial infarction, or stroke in a broad population of patients with acute coronary syndromes." | 5.17 | Health-related quality of life of ticagrelor versus clopidogrel in patients with acute coronary syndromes-results from the PLATO trial. ( Andersson, D; Bergström, G; Bernfort, L; Janzon, M; Kaul, P; Lamm, CJ; Levin, LÅ; Storey, RF; Wallentin, L, 2013) |
| "A total of 9326 medically managed patients with acute coronary syndromes from the Targeted Platelet Inhibition to Clarify the Optimal Strategy to Medically Manage Acute Coronary Syndromes (TRILOGY ACS) trial (<75 years of age, n=7243; ≥75 years of age, n=2083) were randomized to prasugrel (10 mg/d; 5 mg/d for those ≥75 or <75 years of age and <60 kg in weight) or clopidogrel (75 mg/d) plus aspirin for ≤30 months." | 5.17 | Elderly patients with acute coronary syndromes managed without revascularization: insights into the safety of long-term dual antiplatelet therapy with reduced-dose prasugrel versus standard-dose clopidogrel. ( Ardissino, D; Armstrong, PW; Aylward, PE; Bassand, JP; Boden, WE; Dalby, AJ; Fox, KA; Goodman, SG; Gottlieb, S; Hochman, JS; Martinez, F; McGuire, DK; Ohman, EM; Prabhakaran, D; Roe, MT; Stevens, SR; White, HD; Winters, KJ, 2013) |
| "The PLATO (Platelet Inhibition and Patient Outcomes) angiographic substudy sought to compare the efficacy of ticagrelor versus clopidogrel with respect to angiographic outcomes before and after PCI in the setting of acute coronary syndrome." | 5.17 | Angiographic outcomes in the PLATO Trial (Platelet Inhibition and Patient Outcomes). ( Emanuelsson, H; Gibson, CM; Harrington, RA; Horrow, J; James, SK; Katus, H; Kunadian, V; Maya, J; Steg, PG; Storey, RF; Wallentin, L; Wojdyla, DM; Wu, J; Zorkun, C, 2013) |
| "Ticagrelor compared with clopidogrel reduces the incidence of stent thrombosis in patients with acute coronary syndromes, with consistent benefit across a broad range of patient, stent, and treatment characteristics." | 5.17 | Stent thrombosis with ticagrelor versus clopidogrel in patients with acute coronary syndromes: an analysis from the prospective, randomized PLATO trial. ( Emanuelsson, H; Harrington, RA; James, SK; Katus, HA; Lewis, BS; Mahaffey, KW; Maurer, G; Meier, B; Steg, PG; Storey, RF; Wallentin, L; Wojdyla, DM, 2013) |
| "Among patients who had angiography who took prasugrel there were fewer cardiovascular deaths, myocardial infarctions, or strokes than in those who took clopidogrel." | 5.17 | Prasugrel versus clopidogrel for patients with unstable angina or non-ST-segment elevation myocardial infarction with or without angiography: a secondary, prespecified analysis of the TRILOGY ACS trial. ( Armstrong, PW; Bhatt, DL; Boden, WE; Clemmensen, P; Fox, KA; Hafley, G; Hamm, C; Leiva-Pons, J; Lokhnygina, Y; Menozzi, A; Nicolau, JC; Ohman, EM; Oto, A; Pavlides, G; Prabhakaran, D; Roe, MT; Ruzyllo, W; White, HD; Widimsky, P; Winters, KJ; Wiviott, SD, 2013) |
| "Adding a prasugrel loading dose (LD) to a clopidogrel LD could be desirable because clopidogrel may fail to provide adequate levels of platelet inhibition in patients with acute coronary syndrome undergoing percutaneous coronary intervention." | 5.17 | Effect on platelet reactivity from a prasugrel loading dose after a clopidogrel loading dose compared with a prasugrel loading dose alone: Transferring From Clopidogrel Loading Dose to Prasugrel Loading Dose in Acute Coronary Syndrome Patients (TRIPLET): ( Angiolillo, DJ; Cardillo, TE; Diodati, JG; Effron, MB; Fisher, HN; French, JK; Fung, AY; Henneges, C; Saucedo, JF, 2013) |
| "The aim of this study was to evaluate the cost-effectiveness of ticagrelor and generic clopidogrel as add-on therapy to acetylsalicylic acid (ASA) in patients with acute coronary syndrome (ACS), from a Swiss perspective." | 5.17 | Cost-effectiveness of ticagrelor and generic clopidogrel in patients with acute coronary syndrome in Switzerland. ( Gasche, D; Greiner, RA; Meier, B; Ulle, T, 2013) |
| " Eligible patients were those with stable coronary artery disease or history of low-risk acute coronary syndrome (ACS) undergoing PCI with zotarolimus-eluting stents." | 5.17 | Three vs twelve months of dual antiplatelet therapy after zotarolimus-eluting stents: the OPTIMIZE randomized trial. ( Abizaid, A; Abizaid, AS; Bhatt, DL; Botelho, RV; Castello, HJ; Costa, JR; Costa, RA; de Castro, JP; de Paula, JE; Devito, FS; Feres, F; Gusmão, M; King, SB; Labrunie, A; Leon, MB; Liu, M; Mangione, JA; Marin-Neto, JA; Meireles, GX; Negoita, M; Nicolela, EL; Perin, MA; Salvadori, D; Staico, R, 2013) |
| "The TRITON-TIMI 38 (Trial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet Inhibition With Prasugrel-Thrombolysis in Myocardial Infarction 38) enrolled 13,608 patients with an acute coronary syndrome (ACS) and planned percutaneous coronary intervention (PCI), and randomized them to clopidogrel or prasugrel." | 5.17 | Concomitant administration of clopidogrel with statins or calcium-channel blockers: insights from the TRITON-TIMI 38 (trial to assess improvement in therapeutic outcomes by optimizing platelet inhibition with prasugrel-thrombolysis in myocardial infarctio ( Antman, EM; Bates, ER; Mega, JL; Murphy, SA; O'Donoghue, ML; Ojeifo, O; Sabatine, MS; Udell, JA; Wiviott, SD, 2013) |
| " Clopidogrel in the patients with acute coronary syndromes (ACS) undergoing percutaneous coronary intervention (PCI) by measuring inhibition of platelet aggregation after loading and maintenance dose of both the drugs." | 5.17 | A comparative evaluation of prasugrel and clopidogrel in patients with acute coronary syndrome undergoing percutaneous coronary intervention. ( Alexander, T; Babu, PR; Dani, S; Dasbiswas, A; Hiremath, S; Nayak, R; Patel, T; Pathak, K; Prakash, VS; Rao, MS; Singh, DP; Srivastava, A; Tyagi, S; Vijayvergiya, R; Yadav, MK, 2013) |
| " The aim of the study was to assess the antiplatelet activity and safety of a combined antiplatelet treatment with indobufen and clopidogrel in acute coronary syndrome (ACS) patients with hypersensitivity to aspirin, undergoing coronary stenting." | 5.17 | Clopidogrel plus indobufen in acute coronary syndrome patients with hypersensitivity to aspirin undergoing percutaneous coronary intervention. ( Acconcia, MC; Barillà, F; Dominici, T; Gaudio, C; Mangieri, E; Paravati, V; Pellicano, M; Pulcinelli, FM; Tanzilli, G; Torromeo, C, 2013) |
| " clopidogrel in patients with acute coronary syndromes (ACS) are well documented in the PLATelet inhibition and patient Outcomes trial (PLATO)." | 5.17 | Cost-effectiveness of treating acute coronary syndrome patients with ticagrelor for 12 months: results from the PLATO study. ( Hauch, O; Henriksson, M; Janzon, M; Nikolic, E; Wallentin, L, 2013) |
| "On average, acute coronary syndrome patients treated with prasugrel experience fewer ischemic complications, but more bleeding, than those receiving clopidogrel." | 5.17 | Selecting antiplatelet therapy at the time of percutaneous intervention for an acute coronary syndrome: weighing the benefits and risks of prasugrel versus clopidogrel. ( Cohen, DJ; Jones, PG; Li, Y; Salisbury, AC; Spertus, JA; Wang, K, 2013) |
| "The prevalence of high platelet reactivity (HPR) in patients who have switched from clopidogrel to prasugrel during maintenance phase after an acute coronary syndrome (ACS) event is unknown." | 5.17 | Decrease in high on-treatment platelet reactivity (HPR) prevalence on switching from clopidogrel to prasugrel: insights from the switching anti-platelet (SWAP) study. ( Angiolillo, DJ; Costigan, TM; DeRaad, R; Duvvuru, S; Effron, MB; Frelinger, AL; Gurbel, PA; Jakubowski, JA; Ojeh, CK; Saucedo, JF, 2013) |
| "Elderly patients with acute coronary syndrome (ACS) undergoing percutaneous coronary intervention (PCI) frequently exhibit high platelet reactivity (HPR) while on clopidogrel." | 5.17 | Pharmacodynamic effect of prasugrel 5 mg vs clopidogrel 150 mg in elderly patients with high on-clopidogrel platelet reactivity. ( Alexopoulos, D; Damelou, A; Davlouros, P; Hahalis, G; Mavronasiou, E; Plakomyti, TE; Theodoropoulos, KC; Xanthopoulou, I, 2013) |
| "In the PLATelet inhibition and patient Outcomes (PLATO) study, 18 624 patients presenting with acute coronary syndromes randomly received ticagrelor (n=9333) or clopidogrel (n=9291)." | 5.17 | Reduction in first and recurrent cardiovascular events with ticagrelor compared with clopidogrel in the PLATO Study. ( Angiolillo, DJ; Ardissino, D; Cannon, CP; Horrow, J; Husted, S; James, SK; Kohli, P; Maurer, G; Morais, J; Nicolau, JC; Oto, A; Reyes, E; Storey, RF; Wallentin, L, 2013) |
| "Little is known about the efficacy of proton pump inhibitors compared with H(2) receptor antagonists in preventing adverse upper gastrointestinal complications in patients with acute coronary syndrome (ACS) or ST elevation myocardial infarction (STEMI) receiving aspirin, clopidogrel, and enoxaparin or thrombolytics." | 5.16 | Esomeprazole compared with famotidine in the prevention of upper gastrointestinal bleeding in patients with acute coronary syndrome or myocardial infarction. ( Chan, K; Chu, WM; Keung, KK; Kng, C; Kwan, A; Lam, KF; Lau, YK; Li, A; Ng, FH; Tunggal, P; Wong, BC, 2012) |
| "The efficacy of clopidogrel therapy in patients with an acute coronary syndrome (ACS) has been established using the clopidogrel hydrogen sulfate (CHS) formulation." | 5.16 | Antiplatelet efficacy of long-term treatment with clopidogrel besylate in patients with a history of acute coronary syndrome: comparison with clopidogrel hydrogen sulfate. ( Dimitriou, AA; Goudevenos, IA; Kalantzi, KI; Ntalas, IV; Tselepis, AD; Tsoumani, ME, 2012) |
| "Ticagrelor, when compared with clopidogrel, reduced the 12-month risk of vascular death/myocardial infarction and stroke in patients with ST-elevation acute coronary syndromes intended to undergo primary percutaneous coronary intervention in the PLATelet inhibition and patient Outcomes (PLATO) trial." | 5.16 | ST-elevation acute coronary syndromes in the Platelet Inhibition and Patient Outcomes (PLATO) trial: insights from the ECG substudy. ( Armstrong, PW; Clemmensen, P; Fu, Y; Harrington, RA; Horrow, J; James, SK; Katus, H; Siha, H; Steg, PG; Storey, RF; Wallentin, L; Westerhout, CM, 2012) |
| "The efficacy of clopidogrel therapy in patients with an acute coronary syndrome (ACS) has been established using the clopidogrel hydrogen sulfate (CHS) formulation." | 5.16 | Effect of clopidogrel besylate on platelet reactivity in patients with acute coronary syndromes. Comparison with clopidogrel hydrogen sulfate. ( Dimitriou, AA; Goudevenos, IA; Kalantzi, KI; Ntalas, IV; Tselepis, AD; Tsoumani, ME, 2012) |
| "Clopidogrel use prior to coronary artery bypass graft surgery in patients presenting with acute coronary syndromes is associated with a greater incidence of procedural related morbidity." | 5.16 | Bleeding-associated outcomes with preoperative clopidogrel use in on- and off-pump coronary artery bypass. ( Becker, RC; Berger, JS; Frye, CB; Harshaw, Q; Herout, PM; Steinhubl, SR, 2012) |
| "The main findings were a significant reduction of the primary outcome (death from vascular causes/myocardial infarction/stroke) with ticagrelor versus clopidogrel [9." | 5.16 | Lessons from platelet inhibition and patient outcomes. ( Held, C, 2012) |
| "We evaluated treatment effects of ticagrelor versus clopidogrel in patients with acute coronary syndrome with and without a history of prior stroke or TIA in the PLATelet inhibition and patient Outcomes (PLATO) trial." | 5.16 | Ticagrelor versus clopidogrel in patients with acute coronary syndromes and a history of stroke or transient ischemic attack. ( Becker, RC; Husted, S; James, SK; Keltai, M; Khurmi, NS; Lopes, RD; Lopez-Sendon, JL; Mahaffey, KW; Maya, J; Morais, J; Nicolau, JC; Pais, P; Raev, D; Stevens, SR; Storey, RF, 2012) |
| "A subset of the TRITON-TIMI 38 study (Trial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet Inhibition with Prasugrel-Thrombolysis In Myocardial Infarction 38), in which patients with acute coronary syndrome were randomized to treatment with aspirin and either clopidogrel or prasugrel, underwent isolated CABG (N = 346)." | 5.16 | Mortality benefit with prasugrel in the TRITON-TIMI 38 coronary artery bypass grafting cohort: risk-adjusted retrospective data analysis. ( Goodnough, LT; Lenarz, LA; Levy, JH; Poston, RS; Short, MA; Smith, PK; Weerakkody, GJ, 2012) |
| "The study aimed to compare the antiplatelet action of ticagrelor with prasugrel in acute coronary syndrome (ACS) patients with high on-treatment platelet reactivity (HTPR) while on clopidogrel after percutaneous coronary intervention (PCI)." | 5.16 | Ticagrelor versus prasugrel in acute coronary syndrome patients with high on-clopidogrel platelet reactivity following percutaneous coronary intervention: a pharmacodynamic study. ( Alexopoulos, D; Damelou, A; Davlouros, P; Galati, A; Hahalis, G; Kassimis, G; Makris, G; Mavronasiou, E; Theodoropoulos, KC; Tsigkas, G; Xanthopoulou, I, 2012) |
| "Clopidogrel is recommended in addition to aspirin to prevent atherothrombotic events in patients with acute coronary syndromes (ACS) and in those undergoing percutaneous coronary intervention (PCI)." | 5.16 | The impact of CYP3A5*1/*3, PIA1/A2 and T744C polymorphisms on clopidogrel and acetylsalicylic acid response variability in Mexican population. ( de la Peña, NC; Isordia-Salas, I; Olalde-Román, MJ; Santiago-Germán, D; Valencia-Sánchez, JS, 2012) |
| "It remains unclear whether concomitant use of omeprazole attenuates platelet function as compared with that of famotidine in patients with acute coronary syndromes (ACS) who receive clopidogrel." | 5.16 | Influence of omeprazole and famotidine on the antiplatelet effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes: a prospective, randomized, multicenter study. ( Endo, T; Fukui, K; Hibi, K; Himeno, H; Kimura, K; Morita, S; Sugano, T; Tsukahara, K; Umemura, S; Yano, H, 2012) |
| "Among patients with unstable angina or myocardial infarction without ST-segment elevation, prasugrel did not significantly reduce the frequency of the primary end point, as compared with clopidogrel, and similar risks of bleeding were observed." | 5.16 | Prasugrel versus clopidogrel for acute coronary syndromes without revascularization. ( Ardissino, D; Armstrong, PW; Aylward, PE; Bhatt, DL; Boden, WE; Brown, EB; Cinteză, M; Clemmensen, P; Corbalan, R; Cornel, JH; Dalby, AJ; Fox, KA; Gasparovic, V; Goodman, SG; Gottlieb, S; Goudev, AR; Gurbel, PA; Hamm, C; Hochman, JS; Huber, K; Leiva-Pons, JL; Lokhnygina, Y; Martinez, F; McGuire, DK; McLendon, RC; Merkely, B; Nicolau, JC; Ohman, EM; Oto, A; Parkhomenko, A; Pavlides, G; Prabhakaran, D; Roe, MT; Ruzyllo, W; Topacio, GO; Tseng, CD; White, HD; Winters, KJ, 2012) |
| " In the PLATO trial, ticagrelor compared to clopidogrel in patients with acute coronary syndromes (ACS) reduced the primary composite end point of vascular death, myocardial infarction and stroke, without increasing overall rates of major bleeding." | 5.16 | Prior smoking status, clinical outcomes, and the comparison of ticagrelor with clopidogrel in acute coronary syndromes-insights from the PLATelet inhibition and patient Outcomes (PLATO) trial. ( Becker, RC; Cornel, JH; Goodman, SG; Harrington, R; Horrow, J; Husted, S; James, S; Katus, H; Santoso, A; Steg, G; Storey, RF; Sun, JL; Vintila, M; Wallentin, L, 2012) |
| "The significant clinical benefit and overall safety of ticagrelor compared with clopidogrel in acute coronary syndrome patients in the PLATO cohort were not found to depend on age." | 5.16 | Ticagrelor versus clopidogrel in elderly patients with acute coronary syndromes: a substudy from the prospective randomized PLATelet inhibition and patient Outcomes (PLATO) trial. ( Bach, RG; Becker, RC; Cannon, CP; Heras, M; Horrow, J; Husted, S; James, S; Katus, H; Lopes, RD; Mahaffey, KW; Morais, J; Storey, RF; Wallentin, L; Wojdyla, D, 2012) |
| " Thrombus area was measured in T2DM and non-diabetic patients receiving aspirin and clopidogrel 7-10 days after troponin positive Non ST-elevation acute coronary syndrome (NSTE-ACS)." | 5.16 | Thrombus and antiplatelet therapy in type 2 diabetes mellitus. A prospective study after non-ST elevation acute coronary syndrome and a randomised, blinded, placebo-controlled study in stable angina. ( Badimon, JJ; Balasubramaniam, K; Marshall, SM; Schechter, CB; Viswanathan, GN; Zaman, AG, 2012) |
| "Patients with medically managed unstable angina or non-ST-segment elevation myocardial infarction were enrolled in the TRILOGY ACS trial (2008 to 2011) comparing clopidogrel vs prasugrel." | 5.16 | Platelet function during extended prasugrel and clopidogrel therapy for patients with ACS treated without revascularization: the TRILOGY ACS platelet function substudy. ( Armstrong, PW; Brown, E; Chan, MY; Cornel, JH; Erlinge, D; Fox, KA; Goodman, SG; Gurbel, PA; Huber, K; Jakubowski, JA; Neely, B; Neely, M; Ohman, EM; Prabhakaran, D; Roe, MT; Tantry, US; White, HD; Zhou, C, 2012) |
| "To investigate if ticagrelor treatment and other clinical characteristics were associated with increased cystatin C concentrations and if a deterioration in estimated renal function was associated with worse outcome in patients with acute coronary syndromes (ACS)." | 5.16 | Outcome and causes of renal deterioration evaluated by serial cystatin C measurements in acute coronary syndrome patients -- results from the PLATelet inhibition and patient Outcomes (PLATO) study. ( Akerblom, A; Asenblad, N; Becker, RC; Budaj, A; Claeys, MJ; Horrow, J; Husted, S; James, SK; Katus, H; Siegbahn, A; Storey, RF; Wallentin, L, 2012) |
| "Presentation with an acute coronary syndrome (ACS) on chronic aspirin therapy is an independent predictor of adverse short-term outcomes." | 5.15 | Impact of chronic antiplatelet therapy before hospitalization on ischemic and bleeding events in invasively managed patients with acute coronary syndromes: the ACUITY trial. ( Ambrosio, G; Bertrand, ME; Gresele, P; Lincoff, AM; Mehran, R; Moses, JW; Ohman, EM; Steinhubl, S; Stone, GW; Tritto, I; White, HD; Zuchi, C, 2011) |
| "In large clinical trials enrolling patients with acute coronary syndromes, a high loading dose of clopidogrel (600 mg) has been found to be more effective compared to a low loading dose (300 mg)." | 5.15 | Comparison of adverse cardiovascular events and bleeding complications of loading dose of clopidogrel 300 mg versus 600 mg in stable patients undergoing elective percutaneous intervention (from the CADICE study). ( Aboodi, MS; Delgado, JA; Fernandez, A; Granada, JF; Milewski, K; Rodríguez, A, 2011) |
| " We investigated the effects of cilostazol 200 mg, in addition to aspirin 100 mg and clopidogrel 75 mg, on carotid intima-media thickness (IMT) progression during a 2-year follow-up period in patients with acute coronary syndrome (ACS) requiring stent implantation." | 5.15 | Cilostazol reduces the progression of carotid intima-media thickness without increasing the risk of bleeding in patients with acute coronary syndrome during a 2-year follow-up. ( Ahn, CM; Hong, SJ; Kim, JS; Lim, DS; Park, JH, 2011) |
| "Any bleeding and TIMI major bleeding complications increase in patients aged ≥75 years treated with clopidogrel in addition to aspirin." | 5.15 | Safety of clopidogrel in older patients: a nonrandomized, parallel-group, controlled, two-centre study. ( Aydogdu, S; Balbay, Y; Cagirci, G; Cay, S; Demir, AD; Erbay, AR; Maden, O; Sen, N, 2011) |
| "Routine early eptifibatide use, compared with delayed provisional use, may be associated with lower 30-day ischemic risk in non-ST-elevation acute coronary syndrome patients also treated with clopidogrel before angiography." | 5.15 | Upstream clopidogrel use and the efficacy and safety of early eptifibatide treatment in patients with acute coronary syndrome: an analysis from the Early Glycoprotein IIb/IIIa Inhibition in Patients with Non-ST-Segment Elevation Acute Coronary Syndrome (E ( Armstrong, PW; Braunwald, E; Califf, RM; Giugliano, RP; Harrington, RA; James, SK; Montalescot, G; Newby, LK; Tricoci, P; Van de Werf, F; Wang, TY; White, JA; Zeymer, U, 2011) |
| "Abciximab reduced the combined endpoint of death, myocardial infarction (MI) and target vessel revascularization in patients with non-ST-segment elevation acute coronary syndromes (NSTE-ACS) undergoing percutaneous coronary intervention (PCI) with stent implantation after a 600-mg loading dose of clopidogrel." | 5.15 | Influence of abciximab on evolution of left ventricular function in patients with non-ST-segment elevation acute coronary syndromes undergoing PCI after clopidogrel pretreatment: lessons from the ISAR-REACT 2 trial. ( Birkmeier, KA; Byrne, RA; Dommasch, M; Dotzer, F; Kastrati, A; Kufner, S; Mehilli, J; Ndrepepa, G; Schömig, A; Schulz, S; Tiroch, K, 2011) |
| "Omeprazole, usually used in the antiplatelet therapy during percutaneous coronary intervention (PCI) in acute coronary syndrome (ACS), has been reported to increase ischemic events in retrospective studies." | 5.15 | Omeprazole affects clopidogrel efficacy but not ischemic events in patients with acute coronary syndrome undergoing elective percutaneous coronary intervention. ( Chen, JS; Chen, L; Chen, YD; Guo, YS; Huang, TT; Liu, HB; Ren, YH; Sun, ZJ; Wang, CY; Wang, Y; Xie, YJ; Zhao, M, 2011) |
| "The aim of this study was to determine whether ticagrelor increased the risk of ventricular pauses compared with clopidogrel and whether these pauses were associated with any clinical bradycardic events in patients presenting with acute coronary syndromes." | 5.15 | The incidence of bradyarrhythmias and clinical bradyarrhythmic events in patients with acute coronary syndromes treated with ticagrelor or clopidogrel in the PLATO (Platelet Inhibition and Patient Outcomes) trial: results of the continuous electrocardiogr ( Cannon, CP; Emanuelsson, H; Harrington, RA; Husted, S; James, S; Katus, H; Michelson, EL; Pais, P; Raev, D; Scirica, BM; Spinar, J; Steg, PG; Storey, RF; Wallentin, L, 2011) |
| "After an acute coronary syndrome, patients remain at risk of recurrent ischaemic events, despite contemporary treatment, including aspirin and clopidogrel." | 5.15 | Dabigatran vs. placebo in patients with acute coronary syndromes on dual antiplatelet therapy: a randomized, double-blind, phase II trial. ( Budaj, A; Granger, CB; Khder, Y; Oldgren, J; Roberts, J; Siegbahn, A; Tijssen, JG; Van de Werf, F; Wallentin, L, 2011) |
| "In patients with acute coronary syndrome initially intended for non-invasive management, the benefits of ticagrelor over clopidogrel were consistent with those from the overall PLATO results, indicating the broad benefits of P2Y12 inhibition with ticagrelor regardless of intended management strategy." | 5.15 | Ticagrelor versus clopidogrel in patients with acute coronary syndromes intended for non-invasive management: substudy from prospective randomised PLATelet inhibition and patient Outcomes (PLATO) trial. ( Cannon, CP; Cornel, JH; Harrington, RA; Horrow, J; Husted, S; James, SK; Katus, H; Morais, J; Roe, MT; Steg, PG; Stevens, S; Storey, RF; Wallentin, L, 2011) |
| "Patients with a history of an acute coronary syndrome who had previously received clopidogrel were recruited." | 5.15 | Randomized double-blind placebo-controlled crossover study to determine the effects of esomeprazole on inhibition of platelet function by clopidogrel. ( Bassler, N; Dart, AM; Fernando, H; Habersberger, J; Peter, KH; Sharma, R; Shaw, JA; Sheffield, LJ, 2011) |
| "Residual platelet reactivity (RPR) after clopidogrel loading, measured by the VerifyNow assay, has been shown to predict 12-month clinical events in patients with acute coronary syndromes." | 5.15 | Residual platelet reactivity after clopidogrel loading in patients with ST-elevation myocardial infarction undergoing an unexpectedly delayed primary percutaneous coronary intervention. - Impact on intracoronary thrombus burden and myocardial perfusion-. ( Archontakis, S; Gafou, A; Kalogeras, KI; Kariori, MG; Moldovan, C; Papaioannou, TG; Stefanadis, C; Tzamalis, P; Vavuranakis, M; Vrachatis, DA, 2011) |
| "AIMS To describe the incidence of dyspnoea and its associations with demographic characteristics and clinical outcomes in patients with acute coronary syndromes (ACS) treated with ticagrelor or clopidogrel in the PLATelet inhibition and patient Outcomes (PLATO) study." | 5.15 | Characterization of dyspnoea in PLATO study patients treated with ticagrelor or clopidogrel and its association with clinical outcomes. ( Becker, RC; Cairns, R; Cannon, CP; Cools, F; Cooper, A; Emanuelsson, H; Harrington, RA; Husted, S; James, SK; Khurmi, NS; Steg, PG; Storey, RF; Wallentin, L, 2011) |
| "The aim of this study is to investigate the relationship between the duration of clopidogrel use and the inflammation process after acute coronary syndrome in patients who received bare metal stent (BMS) or drug eluting stent (DES)." | 5.15 | The effect of the duration of clopidogrel use on hsCRP levels after stenting the target vessel in patients with acute coronary syndrome. ( Akbulut, M; Bilen, MN; Bulut, M; Cekici, Y; Celik, A; Korkmaz, H, 2011) |
| " On-clopidogrel platelet reactivity was investigated in patients with previous angiographically confirmed STh, myocardial infarction (MI), and controls." | 5.15 | Relationship between clopidogrel-induced platelet P2Y12 inhibition and stent thrombosis or myocardial infarction after percutaneous coronary intervention-a case-control study. ( Erlinge, D; James, S; Koul, S; Lagerqvist, B; Siegbahn, A; Varenhorst, C; Wallentin, L, 2011) |
| "In the Gauging Responsiveness With A VerifyNow P2Y12 Assay: Impact on Thrombosis and Safety (GRAVITAS) trial, 6 months of high-dose clopidogrel did not reduce cardiovascular events compared with standard-dose clopidogrel in patients with high on-treatment platelet reactivity (OTR) after percutaneous coronary intervention, defined as OTR ≥230 P2Y12 reaction units according to the VerifyNow P2Y12 platelet function test." | 5.15 | Platelet reactivity and cardiovascular outcomes after percutaneous coronary intervention: a time-dependent analysis of the Gauging Responsiveness with a VerifyNow P2Y12 assay: Impact on Thrombosis and Safety (GRAVITAS) trial. ( Angiolillo, DJ; Berger, PB; Cannon, CP; Lillie, E; Manoukian, SV; Price, MJ; Tanguay, JF; Teirstein, PS; Topol, EJ, 2011) |
| "The Platelet Inhibition and Patient Outcomes (PLATO) trial showed that ticagrelor reduced the risk for cardiovascular events in patients with acute coronary syndromes compared to clopidogrel but was associated with increased incidence of dyspnea." | 5.15 | Pulmonary function in patients with acute coronary syndrome treated with ticagrelor or clopidogrel (from the Platelet Inhibition and Patient Outcomes [PLATO] pulmonary function substudy). ( Becker, RC; Cannon, CP; Cools, F; Emanuelsson, H; Harrington, RA; Husted, S; James, SK; Katus, HA; Khurmi, NS; Lim, ST; Steg, PG; Storey, RF; Wallentin, L, 2011) |
| "Patients with acute coronary syndrome or elective percutaneous coronary interventions treated with aspirin and clopidogrel cotherapy were randomized to receive esomeprazole 20 mg daily or famotidine 40 mg daily." | 5.15 | Effect of esomeprazole versus famotidine on platelet inhibition by clopidogrel: a double-blind, randomized trial. ( Chan, FK; Lam, KF; Lau, YK; Ng, FH; Tunggal, P, 2011) |
| "To examine if tirofiban may improve the prognosis in aged acute coronary syndrome (ACS) patients received percutaneous coronary intervention (PCI)." | 5.15 | [Tirofiban improved the prognosis of senior acute coronary syndrome patients received percutaneous coronary intervention]. ( Chen, R; Gao, L; Gao, W; Li, LJ; Lu, CY; Tian, JW; Xue, Q; Zhai, JY; Zhang, YX; Zhou, SH, 2011) |
| "We compared the effects of a 600- versus a 300-mg LD of clopidogrel on inhibition of platelet aggregation, myonecrosis, and clinical outcomes in patients with NSTEACS undergoing an early invasive management strategy." | 5.14 | Randomized trial comparing 600- with 300-mg loading dose of clopidogrel in patients with non-ST elevation acute coronary syndrome undergoing percutaneous coronary intervention: results of the Platelet Responsiveness to Aspirin and Clopidogrel and Troponin ( Brieger, D; Chew, DP; Dick, R; Eccleston, D; Eikelboom, JW; Ferguson, L; French, J; Hockings, B; Rankin, J; Thom, J; Walters, D; Whelan, A; Yong, G, 2009) |
| "In this prospective study, 1,212 patients with acute coronary syndromes were randomly assigned to receive either standard dual-antiplatelet treatment with aspirin and clopidogrel (n = 608) or triple-antiplatelet therapy with the addition of a 6-month course of cilostazol (n = 604) after successful PCI." | 5.14 | Cilostazol in addition to aspirin and clopidogrel improves long-term outcomes after percutaneous coronary intervention in patients with acute coronary syndromes: a randomized, controlled study. ( Han, Y; Jing, Q; Li, Y; Shu, Q; Tang, X; Wang, D; Wang, S; Wang, Z, 2009) |
| "The effect of atorvastatin 10 mg vs 40 mg in clopidogrel resistance and clinical events after coronary stenting was compared in patients with acute coronary syndrome (ACS)." | 5.14 | Comparison of low vs moderate dose of atorvastatin in clopidogrel resistance after coronary stenting in Korean patients with acute coronary syndrome. ( Ahn, CM; Hong, SJ; Kim, KA; Kim, YH; Lim, DS; Park, JS; Park, JY; Park, SM; Shim, WJ, 2009) |
| "TRITON-TIMI 38 randomized acute coronary syndrome (ACS) patients undergoing percutaneous coronary intervention (PCI) to prasugrel or standard dose clopidogrel." | 5.14 | Pharmacodynamic assessment of platelet inhibition by prasugrel vs. clopidogrel in the TRITON-TIMI 38 trial. ( Angiolillo, DJ; Antman, EM; Braunwald, E; Downey, WE; Frelinger, AL; Jakubowski, JA; Li, Y; McCabe, CH; Michelson, AD; Murphy, SA; Qin, J; Wiviott, SD; Xenopoulos, NP, 2009) |
| "Prasugrel is a novel thienopyridine that reduces new or recurrent myocardial infarctions (MIs) compared with clopidogrel in patients with acute coronary syndrome undergoing percutaneous coronary intervention." | 5.14 | Effect of the novel thienopyridine prasugrel compared with clopidogrel on spontaneous and procedural myocardial infarction in the Trial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet Inhibition with Prasugrel-Thrombolysis in Myocardi ( Antman, EM; Bonaca, MP; Bramucci, E; Braunwald, E; McCabe, CH; Morrow, DA; Murphy, SA; Nicolau, JC; Ruff, CT; Scirica, BM; White, HD; Wiviott, SD, 2009) |
| "This study sought to evaluate the impact of upstream clopidogrel in patients with non-ST-segment elevation acute coronary syndromes (NSTE-ACS) requiring coronary artery bypass grafting (CABG) from the ACUITY (Acute Catheterization and Urgent Intervention Triage strategY) trial." | 5.14 | Outcomes following pre-operative clopidogrel administration in patients with acute coronary syndromes undergoing coronary artery bypass surgery: the ACUITY (Acute Catheterization and Urgent Intervention Triage strategY) trial. ( Cox, DA; Dyke, C; Ebrahimi, R; Feit, F; Gersh, BJ; Lincoff, AM; Manoukian, SV; Mehran, R; Moses, JW; Ohman, EM; Stone, GW; Ware, JH; White, HD, 2009) |
| " Apixaban, an oral direct factor Xa inhibitor, is a novel anticoagulant that may reduce these events but also poses a risk of bleeding." | 5.14 | Apixaban, an oral, direct, selective factor Xa inhibitor, in combination with antiplatelet therapy after acute coronary syndrome: results of the Apixaban for Prevention of Acute Ischemic and Safety Events (APPRAISE) trial. ( Alexander, JH; Becker, RC; Bhatt, DL; Cools, F; Crea, F; Dellborg, M; Fox, KA; Goodman, SG; Harrington, RA; Huber, K; Husted, S; Lewis, BS; Lopez-Sendon, J; Mohan, P; Montalescot, G; Ruda, M; Ruzyllo, W; Verheugt, F; Wallentin, L, 2009) |
| "To observe the effects of upstream versus downstream application of tirofiban on platelet aggregation and clinical outcomes (major adverse cardiovascular event, MACE) in patients with high-risk non-ST-segment elevation acute coronary syndromes (NSTE-ACS) undergoing percutaneous coronary intervention (PCI)." | 5.14 | [Effects of upstream tirofiban versus downstream tirofiban on platelet aggregation and clinical outcomes in patients with high-risk acute coronary syndromes undergoing percutaneous coronary interventions]. ( Cheng, WJ; Guo, YH; Li, YP; Liu, T; Liu, YY; Ma, HY; Shi, DM; Xie, Y; Zhao, YX; Zhou, YJ, 2009) |
| "Prasugrel reduced cardiovascular events as compared with clopidogrel in TRITON-TIMI 38 (Trial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet Inhibition with Prasugrel-Thrombolysis in Myocardial Infarction 38) but with increased bleeding." | 5.14 | The efficacy and safety of prasugrel with and without a glycoprotein IIb/IIIa inhibitor in patients with acute coronary syndromes undergoing percutaneous intervention: a TRITON-TIMI 38 (Trial to Assess Improvement in Therapeutic Outcomes by Optimizing Pla ( Antman, EM; Braunwald, E; Finkelstein, A; Fridrich, V; McCabe, CH; Murphy, SA; O'Donoghue, M; Penny, WF; Sabatine, MS; Steg, PG; Wiviott, SD, 2009) |
| "Prasugrel led to a significant reduction in ischemic cardiovascular events among patients with acute coronary syndrome (ACS) undergoing percutaneous coronary intervention (PCI) with stent implantation compared to clopidogrel." | 5.14 | Effect of prasugrel versus clopidogrel on outcomes among patients with acute coronary syndrome undergoing percutaneous coronary intervention without stent implantation: a TRial to assess Improvement in Therapeutic Outcomes by optimizing platelet inhibitio ( Antman, EM; Braunwald, E; Buros, JL; Gibson, CM; Pride, YB; Tariq, MU; Wiviott, SD; Zorkun, C, 2009) |
| "In patients who have an acute coronary syndrome with or without ST-segment elevation, treatment with ticagrelor as compared with clopidogrel significantly reduced the rate of death from vascular causes, myocardial infarction, or stroke without an increase in the rate of overall major bleeding but with an increase in the rate of non-procedure-related bleeding." | 5.14 | Ticagrelor versus clopidogrel in patients with acute coronary syndromes. ( Becker, RC; Budaj, A; Cannon, CP; Emanuelsson, H; Freij, A; Harrington, RA; Held, C; Horrow, J; Husted, S; James, S; Katus, H; Mahaffey, KW; Scirica, BM; Skene, A; Steg, PG; Storey, RF; Thorsén, M; Wallentin, L, 2009) |
| "Thirty-two high risk acute coronary syndrome patients were randomised to bivalirudin and provisional GPIIb/IIIa inhibition (GPIIb/IIIa) or unfractionated heparin (UFH) and mandatory GPIIb/IIIa." | 5.14 | A comparison of anticoagulation with bivalirudin and provisional GPIIb/IIIa inhibition with unfractionated heparin and mandatory GPIIb/IIIa inhibition during percutaneous coronary intervention in relation to platelet activation and the inhibition of coagu ( Bett, N; Juneja, M; Ray, MJ; Walters, DL, 2009) |
| "This study sought to compare the effect of 2 proton pump inhibitors (PPIs) on platelet response to clopidogrel after coronary stenting for non-ST-segment elevation acute coronary syndrome (NSTE ACS)." | 5.14 | Comparison of omeprazole and pantoprazole influence on a high 150-mg clopidogrel maintenance dose the PACA (Proton Pump Inhibitors And Clopidogrel Association) prospective randomized study. ( Alessi, MC; Bali, L; Bonnet, JL; Brissy, O; Cuisset, T; Frere, C; Gaborit, B; Morange, PE; Poyet, R; Quilici, J, 2009) |
| "Our aim was to determine whether a 600-mg loading dose of clopidogrel compared with 300 mg results in improved clinical outcomes in patients with ST-segment elevation myocardial infarction (STEMI) undergoing primary percutaneous coronary intervention (PCI)." | 5.14 | Role of clopidogrel loading dose in patients with ST-segment elevation myocardial infarction undergoing primary angioplasty: results from the HORIZONS-AMI (harmonizing outcomes with revascularization and stents in acute myocardial infarction) trial. ( Aoki, J; Brodie, BR; Caixeta, A; Dangas, G; Dudek, D; Guagliumi, G; Kornowski, R; Mehran, R; Parise, H; Peruga, JZ; Rabbani, LE; Stone, GW; Witzenbichler, B, 2009) |
| "Cangrelor, when administered intravenously 30 minutes before PCI and continued for 2 hours after PCI, was not superior to an oral loading dose of 600 mg of clopidogrel, administered 30 minutes before PCI, in reducing the composite end point of death from any cause, myocardial infarction, or ischemia-driven revascularization at 48 hours." | 5.14 | Platelet inhibition with cangrelor in patients undergoing PCI. ( Amine, M; Angiolillo, DJ; Becker, RC; Bhatt, DL; Chew, DP; French, WJ; Gibson, CM; Goodman, SG; Harrington, RA; Kleiman, NS; Leisch, F; Lincoff, AM; Mahaffey, KW; McNulty, S; Montalescot, G; Parikh, KH; Pollack, CV; Skerjanec, S; Stone, GW; White, HD, 2009) |
| "Co-administration of pantoprazole may enhance the antiplatelet effect of enteric-coated aspirin in patients with acute coronary syndrome undergoing PCI." | 5.14 | Pantoprazole may enhance antiplatelet effect of enteric-coated aspirin in patients with acute coronary syndrome. ( Bielis, L; Boinska, J; Budzyński, J; Kasprzak, M; Koziński, M; Kubica, J; Marciniak, A; Plazuk, W; Rość, D; Siller-Matula, J, 2009) |
| "Compared with the approved dose regimen of clopidogrel (300-mg loading dose [LD], 75-mg maintenance dose [MD]), prasugrel has been demonstrated to reduce ischaemic events in patients with acute coronary syndrome (ACS) undergoing percutaneous coronary intervention (PCI)." | 5.14 | Prasugrel compared with high-dose clopidogrel in acute coronary syndrome. The randomised, double-blind ACAPULCO study. ( Bal dit Sollier, C; Barthélémy, O; Beygui, F; Cohen, R; Collet, JP; Drouet, L; Henry, P; Lim, P; Luo, J; Marshall, D; Meuleman, C; Montalescot, G; Petitjean, H; Sideris, G, 2010) |
| "Variation in and irreversibility of platelet inhibition with clopidogrel has led to controversy about its optimum dose and timing of administration in patients with acute coronary syndromes." | 5.14 | Comparison of ticagrelor with clopidogrel in patients with a planned invasive strategy for acute coronary syndromes (PLATO): a randomised double-blind study. ( Ardissino, D; Becker, RC; Cannon, CP; Emanuelsson, H; Harrington, RA; Husted, S; James, S; Katus, H; Keltai, M; Khurmi, NS; Kontny, F; Lewis, BS; Steg, PG; Storey, RF; Wallentin, L; Wojdyla, D, 2010) |
| "The current clinical study is designed to confirm superior inhibition of platelet aggregation with prasugrel versus clopidogrel in the treatment of Asian subjects with acute coronary syndrome (ACS) undergoing percutaneous coronary intervention (PCI)." | 5.14 | Prasugrel versus clopidogrel in Asian patients with acute coronary syndromes: design and rationale of a multi-dose, pharmacodynamic, phase 3 clinical trial. ( Boonbaichaiyapruck, S; Ge, J; Goh, YS; Hong, BK; Hou, CJ; Pinton, P; Zhu, J, 2010) |
| "To observe the impact of various application time of aspirin and clopidogrel on the circadian rhythm changes of platelet aggregation in patients with acute coronary syndrome." | 5.14 | [Impact of application time of aspirin and clopidogrel on platelet aggregation in patients with acute coronary syndrome]. ( Cui, W; Li, Z; Liu, F; Liu, J; Lu, JC; Ren, XJ; Xie, RQ; Yang, XC; Zheng, HM, 2010) |
| " We evaluated the immediate and early outcomes in patients with high-risk non-ST elevation acute coronary syndrome (NSTE ACS) who received tirofiban with conventional therapy compared to patients who received only conventional therapy (a combination of aspirin, clopidogrel, low-molecular-weight heparin with or without beta-blockers and angiotensin-converting enzyme inhibitors)." | 5.14 | Randomised controlled trial evaluating the role of tirofiban in high-risk non-ST elevation acute coronary syndromes: an East Indian perspective. ( Basak, S; Bhattacharya, R; Das Baksi, S; Dutta, D; Gangopadhyay, S; Pani, A; Sarkar, RN, 2010) |
| "ticagrelor, when compared with clopidogrel, reduced ischaemic events in ACS patients irrespective of diabetic status and glycaemic control, without an increase in major bleeding events." | 5.14 | Ticagrelor vs. clopidogrel in patients with acute coronary syndromes and diabetes: a substudy from the PLATelet inhibition and patient Outcomes (PLATO) trial. ( Angiolillo, DJ; Cornel, JH; Erlinge, D; Husted, S; James, S; Kontny, F; Maya, J; Nicolau, JC; Spinar, J; Stevens, SR; Storey, RF; Wallentin, L, 2010) |
| "In acute coronary syndrome patients with chronic kidney disease, ticagrelor compared with clopidogrel significantly reduces ischemic end points and mortality without a significant increase in major bleeding but with numerically more non-procedure-related bleeding." | 5.14 | Ticagrelor versus clopidogrel in acute coronary syndromes in relation to renal function: results from the Platelet Inhibition and Patient Outcomes (PLATO) trial. ( Aylward, P; Buck, KK; Budaj, A; Cannon, CP; Cornel, JH; Harrington, RA; Horrow, J; James, S; Katus, H; Keltai, M; Lewis, BS; Parikh, K; Storey, RF; Szummer, K; Wallentin, L; Wojdyla, D, 2010) |
| " 25,086 individuals with acute coronary syndromes and intended early PCI were randomly assigned to double-dose (600 mg on day 1, 150 mg on days 2-7, then 75 mg daily) versus standard-dose (300 mg on day 1 then 75 mg daily) clopidogrel, and high-dose (300-325 mg daily) versus low-dose (75-100 mg daily) aspirin." | 5.14 | Double-dose versus standard-dose clopidogrel and high-dose versus low-dose aspirin in individuals undergoing percutaneous coronary intervention for acute coronary syndromes (CURRENT-OASIS 7): a randomised factorial trial. ( Ajani, AE; Avezum, A; Bassand, JP; Budaj, A; Chrolavicius, S; Di Pasquale, G; Eikelboom, JW; Faxon, DP; Fox, KA; Gao, P; Granger, CB; Jolly, SS; Joyner, CD; Macaya, C; Mehta, SR; Montalescot, G; Niemela, K; Rupprecht, HJ; Steg, PG; Tanguay, JF; White, HD; Widimsky, P; Yusuf, S, 2010) |
| "In patients with an acute coronary syndrome who were referred for an invasive strategy, there was no significant difference between a 7-day, double-dose clopidogrel regimen and the standard-dose regimen, or between higher-dose aspirin and lower-dose aspirin, with respect to the primary outcome of cardiovascular death, myocardial infarction, or stroke." | 5.14 | Dose comparisons of clopidogrel and aspirin in acute coronary syndromes. ( Afzal, R; Bassand, JP; Chrolavicius, S; Diaz, R; Eikelboom, JW; Fox, KA; Granger, CB; Jolly, S; Joyner, CD; Mehta, SR; Pogue, J; Rupprecht, HJ; Widimsky, P; Yusuf, S, 2010) |
| "The PLATO (PLATelet inhibition and patient Outcomes) PLATELET substudy aimed to compare the antiplatelet effects of clopidogrel and ticagrelor in patients with acute coronary syndromes." | 5.14 | Inhibitory effects of ticagrelor compared with clopidogrel on platelet function in patients with acute coronary syndromes: the PLATO (PLATelet inhibition and patient Outcomes) PLATELET substudy. ( Angiolillo, DJ; Becker, RC; Cannon, CP; Desai, B; Ecob, R; Emanuelsson, H; Husted, S; Patil, SB; Storey, RF; Wallentin, L, 2010) |
| "The objective was to evaluate the pharmacodynamic response of switching patients on maintenance phase clopidogrel therapy after an acute coronary syndrome (ACS) to prasugrel." | 5.14 | Increased platelet inhibition after switching from maintenance clopidogrel to prasugrel in patients with acute coronary syndromes: results of the SWAP (SWitching Anti Platelet) study. ( Angiolillo, DJ; Costigan, TM; Deraad, R; Effron, MB; Frelinger, AL; Gurbel, PA; Jakubowski, JA; Ojeh, CK; Saucedo, JF, 2010) |
| "We genotyped patients from two large, randomized trials that showed that clopidogrel, as compared with placebo, reduced the rate of cardiovascular events (the primary efficacy outcome) among patients with acute coronary syndromes and among patients with atrial fibrillation." | 5.14 | Effects of CYP2C19 genotype on outcomes of clopidogrel treatment. ( Anand, SS; Bhatt, DL; Connolly, SJ; Eikelboom, JW; Fox, KA; Hirsh, J; Mehta, SR; Paré, G; Simonsen, K; Yusuf, S, 2010) |
| "Aspirin and clopidogrel are recommended for patients with acute coronary syndromes (ACS) or undergoing coronary stenting." | 5.14 | Ticagrelor versus clopidogrel in patients with ST-elevation acute coronary syndromes intended for reperfusion with primary percutaneous coronary intervention: A Platelet Inhibition and Patient Outcomes (PLATO) trial subgroup analysis. ( Ardissino, D; Becker, RC; Cannon, CP; Emanuelsson, H; Finkelstein, A; Harrington, RA; Husted, S; James, S; Katus, H; Kilhamn, J; Olofsson, S; Steg, PG; Storey, RF; Wallentin, L; Weaver, WD, 2010) |
| "In data we published earlier, there is a correlation between platelet aggregation in patients with acute coronary syndrome (ACS) who are receiving aspirin and elevated hsCRP-level." | 5.13 | The antiplatelet effect of atorvastatin in patients with acute coronary syndrome depends on the hs-CRP level. ( Kasyanova, O; Shpektor, A; Vasilieva, E, 2008) |
| "In the TRITON-TIMI 38 trial, greater platelet inhibition with prasugrel reduced the first occurrence of the primary endpoint (cardiovascular death, MI, or stroke) compared with clopidogrel in patients with an acute coronary syndrome (ACS) undergoing planned percutaneous coronary intervention." | 5.13 | Reduction in recurrent cardiovascular events with prasugrel compared with clopidogrel in patients with acute coronary syndromes from the TRITON-TIMI 38 trial. ( Antman, EM; Braunwald, E; Huber, K; Lopez-Sendon, J; McCabe, CH; Morocutti, G; Murphy, SA; Weerakkody, G; Wiviott, SD, 2008) |
| "Antiplatelet therapy with clopidogrel and acetylsalicylic acid (ASA) reduces major cardiovascular events in patients with ST and non-ST-segment-elevation acute coronary syndromes (ACS)." | 5.13 | Design and rationale of CURRENT-OASIS 7: a randomized, 2 x 2 factorial trial evaluating optimal dosing strategies for clopidogrel and aspirin in patients with ST and non-ST-elevation acute coronary syndromes managed with an early invasive strategy. ( Bassand, JP; Chrolavicius, S; Diaz, R; Fox, KA; Granger, CB; Jolly, S; Mehta, SR; Rupprecht, HJ; Widimsky, P; Yusuf, S, 2008) |
| "This prospective registered study was conducted to investigate the impact of statins (pravastatin, fluvastatin, atorvastatin) on clopidogrel platelet inhibition in patients with acute coronary syndrome (ACS) or stable angina." | 5.13 | [Impact of statins on clopidogrel platelet inhibition in patients with acute coronary syndrome or stable angina]. ( Shen, J; Zhang, Q; Zhang, RY, 2008) |
| "This post-hoc analysis suggests that in acute coronary syndrome patients, as long as clopidogrel is administered before or within 30 min of PCI treatment with bivalirudin alone is similarly effective to heparin plus a GP IIb/IIIa inhibitor in suppressing 30-day ischemic events with significantly less bleeding." | 5.13 | Influence of timing of clopidogrel treatment on the efficacy and safety of bivalirudin in patients with non-ST-segment elevation acute coronary syndromes undergoing percutaneous coronary intervention: an analysis of the ACUITY (Acute Catheterization and U ( Bertrand, ME; Chew, D; Cox, DA; Desmet, W; Feit, F; Lincoff, AM; Manoukian, SV; Mehran, R; Ohman, EM; Pollack, CV; Steinhubl, SR; Stone, GW; Ware, JH, 2008) |
| "We investigated how does troponin level (TnT) affect the benefit achieved by abciximab in patients with acute coronary syndromes (ACS) undergoing percutaneous coronary intervention (PCI) after pretreatment with a high loading dose of clopidogrel." | 5.13 | Troponin level and efficacy of abciximab in patients with acute coronary syndromes undergoing early intervention after clopidogrel pretreatment. ( Berger, PB; Bruskina, O; Dirschinger, J; Dotzer, F; Iijima, R; Kastrati, A; Mehilli, J; Ndrepepa, G; Neumann, FJ; Schömig, A; Schulz, S; ten Berg, J, 2008) |
| "Unresponsiveness to clopidogrel or aspirin has been reported in patients with acute coronary syndrome (ACS)." | 5.13 | Variable responsiveness to clopidogrel and aspirin among patients with acute coronary syndrome as assessed by platelet function tests. ( Einav, Y; Fefer, P; Hod, H; Lubetsky, A; Matetzky, S; Savion, N; Shenkman, B; Varon, D, 2008) |
| "The aim of this study is to investigate whether the benefit of abciximab in patients with non-ST-segment elevation acute coronary syndromes (NSTE-ACSs) undergoing percutaneous coronary intervention (PCI) after pre-treatment with 600 mg clopidogrel is sustained at 1 year." | 5.13 | One-year clinical outcomes with abciximab vs. placebo in patients with non-ST-segment elevation acute coronary syndromes undergoing percutaneous coronary intervention after pre-treatment with clopidogrel: results of the ISAR-REACT 2 randomized trial. ( Berger, PB; Bruskina, O; Dirschinger, J; Dotzer, F; Kastrati, A; Mehilli, J; Ndrepepa, G; Neumann, FJ; Pache, J; Schömig, A; Seyfarth, M; ten Berg, J, 2008) |
| "Intensive antiplatelet therapy with prasugrel resulted in fewer ischaemic outcomes including stent thrombosis than with standard clopidogrel." | 5.13 | Intensive oral antiplatelet therapy for reduction of ischaemic events including stent thrombosis in patients with acute coronary syndromes treated with percutaneous coronary intervention and stenting in the TRITON-TIMI 38 trial: a subanalysis of a randomi ( Antman, EM; Braunwald, E; Downey, WE; Herrman, JP; Horvath, I; Keltai, M; McCabe, CH; Murphy, SA; Scirica, BM; Van de Werf, F; Wiviott, SD, 2008) |
| "The ISAR-REACT 2 trial was designed to assess the effect of abciximab in patients with acute coronary syndromes undergoing percutaneous coronary intervention after a 600-mg loading dose of clopidogrel." | 5.13 | Effect of abciximab on clinical and angiographic restenosis in patients with non-ST-segment elevation acute coronary syndromes. ( Dirschinger, J; Iijima, R; Kastrati, A; Mehilli, J; Ndrepepa, G; Pache, J; Schömig, A; Seyfarth, M, 2008) |
| "In the PROVE IT-TIMI 22 study, 4162 patients with an acute coronary syndrome within the preceding 10 days were randomly assigned in a 1:1 fashion to pravastatin 40 mg or atorvastatin 80 mg daily." | 5.13 | High-dose atorvastatin does not negatively influence clinical outcomes among clopidogrel treated acute coronary syndrome patients--a Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis in Myocardial Infarction 22 (PROVE IT-TIMI 22) a ( Cannon, CP; Giugliano, GR; Lotfi, A; Murphy, SA; Schweiger, MJ, 2008) |
| "Prasugrel is superior to clopidogrel in preventing ischemic events in patients with an acute coronary syndrome who are undergoing percutaneous coronary intervention, but it is associated with an increased risk of major bleeding." | 5.13 | Early and late benefits of prasugrel in patients with acute coronary syndromes undergoing percutaneous coronary intervention: a TRITON-TIMI 38 (TRial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet InhibitioN with Prasugrel-Thrombolys ( Antman, EM; Braunwald, E; Chandna, H; Hasin, Y; Macias, W; McCabe, CH; Murphy, SA; Voitk, J; Widimsky, P; Wiviott, SD, 2008) |
| "Our goal was to compare the safety and initial efficacy of AZD6140, the first reversible oral adenosine diphosphate receptor antagonist, with clopidogrel in patients with non-ST-segment elevation acute coronary syndromes (NSTE-ACS)." | 5.12 | Safety, tolerability, and initial efficacy of AZD6140, the first reversible oral adenosine diphosphate receptor antagonist, compared with clopidogrel, in patients with non-ST-segment elevation acute coronary syndrome: primary results of the DISPERSE-2 tri ( Cannon, CP; Emanuelsson, H; Harrington, RA; Husted, S; Peters, G; Scirica, BM; Storey, RF, 2007) |
| " clopidogRel in non-ST-segment Elevation myocardial infarction)-2, we compared the antiplatelet effects of AZD6140 and clopidogrel and assessed the effects of AZD6140 in clopidogrel-pretreated patients." | 5.12 | Inhibition of platelet aggregation by AZD6140, a reversible oral P2Y12 receptor antagonist, compared with clopidogrel in patients with acute coronary syndromes. ( Cannon, CP; Emanuelsson, H; Grande, P; Gurbel, P; Harrington, RA; Heptinstall, S; Husted, S; Peters, G; Storey, RF; Wickens, M; Wilcox, RG, 2007) |
| "Dual-antiplatelet therapy with aspirin and a thienopyridine is a cornerstone of treatment to prevent thrombotic complications of acute coronary syndromes and percutaneous coronary intervention." | 5.12 | Prasugrel versus clopidogrel in patients with acute coronary syndromes. ( Antman, EM; Ardissino, D; Braunwald, E; De Servi, S; Gibson, CM; Gottlieb, S; McCabe, CH; Montalescot, G; Murphy, SA; Neumann, FJ; Riesmeyer, J; Ruzyllo, W; Weerakkody, G; Wiviott, SD, 2007) |
| " The Clopidogrel in Unstable angina to prevent Recurrent Events (CURE) trial demonstrated the effectiveness of clopidogrel plus acetylsalicylic acid (ASA) compared with ASA alone in reducing cardiovascular events in patients with acute coronary syndromes and, in addition, patients undergoing percutaneous coronary intervention in the Percutaneous Coronary Intervention in CURE (PCI-CURE) trial." | 5.12 | Cost-effectiveness of clopidogrel in acute coronary syndromes in Canada: a long-term analysis based on the CURE trial. ( Kolm, P; Mehta, SR; O'Brien, JA; Veledar, E; Weintraub, WS; Yuan, Y, 2007) |
| "To evaluate the interaction of atorvastatin or pravastatin with clopidogrel on platelet activation and aggregation function in patients with acute coronary syndromes (ACS) undergoing coronary stenting." | 5.12 | [The antiplatelet effect of clopidogrel is not attenuated by statin treatment in patients with acute coronary syndromes undergone coronary stenting]. ( Han, YL; Kang, J; Li, CY; Li, Y; Yan, CH, 2007) |
| "P2Y12 inhibitors, including clopidogrel have become an integral part of treatment for patients receiving coronary stent placement as a result of stable coronary artery disease or acute coronary syndromes (ACS) and also for medically managed ACS patients." | 4.98 | Role of CYP2C19 genotype testing in clinical use of clopidogrel: is it really useful? ( Bella, J; Krim, N; Zeb, I, 2018) |
| "Clopidogrel has significantly reduced the incidence of recurrent atherothrombotic events in patients with acute coronary syndrome (ACS) and in those undergoing percutaneous coronary intervention (PCI)." | 4.95 | Pharmacokinetic and Pharmacodynamic Responses to Clopidogrel: Evidences and Perspectives. ( Chen, XP; Li, MP; Tang, J; Zhang, YJ, 2017) |
| "Compared with standard clopidogrel therapy, individualized intensified antiplatelet therapy on the basis of platelet reactivity testing reduces the incidence of cardiovascular events in patient undergoing PCI, without increasing the risk of bleeding." | 4.95 | Individualized dual antiplatelet therapy based on platelet function testing in patients undergoing percutaneous coronary intervention: a meta-analysis of randomized controlled trials. ( Huang, C; Wang, Y; Wu, Y; Xu, W; Yan, H; Zhang, L; Zhou, Y; Zhu, J; Zhu, W, 2017) |
| " The combination of aspirin and a P2Y12 inhibitor in patients who receive a coronary stent reduces the rate of stent thrombosis and the rates of major adverse cardiovascular events." | 4.95 | The role of prasugrel in the management of acute coronary syndromes: a systematic review. ( Athanasiou, A; Damaskos, C; Moris, D; Politou, M; Spartalis, E; Spartalis, M; Tzatzaki, E, 2017) |
| "It is unknown whether pretreatment with clopidogrel in acute coronary syndrome (ACS) managed invasively, is superior to a strategy of administering clopidogrel in the cardiac catheterization laboratory at the time of percutaneous coronary intervention (PCI)." | 4.95 | Meta-analysis of clopidogrel pretreatment in acute coronary syndrome patients undergoing invasive strategy. ( Mukherjee, D; Naidu, SS; Nairooz, R; Pothineni, NV; Raina, S; Rochlani, Y; Sardar, P; Shavelle, DM; Valgimigli, M, 2017) |
| "A review of the literature was conducted for clinical trials evaluating the antiplatelet P2Y12 receptor antagonists, clopidogrel, prasugrel, and ticagrelor, as well as the guidelines for the management of acute coronary syndrome (ACS) or myocardial infarction." | 4.93 | Developments in Oral Antiplatelet Agents for the Treatment of Acute Coronary Syndromes: Clopidogrel, Prasugrel, and Ticagrelor. ( Roffman, DS, 2016) |
| "Despite the demonstrated benefits of Prasugrel, a new generation thienopyridine, in the prevention of thrombotic complications after percutaneous coronary interventions (PCI) for Acute Coronary Syndromes (ACS), its use is still precluded to those many patients arriving to the cath lab pre-treated with Clopidogrel." | 4.93 | Switching from Clopidogrel to Prasugrel in patients undergoing PCI: A meta-analytic overview. ( Barbieri, L; De Luca, G; Suryapranata, H; Verdoia, M, 2016) |
| "High on-clopidogrel platelet reactivity (HcPR) during dual-antiplatelet therapy is a marker of vascular risk, in particular stent thrombosis, in patients with acute coronary syndromes (ACS)." | 4.93 | On-treatment platelet reactivity: State of the art and perspectives. ( Giusti, B; Grifoni, E; Marcucci, R, 2016) |
| "Pretreatment with oral P2Y12 inhibitors occurs each time clopidogrel, prasugrel, ticagrelor are given to patients with suspected coronary artery disease before definition of the coronary anatomy." | 4.93 | Reviewing the controversy surrounding pre-treatment with P2Y12 inhibitors in acute coronary syndrome patients. ( Angiolillo, DJ; Capodanno, D, 2016) |
| " Current guidelines recommend various antiplatelet agents in addition to aspirin for patients with acute coronary syndromes." | 4.93 | The pharmacodynamics of antiplatelet compounds in thrombosis treatment. ( Geraldine, P; Jayakumar, T; Sheu, JR; Yang, CH; Yen, TL, 2016) |
| "Clopidogrel and aspirin are among the most prescribed dual antiplatelet therapies to treat the acute coronary syndrome and heart attacks." | 4.93 | Cytochrome allelic variants and clopidogrel metabolism in cardiovascular diseases therapy. ( Behl, S; Ganah, H; Jarrar, M; Manyam, G; Moustafa, K; Nasab, R; Nazir, M, 2016) |
| "Dual antiplatelet therapy (DAPT) with aspirin combined with either a thienopyridine (clopidogrel or prasugrel) or acyclopentyl-triazolo-pyrimidine (ticagrelor) plays a vital role in the management of acute coronary syndrome (ACS) especially in those undergoing percutaneous coronary intervention (PCI) but even those being managed medically." | 4.93 | Prasugrel hydrochloride for the treatment of acute coronary syndrome patients. ( Gershlick, AH; Gunarathne, A; Hussain, S, 2016) |
| "After acute coronary syndromes (ACS), the so-called dual antiplatelet therapy (DAPT), which usually consists of low-dose of aspirin in combination with a thienopyridine (clopidogrel, prasugrel) or with a cyclopentyltriazolopyrimidine (ticagrelor), reduces the risk of ischemic events." | 4.93 | Pharmacokinetics and pharmacodynamics of ticagrelor in the treatment of cardiac ischemia. ( Bianco, D; Brunelli, C; Chiarella, F; Massobrio, L; Rosa, GM; Valbusa, A, 2016) |
| "Clopidogrel combined with aspirin is routinely prescribed after coronary artery stenting, in patients with acute coronary syndromes, and recently to prevent stroke in patients with acute minor ischemic stroke and TIA." | 4.91 | Effect of addition of clopidogrel to aspirin on subdural hematoma: meta-analysis of randomized clinical trials. ( Bakheet, MF; Hart, RG; Pearce, LA, 2015) |
| "Clopidogrel is an antiplatelet agent widely prescribed for acute coronary syndrome (ACS), and it is activated by the CYP enzyme system to active metabolite." | 4.91 | Review of pharmacoeconomic evaluation of genotype-guided antiplatelet therapy. ( Jiang, M; You, JH, 2015) |
| "Prasugrel has similar effects as clopidogrel in terms of all causes of death, MI, and stroke in ACS patients." | 4.91 | Novel oral P2Y12 inhibitor prasugrel vs. clopidogrel in patients with acute coronary syndrome: evidence based on 6 studies. ( Chen, K; Chu, H; Jia, M; Li, L; Li, Z, 2015) |
| " We present a case of profound thrombocytopenia due to administration of a glycoprotein IIb/IIIa receptor antagonist, eptifibatide, after percutaneous coronary intervention for an inferior ST-elevation myocardial infarction." | 4.91 | Thrombocytopenia in acute coronary syndromes: etiologies and proposed management. ( Bainey, KR; Ferguson, C; Sharma, A, 2015) |
| "Ticagrelor is recommended in local and international guidelines as first-line therapy in combination with aspirin in patients presenting with acute coronary syndromes (ACS)." | 4.91 | Practical experience with ticagrelor: an Australian and New Zealand perspective. ( Amerena, J; Aylward, PE; Gunasekara, A; Harding, SA; Mussap, CJ; Schrale, R; Van Gaal, WJ, 2015) |
| " Ticagrelor or prasugrel in addition to aspirin should be used preferentially for patients with ST-elevation myocardial infarction because of significant anti-ischemic benefits." | 4.91 | Current Evidence on Platelet P2Y12 Receptor Inhibitors: Is There Still a Role for Clopidogrel in 2015? ( Chong, AY; Qutub, MA; So, DY, 2015) |
| " However, prasugrel and ticagrelor have a more consistent, faster-acting and more potent antiplatelet effect than clopidogrel, which translates into improved clinical outcomes, although at the expense of an increased bleeding risk." | 4.91 | Antiplatelet therapy in acute coronary syndromes. ( Grove, EL; Kristensen, SD; Thomas, MR; Würtz, M, 2015) |
| "New P2Y12 inhibitors decreased death in patients undergoing PCI compared with clopidogrel with a considerable safety and tolerability profile; however, the risk/benefit ratio of ischemic and bleeding events should be further investigated." | 4.91 | Efficacy and safety analysis of new P2Y12 inhibitors versus clopidogrel in patients with percutaneous coronary intervention: a meta-analysis. ( Ding, SL; Fang, D; Fang, Q; Gan, XD; Li, KY; Peng, S; Wan, J; Wei, BZ, 2015) |
| "Dual antiplatelet therapy with aspirin and clopidogrel reduces cardiovascular events following an acute coronary syndrome or stent implantation, but the associated increased risk of gastro-intestinal bleeding often leads to the co-administration of proton pump inhibitors (PPIs)." | 4.90 | Proton pump inhibitors and clopidogrel: an association to avoid? ( D'Ugo, E; De Caterina, R; Rossi, S, 2014) |
| "Literature archives (Pubmed, EMBASE, Cochrane) and main scientific sessions abstracts were scanned for randomized trials comparing new ADP antagonists with clopidogrel in patients with acute coronary syndromes or stable angina." | 4.90 | Benefits from new ADP antagonists as compared with clopidogrel in patients with stable angina or acute coronary syndrome undergoing invasive management: a meta-analysis of randomized trials. ( Barbieri, L; Cassetti, E; De Luca, G; Galasso, G; Marino, P; Piccolo, R; Schaffer, A; Sinigaglia, F; Verdoia, M, 2014) |
| " Laboratory and clinical data have convincingly shown the benefit of P2Y12 inhibition combined with aspirin in patients with acute coronary syndrome (ACS)/undergoing percutaneous coronary intervention (PCI)." | 4.90 | p2y12 receptor inhibitors in acute coronary syndromes: from the research laboratory to the clinic and vice versa. ( Alexopoulos, D, 2014) |
| " These P2Y12 inhibitors might be superior to clopidogrel for reducing ischemic events in patients with coronary artery disease (CAD)." | 4.90 | Impact of new oral or intravenous P2Y12 inhibitors and clopidogrel on major ischemic and bleeding events in patients with coronary artery disease: a meta-analysis of randomized trials. ( Fan, JY; Jin, C; Meng, J; Tang, XF; Yang, YJ; Yuan, JQ, 2014) |
| "Patients presenting with acute coronary syndrome (ACS) are treated with dual antiplatelet agents, including aspirin and clopidogrel, to prevent mortality and recurrent ischemia." | 4.90 | Should clopidogrel be discontinued before coronary artery bypass grafting for patients with acute coronary syndrome? A systematic review and meta-analysis. ( Ang, SC; Bannon, PG; Cao, C; Indraratna, P; Manganas, C; Park, J; Yan, TD, 2014) |
| "The two new drugs prasugrel and ticagrelor were included in the current guidelines for the treatment of patients with acute coronary syndrome." | 4.90 | [Dual platelet inhibitors in intensive care units]. ( Delle Karth, G; Siller-Matula, JM, 2014) |
| " Treatment guidelines for acute coronary syndrome and percutaneous coronary intervention now recommend the use of oral antiplatelet agents including clopidogrel in combination with aspirin (dual antiplatelet therapy: DAPT) for the prevention of recurrent ischemic events." | 4.90 | [Antiplatelet drugs]. ( Nishikawa, M, 2014) |
| "Dual antiplatelet therapy with aspirin and a P2Y12 receptor antagonist, either clopidogrel or the newer more potent agents prasugrel or ticagrelor, is standard therapy in patients receiving a coronary stent and those with a recent acute coronary syndrome." | 4.90 | Pharmacodynamic and clinical implications of switching between P2Y12 receptor antagonists: considerations for practice. ( Bagai, A; Chua, D; Cohen, EA; Fitchett, D; Saw, J; Verma, S; Vijayaraghavan, R; Welsh, R, 2014) |
| " In the second part of the review is discussed higher incidence of myocardial infarction in controlled group in the trial comparing treatment of dabigatran with warfarin." | 4.90 | [Anticoagulant therapy in secondary prevention of coronary events]. ( Bultas, J, 2014) |
| "Clopidogrel is one of the most commonly prescribed medications and is currently recommended along with aspirin as treatment to be used for 1 year in all patients without contraindications following an acute coronary syndrome." | 4.89 | Dual antiplatelet therapy with aspirin and clopidogrel: what is the risk in noncardiac surgery? A narrative review. ( Finkel, JB; Marhefka, GD; Weitz, HH, 2013) |
| "The novel oral P2Y12 inhibitors (prasugrel and ticagrelor) have been incorporated into the recently updated acute coronary syndrome (ACS) guidelines, as an adjunct antiplatelet treatment to aspirin." | 4.89 | [Prominent features of management strategies in acute coronary syndromes with the new oral antiplatelet agents]. ( Enar, R, 2013) |
| "Aspirin is a cornerstone of therapy in the treatment of patients with acute coronary syndromes (ACS)." | 4.89 | Clopidogrel, prasugrel, or ticagrelor? a practical guide to use of antiplatelet agents in patients with acute coronary syndromes. ( Dinicolantonio, JJ; Norgard, NB, 2013) |
| " As part of a planned re-evaluation within 2 years, we conducted an extensive literature search encompassing all topics included in the 2010 CCS Guidelines, and concluded that there were sufficient new data to merit revisiting the guidance on antiplatelet therapy for secondary prevention in the first year after acute coronary syndrome (ACS), percutaneous coronary intervention, or coronary artery bypass grafting, and the interaction between clopidogrel and proton pump inhibitors." | 4.89 | Focused 2012 update of the Canadian Cardiovascular Society guidelines for the use of antiplatelet therapy. ( Ackman, ML; Bauer, RD; Bell, AD; Cartier, R; Chan, WS; Douketis, J; Mehta, SR; Roussin, A; Schnell, G; Tanguay, JF; Verma, S; Wong, G, 2013) |
| "Dual antiplatelet therapy (DAPT) with aspirin and a P2Y12 receptor antagonist is the standard of care in acute coronary syndromes." | 4.89 | Triple versus dual antiplatelet therapy in acute coronary syndromes: adding cilostazol to aspirin and clopidogrel? ( Bangalore, S; Dinicolantonio, JJ; Lavie, CJ; Meier, P; Niazi, AK; O'Keefe, JH, 2013) |
| "Aspirin is still the mainstay of therapy in patients with acute coronary syndromes." | 4.89 | Dual antiplatelet therapy -- management in general practice. ( Adsett, G; Jayasinghe, R; Markham, R, 2013) |
| " In the large Phase III trial, PLATO, ticagrelor significantly reduced the composite of cardiovascular death, myocardial infarction, or stroke as well as cardiovascular and all-cause mortality compared with clopidogrel in patients presenting with acute coronary syndromes." | 4.89 | Ticagrelor for acute coronary syndromes. ( Bansilal, S; Bonaca, MP; Sabatine, MS, 2013) |
| "Clopidogrel is an oral tyenopiridin with a central role in the management of acute coronary syndromes and after stent implantation." | 4.89 | What's new about clopidogrel. ( Biasucci, LM; Camaioni, C; Cialdella, P; Gustapane, M, 2013) |
| "The antiplatelet drug clopidogrel is a commonly prescribed therapy in patients with acute coronary syndrome." | 4.89 | Genetic and nongenetic factors influencing the response to clopidogrel. ( Bontardelli, F; Merlini, PA; Notarangelo, MF, 2013) |
| "Clopidogrel, a pro-drug whose active metabolite is an inhibitor of the platelet P2Y12 receptor, is used mostly for the prevention of cardiovascular events in patients with acute coronary syndromes undergoing percutaneous coronary interventions." | 4.89 | Potential clinical utility of genetic and platelet function tests in patients on treatment with clopidogrel. ( Cattaneo, M, 2013) |
| "Some patients with acute coronary syndromes and/or who are undergoing percutaneous coronary interventions (PCI) remain at risk for cardiovascular events despite antiplatelet treatment with clopidogrel." | 4.89 | Identifying responsiveness to oral P2Y12 receptor blockers: platelet function assays and genetic tests. ( Valgimigli, M, 2013) |
| "Dual antiplatelet therapy with aspirin plus a P2Y(12) receptor inhibitor is the cornerstone of treatment for patients with acute coronary syndrome and in those undergoing percutaneous coronary intervention." | 4.89 | Switching antiplatelet regimens: alternatives to clopidogrel in patients with acute coronary syndrome undergoing PCI: a review of the literature and practical considerations for the interventional cardiologist. ( Angiolillo, DJ; Azmoon, S, 2013) |
| "Until a few years ago, the mainstay of anti-platelet therapy in patients with acute coronary syndrome (ACS) was the combination of aspirin and clopidogrel, a P2Y12 receptor inhibitor." | 4.89 | A critical overview on ticagrelor in acute coronary syndromes. ( Austin, D; Buffon, A; De Servi, S; Kozinski, M; Kubica, J; Kunadian, V; Navarese, EP; Obonska, K; Rychter, M; Sukiennik, A, 2013) |
| " The thienopyridines are an integral part of antithrombotic therapy and are prescribed for various indications including acute coronary syndrome, peripheral vascular disease and cerebrovascular disease." | 4.89 | Metabolic differences of current thienopyridine antiplatelet agents. ( Fareed, J; Jeske, W; Thethi, I, 2013) |
| "Thrombosis risk necessitates dual antiplatelet therapy with aspirin and an adenosine diphosphate (ADP) receptor antagonist, in patients who have acute coronary syndrome." | 4.88 | A comprehensive comparative review of adenosine diphosphate receptor antagonists. ( Abraham, T; Balmir, E; Oh, EY; Rapp, JH; Saad, N; Vastey, FL, 2012) |
| " In comparison with mono antiplatelet therapy, dual therapy (aspirin+dipyridamole and aspirin+clopidogrel) significantly reduced stroke recurrence, dual 58 (3." | 4.88 | Dual or mono antiplatelet therapy for patients with acute ischemic stroke or transient ischemic attack: systematic review and meta-analysis of randomized controlled trials. ( Algra, A; Bath, MW; Bath, PM; Chen, C; Dengler, R; Diener, HC; Geeganage, CM; Markus, HS; Topol, EJ, 2012) |
| " In the last few years, cilostazol, a phosphodiesterase (PDE) 3 inhibitor, has been tested in the setting of acute coronary syndromes: it exerts not only anti-platelet actions, but also pleiotropic effects, including inhibition on neointimal hyperplasia, therefore preventing both stent restenosis and thrombosis." | 4.88 | Cilostazol and primary-PCI: mirage or good alternative? ( Crea, F; D'Amario, D; Porto, I, 2012) |
| "In patients with acute coronary syndromes undergoing percutaneous coronary intervention, the combination of aspirin and clopidogrel, a P2Y12 adenosine diphosphate (ADP) receptor antagonist, is the gold standard of antiplatelet therapy." | 4.88 | Latest evidence in personalized antiplatelet therapy in patients with acute coronary syndromes undergoing percutaneous coronary intervention. ( Bessereau, J; Bonello, L; Camoin-Jau, L; Paganelli, F; Uhry, S, 2012) |
| "P2Y12 adenosine di-phosphate (ADP) receptor antagonists are critical to reduce thrombotic recurrences in acute coronary syndromes patients and for those undergoing percutaneous coronary revascularization." | 4.88 | Tailoring antiplatelet therapy: a step toward individualized therapy to improve clinical outcome? ( Bessereau, J; Bonello, L; Camoin-Jau, L; Laine, M; Paganelli, F; Sébastien, A, 2012) |
| "Ticagrelor, an oral P2Y(12) receptor antagonist used as part of dual antiplatelet therapy in the treatment of acute coronary syndromes (ACS), has many favorable characteristics when compared with the more frequently used P2Y(12) receptor antagonist clopidogrel." | 4.88 | Review of ticagrelor in the management of acute coronary syndromes. ( Burgess, S; Juergens, CP; Mallard, TA, 2012) |
| "Although some patients suffer from dyspnea when administered with ticagrelor, there is no evidence of any untoward effects on the cardiovascular or pulmonary systems." | 4.88 | Safety profile and bleeding risk of ticagrelor compared with clopidogrel. ( Lincoff, AM; May, CH, 2012) |
| "Dual antiplatelet therapy with acetylsalicylic acid (aspirin) and clopidogrel is a guideline-recommended standard of care for patients with acute coronary syndromes (ACS) and those who undergo percutaneous coronary intervention (PCI)." | 4.88 | Clopidogrel: the data, the experience, and the controversies. ( Sadanandan, S; Singh, IM, 2012) |
| "To evaluate the association of clopidogrel pretreatment vs no treatment with mortality and major bleeding after PCI." | 4.88 | Association of clopidogrel pretreatment with mortality, cardiovascular events, and major bleeding among patients undergoing percutaneous coronary intervention: a systematic review and meta-analysis. ( Barthélémy, O; Bellemain-Appaix, A; Bernasconi, F; Beygui, F; Collet, JP; Cucherat, M; Jacq, L; Montalescot, G; O'Connor, SA; Silvain, J, 2012) |
| "Enhanced platelet inhibition by clopidogrel decreases the risk of ischemic events but carries a risk for a concomitant increase in bleeding." | 4.87 | Impact of clopidogrel loading dose on clinical outcome in patients undergoing percutaneous coronary intervention: a systematic review and meta-analysis. ( Christ, G; Herkner, H; Huber, K; Jilma, B; Kubica, J; Schrör, K; Siller-Matula, JM, 2011) |
| "The widespread use of clopidogrel alone or in combination with aspirin has significantly benefited patients with acute coronary syndrome who are managed medically or by percutaneous coronary intervention and stent implantation, greatly improving their survival." | 4.87 | Individual variability in the disposition of and response to clopidogrel: pharmacogenomics and beyond. ( Chen, SL; Hu, ZY; Xie, HG; Ye, F; Zhang, JJ; Zou, JJ, 2011) |
| "Clinicians will be able to understand the safety profile of using different doses of clopidogrel and the incidence of bleeding when used alone or in combination with other antiplatelet agents." | 4.87 | The safety of clopidogrel. ( Kleiman, NS; Mangalpally, KK, 2011) |
| "Dual antiplatelet therapy with aspirin and clopidogrel is routinely indicated in patients with acute coronary syndromes and following percutaneous coronary intervention to reduce the risk of cardiovascular mortality and ischaemic events." | 4.87 | Clopidogrel withdrawal: is there a "rebound" phenomenon? ( Curzen, N; Sambu, N; Warner, T, 2011) |
| " The withdrawal of clopidogrel earlier than 4-6 weeks after bare metal stent implantation or less than 12 months after drug-eluting stent implantation is very risky and poses a high risk of stent thrombosis and high perioperative mortality." | 4.87 | Antiplatelet therapy in the perioperative period. ( Táborský, M; Václavík, J, 2011) |
| "Literature was accessed through MEDLINE (1966-October 2010 week 1), EMBASE (1980-2010 week 40), and a bibliographic review of published articles using the search terms acute coronary syndrome, clopidogrel, and prasugrel." | 4.87 | Thienopyridines in Acute Coronary Syndrome. ( Desilets, AR; Goodwin, MM; Willett, KC, 2011) |
| "Although the exact prevalence of antiplatelet resistance in ischemic stroke is not known, estimates about the two most widely used antiplatelet agents - aspirin and clopidogrel - suggest that the resistance rate is high, irrespective of the definition used and parameters measured." | 4.87 | Antiplatelet resistance in stroke. ( Arsava, EM; Ay, H; Topçuoglu, MA, 2011) |
| "The use of triple therapy (warfarin plus dual antiplatelet therapy) has increased in recent years due to an aging population with a higher risk for atrial fibrillation, as well as the increased use of coronary stents for acute coronary syndromes." | 4.87 | Triple therapy in hospitalized patients: facts and controversies. ( Smetana, GW; Srour, JF, 2011) |
| "Clopidogrel has become part of the mainstay of therapy for acute coronary syndromes and in patients post stenting." | 4.87 | Proton pump inhibitors, genetic polymorphisms and response to clopidogrel therapy. ( Dart, AM; Fernando, H; Peter, K; Shaw, JA, 2011) |
| "Clopidogrel use is associated with a significant decrease in major adverse cardiac events when used in patients with non-ST elevation acute coronary syndromes (NSTE-ACS), and guidelines give a class I level of evidence A recommendation for the use of clopidogrel in these patients." | 4.87 | Early clopidogrel use in non-ST elevation acute coronary syndrome and subsequent coronary artery bypass grafting. ( Burke, MA; Fintel, DJ; Lee, R, 2011) |
| " The benefits in mortality and reinfarction were driven by the treatment with prasugrel or ticagrelor, without a significant difference in terms of major bleeding complications as compared to standard-dose clopidogrel (5% vs." | 4.87 | Ischaemic and bleeding complications with new, compared to standard, ADP-antagonist regimens in acute coronary syndromes: a meta-analysis of randomized trials. ( Castriota, F; De Luca, G; De Servi, S; Kozinski, M; Kubica, J; Navarese, EP; Schaffer, A; Suriano, P; Verdoia, M, 2011) |
| "Dual antiplatelet therapy with aspirin and clopidogrel is a well-established standard of care for patients with acute coronary syndromes." | 4.87 | Beyond aspirin and clopidogrel: is there a need for additional antiplatelet therapy in ACS? ( Moliterno, DJ; Rajan, L, 2011) |
| "Current guidelines from the National Institute for Clinical Excellence (NICE) recommend antiplatelet therapy comprising aspirin plus either clopidogrel or prasugrel for patients with acute coronary syndrome (ACS)." | 4.87 | Ticagrelor for acute coronary syndrome? ( , 2011) |
| "Prasugrel's clinical benefits were counterbalanced by an increase in bleeding risk compared with conventional thienopyridine treatment with clopidogrel." | 4.87 | Emerging antiplatelet therapies in percutaneous coronary intervention: a focus on prasugrel. ( Martin, MT; Nutescu, EA; Spinler, SA, 2011) |
| "The optimal length of clopidogrel therapy in patients with acute coronary syndromes or in those who have undergone percutaneous coronary intervention (PCI) remains controversial." | 4.87 | Systematic review of thienopyridine discontinuation and its impact upon clinical outcomes. ( Gaglia, MA; Waksman, R, 2011) |
| " In clinical trials the antiplatelet agent reduced significantly vascular mortality and death from any cause when compared to clopidogrel in patients with acute coronary syndrome." | 4.87 | [Ticagrelor: a novel antiplatelet agent for patients with acute coronary syndrome]. ( Hinneburg, I, 2011) |
| " Eligibility criteria for selecting studies Original full length reports assessing the cumulative incidence of major adverse cardiovascular events or stent thrombosis over a follow-up period of at least a month in association with carrier status for the loss of function or gain of function CYP2C19 allele in adult patients with coronary artery disease and a clinical presentation of acute coronary syndrome or stable angina pectoris who were taking clopidogrel." | 4.87 | Impact of CYP2C19 variant genotypes on clinical efficacy of antiplatelet treatment with clopidogrel: systematic review and meta-analysis. ( Bauer, T; Bouman, HJ; Ford, NF; Taubert, D; ten Berg, JM; van Werkum, JW, 2011) |
| "Dual oral antiplatelet therapy with aspirin and clopidogrel is the therapy of choice in patients with acute coronary syndromes and in patients undergoing coronary stent placement to lower the risk of thrombotic events." | 4.87 | The future of platelet function testing to guide therapy in clopidogrel low and enhanced responders. ( Bernlochner, I; Byrne, RA; Kastrati, A; Sibbing, D, 2011) |
| "Current guidelines recommend dual antiplatelet therapy, a combination of aspirin and a P2Y(12) inhibitor, for 6?12 months after percutaneous coronary intervention with drug-eluting stent implantation in all patients and for 1 year in all patients after an acute coronary syndrome (ACS), irrespective of revascularization strategy." | 4.87 | Antiplatelet options for secondary prevention in acute coronary syndromes. ( Cayla, G; Collet, JP; Montalescot, G; O'Connor, SA; Silvain, J, 2011) |
| " The phase 3 PLATelet Inhibition and Patient Outcomes (PLATO) trial (NCT00391872) evaluated ticagrelor compared with clopidogrel in 18 624 patients with acute coronary syndromes (ACS), and demonstrated a significant reduction in the risk of death from vascular causes/myocardial infarction (MI)/stroke with ticagrelor (9." | 4.87 | Evaluating the risk-benefit profile of the direct-acting P2Y(12) inhibitor ticagrelor in acute coronary syndromes. ( Husted, S, 2011) |
| "Early initiation of antiplatelet therapy in addition to aspirin is critical for all patients with acute coronary syndrome (ACS) due to improved short- and long-term outcomes." | 4.86 | Unresolved issues associated with early initiation of antiplatelet therapy in acute coronary syndromes. ( Alagona, P, 2010) |
| "To summarize the pharmacokinetic and pharmacodynamic properties of ticagrelor, a selective P2Y12 receptor antagonist, and evaluate its role in the treatment of patients with acute coronary syndromes (ACS)." | 4.86 | Efficacy and safety of ticagrelor: a reversible P2Y12 receptor antagonist. ( Anderson, SD; Epstein, BJ; Shah, NK; Yim, J, 2010) |
| "Clopidogrel in combination with aspirin is the recommended standard of care for reducing the occurrence of cardiovascular events in patients presenting with acute coronary syndromes; these protective effects of clopidogrel have been shown both in patients undergoing percutaneous coronary intervention (PCI) and in those treated with medical therapy alone." | 4.86 | [Extent of platelet aggregation inhibition and clinical events: new evidence with prasugrel]. ( Abbate, R; Crea, F; De Servi, S; Filippi, E; Gensini, GF; Golinos, P; Savonitto, S, 2010) |
| "Standard double antiplatelet therapy (aspirin plus clopidogrel) used in patients with coronary artery disease during acute coronary syndromes (ACS) and/or in conjunction with percutaneous coronary interventions (PCI) has some limitations." | 4.86 | [Antiplatelet therapy in coronary heart disease. Some problems and achivements]. ( Gratsianskiĭ, NA, 2010) |
| " The long-term benefit of dual anti-platelet therapy with clopidogrel and aspirin is well established for patients with acute coronary syndrome and for secondary prophylaxis of coronary artery disease." | 4.86 | [Platelet inhibition with prasugrel]. ( Caglayan, E; Er, F; Erdmann, E; Gassanov, N; Nia, AM, 2010) |
| " Newer agents, such as bivalirudin or fondaparinux, reduce bleeding complications, with no improvement in anti-ischemic efficacy." | 4.86 | Pharmacologic therapy for non ST-segment elevation acute coronary syndromes: focus on antithrombotic therapy. ( Aïssaoui, N; Danchin, N, 2010) |
| "The use of clopidogrel and aspirin has become standard therapy in patients with acute coronary syndromes and stent implantation." | 4.86 | Nonresponders to clopidogrel: pharmacokinetics and interactions involved. ( Di Girolamo, G; Giorgi, MA; González, CD, 2010) |
| "The platelet ADP receptor antagonist clopidogrel is recommended for the treatment of patients with acute coronary syndrome and/or percutaneous coronary intervention." | 4.86 | Clopidogrel in acute coronary syndrome: implications of recent study findings. ( Bode, C; Duerschmied, D; Moser, M, 2010) |
| "The administration of dual antiplatelet therapy with aspirin and a thienopyridine for the prevention of thrombosis in patients with acute coronary syndrome undergoing percutaneous coronary intervention is proven to reduce mortality." | 4.86 | A comparison of the metabolism of clopidogrel and prasugrel. ( Laizure, SC; Parker, RB, 2010) |
| "Among patients treated with clopidogrel for percutaneous coronary intervention, carriage of even 1 reduced-function CYP2C19 allele appears to be associated with a significantly increased risk of major adverse cardiovascular events, particularly stent thrombosis." | 4.86 | Reduced-function CYP2C19 genotype and risk of adverse clinical outcomes among patients treated with clopidogrel predominantly for PCI: a meta-analysis. ( Anderson, JL; Antman, EM; Bliden, K; Cannon, CP; Collet, JP; Danchin, N; Giusti, B; Gurbel, P; Horne, BD; Hulot, JS; Kastrati, A; Mega, JL; Montalescot, G; Neumann, FJ; Sabatine, MS; Shen, L; Sibbing, D; Simon, T; Steg, PG; Trenk, D; Wiviott, SD, 2010) |
| "A proton pump inhibitor (PPI) is often co-prescribed with clopidogrel to reduce the gastrointestinal risk of bleeding ulcers in patients following acute coronary syndrome or a stent implant." | 4.86 | Controversy of proton pump inhibitor and clopidogrel interaction: a review. ( Tan, HJ, 2010) |
| "Clopidogrel plus aspirin is considered the antiplatelet treatment of choice in patients with acute coronary syndrome, whether or not they are undergoing a percutaneous coronary intervention (PCI)." | 4.86 | Inhibition of the antithrombotic effects of clopidogrel by proton pump inhibitors: facts or fancies? ( Lettino, M, 2010) |
| " Recent phase III data demonstrate that prasugrel is superior to clopidogrel in preventing cardiovascular morbidity and mortality in patients with acute coronary syndrome undergoing percutaneous coronary intervention, although with a greater risk of bleeding." | 4.86 | Prasugrel: an efficacy and safety review of a new antiplatelet therapy option. ( Armani, AM, 2010) |
| "Antiplatelet therapy (aspirin + clopidogrel) is the cornerstone of treatment for patients with acute coronary syndromes and/or undergoing percutaneous coronary interventions (PCI)." | 4.86 | [Current options to manage clopidogrel poor responsiveness]. ( Campo, G; Ferrari, R; Fileti, L; Marchesini, J; Valgimigli, M, 2010) |
| " Although monotherapy with either aspirin or clopidogrel has been validated in secondary prevention, for high-risk patients such as those with acute coronary syndromes or requiring percutaneous coronary intervention, dual antiplatelet therapy appears to be most beneficial." | 4.85 | Role of antiplatelet therapy across the spectrum of patients with coronary artery disease. ( Bhatt, DL, 2009) |
| "Patients with acute coronary syndromes and patients who undergo coronary stent implantation frequently receive dual antiplatelet therapy with aspirin and a thienopyridine." | 4.85 | Monitoring platelet function to reduce the risk of ischemic and bleeding complications. ( Price, MJ, 2009) |
| "Clopidogrel is important for the management of acute coronary syndromes and, along with aspirin, is recommended in the American College of Cardiology/American Heart Association guideline." | 4.85 | Clopidogrel resistance: pharmacokinetic or pharmacogenetic? ( Ford, NF, 2009) |
| "Antiplatelet agents like aspirin and clopidogrel are treatment cornerstones for acute coronary syndromes (ACS)." | 4.85 | Unmet needs in oral antiplatelet therapy with ADP receptor blocking agents. ( Husted, S, 2009) |
| " Administration of antiplatelet therapy--a glycoprotein IIb-IIIa inhibitor with or without clopidogrel--before catheterization in patients with high-risk features confers substantially reduced risk of ischemic events while potentially increasing bleeding risk." | 4.85 | Does timing matter? Upstream or downstream administration of antiplatelet therapy. ( Pollack, CV; Slattery, D, 2009) |
| "Currently, dual antiplatelet therapy with aspirin and clopidogrel represents the key treatment strategy for the prevention of ischemic events in patients with acute coronary syndrome (ACS) and/or undergoing percutaneous coronary intervention (PCI)." | 4.85 | Prasugrel in acute coronary syndrome patients undergoing percutaneous coronary intervention. ( Angiolillo, DJ; Capranzano, P; Ferreiro, JL, 2009) |
| "Since the development and market entry of clopidogrel, a platelet ADP blocker, physicians have had few new antiplatelet options available to them for the treatment of acute and chronic coronary disease, specifically in the setting of acute coronary syndromes, percutaneous coronary intervention, and chronic stent management." | 4.85 | A new generation of antiplatelet agents. ( Harrington, RA; Sellers, MB; Tricoci, P, 2009) |
| "To update the previous systematic review of the use of clopidogrel in combination with aspirin for patients with non-ST-elevation acute coronary syndrome (NSTE-ACS), investigating the optimal duration of treatment and effects of withdrawal from treatment." | 4.85 | The effect of different treatment durations of clopidogrel in patients with non-ST-segment elevation acute coronary syndromes: a systematic review and value of information analysis. ( Burch, J; Craigs, C; Golder, S; Palmer, S; Rogowski, W; Woolacott, N, 2009) |
| "Currently, clopidogrel is recommended for treatment of patients with acute coronary syndrome and/or percutaneous coronary intervention." | 4.85 | P2Y(12) inhibitors: differences in properties and mechanisms of action and potential consequences for clinical use. ( Wallentin, L, 2009) |
| "Earlier studies may have overestimated the risk of bleeding in patient undergoing CABG with prior clopidogrel exposure (5-10-fold increase)." | 4.85 | Coronary bypass surgery in patients treated with clopidogrel. Is it safe? ( Carrel, T; Englberger, L, 2009) |
| "Current guidelines support dual antiplatelet therapy with aspirin and clopidogrel (Plavix) in a number of clinical scenarios, ie, in ST-segment-elevation myocardial infarction (MI), non-ST-elevation MI, and percutaneous coronary intervention." | 4.85 | Dual antiplatelet therapy in coronary artery disease: a case-based approach. ( Menon, V; Raymond, C, 2009) |
| "Dual antiplatelet therapy with aspirin and clopidogrel is a cornerstone of the management of patients with acute coronary syndromes and following percutaneous coronary intervention." | 4.85 | Prasugrel: Clinical development and therapeutic application. ( Guerra, DR; Tcheng, JE, 2009) |
| "The current standard of care for patients with non-ST-elevation acute coronary syndromes--aspirin, clopidogrel, and glycoprotein IIb-IIIa inhibitors for the majority of patients--is being challenged by recent clinical trials (Intracoronary Stenting and Antithrombotic Regimen: Rapid Early Action for Coronary Treatment, Intracoronary Stenting and Antithrombotic Regimen: Rapid Early Action for Coronary Treatment 2, Randomized Evaluation of Percutaneous coronary intervention Linking Angiomax to Reduced Clinical Events-2, Acute Catheterization and Urgent Intervention Triage StrategY), raising important questions regarding the value of glycoprotein IIb-IIIa inhibitors as accompaniments of high-dose clopidogrel pretreatment and increased use of the anticoagulant bivalirudin." | 4.84 | Antiplatelet and anticoagulant agents: key differences in mechanisms of action, clinical application, and therapeutic benefit in patients with non-ST-segment-elevation acute coronary syndromes. ( Jennings, LK; Saucedo, JF, 2008) |
| " In patients with ACS, inhibition of platelet activation beyond that produced by clopidogrel 600 mg has been associated with an increased bleeding risk." | 4.84 | Benefits and risks of clopidogrel use in patients with coronary artery disease: evidence from randomized studies and registries. ( Kala, P; Motovska, Z, 2008) |
| "The clinical benefit of the combination of aspirin plus clopidogrel over aspirin alone to prevent recurrent events after acute coronary syndrome is obviously a key step of the past few years in the management of coronary artery disease." | 4.84 | [Management coronary syndrome in the acute phase]. ( Collet, JP; Montalescot, G, 2007) |
| "The P2Y12 antagonist clopidogrel has a well-established role as an antithrombotic agent in the settings of percutaneous coronary intervention and acute coronary syndromes." | 4.84 | P2Y12 antagonism: promises and challenges. ( Michelson, AD, 2008) |
| " We explore the role of glycoprotein IIb-IIIa inhibitors and the direct thrombin inhibitor bivalirudin in ACS patients, and consider the difficulties involved in reducing ischemic events while limiting bleeding risks." | 4.84 | Current update on glycoprotein IIb-IIIa and direct thrombin inhibition in percutaneous coronary intervention for non-ST elevation acute coronary syndromes: balancing bleeding risk and antiplatelet efficacy. ( Kwa, AT; Rogers, JH, 2008) |
| "Prasugrel has demonstrated a greater platelet inhibition and a decreased incidence of ischemic events compared with clopidogrel, but with an increased incidence of bleeding events." | 4.84 | Prasugrel: a novel antiplatelet agent. ( Haber, SL; Riley, AB; Tafreshi, MJ, 2008) |
| "The CYP2C19*2 allele variants and poor metabolizers were found to be associated with MACE in a clopidogrel-treated Kazak population with acute coronary syndrome following PCI." | 4.31 | The Cytochrome P450 2C19 Polymorphism Associated with Major Adverse Cardiovascular Events Risk in Kazak Patients Undergoing Percutaneous Coronary Intervention and Receiving Clopidogrel. ( Feng, J; Li, H; Shen, H; Sun, L; Wang, T; Wu, J; Xu, L; Yu, L; Zhang, H; Zhao, T; Zhou, L, 2023) |
| "Bleeding is a major adverse event during clopidogrel treatment in patients with acute coronary syndrome (ACS)." | 4.31 | miR-6076 rs1463411 polymorphisms are associated with bleeding during clopidogrel treatment in patients with acute coronary syndrome. ( Chen, BL; Dai, W; Mo, ZZ; Peng, YY; Tang, J; Wang, G; Yuan, Z; Zhang, W; Zhou, WL, 2023) |
| " A total of 477 patients receiving double antiaggregation therapy with aspirin and clopidogrel, after suffering a first event, were followed for 1 year to record relapse, as a surrogate end point to measure their therapeutic response, as defined by presenting with an acute coronary event (unstable angina, ST-segment-elevation myocardial infarction, or non-ST-segment-elevation myocardial infarction), stent thrombosis/restenosis, or cardiac mortality." | 4.12 | Clinical and Pharmacological Parameters Determine Relapse During Clopidogrel Treatment of Acute Coronary Syndrome. ( Martínez-Quintana, E; Medina-Gil, JM; Rodríguez-González, F; Saavedra-Santana, P; Santana-Mateos, M; Tugores, A, 2022) |
| "Pharmacogenetics is a potential driver of the "East Asian paradox," in which East Asian acute coronary syndrome (ACS) patients receiving dual antiplatelet therapy (DAPT) with clopidogrel following percutaneous coronary intervention (PCI) demonstrate higher levels of platelet reactivity on treatment than Western patients, yet have lower ischemic risk and higher bleeding risk at comparable doses." | 4.12 | Effect of CYP2C19 status on platelet reactivity in Taiwanese acute coronary syndrome patients switching to prasugrel from clopidogrel: Switch Study. ( Cheng, LC; Chu, PH; Huang, CL; Kuo, FY; Lan, WR; Lee, CH; Lee, WL; Lin, WS; Liu, PY; Lo, PH; Lu, TM; Su, CH; Tsukiyama, S; Wang, YC; Yang, WC; Yin, WH, 2022) |
| "Hyperuricemia was significantly associated with increased on-treatment residual ADP-inducible platelet reactivity in clopidogrel- and prasugrel-treated patients in univariate analyses and after adjustment for differences in patient characteristics by multivariate regression analyses." | 4.02 | Decreased Platelet Inhibition by Thienopyridines in Hyperuricemia. ( Gremmel, T; Hoberstorfer, T; Kopp, CW; Lee, S; Panzer, S; Pultar, J; Wadowski, PP; Weikert, C, 2021) |
| "The PLATelet inhibition and patient Outcomes (PLATO) trial (NCT00391872) demonstrated that ticagrelor compared to clopidogrel significantly reduced the rate of death from cardiovascular causes, myocardial infarction or stroke in patients with acute coronary syndrome (ACS)." | 4.02 | Cost-Effectiveness of Ticagrelor Compared with Clopidogrel in Patients with Acute Coronary Syndrome from Vietnamese Healthcare Payers' Perspective. ( Cong Luu, T; Le Phuong, T; Manh Pham, H; Mellstrom, C; Quang Nguyen, T; Thi Thu Nguyen, T; Van Do, D; Van Hoang, S, 2021) |
| "The positive interaction of ticagrelor with the metabolism of adenosine has been claimed for the large antithrombotic and antiischemic benefits of this antiplatelet agent in acute coronary syndromes (ACS)." | 3.96 | Impact of the rs73598374 polymorphism of the adenosine deaminase gene on platelet reactivity and long-term outcomes among patients with acute coronary syndrome treated with ticagrelor. ( De Luca, G; Fierro, N; Gioscia, R; Nardin, M; Negro, F; Pergolini, P; Rolla, R; Sagazio, E; Tonon, F; Verdoia, M, 2020) |
| "Dual antiplatelet therapy (DAPT) with aspirin and clopidogrel administered to treat patients with acute coronary syndrome (ACS) is still being used." | 3.91 | Distribution of polymorphisms in the CYP2C19 and ABCB1 genes among patients with acute coronary syndrome in Lower Silesian population. ( Gamian, A; Jonkisz, A; Kuliczkowski, W; Lebioda, A; Mysiak, A; Protasiewicz, M; Ściborski, K; Szymkiewicz, P; Wiśniewski, J; Wójcik, T, 2019) |
| "To study the comparative efficacy and safety of clopidogrel and ticagrelor in the "double" antiplatelet therapy (DATT) in patients with acute coronary syndrome (ACS) after percutaneous coronary intervention (PCI) in the early and late periods in real clinical practice, and to assess adherence to treatment." | 3.91 | [Double antiplatelet therapy in patients with acute coronary syndrome after percutaneous coronary intervention: individual efficacy and hemorrhagic safety of P2Y12 blockers of ticagrelor and clopidogrel in actual clinical practice]. ( Koroleva, LY; Korotaeva, ES; Kovaleva, GV; Kuzmenko, EA; Nosov, VP, 2019) |
| "Current clinical guidelines of acute coronary syndromes (ACS) recommend the use of potent antiplatelet therapy, prasugrel or ticagrelor, because both drugs consistently reduce cardiovascular events." | 3.88 | Temporal Trends in the Use of Antiplatelet Therapy in Patients With Acute Coronary Syndromes. ( Candela Sánchez, E; Carrillo Alemán, L; Esteve-Pastor, MA; Lozano, T; MacíasVillanego, MJ; Marín, F; Orenes-Piñero, E; PerniasEscrig, V; Quintana-Giner, M; Rivera-Caravaca, JM; Ruíz-Nodar, JM; Sandín Rollán, M; Tello-Montoliu, A; Valdés, M; Véliz-Martínez, A; Vicente-Ibarra, N, 2018) |
| "The objective of this study is to evaluate the effects of cytochrome P450 2C19 (CYP2C19) polymorphism on adverse cardiovascular events (MACE) in Hakka patients with acute coronary syndrome (ACS) receiving clopidogrel who had undergone coronary drug-eluting stent placement after percutaneous coronary intervention (PCI) in southern China." | 3.88 | Effect of cytochrome P450 2C19 polymorphism on adverse cardiovascular events after drug-eluting stent implantation in a large Hakka population with acute coronary syndrome receiving clopidogrel in southern China. ( He, X; Hou, J; Li, B; Li, C; Liu, Z; Wu, H; Yang, M; Zhang, Q; Zhao, P; Zhong, M; Zhong, W; Zhong, Z, 2018) |
| "The main objective of our study was to investigate the association of CYP2C19*2 and CYP2C19*3 loss-of-function and CYP2C19*17 gain-of-function variants of CYP2C19 gene with Clopidogrel resistance in a sample of Moroccan Acute Coronary Syndromes patients." | 3.88 | A synergic effect between CYP2C19*2, CYP2C19*3 loss-of-function and CYP2C19*17 gain-of-function alleles is associated with Clopidogrel resistance among Moroccan Acute Coronary Syndromes patients. ( Akoudad, H; Habbal, R; Hassani Idrissi, H; Hmimech, W; Khorb, NE; Nadifi, S, 2018) |
| "In percutaneous coronary intervention (PCI)-treated acute coronary syndrome (ACS) patients on clopidogrel therapy, high on-treatment platelet adenosine diphosphate (ADP) reactivity was observed in numerous studies, with significant increases in non-fatal myocardial infarction, definite/probable stent thrombosis, or cardiovascular mortality." | 3.88 | Antiplatelet Therapy in ACS Patients: Comparing Appropriate P2Y12 Inhibition by Clopidogrel to the Use of New P2Y12 Inhibitors. ( Hess, S; Jesel, L; Kibler, M; Marchandot, B; Messas, N; Meyer, N; Morel, O; Ohlmann, P; Ristorto, J; Schaeffer, M; Tuzin, N, 2018) |
| "PROMETHEUS was a multicentre observational study that compared clopidogrel vs prasugrel in acute coronary syndrome patients who underwent PCI (n = 19,914)." | 3.88 | Associations Between Complex PCI and Prasugrel or Clopidogrel Use in Patients With Acute Coronary Syndrome Who Undergo PCI: From the PROMETHEUS Study. ( Aquino, M; Baber, U; Baker, BA; Chandrasekhar, J; Dangas, G; DeFranco, A; Effron, MB; Farhan, S; Ge, Z; Henry, TD; Kapadia, S; Keller, S; Kini, AS; Mehran, R; Muhlestein, JB; Pocock, S; Rao, S; Sartori, S; Sorrentino, S; Strauss, C; Toma, C; Vogel, B; Weintraub, W; Weiss, S, 2018) |
| "The clinical significance of the laboratory-based phenomenon of clopidogrel hypo-responsiveness and platelet reactivity associated with acute myocardial infarction, despite chronic clopidogrel therapy, is largely unknown." | 3.88 | Acute myocardial infarction occurring while on chronic clopidogrel therapy ('clopidogrel failure') is associated with high incidence of clopidogrel poor responsiveness and stent thrombosis. ( Asher, E; Beigel, R; Fefer, P; Matetzky, S; Mazin, I; Regev, E, 2018) |
| " We aimed to evaluate the economic outcomes of ticagrelor versus clopidogrel for patients with acute coronary syndrome (ACS) in China, Japan, Korea, Taiwan and Hong Kong." | 3.88 | Health Economic Analysis of Antiplatelet Therapy for Acute Coronary Syndromes in the Context of Five Eastern Asian Countries. ( He, B; Liu, Y; Tobe, RG; Wu, B, 2018) |
| "In patients with acute coronary syndrome (ACS) treated with percutaneous coronary intervention (PCI), newer antiplatelet agents prasugrel and ticagrelor have lower rates of cardiovascular events when compared with clopidogrel." | 3.88 | Comparison of 6-Month Costs Between Oral Antiplatelet Agents Following Acute Coronary Syndrome. ( Ardati, AK; DiDomenico, RJ; Kim, K; Lee, TA; Touchette, DR; Walton, SM, 2018) |
| " Patients receiving ticagrelor or clopidogrel were further subdivided according to basic bleeding risk." | 3.88 | Impact of Baseline Bleeding Risk on Efficacy and Safety of Ticagrelor versus Clopidogrel in Chinese Patients with Acute Coronary Syndrome Undergoing Percutaneous Coronary Intervention. ( Han, YL; Li, J; Li, Y; Wang, HY; Xu, XM, 2018) |
| "The level of platelet reactivity during P2Y12-adenosine diphosphate receptor antagonist is associated with ischemic and bleeding risks following percutaneous coronary intervention in acute coronary syndrome." | 3.88 | Validation of a New ELISA-Based Vasodilator-Associated Stimulated Phosphoprotein Phosphorylation Assay to Assess Platelet Reactivity Index in a Chinese Population. ( Chen, N; Ding, P; Liu, H; Wei, Y, 2018) |
| "A complete set of fifty-nine demographic, clinical, genetic data was available of 603 patients with acute coronary syndromes enrolled in the prospective GEPRESS study, which showed that HPR after 1month of clopidogrel treatment independently predicted adverse cardiovascular events in patients with Syntax Score >14." | 3.85 | Prediction of high on-treatment platelet reactivity in clopidogrel-treated patients with acute coronary syndromes. ( Buscema, M; Calabrò, P; Capodanno, D; Cattaneo, M; De Carlo, M; de Servi, S; Della Riva, D; Femia, EA; Genereux, P; Grossi, E; Maffeo, D; Palmerini, T; Palmieri, C; Piscione, F; Podda, GM; Toso, A, 2017) |
| "Diabetes mellitus (DM) is associated with enhanced platelet reactivity and impaired response to oral antiplatelet therapy, including clopidogrel." | 3.85 | Impact of Diabetes Mellitus on the Pharmacodynamic Effects of Ticagrelor Versus Clopidogrel in Troponin-Negative Acute Coronary Syndrome Patients Undergoing Ad Hoc Percutaneous Coronary Intervention. ( Angiolillo, DJ; Carlson, GF; Dangas, G; Franchi, F; Khan, ND; Mehran, R; Raveendran, G; Rollini, F; Sweeny, JM; Teng, R; Waksman, R; Zhao, Y, 2017) |
| "Gene variants contribute to variability in individual responsiveness to clopidogrel and influence cardiovascular outcomes in Caucasian patients with acute coronary syndrome (ACS)." | 3.85 | Gene variants in responsiveness to clopidogrel have no impact on clinical outcomes in Chinese patients undergoing percutaneous coronary intervention - A multicenter study. ( Cao, Y; Cui, W; Cui, Y; Guo, X; Li, C; Li, J; Li, S; Shen, X; Sun, Y; Wang, D; Wang, DW; Wang, H; Wang, Y; Yan, J; Yang, J; You, L; Zeng, H; Zhang, L; Zhang, Y, 2017) |
| "Clopidogrel resistance in patients with acute coronary syndrome (ACS) is one of the key causes of recurrent cardiovascular disease (CVD) events after percutaneous coronary intervention (PCI)." | 3.85 | Associations between P2RY12 gene polymorphisms and risks of clopidogrel resistance and adverse cardiovascular events after PCI in patients with acute coronary syndrome. ( Huang, Y; Li, M; Shi, X; Wang, H; Xuan, L; Zhang, N; Zhou, T, 2017) |
| " Prasugrel was associated with fewer MACE, whereas clopidogrel had fewer major bleeding events." | 3.85 | Comparative Effectiveness and Safety Analysis of Dual Antiplatelet Therapies Within an Integrated Delivery System. ( Boyd, A; Chambers, A; Chanas, T; Coons, JC; Eckardt, J; Ensor, CR; Iasella, CJ; Lemon, LS; Lyons, J; Merkel, A; Rihtarchik, L; Smith, R; Wang, N; Williams, K, 2017) |
| "Data on the clinical impact of gender in "real-life" patients with acute coronary syndrome (ACS) undergoing percutaneous coronary intervention (PCI), receiving clopidogrel, prasugrel, or ticagrelor are limited." | 3.85 | Gender-related differences in antiplatelet treatment patterns and outcome: Insights from the GReekAntiPlatElet Registry. ( Alexopoulos, D; Davlouros, P; Deftereos, S; Goudevenos, J; Hamilos, M; Kanakakis, I; Lekakis, J; Sitafidis, G; Vavouranakis, M; Xanthopoulou, I, 2017) |
| "In randomized controlled trials, prasugrel and ticagrelor reduced cardiovascular complications in patients with acute coronary syndrome (ACS) compared with clopidogrel." | 3.85 | Comparative Effectiveness of Oral Antiplatelet Agents in Patients with Acute Coronary Syndrome. ( Ardati, AK; DiDomenico, RJ; Kim, K; Lee, TA; Touchette, DR; Walton, SM, 2017) |
| " Patients with known diabetes mellitus received clopidogrel in 51% of the cases, whereas most patients with hyperglycemia (72%) received a new P2Y12 inhibitor: according to clinical presentation in case STEMI prasugrel/ticagrelor were more prescribed than clopidogrel (70 vs." | 3.85 | Management of diabetic patients hospitalized for acute coronary syndromes: a prospective multicenter registry. ( Bognetti, P; Cardile, A; De Servi, S; Demarchi, A; Ferlini, M; Frattini, S; Grieco, N; Ielasi, A; Lettieri, C; Mafrici, A; Musumeci, G; Rossini, R; Russo, A; Sponzilli, C; Vecchiato, C; Visconti, LO, 2017) |
| " Parameters associated with a presumably higher risk of bleeding and side-effects against the more effective P2Y12 inhibitors were the most prominent factors for the prescription of clopidogrel." | 3.85 | Contemporary use of P2Y12-inhibitors in patients with acute coronary syndrome undergoing percutaneous coronary intervention in Austria: A prospective, multi-centre registry. ( Adlbrecht, C; Eber, B; Egger, F; Hajos, J; Helmreich, W; Huber, K; Machata, M; Michael, N; Neumayr, M; Rohla, M; Suppan, M; Tscharre, M; Weiss, TW; Zweiker, R, 2017) |
| "Base-case scenario results at 30 days indicated that the incremental cost per major cardiovascular or bleeding event avoided for genotype-guided treatment was US$8525 and US$42,198 compared with universal clopidogrel and prasugrel, respectively." | 3.85 | CYP2C19-guided antiplatelet therapy: a cost-effectiveness analysis of 30-day and 1-year outcomes following percutaneous coronary intervention. ( Borse, MS; Dong, OM; Farley, JF; Lee, CR; Polasek, MJ; Stouffer, GA, 2017) |
| "To describe contemporary trends of P2Y12 inhibitor use in patients with acute coronary syndrome (ACS) and comorbid diabetes mellitus (DM) and/or chronic kidney disease (CKD) who have a higher risk of recurring ACS and may benefit from treatment with higher efficacy third-generation agents (prasugrel and ticagrelor)." | 3.85 | Contemporary Time Trends in Use of Antiplatelet Agents Among Patients with Acute Coronary Syndrome and Comorbid Diabetes Mellitus or Chronic Kidney Disease. ( Desai, RJ; Gagne, JJ; Mogun, H; Spoendlin, J, 2017) |
| "Clopidogrel is an antiplatelet drug widely used in patients with acute coronary syndromes or stroke." | 3.85 | The Impact of CYP2C19 Loss-of-Function Polymorphisms, Clinical, and Demographic Variables on Platelet Response to Clopidogrel Evaluated Using Impedance Aggregometry. ( Bălaşa, R; Bănescu, C; Dobreanu, M; Maier, S; Mărginean, A; Mărginean, M; Moldovan, V; Scridon, A; Ţăruşi, M, 2017) |
| "Acetylsalicylic acid (ASA) and clopidogrel combined therapy has been reported to be beneficial in patients with acute coronary syndrome (ACS)." | 3.85 | ABCC3 Polymorphisms and mRNA Expression Influence the Concentration of a Carboxylic Acid Metabolite in Patients on Clopidogrel and Aspirin Therapy. ( Bortolin, RH; Bravo, M; Brion, M; Carracedo, A; Concheiro, M; Cruz, A; Germano, JF; Hirata, MH; Hirata, RD; Iñiguez, A; López-Rivadulla, M; Luchessi, AD; Quintela, O; Silbiger, VN; Sousa, AG, 2017) |
| "In this retrospective study, we compared ticagrelor (180mg loading dose 90mg twice daily thereafter), clopidogrel (300mg loading dose, 75mg or 150mg daily thereafter) for the prevention of cardiovascular events in 273 high-risk patients admitted to coronary care unit with acute coronary syndrome." | 3.85 | Efficacy and safety of ticagrelor versus clopidogrel with different dosage in high-risk patients with acute coronary syndrome. ( Gao, Y; Guan, QG; Guo, L; Jia, DL; Li, YZ; Qi, GX; Sun, YX; Tian, W; Xin, YG; Xu, F; Yu, HJ; Zhang, HS; Zhang, XG; Zhang, YL, 2017) |
| "Scarce and conflicting evidence exists on whether clopidogrel is effective and whether dual antiplatelet treatment (DAPT) is safe in patients with acute coronary syndrome and chronic kidney disease (CKD)." | 3.85 | Long-term versus short-term dual antiplatelet therapy was similarly associated with a lower risk of death, stroke, or infarction in patients with acute coronary syndrome regardless of underlying kidney disease. ( Carrero, JJ; Evans, M; Held, C; James, S; Jensevik, K; Jernberg, T; Lagerqvist, B; Spaak, J; Szummer, K; Varenhorst, C, 2017) |
| "To evaluate the incremental cost-effectiveness ratio (ICER) of the use of ticagrelor as a substitute for clopidogrel for secondary prevention of acute coronary syndrome in Chile." | 3.85 | Latin American Clinical Epidemiology Network Series - Paper 8: Ticagrelor was cost-effective vs. clopidogrel in acute coronary syndrome in Chile. ( Bustos, L; De la Puente, C; Lanas, F; Vallejos, C; Velasquez, M; Zaror, C, 2017) |
| "Recent trials demonstrated the efficacy of prasugrel and ticagrelor compared with clopidogrel in the reduction of cardiovascular complications in patients with acute coronary syndrome (ACS)." | 3.85 | Contemporary Trends in Oral Antiplatelet Agent Use in Patients Treated with Percutaneous Coronary Intervention for Acute Coronary Syndrome. ( Ardati, AK; DiDomenico, RJ; Kim, K; Lee, TA; Touchette, DR; Walton, SM, 2017) |
| "Acute coronary syndrome patients infected with HIV (n = 80) were matched to ACS patients without HIV (n = 160) on age, sex, diabetes, and DAPT (aspirin 100%, clopidogrel 68%, prasugrel 31%, ticagrelor 1%)." | 3.85 | Platelet reactivity in human immunodeficiency virus infected patients on dual antiplatelet therapy for an acute coronary syndrome: the EVERE2ST-HIV study. ( Boccara, F; Boyd, A; Brugier, D; Cohen, A; Collet, JP; Curjol, A; Galier, S; Hauguel-Moreau, M; Hulot, JS; Kerneis, M; Montalescot, G; Salem, JE; Silvain, J, 2017) |
| "Although aspirin-clopidogrel combination is more useful for acute coronary syndrome (ACS), the renal safety of this combination had not been established." | 3.83 | Short Communication: Evaluation of nephrotoxicity by aspirin-clopidogrel combination therapy in patients with acute coronary syndrome. ( Baber, M; HamidAkash, MS; Hussain, SB; Irfan, M; Qadir, MI; Rehman, A, 2016) |
| "Despite the growing use of clopidogrel, limited data exist regarding the prognostic significance of chronic clopidogrel therapy in patients sustaining acute coronary syndrome (ACS)." | 3.83 | Prior chronic clopidogrel therapy is associated with increased adverse events and early stent thrombosis. ( Asher, E; Atar, S; Beigel, R; Fefer, P; Hammerman, H; Herscovici, R; Matetzky, S; Mazin, I; Polak, A; Regev, E; Sabbag, A; Shlomo, N; Zahger, D, 2016) |
| "Ticagrelor can lower the resting heart rate of patients and cause bradyarrhythmias in the 12th month after PCI." | 3.83 | Ticagrelor vs. clopidogrel in non-ST-elevation acute coronary syndromes. ( Dong, C; Liu, X; Ren, C; Ren, Q; Zhang, X, 2016) |
| "Patients (n=18) with acute coronary syndrome who required urgent CABG and had been treated for up to 2 days before surgery with aspirin plus clopidogrel (n=13) or aspirin plus ticagrelor (n=5) were enrolled." | 3.83 | Factors influencing platelet reactivity in patients undergoing coronary artery bypass surgery. ( Chava, S; Schneider, DJ, 2016) |
| "We observed a potential late treatment effect for prasugrel versus clopidogrel for a reduced risk of ischemic stroke in medically managed patients with ACS aged <75 years." | 3.83 | Time-Varying Effects of Prasugrel Versus Clopidogrel on the Long-Term Risks of Stroke After Acute Coronary Syndromes: Results From the TRILOGY ACS Trial. ( Armstrong, PW; Chin, CT; Corbalán, R; Fox, KA; Magnus Ohman, E; Neely, B; Prabhakaran, D; Roe, MT; White, HD; Winters, KJ, 2016) |
| "Guidelines recommend prasugrel or ticagrelor instead of clopidogrel in patients with acute coronary syndromes (ACS) undergoing percutaneous coronary interventions (PCI)." | 3.83 | Clopidogrel, prasugrel or ticagrelor in patients with acute coronary syndromes undergoing percutaneous coronary intervention. ( Ajani, AE; Andrianopoulos, N; Brennan, A; Clark, DJ; Duffy, SJ; Eccleston, D; Farouque, O; Lefkovits, J; Oqueli, E; Ramchand, J; Reid, CM; Yip, T; Yudi, MB, 2016) |
| "To investigate the impact of novel P2Y(12) receptor inhibitors including prasugrel or ticagrelor on platelet reactivity in patients with acute coronary syndrome (ACS) receiving percutaneous coronary intervention (PCI), and provide clinical data for novel oral P2Y(12) receptor inhibitors use among Chinese patients." | 3.83 | [Impact of novel P2Y12 receptor inhibitors on platelet reactivity in acute coronary syndrome patients undergoing percutaneous coronary intervention]. ( Chong Tou, TJ; Lei Put, PZ; Lei Sio, ZW; Lei Sok, SM; Liu, PM; O U, YF; Sio Cham, ZC; Wang, JF; Wu, W; Zhou, SX, 2016) |
| " In patients treated with ASA (100-160 mg) and clopidogrel (75 mg daily) or ticagrelor (90 mg twice a day) platelet reactivity and the reticulated platelets fraction (immature platelets fraction, IPF) were assessed at 30-90 days post-discharge for an acute coronary syndrome or elective PCI." | 3.83 | Impact of diabetes on immature platelets fraction and its relationship with platelet reactivity in patients receiving dual antiplatelet therapy. ( Barbieri, L; Bellomo, G; De Luca, G; Marino, P; Nardin, M; Pergolini, P; Rolla, R; Schaffer, A; Suryapranata, H; Verdoia, M, 2016) |
| "Results of a study of bleeding events and other inhospital outcomes with the use of clopidogrel versus prasugrel in patients with acute coronary syndrome (ACS) managed with percutaneous coronary intervention (PCI) are reported." | 3.83 | Comparative resource utilization and costs for patients with acute coronary syndrome managed with percutaneous coronary intervention and treated with clopidogrel or prasugrel. ( Bae, JP; Effron, MB; Ernst, FR; Faries, DE; Lieu, HD; Lipkin, C; Moretz, C; Zhao, Z, 2016) |
| " Objectives To investigate long-term efficacy and safety in 'real-life' acute coronary syndrome (ACS) patients treated by percutaneous coronary intervention (PCI) with contemporary use of clopidogrel, prasugrel and ticagrelor." | 3.83 | Contemporary antiplatelet treatment in acute coronary syndrome patients undergoing percutaneous coronary intervention: 1-year outcomes from the GReek AntiPlatElet (GRAPE) Registry. ( Alexopoulos, D; Davlouros, P; Deftereos, S; Goudevenos, J; Hahalis, G; Hamilos, M; Kanakakis, I; Pentara, I; Sitafidis, G; Vavouranakis, M; Xanthopoulou, I, 2016) |
| " Onclopidogrel PR was detected by the original impedance whole blood platelet aggregation assay, modified assay, and flow cytometric vasodilator stimulated phosphoprotein (VASP) assay in 168 patients with acute coronary syndromes (ACS)." | 3.83 | Comparison of Modified Impedance Whole Blood Platelet Aggregation Method Detecting Platelet Function in ACS Patients with Different CYP2C19 Genotypes. ( Cui, C; Qiao, R; Zhang, J, 2016) |
| "Dual-antiplatelet therapy with aspirin and clopidogrel after percutaneous coronary intervention reduces the risk for coronary thrombotic events (CTEs) at the expense of increasing risk for major bleeding (MB)." | 3.83 | Coronary Thrombosis and Major Bleeding After PCI With Drug-Eluting Stents: Risk Scores From PARIS. ( Ariti, C; Baber, U; Chieffo, A; Cohen, DJ; Colombo, A; Dangas, G; Gibson, CM; Giustino, G; Henry, TD; Kini, AS; Kirtane, AJ; Krucoff, MW; Litherland, C; Mehran, R; Moliterno, DJ; Pocock, S; Sartori, S; Steg, PG; Stone, GW; Weisz, G; Witzenbichler, B, 2016) |
| "In patients receiving dual antiplatelet therapy for coronary artery disease, higher PTH levels are associated with an increased ADP-mediated platelet reactivity and suboptimal response to clopidogrel, especially for values above 96." | 3.83 | Parathyroid Hormone Levels and High-Residual Platelet Reactivity in Patients Receiving Dual Antiplatelet Therapy With Acetylsalicylic Acid and Clopidogrel or Ticagrelor. ( Barbieri, L; Bellomo, G; De Luca, G; Marino, P; Nardin, M; Pergolini, P; Rolla, R; Schaffer, A; Suryapranata, H; Verdoia, M, 2016) |
| "To observe the relationship between ATP-binding cassette subfamily B member 1 (ABCB1) and cytochrome P450 (CYP)2C19 polymorphisms and the effect of clopidogrel post percutaneous coronary intervention in patients with coronary artery disease." | 3.83 | [Relationship between ATP-binding cassette subfamily B member 1 and cytochrome P450 2C19 polymorphisms and the effect of clopidogrel post percutaneous coronary intervention in patients with acute coronary syndrome]. ( Fu, ZH; Han, BS; Li, DY; Ren, YH; Song, YQ; Xue, Q; Yi, J; Zhou, CF, 2016) |
| "New antithrombotic therapies have significantly improved the outcomes of patients with acute coronary syndrome (ACS), where the introduction of ticagrelor has provided the greatest mortality benefits." | 3.83 | Serum uric acid levels during dual antiplatelet therapy with ticagrelor or clopidogrel: Results from a single-centre study. ( Barbieri, L; Bellomo, G; De Luca, G; Marino, P; Nardin, M; Pergolini, P; Rolla, R; Schaffer, A; Suryapranata, H; Verdoia, M, 2016) |
| "We performed a sub-group analysis of a randomized trial comparing ticagrelor and clopidogrel in acute coronary syndrome (ACS) patients undergoing PCI." | 3.83 | Platelet reactivity in patients receiving a maintenance dose of P2Y12-ADP receptor antagonists undergoing elective percutaneous coronary intervention. ( Berbis, J; Bonello, L; Dignat-George, F; Frere, C; Kerbaul, F; Laine, M; Lemesle, G; Paganelli, F; Roch, A; Thuny, F, 2016) |
| " In patients with ST-elevation acute coronary syndrome with an indication to primary angioplasty, the administration of unfractionated heparin and aspirin is considered the pre-procedural standard treatment." | 3.83 | [ANMCO/SIC/SICI-GISE/SICCH Consensus document: Clinical approach to pharmacological pretreatment for patients undergoing myocardial revascularization]. ( Borzi, M; Caporale, R; Casolo, G; Colivicchi, F; Di Bartolomeo, R; Formigli, D; Geraci, G; Gerometta, P; Gulizia, MM; Ledda, A; Menozzi, A; Musumeci, G; Romeo, F; Scherillo, M; Tarantini, G, 2016) |
| "The goal of this study was to explore the polymorphisms of CYP2C19 (CYP2C19*2, CYP2C19*3) in patients with acute coronary syndrome (ACS) undergoing percutaneous coronary intervention (PCI) on clopidogrel therapy in Zhengzhou city for guidance on clinical medication and reduction in the incidence of thromboembolic events." | 3.83 | CYP2C19 polymorphisms in acute coronary syndrome patients undergoing clopidogrel therapy in Zhengzhou population. ( Guo, YM; Li, HZ; Li, Z; Sun, HL; Zhang, L; Zhao, ZC, 2016) |
| "The efficacy and safety of ticagrelor compared with clopidogrel in acute coronary syndrome has not previously been evaluated in an Eastern Asian population, which is recognized to have a different response to P2Y12 antagonists compared with the Caucasian population in real-life situations." | 3.83 | Efficacy and safety of ticagrelor versus clopidogrel in acute coronary syndrome in Taiwan: A multicenter retrospective pilot study. ( Chao, TH; Chen, IC; Chen, Y; Cheng, CL; Fang, CC; Lee, CH; Li, YH; Lin, CC; Lin, CY; Yu, CL, 2016) |
| "Ticagrelor reduces ischaemic events and mortality in acute coronary syndrome (ACS) vs." | 3.83 | Outcomes in patients treated with ticagrelor or clopidogrel after acute myocardial infarction: experiences from SWEDEHEART registry. ( Erlinge, D; James, SK; Jernberg, T; Lagerqvist, B; Omerovic, E; Renlund, H; Sahlén, A; Varenhorst, C; Wallentin, L, 2016) |
| "Proton pump inhibitors (PPIs) reduce gastrointestinal bleeding events but may alter clopidogrel metabolism." | 3.83 | Impact of Proton Pump Inhibitor Use on the Comparative Effectiveness and Safety of Prasugrel Versus Clopidogrel: Insights From the Treatment With Adenosine Diphosphate Receptor Inhibitors: Longitudinal Assessment of Treatment Patterns and Events After Acu ( Baker, BA; Cohen, DJ; Effron, MB; Faries, DE; Jackson, LR; Ju, C; McCoy, LA; Messenger, JC; Peterson, ED; Wang, TY; Zettler, M, 2016) |
| "The main objective was to investigate if the unit of first contact influenced the frequency and time of aspirin treatment in the Strategy of Registry of Acute Coronary Syndrome (ERICO) study." | 3.83 | Time-To-Treatment of Acute Coronary Syndrome and Unit of First Contact in the ERICO Study. ( Bensenor, IM; Bittencourt, MS; Brandão, RM; Goulart, AC; Kisukuri, AL; Lotufo, PA; Santos, IS; Santos, RC; Sitnik, D; Staniak, HL, 2016) |
| " The aim of the study was to verify whether clopidogrel response measured by Multiplate analyzer (ADPtest) in diabetic ACS patients treated with PCI predicts the risk of stent thrombosis or cardiovascular mortality and bleeding." | 3.83 | Platelet aggregation and risk of stent thrombosis or bleeding in interventionally treated diabetic patients with acute coronary syndrome. ( Bekta, P; Chmielak, Z; Debski, A; Jamiolkowski, J; Klopotowski, M; Kukula, K; Kunicki, PK; Polanska-Skrzypczyk, M; Witkowski, A, 2016) |
| "We genotyped variants CES1, CYP2C19*2 and *3 in 502 patients with acute coronary syndrome (ACS) receiving clopidogrel therapy, and analyzed the effects of ACEIs on responsiveness to clopidogrel by the vasodilator-stimulated phosphoprotein (VASP) phosphorylation assay and ADP-stimulated impedance whole blood platelet aggregation assay." | 3.83 | Angiotensin-Converting Enzyme Inhibitors' Influence on Antiplatelet Therapy of Clopidogrel in ACS. ( Cui, C; Qiao, R; Yang, S; Zhang, J, 2016) |
| " We report a case of clopidogrel-induced severe neutropenia in a patient treated with coronary stent and safety of alternative treatment with ticagrelor." | 3.81 | Ticagrelor as an alternative in clopidogrel-associated neutropenia. ( Belalcazar-Portacio, A; Keough, LA; Ramanathan, KB; Shah, R, 2015) |
| "Dual antiplatelet therapy with aspirin and a P2Y12 antagonist is widely prescribed for the prevention of thrombotic events in patients with an acute coronary syndrome or undergoing percutaneous coronary intervention (PCI)." | 3.81 | Variation in thromboxane B2 concentrations in serum and plasma in patients taking regular aspirin before and after clopidogrel therapy. ( Good, RI; Goodall, AH; James, TE; McConnachie, A; McGarrity, A; Miller, H; Oldroyd, KG; Sheehan, R; Stephens, J; Watkins, S, 2015) |
| "High-post clopidogrel platelet reactivity in acute coronary syndrome (ACS) patients is associated with adverse outcomes and may be related to clopidogrel dosing." | 3.81 | Evaluation of platelet response to different clopidogrel dosing regimens in patients with acute coronary syndrome in clinical practice. ( Beigel, R; Fefer, P; Gannot, S; Hod, H; Matetzky, S; Rosenberg, N; Savion, N; Shechter, M; Varon, D, 2015) |
| "VerifyNow® and Multiplate® aggregometry were used before, and 4, 12, 22 and 48 hours after 600 mg clopidogrel treatment in 28 post-cardiac arrest hypothermic patients and in 14 normothermic patients with acute coronary syndrome." | 3.81 | Platelet reactivity in comatose survivors of cardiac arrest undergoing percutaneous coronary intervention and hypothermia. ( Blinc, A; Bozic-Mijovski, M; Kranjec, I; Melkic, E; Noc, M; Steblovnik, K, 2015) |
| "To investigate whether an intensified antiplatelet regimen could improve prognosis in stable or non-ST elevation in acute coronary syndrome (ACS) patients exhibiting high on-treatment platelet reactivity (HTPR) on clopidogrel and treated with percutaneous coronary intervention (PCI)." | 3.81 | Tailored antiplatelet therapy to improve prognosis in patients exhibiting clopidogrel low-response prior to percutaneous coronary intervention for stable angina or non-ST elevation acute coronary syndrome. ( Clemmensen, P; Engstrøm, T; Helqvist, S; Holmvang, L; Johansson, PI; Jørgensen, E; Kelbæk, H; Kollslid, R; Lønborg, JT; Paarup Dridi, N; Pedersen, F; Qayyum, A; Radu, MD; Saunamäki, K, 2015) |
| "Treatment with warfarin in combination with clopidogrel has been shown to reduce the incidence of major bleeding as compared to triple antithrombotic therapy (TT; warfarin, clopidogrel and aspirin)." | 3.81 | Concomitant use of warfarin and ticagrelor as an alternative to triple antithrombotic therapy after an acute coronary syndrome. ( Bico, B; Braun, OÖ; Chaudhry, U; Gustav Smith, J; Jovinge, S; Koul, S; Scherstén, F; Svensson, PJ; Tydén, P; van der Pals, J; Wagner, H, 2015) |
| "Patients were prospectively included if they had a successful percutaneous coronary intervention (PCI) for acute coronary syndrome (ACS) and received clopidogrel and aspirin." | 3.81 | The relationship between on-clopidogrel platelet reactivity, genotype, and post-percutaneous coronary intervention outcomes in Chinese patients. ( Qin, J; Sun, Z; Tang, N; Xu, X; Yin, S, 2015) |
| "In acute coronary syndrome (ACS), inflammation and redox response are associated with increased residual platelet reactivity (RPR) on clopidogrel therapy." | 3.81 | Inflammatory and antioxidant pattern unbalance in "clopidogrel-resistant" patients during acute coronary syndrome. ( Abbate, R; Caruso, R; Cecchettini, A; Citti, L; Cozzi, L; Giusti, B; Gori, AM; Marcucci, R; Parodi, G; Parodi, O; Parolini, M; Rocchiccioli, S; Romagnuolo, I, 2015) |
| "We included patients treated with acetylsalycilic acid (ASA) (100-160 mg) and clopidogrel (75 mg) or ticagrelor (90 mg twice a day) for acute coronary syndromes or drug-eluting stent implantation." | 3.81 | Body Mass Index and Platelet Reactivity During Dual Antiplatelet Therapy With Clopidogrel or Ticagrelor. ( Barbieri, L; Bellomo, G; De Luca, G; Marino, P; Nardin, M; Pergolini, P; Rolla, R; Sartori, C; Schaffer, A; Suryapranata, H; Verdoia, M, 2015) |
| "After coronary stent implantation, patients with acute coronary syndrome commonly take clopidogrel, and few patients develop severe thrombocytopenia related to clopidogrel." | 3.81 | The change in platelet count in patients with acute coronary syndrome 6 months after coronary stent implantation. ( An, L; Du, D; Lai, X; Li, Y; Wang, F; Zhang, Z, 2015) |
| "Secondary prevention treatment with aspirin/ clopidogrel, beta blockers, inhibitors of the rennin-angiotensin-aldosterone converting system and statins reduces the morbidity and mortality of patients after acute coronary syndrome (ACS)." | 3.81 | [SECONDARY PREVENTION IN PATIENTS WITH ACUTE CORONARY SYNDROME HOSPITALIZED IN INTERNAL MEDICINE DEPARTMENTS]. ( Elis, A; Lishner, M; Pereg, D; Yahia, DH, 2015) |
| "Laboratories are increasingly requested to perform CYP2C19 genetic testing when managing clopidogrel therapy, especially in patients with acute coronary syndrome undergoing percutaneous coronary intervention." | 3.81 | Implementation of Cell Samples as Controls in National Proficiency Testing for Clopidogrel Therapy-Related CYP2C19 Genotyping in China: A Novel Approach. ( Li, J; Lin, G; Wang, L; Xie, J; Yi, L; Zhang, K; Zhang, R, 2015) |
| "To investigate the contributions of CYP2C19 polymorphisms to the various clopidogrel responses tested by thrombelastography (TEG) in Chinese patients with the acute coronary syndrome (ACS)." | 3.81 | CYP2C19*2 and Other Allelic Variants Affecting Platelet Response to Clopidogrel Tested by Thrombelastography in Patients with Acute Coronary Syndrome. ( Liu, J; Lu, Y; Nie, XY; Shi, LW; Wang, WM; Zhang, Y, 2015) |
| "Greater antithrombotic potency new antiplatelet agents have been added such as prasugrel (PR) and ticagrelor to the traditional use of clopidogrel (CL) in the treatment of acute coronary syndrome (ACS)." | 3.81 | [Clopidogrel versus prasugrel in acute coronary syndrome treated with coronary angioplasty]. ( Conde, D; Cura, F; Elissamburu, P; Filipini, E; Lalor, N; Nau, G; Rodríguez, L; Trivi, M, 2015) |
| "A decision-analytic model was used to simulate life-long medical costs and quality-adjusted life-years (QALYs) of three antiplatelet strategies in a hypothetical cohort of 60-year-old patients with acute coronary syndrome after a percutaneous coronary intervention: (a) universal clopidogrel (75 mg daily), (b) universal alternative antiplatelet therapy (prasugrel or ticagrelor), and (c) all PG-PRT patients were genotyped." | 3.81 | CYP2C19 genotype plus platelet reactivity-guided antiplatelet therapy in acute coronary syndrome patients: a decision analysis. ( Jiang, M; You, JH, 2015) |
| "To compare healthcare costs between clopidogrel and prasugrel over 30-day and 365-day periods after discharge from the hospital or emergency room (ER) in patients treated with prasugrel who were hospitalized or had an ER visit for an acute coronary syndrome (ACS) event." | 3.81 | Economic outcomes with prasugrel versus clopidogrel in acute coronary syndrome patients: observations from prasugrel users and matched clopidogrel users. ( Crivera, C; Dea, K; Germain, G; Laliberté, F; Lefebvre, P; Lynch, SM; Ma, YW; Olson, WH; Schein, J, 2015) |
| "High on treatment platelet reactivity (HTPR) is common in patients receiving clopidogrel following an acute coronary syndrome (ACS); it's also associated with increased morbidity and mortality." | 3.81 | Changes in platelet function independent of pharmacotherapy following coronary intervention in non-ST-elevation myocardial infarction patients. ( Anderson, RA; Freeman, PM; Hinz, C; James, PE; Kinnaird, TD; Moschonas, KE; O'Donnell, VB, 2015) |
| "Dual antiplatelet therapy with aspirin and a platelet P2Y12 receptor inhibitors (clopidogrel, prasugrel, ticagrelor) is a cornerstone of antithrombotic treatment in patients with acute coronary syndromes (ACS)." | 3.81 | Rapid and portable, lab-on-chip, point-of-care genotyping for evaluating clopidogrel metabolism. ( Ardissino, D; Bianchessi, M; Boffetti, F; Caporale, V; Casu, G; Cereda, M; Cocci, A; Coppini, L; Crocamo, A; del Giudice, F; Demola, MA; Guidorossi, A; Manzalini, C; Marziliano, N; Merlini, PA; Notarangelo, MF; Orsini, F; Pigazzani, F; Pirola, D, 2015) |
| " The odds of an adverse incidence of death/myocardial infarction/stroke 1 year after discharge was significantly reduced in patients receiving aspirin and clopidogrel for ≥9 months and was consequently higher in patients in whom dual antiplatelet therapy was discontinued or prescribed for <9 months." | 3.80 | Predictors of 1-year outcomes in the Taiwan Acute Coronary Syndrome Full Spectrum Registry. ( Chiang, FT; Hou, CJ; Hwang, JJ; Kuo, C; Kuo, CT; Lai, WT; Li, AH; Li, YH; Lin, SJ; Mar, GY; Shyu, KG; Wen, MS; Wu, CJ, 2014) |
| " We aimed to evaluate the effect of DAPT duration with clopidogrel and aspirin on the recurrence of ischaemic events and bleeding in a large, unselected ACS population." | 3.80 | Duration of dual antiplatelet treatment with clopidogrel and aspirin in patients with acute coronary syndrome. ( Hasvold, P; Held, C; James, S; Jensevik, K; Jernberg, T; Lagerqvist, B; Sundström, A; Varenhorst, C, 2014) |
| "We aimed to investigate the association of aspirin and/or clopidogrel low response with -455G/A polymorphism of β-fibrinogen in patients with acute coronary syndrome (ACS)." | 3.80 | Impact of -455G/a polymorphism of the β-fibrinogen gene on platelet aggregation in patients with acute coronary syndrome. ( Bakirci, EM; Borekci, A; Kalkan, K; Karakoyun, S; Sevimli, S; Topcu, S; Vançelik, S, 2014) |
| "P2Y12 inhibitor switching has appeared in clinical practice as a consequence of prasugrel and ticagrelor availability, apart from clopidogrel, for use in patients with acute coronary syndrome (ACS) undergoing percutaneous coronary intervention (PCI)." | 3.80 | In-hospital switching of oral P2Y12 inhibitor treatment in patients with acute coronary syndrome undergoing percutaneous coronary intervention: prevalence, predictors and short-term outcome. ( Alexopoulos, D; Angelidis, C; Davlouros, P; Deftereos, S; Goudevenos, J; Hamilos, M; Kanakakis, I; Parissis, H; Petousis, S; Sitafidis, G; Stakos, D; Stefanadis, C; Vavouranakis, M; Xanthopoulou, I, 2014) |
| "To investigate the association between adenosine diphosphate (ADP)-induced platelet aggregation measured by single-platelet count testing and postoperative blood loss in clopidogrel-treated patients with acute coronary syndromes undergoing coronary artery bypass grafting (CABG)." | 3.80 | Adenosine diphosphate-induced single-platelet count aggregation and bleeding in clopidogrel-treated patients undergoing coronary artery bypass grafting. ( Dalén, M; Holm, M; Ivert, T; Lindvall, G; van der Linden, J, 2014) |
| "Clopidogrel therapy is the standard of care in patients with acute coronary syndrome (ACS) and stent implantation." | 3.80 | Diagnostic accuracy of mean platelet volume in prediction of clopidogrel resistance in patients with acute coronary syndrome. ( Akdeniz, B; Aytemiz, F; Badak, O; Barış, N; Göldeli, O; Ozpelit, E; Uzel, H, 2014) |
| "Switching patients with ACS who have HPR to treatment with prasugrel reduces thrombotic and bleeding events to a level similar to that of those without HPR; however, there is a higher risk of both thrombotic and bleeding complications with high-dose clopidogrel." | 3.80 | Optimizing P2Y12 receptor inhibition in patients with acute coronary syndrome on the basis of platelet function testing: impact of prasugrel and high-dose clopidogrel. ( Aradi, D; Faluközy, J; Horváth, IG; Komócsi, A; Kónyi, A; Magyari, B; Pintér, T; Tornyos, A; Veress, G; Vorobcsuk, A, 2014) |
| "To evaluate the effect of drug interaction between omeprazol and clopidogrel in hospital readmission of patients with acute coronary syndrome (ACS)." | 3.80 | [Effect of drug interaction between clopidogrel and omeprazole in hospital readmision of patients by a recurrent acute coronary syndrome: a case-control study]. ( Amariles, P; Angulo, NY; Betancourth, PM; Ceballos, M; Holguín, H, 2014) |
| "The aim of this study was to assess antiplatelet effect of prasugrel in acute coronary syndrome (ACS) patients with high on-treatment platelet reactivity (HTPR) on clopidogrel, undergoing percutaneous coronary intervention (PCI)." | 3.80 | Prasugrel overcomes high on-clopidogrel platelet reactivity in the acute phase of acute coronary syndrome and maintains its antiplatelet potency at 30-day follow-up. ( De Servi, S; Fabiszak, T; Kasprzak, M; Koziński, M; Kubica, J; Navarese, EP; Obońska, K; Rość, D; Siller-Matula, JM; Stankowska, K; Stolarek, W, 2014) |
| "The choice of antiplatelet therapy after acute coronary syndrome (ACS) is complicated: Ticagrelor and prasugrel are novel alternatives to clopidogrel, patients with some genotypes may not respond to clopidogrel, and low-cost generic formulations of clopidogrel are available." | 3.80 | Cost-effectiveness of genotype-guided and dual antiplatelet therapies in acute coronary syndrome. ( Boothroyd, DB; Dudley, RA; Garber, AM; Hlatky, MA; Kazi, DS; Mell, MW; Moshkevich, S; Owens, DK; Rhee, C; Shah, RU, 2014) |
| "Two oral antiplatelet agents have been recently introduced for acute coronary syndromes indication providing alternatives for dual therapy with aspirin and clopidogrel." | 3.80 | Viewpoint: "underutilisation of novel antiplatelet agents--myths, generics, and economics". ( Fortmann, SD; Serebruany, VL, 2014) |
| "Ticagrelor is the first reversibly binding oral P2Y12 receptor antagonist designed to reduce clinical thrombotic events in patients with acute coronary syndrome (ACS)." | 3.80 | Direct healthcare costs and cost-effectiveness of acute coronary syndrome secondary prevention with ticagrelor compared to clopidogrel: economic evaluation from the public payer's perspective in Poland based on the PLATO trial results. ( Budaj, A; Macioch, T; Niewada, M; Pawęska, J; Perkowski, P, 2014) |
| "To compare 30 and 90 day real-world acute myocardial infarction (AMI) and bleeding related rehospitalization rates in acute coronary syndrome (ACS) patients receiving percutaneous coronary intervention (PCI; ACS-PCI) treated with clopidogrel or prasugrel." | 3.80 | Real-world observations with prasugrel compared to clopidogrel in acute coronary syndrome patients treated with percutaneous coronary intervention in the United States. ( Bae, JP; Effron, MB; Ernst, FR; Faries, DE; Lieu, HD; Lipkin, C; Moretz, C; Zhao, Z, 2014) |
| "To assess the cost-effectiveness relationship of Ticagrelor versus Clopidogrel for the management of acute coronary syndrome in Spain." | 3.80 | [Long-term cost-effectiveness of ticagrelor versus clopidogrel in acute coronary syndrome in Spain]. ( Mateo-Carrasco, H; Molina-Cuadrado, E; Nieto-Guindo, P; Rodríguez-Gómez, P, 2014) |
| "Current guidelines recommend a combination of clopidogrel and aspirin for management of patients who have experienced an acute coronary syndrome (ACS)." | 3.80 | Prasugrel vs. clopidogrel in acute coronary syndrome patients treated with prasugrel. ( Crivera, C; Dea, K; Fields, LE; Germain, G; Laliberté, F; Lefebvre, P; Lynch, SM; Ma, YW; Olson, WH; Schein, JR, 2014) |
| "This study established a population pharmacokinetics-pharmacodynamics model of clopidogrel in patients with acute coronary syndrome." | 3.80 | [Population pharmacokinetics and pharmacodynamics of clopidogrel in patients with acute coronary syndrome]. ( Ding, XL; Gao, J; Hang, YF; Jiang, B; Miao, LY; Xie, C; Xue, L, 2014) |
| " Totally, 202 patients with acute coronary syndrome (ACS) were followed up for 10 months for major clinical events of myocardial infarction, cerebrovascular accident (CVA), and all cause mortality, and RPA after clopidogrel loading was assessed in 30 patients." | 3.80 | Monitoring residual platelet activity among patients with acute coronary syndrome. ( Li, L; Qiao, R; Zhang, J, 2014) |
| " Patients displaying low on-treatment platelet reactivity (LPR) and/or at high risk of bleeding were switched to clopidogrel 75 mg and tested again 15 days later." | 3.79 | Switching acute coronary syndrome patients from prasugrel to clopidogrel. ( Abtan, J; Barthélémy, O; Beygui, F; Brugier, D; Cayla, G; Collet, JP; Kerneis, M; Martin, R; Montalescot, G; O'Connor, SA; Silvain, J; Vignalou, JB, 2013) |
| "Ticagrelor is a reversible inhibitor of platelet-aggregation, and is used instead of clopidogrel in the treatment of acute coronary syndrome (ACS)." | 3.79 | [Gastrointestinal bleeding after treatment with ticagrelor]. ( Hauge, J; Kragh, R; Poulsen, BK, 2013) |
| "Coexisting polymorphisms of different genes affected clopidogrel responsiveness and clinical outcome more than single polymorphism in Chinese patients with acute coronary syndrome undergoing percutaneous coronary intervention." | 3.79 | Effects of coexisting polymorphisms of CYP2C19 and P2Y12 on clopidogrel responsiveness and clinical outcome in patients with acute coronary syndromes undergoing stent-based coronary intervention. ( Chen, J; Chen, JL; Gao, RL; Han, YL; Qiao, SB; Tang, XF; Wang, J; Wu, Y; Wu, YJ; Xu, B; Yang, YJ; Yuan, JQ; Zhang, JH, 2013) |
| " The PLATO trial compared ticagrelor and aspirin to clopidogrel and aspirin in patients with acute coronary syndromes (ACS)." | 3.79 | Lifetime cost-effectiveness analysis of ticagrelor in patients with acute coronary syndromes based on the PLATO trial: a Singapore healthcare perspective. ( Chin, CT; Chua, TS; Matchar, DB; Mellstrom, C, 2013) |
| "Aim of this multicenter retrospective study was assessment of effect of intracoronary administration of tirofiban loading dose in troponin positive patients with acute coronary syndrome (ACS)." | 3.79 | [Effect of intracoronary and intravenous administration of tirofiban loading dose in patients underwent percutaneous coronary interventions because of acute coronary syndrome]. ( Arystanova, AZh; Balli, M; Batyraliev, TA; Fettser, DV; Kagliian, KÉ; Samko, AN; Serchelik, A; Sidorenko, BA; Tekin, K; Turkmen, S, 2013) |
| "The novel P2Y12 antagonist ticagrelor inhibits adenosine diphosphate (ADP)-induced platelet aggregation more potently than clopidogrel and reduces the incidence of myocardial infarction and total death in patients with an acute coronary syndrome (ACS)." | 3.79 | Ticagrelor improves peripheral arterial function in patients with a previous acute coronary syndrome. ( Erlinge, D; Larsson, J; Ohman, J; Salmi, H; Torngren, K, 2013) |
| "Five-hundred Chinese-Han patients treated with clopidogrel for acute coronary syndrome (ACS) were consecutively recruited from the Department of Geriatric Cardiology, General Hospital of Chinese People's Liberation Army, from September 2010 to September 2012." | 3.79 | Genetic determinants of high on-treatment platelet reactivity in clopidogrel treated Chinese patients. ( Chen, Y; Jin, Y; Li, J; Li, X; Li, Y; Lu, C; Ma, C; Qu, F; Wang, H; Xu, B; Yang, J; Yin, T; Zhang, L; Zhang, Y, 2013) |
| "Recent European Society of Cardiology (ESC) Guidelines declare superiority of prasugrel and ticagrelor over clopidogrel in non-ST segment elevation myocardial infarction (NSTEMI) and STEMI patients with acute coronary syndromes (ACS)." | 3.79 | Viewpoint: mismatch between the European and American guidelines on oral antiplatelet P2Y12 inhibitors after acute coronary syndromes. ( DiNicolantonio, JJ; Serebruany, VL, 2013) |
| "Current guidelines offer a choice of P2Y12 receptor antagonist among clopidogrel, prasugrel or ticagrelor on top of aspirin (ASA) for dual antiplatelet therapy (DAPT) in patients after acute coronary syndromes (ACS)." | 3.79 | Gastrointestinal adverse events after dual antiplatelet therapy: clopidogrel is safer than ticagrelor, but prasugrel data are lacking or inconclusive. ( Can, MM; Dinicolantonio, JJ; Kuliczkowski, W; Pershukov, IV; Serebruany, VL, 2013) |
| "The current study sought to evaluate the clinical impact of newly reported genetic variations and their association with clopidogrel high on-treatment platelet reactivity (HTPR) in acute coronary syndrome (ACS) patients after drug-eluting stent (DES) implantation." | 3.79 | The impact of gene polymorphism and high on-treatment platelet reactivity on clinical follow-up: outcomes in patients with acute coronary syndrome after drug-eluting stent implantation. ( Han, YL; Kang, J; Li, Y; Liang, ZY; Yan, CH; Zhang, XL, 2013) |
| "It remains unknown whether the time course of the antiplatelet effects of clopidogrel differs according to cytochrome P450 (CYP) 2C19 phenotype in Japanese patients with acute coronary syndromes (ACS)." | 3.79 | Platelet reactivity in the early and late phases of acute coronary syndromes according to cytochrome P450 2C19 phenotypes. ( Endo, T; Fukui, K; Hibi, K; Himeno, H; Kimura, K; Morita, S; Nagashima, Z; Sugano, T; Tsukahara, K; Umemura, S, 2013) |
| "The PLATO (Platelet Inhibition and Patient Outcomes) randomized trial (NCT00391872) in patients with acute coronary syndromes (ACS) reported that ticagrelor (in addition to aspirin) reduced the rate of the composite end point of myocardial infarction (MI), stroke, or cardiovascular death compared with clopidogrel (in addition to aspirin) by 16% over 12 months (P < 0." | 3.79 | Cost-effectiveness of 12-month treatment with ticagrelor compared with clopidogrel in the management of acute coronary syndromes. ( Adena, M; Aylward, P; Chim, L; De Abreu Lourenço, R; Liew, D, 2013) |
| "Treatment with clopidogrel, a selective platelet P2Y12 receptor antagonist, reduces risk of recurrent ischemic events in patients with acute coronary syndrome (ACS), by limiting platelet aggregation and activation." | 3.79 | Plasma and whole blood clot strength measured by thrombelastography in patients treated with clopidogrel during acute coronary syndromes. ( Kreutz, RP; Lu, D; Owens, J, 2013) |
| "Clopidogrel could decrease mortality and improve cardiovascular outcomes without increasing risk of bleeding in ACS patients with CKD." | 3.79 | Effects of clopidogrel on mortality, cardiovascular and bleeding outcomes in patients with chronic kidney disease - data from Taiwan acute coronary syndrome full spectrum registry. ( Chang, SC; Chiang, FT; Hsin, HT; Hwang, JJ; Kuo, CT; Lai, WT; Li, AH; Lin, TH; Wang, CL, 2013) |
| "Our study confirms that initial clinical presentation, especially ACS, is a strong predictor of clopidogrel low response; this suggests that the evolution of coronary artery disease for one patient influences the clopidogrel response over time." | 3.79 | Impact of initial clinical presentation on clopidogrel low response. ( Bauters, A; Bauters, C; Bonello, L; Delhaye, C; Lablanche, JM; Landel, JB; Lemesle, G; Sudre, A; Susen, S, 2013) |
| "Patients with recent acute coronary syndrome or percutaneous coronary intervention prescribed clopidogrel were offered CYP2C19 testing." | 3.79 | Impact of CYP2C19 genetic testing on provider prescribing patterns for antiplatelet therapy after acute coronary syndromes and percutaneous coronary intervention. ( Brennan, T; Canestaro, WJ; Chaplin, D; Choudhry, NK; Desai, NR; Kyrychenko, P; Martell, LA; Matlin, OS, 2013) |
| "We sought to evaluate outcomes, costs of care, quality of life and predictors at 12 months in patients with an acute coronary syndrome (ACS) who underwent percutaneous coronary intervention (PCI) and evaluated use of optimal secondary prevention therapy, defined as use of aspirin and clopidogrel along with ≥ 3 of the following 4 therapies at both hospital discharge and at one-year post-PCI: statins, beta-blockers, ARB/ACE-inhibitors, and exercise or diet." | 3.79 | Predictors, cost, and outcomes of patients with acute coronary syndrome who receive optimal secondary prevention therapy: results from the antiplatelet treatment observational registries (APTOR). ( Bakhai, A; Belger, M; Berkenboom, G; Coufal, Z; Norrbacka, K; Sartral, M; Zeymer, U, 2013) |
| "This study aims to assess the cost-effectiveness in Australia of screening CYP2C19 loss-of-function (LoF) alleles to guide selection of clopidogrel or ticagrelor for individuals with acute coronary syndrome who are likely to undergo coronary stenting." | 3.79 | Cost-effectiveness of using CYP2C19 genotype to guide selection of clopidogrel or ticagrelor in Australia. ( Horowitz, JD; Karnon, JD; Pekarsky, B; Sorich, MJ; Sorich, W; Wiese, MD, 2013) |
| "To investigate the relationship between cytochrome P450 (CYP) 2C19 genetic polymorphism and clopidogrel resistance(CR) in patients with acute coronary syndrome(ACS), and to assess the effects of genetic polymorphism at CYP2C19 (681G>A) on the prognosis of ACS patients." | 3.79 | [The effects of cytochrome P450 2C19 genetic polymorphism on clopidogrel resistance and recent prognosis of patients with acute coronary syndrome]. ( Chen, PA; Lei, XM; Li, GL; Li, SN; Liu, Z; Luo, Y, 2013) |
| "High on clopidogrel platelet reactivity (HPR) has been associated with adverse outcomes following acute coronary syndromes (ACS)." | 3.79 | Suboptimal response to clopidogrel and the effect of prasugrel in acute coronary syndromes. ( Harding, SA; Johnston, LR; La Flamme, AC; Larsen, PD; Michel, JM; Simmonds, MB, 2013) |
| "The CYP2C19 genotype is a predictor of adverse cardiovascular events in acute coronary syndrome (ACS) patients undergoing percutaneous coronary intervention (PCI) treated with clopidogrel." | 3.79 | Genetic testing in patients with acute coronary syndrome undergoing percutaneous coronary intervention: a cost-effectiveness analysis. ( Berger, JS; Hochman, JS; Ladapo, JA; Lala, A; Scott Braithwaite, R; Sharma, G, 2013) |
| "Patients with acute coronary syndrome undergoing percutaneous coronary intervention (PCI) commonly receive a loading dose of either clopidogrel or prasugrel, in addition to aspirin." | 3.79 | Safety of reloading prasugrel in addition to clopidogrel loading in patients with acute coronary syndrome undergoing percutaneous coronary intervention. ( Chen, F; Kent, KM; Kitabata, H; Loh, JP; Pendyala, LK; Pichard, AD; Satler, LF; Suddath, WO; Torguson, R; Waksman, R, 2013) |
| "In the TRITON-TIMI 38 trial, patients with an acute coronary syndrome (ACS) undergoing percutaneous coronary intervention (PCI) were treated with prasugrel or clopidogrel." | 3.79 | Prasugrel vs clopidogrel in patients with acute coronary syndrome undergoing percutaneous coronary intervention: a model-based cost-effectiveness analysis for Germany, Sweden, the Netherlands, and Turkey. ( Bakhai, A; Barrett, A; Davies, A; Graham-Clarke, P; Schmitt, C; Sculpher, M, 2013) |
| "The present study was performed to compare the influence of cytochrome P459 2C19 (CYP2C19) *2 and *17 genetic variants on the platelet response to clopidogrel and prasugrel maintenance therapy and to assess the relation between platelet reactivity and bleeding complications." | 3.79 | Effect of CYP2C19*2 and *17 genetic variants on platelet response to clopidogrel and prasugrel maintenance dose and relation to bleeding complications. ( Alessi, MC; Beguin, S; Bonnet, JL; Camoin, L; Cohen, W; Cuisset, T; Gaborit, B; Grosdidier, C; Lambert, M; Loosveld, M; Morange, PE; Moro, PJ; Pankert, M; Quilici, J; Saut, N, 2013) |
| "We sought to compare the 1-year risk of re-hospitalization for acute coronary syndrome (ACS) between patients taking clopidogrel with proton pump inhibitors (PPIs) vs." | 3.78 | One-year clinical outcome in patients with acute coronary syndrome treated with concomitant use of clopidogrel and proton pump inhibitors: results from a regional cohort study. ( Branzi, A; De Palma, R; Marino, M; Marzocchi, A; Ortolani, P, 2012) |
| "An economic model estimating the cost-effectiveness of prasugrel plus aspirin relative to clopidogrel plus aspirin for patients with acute coronary syndromes (ACS) undergoing percutaneous coronary intervention (PCI) was developed from a managed care organization (MCO) perspective." | 3.78 | Cost-effectiveness of prasugrel in a US managed care population. ( Bae, JP; Cohen, DJ; Graham, JB; Magnuson, EA; Mauskopf, JA; Meadows, ES; Ramaswamy, K; Zagar, AJ, 2012) |
| "Our study indicated no statistically significant increase in the risk of rehospitalization for acute coronary syndrome due to concurrent use of clopidogrel and PPIs in an Asian population with higher prevalence of CYP2C19 intermediate and poor metabolizers." | 3.78 | Cardiovascular outcomes associated with concomitant use of clopidogrel and proton pump inhibitors in patients with acute coronary syndrome in Taiwan. ( Bai, CH; Gau, CS; Lin, CF; Shen, LJ; Wu, FL, 2012) |
| "Guidelines stipulate that clopidogrel should be interrupted ≥ 5 days prior to elective coronary artery bypass graft (CABG) surgery to reduce the risk of bleeding unless the need for revascularization and/or the net benefit of the clopidogrel outweighs the potential risks of bleeding." | 3.78 | Coronary artery bypass graft surgery in acute coronary syndrome: incidence, cost impact, and acute clopidogrel interruption. ( Bell, K; Gdovin, J; Graham, J; Jing, Y; Johnston, SS, 2012) |
| "Recent concerns about clopidogrel and proton pump inhibitor (PPI) co-administration in patients following an acute coronary syndrome (ACS) led us to investigate our practice." | 3.78 | Reducing co-administration of clopidogrel and proton pump inhibitors in acute coronary syndromes. ( Kavvoura, F; Rowlands, DB; Schofield, R; Silva, A; Vassiliou, V, 2012) |
| "Simulated cohort of patients with acute coronary syndrome scheduled to undergo percutaneous coronary intervention (PCI), consisting of three arms: those receiving genotype-guided antiplatelet therapy with clopidogrel or prasugrel, those receiving clopidogrel regardless of genotype, and those receiving prasugrel regardless of genotype." | 3.78 | Cost-effectiveness of cytochrome P450 2C19 genotype screening for selection of antiplatelet therapy with clopidogrel or prasugrel. ( Beitelshees, AL; Daniel Mullins, C; Onukwugha, E; Reese, ES, 2012) |
| " We aimed to determine the relationship between high on-treatment platelet reactivity (HTPR) and ST-elevation myocardial infarction (STEMI) following a 600 mg loading dose (LD) of clopidogrel." | 3.78 | Biological efficacy of a 600 mg loading dose of clopidogrel in ST-elevation myocardial infarction. ( Armero, S; Barragan, P; Berbis, J; Bessereau, J; Bonello, C; Bonello, L; Camillieri, E; Camoin-Jau, L; Dignat-George, F; Jacquin, L; Laine, M; Paganelli, F, 2012) |
| "The early administration of the anti-platelet agent clopidogrel in patients with acute coronary syndromes with or without ST-segment elevation has a beneficial effect on mortality and major adverse cardiac events." | 3.78 | Dramatic effect of early clopidogrel administration in reducing mortality and MACE rates in ACS patients. Data from the Swiss registry AMIS-Plus. ( Duvoisin, N; Erne, P; Goy, JJ; Radovanovic, D; Rickli, H; Stauffer, JC, 2012) |
| "One-year treatment with clopidogrel in addition to aspirin is a cost-effective treatment option for secondary prevention in patients with acute coronary syndrome without ST-segment elevation in Greece." | 3.78 | Economic evaluation of clopidogrel in acute coronary syndrome patients without ST-segment elevation in Greece: a cost-utility analysis. ( Fragoulakis, V; Kourlaba, G; Maniadakis, N, 2012) |
| "A total of 10,101 patients aged 18 years or older with a diagnosis of acute coronary syndrome (ACS) made during a hospitalization or emergency department visit between 2001 and 2008 and who had their first clopidogrel prescription within 90 days after their ACS diagnosis were included in the study." | 3.78 | Effect of the clopidogrel-proton pump inhibitor drug interaction on adverse cardiovascular events in patients with acute coronary syndrome. ( Bhurke, SM; Bursac, Z; Franks, AM; Li, C; Martin, BC; Said, Q, 2012) |
| "On July 20, 2011, the Food and Drug Administration (FDA) approved ticagrelor (Brilinta™) for use during acute coronary syndromes." | 3.78 | Ticagrelor FDA approval issues revisited. ( Serebruany, VL, 2012) |
| " In particular, an herbal combination including Tribulus terrestris (TT), Avena sativa (AS), and Panax Ginseng (PG), which may be effective in treatment of atherosclerosis and thrombosis, is used by patients with coronary artery disease." | 3.78 | [Three case reports of the use of herbal combinations resulted in stent thrombosis: herbal combinations; friend or foe?]. ( Erdoğan, E; Göktekin, Ö; Tasal, A; Vatankulu, MA, 2012) |
| " Fatal or nonfatal (requiring hospitalization) bleeding was determined according to antithrombotic treatment regimen: triple therapy (TT) with vitamin K antagonist (VKA)+aspirin+clopidogrel, VKA+antiplatelet, and dual antiplatelet therapy with aspirin+clopidogrel." | 3.78 | Bleeding after initiation of multiple antithrombotic drugs, including triple therapy, in atrial fibrillation patients following myocardial infarction and coronary intervention: a nationwide cohort study. ( Gislason, GH; Hansen, CM; Hansen, ML; Karasoy, D; Kristensen, SL; Køber, L; Lamberts, M; Olesen, JB; Ruwald, MH; Torp-Pedersen, C, 2012) |
| "High platelet reactivity (HPR) after clopidogrel treatment is linked to an increased risk of periprocedural myocardial infarction (PMI)." | 3.78 | Association of CYP2C19 genotype with periprocedural myocardial infarction after uneventful stent implantation in Chinese patients receiving clopidogrel pretreatment. ( Ge, J; Qian, J; Sun, A; Wang, Q; Wu, H, 2012) |
| "A recent clinical trial has demonstrated that patients with acute coronary syndromes (ACS) and the reduced function allele CYP2C19*2 (*2 allele), who are treated with thienopyridines, have an increased risk of adverse cardiac events with clopidogrel, but not with prasugrel." | 3.78 | The cost effectiveness of genetic testing for CYP2C19 variants to guide thienopyridine treatment in patients with acute coronary syndromes: a New Zealand evaluation. ( Brown, PM; Gladding, P; Panattoni, L; Te Ao, B; Webster, M, 2012) |
| "In conclusion, the present study showed that initial clopidogrel response in patients with acute coronary syndrome is not a reliable predictor of response to maintenance therapy and their values for prediction of clinical outcome are likely to be different." | 3.78 | Comparison between initial and chronic response to clopidogrel therapy after coronary stenting for acute coronary syndrome and influence on clinical outcomes. ( Alessi, MC; Bonnet, JL; Cuisset, T; Fourcade, L; Gaborit, B; Gil, JM; Grosdidier, C; Loosveld, M; Morange, PE; Moro, PJ; Quilici, J, 2012) |
| "The aim of this study was to evaluate the prevalence of triple antithrombotic therapy (TT) (warfarin, aspirin and clopidogrel) in patients following an acute coronary syndrome (ACS), the bleeding risk compared to double antiplatelet therapy (DAPT) (aspirin and clopidogrel) and evaluate the accuracy of the HAS-BLED risk score in predicting serious bleeding events in TT patients." | 3.78 | Triple antithrombotic therapy following an acute coronary syndrome: prevalence, outcomes and prognostic utility of the HAS-BLED score. ( Braun, OÖ; Koul, S; Lumsden, J; Ohman, J; Rydell, E; Scherstén, F; Smith, JG; Svensson, PJ; van der Pals, J; Wieloch, M, 2012) |
| "Our results show that renal failure history and clopidogrel and GPIIb/IIIa receptor antagonist use are independent risk factors for in-hospital bleeding in patients with acute coronary syndrome." | 3.78 | [Analysis of the risk factors of patients with acute coronary syndrome suffering hemorrhage during hospitalization]. ( Chen, YD; Jin, ZN; Liu, H; Liu, X; Lü, SZ; Song, XT, 2012) |
| "To detect the single nucleotide polymorphisms of clopidogrel metabolism related genes (CYP2C19, ABCB1 and PON1) in Chinese patients with acute coronary syndrome (ACS) by genotype analysis." | 3.78 | [Clopidogrel metabolism related gene polymorphisms in Chinese patients with acute coronary syndrome]. ( Bai, Y; Chen, T; Feng, GX; Liang, Y; Liu, X; Wang, XY; Yang, YJ; Yang, YM; Zhu, J, 2012) |
| "Clopidogrel should be initiated as soon as possible in patients with non-ST-segment elevation acute coronary syndrome (NSTE-ACS) except those who urgently require coronary artery bypass grafting (CABG)." | 3.77 | An early and simple predictor of severe left main and/or three-vessel disease in patients with non-ST-segment elevation acute coronary syndrome. ( Ebina, T; Endo, M; Hibi, K; Ishikawa, T; Iwahashi, N; Kimura, K; Kosuge, M; Maejima, N; Morita, S; Okada, K; Umemura, S, 2011) |
| "The purpose of this study is to evaluate the efficacy and safety of ticagrelor and clopidogrel in patients with acute coronary syndrome undergoing coronary artery bypass graft surgery (CABG), as a post-randomization strategy." | 3.77 | Ticagrelor versus clopidogrel in patients with acute coronary syndromes undergoing coronary artery bypass surgery: results from the PLATO (Platelet Inhibition and Patient Outcomes) trial. ( Asenblad, N; Bassand, JP; Becker, RC; Cannon, CP; Claeys, MJ; Harrington, RA; Held, C; Horrow, J; Husted, S; James, SK; Mahaffey, KW; Nicolau, JC; Scirica, BM; Storey, RF; Vintila, M; Wallentin, L; Ycas, J, 2011) |
| "Recent guidelines recommend use of aspirin and either clopidogrel or prasugrel for at least 12 months following use of drug-eluting or bare metal stents in patients with acute coronary syndromes (ACS) undergoing percutaneous coronary intervention (PCI)." | 3.77 | Factors associated with clopidogrel use, adherence, and persistence in patients with acute coronary syndromes undergoing percutaneous coronary intervention. ( Anderson, J; Bae, JP; Fu, H; Lenarz, L; McCollam, P; Zettler, M; Zhao, Z; Zhu, B, 2011) |
| "Clopidogrel reduces long-term ischemic events in patients with acute coronary syndrome or stable angina (SA) undergoing percutaneous coronary intervention (PCI)." | 3.77 | Relationship between peripheral arterial reactive hyperemia and residual platelet reactivity after 600 mg clopidogrel. ( Barbato, E; Bartunek, J; Cuisset, T; De Bruyne, B; Dierickx, K; Hamilos, M; Mangiacapra, F; Meeus, P; Muller, O; Ntalianis, A; Sarno, G; Trana, C; Wijns, W, 2011) |
| "1%, respectively) after clopidogrel, which have never been seen in any previous acute coronary syndrome (ACS) trial." | 3.77 | Viewpoint: paradoxical excess mortality in the PLATO trial should be independently verified. ( Serebruany, VL, 2011) |
| "Guidelines support clopidogrel therapy in medically-treated or percutaneous coronary intervention (PCI) patients after hospitalization for acute coronary syndrome (ACS)." | 3.77 | Incidence of death and recurring acute coronary syndrome after stopping clopidogrel therapy in a large commercially-insured population in the US. ( Chang, CL; Cziraky, MJ; Devecchis Wygant, G; Hauch, O; Stephenson, JJ, 2011) |
| "Clopidogrel has been widely used to prevent recurrent ischemia in patients with acute coronary syndrome (ACS)." | 3.77 | Clinical, pharmacokinetic, and pharmacogenetic determinants of clopidogrel resistance in Korean patients with acute coronary syndrome. ( Chung, HS; Han, JY; Kim, HJ; Kim, SR; Lee, SY; Park, KJ, 2011) |
| " Triple therapy (OAC, clopidogrel plus aspirin) was associated with four times higher risk of any bleeding than OAC plus aspirin, adj." | 3.77 | Efficacy and safety of clopidogrel after PCI with stenting in patients on oral anticoagulants with acute coronary syndrome. ( Hofman-Bang, C; Lagerqvist, B; Lindbäck, J; Persson, J; Samnegard, A; Stenestrand, U, 2011) |
| "Results of a study of the association between early discontinuation of clopidogrel therapy and rehospitalization rates among patients with acute coronary syndrome (ACS) are reported." | 3.77 | Effect of early clopidogrel discontinuation on rehospitalization in acute coronary syndrome: results from two distinct patient populations. ( Curkendall, S; Ernst, FR; Johnston, S; Mozaffari, E; Stemkowski, S, 2011) |
| "Although clopidogrel pretreatment benefits patients undergoing percutaneous coronary intervention (PCI) for acute coronary syndromes, these benefits are less well established among patients undergoing elective PCI--in particular, when they are treated with the direct thrombin inhibitor, bivalirudin." | 3.77 | Effect of clopidogrel pretreatment on ischemic complications of percutaneous coronary intervention among bivalirudin-treated patients (from the EVENT registry). ( Amin, AP; Berger, P; Cohen, DJ; Kennedy, KF; Kleiman, N; Lopez, J; Pencina, M; Piana, RN, 2011) |
| "The clinical safety and efficacy of clopidogrel reloading in patients receiving long-term clopidogrel therapy who present with acute coronary syndromes and undergo percutaneous coronary intervention have not yet been evaluated." | 3.77 | Safety and efficacy of clopidogrel reloading in patients on chronic clopidogrel therapy who present with an acute coronary syndrome and undergo percutaneous coronary intervention. ( Ben-Dor, I; Gaglia, MA; Gonzalez, M; Mahmoudi, M; Maluenda, G; Pichard, AD; Sardi, G; Satler, LF; Suddath, WO; Syed, AI; Torguson, R; Wakabayashi, K; Waksman, R; Xue, Z, 2011) |
| "We conducted a retrospective cohort study to assess CV outcomes of 9753 patients taking dual antiplatelet therapy of aspirin plus clopidogrel with or without a PPI after hospitalization for acute coronary syndrome (ACS)." | 3.77 | Relationship between cardiovascular outcomes and proton pump inhibitor use in patients receiving dual antiplatelet therapy after acute coronary syndrome. ( Chen, PF; Hsiao, FY; Huang, WF; Mullins, CD; Tsai, YW; Wen, YW, 2011) |
| "Current clinical practice guidelines recommend dual antiplatelet therapy with aspirin and clopidogrel or prasugrel for patients with acute coronary syndrome (ACS)." | 3.77 | Impact of dyspnea on medical utilization and affiliated costs in patients with acute coronary syndrome. ( Bonafede, M; Deitelzweig, SB; Gdovin Bergeson, J; Graham, J; Jing, Y; Liffmann, D; Makenbaeva, D, 2011) |
| "To test the hypothesis that HRPR after clopidogrel loading is an independent prognostic marker of risk of long-term thrombotic events in patients with acute coronary syndromes (ACS) undergoing an invasive procedure and antithrombotic treatment adjusted according to the results of platelet function tests." | 3.77 | High residual platelet reactivity after clopidogrel loading and long-term cardiovascular events among patients with acute coronary syndromes undergoing PCI. ( Abbate, R; Antoniucci, D; Buonamici, P; Gensini, GF; Giusti, B; Gori, AM; Marcucci, R; Migliorini, A; Parodi, G; Valenti, R, 2011) |
| "The antiplatelet agent clopidogrel is an effective drug for the prevention of thrombotic events in patients with acute coronary syndrome and in those undergoing percutaneous coronary intervention with the deployment of a coronary stent." | 3.77 | [Stent thrombosis and clopidogrel response variability: is the genetic test useful in clinical practice?]. ( Ardissino, D; Conte, G; Demola, MA; Giacalone, R; Mantovani, F; Marziliano, N; Notarangelo, MF, 2011) |
| "Of 1381 patients admitted with hip fractures, 114 were receiving regular clopidogrel therapy with a median age of 83." | 3.77 | Perioperative management of clopidogrel therapy: the effects on in-hospital cardiac morbidity in older patients with hip fractures. ( Collyer, TC; Corcoran, T; Kilshaw, L; Reynolds, HC; Truyens, E, 2011) |
| "Increased baseline platelet reactivity as well as diabetes mellitus and acute coronary syndrome are associated with low aspirin response in the aged patients." | 3.77 | [Aspirin response and related factors in aged patients]. ( Fan, Y; Feng, XR; Liu, F; Liu, ML; Liu, QZ; Tian, QP, 2011) |
| " Based on the indirect comparison of TRITON and PLATO trial data, ticagrelor is clearly superior to prasugrel in a population of patients with acute coronary syndrome (ACS) because of absolute mortality reduction, realistic second myocardial infarction (MI) prevention, growing over time vascular outcome benefit, fewer haemorrhagic fatalities, potentially less coronary artery bypass graft (CABG)- related bleeding events, and lack of cancer risks." | 3.76 | The TRITON versus PLATO trials: differences beyond platelet inhibition. ( Serebruany, VL, 2010) |
| "In patients with acute coronary syndromes and planned percutaneous coronary intervention, the Trial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet Inhibition With Prasugrel-Thrombolysis in Myocardial Infarction 38 (TRITON-TIMI 38) demonstrated that treatment with prasugrel versus clopidogrel was associated with reduced rates of cardiovascular death, MI, or stroke and an increased risk of major bleeding." | 3.76 | Cost-effectiveness of prasugrel versus clopidogrel in patients with acute coronary syndromes and planned percutaneous coronary intervention: results from the trial to assess improvement in therapeutic outcomes by optimizing platelet inhibition with Prasug ( Antman, E; Arnold, SV; Braunwald, E; Cohen, DJ; Mahoney, EM; Proskorovsky, I; Wang, K; Wiviott, S, 2010) |
| "Current guidelines recommend pretreatment with a loading dose of clopidogrel before percutaneous coronary intervention (PCI) to reduce the incidence of periprocedural myocardial infarctions in patients undergoing PCI." | 3.76 | Efficacy of high-dose clopidogrel treatment (600 mg) less than two hours before percutaneous coronary intervention in patients with non-ST-segment elevation acute coronary syndromes. ( Bergman, G; Fakorede, F; Feldman, DN; Minutello, RM; Moussa, I; Wong, SC, 2010) |
| "We performed a post hoc analysis of the ALBION study; early kinetic profiles of adenosine diphosphate 20 micromol/l maximal platelet aggregation (MPA) and DeltaMPA (with baseline sample as reference) were studied at 8 time points within the 24 h after clopidogrel loading (300, 600, or 900 mg) in non-ST-segment elevation acute coronary syndrome patients." | 3.76 | Slow response to clopidogrel predicts low response. ( Bal-Dit-Sollier, C; Barthélémy, O; Bellemain-Appaix, A; Beygui, F; Collet, JP; Drouet, L; Ducrocq, G; Henry, P; Lellouche, N; Meuleman, C; Milleron, O; Montalescot, G; Sideris, G; Silvain, J; Slama, M, 2010) |
| "This was a retrospective cohort study of 2017 patients with acute coronary syndrome discharged on clopidogrel from an integrated health care delivery system." | 3.76 | Adverse events after stopping clopidogrel in post-acute coronary syndrome patients: Insights from a large integrated healthcare delivery system. ( Clarke, CL; Go, AS; Ho, PM; Magid, DJ; Peterson, ED; Rumsfeld, JS; Sedrakyan, A; Shetterly, SM; Tsai, TT; Wang, TY, 2010) |
| " The study was performed in healthy subjects, patients with coronary artery disease, patients with end-stage renal disease, and patients with acute coronary syndrome after treatment with prasugrel or clopidogrel." | 3.76 | A comparison of the VerifyNow P2Y12 point-of-care device and light transmission aggregometry to monitor platelet function with prasugrel and clopidogrel: an integrated analysis. ( Jakubowski, JA; Li, YG; Luo, J; Payne, CD; Small, DS; Tomlin, ME; Winters, KJ, 2010) |
| "We initiated this study to investigate the utility of s-TEG in assessing the response to clopidogrel in patients presenting with acute coronary syndromes (ACS) and to compare these results with established clopidogrel monitoring techniques." | 3.76 | Individualised assessment of response to clopidogrel in patients presenting with acute coronary syndromes: a role for short thrombelastography? ( Amoah, V; Cotton, JM; Curzen, N; Dunmore, S; Hobson, AR; Nevill, AM; Raghuraman, RP; Rajendra, R; Smallwood, A; Vickers, J; Worrall, AM, 2010) |
| "Previous observational studies reported that concomitant use of clopidogrel and proton pump inhibitors (PPIs) in patients with prior acute coronary syndrome (ACS) was associated with adverse cardiovascular outcomes." | 3.76 | Histamine2-receptor antagonists are an alternative to proton pump inhibitor in patients receiving clopidogrel. ( Chan, FK; Kuo, KN; Lin, JT; Tsao, CR; Wang, CB; Wu, CY; Wu, MS, 2010) |
| "We aimed to investigate the biological impact of a tailored clopidogrel loading dose (LD) according to platelet reactivity monitoring in carriers of the cytochrome (CYP) 2C19*2 loss-of-function polymorphism undergoing percutaneous coronary intervention for an acute coronary syndromes." | 3.76 | Clopidogrel loading dose adjustment according to platelet reactivity monitoring in patients carrying the 2C19*2 loss of function polymorphism. ( Ait Mokhtar, O; Aldebert, P; Armero, S; Arques, S; Barragan, P; Bartholomei, MN; Bonello, L; Bonello, N; Bonello-Burignat, C; Camoin-Jau, L; Dignat-George, F; Giacomoni, MP; Mancini, J; Paganelli, F; Saut, N, 2010) |
| "A database of deidentified electronic medical records from hospitals and hospital-affiliated outpatient facilities throughout the United States was analyzed for PCI patients with or without a diagnosis of acute coronary syndrome (ACS) who received clopidogrel loading doses of > or =300 mg between 48 hours before and 6 hours after PCI." | 3.76 | Pattern of clopidogrel use in hospitalized patients receiving percutaneous coronary interventions. ( Bae, JP; Dean, BB; Emons, MF; Fiske, S; Meadows, E; Xiong, Y; Yu, HT, 2010) |
| "The platelet inhibitor clopidogrel is administered to patients treated with therapeutic hypothermia following cardiac arrest due to acute coronary syndromes." | 3.76 | Antiplatelet effect of clopidogrel is reduced in patients treated with therapeutic hypothermia after cardiac arrest. ( Bjelland, TW; Dale, O; Haugen, BO; Hjertner, Ø; Kaisen, K; Klepstad, P, 2010) |
| "We genotyped ABCB1 in 2932 patients with acute coronary syndromes undergoing percutaneous intervention who were treated with clopidogrel (n=1471) or prasugrel (n=1461) in the TRITON-TIMI 38 trial." | 3.76 | Genetic variants in ABCB1 and CYP2C19 and cardiovascular outcomes after treatment with clopidogrel and prasugrel in the TRITON-TIMI 38 trial: a pharmacogenetic analysis. ( Antman, EM; Braunwald, E; Close, SL; Mega, JL; Sabatine, MS; Shen, L; Simon, T; Walker, JR; Wiviott, SD, 2010) |
| "In the PLATO trial of ticagrelor versus clopidogrel for treatment of acute coronary syndromes, ticagrelor reduced the composite outcome of cardiovascular death, myocardial infarction, and stroke, but increased events of major bleeding related to non-coronary artery bypass graft (CABG)." | 3.76 | Effect of CYP2C19 and ABCB1 single nucleotide polymorphisms on outcomes of treatment with ticagrelor versus clopidogrel for acute coronary syndromes: a genetic substudy of the PLATO trial. ( Armstrong, M; Barratt, BJ; Becker, RC; Horrow, J; Husted, S; James, S; Katus, H; Shah, SH; Steg, PG; Storey, RF; Wallentin, L, 2010) |
| "to reveal the frequency of clopidogrel resistance in patients with acute coronary syndrome (ACS) and its impact on prognosis in these patients." | 3.76 | [Clopidogrel resistance in patients with acute coronary syndrome]. ( Dobrovol'skiĭ, AB; Frolova, NS; Ruda, MIa; Shakhnovich, RM; Sirotkina, OV, 2010) |
| "In patients presenting with ACS and receiving clopidogrel treatment after angiography (before or within 30 min of PCI), peri-procedural bivalirudin monotherapy suppresses acute and long-term adverse events to a similar extent as does UFH plus GP IIb/IIIa inhibitors, while significantly lowering the risk of bleeding complications." | 3.76 | Efficacy and safety of bivalirudin in patients receiving clopidogrel therapy after diagnostic angiography for percutaneous coronary intervention in acute coronary syndromes. ( Bergman, G; Feldman, DN; Minutello, RM; Moussa, I; Wong, SC, 2010) |
| "The aim of the study was to evaluate the effect of the concomitant treatment with proton-pump inhibitors (PPIs) and clopidogrel on the incidence of stent thrombosis, acute coronary syndrome (ACS) and death in patients who underwent percutaneous coronary intervention (PCI) and stent implantation." | 3.76 | Impact of concomitant treatment with proton pump inhibitors and clopidogrel on clinical outcome in patients after coronary stent implantation. ( Brozovic, I; Farhan, S; Geppert, A; Huber, K; Jarai, R; Siller-Matula, J; Smetana, P; Tentzeris, I; Wojta, J, 2010) |
| "Current guidelines recommend dual antiplatelet therapy using aspirin and clopidogrel for non-ST elevation acute coronary syndromes (ACS)." | 3.75 | Efficacy and safety of prasugrel compared with clopidogrel in patients with acute coronary syndromes: results of TRITON-TIMI 38 trials. ( De Servi, S; Mariani, G; Mariani, M, 2009) |
| "Among persons treated with clopidogrel, carriers of a reduced-function CYP2C19 allele had significantly lower levels of the active metabolite of clopidogrel, diminished platelet inhibition, and a higher rate of major adverse cardiovascular events, including stent thrombosis, than did noncarriers." | 3.75 | Cytochrome p-450 polymorphisms and response to clopidogrel. ( Antman, EM; Brandt, JT; Braunwald, E; Close, SL; Hockett, RD; Macias, W; Mega, JL; Sabatine, MS; Shen, L; Walker, JR; Wiviott, SD, 2009) |
| "To assess the prognosis of patients presenting with an acute coronary syndrome (ACS) despite chronic clopidogrel therapy (CCT)." | 3.75 | Prognosis of patients suffering an acute coronary syndrome while already under chronic clopidogrel therapy. ( Bonello, L; De Labriolle, A; Kent, KM; Lemesle, G; Pichard, AD; Roy, P; Satler, LF; Steinberg, DH; Suddath, WO; Torguson, R; Waksman, R, 2009) |
| " The objective of this study is to assess the relationship between response to clopidogrel and post-treatment platelet reactivity (PPR) and 1-year major adverse cardiovascular events (MACE) in patients with non-ST segment elevation acute coronary syndrome (NSTEACS)." | 3.75 | Post-treatment platelet reactivity predicts long-term adverse events better than the response to clopidogrel in patients with non-ST-segment elevation acute coronary syndrome. ( Alonso Orcajo, N; Alonso Rodríguez, D; Carbonell de Blas, R; Cuellas Ramón, C; de Miguel Castro, A; Diego Nieto, A; Fernández Vázquez, F; Pascual Vicente, C; Pérez de Prado, A; Samaniego Lampón, B, 2009) |
| "To assess outcomes of patients taking clopidogrel with or without a proton pump inhibitor (PPI) after hospitalization for acute coronary syndrome (ACS)." | 3.75 | Risk of adverse outcomes associated with concomitant use of clopidogrel and proton pump inhibitors following acute coronary syndrome. ( Fihn, SD; Ho, PM; Jesse, RL; Maddox, TM; Peterson, ED; Rumsfeld, JS; Wang, L, 2009) |
| "Randomized trials have established efficacy of clopidogrel in various types of acute coronary syndromes (ACS)." | 3.75 | Temporal trends and patterns of early clopidogrel use across the spectrum of acute coronary syndromes. ( DeYoung, JP; Fox, KA; Gallo, R; Goodman, SG; Gore, JM; Grondin, FR; Rao, RV; Rose, B; Spencer, FA; Yan, AT; Yan, RT, 2009) |
| "In patients with non-ST-segment elevation acute coronary syndromes (NSTE-ACS), identification of left main and/or 3-vessel disease (LM/3VD) is crucial for deciding whether to initiate early treatment with clopidogrel, which can increase the risk of surgical bleeding." | 3.75 | Early, accurate, non-invasive predictors of left main or 3-vessel disease in patients with non-ST-segment elevation acute coronary syndrome. ( Ebina, T; Hashiba, K; Hibi, K; Kimura, K; Kiyokuni, M; Komura, N; Kosuge, M; Morita, S; Nakayama, N; Umemura, S, 2009) |
| " The present study was designed to assess the predictive value of adenosine diphosphate (ADP)-induced platelet aggregation (ADP-Ag) and the Platelet Reactivity Index of vasodilator-stimulated phosphoprotein for the occurrence of stent thrombosis in patients admitted for non-ST-elevation acute coronary syndrome undergoing percutaneous coronary intervention." | 3.75 | Predictive values of post-treatment adenosine diphosphate-induced aggregation and vasodilator-stimulated phosphoprotein index for stent thrombosis after acute coronary syndrome in clopidogrel-treated patients. ( Alessi, MC; Bali, L; Bonnet, JL; Castelli, C; Cuisset, T; Frere, C; Gaborit, B; Morange, PE; Poyet, R; Quilici, J, 2009) |
| "This retrospective claims study was performed to evaluate the initial and subsequent healthcare costs in patients with acute coronary syndrome (ACS) who had been treated with stent placement and clopidogrel following discharge from the hospital." | 3.75 | Evaluation of hospitalization and follow-up care costs among patients hospitalized with ACS treated with a stent and clopidogrel. ( Chastek, B; Hauch, O; Riedel, AA; Wygant, G, 2009) |
| "(1) For patients with acute coronary syndromes who have undergone percutaneous angioplasty and stenting, the best-assessed treatment for preventing relapses is a combination of aspirin and clopidogrel; (2) Prasugrel, an antiplatelet drug belonging the same chemical class as clopidogrel, is authorized in the EU for use in this indication; (3) Clinical evaluation is based on a randomized double-blind trial comparing prasugrel + aspirin versus clopidogrel + aspirin in 13 608 patients with acute coronary syndromes, half of whom were treated for at least 15 months." | 3.75 | Prasugrel: new drug. After angioplasty and stenting: continue to use aspirin + clopidogrel. ( , 2009) |
| "Despite the clinical benefit associated with the combined use of aspirin and clopidogrel in patients with acute coronary syndrome or those undergoing percutaneous coronary intervention, a considerable interindividual variability in response to these drugs have been consistently reported." | 3.75 | Platelet monitoring for PCI: which test is the one to choose? ( Angiolillo, DJ; Capodanno, D, 2009) |
| "Clopidogrel is widely used in patients with acute coronary syndromes and following percutaneous coronary intervention with stent implantation." | 3.75 | Potential Interaction between clopidogrel and proton pump inhibitors. ( Howard, PA; Vacek, JL, 2009) |
| "There are limited contemporary data on the early use of clopidogrel or glycoprotein (Gp) IIb/IIIa inhibitors, alone versus combination therapies, in non-ST-elevation acute coronary syndrome (NSTE-ACS)." | 3.75 | Underutilization of clopidogrel and glycoprotein IIb/IIIa inhibitors in non-ST-elevation acute coronary syndrome patients: the Canadian global registry of acute coronary events (GRACE) experience. ( Banihashemi, B; Goodman, SG; Gyenes, G; Kornder, JM; Mehta, SR; Montalescot, G; Steg, PG; Welsh, RC; Wong, GC; Yan, AT; Yan, RT, 2009) |
| "Acute coronary syndrome (ACS) guidelines recommend that most patients receive dual antiplatelet therapy with clopidogrel and acetylsalicylic acid (ASA) at the time of presentation to prevent recurrent ischemic events." | 3.75 | Dual antiplatelet therapy in patients requiring urgent coronary artery bypass grafting surgery: a position statement of the Canadian Cardiovascular Society. ( Bittira, B; Brister, S; Eikelboom, J; Fitchett, D; Fremes, S; Graham, J; Gupta, M; Karkouti, K; Lee, A; Love, M; Mazer, D; McArthur, R; Peterson, M; Singh, S; Verma, S; Yau, T, 2009) |
| "To observe and assess the effect of different dosages of aspirin on inflammatory biomarkers, hemorheology (platelet aggregation rate) and clinical prognosis in patients with acute coronary syndrome (ACS)." | 3.75 | [The effect of different dosage of aspirin on inflammatory biomarkers and prognosis in acute coronary syndrome.]. ( Hu, DY; Li, RJ; Liang, YQ; Ren, WL; Song, LF; Xu, YY; Yin, ZN, 2009) |
| "635 Non ST Elevation Acute Coronary Syndrome (NSTE ACS) patients were included and received loading doses of 250 mg aspirin and 600 mg clopidogrel." | 3.75 | Relationship between aspirin and clopidogrel responses in acute coronary syndrome and clinical predictors of non response. ( Alessi, MC; Bali, L; Bonnet, JL; Camoin, L; Cuisset, T; Frere, C; Juhan-Vague, I; Lambert, M; Morange, PE; Quilici, J, 2009) |
| " Among the key recommendations are the following: for all patients presenting with non-ST-segment elevation (NSTE) acute coronary syndrome (ACS), without a clear allergy to aspirin, we recommend immediate aspirin (162 to 325 mg po) and then daily oral aspirin (75 to 100 mg) [Grade 1A]." | 3.74 | Antithrombotic therapy for non-ST-segment elevation acute coronary syndromes: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). ( Becker, RC; Cannon, CP; Goodman, SG; Gutterman, D; Guyatt, GH; Harrington, RA; Lincoff, AM; Popma, JJ; Steg, G, 2008) |
| "In the case of stent thrombosis and resistance to clopidogrel, choices of an alternative drug remain limited." | 3.74 | Repeated high doses of clopidogrel in 2 cases of pharmacological resistance. ( Cayla, G; Leclercq, F; Macia, JC; Piot, C; Rabesendratana, H; Roubille, F; Schved, JF, 2008) |
| "The purpose of our multicenter study was to examine the impact of pre-operative administration of clopidogrel on reoperation rates, incidence of life-threatening bleeding, inpatient length of stay, and other bleeding-related outcomes in acute coronary syndrome (ACS) patients requiring cardiopulmonary bypass (coronary artery bypass graft surgery [CABG]) in a broad cross section of U." | 3.74 | Impact of clopidogrel in patients with acute coronary syndromes requiring coronary artery bypass surgery: a multicenter analysis. ( Becker, RC; Berger, JS; Edwards, FH; Frye, CB; Harshaw, Q; Steinhubl, SR, 2008) |
| "Patients with acute coronary syndrome without ST-segment elevation receiving clopidogrel in addition to acetylsalicylic acid (ASA) showed a 20% risk reduction in comparison to patients receiving ASA monotherapy (CURE trial)." | 3.74 | Long-term cost-effectiveness of clopidogrel in patients with acute coronary syndrome without ST-segment elevation in Germany. ( Brüggenjürgen, B; Ehlken, B; Lindgren, P; Rupprecht, HJ; Willich, SN, 2007) |
| "This study sought to assess whether patients with acute coronary syndromes (ACS) undergoing PCI would receive additional benefit from higher-than-standard (300 mg) loading doses of clopidogrel." | 3.74 | Clopidogrel loading doses and outcomes of patients undergoing percutaneous coronary intervention for acute coronary syndromes. ( Bae, JP; Griffin, B; He, J; Kereiakes, DJ; McCollam, P; Wang, C, 2007) |
| "To determine the risk of major and minor bleeding associated with the CTT compared with two other regimens using the combination of either ASA and clopidogrel or ASA and warfarin in patients with cardiovascular disease." | 3.74 | Safety of the cardiac triple therapy: the experience of the Quebec Heart Institute. ( Bergeron, S; Brulotte, S; Lemieux, A; Magne, J; Nguyen, CM; Poirier, P; Sénéchal, M, 2007) |
| "Clopidogrel responsiveness has been proposed to be involved in recurrent ischemic events after stenting for non-ST elevation acute coronary syndromes (NSTE ACS)." | 3.74 | ADP-induced platelet aggregation and platelet reactivity index VASP are good predictive markers for clinical outcomes in non-ST elevation acute coronary syndrome. ( Alessi, MC; Bonnet, JL; Camoin, L; Carvajal, J; Cuisset, T; Frere, C; Juhan-Vague, I; Lambert, M; Morange, PE; Quilici, J, 2007) |
| "The aim of this study was to evaluate the effect of polymorphisms affecting the clopidogrel metabolism (CYP3A4 IVS10+12G/A and CYP2C19*2) and the P2Y12 receptor (P2Y12 T744C) on modulating platelet function in acute coronary syndrome patients on dual antiplatelet treatment." | 3.74 | Cytochrome P450 2C19 loss-of-function polymorphism, but not CYP3A4 IVS10 + 12G/A and P2Y12 T744C polymorphisms, is associated with response variability to dual antiplatelet treatment in high-risk vascular patients. ( Abbate, R; Antoniucci, D; Gensini, GF; Giusti, B; Gori, AM; Marcucci, R; Paniccia, R; Saracini, C; Sestini, I; Valente, S, 2007) |
| "The combination of aspirin, clopidogrel, and enoxaparin (combination therapy) is the standard treatment for acute coronary syndrome but is associated with gastrointestinal bleeding." | 3.74 | Gastrointestinal bleeding in patients receiving a combination of aspirin, clopidogrel, and enoxaparin in acute coronary syndrome. ( Chang, CM; Chu, WM; Lam, KF; Lau, YK; Ng, FH; Wong, BC; Wong, SY, 2008) |
| "Rate of all-cause mortality or acute myocardial infarction (AMI) after stopping treatment with clopidogrel." | 3.74 | Incidence of death and acute myocardial infarction associated with stopping clopidogrel after acute coronary syndrome. ( Fihn, SD; Ho, PM; Jesse, RA; Larsen, GC; Magid, DJ; Peterson, ED; Rumsfeld, JS; Wang, L, 2008) |
| "Preoperative continuous administration of clopidogrel did not increase the risk of hemorrhagic complications in patients with acute coronary syndrome undergoing isolated off-pump coronary artery bypass surgery." | 3.74 | Effects of continuous administration of clopidogrel before off-pump coronary artery bypass grafting in patients with acute coronary syndrome. ( Lee, S; Song, SW; Yi, G; Yoo, KJ; Youn, YN, 2008) |
| " This study was conducted to analyze, in 603 patients with non-ST elevation acute coronary syndromes, the effect of CYP3A4, CYP3A5, and CYP2C19 gene polymorphisms on clopidogrel response and post-treatment platelet reactivity assessed by adenosine diphosphate (ADP)-induced platelet aggregation, vasodilator-stimulated phosphoprotein phosphorylation index, and ADP-induced P-selectin expression." | 3.74 | Effect of cytochrome p450 polymorphisms on platelet reactivity after treatment with clopidogrel in acute coronary syndrome. ( Alessi, MC; Bonnet, JL; Camoin-Jau, L; Cuisset, T; Faille, D; Frere, C; Juhan-Vague, I; Lambert, M; Morange, PE; Quilici, J; Saut, N, 2008) |
| " The aim of this article is to provide the nonexpert reader with a basic understanding of these analyses, using pharmacoeconomic evaluations of clopidogrel for acute coronary syndromes as examples." | 3.74 | Pharmacoeconomic concepts in antiplatelet therapy: understanding cost-effectiveness analyses using clopidogrel as an example. ( Weintraub, WS, 2008) |
| " A fixed-dose combination (FDC) capsule (HCP0911) has been developed to provide dosing convenience and improve adherence." | 2.84 | Pharmacodynamic effects of a new fixed-dose clopidogrel-aspirin combination compared with separate administration of clopidogrel and aspirin in patients treated with coronary stents: The ACCEL-COMBO trial. ( Ahn, JH; Gurbel, PA; Hwang, JY; Hwang, SJ; Jang, JY; Jeong, YH; Kang, MG; Kim, K; Koh, JS; Kwak, CH; Park, HW; Park, JR; Park, Y; Tantry, US, 2017) |
| "Nonsustained ventricular tachycardia (NSVT) is common after acute coronary syndrome (ACS) and a marker of increased risk of arrhythmogenic death." | 2.82 | Relationship Between Early and Late Nonsustained Ventricular Tachycardia and Cardiovascular Death in Patients With Acute Coronary Syndrome in the Platelet Inhibition and Patient Outcomes (PLATO) Trial. ( Bui, AH; Cannon, CP; Guo, J; Held, C; Himmelmann, A; Husted, S; Im, K; James, SK; Michelson, EL; Scirica, BM; Steg, PG; Storey, RF; Varenhorst, C; Wallentin, L, 2016) |
| " Platelet activation markers were measured by flow cytometry on unstimulated or stimulated (adenosine diphosphate (ADP) 20 μM) platelets, before and after each dosing period." | 2.82 | Prasugrel 5 mg inhibits platelet P-selectin and GPIIb-IIIa expression in very elderly and non elderly: results from the GENERATIONS trial, a pharmacodynamic study in stable CAD patients. ( Borna, C; Brown, P; Erlinge, D; Gidlöf, O; Jakubowski, JA; Lood, C; Truedsson, L; Wagner, H; Winters, K; Zhou, C, 2016) |
| "Major bleeding is associated with high subsequent mortality in ACS." | 2.80 | Association of spontaneous and procedure-related bleeds with short- and long-term mortality after acute coronary syndromes: an analysis from the PLATO trial. ( Becker, RC; Cannon, CP; Ducrocq, G; Harrington, RA; Held, C; Himmelmann, A; Lassila, R; Schulte, PJ; Sorbets, E; Steg, PG; Storey, RF; Wallentin, L, 2015) |
| " The primary efficacy endpoint was the incidence of major adverse cardiovascular events (MACE) at 24 weeks, defined as a composite of cardiovascular death, nonfatal myocardial infarction, and nonfatal ischemic stroke." | 2.79 | Efficacy and safety of adjusted-dose prasugrel compared with clopidogrel in Japanese patients with acute coronary syndrome: the PRASFIT-ACS study. ( Isshiki, T; Kimura, T; Kitagawa, K; Miyazaki, S; Nakamura, M; Nanto, S; Nishikawa, M; Ogawa, H; Saito, S; Takayama, M; Yokoi, H, 2014) |
| "Major bleeding was strongly associated with 30-day mortality (OR 50." | 2.76 | Trans-radial approach for catheterisation in non-ST segment elevation acute coronary syndrome: an analysis of major bleeding complications in the ABOARD Study. ( Aout, M; Barthelemy, O; Bellemain-Appaix, A; Beygui, F; Cayla, G; Collet, JP; Connor, S'; Montalescot, G; Payot, L; Silvain, J; Vicaut, E, 2011) |
| "Fatal bleeding was low and did not differ between groups." | 2.76 | Bleeding complications with the P2Y12 receptor antagonists clopidogrel and ticagrelor in the PLATelet inhibition and patient Outcomes (PLATO) trial. ( Bassand, JP; Becker, RC; Budaj, A; Cornel, JH; French, J; Harrington, RA; Held, C; Horrow, J; Husted, S; James, SK; Lassila, R; Lopez-Sendon, J; Mahaffey, KW; Storey, RF; Wallentin, L; Wojdyla, DM, 2011) |
| "Cilostazol 100 mg b." | 2.75 | Effect of cilostazol on platelet aggregation in patients with non-ST elevation acute coronary syndrome. ( Ahluwalia, J; Bhalla, A; Malhotra, S; Pandhi, P; Pattanaik, S; Sharma, YP, 2010) |
| " Monafram was introduced intravenously to 284 patients just before angioplasty at standard dosage - 0." | 2.75 | [Glycoprotein IIb-IIIa antagonist Monafram in primary angioplasty of patients with acute coronary syndrome without st segment elevation]. ( Frolova, NS; Mazurov, AV; Pevzner, DV; Ruda, MY; Samko, AN; Staroverov, II, 2010) |
| "The field of acute coronary syndromes is characterised by an increasing tendency towards early invasive catheter-based diagnostics and therapeutics-a practice based on observational and retrospective data." | 2.74 | Immediate versus deferred coronary angioplasty in non-ST-segment elevation acute coronary syndromes. ( Amoroso, G; Kiemeneij, F; Laarman, GJ; Patterson, MS; Riezebos, RK; Ronner, E; Slagboom, T; Smits, PC; Suttorp, MJ; ten Berg, JM; Ter Bals, E; Tijssen, JG, 2009) |
| "Antiplatelet therapy is essential treatment for acute coronary syndromes (ACS)." | 2.74 | Comparison of ticagrelor, the first reversible oral P2Y(12) receptor antagonist, with clopidogrel in patients with acute coronary syndromes: Rationale, design, and baseline characteristics of the PLATelet inhibition and patient Outcomes (PLATO) trial. ( Akerblom, A; Becker, R; Cannon, CP; Emanuelsson, H; Harrington, R; Husted, S; James, S; Katus, H; Skene, A; Steg, PG; Storey, RF; Wallentin, L, 2009) |
| "Recurrent ischemic events occurred even during routine use of 75 mg clopidogrel in addition to aspirin, that indicated a potentially insufficient maintenance dosage of clopidogrel." | 2.74 | A high maintenance dose of clopidogrel improves short-term clinical outcomes in patients with acute coronary syndrome undergoing drug-eluting stent implantation. ( Han, YL; Jing, QM; Li, Y; Ma, YY; Wang, B; Wang, DM; Wang, G; Wang, SL; Wang, ZL; Xu, K, 2009) |
| "The risk and benefit of GP-IIb/IIIa Inhibition (GPI) in combination with recent antiplatelet regimens in acute coronary syndromes (ACS) remain unassessed." | 2.55 | Safety and efficacy of IIb/IIIa inhibitors in combination with highly active oral antiplatelet regimens in acute coronary syndromes: A meta-analysis of pivotal trials. ( Agueznai, M; Ardouin, P; Beygui, F; Blanchart, K; Collet, JP; Lemaître, A; Milliez, P; Montalescot, G; Roule, V; Sabatier, R, 2017) |
| "Ticagrelor is a novel ADP receptor blocker that has shown greater, more rapid and more consistent platelet inhibition than clopidogrel." | 2.53 | Ticagrelor: a safe and effective approach for overcoming clopidogrel resistance in patients with stent thrombosis? ( Duraj, L; Fedor, M; Galajda, P; Kovář, F; Kubisz, P; Mokáň, M; Samoš, M; Stančiaková, L; Staško, J, 2016) |
| "Uncertainty regarding clopidogrel effectiveness attenuation because of a drug-drug interaction with proton pump inhibitors (PPI) has led to conflicting guidelines on concomitant therapy." | 2.53 | Clopidogrel-Proton Pump Inhibitor Drug-Drug Interaction and Risk of Adverse Clinical Outcomes Among PCI-Treated ACS Patients: A Meta-analysis. ( Guzauskas, GF; Serbin, MA; Veenstra, DL, 2016) |
| " Endpoints included major adverse cardiac effects (MACEs), target lesion revascularization (TLR), target vessel revascularization (TVR), death, stent thrombosis, bleeding and adverse drug reactions during a 9-12 months period, as well as platelet activities." | 2.52 | Comparing the effectiveness and safety between triple antiplatelet therapy and dual antiplatelet therapy in type 2 diabetes mellitus patients after coronary stents implantation: a systematic review and meta-analysis of randomized controlled trials. ( Bundhun, PK; Chen, MH; Qin, T, 2015) |
| "This article focuses on the pharmacokinetics of prasugrel and recently published pharmacodynamic and clinical studies." | 2.50 | Pharmacokinetic evaluation of prasugrel for the treatment of myocardial infarction. ( Coons, JC; Harris, J; Schwier, N; Seybert, AL, 2014) |
| " Other adverse events observed in patients treated with this platelet inhibitor are discussed, including hematological complications, and cutaneous and hepatic idiosyncratic reactions." | 2.50 | Efficacy and safety of prasugrel in acute coronary syndrome patients. ( Delzor, F; Nanau, RM; Neuman, MG, 2014) |
| " A review of data regarding aspirin use for secondary prevention of events in ACS demonstrated that low aspirin doses (75 to 160 mg/day) are consistently favored for short- and long-term use because of the lack of a dose-response relationship between increasing aspirin dose and improved efficacy, and a higher incidence of gastrointestinal bleeding with increasing aspirin dose." | 2.49 | Aspirin, clopidogrel, and ticagrelor in acute coronary syndromes. ( Berger, JS, 2013) |
| "Patients with unstable angina pectoris/non-ST-elevation myocardial infarction (NSTEMI) should be treated with dual antiplatelet therapy with the use of aspirin plus either clopidogrel, prasugrel, or ticagrelor depending on the clinical circumstances as discussed in this article." | 2.49 | Use of antiplatelet drugs in the treatment of acute coronary syndromes. ( Aronow, WS, 2013) |
| "Non-ST elevation acute coronary syndromes are responsible for approximately 1 million admissions to U." | 2.48 | Unstable angina and non-ST elevation myocardial infarction. ( Braunwald, E, 2012) |
| "The ABCB1 C3435T polymorphism limits oral bioavailability of clopidogrel and may influence prognosis of patients treated with clopidogrel." | 2.48 | ABCB1 C3435T polymorphism and risk of adverse clinical events in clopidogrel treated patients: a meta-analysis. ( Li, J; Luo, M; Sheng, W; Sun, X; Xu, X, 2012) |
| " In consideration for prescribing DAPT (drug, dosage and duration) the clinician will have to weigh the potential benefits (reduction in death from cardiovascular causes, nonfatal myocardial infarction, and nonfatal stroke) and risks (severe or life-threatening bleeding) for each and every patient." | 2.48 | Dual antiplatelet therapy for primary and secondary prevention. ( Dhruvakumar, S; Gerula, C; Kaluski, E; Klapholz, M; Maher, J; Mathur, AP; Mazza, V; Waller, AH, 2012) |
| " This has led to the development of other P2Y12 receptor inhibitors, such as prasugrel and ticagrelor, with different pharmacokinetic characteristics that influence their pharmacodynamics." | 2.47 | Beyond efficacy: pharmacokinetic differences between clopidogrel, prasugrel and ticagrelor. ( Cohen Arazi, H; Di Girolamo, G; Giorgi, MA; Gonzalez, CD, 2011) |
| " Combined major adverse cardiovascular event (stroke, MI, and death) was not different in the two groups (OR 1." | 2.47 | Safety of clopidogrel being continued until the time of coronary artery bypass grafting in patients with acute coronary syndrome: a meta-analysis of 34 studies. ( Athanasiou, T; Malik, IS; Nijjer, SS; Watson, G, 2011) |
| "Platelet-mediated thrombosis is a dreaded clinical event and is the primary cause of acute coronary syndromes and post-percutaneous intervention (PCI) ischaemic events." | 2.47 | Clopidogrel response variability and the advent of personalised antiplatelet therapy. A bench to bedside journey. ( Gurbel, PA; Tantry, US, 2011) |
| "Aspirin is a relatively weak anti platelet agent." | 2.47 | Anti-Platelet Therapy for Acute Coronary Syndrome: A Review of Currently Available Agents and What the Future Holds. ( Bett, JH; Syed, FA; Walters, DL, 2011) |
| "Tirofiban is safe and effective in patients with ACS." | 2.46 | Safety evaluation of tirofiban. ( Tebaldi, M; Valgimigli, M, 2010) |
| "Aspirin alone is a relatively weak antiplatelet agent because it inhibits only one of many paths to platelet activation." | 2.45 | Variability in responsiveness to oral antiplatelet therapy. ( Angiolillo, DJ, 2009) |
| "Ticagrelor treatment was well tolerated in DISPERSE-2, and discontinuation rates were comparable to those observed for clopidogrel." | 2.45 | Ticagrelor: the first reversibly binding oral P2Y12 receptor antagonist. ( Husted, S; van Giezen, JJ, 2009) |
| " In the forth communication we consider data of randomized studies in which efficacy and safety of clopidogrel in combination with has acetylsalicylic acid (ASA) been assessed in comparison with (ASA) in various acute coronary syndromes (ACS), as well as before, during, and after percutaneous coronary interventions (PCI)." | 2.45 | [Thienopyridines in the treatment and prevention of cardiovascular diseases. Part IV. therapeutic application of clopidogrel in combination with acetylsalicylic acid in acute coronary syndromes and percutaneous coronary interventions]. ( Avsar, O; Batyraliev, TA; Fettser, DV; Islek, M; Preobrazhenskiĭ, DV; Sidorenko, BA; Vural, A, 2009) |
| "Fundamentally, acute coronary syndromes are platelet-centric diseases, resulting from platelet-rich thrombi that develop at the site of vessel wall injury." | 2.44 | The rationale for and comparisons of different antiplatelet treatments in acute coronary syndrome. ( Gurbel, PA; Tantry, US, 2008) |
| " Coupled with the results from previous multicentre trials, these two studies provide a guide for the early and long-term use of clopidogrel in the whole spectrum of ACS." | 2.44 | Clinical use of clopidogrel in acute coronary syndrome. ( Chow, WH; Hwang, JJ; Javier, S; Kwok, OH; Mak, KH; Piyamitr, S; Suryawan, R; Tri Ho, HQ; Zambahari, R, 2007) |
| " The specific dosing and its clinical usefulness of each medication are considered." | 2.44 | [Platelet aggregation inhibition in acute coronary syndrome. Facts and expectations]. ( Keltai, M, 2008) |
| " This modified dosage regimen has been established in studies conducted in Japan; however, the efficacy and safety of switching from clopidogrel to prasugrel DAPT among Taiwanese patients remain to be explored." | 1.72 | Prasugrel switching from clopidogrel after percutaneous coronary intervention for acute coronary syndrome in Taiwanese patients: an analysis of safety and efficacy. ( Cheng, LC; Chu, PH; Huang, CL; Kuo, FY; Lan, WR; Lee, CH; Lee, WL; Lin, WS; Liu, PY; Lo, PH; Lu, TM; Nikolajsen, C; Rafael, V; Su, CH; Tsukiyama, S; Wang, YC; Yang, WC; Yin, WH, 2022) |
| " The impact of LOF alleles on the pharmacodynamic response to half-dose prasugrel in patients with non-ST-elevation acute coronary syndrome (NSTE-ACS) undergoing percutaneous coronary intervention (PCI) is unknown." | 1.56 | Pharmacodynamic study of prasugrel or clopidogrel in non-ST-elevation acute coronary syndrome with CYP2C19 genetic variants undergoing percutaneous coronary intervention (PRAISE-GENE trial). ( Ann, SH; Cho, YR; Guo, LZ; Jin, C; Jin, E; Kim, MH; Kim, SJ; Lee, MS; Park, JS; Shin, ES, 2020) |
| "Setting Department for the Treatment of Acute Coronary Syndrome in tertiary teaching hospital, Serbia." | 1.48 | The association of clopidogrel and 2-oxo-clopidogrel plasma levels and the 40 months clinical outcome after primary PCI. ( Apostolovic, S; Konstantinovic, SS; Lilic, J; Marinkovic, V; Nikolic, VN; Pavlovic, M; Stokanovic, D; Zvezdanovic, JB, 2018) |
| " However, a substantial number of patients do not respond to clopidogrel despite a standardized dosage regimen, and this is directly associated with poor prognosis." | 1.46 | Effects of four novel genetic polymorphisms on clopidogrel efficacy in Chinese acute coronary syndromes patients. ( Cao, S; Chen, BL; Fan, L; Liu, M; Liu, ZQ; Xiao, FY; Zhang, W; Zhou, G; Zhou, HH, 2017) |
| "Evaluation of antithrombotic treatments for acute coronary syndromes (ACS) requires balancing ischemic and bleeding risks to assess net benefit." | 1.46 | Balancing the risk of spontaneous ischemic and major bleeding events in acute coronary syndromes. ( Becker, RC; Budaj, A; Cannon, CP; Cornel, JH; Ducrocq, G; Held, C; Himmelmann, A; Husted, S; James, SK; Katus, HA; Lopes, RD; Schulte, PJ; Sorbets, E; Steg, PG; Storey, RF; Wallentin, L, 2017) |
| "Acute coronary syndrome was the indication for index-PCI in 74% of the patients." | 1.46 | High risk of stent thrombosis in the first 6 months after coronary stenting: Do not discontinue clopidogrel early after ACS. ( Godschalk, TC; Kelder, JC; Ten Berg, JM; Zwart, B, 2017) |
| "Aspirin has been regarded as the drug of first choice in the prevention of thromboembolic diseases." | 1.46 | Evidences about combination use of acetylsalicylic acid (aspirin) and clopidogrel in acute coronary syndrome. ( Velázquez de Campos, O, 2017) |
| "The primary end point was recurrence of ACS or death >30days after the index event." | 1.46 | Clopidogrel, prasugrel, or ticagrelor use and clinical outcome in patients with acute coronary syndrome: A nationwide long-term registry analysis from 2009 to 2014. ( Geroldinger, A; Heinze, G; Reichardt, B; Sheikh Rezaei, S; Wolzt, M, 2017) |
| "ESSENTIALS: The reliability of platelet tests as markers of the variable bioavailability of clopidogrel is not yet defined." | 1.43 | Relationship between pharmacokinetics and pharmacodynamics of clopidogrel in patients undergoing percutaneous coronary intervention: comparison between vasodilator-stimulated phosphoprotein phosphorylation assay and multiple electrode aggregometry. ( Beltrame, F; Benati, M; Calabria, S; Cattaneo, M; Danese, E; Fava, C; Gelati, M; Gottardo, R; Guidi, GC; Minuz, P; Tagliaro, F; Tavella, D, 2016) |
| "7, p NS], and in adverse cardiac or cerebrovascular events (MACCE) (5 vs." | 1.42 | Safety and efficacy of in-hospital clopidogrel-to-prasugrel switching in patients with acute coronary syndrome. An analysis from the 'real world'. ( Almendro-Delia, M; Blanco Ponce, E; Caballero-Garcia, A; Cruz-Fernandez, MJ; Garcia-Rubira, JC; Gomez-Domínguez, R; Gonzalez-Matos, C; Hidalgo-Urbano, R; Lobo-Gonzalez, M, 2015) |
| "Kounis syndrome is the concurrence of acute coronary syndrome with allergic reactions, such as anaphylaxis or anaphylactoid reactions." | 1.42 | An Extraordinary Case Associated with an Allergic Reaction to Clopidogrel: Coronary Artery Spasm or Kounis Syndrome? ( Bin, H; Liping, Z; Qiming, F, 2015) |
| "Despite recent advances in stent design and constantly improving protective pharmacological strategies, complications and adverse events following percutaneous coronary interventions (PCI) are still major factors influencing morbidity and mortality." | 1.42 | Independent Predictors of Major Adverse Events following Coronary Stenting over 28 Months of Follow-Up. ( Bulaeva, NI; Fortmann, S; Golukhova, EZ; Grigorian, MV; Ryabinina, MN; Serebruany, VL, 2015) |
| "T2DM was associated with increased thrombus [14861 (8003 to 30161) vs 8908 (6812 to 11996), μ(2)/mm, median (IQR), p=0." | 1.40 | Differences in thrombus structure and kinetics in patients with type 2 diabetes mellitus after non ST elevation acute coronary syndrome. ( Badimon, JJ; Balasubramaniam, K; Marshall, SM; Viswanathan, GN; Zaman, AG, 2014) |
| "Twice daily dosing is often perceived as inferior to once daily dosing due to a higher likelihood of missing a dose." | 1.40 | Projected inhibition of platelet aggregation with ticagrelor twice daily vs. clopidogrel once daily based on patient adherence data (the TWICE project). ( Claeys, MJ; Legrand, V; Van de Werf, F; Vandendriessche, E; Vrijens, B, 2014) |
| " Use of β-adrenergic blockers is recommended in most guidelines, but the clinical trials to support this recommendation were performed more than 30 years ago, and routine long-term use may not be relevant to modern treatment, except when there is cardiac failure or left ventricular dysfunction." | 1.40 | Optimising pharmacotherapy for secondary prevention of non-invasively managed acute coronary syndrome. ( Judkins, C; Thompson, AG; Thompson, PL, 2014) |
| " Moreover, inappropriate statin dosing restrictions (underdosing of simvastatin and lovastatin) were deliberately utilized in PLATO, potentially contributing to the beneficial effect of ticagrelor." | 1.39 | Exploring the ticagrelor-statin interplay in the PLATO trial. ( Dinicolantonio, JJ; Serebruany, VL, 2013) |
| " In conclusion, compared with immediate PCI, d-PCI after ATT in selected, stabilized patients with ACS and a large intracoronary thrombus and without an urgent need for revascularization is probably safe and associated with a reduction in thrombotic burden, angiographic complications, and the need of revascularization." | 1.39 | Safety and efficacy of intense antithrombotic treatment and percutaneous coronary intervention deferral in patients with large intracoronary thrombus. ( Alfonso, F; Bañuelos, C; Echavarría-Pinto, M; Escaned, J; Fernández, C; Fernandez-Ortiz, A; García, E; Gonzalo, N; Gorgadze, T; Hernández, R; Ibañez, B; Jiménez-Quevedo, P; Lopes, R; Macaya, C; Nuñez-Gil, IJ, 2013) |
| "Adenosine diphosphate (ADP) plays a pivotal role as an agonist of platelet activation." | 1.39 | P2Y12 receptor gene polymorphism and antiplatelet effect of clopidogrel in patients with coronary artery disease after coronary stenting. ( Abd Elhamid, S; Abulata, N; El Sobky, M; Khafagy, D; Mostafa, A; Zoheir, N, 2013) |
| " There was no significant difference in the pharmacodynamic effects of clopidogrel on platelet reactivity from baseline to 6-months follow-up (297 ± 57 vs." | 1.39 | Pharmacodynamic effect of clopidogrel in patients undergoing transcatheter aortic valve implantation. ( Bednar, F; Kocka, V; Linkova, H; Sulzenko, J; Tousek, P; Widimsky, P, 2013) |
| " At 1-year follow-up, major adverse cardiac events (MACE), defined as death, myocardial infarction (MI), acute coronary syndrome leading to hospitalization and nonfatal stroke, were recorded." | 1.37 | Safety of clopidogrel and proton pump inhibitors in patients undergoing drug-eluting stent implantation. ( Capodanno, D; Cicorella, N; Gavazzi, A; Guagliumi, G; Lettieri, C; Lortkipanidze, N; Musumeci, G; Nijaradze, T; Romano, M; Rosiello, R; Rossini, R; Sirbu, V; Tarantini, G; Valsecchi, O, 2011) |
| "Approaches to the treatment of acute coronary syndrome in patients with thrombocytopenia might be better directed toward the evaluation of platelet function rather than toward absolute platelet count, and the risk-benefit equation of invasive procedures and antithrombotic therapies may need to incorporate this information." | 1.36 | Antiplatelet therapy and percutaneous coronary intervention in patients with acute coronary syndrome and thrombocytopenia. ( Bathina, JD; Daher, IN; Durand, JB; Iliescu, C; Yusuf, SW, 2010) |
| "Ticagrelor has shown a significant ischemic benefit and an increase in non-surgical bleeding over clopidogrel in the large phase 3 Platelet Inhibition and Patient Outcomes trial." | 1.36 | Emerging oral antiplatelet therapies for acute coronary syndromes. ( Pollack, CV, 2010) |
| "Ticlopidine was initially used in association with aspirin in patients treated with percutaneous coronary interventions (PCI), demonstrating a dramatic reduction of the risk of stent thrombosis." | 1.36 | [Antiplatelet therapy in acute coronary syndromes: state of the art and new perspectives]. ( Calabrese, D; Casella, G; Di Pasquale, G; Pallotti, MG; Riva, L; Zagnoni, S, 2010) |
| "Antiplatelet therapies for the treatment of acute coronary syndromes (ACS) act to interrupt various pathways of platelet activation." | 1.35 | Novel antiplatelet strategies in acute coronary syndromes. ( Sabatine, MS, 2009) |
| "Genetic C3435T polymorphism of the multidrug resistance gene-1 (MDR-1) limits oral bioavailability of clopidogrel and influences prognosis in patients with myocardial infarction." | 1.35 | Influence of C3435T multidrug resistance gene-1 (MDR-1) polymorphism on platelet reactivity and prognosis in patients with acute coronary syndromes. ( Filipiak, KJ; Kisiel, B; Kostrzewa, G; Małek, ŁA; Opolski, G; Płoski, R; Serafin, A; Spiewak, M, 2009) |
| "Non-ST-elevation acute coronary syndrome is associated with significant morbidity and mortality." | 1.35 | Glycoprotein IIb-IIIa inhibitors in the emergency department for patients with non-ST-elevation acute coronary syndromes: principles and practices. ( Bonaca, M; Giugliano, R; Hoekstra, JW; Lefebvre, CW, 2009) |
| "6) by PFA-100], chronic use of aspirin [OR=0." | 1.34 | Residual platelet reactivity is associated with clinical and laboratory characteristics in patients with ischemic heart disease undergoing PCI on dual antiplatelet therapy. ( Abbate, R; Antoniucci, D; Buonamici, P; Gensini, GF; Giglioli, C; Gori, AM; Marcucci, R; Paniccia, R, 2007) |
| " One major adverse clinical event (0." | 1.34 | Effectiveness and safety of reduced-dose enoxaparin in non-ST-segment elevation acute coronary syndrome followed by antiplatelet therapy alone for percutaneous coronary intervention. ( Davis, KE; Denardo, SJ; Tcheng, JE, 2007) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 234 (18.13) | 29.6817 |
| 2010's | 1006 (77.92) | 24.3611 |
| 2020's | 51 (3.95) | 2.80 |
| Authors | Studies |
|---|---|
| Zhang, Y | 9 |
| Zhao, X | 3 |
| Ye, Y | 1 |
| Li, Q | 1 |
| Zeng, Y | 1 |
| Santana-Mateos, M | 1 |
| Medina-Gil, JM | 1 |
| Saavedra-Santana, P | 1 |
| Martínez-Quintana, E | 1 |
| Rodríguez-González, F | 1 |
| Tugores, A | 1 |
| Baturina, O | 1 |
| Andreev, D | 1 |
| Fedina, L | 1 |
| Mirzaev, K | 1 |
| Ivashchenko, D | 1 |
| Ryzhikova, K | 1 |
| Grishina, E | 1 |
| Bochkov, P | 1 |
| Shevchenko, R | 1 |
| Sychev, D | 1 |
| Schäfer, A | 2 |
| Kuo, FY | 2 |
| Lee, CH | 3 |
| Lan, WR | 2 |
| Su, CH | 2 |
| Lee, WL | 2 |
| Wang, YC | 2 |
| Lin, WS | 2 |
| Chu, PH | 2 |
| Lu, TM | 2 |
| Lo, PH | 2 |
| Tsukiyama, S | 2 |
| Yang, WC | 2 |
| Cheng, LC | 2 |
| Huang, CL | 2 |
| Yin, WH | 2 |
| Liu, PY | 2 |
| Jin, Y | 2 |
| Ma, J | 2 |
| Wang, Z | 4 |
| Zou, Y | 1 |
| Wang, G | 4 |
| Wu, Y | 5 |
| Wang, Y | 11 |
| Liu, H | 3 |
| Yin, T | 6 |
| Ye, P | 1 |
| Lee, YJ | 1 |
| Cho, JY | 3 |
| Yun, KH | 2 |
| Lee, SJ | 1 |
| Hong, SJ | 4 |
| Ahn, CM | 4 |
| Kim, BK | 4 |
| Ko, YG | 2 |
| Choi, D | 2 |
| Hong, MK | 3 |
| Jang, Y | 3 |
| Kim, JS | 3 |
| Sukhinina, TS | 1 |
| Pevzner, DV | 2 |
| Mazurov, AV | 5 |
| Vlasik, TN | 1 |
| Solovieva, NG | 1 |
| Kostritca, NS | 1 |
| Shakhnovich, RM | 2 |
| Yavelov, IS | 1 |
| Wang, T | 1 |
| Feng, J | 1 |
| Zhou, L | 1 |
| Zhao, T | 1 |
| Zhang, H | 3 |
| Shen, H | 1 |
| Xu, L | 1 |
| Sun, L | 1 |
| Wu, J | 3 |
| Li, H | 2 |
| Yu, L | 1 |
| van den Broek, WWA | 1 |
| van Paassen, JG | 1 |
| Gimbel, ME | 1 |
| Deneer, VHM | 1 |
| Ten Berg, JM | 8 |
| Vreman, RA | 1 |
| Crea, F | 4 |
| Pradhan, A | 1 |
| Tiwari, A | 1 |
| Caminiti, G | 1 |
| Salimei, C | 1 |
| Muscoli, S | 1 |
| Sethi, R | 1 |
| Perrone, MA | 1 |
| Capranzano, P | 3 |
| Li, J | 13 |
| Yang, J | 5 |
| Yu, Q | 1 |
| Chen, L | 4 |
| Shi, X | 2 |
| Su, J | 1 |
| Zhu, K | 1 |
| Verdoia, M | 16 |
| Nardin, M | 9 |
| Gioscia, R | 3 |
| Suryapranata, H | 11 |
| Kedhi, E | 3 |
| Rognoni, A | 2 |
| DE Luca, G | 16 |
| Galli, M | 1 |
| Ortega-Paz, L | 1 |
| Angiolillo, DJ | 36 |
| Anchidin, OI | 1 |
| Rosianu, SH | 1 |
| Nemes, A | 1 |
| Aldica, M | 1 |
| Blendea, D | 1 |
| Molnar, A | 1 |
| Moldovan, H | 1 |
| Pop, D | 1 |
| Serebruany, VL | 27 |
| Tanguay, JF | 7 |
| Gurvich, ML | 1 |
| Marciniak, TA | 2 |
| Atar, D | 2 |
| Mo, ZZ | 1 |
| Yuan, Z | 1 |
| Peng, YY | 1 |
| Zhou, WL | 1 |
| Dai, W | 1 |
| Tang, J | 2 |
| Zhang, W | 2 |
| Chen, BL | 2 |
| Lee, SH | 2 |
| Jeong, YH | 6 |
| Hong, D | 1 |
| Choi, KH | 2 |
| Lee, JM | 3 |
| Park, TK | 3 |
| Yang, JH | 3 |
| Hahn, JY | 4 |
| Choi, SH | 4 |
| Gwon, HC | 4 |
| Jeong, MH | 3 |
| Joo, HJ | 1 |
| Chang, K | 2 |
| Park, Y | 3 |
| Ahn, SG | 1 |
| Suh, JW | 1 |
| Lee, SY | 2 |
| Cho, JR | 1 |
| Her, AY | 2 |
| Kim, HS | 6 |
| Kim, MH | 7 |
| Lim, DS | 3 |
| Shin, ES | 3 |
| Song, YB | 4 |
| Perla, HT | 1 |
| Thomson, VS | 1 |
| Attumalil, TV | 1 |
| Geevar, T | 1 |
| Alex, AG | 1 |
| Dave, RG | 1 |
| Nair, SC | 1 |
| Gowri, SM | 1 |
| Mony, PK | 1 |
| George, P | 1 |
| Joseph, G | 1 |
| Girotra, S | 1 |
| Stebbins, A | 2 |
| Wruck, L | 1 |
| Marquis-Gravel, G | 1 |
| Gupta, K | 2 |
| Farrehi, P | 1 |
| Benziger, CP | 1 |
| Effron, MB | 11 |
| Whittle, J | 1 |
| Muñoz, D | 1 |
| Kripalani, S | 1 |
| Anderson, RD | 1 |
| Jain, SK | 1 |
| Polonsky, TS | 1 |
| Ahmad, FS | 1 |
| Roe, MT | 29 |
| Rothman, RL | 1 |
| Harrington, RA | 38 |
| Hernandez, AF | 1 |
| Jones, WS | 1 |
| Metzinger, L | 1 |
| Metzinger-Le Meuth, V | 1 |
| Lomakin, NV | 1 |
| Buryachkovskaya, LI | 1 |
| Sumarokov, AB | 1 |
| Gabbasov, ZA | 1 |
| Gerasimov, AN | 1 |
| Jneid, H | 1 |
| Doukas, D | 1 |
| Schimmer, H | 1 |
| Zehtabchi, S | 1 |
| Wójcik, T | 1 |
| Szymkiewicz, P | 1 |
| Wiśniewski, J | 1 |
| Lebioda, A | 1 |
| Jonkisz, A | 1 |
| Gamian, A | 1 |
| Kuliczkowski, W | 2 |
| Ściborski, K | 1 |
| Mysiak, A | 1 |
| Protasiewicz, M | 1 |
| Jimeno-Sánchez, J | 1 |
| Fuertes-Ferre, G | 1 |
| Ruiz-Aranjuelo, A | 1 |
| Caballero-Jambrina, I | 1 |
| Diarte-de Miguel, JA | 1 |
| Ortas-Nadal, MR | 1 |
| Montalto, C | 1 |
| Crimi, G | 3 |
| Savonitto, S | 4 |
| De Servi, S | 22 |
| Jin, C | 2 |
| Guo, LZ | 1 |
| Jin, E | 1 |
| Ann, SH | 1 |
| Cho, YR | 1 |
| Park, JS | 4 |
| Kim, SJ | 1 |
| Lee, MS | 1 |
| Flather, M | 3 |
| Ayton, S | 1 |
| Kim, Y | 1 |
| Johnson, TW | 2 |
| Chen, ZQ | 1 |
| Chen, F | 5 |
| Li, L | 4 |
| Park, DW | 3 |
| Park, SJ | 4 |
| Zelenskaya, EM | 1 |
| Lifshits, GI | 1 |
| Nikolaev, KY | 1 |
| Donirova, OS | 1 |
| Altayev, VD | 1 |
| Apartsin, KA | 1 |
| Voronina, EN | 1 |
| Protasov, KV | 1 |
| Sychev, DA | 1 |
| Huynh, K | 2 |
| Wang, L | 5 |
| Di, Y | 1 |
| Guo, T | 1 |
| Ming, JE | 1 |
| Kong, F | 1 |
| Yin, H | 1 |
| Zhang, L | 11 |
| Xie, F | 1 |
| Yang, N | 1 |
| Ping, C | 1 |
| Li, Y | 15 |
| Hou, J | 2 |
| Ayoub, F | 1 |
| Sengupta, N | 1 |
| Cho, YH | 1 |
| Kim, YH | 3 |
| Suh, Y | 1 |
| Cho, S | 1 |
| Jeon, DW | 2 |
| Yoo, SY | 1 |
| Cho, DK | 3 |
| Hong, BK | 2 |
| Kwon, H | 1 |
| Shin, DH | 1 |
| Nam, CM | 1 |
| Lee, S | 4 |
| Wadowski, PP | 2 |
| Hoberstorfer, T | 1 |
| Weikert, C | 2 |
| Pultar, J | 2 |
| Kopp, CW | 1 |
| Panzer, S | 2 |
| Gremmel, T | 2 |
| Walterscheid, B | 1 |
| Nguyen, J | 1 |
| Tarbox, M | 1 |
| Eshak, N | 1 |
| Tonon, F | 1 |
| Fierro, N | 1 |
| Sagazio, E | 1 |
| Negro, F | 2 |
| Pergolini, P | 9 |
| Rolla, R | 9 |
| Tscharre, M | 2 |
| Eichelberger, B | 1 |
| Kim, JH | 1 |
| Tan, DS | 1 |
| Chan, MYY | 1 |
| Kleiman, NS | 4 |
| Viglione, F | 1 |
| Alkhalil, M | 1 |
| Kuzemczak, M | 1 |
| Kessler, T | 1 |
| Cassese, S | 1 |
| Kastrati, A | 13 |
| Ferracane, E | 1 |
| Bartoli, L | 1 |
| Messori, A | 1 |
| Ge, Z | 2 |
| Gao, XF | 1 |
| Kan, J | 1 |
| Kong, XQ | 1 |
| Zuo, GF | 1 |
| Ye, F | 3 |
| Tian, NL | 1 |
| Lin, S | 1 |
| Liu, ZZ | 1 |
| Shao, YB | 1 |
| He, YQ | 1 |
| Wen, SY | 1 |
| Yang, Q | 2 |
| Xia, Y | 1 |
| Wang, ZZ | 1 |
| Xiao, PX | 1 |
| Li, F | 1 |
| Zeng, HS | 1 |
| Yang, S | 2 |
| Tao, L | 1 |
| Gao, DS | 1 |
| Qu, H | 1 |
| Qian, XS | 1 |
| Han, YL | 8 |
| Zhang, JJ | 2 |
| Chen, SL | 2 |
| You, SC | 1 |
| Gupta, A | 1 |
| Krumholz, HM | 2 |
| Rafael, V | 1 |
| Nikolajsen, C | 1 |
| Dong, Z | 1 |
| Zhai, H | 1 |
| Pan, L | 1 |
| Zhang, B | 2 |
| Thi Thu Nguyen, T | 1 |
| Van Do, D | 1 |
| Mellstrom, C | 3 |
| Quang Nguyen, T | 1 |
| Manh Pham, H | 1 |
| Van Hoang, S | 1 |
| Cong Luu, T | 1 |
| Le Phuong, T | 1 |
| De Luca, L | 4 |
| Parodi, G | 9 |
| Bellandi, B | 1 |
| Tarantini, G | 3 |
| Scudiero, F | 1 |
| Valenti, R | 4 |
| Marcucci, R | 13 |
| Migliorini, A | 4 |
| Marchionni, N | 1 |
| Gori, AM | 9 |
| Zocchi, C | 1 |
| Antoniucci, D | 8 |
| Ohman, EM | 29 |
| Steg, PG | 44 |
| James, SK | 35 |
| Povsic, TJ | 2 |
| White, J | 2 |
| Rockhold, F | 1 |
| Plotnikov, A | 2 |
| Mundl, H | 2 |
| Strony, J | 2 |
| Sun, X | 2 |
| Husted, S | 39 |
| Tendera, M | 1 |
| Montalescot, G | 31 |
| Bahit, MC | 1 |
| Ardissino, D | 14 |
| Bueno, H | 1 |
| Claeys, MJ | 4 |
| Nicolau, JC | 12 |
| Cornel, JH | 17 |
| Goto, S | 5 |
| Kiss, RG | 5 |
| Güray, Ü | 1 |
| Bode, C | 3 |
| Welsh, RC | 4 |
| Gibson, CM | 11 |
| Zhang, YJ | 1 |
| Li, MP | 1 |
| Chen, XP | 1 |
| Podda, GM | 2 |
| Grossi, E | 1 |
| Palmerini, T | 8 |
| Buscema, M | 1 |
| Femia, EA | 3 |
| Della Riva, D | 5 |
| Calabrò, P | 6 |
| Piscione, F | 6 |
| Maffeo, D | 4 |
| Toso, A | 6 |
| Palmieri, C | 4 |
| De Carlo, M | 4 |
| Capodanno, D | 10 |
| Genereux, P | 4 |
| Cattaneo, M | 13 |
| Sweeny, JM | 3 |
| Franchi, F | 4 |
| Rollini, F | 5 |
| Waksman, R | 11 |
| Raveendran, G | 2 |
| Dangas, G | 6 |
| Khan, ND | 1 |
| Carlson, GF | 1 |
| Zhao, Y | 3 |
| Teng, R | 2 |
| Mehran, R | 16 |
| D'Ascenzo, F | 3 |
| Musumeci, G | 5 |
| Saia, F | 2 |
| Varbella, F | 1 |
| Marchese, A | 1 |
| Berti, S | 2 |
| Bolognese, L | 3 |
| Qadir, MI | 1 |
| Rehman, A | 1 |
| HamidAkash, MS | 1 |
| Irfan, M | 1 |
| Baber, M | 1 |
| Hussain, SB | 1 |
| Li, C | 5 |
| Wang, H | 5 |
| Li, S | 2 |
| You, L | 1 |
| Sun, Y | 2 |
| Wang, D | 2 |
| Cui, Y | 1 |
| Cao, Y | 1 |
| Shen, X | 2 |
| Cui, W | 2 |
| Yan, J | 1 |
| Zeng, H | 1 |
| Guo, X | 1 |
| Wang, DW | 2 |
| Kanic, V | 1 |
| Vollrath, M | 1 |
| Penko, M | 1 |
| Markota, A | 1 |
| Kompara, G | 1 |
| Kanic, Z | 1 |
| Alfredsson, J | 2 |
| Neely, B | 9 |
| Neely, ML | 8 |
| Bhatt, DL | 31 |
| Goodman, SG | 17 |
| Tricoci, P | 4 |
| Mahaffey, KW | 19 |
| White, HD | 32 |
| Fox, KA | 26 |
| Prabhakaran, D | 20 |
| Winters, KJ | 15 |
| Armstrong, PW | 26 |
| Li, M | 1 |
| Xuan, L | 1 |
| Zhou, T | 1 |
| Zhang, N | 1 |
| Huang, Y | 1 |
| Tsukahara, K | 5 |
| Choi, YJ | 1 |
| Kim, N | 1 |
| Jang, IJ | 1 |
| Nam, RH | 1 |
| Park, JH | 2 |
| Jo, HJ | 1 |
| Yoon, H | 1 |
| Shin, CM | 1 |
| Park, YS | 1 |
| Lee, DH | 1 |
| Jung, HC | 1 |
| Goldstein, SA | 1 |
| Newby, LK | 3 |
| Cyr, DD | 7 |
| Neely, M | 3 |
| Lüscher, TF | 2 |
| Brown, EB | 2 |
| Hamm, CW | 4 |
| Mannacio, V | 3 |
| Mannacio, L | 1 |
| Antignano, A | 3 |
| Pinna, GB | 1 |
| Lindholm, D | 3 |
| Hagström, E | 3 |
| Becker, RC | 37 |
| Cannon, CP | 44 |
| Himmelmann, A | 17 |
| Katus, HA | 13 |
| Maurer, G | 4 |
| López-Sendón, JL | 2 |
| Storey, RF | 61 |
| Siegbahn, A | 8 |
| Wallentin, L | 58 |
| Liu, J | 8 |
| Yan, HB | 1 |
| Song, L | 1 |
| Hua, YH | 1 |
| Zhao, HJ | 1 |
| Liu, C | 1 |
| Zhou, P | 1 |
| Li, JN | 1 |
| Tan, Y | 1 |
| Yang, YM | 2 |
| Daffara, V | 2 |
| Marino, P | 10 |
| Bellomo, G | 8 |
| Carriero, A | 1 |
| Coons, JC | 2 |
| Iasella, CJ | 1 |
| Chanas, T | 1 |
| Wang, N | 1 |
| Williams, K | 1 |
| Boyd, A | 2 |
| Lyons, J | 1 |
| Eckardt, J | 1 |
| Rihtarchik, L | 1 |
| Merkel, A | 1 |
| Chambers, A | 1 |
| Lemon, LS | 1 |
| Smith, R | 1 |
| Ensor, CR | 1 |
| Xiao, FY | 1 |
| Liu, M | 3 |
| Cao, S | 1 |
| Fan, L | 1 |
| Liu, ZQ | 1 |
| Zhou, HH | 1 |
| Zhou, G | 1 |
| Hauch, O | 4 |
| Ryu, DG | 1 |
| Choi, CW | 1 |
| Kang, DH | 1 |
| Kim, HW | 1 |
| Jeong, DI | 1 |
| Kim, WC | 1 |
| Shin, JG | 2 |
| Lim, TW | 1 |
| Ducrocq, G | 3 |
| Schulte, PJ | 4 |
| Budaj, A | 10 |
| Held, C | 15 |
| Lopes, RD | 9 |
| Sorbets, E | 2 |
| Xanthopoulou, I | 10 |
| Davlouros, P | 7 |
| Deftereos, S | 5 |
| Hamilos, M | 8 |
| Sitafidis, G | 6 |
| Kanakakis, I | 5 |
| Vavouranakis, M | 5 |
| Goudevenos, J | 5 |
| Lekakis, J | 4 |
| Alexopoulos, D | 13 |
| Vogel, B | 5 |
| Baber, U | 7 |
| Cuisset, T | 27 |
| Deharo, P | 3 |
| Quilici, J | 21 |
| Deffarges, S | 1 |
| Bassez, C | 1 |
| Bonnet, G | 3 |
| Fourcade, L | 4 |
| Mouret, JP | 1 |
| Lambert, M | 7 |
| Verdier, V | 2 |
| Morange, PE | 18 |
| Alessi, MC | 25 |
| Bonnet, JL | 23 |
| Wilson, S | 1 |
| Newby, DE | 1 |
| Kim, K | 4 |
| Lee, TA | 3 |
| Ardati, AK | 3 |
| DiDomenico, RJ | 3 |
| Touchette, DR | 3 |
| Walton, SM | 3 |
| Ovrakh, T | 1 |
| Serik, S | 1 |
| Kochubiei, O | 1 |
| Dalby, AJ | 4 |
| Gottlieb, S | 5 |
| Magnus Ohman, E | 3 |
| McGuire, DK | 4 |
| Ruzyllo, W | 5 |
| Wiviott, SD | 25 |
| Fox, KAA | 3 |
| Sartori, S | 5 |
| Aquino, M | 4 |
| Kini, A | 2 |
| Kapadia, S | 4 |
| Weiss, S | 4 |
| Strauss, C | 4 |
| Muhlestein, JB | 3 |
| Toma, C | 5 |
| Rao, SV | 3 |
| DeFranco, A | 4 |
| Poddar, KL | 1 |
| Chandrasekhar, J | 4 |
| Weintraub, W | 4 |
| Henry, TD | 5 |
| Bansilal, S | 3 |
| Baker, BA | 5 |
| Marrett, E | 1 |
| Keller, S | 4 |
| Effron, M | 2 |
| Pocock, S | 5 |
| Ferlini, M | 3 |
| Demarchi, A | 1 |
| Grieco, N | 2 |
| Mafrici, A | 1 |
| Rossini, R | 2 |
| Sponzilli, C | 2 |
| Bognetti, P | 1 |
| Cardile, A | 1 |
| Frattini, S | 1 |
| Ielasi, A | 1 |
| Russo, A | 1 |
| Vecchiato, C | 1 |
| Lettieri, C | 2 |
| Visconti, LO | 1 |
| Pollack, CV | 9 |
| Davoudi, F | 1 |
| Diercks, DB | 2 |
| Lim, ST | 3 |
| Spinar, J | 3 |
| Lowenstern, A | 2 |
| Sun, JL | 2 |
| Huber, K | 17 |
| Morais, J | 8 |
| Zhou, Y | 2 |
| Huang, C | 1 |
| Yan, H | 2 |
| Zhu, W | 1 |
| Xu, W | 1 |
| Zhu, J | 3 |
| Egger, F | 1 |
| Machata, M | 1 |
| Rohla, M | 1 |
| Michael, N | 1 |
| Neumayr, M | 1 |
| Zweiker, R | 1 |
| Hajos, J | 1 |
| Adlbrecht, C | 1 |
| Suppan, M | 1 |
| Helmreich, W | 1 |
| Eber, B | 1 |
| Weiss, TW | 1 |
| Nakamura, M | 7 |
| Iijima, R | 4 |
| Ako, J | 3 |
| Shinke, T | 1 |
| Okada, H | 1 |
| Ito, Y | 1 |
| Ando, K | 1 |
| Anzai, H | 1 |
| Tanaka, H | 1 |
| Ueda, Y | 2 |
| Takiuchi, S | 1 |
| Nishida, Y | 1 |
| Ohira, H | 1 |
| Kawaguchi, K | 1 |
| Kadotani, M | 1 |
| Niinuma, H | 1 |
| Omiya, K | 1 |
| Morita, T | 1 |
| Zen, K | 1 |
| Yasaka, Y | 1 |
| Inoue, K | 1 |
| Ishiwata, S | 1 |
| Ochiai, M | 1 |
| Hamasaki, T | 1 |
| Yokoi, H | 4 |
| Schoener, L | 1 |
| Jellinghaus, S | 1 |
| Richter, B | 1 |
| Pfluecke, C | 1 |
| Ende, G | 1 |
| Christoph, M | 1 |
| Quick, S | 1 |
| Loehn, T | 1 |
| Speiser, U | 1 |
| Poitz, DM | 1 |
| Mierke, J | 1 |
| Strasser, RH | 1 |
| Ibrahim, K | 1 |
| Schellenberg, A | 1 |
| Shmyr, D | 1 |
| Koziol, K | 1 |
| Martens, B | 1 |
| Kosar, L | 1 |
| Jiang, M | 4 |
| You, JHS | 1 |
| Furuse, E | 1 |
| Takano, H | 1 |
| Yamamoto, T | 1 |
| Kubota, Y | 1 |
| Yoshizane, T | 1 |
| Kitamura, M | 1 |
| Miyachi, H | 1 |
| Hosokawa, Y | 1 |
| Shimizu, W | 1 |
| Peng, L | 3 |
| Qin, L | 1 |
| Xi, S | 1 |
| Lu, C | 4 |
| Borse, MS | 1 |
| Dong, OM | 1 |
| Polasek, MJ | 1 |
| Farley, JF | 1 |
| Stouffer, GA | 1 |
| Lee, CR | 1 |
| Kini, AS | 3 |
| Faggioni, M | 2 |
| Farhan, S | 4 |
| Rao, S | 3 |
| Esteve-Pastor, MA | 1 |
| Ruíz-Nodar, JM | 2 |
| Orenes-Piñero, E | 1 |
| Rivera-Caravaca, JM | 1 |
| Quintana-Giner, M | 1 |
| Véliz-Martínez, A | 1 |
| Tello-Montoliu, A | 4 |
| PerniasEscrig, V | 1 |
| Sandín Rollán, M | 1 |
| Vicente-Ibarra, N | 1 |
| MacíasVillanego, MJ | 1 |
| Candela Sánchez, E | 1 |
| Carrillo Alemán, L | 1 |
| Lozano, T | 1 |
| Valdés, M | 3 |
| Marín, F | 6 |
| Koscielny, J | 1 |
| von Heymann, C | 1 |
| Zeymer, U | 9 |
| Cremer, J | 1 |
| Spannagl, M | 1 |
| Labenz, J | 1 |
| Giannitsis, E | 5 |
| Goss, F | 1 |
| Xie, HG | 2 |
| Jia, YM | 1 |
| Tai, T | 1 |
| Ji, JZ | 1 |
| Wein, B | 2 |
| Coslovsky, M | 1 |
| Jabbari, R | 1 |
| Galatius, S | 1 |
| Pfisterer, M | 2 |
| Kaiser, C | 3 |
| Desai, RJ | 1 |
| Spoendlin, J | 1 |
| Mogun, H | 1 |
| Gagne, JJ | 1 |
| Petousis, S | 3 |
| Kanakakis, J | 1 |
| Skalidis, E | 1 |
| Kochiadakis, G | 1 |
| Vardas, PE | 1 |
| Zwart, B | 1 |
| Godschalk, TC | 1 |
| Kelder, JC | 2 |
| Leoncini, M | 2 |
| Bartorelli, A | 3 |
| Bellandi, F | 2 |
| Barozzi, C | 3 |
| Tomasi, L | 3 |
| Vyas, A | 1 |
| Bash, LD | 1 |
| Patel, MD | 1 |
| Simpson, RJ | 2 |
| Sibbing, D | 13 |
| Aradi, D | 8 |
| Jacobshagen, C | 3 |
| Gross, L | 4 |
| Trenk, D | 5 |
| Geisler, T | 8 |
| Orban, M | 3 |
| Hadamitzky, M | 2 |
| Merkely, B | 4 |
| Komócsi, A | 7 |
| Dézsi, CA | 2 |
| Holdt, L | 2 |
| Felix, SB | 2 |
| Parma, R | 2 |
| Klopotowski, M | 2 |
| Schwinger, RHG | 1 |
| Rieber, J | 2 |
| Neumann, FJ | 10 |
| Koltowski, L | 2 |
| Mehilli, J | 9 |
| Huczek, Z | 4 |
| Massberg, S | 5 |
| Harding, SA | 3 |
| Holley, A | 1 |
| Wilkins, B | 1 |
| Fairley, S | 1 |
| Simmonds, M | 1 |
| Larsen, PD | 2 |
| Park, KH | 1 |
| Spartalis, M | 3 |
| Tzatzaki, E | 3 |
| Athanasiou, A | 2 |
| Spartalis, E | 3 |
| Qi, J | 1 |
| Tang, Y | 2 |
| Han, Y | 4 |
| Rasia, M | 1 |
| Solinas, E | 2 |
| Marino, M | 4 |
| Guastaroba, P | 2 |
| Menozzi, A | 4 |
| Cattabiani, MA | 1 |
| Tadonio, I | 1 |
| De Palma, R | 3 |
| Vignali, L | 1 |
| Gragnano, F | 1 |
| Bossard, M | 1 |
| Granger, CB | 7 |
| Faxon, DP | 5 |
| Jolly, SS | 2 |
| Widimsky, P | 9 |
| Niemela, K | 2 |
| Natarajan, MK | 1 |
| Gao, P | 2 |
| Yusuf, S | 5 |
| Mehta, SR | 12 |
| Savarese, G | 1 |
| Lund, LH | 1 |
| Damaskos, C | 1 |
| Moris, D | 1 |
| Politou, M | 1 |
| Castini, D | 1 |
| Persampieri, S | 1 |
| Cazzaniga, S | 1 |
| Ferrante, G | 1 |
| Centola, M | 1 |
| Lucreziotti, S | 1 |
| Salerno-Uriarte, D | 1 |
| Carugo, S | 1 |
| Zocca, P | 1 |
| van der Heijden, LC | 1 |
| Kok, MM | 1 |
| Löwik, MM | 1 |
| Hartmann, M | 1 |
| Stoel, MG | 1 |
| Louwerenburg, JW | 1 |
| de Man, FHAF | 1 |
| Linssen, GCM | 1 |
| Knottnerus, IL | 1 |
| Doggen, CJM | 1 |
| van Houwelingen, KG | 1 |
| von Birgelen, C | 1 |
| Nikiteas, NI | 1 |
| Somaschini, A | 1 |
| Tilemann, L | 1 |
| Mohr, SK | 1 |
| Preusch, M | 1 |
| Chorianopoulos, E | 1 |
| Müller, OJ | 1 |
| Zhong, Z | 1 |
| Zhang, Q | 2 |
| Li, B | 1 |
| Liu, Z | 2 |
| Yang, M | 1 |
| Zhong, W | 1 |
| He, X | 1 |
| Wu, H | 4 |
| Zhong, M | 1 |
| Zhao, P | 1 |
| Kwong, KM | 1 |
| Tam, CC | 2 |
| Chan, R | 2 |
| Lee, SWL | 1 |
| Ip, P | 1 |
| Kwok, J | 2 |
| Bates, ER | 3 |
| Ozawa, T | 1 |
| Suda, M | 1 |
| Ikegami, R | 1 |
| Takano, T | 1 |
| Wakasugi, T | 1 |
| Yanagawa, T | 1 |
| Tanaka, K | 1 |
| Ozaki, K | 1 |
| Hirono, S | 1 |
| Minamino, T | 1 |
| Ottani, F | 2 |
| Caravita, L | 1 |
| Attanasio, C | 1 |
| Galvani, M | 1 |
| Hassani Idrissi, H | 1 |
| Hmimech, W | 1 |
| Khorb, NE | 1 |
| Akoudad, H | 1 |
| Habbal, R | 1 |
| Nadifi, S | 1 |
| Okere, AN | 1 |
| Ezendu, K | 1 |
| Berthe, A | 1 |
| Diaby, V | 1 |
| Tanriverdi, Z | 1 |
| Besli, F | 1 |
| Gungoren, F | 1 |
| Altiparmak, İH | 1 |
| Ristorto, J | 1 |
| Messas, N | 1 |
| Marchandot, B | 1 |
| Kibler, M | 1 |
| Hess, S | 2 |
| Meyer, N | 2 |
| Schaeffer, M | 1 |
| Tuzin, N | 1 |
| Ohlmann, P | 4 |
| Jesel, L | 3 |
| Morel, O | 5 |
| Sorrentino, S | 2 |
| Yang, BS | 2 |
| Wang, XZ | 2 |
| Ge, ML | 1 |
| Jing, QM | 3 |
| Ma, YY | 3 |
| Liu, HW | 1 |
| Wang, B | 2 |
| Xu, K | 3 |
| Pennacchi, M | 1 |
| Gallo, P | 1 |
| Rigattieri, S | 1 |
| Granatelli, A | 1 |
| Gulizia, MM | 2 |
| Motovska, Z | 4 |
| Oh, JH | 2 |
| Lee, JB | 2 |
| Doh, JH | 2 |
| Kim, SH | 3 |
| Jeong, JO | 2 |
| Bae, JH | 1 |
| Kim, BO | 1 |
| Cho, JH | 1 |
| Suh, IW | 1 |
| Kim, DI | 2 |
| Park, HK | 1 |
| Choi, WG | 1 |
| Lee, WS | 1 |
| Kim, J | 3 |
| Choi, JH | 3 |
| Peterson, BE | 1 |
| Nusdeo, G | 1 |
| Terrosu, P | 1 |
| Zeb, I | 1 |
| Krim, N | 1 |
| Bella, J | 1 |
| Regev, E | 2 |
| Asher, E | 4 |
| Fefer, P | 4 |
| Beigel, R | 5 |
| Mazin, I | 3 |
| Matetzky, S | 6 |
| Olechowski, B | 1 |
| Dalton, RT | 1 |
| Khanna, V | 1 |
| Ashby, A | 1 |
| Vavyla, M | 1 |
| Mariathas, M | 1 |
| Harris, S | 1 |
| Nicholas, Z | 1 |
| Mahmoudi, M | 2 |
| Curzen, N | 4 |
| Wu, B | 1 |
| Tobe, RG | 1 |
| Liu, Y | 2 |
| He, B | 1 |
| SHalaev, SV | 2 |
| Safiullina, ZM | 1 |
| Lim, HH | 1 |
| An, GD | 1 |
| Woo, KS | 3 |
| Kim, KH | 3 |
| Kim, JM | 3 |
| Han, JY | 4 |
| Parker, WAE | 1 |
| Eriksson, N | 1 |
| Voora, D | 1 |
| Åkerblom, A | 4 |
| Bangalore, S | 3 |
| Velázquez de Campos, O | 1 |
| Mazlan-Kepli, W | 1 |
| Dawson, J | 1 |
| Berry, C | 1 |
| Walters, M | 1 |
| Wang, HY | 2 |
| Xu, XM | 1 |
| Yan, G | 1 |
| De Rosa, R | 2 |
| Frelinger, AL | 4 |
| Gachet, C | 3 |
| Mumford, AD | 1 |
| Noris, P | 1 |
| Mezzano, D | 1 |
| Harrison, P | 1 |
| Gresele, P | 2 |
| de la Torre Hernández, JM | 2 |
| Pavlovic, M | 1 |
| Apostolovic, S | 1 |
| Stokanovic, D | 1 |
| Lilic, J | 1 |
| Konstantinovic, SS | 1 |
| Zvezdanovic, JB | 1 |
| Marinkovic, V | 1 |
| Nikolic, VN | 1 |
| Mansurova, JA | 1 |
| Karazhanova, LK | 1 |
| Kinnaird, T | 1 |
| Ashby, D | 1 |
| Lyon, C | 1 |
| Koyabu, Y | 1 |
| Abe, S | 1 |
| Sakuma, M | 1 |
| Kanaya, T | 1 |
| Obi, S | 1 |
| Yoneda, S | 1 |
| Toyoda, S | 1 |
| Nakajima, T | 1 |
| Inoue, T | 1 |
| Korotaeva, ES | 1 |
| Koroleva, LY | 1 |
| Kovaleva, GV | 1 |
| Kuzmenko, EA | 1 |
| Nosov, VP | 1 |
| Staroverov, II | 2 |
| Merkulova, IA | 1 |
| Avetisyan, EA | 1 |
| Nichol, MB | 1 |
| Yan, BP | 2 |
| Tomlinson, B | 1 |
| Lee, VW | 1 |
| Dinicolantonio, JJ | 6 |
| Kerneis, M | 7 |
| Silvain, J | 13 |
| Abtan, J | 5 |
| Cayla, G | 10 |
| O'Connor, SA | 8 |
| Barthélémy, O | 10 |
| Vignalou, JB | 3 |
| Beygui, F | 9 |
| Brugier, D | 5 |
| Martin, R | 2 |
| Collet, JP | 22 |
| Leonardi, S | 5 |
| Lokhnygina, Y | 5 |
| Todd, M | 2 |
| Stone, GW | 16 |
| Lincoff, AM | 9 |
| Dauerman, HL | 1 |
| Parikh, KH | 2 |
| Gruberg, L | 1 |
| Herrmann, HC | 1 |
| McLaurin, BT | 1 |
| Finkel, JB | 1 |
| Marhefka, GD | 1 |
| Weitz, HH | 1 |
| Theidel, U | 1 |
| Asseburg, C | 1 |
| Katus, H | 15 |
| Hauge, J | 1 |
| Kragh, R | 1 |
| Poulsen, BK | 1 |
| Mavronasiou, E | 3 |
| Stavrou, K | 1 |
| Siapika, A | 1 |
| Tsoni, E | 1 |
| Tang, XF | 2 |
| Zhang, JH | 1 |
| Wang, J | 1 |
| Xu, B | 2 |
| Qiao, SB | 1 |
| Wu, YJ | 1 |
| Chen, J | 2 |
| Chen, JL | 1 |
| Gao, RL | 1 |
| Yang, YJ | 3 |
| Yuan, JQ | 2 |
| Echavarría-Pinto, M | 1 |
| Lopes, R | 1 |
| Gorgadze, T | 1 |
| Gonzalo, N | 1 |
| Hernández, R | 1 |
| Jiménez-Quevedo, P | 2 |
| Alfonso, F | 1 |
| Bañuelos, C | 1 |
| Nuñez-Gil, IJ | 2 |
| Ibañez, B | 1 |
| Fernández, C | 1 |
| Fernandez-Ortiz, A | 2 |
| García, E | 1 |
| Macaya, C | 3 |
| Escaned, J | 2 |
| Patti, G | 8 |
| Mangiacapra, F | 4 |
| Ricottini, E | 3 |
| Cannatà, A | 1 |
| Cavallari, I | 1 |
| Vizzi, V | 3 |
| D'Ambrosio, A | 3 |
| Dicuonzo, G | 1 |
| Di Sciascio, G | 7 |
| Chin, CT | 3 |
| Chua, TS | 1 |
| Matchar, DB | 1 |
| Turkmen, S | 1 |
| Fettser, DV | 3 |
| Kagliian, KÉ | 1 |
| Serchelik, A | 1 |
| Arystanova, AZh | 1 |
| Tekin, K | 1 |
| Balli, M | 1 |
| Batyraliev, TA | 3 |
| Samko, AN | 2 |
| Sidorenko, BA | 3 |
| Homan, DJ | 1 |
| Price, MJ | 11 |
| Pieper, KS | 4 |
| Wang, WE | 1 |
| Wang, X | 6 |
| Zeng, C | 1 |
| Swiger, KJ | 1 |
| Yousuf, O | 1 |
| Bliden, KP | 2 |
| Tantry, US | 16 |
| Gurbel, PA | 23 |
| Torngren, K | 1 |
| Ohman, J | 2 |
| Salmi, H | 1 |
| Larsson, J | 1 |
| Erlinge, D | 9 |
| Blancas Gómez-Casero, R | 1 |
| Quintana Díaz, M | 1 |
| Chana García, M | 1 |
| Martín Parra, C | 1 |
| López Matamala, B | 1 |
| Estébanez Montiel, B | 1 |
| Ballesteros Ortega, D | 1 |
| Martínez González, O | 1 |
| Vigil Escribano, D | 1 |
| Prieto Valderrey, F | 1 |
| Marina Martínez, L | 1 |
| Castro Gallego, O | 1 |
| Pasceri, V | 3 |
| Colonna, G | 1 |
| Montinaro, A | 1 |
| Wijns, W | 3 |
| Barbato, E | 3 |
| Coleman, CI | 1 |
| Limone, BL | 1 |
| Enar, R | 1 |
| Khaspekova, SG | 3 |
| Yakushkin, VV | 1 |
| Khachikyan, MV | 1 |
| Zyuryaev, IT | 1 |
| Ruda, MY | 2 |
| Göddertz, R | 1 |
| Jiang, Z | 1 |
| Duan, Z | 1 |
| Hu, K | 1 |
| Zhang, Z | 2 |
| Fischer, MJ | 1 |
| Ho, PM | 4 |
| McDermott, K | 1 |
| Lowy, E | 1 |
| Parikh, CR | 1 |
| Chen, Y | 5 |
| Qu, F | 1 |
| Ma, C | 1 |
| Li, X | 4 |
| Lip, GY | 2 |
| Campo, G | 3 |
| Valgimigli, M | 9 |
| Taglieri, N | 2 |
| Tondi, S | 2 |
| Manari, A | 1 |
| Guiducci, V | 1 |
| Sangiorgio, P | 1 |
| Varani, E | 1 |
| Magnavacchi, P | 1 |
| Marzocchi, A | 2 |
| Wheatcroft, S | 1 |
| Zoheir, N | 1 |
| Abd Elhamid, S | 1 |
| Abulata, N | 1 |
| El Sobky, M | 1 |
| Khafagy, D | 1 |
| Mostafa, A | 1 |
| Berger, JS | 4 |
| Rodriguez, L | 3 |
| Conde, D | 3 |
| Lalor, N | 3 |
| Elissamburu, P | 3 |
| Trivi, M | 3 |
| Christ, G | 3 |
| Hafner, T | 1 |
| Siller-Matula, JM | 6 |
| Francesconi, M | 2 |
| Grohs, K | 2 |
| Wilhelm, E | 1 |
| Podczeck-Schweighofer, A | 2 |
| Westerhout, CM | 5 |
| Fu, Y | 3 |
| James, S | 18 |
| Levin, LÅ | 2 |
| Bernfort, L | 1 |
| Andersson, D | 1 |
| Bergström, G | 1 |
| Lamm, CJ | 1 |
| Janzon, M | 6 |
| Kaul, P | 3 |
| Cano, P | 1 |
| Consuegra-Sánchez, L | 1 |
| Conesa, P | 1 |
| Torres-Moreno, D | 1 |
| Jaulent, L | 1 |
| Dau, D | 1 |
| Picó, F | 1 |
| Villegas, M | 1 |
| Stevens, SR | 4 |
| Hochman, JS | 6 |
| Martinez, F | 5 |
| Boden, WE | 6 |
| Aylward, PE | 5 |
| Bassand, JP | 6 |
| Can, MM | 2 |
| Pershukov, IV | 1 |
| Aronow, WS | 2 |
| Kunadian, V | 2 |
| Wojdyla, DM | 5 |
| Zorkun, C | 2 |
| Emanuelsson, H | 17 |
| Horrow, J | 16 |
| Maya, J | 4 |
| Huo, Y | 2 |
| Keßler, M | 1 |
| Rottbauer, W | 1 |
| Koenig, W | 1 |
| Liang, ZY | 1 |
| Zhang, XL | 1 |
| Yan, CH | 2 |
| Kang, J | 2 |
| López, J | 2 |
| Morales, C | 1 |
| Avanzas, P | 1 |
| Callejo, F | 1 |
| Hernández-Vaquero, D | 1 |
| Llosa, JC | 1 |
| Nagashima, Z | 2 |
| Morita, S | 5 |
| Endo, T | 2 |
| Sugano, T | 3 |
| Hibi, K | 6 |
| Himeno, H | 2 |
| Fukui, K | 2 |
| Umemura, S | 6 |
| Kimura, K | 6 |
| Liew, D | 1 |
| De Abreu Lourenço, R | 1 |
| Adena, M | 1 |
| Chim, L | 1 |
| Aylward, P | 2 |
| Meier, B | 4 |
| Lewis, BS | 5 |
| Badar, A | 1 |
| Scaife, J | 1 |
| Yan, AT | 5 |
| Robinson, SD | 1 |
| Zaman, AG | 3 |
| Purcell, IF | 1 |
| Ahmed, JM | 1 |
| Egred, M | 1 |
| Edwards, RJ | 1 |
| Spyridopoulos, I | 1 |
| Keavney, BD | 1 |
| Bagnall, AJ | 1 |
| Pons, C | 2 |
| Pankert, M | 7 |
| Grosdidier, C | 6 |
| Beguin, S | 4 |
| Morange, P | 2 |
| Lu, D | 1 |
| Owens, J | 1 |
| Kreutz, RP | 1 |
| Norgard, NB | 2 |
| Hafley, G | 3 |
| Hamm, C | 2 |
| Clemmensen, P | 9 |
| Oto, A | 3 |
| Leiva-Pons, J | 1 |
| Pavlides, G | 2 |
| Tousek, P | 1 |
| Kocka, V | 1 |
| Sulzenko, J | 1 |
| Bednar, F | 2 |
| Linkova, H | 1 |
| Loundou, AD | 2 |
| Loosveld, M | 4 |
| Camoin, L | 6 |
| Sinhal, AR | 1 |
| Goudevenos, JA | 3 |
| Parissis, H | 2 |
| Ntalas, IV | 4 |
| Angelidis, C | 2 |
| Vavuranakis, M | 2 |
| Hahalis, G | 4 |
| Stefanadis, C | 4 |
| Bell, AD | 1 |
| Ackman, ML | 1 |
| Bauer, RD | 1 |
| Cartier, R | 1 |
| Chan, WS | 1 |
| Douketis, J | 1 |
| Roussin, A | 1 |
| Schnell, G | 1 |
| Verma, S | 6 |
| Wong, G | 1 |
| Lin, TH | 1 |
| Lai, WT | 3 |
| Hsin, HT | 1 |
| Li, AH | 2 |
| Wang, CL | 1 |
| Kuo, CT | 2 |
| Hwang, JJ | 3 |
| Chiang, FT | 2 |
| Chang, SC | 1 |
| D'Ugo, E | 1 |
| Rossi, S | 1 |
| De Caterina, R | 2 |
| Gaddam, S | 1 |
| Wu, WC | 1 |
| Behera, V | 1 |
| Sharma, S | 2 |
| Choudhary, G | 1 |
| Mogabgab, O | 1 |
| Sloan, S | 1 |
| Sabatine, MS | 10 |
| Antman, EM | 18 |
| Braunwald, E | 19 |
| Giugliano, RP | 5 |
| Diodati, JG | 2 |
| Saucedo, JF | 6 |
| French, JK | 2 |
| Fung, AY | 1 |
| Cardillo, TE | 2 |
| Henneges, C | 2 |
| Fisher, HN | 2 |
| Gulba, D | 1 |
| Bonello, L | 13 |
| Landel, JB | 1 |
| Bauters, A | 1 |
| Delhaye, C | 1 |
| Sudre, A | 1 |
| Susen, S | 1 |
| Bauters, C | 1 |
| Lablanche, JM | 1 |
| Lemesle, G | 4 |
| Shyu, KG | 1 |
| Wu, CJ | 2 |
| Mar, GY | 1 |
| Hou, CJ | 2 |
| Wen, MS | 1 |
| Lin, SJ | 1 |
| Kuo, C | 1 |
| Li, YH | 2 |
| Gasche, D | 1 |
| Ulle, T | 1 |
| Greiner, RA | 1 |
| Niazi, AK | 1 |
| Lavie, CJ | 1 |
| O'Keefe, JH | 1 |
| Meier, P | 4 |
| Joshi, RR | 1 |
| Hossain, R | 1 |
| Morton, AC | 2 |
| Ecob, R | 3 |
| Judge, HM | 2 |
| Wales, C | 1 |
| Walker, JV | 1 |
| Karunakaran, A | 1 |
| Acharji, S | 1 |
| Lakshmanadoss, U | 1 |
| Rudzinski, W | 1 |
| Stapleton, DD | 1 |
| Kaluski, E | 2 |
| Varenhorst, C | 9 |
| Jensevik, K | 2 |
| Jernberg, T | 3 |
| Sundström, A | 1 |
| Hasvold, P | 1 |
| Lagerqvist, B | 6 |
| Jayasinghe, R | 1 |
| Markham, R | 1 |
| Adsett, G | 1 |
| Bosch, X | 3 |
| Marrugat, J | 5 |
| Sanchis, J | 3 |
| Rubboli, A | 3 |
| Oldgren, J | 2 |
| Lip, G | 1 |
| Kohli, P | 2 |
| Udell, JA | 3 |
| Murphy, SA | 14 |
| Bonaca, MP | 3 |
| Damman, P | 2 |
| Koul, S | 5 |
| Eriksson, P | 1 |
| Wernroth, L | 1 |
| Campbell, CL | 1 |
| Moliterno, DJ | 4 |
| Feres, F | 3 |
| Costa, RA | 2 |
| Abizaid, A | 2 |
| Leon, MB | 1 |
| Marin-Neto, JA | 1 |
| Botelho, RV | 1 |
| King, SB | 2 |
| Negoita, M | 1 |
| de Paula, JE | 1 |
| Mangione, JA | 1 |
| Meireles, GX | 1 |
| Castello, HJ | 1 |
| Nicolela, EL | 1 |
| Perin, MA | 1 |
| Devito, FS | 1 |
| Labrunie, A | 1 |
| Salvadori, D | 1 |
| Gusmão, M | 1 |
| Staico, R | 1 |
| Costa, JR | 1 |
| de Castro, JP | 1 |
| Abizaid, AS | 1 |
| Desai, NR | 1 |
| Canestaro, WJ | 1 |
| Kyrychenko, P | 1 |
| Chaplin, D | 1 |
| Martell, LA | 1 |
| Brennan, T | 1 |
| Matlin, OS | 1 |
| Choudhry, NK | 2 |
| Zhang, YY | 1 |
| Zhou, X | 1 |
| Ji, WJ | 1 |
| Shi, R | 1 |
| Lu, RY | 1 |
| Li, JL | 1 |
| Yang, GH | 1 |
| Luo, T | 1 |
| Zhang, JQ | 1 |
| Zhao, JH | 1 |
| Jiang, TM | 1 |
| Li, YM | 1 |
| Sevimli, S | 1 |
| Karakoyun, S | 1 |
| Bakirci, EM | 1 |
| Topcu, S | 1 |
| Kalkan, K | 1 |
| Borekci, A | 1 |
| Vançelik, S | 1 |
| Berkenboom, G | 1 |
| Coufal, Z | 1 |
| Belger, M | 2 |
| Sartral, M | 2 |
| Norrbacka, K | 1 |
| Bakhai, A | 3 |
| Verheugt, FW | 5 |
| Ojeifo, O | 1 |
| Mega, JL | 7 |
| O'Donoghue, ML | 4 |
| Cully, M | 1 |
| Cialdella, P | 1 |
| Gustapane, M | 1 |
| Camaioni, C | 1 |
| Biasucci, LM | 1 |
| Mahla, E | 1 |
| Sorich, MJ | 1 |
| Horowitz, JD | 1 |
| Sorich, W | 1 |
| Wiese, MD | 1 |
| Pekarsky, B | 1 |
| Karnon, JD | 1 |
| Lin, CF | 2 |
| Shen, LJ | 3 |
| Hsiao, FY | 5 |
| Gau, CS | 3 |
| Wu, FL | 2 |
| Laine, M | 5 |
| Kipson, N | 2 |
| Mancini, J | 4 |
| Helal, O | 1 |
| Fromonot, J | 2 |
| Gariboldi, V | 1 |
| Condo, J | 1 |
| Thuny, F | 3 |
| Frere, C | 15 |
| Camoin-Jau, L | 8 |
| Paganelli, F | 10 |
| Dignat-George, F | 6 |
| Guieu, R | 3 |
| Morino, Y | 2 |
| Kobayashi, M | 1 |
| De Franco, AC | 1 |
| Oldridge, N | 1 |
| Stakos, D | 2 |
| Schaffer, A | 8 |
| Barbieri, L | 9 |
| Cassetti, E | 1 |
| Piccolo, R | 2 |
| Galasso, G | 1 |
| Sinigaglia, F | 1 |
| del Castillo-Carnevali, H | 1 |
| Barrios Alonso, V | 1 |
| Zamorano Gómez, JL | 1 |
| Notarangelo, MF | 3 |
| Bontardelli, F | 1 |
| Merlini, PA | 3 |
| Golino, P | 1 |
| Arntz, HR | 2 |
| Boudriot, E | 2 |
| Garlichs, C | 2 |
| Hoffmann, S | 2 |
| Ince, H | 4 |
| Klingenheben, T | 2 |
| Weil, J | 2 |
| Zugck, C | 2 |
| Helms, TM | 2 |
| Silber, S | 2 |
| Shah, R | 1 |
| Keough, LA | 1 |
| Belalcazar-Portacio, A | 1 |
| Ramanathan, KB | 1 |
| Thomas, MR | 2 |
| Wijeyeratne, YD | 2 |
| May, JA | 1 |
| Johnson, A | 1 |
| Heptinstall, S | 3 |
| Fox, SC | 1 |
| Good, RI | 1 |
| McGarrity, A | 1 |
| Sheehan, R | 1 |
| James, TE | 1 |
| Miller, H | 1 |
| Stephens, J | 1 |
| Watkins, S | 1 |
| McConnachie, A | 1 |
| Goodall, AH | 1 |
| Oldroyd, KG | 1 |
| Li, SN | 1 |
| Luo, Y | 2 |
| Chen, PA | 1 |
| Lei, XM | 1 |
| Li, GL | 1 |
| Dalén, M | 1 |
| van der Linden, J | 2 |
| Holm, M | 1 |
| Lindvall, G | 2 |
| Ivert, T | 1 |
| Caiazzo, G | 3 |
| De Rosa, S | 3 |
| Torella, D | 3 |
| Spaccarotella, C | 3 |
| Mongiardo, A | 3 |
| Giampà, S | 2 |
| Micieli, M | 2 |
| Palella, E | 2 |
| Gulletta, E | 2 |
| Indolfi, C | 3 |
| Uzel, H | 1 |
| Ozpelit, E | 2 |
| Badak, O | 1 |
| Akdeniz, B | 2 |
| Barış, N | 1 |
| Aytemiz, F | 1 |
| Göldeli, O | 1 |
| Gasparovic, H | 1 |
| Petricevic, M | 6 |
| Dasbiswas, A | 1 |
| Rao, MS | 1 |
| Babu, PR | 1 |
| Vijayvergiya, R | 1 |
| Nayak, R | 1 |
| Dani, S | 1 |
| Tyagi, S | 1 |
| Hiremath, S | 1 |
| Patel, T | 1 |
| Alexander, T | 1 |
| Prakash, VS | 1 |
| Singh, DP | 1 |
| Yadav, MK | 1 |
| Pathak, K | 1 |
| Srivastava, A | 1 |
| Hirschl, MM | 1 |
| Hansson, EC | 1 |
| Rexius, H | 1 |
| Dellborg, M | 2 |
| Albertsson, P | 1 |
| Jeppsson, A | 1 |
| Tornyos, A | 1 |
| Pintér, T | 1 |
| Vorobcsuk, A | 2 |
| Kónyi, A | 1 |
| Faluközy, J | 1 |
| Veress, G | 1 |
| Magyari, B | 1 |
| Horváth, IG | 1 |
| Singh, D | 1 |
| Vacek, JL | 3 |
| Di Tommaso, L | 3 |
| De Amicis, V | 3 |
| Vosa, C | 3 |
| Ice, DS | 1 |
| Shapiro, TA | 1 |
| Gnall, EM | 1 |
| Kowey, PR | 1 |
| Chen, SC | 1 |
| Lee, CM | 2 |
| Hsu, WW | 1 |
| Fan, JY | 2 |
| Meng, J | 1 |
| Juurlink, D | 1 |
| Schwier, N | 1 |
| Harris, J | 1 |
| Seybert, AL | 1 |
| Amariles, P | 1 |
| Holguín, H | 1 |
| Angulo, NY | 1 |
| Betancourth, PM | 1 |
| Ceballos, M | 1 |
| Viswanathan, GN | 2 |
| Marshall, SM | 2 |
| Balasubramaniam, K | 2 |
| Badimon, JJ | 2 |
| Choi, JL | 2 |
| Kim, BR | 2 |
| Kim, JE | 1 |
| Rosenberg, N | 1 |
| Shechter, M | 1 |
| Gannot, S | 1 |
| Varon, D | 3 |
| Savion, N | 2 |
| Hod, H | 3 |
| Sabouret, P | 1 |
| Taiel-Sartral, M | 1 |
| Fiedler, KA | 1 |
| Kufner, S | 3 |
| Schlichting, A | 1 |
| Ibrahim, T | 2 |
| Ott, I | 1 |
| Schunkert, H | 3 |
| Laugwitz, KL | 2 |
| Schulz, S | 4 |
| Henriksson, M | 3 |
| Nikolic, E | 3 |
| Ohna, A | 1 |
| Nanau, RM | 1 |
| Delzor, F | 1 |
| Neuman, MG | 1 |
| Koziński, M | 4 |
| Obońska, K | 2 |
| Stankowska, K | 1 |
| Navarese, EP | 4 |
| Fabiszak, T | 1 |
| Stolarek, W | 1 |
| Kasprzak, M | 2 |
| Rość, D | 2 |
| Kubica, J | 6 |
| Bach, RG | 2 |
| Heras, M | 3 |
| Lassila, R | 3 |
| Wojdyla, D | 4 |
| Greene, SJ | 1 |
| Alkhawam, L | 1 |
| Vaduganathan, M | 2 |
| Jakubowski, JA | 9 |
| Lipkin, FR | 1 |
| Walker, JR | 4 |
| Duvvuru, S | 4 |
| Sundseth, SS | 3 |
| Kazi, DS | 2 |
| Garber, AM | 1 |
| Shah, RU | 1 |
| Dudley, RA | 1 |
| Mell, MW | 1 |
| Rhee, C | 1 |
| Moshkevich, S | 1 |
| Boothroyd, DB | 1 |
| Owens, DK | 1 |
| Hlatky, MA | 2 |
| Ondrakova, M | 2 |
| Doktorova, M | 1 |
| Saito, S | 3 |
| Isshiki, T | 3 |
| Kimura, T | 4 |
| Ogawa, H | 4 |
| Nanto, S | 3 |
| Takayama, M | 3 |
| Kitagawa, K | 3 |
| Nishikawa, M | 3 |
| Miyazaki, S | 2 |
| Vila, J | 2 |
| Elosua, R | 2 |
| Catalá-López, F | 1 |
| Steblovnik, K | 1 |
| Blinc, A | 1 |
| Bozic-Mijovski, M | 1 |
| Kranjec, I | 1 |
| Melkic, E | 1 |
| Noc, M | 1 |
| Schnorbus, B | 1 |
| Daiber, A | 1 |
| Jurk, K | 1 |
| Warnke, S | 1 |
| König, J | 1 |
| Krahn, U | 1 |
| Lackner, K | 1 |
| Munzel, T | 1 |
| Gori, T | 2 |
| Fortmann, SD | 2 |
| Beyan, C | 1 |
| Beyan, E | 1 |
| Lhermusier, T | 5 |
| Voisin, S | 2 |
| Murat, G | 1 |
| Mejean, S | 2 |
| Garcia, C | 2 |
| Bataille, V | 1 |
| Lipinski, MJ | 3 |
| Carrié, D | 3 |
| Sié, P | 2 |
| Roguin, A | 1 |
| Musallam, A | 1 |
| Patel, MR | 1 |
| Hiatt, WR | 1 |
| Christodoulidis, G | 1 |
| Pawęska, J | 1 |
| Macioch, T | 1 |
| Perkowski, P | 1 |
| Niewada, M | 1 |
| Samardzic, J | 2 |
| Krpan, M | 2 |
| Skoric, B | 2 |
| Pasalic, M | 2 |
| Milicic, D | 2 |
| Rafeedheen, R | 1 |
| Vrijens, B | 1 |
| Legrand, V | 1 |
| Vandendriessche, E | 1 |
| Van de Werf, F | 7 |
| Maggioni, AP | 1 |
| Park, SD | 1 |
| Baek, YS | 1 |
| Woo, SI | 1 |
| Shin, SH | 1 |
| Kim, DH | 2 |
| Kwan, J | 1 |
| Park, KS | 1 |
| Manchette, AM | 1 |
| Drucker, AG | 1 |
| Januzzi, JL | 1 |
| Schühlen, H | 1 |
| Chan, NC | 1 |
| Eikelboom, JW | 8 |
| Ginsberg, JS | 1 |
| Lauw, MN | 1 |
| Vanassche, T | 1 |
| Weitz, JI | 1 |
| Hirsh, J | 2 |
| Sritara, P | 1 |
| Zamoryakhin, D | 4 |
| Cao, C | 1 |
| Indraratna, P | 1 |
| Ang, SC | 1 |
| Manganas, C | 1 |
| Park, J | 1 |
| Bannon, PG | 1 |
| Yan, TD | 1 |
| Alström, U | 2 |
| Braun, OÖ | 3 |
| Bertilsson, M | 2 |
| Scirica, BM | 9 |
| Delle Karth, G | 1 |
| Fedor, M | 2 |
| Samoš, M | 2 |
| Šimonová, R | 1 |
| Fedorová, J | 1 |
| Škorňová, I | 1 |
| Duraj, L | 2 |
| Staško, J | 2 |
| Kovář, F | 2 |
| Mokáň, M | 2 |
| Kubisz, P | 2 |
| Mahaffey, KM | 1 |
| Wilcox, R | 1 |
| Iqbal, K | 1 |
| Costigan, T | 1 |
| Lopez-Sendon, J | 4 |
| Ramos, Y | 2 |
| Sardella, G | 2 |
| Calcagno, S | 1 |
| Bae, JP | 8 |
| Faries, DE | 3 |
| Ernst, FR | 3 |
| Lipkin, C | 2 |
| Zhao, Z | 3 |
| Moretz, C | 2 |
| Lieu, HD | 2 |
| Drenning, D | 1 |
| Marso, S | 1 |
| Torguson, R | 5 |
| Bernardo, E | 1 |
| Feltes, G | 1 |
| Mejía-Rentería, HD | 1 |
| De Agustín, JA | 1 |
| Vivas, D | 1 |
| Nombela-Franco, L | 1 |
| Gaglia, MA | 5 |
| Liu, L | 1 |
| Zhang, S | 1 |
| Ye, J | 1 |
| Wen, Z | 1 |
| Ding, J | 1 |
| Kunapuli, SP | 1 |
| Luo, X | 1 |
| Ding, Z | 1 |
| Molina-Cuadrado, E | 1 |
| Mateo-Carrasco, H | 1 |
| Nieto-Guindo, P | 1 |
| Rodríguez-Gómez, P | 1 |
| Arima, Y | 1 |
| Hokimoto, S | 1 |
| Akasaka, T | 1 |
| Mizobe, K | 1 |
| Kaikita, K | 1 |
| Oniki, K | 1 |
| Nakagawa, K | 1 |
| Paarup Dridi, N | 1 |
| Johansson, PI | 1 |
| Lønborg, JT | 1 |
| Radu, MD | 1 |
| Qayyum, A | 1 |
| Pedersen, F | 1 |
| Kollslid, R | 1 |
| Helqvist, S | 1 |
| Saunamäki, K | 1 |
| Kelbæk, H | 1 |
| Jørgensen, E | 1 |
| Engstrøm, T | 1 |
| Holmvang, L | 1 |
| Koziolova, NA | 1 |
| Danchin, N | 4 |
| Goedicke, J | 2 |
| Schmitt, J | 1 |
| Goldstein, P | 1 |
| Schreiber, P | 1 |
| Fauchère, I | 1 |
| Wyss, C | 2 |
| Seo, KW | 1 |
| Tahk, SJ | 1 |
| Yang, HM | 1 |
| Yoon, MH | 1 |
| Shin, JH | 1 |
| Choi, SY | 1 |
| Lim, HS | 1 |
| Hwang, GS | 1 |
| Choi, BJ | 1 |
| Shin, JS | 1 |
| Lee, YH | 1 |
| Choi, YW | 1 |
| Jin, XJ | 1 |
| Mariani, A | 1 |
| Reggiani, LB | 1 |
| Bianchi, R | 1 |
| Mariani, M | 3 |
| Podda, G | 1 |
| Olson, WH | 2 |
| Ma, YW | 2 |
| Laliberté, F | 2 |
| Lefebvre, P | 2 |
| Crivera, C | 2 |
| Schein, JR | 1 |
| Fields, LE | 1 |
| Dea, K | 2 |
| Germain, G | 2 |
| Lynch, SM | 2 |
| Vengoechea, F | 1 |
| Burcar, I | 2 |
| Biocina, B | 3 |
| Bulum, J | 1 |
| Almendro-Delia, M | 2 |
| Blanco Ponce, E | 1 |
| Gomez-Domínguez, R | 1 |
| Gonzalez-Matos, C | 1 |
| Lobo-Gonzalez, M | 1 |
| Caballero-Garcia, A | 1 |
| Hidalgo-Urbano, R | 2 |
| Cruz-Fernandez, MJ | 1 |
| Garcia-Rubira, JC | 1 |
| Dechant, C | 1 |
| Nachmias, B | 1 |
| Leibowitz, D | 1 |
| Thompson, PL | 1 |
| Thompson, AG | 1 |
| Judkins, C | 1 |
| Bagai, A | 3 |
| Chua, D | 2 |
| Cohen, EA | 2 |
| Saw, J | 1 |
| Vijayaraghavan, R | 2 |
| Welsh, R | 2 |
| Fitchett, D | 2 |
| Maioli, M | 1 |
| Tropeano, F | 1 |
| Badia, T | 1 |
| Villani, S | 1 |
| Anderson, RA | 2 |
| Bundhoo, S | 1 |
| James, PE | 2 |
| Wan, S | 1 |
| Huang, Z | 2 |
| Chen, E | 1 |
| Jennings, LK | 2 |
| Guo, W | 1 |
| Xu, Q | 2 |
| Geersing, GJ | 1 |
| Kappelle, LJ | 1 |
| Bico, B | 1 |
| Chaudhry, U | 1 |
| Wagner, H | 2 |
| Tydén, P | 1 |
| Scherstén, F | 3 |
| Jovinge, S | 1 |
| Svensson, PJ | 2 |
| Gustav Smith, J | 1 |
| van der Pals, J | 2 |
| Bakheet, MF | 1 |
| Pearce, LA | 1 |
| Hart, RG | 1 |
| Sáez, ME | 1 |
| González-Pérez, A | 1 |
| Johansson, S | 2 |
| Nagy, P | 1 |
| Rodríguez, LA | 1 |
| Giusti, B | 11 |
| Carrabba, N | 1 |
| Paniccia, R | 6 |
| Cantini, G | 1 |
| Marrani, M | 1 |
| Gensini, GF | 9 |
| Abbate, R | 13 |
| Ziuriaev, IT | 2 |
| Iakushkin, VV | 2 |
| Sirotkina, OV | 2 |
| Ruda, MIa | 3 |
| Wang, XQ | 1 |
| Shen, CL | 1 |
| Wang, BN | 1 |
| Huang, XH | 1 |
| Hu, ZL | 1 |
| Jiang, XL | 1 |
| Samant, S | 1 |
| Lesko, LJ | 1 |
| Schmidt, S | 1 |
| Xie, C | 1 |
| Ding, XL | 1 |
| Xue, L | 1 |
| Jiang, B | 1 |
| Hang, YF | 1 |
| Gao, J | 1 |
| Miao, LY | 1 |
| Cavallini, C | 2 |
| Levine, GN | 1 |
| Anderson, JL | 2 |
| Taubert, K | 1 |
| Smith, SC | 2 |
| Tang, N | 1 |
| Yin, S | 1 |
| Sun, Z | 1 |
| Xu, X | 2 |
| Qin, J | 2 |
| Kurz, DJ | 1 |
| Radovanovic, D | 2 |
| Seifert, B | 1 |
| Bernheim, AM | 1 |
| Roffi, M | 4 |
| Pedrazzini, G | 1 |
| Windecker, S | 3 |
| Erne, P | 2 |
| Eberli, FR | 2 |
| Zhao, D | 2 |
| Qi, Y | 1 |
| Sun, J | 1 |
| Wang, W | 1 |
| Garg, P | 1 |
| Galper, BZ | 1 |
| Cohen, DJ | 9 |
| Yeh, RW | 3 |
| Mauri, L | 3 |
| You, JH | 3 |
| Roffman, DS | 1 |
| Cowper, PA | 1 |
| Pan, W | 1 |
| Anstrom, KJ | 3 |
| Davidson-Ray, L | 2 |
| Mark, DB | 2 |
| Ikeda, Y | 3 |
| Bultas, J | 1 |
| Costa, F | 1 |
| Vranckx, P | 1 |
| Moscarella, E | 1 |
| Ando, G | 1 |
| Oreto, G | 1 |
| Zijlstra, F | 1 |
| Gonzalez-Torres, L | 1 |
| Garcia-Alcantara, Á | 1 |
| Reina-Toral, A | 1 |
| Arboleda Sánchez, JA | 1 |
| Rodríguez Yañez, JC | 1 |
| García Rubira, JC | 1 |
| Bozina, N | 1 |
| Ganoci, L | 1 |
| Cointe, S | 1 |
| Kerbaul, F | 2 |
| Arnaud, L | 1 |
| Sabatier, F | 1 |
| Caruso, R | 1 |
| Rocchiccioli, S | 1 |
| Cecchettini, A | 1 |
| Cozzi, L | 1 |
| Parolini, M | 1 |
| Romagnuolo, I | 1 |
| Citti, L | 1 |
| Parodi, O | 1 |
| Jia, M | 1 |
| Li, Z | 4 |
| Chu, H | 1 |
| Chen, K | 1 |
| Alexander, KP | 1 |
| Sharma, A | 1 |
| Ferguson, C | 1 |
| Bainey, KR | 2 |
| Knot, J | 1 |
| Ulman, J | 1 |
| Maly, M | 1 |
| Bomb, R | 1 |
| Oliphant, CS | 1 |
| Khouzam, RN | 1 |
| Cecchi, E | 2 |
| Chiostri, M | 1 |
| Mecarocci, V | 1 |
| Spini, V | 1 |
| Innocenti, L | 1 |
| Calabretta, R | 1 |
| Cordisco, A | 1 |
| Romano, SM | 1 |
| Giglioli, C | 4 |
| Hassell, ME | 1 |
| Hildick-Smith, D | 1 |
| Durand, E | 2 |
| Kikkert, WJ | 2 |
| Wiegerinck, EM | 1 |
| Stabile, E | 1 |
| Ussia, GP | 1 |
| Baan, J | 1 |
| Eltchaninoff, H | 2 |
| Rubino, P | 1 |
| Barbanti, M | 1 |
| Tamburino, C | 2 |
| Poliacikova, P | 1 |
| Blanchard, D | 1 |
| Piek, JJ | 1 |
| Delewi, R | 1 |
| Maybrook, RJ | 1 |
| Fischer, R | 1 |
| Deibert, B | 1 |
| Gillihan, R | 1 |
| Laarman, R | 1 |
| Fraga, G | 1 |
| Aires, D | 1 |
| Gollub, S | 1 |
| Cui, C | 3 |
| Qiao, R | 4 |
| Zhang, J | 5 |
| Yudi, MB | 2 |
| Eccleston, D | 3 |
| Andrianopoulos, N | 3 |
| Farouque, O | 2 |
| Duffy, SJ | 3 |
| Brennan, A | 2 |
| Reid, C | 1 |
| Clark, DJ | 3 |
| Ajani, AE | 4 |
| Kang, HJ | 1 |
| Clare, RM | 1 |
| Gao, R | 1 |
| Santoso, A | 3 |
| Yu, CM | 1 |
| Lindahl, TL | 1 |
| Gustafsson, KM | 1 |
| Jonasson, L | 1 |
| Logander, E | 1 |
| Nilsson, L | 1 |
| Swahn, E | 1 |
| Sartori, C | 1 |
| Van Gaal, WJ | 1 |
| Schrale, R | 1 |
| Gunasekara, A | 1 |
| Amerena, J | 1 |
| Mussap, CJ | 1 |
| Johnson, SG | 1 |
| Gruntowicz, D | 1 |
| Chua, T | 1 |
| Morlock, RJ | 1 |
| Haq, MM | 1 |
| Ahsan, CH | 1 |
| Amin, MN | 1 |
| Karim, MR | 1 |
| Ali, ML | 1 |
| Khan, SR | 1 |
| Chowdhury, MZ | 1 |
| Mansur, M | 1 |
| Millat, MH | 1 |
| Rashid, MA | 1 |
| Bavishi, C | 1 |
| Panwar, S | 1 |
| Messerli, FH | 1 |
| Liping, Z | 1 |
| Bin, H | 1 |
| Qiming, F | 1 |
| Wei, YQ | 1 |
| Wang, DG | 1 |
| Yang, H | 1 |
| Cao, H | 1 |
| Song, PS | 1 |
| Ryu, DR | 1 |
| Hur, SH | 2 |
| Park, HS | 1 |
| An, L | 1 |
| Du, D | 1 |
| Lai, X | 1 |
| Wang, F | 1 |
| Yahia, DH | 1 |
| Pereg, D | 1 |
| Lishner, M | 1 |
| Elis, A | 1 |
| Lin, G | 1 |
| Yi, L | 1 |
| Zhang, K | 1 |
| Zhang, R | 1 |
| Xie, J | 1 |
| Melloni, C | 1 |
| Ford, NF | 3 |
| Qutub, MA | 1 |
| Chong, AY | 2 |
| So, DY | 3 |
| Hizoh, I | 1 |
| Kovacs, A | 1 |
| Horvath, Z | 1 |
| Kiss, N | 1 |
| Toth-Zsamboki, E | 1 |
| Boban, M | 1 |
| Mihaljevic, MZ | 1 |
| Pereira, M | 1 |
| Lopes-Conceição, L | 1 |
| Bennett, K | 1 |
| Dias, P | 1 |
| Laszczynska, O | 1 |
| Lunet, N | 1 |
| Azevedo, A | 1 |
| Nie, XY | 1 |
| Lu, Y | 1 |
| Shi, LW | 1 |
| Wang, WM | 1 |
| Golukhova, EZ | 1 |
| Grigorian, MV | 1 |
| Ryabinina, MN | 1 |
| Bulaeva, NI | 1 |
| Fortmann, S | 1 |
| Grove, EL | 2 |
| Würtz, M | 1 |
| Kristensen, SD | 1 |
| Hsieh, CF | 1 |
| Huang, WF | 3 |
| Chiang, YT | 1 |
| Chen, CY | 1 |
| Booth, J | 1 |
| Tavlaki, E | 1 |
| Karathanos, A | 1 |
| Müller, K | 2 |
| Droppa, M | 1 |
| Gawaz, M | 5 |
| Yanez-Lopez, M | 1 |
| Davidson, SJ | 1 |
| Stables, RH | 1 |
| Banya, W | 1 |
| Zaman, A | 1 |
| Dalby, M | 1 |
| Di Pasquale, G | 3 |
| Dong, W | 2 |
| Wan, Z | 1 |
| Cong, H | 1 |
| Hong, T | 1 |
| Filipini, E | 1 |
| Nau, G | 1 |
| Cura, F | 1 |
| Stančiaková, L | 1 |
| Galajda, P | 1 |
| Helft, G | 1 |
| Le Feuvre, C | 1 |
| Georges, JL | 1 |
| Dreyfus, X | 1 |
| Furber, A | 1 |
| Leclercq, F | 2 |
| Falquier, JF | 1 |
| Henry, P | 4 |
| Cattan, S | 1 |
| Sebagh, L | 1 |
| Michel, PL | 1 |
| Tuambilangana, A | 1 |
| Hammoudi, N | 1 |
| Boccara, F | 2 |
| Douard, H | 1 |
| Diallo, A | 1 |
| Berman, E | 1 |
| Komajda, M | 1 |
| Metzger, JP | 1 |
| Vicaut, E | 4 |
| Edem, E | 1 |
| Kirdök, AH | 1 |
| Kınay, AO | 1 |
| Tekin, Üİ | 1 |
| Taş, S | 1 |
| Alpaslan, E | 1 |
| Pabuccu, MT | 1 |
| Huang, CH | 1 |
| Li-Sha, G | 1 |
| Peng, C | 1 |
| Yue-Chun, L | 1 |
| Corbalán, R | 5 |
| Leiva-Pons, JL | 3 |
| Gan, XD | 1 |
| Wei, BZ | 1 |
| Fang, D | 1 |
| Fang, Q | 1 |
| Li, KY | 1 |
| Ding, SL | 1 |
| Peng, S | 1 |
| Wan, J | 1 |
| Schein, J | 1 |
| Brodie, BR | 3 |
| Garg, A | 1 |
| Stuckey, TD | 2 |
| Kirtane, AJ | 4 |
| Witzenbichler, B | 4 |
| Maehara, A | 2 |
| Weisz, G | 3 |
| Rinaldi, MJ | 2 |
| Metzger, DC | 2 |
| Parvataneni, R | 1 |
| Hulot, JS | 9 |
| Mansencal, N | 1 |
| Payot, L | 2 |
| Rousseau, H | 1 |
| Freeman, PM | 1 |
| Moschonas, KE | 1 |
| Hinz, C | 1 |
| O'Donnell, VB | 1 |
| Kinnaird, TD | 1 |
| Sabbag, A | 2 |
| Herscovici, R | 1 |
| Shlomo, N | 1 |
| Zahger, D | 2 |
| Atar, S | 2 |
| Hammerman, H | 1 |
| Polak, A | 2 |
| Okuizumi, K | 1 |
| Usami, M | 1 |
| Bundhun, PK | 1 |
| Qin, T | 1 |
| Chen, MH | 1 |
| Andell, P | 1 |
| Keltai, M | 6 |
| Marziliano, N | 2 |
| Cereda, M | 1 |
| Caporale, V | 1 |
| Coppini, L | 1 |
| Demola, MA | 3 |
| Guidorossi, A | 1 |
| Crocamo, A | 1 |
| Pigazzani, F | 1 |
| Boffetti, F | 1 |
| del Giudice, F | 1 |
| Orsini, F | 1 |
| Pirola, D | 1 |
| Cocci, A | 1 |
| Manzalini, C | 1 |
| Casu, G | 2 |
| Bianchessi, M | 1 |
| Sarma, A | 2 |
| Salaun, E | 1 |
| Tomek, A | 2 |
| Pokov, AN | 1 |
| Grifoni, E | 2 |
| Tanaka, Y | 1 |
| Ren, Q | 1 |
| Ren, C | 1 |
| Liu, X | 7 |
| Dong, C | 1 |
| Zhang, X | 2 |
| Qaderdan, K | 1 |
| Ishak, M | 1 |
| Heestermans, AA | 1 |
| de Vrey, E | 1 |
| Jukema, JW | 1 |
| Voskuil, M | 1 |
| de Boer, MJ | 2 |
| van't Hof, AW | 1 |
| Groenemeijer, BE | 1 |
| Vos, GJ | 1 |
| Janssen, PW | 1 |
| Bergmeijer, TO | 2 |
| Deneer, VH | 2 |
| Amour, J | 1 |
| Mercadier, A | 1 |
| Leprince, P | 1 |
| Amico, F | 1 |
| Amico, A | 1 |
| Mazzoni, J | 1 |
| Moshiyakhov, M | 1 |
| Tamparo, W | 1 |
| Close, SL | 4 |
| Man, M | 1 |
| Delaney, JT | 1 |
| Paré, G | 2 |
| Simon, T | 3 |
| Khalaf, H | 1 |
| Al Meman, AA | 1 |
| Rasool, S | 1 |
| Danese, E | 1 |
| Fava, C | 1 |
| Beltrame, F | 1 |
| Tavella, D | 1 |
| Calabria, S | 1 |
| Benati, M | 1 |
| Gelati, M | 1 |
| Gottardo, R | 1 |
| Tagliaro, F | 1 |
| Guidi, GC | 1 |
| Minuz, P | 1 |
| Sachdeva, A | 1 |
| Eckart, D | 1 |
| Morse, MA | 1 |
| Blackwell, KL | 1 |
| Ready, NE | 1 |
| Zafar, SY | 1 |
| Beaven, AW | 1 |
| Strickler, JH | 1 |
| Onken, JE | 1 |
| Houterloot, L | 1 |
| Schoos, MM | 1 |
| Dangas, GD | 2 |
| Yu, J | 1 |
| Litherland, C | 2 |
| Cox, DA | 4 |
| Duffy, PL | 1 |
| Mazzaferri, EL | 1 |
| Zhang, JR | 1 |
| Wang, DQ | 1 |
| Du, J | 1 |
| Qu, GS | 1 |
| Du, JL | 1 |
| Deng, SB | 1 |
| Liu, YJ | 1 |
| Cai, JX | 1 |
| She, Q | 1 |
| Lozano, I | 1 |
| Sanchez-Insa, E | 1 |
| de Leiras, SR | 1 |
| Carrillo, P | 1 |
| Ruiz-Quevedo, V | 1 |
| Pinar, E | 2 |
| Gopar-Gopar, S | 1 |
| Bayon, J | 1 |
| Mañas, P | 1 |
| Lasa, G | 1 |
| CruzGonzalez, I | 1 |
| Hernandez, F | 1 |
| Fernandez-Portales, J | 1 |
| Fernandez-Fernandez, J | 1 |
| Pérez-Serradilla, A | 1 |
| Gomez-Jaume, A | 1 |
| Berger, PB | 7 |
| Cubero Gómez, JM | 1 |
| Acosta Martínez, J | 1 |
| Mendias Benítez, C | 1 |
| Díaz De La Llera, LS | 1 |
| Fernández-Quero, M | 1 |
| Guisado Rasco, A | 1 |
| Villa Gil-Ortega, M | 1 |
| Sánchez González, Á | 1 |
| Schneider, DJ | 2 |
| Chava, S | 1 |
| Reed Chase, M | 1 |
| Friedman, HS | 1 |
| Navaratnam, P | 1 |
| Heithoff, K | 1 |
| Grohé, C | 1 |
| Bui, AH | 1 |
| Guo, J | 1 |
| Im, K | 1 |
| Michelson, EL | 2 |
| Morofuji, T | 1 |
| Inaba, S | 1 |
| Hitsumoto, T | 1 |
| Takahashi, K | 1 |
| Aisu, H | 1 |
| Higashi, H | 1 |
| Saito, M | 1 |
| Ohshima, K | 1 |
| Ikeda, S | 1 |
| Hamada, M | 1 |
| Sumimoto, T | 1 |
| Luca, GD | 1 |
| Carlson, G | 1 |
| Khan, N | 2 |
| Mărginean, A | 1 |
| Bănescu, C | 1 |
| Moldovan, V | 1 |
| Scridon, A | 1 |
| Mărginean, M | 1 |
| Bălaşa, R | 1 |
| Maier, S | 1 |
| Ţăruşi, M | 1 |
| Dobreanu, M | 1 |
| Lefkovits, J | 2 |
| Ramchand, J | 1 |
| Yip, T | 1 |
| Oqueli, E | 2 |
| Reid, CM | 2 |
| Doll, JA | 1 |
| Kaufmann, J | 1 |
| Wellnhofer, E | 1 |
| Stockmann, H | 1 |
| Graf, K | 1 |
| Fleck, E | 1 |
| Schroeder, T | 1 |
| Stawowy, P | 1 |
| Storm, C | 1 |
| Chong Tou, TJ | 1 |
| Liu, PM | 1 |
| Wang, JF | 2 |
| Sio Cham, ZC | 1 |
| O U, YF | 1 |
| Lei Sio, ZW | 1 |
| Lei Put, PZ | 1 |
| Lei Sok, SM | 1 |
| Zhou, SX | 1 |
| Wu, W | 2 |
| Uchida, K | 1 |
| Karube, N | 1 |
| Ebina, T | 4 |
| Imoto, K | 1 |
| Mancone, M | 1 |
| Pentara, I | 1 |
| de Barros e Silva, PG | 1 |
| Ribeiro, HB | 1 |
| Baruzzi, AC | 1 |
| da Silva, EE | 1 |
| Schiele, F | 2 |
| Biscaglia, S | 1 |
| Pavasini, R | 1 |
| Tebaldi, M | 2 |
| Tumscitz, C | 1 |
| Ferrari, R | 2 |
| Jayakumar, T | 1 |
| Yang, CH | 1 |
| Geraldine, P | 1 |
| Yen, TL | 1 |
| Sheu, JR | 1 |
| Jain, N | 1 |
| Reilly, RF | 2 |
| Jarrar, M | 1 |
| Behl, S | 1 |
| Manyam, G | 1 |
| Ganah, H | 1 |
| Nazir, M | 1 |
| Nasab, R | 1 |
| Moustafa, K | 1 |
| Giustino, G | 1 |
| Ariti, C | 1 |
| Krucoff, MW | 1 |
| Colombo, A | 2 |
| Chieffo, A | 2 |
| Dignat-Georges, F | 1 |
| Rossi, P | 1 |
| Mottola, G | 1 |
| Ruf, J | 1 |
| Joob, B | 1 |
| Wiwanitkit, V | 1 |
| Zhou, CF | 1 |
| Ren, YH | 3 |
| Song, YQ | 1 |
| Yi, J | 1 |
| Han, BS | 1 |
| Xue, Q | 2 |
| Fu, ZH | 1 |
| Li, DY | 1 |
| Pya, Y | 1 |
| Bekbossynova, M | 1 |
| Becher, A | 1 |
| Jennings, E | 1 |
| Westergaard, M | 1 |
| Cryer, BL | 1 |
| Hsieh, WH | 2 |
| Doros, G | 1 |
| Cohen, M | 2 |
| Lanas, A | 1 |
| Schnitzer, TJ | 1 |
| Shook, TL | 1 |
| Lapuerta, P | 1 |
| Goldsmith, MA | 1 |
| Laine, L | 2 |
| Muhlestein, B | 1 |
| Baker, B | 1 |
| Henry, T | 1 |
| Lood, C | 1 |
| Borna, C | 1 |
| Gidlöf, O | 1 |
| Truedsson, L | 1 |
| Brown, P | 1 |
| Zhou, C | 2 |
| Winters, K | 1 |
| Sidhu, MS | 1 |
| Roch, A | 1 |
| Berbis, J | 2 |
| Mancini, GB | 1 |
| Cheema, AN | 1 |
| Niznick, J | 1 |
| Llitjos, JF | 1 |
| Sideris, G | 3 |
| Voicu, S | 1 |
| Bal Dit Sollier, C | 2 |
| Deye, N | 1 |
| Megarbane, B | 1 |
| Drouet, L | 3 |
| Dillinger, JG | 1 |
| Kodaira, M | 1 |
| Miyata, H | 1 |
| Numasawa, Y | 1 |
| Ueda, I | 1 |
| Maekawa, Y | 1 |
| Sueyoshi, K | 1 |
| Ishikawa, S | 1 |
| Ohki, T | 1 |
| Negishi, K | 1 |
| Fukuda, K | 1 |
| Kohsaka, S | 1 |
| Smagulova, G | 1 |
| Kulmurzaeva, N | 1 |
| Seytmaganbetova, N | 1 |
| Kurmanalina, G | 1 |
| Talipova, I | 1 |
| Dadjou, Y | 1 |
| Safavi, S | 1 |
| Kojuri, J | 1 |
| Shimada, YJ | 1 |
| Abu-Much, A | 1 |
| Goldenberg, I | 1 |
| Segev, A | 1 |
| Shlezinger, M | 1 |
| Caporale, R | 1 |
| Geraci, G | 1 |
| Borzi, M | 1 |
| Colivicchi, F | 1 |
| Scherillo, M | 1 |
| Ledda, A | 1 |
| Gerometta, P | 1 |
| Casolo, G | 1 |
| Formigli, D | 1 |
| Romeo, F | 1 |
| Di Bartolomeo, R | 1 |
| Guo, YM | 1 |
| Zhao, ZC | 1 |
| Li, HZ | 1 |
| Sun, HL | 1 |
| Aksakal, E | 1 |
| Abaci, A | 1 |
| Tokgözoğlu, L | 1 |
| Holmes, LE | 1 |
| Gupta, R | 1 |
| Rajendran, S | 1 |
| Luu, J | 1 |
| Juergens, CP | 2 |
| Zang, H | 1 |
| Guo, L | 3 |
| Zhao, W | 1 |
| Tsoumani, ME | 4 |
| Tatsidou, PT | 1 |
| Tselepis, AD | 6 |
| Chen, IC | 1 |
| Fang, CC | 1 |
| Chao, TH | 1 |
| Cheng, CL | 1 |
| Yu, CL | 1 |
| Lin, CC | 1 |
| Lin, CY | 1 |
| Lai, Y | 1 |
| Yao, Y | 1 |
| Zheng, SL | 1 |
| Xu, J | 2 |
| Carino, A | 1 |
| Polimeni, A | 1 |
| Sabatino, J | 1 |
| Strangio, A | 1 |
| Filippis, C | 1 |
| Choi, IJ | 1 |
| Koh, YS | 1 |
| Park, MW | 1 |
| Her, SH | 1 |
| Choi, YS | 1 |
| Park, CS | 1 |
| Park, HJ | 1 |
| Kim, PJ | 1 |
| Chung, WS | 1 |
| Seung, KB | 1 |
| Knežević, B | 1 |
| Musić, L | 1 |
| Batrićević, G | 1 |
| Bošković, A | 1 |
| Bulatović, N | 1 |
| Nenezić, A | 1 |
| Vujović, J | 1 |
| Kalezić, M | 1 |
| Giordana, F | 1 |
| Montefusco, A | 1 |
| Moretti, C | 1 |
| Scarano, S | 1 |
| Abu-Assi, E | 1 |
| Raposeiras-Roubín, S | 1 |
| Henriques, JP | 1 |
| Saucedo, J | 1 |
| González-Juanatey, JR | 1 |
| Wilton, SB | 1 |
| Nuñez-Gil, I | 1 |
| Ariza-Sole, A | 1 |
| Song, X | 1 |
| Liebetrau, C | 1 |
| Kawaji, T | 1 |
| Nie, SP | 1 |
| Fujii, T | 1 |
| Correia, L | 1 |
| Kawashiri, MA | 1 |
| García-Acuña, JM | 1 |
| Southern, D | 1 |
| Alfonso, E | 1 |
| Terol, B | 1 |
| Garay, A | 1 |
| Zhang, D | 1 |
| Osman, N | 1 |
| Möllmann, H | 1 |
| Shiomi, H | 1 |
| Kowara, M | 1 |
| Filipiak, K | 1 |
| Yan, Y | 1 |
| Ikari, Y | 1 |
| Nakahayshi, T | 1 |
| Sakata, K | 1 |
| Yamagishi, M | 1 |
| Kalpak, O | 1 |
| Kedev, S | 1 |
| Gaita, F | 1 |
| Cui, M | 1 |
| Tu, CC | 1 |
| Chen, EZ | 1 |
| Wang, XL | 1 |
| Tan, SC | 1 |
| Chen, C | 2 |
| Sahlén, A | 1 |
| Renlund, H | 1 |
| Omerovic, E | 1 |
| Jin, L | 1 |
| Yu, H | 1 |
| Dong, T | 1 |
| Liao, H | 1 |
| Zou, X | 1 |
| Serbin, MA | 1 |
| Guzauskas, GF | 1 |
| Veenstra, DL | 1 |
| Jackson, LR | 2 |
| Piccini, JP | 1 |
| Abnousi, F | 2 |
| Prats, J | 2 |
| Mangum, S | 1 |
| Wilson, M | 1 |
| Ueno, T | 1 |
| Koiwaya, H | 1 |
| Sasaki, KI | 1 |
| Katsuki, Y | 1 |
| Katsuda, Y | 1 |
| Murasato, Y | 1 |
| Shimamatsu, J | 1 |
| Umeji, K | 1 |
| Otsuka, Y | 1 |
| Kawasaki, T | 1 |
| Shibata, Y | 1 |
| Fukumoto, Y | 1 |
| Chang, CY | 1 |
| Lin, SY | 1 |
| Tsai, JR | 1 |
| Tsai, CH | 1 |
| Chen, YC | 1 |
| Camaro, C | 1 |
| Damen, SA | 1 |
| Brouwer, MA | 1 |
| Lee, SW | 2 |
| van T Hof, AW | 1 |
| Ligtenberg, E | 1 |
| Knight, JD | 1 |
| Gašparović, V | 2 |
| McCollam, P | 3 |
| Fakhouri, W | 1 |
| Cowper, P | 1 |
| Clapp-Channing, N | 1 |
| Gargiulo, G | 1 |
| Ariotti, S | 1 |
| Santucci, A | 1 |
| Baldo, A | 1 |
| Franzone, A | 1 |
| Magnani, G | 2 |
| Esposito, G | 1 |
| Koh, JS | 2 |
| Ahn, JH | 1 |
| Kang, MG | 1 |
| Jang, JY | 1 |
| Park, HW | 1 |
| Park, JR | 1 |
| Hwang, SJ | 2 |
| Kwak, CH | 2 |
| Hwang, JY | 2 |
| Syvänne, M | 1 |
| Kudaravalli, M | 1 |
| Althouse, AD | 1 |
| Marroquin, OC | 1 |
| Khandhar, SJ | 1 |
| Sharbaugh, MS | 1 |
| Conrad Smith, AJ | 1 |
| Schindler, JT | 1 |
| Lee, JS | 1 |
| Mulukutla, SR | 1 |
| Pareek, M | 1 |
| Pang, M | 1 |
| Zhuang, K | 1 |
| Bhat, A | 1 |
| Björquist, A | 1 |
| Di Buduo, CA | 1 |
| Balduini, A | 1 |
| Nylander, S | 1 |
| Parker, WA | 1 |
| Lohaus, R | 1 |
| Michel, J | 1 |
| Mayer, K | 1 |
| Lahmann, AL | 1 |
| Byrne, RA | 5 |
| Wolk, A | 1 |
| Adriaenssens, T | 1 |
| Tölg, R | 1 |
| Seyfarth, M | 3 |
| Maeng, M | 1 |
| Zrenner, B | 1 |
| Wöhrle, J | 1 |
| Morath, T | 1 |
| Bernlochner, I | 3 |
| Fischer, M | 1 |
| Schulz-Schüpke, S | 1 |
| Thalmeier, A | 1 |
| Löw, A | 1 |
| Teupser, D | 1 |
| Malek, L | 1 |
| Horstkotte, J | 1 |
| Baylacher, M | 1 |
| Schwinger, R | 1 |
| Mudra, H | 2 |
| Hausleiter, J | 1 |
| Roule, V | 1 |
| Agueznai, M | 1 |
| Sabatier, R | 1 |
| Blanchart, K | 1 |
| Lemaître, A | 1 |
| Ardouin, P | 1 |
| Milliez, P | 1 |
| Deliargyris, EN | 1 |
| Lev, EI | 1 |
| Gunarathne, A | 1 |
| Hussain, S | 1 |
| Gershlick, AH | 1 |
| Rosa, GM | 1 |
| Bianco, D | 1 |
| Valbusa, A | 1 |
| Massobrio, L | 1 |
| Chiarella, F | 1 |
| Brunelli, C | 1 |
| Myat, A | 1 |
| Petrie, CJ | 1 |
| Pourdjabbar, A | 1 |
| Hibbert, B | 1 |
| Le May, MR | 2 |
| Labinaz, M | 2 |
| Simard, T | 1 |
| Ramirez, FD | 1 |
| Lugomirski, P | 1 |
| Maze, R | 1 |
| Froeschl, M | 2 |
| Glover, C | 2 |
| Dick, A | 2 |
| Marquis, JF | 2 |
| Bernick, J | 1 |
| Wells, G | 1 |
| Fosbøl, EL | 1 |
| Ju, C | 2 |
| Zettler, ME | 1 |
| Messenger, JC | 2 |
| Peterson, ED | 8 |
| Wang, TY | 5 |
| McCoy, LA | 1 |
| Zettler, M | 2 |
| Choi, HK | 1 |
| Ghim, JL | 1 |
| Shon, J | 1 |
| Choi, YK | 1 |
| Jung, JA | 1 |
| Ferri, LA | 1 |
| Morici, N | 1 |
| Grosseto, D | 1 |
| Tortorella, G | 1 |
| Bossi, I | 1 |
| Sganzerla, P | 1 |
| Cacucci, M | 1 |
| Sibilio, G | 1 |
| Ferrario, M | 1 |
| Gandolfo, N | 1 |
| Ravera, A | 1 |
| Corrada, E | 1 |
| Di Ascenzo, L | 1 |
| Petronio, AS | 1 |
| Moffa, N | 1 |
| Santos, RC | 1 |
| Goulart, AC | 1 |
| Kisukuri, AL | 1 |
| Brandão, RM | 1 |
| Sitnik, D | 1 |
| Staniak, HL | 1 |
| Bittencourt, MS | 1 |
| Lotufo, PA | 1 |
| Bensenor, IM | 1 |
| Santos, IS | 1 |
| Wimmer, NJ | 1 |
| Dufour, AB | 1 |
| Cho, K | 1 |
| Gagnon, DR | 1 |
| Quach, L | 1 |
| Ly, S | 1 |
| Do, JM | 1 |
| Ostrowski, S | 1 |
| Michael Gaziano, J | 1 |
| Kinlay, S | 1 |
| Luchessi, AD | 1 |
| Concheiro, M | 1 |
| Germano, JF | 1 |
| Silbiger, VN | 1 |
| Bortolin, RH | 1 |
| Cruz, A | 1 |
| Quintela, O | 1 |
| Brion, M | 1 |
| Carracedo, A | 1 |
| Iñiguez, A | 2 |
| Bravo, M | 1 |
| López-Rivadulla, M | 1 |
| Hirata, RD | 1 |
| Sousa, AG | 1 |
| Hirata, MH | 1 |
| Xin, YG | 1 |
| Zhang, HS | 1 |
| Li, YZ | 1 |
| Guan, QG | 1 |
| Gao, Y | 1 |
| Yu, HJ | 1 |
| Zhang, XG | 1 |
| Xu, F | 1 |
| Zhang, YL | 1 |
| Jia, DL | 1 |
| Sun, YX | 1 |
| Qi, GX | 1 |
| Tian, W | 1 |
| Carrero, JJ | 1 |
| Szummer, K | 2 |
| Evans, M | 1 |
| Spaak, J | 1 |
| Cavallari, LH | 2 |
| Obeng, AO | 1 |
| Nairooz, R | 1 |
| Rochlani, Y | 1 |
| Pothineni, NV | 1 |
| Raina, S | 1 |
| Sardar, P | 1 |
| Mukherjee, D | 2 |
| Naidu, SS | 1 |
| Shavelle, DM | 1 |
| Lu, J | 1 |
| Tian, H | 1 |
| Feng, W | 1 |
| You, H | 1 |
| He, H | 1 |
| Dong, Y | 1 |
| Kukula, K | 1 |
| Kunicki, PK | 1 |
| Jamiolkowski, J | 1 |
| Debski, A | 1 |
| Bekta, P | 1 |
| Polanska-Skrzypczyk, M | 1 |
| Chmielak, Z | 1 |
| Witkowski, A | 2 |
| Wonnacott, D | 1 |
| Berringer, R | 1 |
| Dong, P | 1 |
| Yang, X | 1 |
| Bian, S | 1 |
| De la Puente, C | 1 |
| Vallejos, C | 1 |
| Bustos, L | 1 |
| Zaror, C | 1 |
| Velasquez, M | 1 |
| Lanas, F | 1 |
| Wang, Q | 3 |
| Xue, Y | 1 |
| Lv, Q | 1 |
| Hauguel-Moreau, M | 1 |
| Salem, JE | 1 |
| Curjol, A | 1 |
| Galier, S | 1 |
| Cohen, A | 1 |
| Wang, CY | 3 |
| Lin, ZF | 1 |
| Tsai, YW | 3 |
| Huang, TY | 1 |
| van Diepen, S | 1 |
| Fuster, V | 3 |
| Hamza, TH | 1 |
| Siami, FS | 1 |
| Farkouh, ME | 1 |
| Benedetto, U | 1 |
| Bacchi Reggiani, L | 1 |
| Gilard, M | 1 |
| Morice, MC | 1 |
| Park, KW | 3 |
| Sangiorgi, D | 1 |
| Biondi-Zoccai, G | 1 |
| Angelini, GD | 1 |
| Pufulete, M | 1 |
| Ding, P | 1 |
| Wei, Y | 1 |
| Chen, N | 1 |
| Gesheff, T | 1 |
| Barbour, C | 1 |
| Perperis, A | 1 |
| Giannopoulos, G | 1 |
| Barampoutis, N | 1 |
| Liu, N | 1 |
| Steinvil, A | 1 |
| Kiramijyan, S | 1 |
| Pokharel, S | 1 |
| Lombardi, N | 1 |
| Crescioli, G | 1 |
| Lucenteforte, E | 1 |
| Mugelli, A | 1 |
| Vannacci, A | 1 |
| Hu, D | 1 |
| Yu, T | 1 |
| Tao, M | 1 |
| Li, MN | 1 |
| Kang, PF | 1 |
| Lu, DY | 1 |
| Shi, XJ | 1 |
| Wang, HJ | 1 |
| Wong, A | 1 |
| Yung, A | 1 |
| Shea, C | 1 |
| Kong, SL | 1 |
| Tang, WH | 1 |
| Siu, D | 1 |
| Stefanescu Schmidt, AC | 1 |
| Kereiakes, DJ | 2 |
| Cutlip, DE | 1 |
| D'Agostino, RB | 1 |
| Massaro, JM | 1 |
| Sheikh Rezaei, S | 1 |
| Geroldinger, A | 1 |
| Heinze, G | 1 |
| Reichardt, B | 1 |
| Wolzt, M | 1 |
| Lee, H | 1 |
| Koo, BK | 1 |
| Lim, SW | 1 |
| Rha, SW | 1 |
| Bae, JW | 1 |
| Oh, SK | 1 |
| Kim, BS | 1 |
| Lee, JH | 1 |
| Park, TH | 1 |
| Lee, NH | 1 |
| Alberts, MJ | 1 |
| Hanley, DF | 1 |
| Dixon, SR | 1 |
| Grines, CL | 1 |
| O'Neill, WW | 1 |
| Gutterman, D | 1 |
| Popma, JJ | 1 |
| Steg, G | 2 |
| Guyatt, GH | 1 |
| Malek, LA | 1 |
| Kisiel, B | 2 |
| Spiewak, M | 2 |
| Grabowski, M | 1 |
| Filipiak, KJ | 2 |
| Kostrzewa, G | 2 |
| Ploski, R | 1 |
| Opolski, G | 2 |
| Cundiff, DK | 1 |
| Vasilieva, E | 1 |
| Kasyanova, O | 1 |
| Shpektor, A | 1 |
| Barker, CM | 2 |
| Antonino, MJ | 1 |
| Sosnowski, C | 1 |
| Manzano-Fernández, S | 1 |
| Pastor, FJ | 2 |
| Cambronero, F | 1 |
| Caro, C | 1 |
| Pascual-Figal, DA | 1 |
| Garrido, IP | 1 |
| Lip, GYH | 1 |
| Guzman, LA | 1 |
| Bass, TA | 2 |
| Weerakkody, G | 2 |
| Morocutti, G | 1 |
| McCabe, CH | 7 |
| Yang, TS | 1 |
| Gai, LY | 1 |
| Liu, HB | 2 |
| Xu, XL | 1 |
| Jin, J | 1 |
| Xin, YH | 1 |
| Li, RB | 1 |
| Li, HY | 1 |
| Lin, L | 1 |
| Liu, CX | 1 |
| Uhry, S | 2 |
| Hoekstra, J | 1 |
| Giugliano, R | 2 |
| Hollander, JE | 3 |
| Manoukian, SV | 5 |
| Preobrazhenskiĭ, DV | 4 |
| Nusca, A | 2 |
| Gatto, L | 1 |
| Ramsdale, DR | 1 |
| Rao, A | 1 |
| Asghar, O | 1 |
| Ramsdale, KA | 1 |
| McKay, E | 1 |
| Macia, JC | 1 |
| Roubille, F | 1 |
| Rabesendratana, H | 1 |
| Piot, C | 1 |
| Schved, JF | 1 |
| Black, A | 1 |
| New, G | 1 |
| Lew, R | 1 |
| Shaw, JA | 3 |
| Gurvitch, R | 1 |
| Al-Fiadh, A | 1 |
| Brennan, AL | 1 |
| Banerjee, S | 1 |
| Varghese, C | 1 |
| Samuel, J | 1 |
| Weideman, RA | 1 |
| Little, BB | 1 |
| Kelly, KC | 1 |
| Brilakis, ES | 2 |
| Halperin, JL | 1 |
| Roldán, V | 1 |
| Frye, CB | 2 |
| Harshaw, Q | 2 |
| Edwards, FH | 1 |
| Steinhubl, SR | 5 |
| Chrolavicius, S | 3 |
| Diaz, R | 2 |
| Jolly, S | 2 |
| Rupprecht, HJ | 4 |
| Graber, MA | 1 |
| Dachs, R | 1 |
| Darby-Stewart, A | 1 |
| Yong, G | 1 |
| Rankin, J | 1 |
| Ferguson, L | 1 |
| Thom, J | 1 |
| French, J | 2 |
| Brieger, D | 4 |
| Chew, DP | 4 |
| Dick, R | 2 |
| Hockings, B | 1 |
| Walters, D | 1 |
| Whelan, A | 1 |
| Riezebos, RK | 1 |
| Ronner, E | 1 |
| Ter Bals, E | 1 |
| Slagboom, T | 1 |
| Smits, PC | 1 |
| Kiemeneij, F | 1 |
| Amoroso, G | 1 |
| Patterson, MS | 1 |
| Suttorp, MJ | 1 |
| Tijssen, JG | 3 |
| Laarman, GJ | 1 |
| Heer, T | 1 |
| Juenger, C | 1 |
| Gitt, AK | 1 |
| Bauer, T | 2 |
| Towae, F | 1 |
| Zahn, R | 3 |
| Senges, J | 1 |
| Shen, J | 1 |
| Zhang, RY | 1 |
| Mariani, G | 1 |
| Shen, L | 4 |
| Hockett, RD | 1 |
| Brandt, JT | 1 |
| Macias, W | 2 |
| Vermeer, NS | 1 |
| Bajorek, BV | 1 |
| Freedman, JE | 2 |
| Hylek, EM | 1 |
| De Labriolle, A | 1 |
| Steinberg, DH | 1 |
| Roy, P | 1 |
| Suddath, WO | 3 |
| Satler, LF | 3 |
| Kent, KM | 2 |
| Pichard, AD | 3 |
| de Miguel Castro, A | 1 |
| Cuellas Ramón, C | 1 |
| Diego Nieto, A | 1 |
| Samaniego Lampón, B | 1 |
| Alonso Rodríguez, D | 1 |
| Fernández Vázquez, F | 1 |
| Alonso Orcajo, N | 1 |
| Carbonell de Blas, R | 1 |
| Pascual Vicente, C | 1 |
| Pérez de Prado, A | 2 |
| Maddox, TM | 2 |
| Fihn, SD | 3 |
| Jesse, RL | 1 |
| Rumsfeld, JS | 3 |
| Thomas, D | 2 |
| Kala, P | 1 |
| Slattery, D | 1 |
| Skene, A | 2 |
| Harrington, R | 2 |
| Becker, R | 1 |
| Rao, RV | 1 |
| Yan, RT | 3 |
| Spencer, FA | 1 |
| DeYoung, JP | 2 |
| Rose, B | 1 |
| Grondin, FR | 1 |
| Gallo, R | 1 |
| Gore, JM | 4 |
| Wang, S | 1 |
| Jing, Q | 1 |
| Shu, Q | 1 |
| Tang, X | 1 |
| Mitchell, P | 1 |
| Brackbill, ML | 1 |
| Kidd, RS | 1 |
| Abdoo, AD | 1 |
| Warner, JG | 1 |
| Harralson, AF | 1 |
| Ionescu, CN | 1 |
| Chrissoheris, M | 1 |
| Caraccciolo, EA | 1 |
| Spinler, SA | 3 |
| Bonvini, RF | 1 |
| Reny, JL | 1 |
| Mach, F | 1 |
| Zeller, T | 1 |
| Fontana, P | 1 |
| Kosuge, M | 3 |
| Komura, N | 1 |
| Hashiba, K | 1 |
| Kiyokuni, M | 1 |
| Nakayama, N | 1 |
| Marian, AJ | 1 |
| Ignaszewski, A | 1 |
| Park, JY | 1 |
| Kim, KA | 1 |
| Shim, WJ | 1 |
| Park, SM | 1 |
| Ferreiro, JL | 3 |
| Ou, FS | 1 |
| Gibler, WB | 2 |
| Cuellas, C | 1 |
| Diego, A | 1 |
| de Miguel, A | 1 |
| Samaniego, B | 1 |
| Alonso-Orcajo, N | 1 |
| Carbonell, R | 1 |
| Pascual, C | 1 |
| Fernandez-Vazquez, F | 1 |
| Calabozo, RG | 1 |
| Michelson, AD | 5 |
| Downey, WE | 2 |
| Xenopoulos, NP | 1 |
| Marzot, F | 1 |
| Pengo, V | 2 |
| Podolec, J | 1 |
| Gajos, G | 1 |
| Budziaszek, Ł | 1 |
| Czaniecka, M | 1 |
| Kleczkoska, A | 1 |
| Zmudka', K | 1 |
| Małek, LA | 1 |
| Bilińska, ZT | 1 |
| Sitkiewicz, D | 1 |
| Kłopotowski, M | 1 |
| Ruzyłło, W | 1 |
| Robinson, A | 1 |
| Das, K | 1 |
| Koshy, SK | 1 |
| Das, P | 1 |
| Morrow, DA | 1 |
| Bramucci, E | 1 |
| Ruff, CT | 2 |
| Ball, J | 1 |
| Burrill, PD | 1 |
| Anderson, HV | 1 |
| Ebrahimi, R | 1 |
| Dyke, C | 1 |
| Feit, F | 3 |
| Gersh, BJ | 1 |
| Moses, JW | 3 |
| Ware, JH | 2 |
| Chew, D | 1 |
| Bertrand, ME | 3 |
| Desmet, W | 1 |
| Kapoor, JR | 2 |
| Alexander, JH | 1 |
| Cools, F | 3 |
| Mohan, P | 1 |
| Ruda, M | 1 |
| Verheugt, F | 1 |
| Sartipy, U | 1 |
| Bjessmo, S | 1 |
| Svenarud, P | 1 |
| Lindvall, B | 1 |
| Amsterdam, EA | 1 |
| Wang, SL | 2 |
| Wang, ZL | 1 |
| Wang, DM | 1 |
| Rees, C | 1 |
| Gaborit, B | 12 |
| Sellers, MB | 1 |
| Patel, SS | 1 |
| Mascarenhas, D | 1 |
| Schneider-Lindner, V | 1 |
| Filion, KB | 1 |
| Brophy, JM | 1 |
| Chae, YK | 1 |
| Hayes, S | 1 |
| Dakik, HA | 1 |
| Barada, K | 1 |
| Rogowski, W | 1 |
| Burch, J | 1 |
| Palmer, S | 1 |
| Craigs, C | 1 |
| Golder, S | 1 |
| Woolacott, N | 1 |
| van Giezen, JJ | 1 |
| Kittisupamongkol, W | 1 |
| Xie, Y | 1 |
| Liu, T | 1 |
| Zhou, YJ | 1 |
| Ma, HY | 1 |
| Guo, YH | 1 |
| Li, YP | 1 |
| Cheng, WJ | 1 |
| Liu, YY | 1 |
| Zhao, YX | 1 |
| Shi, DM | 1 |
| Duggan, ST | 1 |
| Keating, GM | 1 |
| O'Donoghue, M | 1 |
| Finkelstein, A | 2 |
| Penny, WF | 1 |
| Fridrich, V | 1 |
| Carrel, T | 1 |
| Englberger, L | 1 |
| Pride, YB | 1 |
| Buros, JL | 1 |
| Tariq, MU | 1 |
| Palot-Bonello, N | 1 |
| Armero, S | 3 |
| Schömig, A | 6 |
| Freij, A | 1 |
| Thorsén, M | 1 |
| Rozenman, Y | 1 |
| Hautvast, RW | 1 |
| Ver Lee, PN | 1 |
| Bandinelli, B | 1 |
| Valente, S | 3 |
| Lazzeri, C | 1 |
| Mannini, L | 1 |
| Poyet, R | 5 |
| Bali, L | 5 |
| Ray, MJ | 1 |
| Juneja, M | 1 |
| Bett, N | 1 |
| Walters, DL | 2 |
| Fermann, GJ | 1 |
| Raja, AS | 1 |
| Hoekstra, JW | 3 |
| Milford-Beland, S | 1 |
| Peacock, WF | 2 |
| Summers, R | 1 |
| Brissy, O | 2 |
| Aranki, SF | 1 |
| Body, SC | 1 |
| Nikolsky, E | 2 |
| Lansky, AJ | 1 |
| McLaurin, B | 1 |
| Fahy, M | 2 |
| Ishikawa, T | 2 |
| Nakano, Y | 1 |
| Endoh, A | 1 |
| Kubota, T | 1 |
| Suzuki, T | 1 |
| Nakata, K | 1 |
| Miyamoto, T | 1 |
| Murakami, M | 1 |
| Sakamoto, H | 1 |
| Imai, K | 1 |
| Mochizuki, S | 1 |
| Yoshimura, M | 1 |
| Mutoh, M | 1 |
| Małek, ŁA | 1 |
| Serafin, A | 1 |
| Płoski, R | 1 |
| Guagliumi, G | 2 |
| Caixeta, A | 1 |
| Aoki, J | 1 |
| Peruga, JZ | 1 |
| Dudek, D | 1 |
| Kornowski, R | 1 |
| Rabbani, LE | 1 |
| Parise, H | 1 |
| Castelli, C | 1 |
| Dobesh, PP | 2 |
| McCollam, PL | 1 |
| Khoynezhad, A | 1 |
| Chastek, B | 1 |
| Riedel, AA | 1 |
| Wygant, G | 1 |
| Depta, JP | 2 |
| Fonarow, GC | 1 |
| Bertrand, OF | 1 |
| Rodés-Cabau, J | 1 |
| Rinfret, S | 1 |
| Larose, E | 1 |
| Bagur, R | 1 |
| Proulx, G | 1 |
| Gleeton, O | 1 |
| Costerousse, O | 1 |
| De Larochellière, R | 1 |
| Roy, L | 1 |
| Stellos, K | 3 |
| Bigalke, B | 5 |
| Henkelmann, N | 1 |
| Furuta, T | 1 |
| Raymond, C | 1 |
| Menon, V | 1 |
| Abu-Fadel, M | 1 |
| Eshaghian, S | 1 |
| Shah, PK | 1 |
| Kaul, S | 1 |
| McNulty, S | 1 |
| Amine, M | 1 |
| French, WJ | 1 |
| Leisch, F | 1 |
| Skerjanec, S | 1 |
| Howard, PA | 1 |
| Poppe, T | 1 |
| Singal, B | 1 |
| Cowen, M | 1 |
| Srikanth, A | 1 |
| Goraya, TY | 1 |
| Rassen, JA | 1 |
| Avorn, J | 1 |
| Schneeweiss, S | 1 |
| Kowalczyk, M | 1 |
| Banach, M | 1 |
| Mikhailidis, DP | 1 |
| Hannam, S | 1 |
| Rysz, J | 1 |
| Kremneva, LV | 1 |
| Reinhart, KM | 1 |
| White, CM | 1 |
| Baker, WL | 1 |
| Farid, NA | 1 |
| Kurihara, A | 1 |
| Wrighton, SA | 1 |
| Bielis, L | 1 |
| Boinska, J | 1 |
| Plazuk, W | 1 |
| Marciniak, A | 1 |
| Budzyński, J | 1 |
| Siller-Matula, J | 2 |
| Lazar, LD | 1 |
| Banihashemi, B | 1 |
| Kornder, JM | 2 |
| Wong, GC | 1 |
| Gyenes, G | 1 |
| Eikelboom, J | 2 |
| Fremes, S | 1 |
| Mazer, D | 1 |
| Singh, S | 1 |
| Bittira, B | 1 |
| Brister, S | 1 |
| Graham, J | 3 |
| Gupta, M | 1 |
| Karkouti, K | 1 |
| Lee, A | 1 |
| Love, M | 1 |
| McArthur, R | 1 |
| Peterson, M | 1 |
| Yau, T | 1 |
| del Río, A | 1 |
| Tomoda, H | 1 |
| Guerra, DR | 1 |
| Tcheng, JE | 3 |
| Mahoney, EM | 1 |
| Wang, K | 2 |
| Arnold, SV | 1 |
| Proskorovsky, I | 1 |
| Wiviott, S | 2 |
| Antman, E | 1 |
| Juhász, M | 1 |
| Herszényi, L | 1 |
| Tulassay, Z | 1 |
| Chhatriwalla, AK | 1 |
| Vural, A | 1 |
| Islek, M | 1 |
| Avsar, O | 1 |
| Robinson, D | 1 |
| Hussain, J | 1 |
| Hirsch, A | 1 |
| Windhausen, F | 1 |
| de Winter, RJ | 1 |
| Alagona, P | 1 |
| Rosenstein, RS | 1 |
| Parra, D | 1 |
| Wartak, SA | 1 |
| Lotfi, A | 2 |
| Rothberg, M | 1 |
| Cohen, R | 1 |
| Meuleman, C | 2 |
| Lim, P | 1 |
| Marshall, D | 1 |
| Luo, J | 2 |
| Petitjean, H | 1 |
| Khurmi, NS | 4 |
| Kontny, F | 2 |
| Feldman, DN | 2 |
| Fakorede, F | 1 |
| Minutello, RM | 2 |
| Bergman, G | 2 |
| Moussa, I | 2 |
| Wong, SC | 2 |
| Sparling, JM | 1 |
| Resnic, FS | 1 |
| Solomon, S | 1 |
| Yamashita, T | 1 |
| Yajima, J | 1 |
| Oikawa, Y | 1 |
| Ogasawara, K | 1 |
| Sagara, K | 1 |
| Kirigaya, H | 1 |
| Koike, A | 1 |
| Nagashima, K | 1 |
| Ohtsuka, T | 1 |
| Uejima, T | 1 |
| Suzuki, S | 1 |
| Sawada, H | 1 |
| Aizawa, T | 1 |
| Anderson, SD | 1 |
| Shah, NK | 1 |
| Yim, J | 1 |
| Epstein, BJ | 1 |
| Yamaguchi, T | 1 |
| Kato, K | 1 |
| Yamaguchi, H | 1 |
| Jensen, P | 1 |
| Serebruany, V | 2 |
| Delrue, M | 1 |
| Verhamme, K | 1 |
| Bartunek, J | 2 |
| Saut, N | 5 |
| Eijgelsheim, M | 1 |
| Pattanaik, S | 1 |
| Malhotra, S | 1 |
| Sharma, YP | 1 |
| Ahluwalia, J | 1 |
| Bhalla, A | 1 |
| Pandhi, P | 1 |
| Bellemain-Appaix, A | 5 |
| Bal-Dit-Sollier, C | 1 |
| Lellouche, N | 1 |
| Slama, M | 1 |
| Milleron, O | 1 |
| Ren, WL | 1 |
| Song, LF | 1 |
| Liang, YQ | 1 |
| Li, RJ | 1 |
| Yin, ZN | 1 |
| Xu, YY | 1 |
| Hu, DY | 1 |
| Lin, GM | 1 |
| Han, CL | 1 |
| Islam, AM | 1 |
| Patel, PM | 1 |
| Momary, KM | 1 |
| Dorsch, MP | 2 |
| Mousa, SA | 1 |
| Jeske, WP | 1 |
| Fareed, J | 2 |
| Gebel, JM | 1 |
| Coppola, A | 1 |
| De Simone, C | 1 |
| Di Capua, M | 1 |
| Tufano, A | 1 |
| Cimino, E | 1 |
| Conca, P | 1 |
| Guida, A | 1 |
| Morisco, C | 1 |
| Di Minno, G | 1 |
| Tsai, TT | 1 |
| Shetterly, SM | 1 |
| Clarke, CL | 1 |
| Go, AS | 1 |
| Sedrakyan, A | 1 |
| Magid, DJ | 2 |
| Li, YG | 1 |
| Small, DS | 1 |
| Payne, CD | 1 |
| Tomlin, ME | 1 |
| Philipson, TJ | 1 |
| Mozaffari, E | 2 |
| Maclean, JR | 1 |
| Kessler, L | 1 |
| Bareiss, P | 2 |
| Cotton, JM | 2 |
| Worrall, AM | 1 |
| Hobson, AR | 1 |
| Smallwood, A | 2 |
| Amoah, V | 2 |
| Dunmore, S | 1 |
| Nevill, AM | 2 |
| Raghuraman, RP | 1 |
| Rajendra, R | 1 |
| Vickers, J | 1 |
| Filippi, E | 1 |
| Golinos, P | 1 |
| Piatek, L | 1 |
| Piatek, K | 1 |
| Polewczyk, A | 1 |
| Sielski, J | 1 |
| Janion, M | 1 |
| Eshtehardi, P | 1 |
| Cook, S | 1 |
| Billinger, M | 1 |
| Togni, M | 1 |
| Garachemani, A | 1 |
| Hess, OM | 1 |
| Wenaweser, P | 1 |
| Amin, AP | 2 |
| Marso, SP | 1 |
| Linchak, RM | 1 |
| Kartasheva, ED | 1 |
| Erdem, G | 1 |
| Flather, MD | 1 |
| Greenhalgh, J | 1 |
| Bagust, A | 1 |
| Boland, A | 1 |
| Saborido, CM | 1 |
| Fleeman, N | 1 |
| McLeod, C | 1 |
| Dundar, Y | 1 |
| Dickson, R | 1 |
| Proudlove, C | 1 |
| Kolamunnage-Dona, R | 1 |
| Fisher, M | 1 |
| Ambrosio, G | 1 |
| Steinhubl, S | 1 |
| Tritto, I | 1 |
| Zuchi, C | 1 |
| Anderson, FA | 2 |
| Avezum, A | 2 |
| Eagle, KA | 4 |
| FitzGerald, G | 1 |
| Dedrick, R | 1 |
| Yusuf, SW | 1 |
| Iliescu, C | 1 |
| Bathina, JD | 1 |
| Daher, IN | 1 |
| Durand, JB | 1 |
| Kalyanasundaram, A | 1 |
| Cheng, CI | 1 |
| Chen, CP | 1 |
| Kuan, PL | 1 |
| Lei, MH | 1 |
| Liau, CS | 1 |
| Ueng, KC | 1 |
| Wu, CY | 1 |
| Chan, FK | 2 |
| Wu, MS | 1 |
| Kuo, KN | 2 |
| Wang, CB | 1 |
| Tsao, CR | 1 |
| Lin, JT | 1 |
| Bonassin, F | 1 |
| Schneemann, M | 1 |
| Ge, J | 3 |
| Boonbaichaiyapruck, S | 1 |
| Goh, YS | 1 |
| Pinton, P | 1 |
| Momary, K | 1 |
| Liu, F | 2 |
| Xie, RQ | 1 |
| Yang, XC | 1 |
| Lu, JC | 1 |
| Zheng, HM | 1 |
| Ren, XJ | 1 |
| Gratsianskiĭ, NA | 3 |
| Frolova, NS | 2 |
| Pakhomov, IaM | 1 |
| Gassanov, N | 2 |
| Caglayan, E | 2 |
| Nia, AM | 1 |
| Erdmann, E | 2 |
| Er, F | 3 |
| Potter, BJ | 1 |
| Le Lorier, J | 1 |
| Merino, A | 1 |
| Roldán, I | 1 |
| Worner, F | 1 |
| Ait Mokhtar, O | 1 |
| Aldebert, P | 1 |
| Bonello, N | 1 |
| Barragan, P | 2 |
| Arques, S | 1 |
| Giacomoni, MP | 1 |
| Bonello-Burignat, C | 1 |
| Bartholomei, MN | 1 |
| Aïssaoui, N | 1 |
| Dean, BB | 1 |
| Yu, HT | 1 |
| Fiske, S | 1 |
| Meadows, E | 1 |
| Xiong, Y | 1 |
| Emons, MF | 1 |
| Kang, MK | 1 |
| Yoon, SE | 1 |
| Kim, IS | 1 |
| Bjelland, TW | 1 |
| Hjertner, Ø | 1 |
| Klepstad, P | 1 |
| Kaisen, K | 1 |
| Dale, O | 1 |
| Haugen, BO | 1 |
| Aichele, S | 1 |
| Herkommer, M | 1 |
| Htun, P | 1 |
| Fateh-Moghadam, S | 1 |
| May, AE | 1 |
| Bhattacharya, R | 1 |
| Pani, A | 1 |
| Dutta, D | 1 |
| Basak, S | 1 |
| Gangopadhyay, S | 1 |
| Das Baksi, S | 1 |
| Sarkar, RN | 1 |
| Schrör, K | 2 |
| Herkner, H | 1 |
| Jilma, B | 2 |
| Pena, A | 1 |
| Armstrong, M | 1 |
| Barratt, BJ | 1 |
| Shah, SH | 1 |
| Buck, KK | 1 |
| Parikh, K | 1 |
| Wen, YW | 2 |
| Chen, PF | 2 |
| Melfi, R | 1 |
| Joyner, CD | 2 |
| Afzal, R | 1 |
| Pogue, J | 1 |
| Moro, PJ | 5 |
| Giorgi, MA | 2 |
| Di Girolamo, G | 2 |
| González, CD | 2 |
| Duerschmied, D | 1 |
| Moser, M | 1 |
| Niiazova-Karben, ZA | 1 |
| Besnili, F | 1 |
| Patil, SB | 1 |
| Desai, B | 1 |
| Laizure, SC | 1 |
| Parker, RB | 1 |
| Deraad, R | 2 |
| Costigan, TM | 2 |
| Ojeh, CK | 2 |
| Pham, SV | 1 |
| Pham, PC | 1 |
| Pham, PM | 1 |
| Miller, JM | 1 |
| Pham, PT | 1 |
| Pham, PA | 1 |
| Caracciolo, M | 1 |
| D'Urbano, M | 2 |
| Dobrovol'skiĭ, AB | 1 |
| Gilchrist, IC | 1 |
| Fletcher, B | 1 |
| Thalinger, KK | 1 |
| Tentzeris, I | 2 |
| Jarai, R | 2 |
| Brozovic, I | 2 |
| Smetana, P | 2 |
| Geppert, A | 2 |
| Wojta, J | 2 |
| Radke, PW | 1 |
| Zou, JJ | 1 |
| Hu, ZY | 1 |
| Bliden, K | 1 |
| Gurbel, P | 3 |
| Horne, BD | 1 |
| Anand, SS | 1 |
| Connolly, SJ | 1 |
| Simonsen, K | 1 |
| Abergel, E | 1 |
| Kilhamn, J | 1 |
| Olofsson, S | 1 |
| Weaver, WD | 1 |
| Páramo, JA | 1 |
| Mangalpally, KK | 1 |
| Tan, HJ | 1 |
| Lotan, C | 1 |
| Heuer, H | 1 |
| Baracioli, L | 1 |
| Seabro-Gomes, R | 1 |
| Sibbald, M | 1 |
| Huang, W | 1 |
| Sambu, N | 1 |
| Warner, T | 1 |
| Lettino, M | 2 |
| Armani, AM | 1 |
| Menown, IB | 1 |
| Fernandez, A | 1 |
| Aboodi, MS | 1 |
| Milewski, K | 1 |
| Delgado, JA | 1 |
| Rodríguez, A | 1 |
| Granada, JF | 1 |
| Ivandic, B | 1 |
| Frey, N | 1 |
| Merella, P | 1 |
| Meloni, I | 1 |
| Vassiliou, VS | 1 |
| Padrini, R | 1 |
| Elhadad, S | 1 |
| Rangé, G | 1 |
| Endo, M | 2 |
| Maejima, N | 2 |
| Iwahashi, N | 2 |
| Okada, K | 1 |
| Masumura, Y | 1 |
| Matsuo, K | 1 |
| Akazawa, Y | 1 |
| Nishio, M | 1 |
| Hirata, A | 1 |
| Kashiwase, K | 1 |
| Nemoto, T | 1 |
| Kashiyama, T | 1 |
| Wada, M | 1 |
| Muller, JE | 1 |
| Kodama, K | 1 |
| Asenblad, N | 4 |
| Vintila, M | 2 |
| Ycas, J | 1 |
| Ağırbaşlı, M | 1 |
| Güvenç, H | 1 |
| Cinçin, A | 1 |
| Lorgis, L | 2 |
| Richard, C | 1 |
| Zeller, M | 2 |
| Gudjoncik, A | 1 |
| Buffet, P | 2 |
| L'Huillier, I | 2 |
| Cottin, Y | 2 |
| Václavík, J | 1 |
| Táborský, M | 1 |
| Zhu, B | 1 |
| Anderson, J | 1 |
| Fu, H | 1 |
| Lenarz, L | 1 |
| El Ghannudi, S | 2 |
| Radulescu, B | 2 |
| Wiesel, ML | 2 |
| Caillard, S | 1 |
| Campia, U | 1 |
| Moulin, B | 1 |
| Ortolani, P | 1 |
| Branzi, A | 1 |
| Cohen Arazi, H | 1 |
| Kalantzi, KI | 5 |
| Dimitriou, AA | 5 |
| Milionis, HJ | 1 |
| Goudevenos, IA | 4 |
| Vassiliou, V | 2 |
| Gaspar, A | 1 |
| Ribeiro, S | 1 |
| Nabais, S | 1 |
| Rocha, S | 1 |
| Azevedo, P | 1 |
| Pereira, MA | 1 |
| Brandāo, A | 1 |
| Salgado, A | 1 |
| Correia, A | 1 |
| Cay, S | 1 |
| Cagirci, G | 1 |
| Aydogdu, S | 1 |
| Balbay, Y | 1 |
| Sen, N | 1 |
| Maden, O | 1 |
| Demir, AD | 1 |
| Erbay, AR | 1 |
| Siasos, G | 1 |
| Tousoulis, D | 1 |
| Schwab, M | 1 |
| Muller, O | 1 |
| Ntalianis, A | 1 |
| Trana, C | 1 |
| Sarno, G | 1 |
| Dierickx, K | 1 |
| Meeus, P | 1 |
| De Bruyne, B | 1 |
| White, JA | 1 |
| Califf, RM | 2 |
| Disney, BR | 1 |
| Watson, RD | 1 |
| Blann, AD | 1 |
| Anderson, MR | 1 |
| Goodwin, MM | 1 |
| Desilets, AR | 1 |
| Willett, KC | 1 |
| Topçuoglu, MA | 1 |
| Arsava, EM | 1 |
| Ay, H | 1 |
| Edwards, J | 1 |
| Chauret, D | 1 |
| Picard, JP | 1 |
| Ferrieres, J | 1 |
| Schmitt, C | 2 |
| Peters, BJ | 1 |
| Harmsze, AM | 1 |
| Maitland-van der Zee, AH | 1 |
| Tjoeng, MM | 1 |
| de Boer, A | 1 |
| Fileti, L | 1 |
| Marchesini, J | 1 |
| Lortkipanidze, N | 1 |
| Romano, M | 1 |
| Nijaradze, T | 1 |
| Cicorella, N | 1 |
| Sirbu, V | 1 |
| Rosiello, R | 1 |
| Valsecchi, O | 1 |
| Gavazzi, A | 1 |
| Srour, JF | 1 |
| Smetana, GW | 1 |
| Ndrepepa, G | 5 |
| Dotzer, F | 3 |
| Dommasch, M | 1 |
| Birkmeier, KA | 1 |
| Tiroch, K | 1 |
| Connor, S' | 1 |
| Aout, M | 1 |
| Steiger, H | 1 |
| Stephenson, JJ | 1 |
| Chang, CL | 1 |
| Devecchis Wygant, G | 1 |
| Cziraky, MJ | 1 |
| Hahne, S | 1 |
| Kozanli, I | 1 |
| Kalla, K | 1 |
| Freynhofer, M | 1 |
| Nürnberg, M | 1 |
| Unger, G | 1 |
| Vestergaard, P | 1 |
| Steinberg, TH | 1 |
| Schwarz, P | 1 |
| Jørgensen, NR | 1 |
| Phillippe, HM | 1 |
| Baty, SR | 1 |
| Griffith, CB | 1 |
| Park, KJ | 1 |
| Chung, HS | 1 |
| Kim, SR | 1 |
| Kim, HJ | 1 |
| Lai, TF | 1 |
| Riva, L | 1 |
| Casella, G | 1 |
| Calabrese, D | 1 |
| Zagnoni, S | 1 |
| Pallotti, MG | 1 |
| Schwarz, AK | 1 |
| Hochadel, M | 1 |
| Kerber, S | 1 |
| Hauptmann, KE | 1 |
| Glunz, HG | 1 |
| Darius, H | 1 |
| Zhao, M | 1 |
| Chen, YD | 2 |
| Sun, ZJ | 1 |
| Chen, JS | 1 |
| Huang, TT | 1 |
| Guo, YS | 1 |
| Xie, YJ | 1 |
| Persson, J | 1 |
| Lindbäck, J | 1 |
| Hofman-Bang, C | 1 |
| Stenestrand, U | 1 |
| Samnegard, A | 1 |
| Fernando, H | 2 |
| Dart, AM | 2 |
| Peter, K | 1 |
| Pais, P | 2 |
| Raev, D | 2 |
| Khder, Y | 1 |
| Roberts, J | 1 |
| Mantovani, F | 2 |
| Burke, MA | 1 |
| Lee, R | 1 |
| Fintel, DJ | 1 |
| Suriano, P | 1 |
| Castriota, F | 1 |
| Cattaneo, GJ | 1 |
| Johnston, S | 1 |
| Curkendall, S | 1 |
| Stemkowski, S | 1 |
| Ge, H | 1 |
| Nie, X | 1 |
| Guo, Y | 1 |
| Chen, W | 1 |
| Rajan, L | 1 |
| Nijjer, SS | 1 |
| Watson, G | 1 |
| Athanasiou, T | 1 |
| Malik, IS | 1 |
| Freynhofer, MK | 1 |
| Bruno, V | 1 |
| Jakl, G | 1 |
| Willheim, M | 1 |
| Hübl, W | 1 |
| Quinlan, DJ | 1 |
| Fitchett, DH | 1 |
| Théroux, P | 1 |
| Martin, MT | 1 |
| Nutescu, EA | 1 |
| Kennedy, KF | 1 |
| Pencina, M | 1 |
| Berger, P | 1 |
| Piana, RN | 1 |
| Kleiman, N | 1 |
| Syed, AI | 1 |
| Ben-Dor, I | 1 |
| Gonzalez, M | 1 |
| Maluenda, G | 1 |
| Sardi, G | 1 |
| Wakabayashi, K | 1 |
| Xue, Z | 1 |
| Timmis, A | 2 |
| Stevens, S | 1 |
| Bassler, N | 1 |
| Habersberger, J | 1 |
| Sheffield, LJ | 1 |
| Sharma, R | 1 |
| Peter, KH | 1 |
| Vrachatis, DA | 1 |
| Papaioannou, TG | 1 |
| Archontakis, S | 1 |
| Kalogeras, KI | 1 |
| Kariori, MG | 1 |
| Gafou, A | 1 |
| Moldovan, C | 1 |
| Tzamalis, P | 1 |
| Scott, SA | 1 |
| Sangkuhl, K | 1 |
| Gardner, EE | 1 |
| Stein, CM | 1 |
| Johnson, JA | 1 |
| Roden, DM | 1 |
| Klein, TE | 1 |
| Shuldiner, AR | 1 |
| Carballo, S | 1 |
| Carballo, D | 1 |
| Keller, PF | 1 |
| Liu, YP | 1 |
| Hao, PP | 1 |
| Zhang, MX | 1 |
| Zhang, C | 1 |
| Gao, F | 1 |
| Chen, YG | 1 |
| Alber, HF | 1 |
| Pachinger, O | 1 |
| Frick, M | 1 |
| Cohen, W | 2 |
| Carrieri, P | 1 |
| Cooper, A | 1 |
| Cairns, R | 1 |
| Ahmad, WA | 1 |
| Ramesh, SV | 1 |
| Zambahari, R | 2 |
| Hinneburg, I | 1 |
| Cekici, Y | 1 |
| Korkmaz, H | 1 |
| Celik, A | 1 |
| Bilen, MN | 1 |
| Bulut, M | 1 |
| Akbulut, M | 1 |
| Clough, JD | 1 |
| Martin, SS | 1 |
| Cope, MW | 1 |
| Bouman, HJ | 1 |
| van Werkum, JW | 2 |
| Taubert, D | 1 |
| Spectre, G | 1 |
| Mosseri, M | 1 |
| Abdelrahman, NM | 1 |
| Briskin, E | 1 |
| Bulut, A | 1 |
| Loncar, S | 1 |
| Alcalai, R | 1 |
| Mullins, CD | 1 |
| Höchtl, T | 1 |
| Molines, L | 1 |
| Boggon, R | 1 |
| van Staa, TP | 1 |
| Hemingway, H | 1 |
| Ray, KK | 1 |
| Begg, A | 1 |
| Emmas, C | 1 |
| Teirstein, PS | 2 |
| Lillie, E | 2 |
| Topol, EJ | 3 |
| Golubeva, NV | 1 |
| Awad, HH | 1 |
| Zubaid, M | 1 |
| Alsheikh-Ali, AA | 2 |
| Al Suwaidi, J | 2 |
| Goldberg, RJ | 1 |
| Bonafede, M | 1 |
| Jing, Y | 2 |
| Gdovin Bergeson, J | 1 |
| Liffmann, D | 1 |
| Makenbaeva, D | 1 |
| Deitelzweig, SB | 1 |
| Chen, M | 1 |
| Wei, JF | 1 |
| Xu, YN | 1 |
| Liu, XJ | 1 |
| Huang, DJ | 1 |
| O'Connor, S | 1 |
| Buonamici, P | 2 |
| Hajjar, R | 1 |
| Giacalone, R | 1 |
| Conte, G | 1 |
| Collyer, TC | 1 |
| Reynolds, HC | 1 |
| Truyens, E | 1 |
| Kilshaw, L | 1 |
| Corcoran, T | 1 |
| Tellis, CC | 1 |
| Syed, FA | 1 |
| Bett, JH | 1 |
| Mauskopf, JA | 1 |
| Graham, JB | 1 |
| Ramaswamy, K | 2 |
| Zagar, AJ | 1 |
| Magnuson, EA | 1 |
| Meadows, ES | 2 |
| Finzi, J | 1 |
| Harrison, RW | 1 |
| Tunggal, P | 2 |
| Ng, FH | 3 |
| Lam, KF | 3 |
| Lau, YK | 3 |
| Basra, SS | 1 |
| Tsai, P | 1 |
| Lakkis, NM | 1 |
| de Lemos, JA | 1 |
| Chu, WM | 2 |
| Li, A | 1 |
| Chan, K | 1 |
| Kng, C | 1 |
| Keung, KK | 1 |
| Kwan, A | 1 |
| Wong, BC | 2 |
| Jover, E | 1 |
| Bernal, A | 1 |
| Lozano, ML | 1 |
| Sánchez-Vega, B | 1 |
| Hurtado, JA | 1 |
| Vicente, V | 1 |
| Rivera, J | 1 |
| Érlikh, AD | 2 |
| Buck, K | 1 |
| Thompson, CA | 1 |
| Zhang, YX | 1 |
| Lu, CY | 1 |
| Zhou, SH | 1 |
| Gao, L | 1 |
| Tian, JW | 1 |
| Gao, W | 1 |
| Chen, R | 1 |
| Zhai, JY | 1 |
| Li, LJ | 1 |
| Cantor, WJ | 1 |
| Buber, J | 1 |
| Vatury, O | 1 |
| Siha, H | 2 |
| Jeger, R | 1 |
| Ishida, M | 1 |
| Watanabe, H | 1 |
| Iino, K | 1 |
| Okawa, M | 1 |
| Kosaka, T | 1 |
| Ito, H | 1 |
| Luo, M | 1 |
| Sheng, W | 1 |
| Oh, EY | 1 |
| Abraham, T | 1 |
| Saad, N | 1 |
| Rapp, JH | 1 |
| Vastey, FL | 1 |
| Balmir, E | 1 |
| Janknegt, R | 1 |
| Ruiters, L | 1 |
| Ten Cate, H | 1 |
| Calvi, V | 1 |
| Saracini, C | 3 |
| Vestrini, A | 1 |
| Galora, S | 1 |
| Armillis, A | 1 |
| Hazarbasanov, D | 1 |
| Velchev, V | 1 |
| Finkov, B | 1 |
| Postadjian, A | 1 |
| Kostov, E | 1 |
| Rifai, N | 1 |
| El-Menyar, A | 1 |
| AlHabib, KF | 1 |
| Al-Motarreb, A | 1 |
| Hersi, A | 1 |
| Al Faleh, H | 1 |
| Asaad, N | 1 |
| Al Saif, S | 1 |
| Almahmeed, W | 1 |
| Sulaiman, K | 1 |
| Amin, H | 1 |
| Al-Lawati, J | 1 |
| AlQahtani, A | 1 |
| Al-Sagheer, NQ | 1 |
| Singh, R | 1 |
| Zghal, FM | 1 |
| Amri, A | 1 |
| Mourali, MS | 1 |
| Farhati, A | 1 |
| Larbi, N | 1 |
| Mechmèche, R | 1 |
| Geeganage, CM | 1 |
| Diener, HC | 1 |
| Algra, A | 1 |
| Dengler, R | 1 |
| Markus, HS | 1 |
| Bath, MW | 1 |
| Bath, PM | 1 |
| Bessereau, J | 4 |
| Ostorero, M | 1 |
| Cequier, AR | 1 |
| Mackay, SM | 1 |
| Feng, XR | 1 |
| Liu, ML | 1 |
| Tian, QP | 1 |
| Fan, Y | 1 |
| Liu, QZ | 1 |
| Porto, I | 1 |
| D'Amario, D | 1 |
| Herout, PM | 1 |
| Contractor, H | 1 |
| Ruparelia, N | 1 |
| Bai, CH | 1 |
| Johnston, SS | 1 |
| Bell, K | 1 |
| Gdovin, J | 1 |
| Stephens, JC | 1 |
| Askari, AT | 1 |
| Silva, A | 1 |
| Kavvoura, F | 1 |
| Schofield, R | 1 |
| Rowlands, DB | 1 |
| Reese, ES | 1 |
| Daniel Mullins, C | 1 |
| Beitelshees, AL | 1 |
| Onukwugha, E | 1 |
| Roberts, JD | 1 |
| Wells, GA | 2 |
| O'Brien, E | 1 |
| Goncalves, S | 1 |
| Druce, I | 1 |
| Stewart, A | 1 |
| Gollob, MH | 1 |
| Johnston, LR | 1 |
| La Flamme, AC | 1 |
| Michel, JM | 1 |
| Simmonds, MB | 1 |
| Häuptle, R | 1 |
| Weilenmann, D | 1 |
| Schneider, T | 1 |
| Haile, SR | 1 |
| Ammann, P | 1 |
| Knellwolf, C | 1 |
| Borovicka, J | 1 |
| Guan, SY | 1 |
| Liu, XD | 1 |
| Jacquin, L | 1 |
| Bonello, C | 1 |
| Camillieri, E | 1 |
| Das, D | 1 |
| Zheng, Y | 1 |
| Stauffer, JC | 1 |
| Goy, JJ | 1 |
| Duvoisin, N | 1 |
| Rickli, H | 1 |
| Azmoon, S | 1 |
| Lyseng-Williamson, KA | 1 |
| Konosic, S | 1 |
| Murray, SS | 1 |
| Smith, EN | 1 |
| Tisch, RL | 1 |
| Schork, NJ | 1 |
| Steiner, S | 1 |
| Moertl, D | 1 |
| Coyle, D | 1 |
| Smith, PK | 2 |
| Goodnough, LT | 2 |
| Levy, JH | 2 |
| Poston, RS | 2 |
| Short, MA | 2 |
| Weerakkody, GJ | 2 |
| Lenarz, LA | 2 |
| Barillà, F | 1 |
| Pulcinelli, FM | 1 |
| Mangieri, E | 1 |
| Torromeo, C | 1 |
| Tanzilli, G | 1 |
| Dominici, T | 1 |
| Pellicano, M | 1 |
| Paravati, V | 1 |
| Acconcia, MC | 1 |
| Gaudio, C | 1 |
| Tsantes, A | 1 |
| Ikonomidis, I | 1 |
| Papadakis, I | 1 |
| Kottaridi, C | 1 |
| Tsante, A | 1 |
| Kalamara, E | 1 |
| Kardoulaki, A | 1 |
| Kopterides, P | 1 |
| Kapsimali, V | 1 |
| Karakitsos, P | 1 |
| Travlou, A | 1 |
| Berwanger, O | 1 |
| Guimarães, HP | 1 |
| Laranjeira, LN | 1 |
| Cavalcanti, AB | 1 |
| Kodama, AA | 1 |
| Zazula, AD | 1 |
| Santucci, EV | 1 |
| Victor, E | 1 |
| Tenuta, M | 1 |
| Carvalho, V | 1 |
| Mira, VL | 1 |
| Weber, B | 1 |
| Mota, LH | 1 |
| Kourlaba, G | 1 |
| Fragoulakis, V | 1 |
| Maniadakis, N | 1 |
| Joshi, R | 1 |
| Ahmad, S | 1 |
| Sébastien, A | 1 |
| Kar, S | 1 |
| Barn, K | 1 |
| Reydel, A | 1 |
| Crimizade, U | 1 |
| Bhurke, SM | 1 |
| Martin, BC | 1 |
| Franks, AM | 1 |
| Bursac, Z | 1 |
| Said, Q | 1 |
| Zagar, A | 1 |
| Sugihara, T | 1 |
| McCracken, R | 1 |
| Heiselman, D | 1 |
| Galati, A | 1 |
| Kassimis, G | 1 |
| Theodoropoulos, KC | 2 |
| Makris, G | 1 |
| Damelou, A | 2 |
| Tsigkas, G | 1 |
| Controtto, F | 1 |
| Scacciatella, P | 1 |
| Cristofori, R | 1 |
| Grasso, C | 1 |
| D'Amico, M | 1 |
| Pennone, M | 1 |
| Marra, S | 1 |
| Isordia-Salas, I | 1 |
| Olalde-Román, MJ | 1 |
| Santiago-Germán, D | 1 |
| de la Peña, NC | 1 |
| Valencia-Sánchez, JS | 1 |
| Geng, DF | 1 |
| Jin, DM | 1 |
| Deng, J | 1 |
| Limper, U | 1 |
| Lynch, J | 1 |
| Teixeira, R | 1 |
| Monteiro, P | 1 |
| Marques, G | 1 |
| Pego, JM | 1 |
| Lourenço, M | 1 |
| Tavares, C | 1 |
| Reboredo, A | 1 |
| Monteiro, S | 1 |
| Gonçalves, F | 1 |
| Ferreira, MJ | 1 |
| Freitas, M | 1 |
| Ribeiro, G | 1 |
| Providência, LA | 1 |
| Yano, H | 1 |
| Vatankulu, MA | 1 |
| Tasal, A | 1 |
| Erdoğan, E | 1 |
| Göktekin, Ö | 1 |
| Lamberts, M | 1 |
| Olesen, JB | 1 |
| Ruwald, MH | 1 |
| Hansen, CM | 1 |
| Karasoy, D | 1 |
| Kristensen, SL | 1 |
| Køber, L | 1 |
| Torp-Pedersen, C | 1 |
| Gislason, GH | 1 |
| Hansen, ML | 1 |
| Renda, G | 1 |
| Fassa, AA | 1 |
| Urban, P | 1 |
| Vavalle, JP | 1 |
| Parkhomenko, A | 1 |
| Topacio, GO | 1 |
| Goudev, AR | 1 |
| Tseng, CD | 1 |
| Cinteză, M | 1 |
| McLendon, RC | 1 |
| Burgess, S | 1 |
| Mallard, TA | 1 |
| Mannacio, VA | 1 |
| Antignan, A | 1 |
| May, CH | 1 |
| Papp, J | 1 |
| Kenyeres, P | 1 |
| Toth, K | 1 |
| Qian, J | 2 |
| Sun, A | 2 |
| Panattoni, L | 1 |
| Brown, PM | 1 |
| Te Ao, B | 1 |
| Webster, M | 2 |
| Gladding, P | 2 |
| Sun, W | 1 |
| Gil, JM | 1 |
| Horiuchi, H | 1 |
| Schechter, CB | 1 |
| Hogue, CW | 1 |
| Brandrup-Wognsen, G | 1 |
| Elefteriades, JA | 1 |
| Sadanandan, S | 1 |
| Singh, IM | 1 |
| Dubois, N | 1 |
| Dutour, A | 1 |
| Smith, JG | 1 |
| Wieloch, M | 1 |
| Lumsden, J | 1 |
| Rydell, E | 1 |
| Buffon, A | 1 |
| Rychter, M | 1 |
| Austin, D | 1 |
| Sukiennik, A | 1 |
| Panchenko, EP | 1 |
| Komarov, AL | 1 |
| Chan, MY | 1 |
| Brown, E | 1 |
| Secco, GG | 1 |
| Iorio, S | 1 |
| Lala, A | 1 |
| Sharma, G | 1 |
| Scott Braithwaite, R | 1 |
| Ladapo, JA | 1 |
| Mathur, AP | 1 |
| Waller, AH | 1 |
| Dhruvakumar, S | 1 |
| Mazza, V | 1 |
| Gerula, C | 1 |
| Maher, J | 1 |
| Klapholz, M | 1 |
| Worrall, AP | 1 |
| Goodridge, K | 1 |
| Lovatt, T | 1 |
| Armesilla, AL | 1 |
| Gardin, JM | 1 |
| Abrams, J | 1 |
| Berra, K | 1 |
| Blankenship, JC | 1 |
| Dallas, AP | 1 |
| Douglas, PS | 1 |
| Foody, JM | 1 |
| Gerber, TC | 1 |
| Hinderliter, AL | 1 |
| Kligfield, PD | 1 |
| Kwong, RY | 1 |
| Lim, MJ | 1 |
| Linderbaum, JA | 1 |
| Mack, MJ | 1 |
| Munger, MA | 1 |
| Prager, RL | 1 |
| Sabik, JF | 1 |
| Shaw, LJ | 1 |
| Sikkema, JD | 1 |
| Smith, CR | 1 |
| Spertus, JA | 2 |
| Williams, SV | 1 |
| Salisbury, AC | 1 |
| Jones, PG | 1 |
| Ahn, JM | 1 |
| Song, HG | 1 |
| Lee, JY | 1 |
| Kim, WJ | 1 |
| Kang, SJ | 1 |
| Yun, SC | 1 |
| Lee, CW | 1 |
| Park, SW | 1 |
| Plakomyti, TE | 1 |
| Rodrigo, C | 1 |
| Amarasuriya, M | 1 |
| Wickramasinghe, S | 1 |
| Constantine, GR | 1 |
| Loh, JP | 1 |
| Pendyala, LK | 1 |
| Kitabata, H | 1 |
| Reyes, E | 1 |
| Cucherat, M | 1 |
| Jacq, L | 1 |
| Bernasconi, F | 1 |
| Jeske, W | 1 |
| Thethi, I | 1 |
| Wordsworth, DR | 1 |
| Halsey, T | 1 |
| Griffiths, R | 1 |
| Parker, MJ | 1 |
| Lynch, DR | 1 |
| Dantzler, DM | 1 |
| Sumaya, W | 1 |
| Daly, RL | 1 |
| Mehra, S | 1 |
| Dhutia, AJ | 1 |
| Howgego, KE | 1 |
| Tomiya, A | 1 |
| Davies, A | 1 |
| Barrett, A | 1 |
| Graham-Clarke, P | 1 |
| Sculpher, M | 1 |
| Cervinski, MA | 1 |
| Schwab, MC | 1 |
| Lefferts, JA | 1 |
| Lewis, LD | 1 |
| Lebel, KA | 1 |
| Tyropolis, AM | 1 |
| Pflueger, SM | 1 |
| Tsongalis, GJ | 1 |
| Lü, SZ | 1 |
| Jin, ZN | 1 |
| Song, XT | 1 |
| Feng, GX | 1 |
| Liang, Y | 1 |
| Bai, Y | 1 |
| Chen, T | 1 |
| Wang, XY | 1 |
| Brüggenjürgen, B | 1 |
| Lindgren, P | 1 |
| Ehlken, B | 1 |
| Willich, SN | 1 |
| Kwok, OH | 1 |
| Javier, S | 1 |
| Mak, KH | 1 |
| Piyamitr, S | 1 |
| Tri Ho, HQ | 1 |
| Suryawan, R | 1 |
| Chow, WH | 1 |
| Niruntraporn, S | 1 |
| Chaiyakunapruk, N | 1 |
| Nathisuwan, S | 1 |
| Thamlikitkul, V | 1 |
| Kapp, M | 1 |
| Göhring-Frischholz, K | 1 |
| Daub, K | 1 |
| Dösch, C | 1 |
| Langer, H | 1 |
| Herdeg, C | 2 |
| Hiscock, M | 1 |
| Beer, JC | 1 |
| Nguyen, C | 1 |
| Schaad, F | 1 |
| Obbee, P | 1 |
| Lagrost, AC | 1 |
| Wang, C | 1 |
| He, J | 1 |
| Griffin, B | 1 |
| Ferguson, JJ | 2 |
| Tom, CW | 1 |
| Brulotte, S | 1 |
| Sénéchal, M | 1 |
| Poirier, P | 1 |
| Nguyen, CM | 1 |
| Lemieux, A | 1 |
| Magne, J | 1 |
| Bergeron, S | 1 |
| Riddell, JW | 1 |
| Chiche, L | 1 |
| Plaud, B | 1 |
| Hamon, M | 1 |
| Carvajal, J | 1 |
| Juhan-Vague, I | 3 |
| Bruskina, O | 3 |
| Grass, D | 1 |
| Drosch, T | 1 |
| Dietz, K | 1 |
| Motivala, AA | 1 |
| Tamhane, U | 1 |
| Saab, F | 1 |
| Rogers, EK | 1 |
| Froehlich, J | 1 |
| Moscucci, M | 1 |
| Gurm, HS | 1 |
| Denardo, SJ | 1 |
| Davis, KE | 1 |
| van der Stelt, CA | 1 |
| Seesing, TH | 1 |
| Berg, JM | 1 |
| Hackeng, CM | 1 |
| Ferrario, C | 1 |
| Renders, F | 1 |
| Cairoli, A | 1 |
| Vuffray, A | 1 |
| Spertini, O | 1 |
| Angelillo-Scherrer, A | 1 |
| Mann, KG | 1 |
| Peters, G | 2 |
| Wilcox, RG | 1 |
| Wickens, M | 1 |
| Grande, P | 1 |
| Riesmeyer, J | 1 |
| Kolm, P | 1 |
| Yuan, Y | 1 |
| Veledar, E | 1 |
| O'Brien, JA | 1 |
| Weintraub, WS | 2 |
| Recio-Mayoral, A | 1 |
| Kaski, JC | 1 |
| McMurray, JJ | 1 |
| Horowitz, J | 1 |
| van Veldhuisen, DJ | 1 |
| Remme, WJ | 1 |
| Sestini, I | 1 |
| ten Berg, J | 2 |
| Dirschinger, J | 3 |
| Gobbi, G | 1 |
| Ippolito, L | 1 |
| Bolognesi, MG | 1 |
| Ruenes, R | 1 |
| Vitale, M | 1 |
| Li, CY | 1 |
| Schreiner, GC | 1 |
| Walker, CW | 1 |
| Dawley, CA | 1 |
| Fletcher, SF | 1 |
| Ortigosa, J | 1 |
| Shenkman, B | 1 |
| Einav, Y | 1 |
| Lubetsky, A | 1 |
| Pache, J | 2 |
| Simmons, BB | 1 |
| Salzman, BE | 1 |
| Wong, SY | 1 |
| Chang, CM | 1 |
| White, H | 2 |
| Aylward, PG | 1 |
| Decalf, V | 1 |
| Sabbah, L | 1 |
| Lafont, A | 1 |
| Kwa, AT | 1 |
| Rogers, JH | 1 |
| Larsen, GC | 1 |
| Jesse, RA | 1 |
| Bramkamp, M | 1 |
| Szucs, TD | 1 |
| Bernhard, N | 1 |
| Desprez, D | 1 |
| Grunebaum, L | 1 |
| Freyssinet, JM | 1 |
| Toti, F | 1 |
| Reaume, KT | 1 |
| Regal, RE | 1 |
| Thomas, J | 1 |
| Brady, WJ | 1 |
| Lefebvre, CW | 1 |
| Bonaca, M | 1 |
| von Lewinski, F | 1 |
| Riggert, J | 1 |
| Paulus, W | 1 |
| Song, SW | 1 |
| Youn, YN | 1 |
| Yi, G | 1 |
| Yoo, KJ | 1 |
| Ormiston, J | 1 |
| Olsen, S | 1 |
| Horvath, I | 1 |
| Herrman, JP | 1 |
| Hankey, GJ | 1 |
| Langton, PE | 1 |
| Faille, D | 1 |
| Nielsen, AA | 1 |
| Veien, KT | 1 |
| Jørgensen, LG | 1 |
| Buck, TC | 1 |
| Brandslund, I | 1 |
| Christensen, C | 1 |
| Schweiger, MJ | 1 |
| Giugliano, GR | 1 |
| Angiolillo, D | 1 |
| Bates, E | 1 |
| Bhatt, D | 1 |
| Furman, MI | 1 |
| Peterson, E | 1 |
| Cairns, JA | 1 |
| Voitk, J | 1 |
| Hasin, Y | 1 |
| Chandna, H | 1 |
| Alvarez, W | 1 |
| Riley, AB | 1 |
| Tafreshi, MJ | 1 |
| Haber, SL | 1 |
| Goyal, SK | 1 |
| Punnam, SR | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| [NCT02513810] | 3,020 participants (Anticipated) | Interventional | 2015-12-02 | Active, not recruiting | |||
| [NCT02494895] | Phase 4 | 3,056 participants (Anticipated) | Interventional | 2015-08-01 | Recruiting | ||
| Comparison of 1-month Versus 12-month Dual Antiplatelet Therapy After Implantation of Drug-Eluting Stents Guided by Either Intravascular Ultrasound or Angiography in Patients With Acute Coronary Syndrome: The Prospective, Multicenter, Randomized, Placebo-[NCT03971500] | 3,710 participants (Actual) | Interventional | 2019-08-20 | Active, not recruiting | |||
| Phase IV, Non-comparative, Open Label, Multicenter, 28-Week Switching Study of Prasugrel Maintenance Dose From Clopidogrel in Patients With Acute Coronary Syndrome (ACS) Who Underwent a Percutaneous Coronary Intervention (PCI) in Taiwan[NCT03672097] | Phase 4 | 204 participants (Actual) | Interventional | 2018-10-16 | Completed | ||
| A Randomised, Double-blind, Parallel Group, Phase 3, Efficacy and Safety Study of Ticagrelor Compared With Clopidogrel for Prevention of Vascular Events in Patients With Non-ST or ST Elevation Acute Coronary Syndromes (ACS) [PLATO- a Study of PLATelet Inh[NCT00391872] | Phase 3 | 18,624 participants (Actual) | Interventional | 2006-10-31 | Completed | ||
| A Randomized, Double-Blind, Double-Dummy, Active-controlled, Parallel-group, Multicenter Study to Compare the Safety of Rivaroxaban Versus Acetylsalicylic Acid in Addition to Either Clopidogrel or Ticagrelor Therapy in Subjects With Acute Coronary Syndrom[NCT02293395] | Phase 2 | 3,037 participants (Actual) | Interventional | 2015-04-20 | Completed | ||
| A Randomized, Open-label Study to Compare the Platelet Inhibition With VerifyNow Assay of Ticagrelor Versus Clopidogrel in Troponin Negative Acute Coronary Syndrome Subjects Undergoing Ad Hoc Percutaneous Coronary Intervention[NCT01603082] | Phase 4 | 343 participants (Actual) | Interventional | 2012-07-31 | Completed | ||
| A Comparison of Prasugrel and Clopidogrel in Acute Coronary Syndrome Subjects With Unstable Angina/Non-ST-Elevation Myocardial Infarction Who Are Medically Managed[NCT00699998] | Phase 3 | 9,326 participants (Actual) | Interventional | 2008-06-30 | Completed | ||
| [NCT02733640] | 42 participants (Actual) | Interventional | 2012-10-31 | Completed | |||
| VerifyNow to Optimise Platelet Inhibition in Coronary Acute Syndrome (VERONICA Trial)[NCT04654052] | Phase 4 | 634 participants (Anticipated) | Interventional | 2021-07-02 | Recruiting | ||
| Nobori Dual Antiplatelet Therapy as Appropriate Duration.[NCT01514227] | Phase 4 | 3,773 participants (Actual) | Interventional | 2011-12-31 | Completed | ||
| Intensified Antiplatelet Therapy in Post-PCI Patients With High On-treatment Platelet Reactivity: the OPTIMA-2 Trial[NCT01955200] | Phase 4 | 1,724 participants (Actual) | Interventional | 2013-10-05 | Completed | ||
| Platelet Function Guided Prasugrel Therapy in ACS Patients Undergoing PCI[NCT01959451] | Phase 4 | 2,600 participants (Actual) | Interventional | 2013-09-30 | Completed | ||
| Randomized, Multinational, Double-blind Study, Comparing a High Loading Dose Regimen of Clopidogrel Versus Standard Dose in Patients With Unstable Angina or Myocardial Infarction Managed With an Early Invasive Strategy.[NCT00335452] | Phase 3 | 25,086 participants (Actual) | Interventional | 2006-06-30 | Completed | ||
| Clopidogrel or Ticagrelor in Acute Coronary Syndrome Patients Treated With Newer-Generation Drug-Eluting Stents: CHANGE DAPT[NCT03197298] | 2,062 participants (Actual) | Observational [Patient Registry] | 2012-12-21 | Completed | |||
| EmploYEd Antithrombotic Therapies in Patients With Acute Coronary Syndromes HOspitalized in iTalian CCUs Registry[NCT02015624] | 2,597 participants (Actual) | Observational | 2013-12-31 | Completed | |||
| Smart Angioplasty Research Team: Safety of 6-month Duration of Dual Antiplatelet Therapy After Percutaneous Coronary Intervention in Patients With Acute Coronary Syndromes (SMART-DATE)[NCT01701453] | 2,712 participants (Actual) | Interventional | 2012-08-31 | Active, not recruiting | |||
| Efficacy and Safety of Sequential Monotherapy of Ticagrelor and Clopidogrel in Patients Undergoing Percutaneous Coronary Intervention With Acute Coronary Syndrome[NCT04937699] | Phase 4 | 2,690 participants (Anticipated) | Interventional | 2023-03-28 | Recruiting | ||
| REACTIC-TAVI Trial: Platelet REACtivity According to TICagrelor Dose After Transcatheter AorticValve Implantation. A Pilot Study.[NCT04331145] | Phase 4 | 40 participants (Actual) | Interventional | 2020-06-23 | Completed | ||
| Τicagrelor Versus Prasugrel in Diabetic Patients: a Pharmacodynamic Study[NCT01642940] | Phase 4 | 30 participants (Actual) | Interventional | 2012-06-30 | Completed | ||
| Cangrelor vs. Ticagrelor for Early Platelet Inhibition in ST-elevation Myocardial Infarction[NCT03182855] | Phase 4 | 80 participants (Anticipated) | Interventional | 2018-09-01 | Not yet recruiting | ||
| Hunting for the Off-Target Properties of Ticagrelor on Endothelial Function and Other Circulating Biomarkers in Humans[NCT02587260] | Phase 4 | 54 participants (Actual) | Interventional | 2015-12-17 | Completed | ||
| Clopidogrel Pharmacogenetic Score System Established for Chinese Patients[NCT01990989] | 500 participants (Anticipated) | Observational | 2014-01-31 | Not yet recruiting | |||
| The Use of BRILInta to Optimize ANTiplatelet Therapy (BRILIANT) Registry: The BRILIANT KOREA Registry[NCT02521038] | 2,000 participants (Anticipated) | Observational [Patient Registry] | 2015-07-31 | Recruiting | |||
| P2Y12 Inhibitors Utilization in Bifurcation and Chronic Total Occlusion PCI With Biologically Active Stents (P2BiTO) Registry[NCT01967615] | 4,500 participants (Actual) | Observational | 2015-01-31 | Completed | |||
| Assessment of Platelet REACtivity After Transcatheter Aortic Valve Implantation[NCT02224066] | Phase 4 | 65 participants (Actual) | Interventional | 2016-01-31 | Completed | ||
| The GReek AntiPlatElet (GRAPE) Registry: A Multicenter Observational Prospective Investigation of Antiplatelet Treatment in Patients With Acute Coronary Syndrome Subjected to Percutaneous Coronary Intervention[NCT01774955] | 2,047 participants (Actual) | Observational [Patient Registry] | 2012-02-29 | Completed | |||
| A Randomized, Open-label, Active-controlled, Parallel-group Study to Investigate the Platelet Inhibition of Ticagrelor Versus Clopidogrel in Patients With Stable Coronary Artery Disease and Type 2 Diabetes Mellitus After Recent Elective Percutaneous Coron[NCT02748330] | Phase 4 | 40 participants (Actual) | Interventional | 2016-06-30 | Completed | ||
| TRansferring From ClopIdogrel Loading Dose to Prasugrel Loading Dose in Acute Coronary Syndrome PatiEnTs: TRIPLET[NCT01115738] | Phase 2 | 282 participants (Actual) | Interventional | 2010-05-31 | Completed | ||
| A Single-center, Randomized, Open-label, Controlled, Dose-escalating, Parallel-group Study to Assess the Anti-platelet Effect of Berberine in Patients Receiving Aspirin and Clopidogrel After Percutaneous Coronary Intervention[NCT03378934] | Phase 4 | 64 participants (Anticipated) | Interventional | 2018-09-26 | Recruiting | ||
| A Retrospective Epidemiological Study to Investigate Outcome and Mortality With Longterm Antithrombotic Therapy in Acute Coronary Syndrome Patients[NCT01623700] | 78,000 participants (Actual) | Observational | 2006-01-31 | Active, not recruiting | |||
| A Comparison of CS-747 and Clopidogrel in Acute Coronary Syndrome Subjects Who Are to Undergo Percutaneous Coronary Intervention[NCT00097591] | Phase 3 | 13,619 participants (Actual) | Interventional | 2004-11-30 | Completed | ||
| Ticagrelor With Aspirin or Alone in High-Risk Patients After Coronary Intervention[NCT02270242] | Phase 4 | 9,006 participants (Actual) | Interventional | 2015-07-31 | Completed | ||
| Optimized Duration of Clopidogrel Therapy Following Treatment With the Endeavor Zotarolimus - Eluting Stent in the Real World Clinical Practice - Optimize Trial[NCT01113372] | Phase 4 | 3,119 participants (Actual) | Interventional | 2010-04-30 | Completed | ||
| WilL LOWer Dose Aspirin be More Effective Following ACS? (WILLOW-ACS)[NCT02741817] | Phase 4 | 20 participants (Actual) | Interventional | 2016-06-26 | Completed | ||
| A Randomized, Single Center Trial to Assess the Endothelial Function With Ticagrelor Monotherapy Compared to Aspirin Monotherapy in Patients With History of Acute Coronary Syndrome[NCT03881943] | Phase 4 | 200 participants (Actual) | Interventional | 2017-01-31 | Completed | ||
| Platelet Aggregation During Pharmacological Shift From Clopidogrel to Ticagrelor in Patients With Acute Coronary Syndrome[NCT01795820] | 50 participants (Actual) | Interventional | 2012-11-30 | Completed | |||
| Targeting Platelets in Chronic HIV Infection[NCT02578706] | Phase 2 | 27 participants (Actual) | Interventional | 2015-10-31 | Completed | ||
| Prospective, Randomized, Double-Blind Trial of Abrupt and Tapered Interruption of Long-term Clopidogrel Therapy After Implantation of a Drug-Eluting Stent[NCT00640679] | Phase 4 | 782 participants (Actual) | Interventional | 2008-04-30 | Terminated (stopped due to Due to slow enrollment the study was stopped prematurely.) | ||
| The Laboratory AntiPlatelet Efficacy and Clinical Outcome Registry[NCT02264912] | 2,016 participants (Actual) | Observational [Patient Registry] | 2008-07-31 | Completed | |||
| Definite Stent Thrombosis in Comatose Out of Hospital Cardiac Arrest Survivors Treated With Percutaneous Coronary Intervention and Hypothermia[NCT03312296] | 151 participants (Actual) | Observational | 2016-08-01 | Completed | |||
| Comparison of Antiplatelet Therapy With Clopidogrel and Ticagrelor in Patients After Cardiac Arrest Treated With Therapeutic Hypothermia[NCT02224274] | Phase 4 | 57 participants (Actual) | Interventional | 2014-08-31 | Completed | ||
| Effects of Clopidogrel vs Prasugel vs Ticagrelor on Endothelial Function, Inflammatory and Oxidative Stress Parameters and Platelet Function in Patients Undergoing Coronary Artery Stenting. A Randomised, Prospective Study.[NCT01700322] | Phase 4 | 126 participants (Actual) | Interventional | 2012-08-31 | Completed | ||
| Comparison of Clopidogrel and Ticagrelor on Microvascular Dysfunction in Acute Coronary Syndrome Patients: The Index of MIcrocirculatory Resistance After PCI in STEMI Patients (TIME Study)[NCT02026219] | Phase 4 | 76 participants (Actual) | Interventional | 2013-10-31 | Completed | ||
| SWITCH 600/60: The Effect of Reloading Prasugrel in a Patient Who Has Already Received a Loading Dose (LD) of Clopidogrel[NCT01365221] | Phase 4 | 77 participants (Actual) | Interventional | 2010-10-31 | Completed | ||
| Point-of-Care Measurements of Platelet Inhibition After Clopidogrel Loading in Patients With Acute Coronary Syndrome: Comparison of Generic Clopidogrel Bisulfate (Plavitor®) With Original Clopidogrel Bisulfate (Plavix®)[NCT02060786] | Phase 4 | 90 participants (Actual) | Interventional | 2010-10-31 | Completed | ||
| Individualizing Dual Antiplatelet Therapy After Percutaneous Coronary Intervention - The IDEAL-PCI Registry[NCT01515345] | Phase 3 | 1,008 participants (Actual) | Interventional | 2011-07-31 | Completed | ||
| Protective Effect of Rosuvastatin and Antiplatelet Therapy On Contrast-induced Nephropathy and Myocardial Damage in Patients With Acute Coronary Syndrome Undergoing Coronary Intervention; PRATO-ACS Trial[NCT01185938] | Phase 4 | 500 participants (Actual) | Interventional | 2010-07-31 | Completed | ||
| PROlonging Dual Antiplatelet Treatment In Patients With Coronary Artery Disease After Graded Stent-induced Intimal Hyperplasia studY[NCT00611286] | Phase 4 | 1,700 participants (Anticipated) | Interventional | 2006-12-31 | Completed | ||
| Evaluating the Benefit of Additional Platelet Inhibition in Acute Coronary Syndrome Patients With High Platelet Reactivity Undergoing PCI[NCT01339026] | Phase 4 | 44 participants (Actual) | Interventional | 2012-02-29 | Terminated (stopped due to Change in guidelines favouring newer antiplatelet drugs in ACS) | ||
| Optimal Duration of Dual Antiplatelet Therapy After Drug Eluting Stent (DES) Implantation[NCT00822536] | Phase 4 | 1,798 participants (Actual) | Interventional | 2009-01-31 | Completed | ||
| An Open-label, Randomized, Prospective Study Exploring Half Dose of Prasugrel and Ticagrelor in Platelet Response After Acute Coronary Syndromes[NCT02944123] | Phase 3 | 120 participants (Actual) | Interventional | 2016-09-30 | Completed | ||
| A Prospective, Randomized, Open-Label, Multicenter Study Assessing Efficacy and Safety of Ticagrelor De-escalation Strategy in East Asian Acute Myocardial Infarction With Coronary Intervention: EASTYLE Trial[NCT04755387] | Phase 4 | 2,000 participants (Anticipated) | Interventional | 2021-02-15 | Recruiting | ||
| Assessment of Dual AntiPlatelet Therapy With Drug Eluting Stents[NCT00638794] | 8,575 participants (Actual) | Observational | 2008-01-31 | Completed | |||
| Ticagrelor or Prasugrel Versus Clopidogrel in Elderly Patients With an Acute Coronary Syndrome and a High Bleeding Risk: Optimization of Antiplatelet Treatment in High-risk Elderly[NCT02317198] | Phase 4 | 1,011 participants (Actual) | Interventional | 2013-06-30 | Active, not recruiting | ||
| A Randomized Study With Loading Dose of Prasugrel Opposed to the Standard Dose of Clopidogrel in Type 2 Diabetic Patients in Acute Coronary Syndrome, Revascularized Through Drug-eluting Stent.[NCT01684813] | Phase 4 | 65 participants (Anticipated) | Interventional | 2012-10-31 | Completed | ||
| Patterns of Non-Adherence to Dual Anti-Platelet Regimen In Stented Patients: An Observational Single-Arm Study (The PARIS Registry)[NCT00998127] | 5,031 participants (Actual) | Observational | 2009-06-30 | Completed | |||
| Platelet Inhibition With Cangrelor in Comatose Survivors of Out-of-hospital Cardiac Arrest Undergoing Primary Percutaneous Coronary Intervention[NCT04005729] | Phase 4 | 30 participants (Actual) | Interventional | 2019-07-01 | Completed | ||
| A Clinical Trial Comparing Cangrelor to Clopidogrel Standard of Care Therapy in Subjects Who Require Percutaneous Coronary Intervention (CHAMPION PHOENIX)[NCT01156571] | Phase 3 | 11,145 participants (Actual) | Interventional | 2010-09-30 | Completed | ||
| Transition From Ticagrelor to Clopidogrel Following Acute Coronary Syndrome: To Bolus or Not? The CAPITAL OPTI-CROSS Study.[NCT02054663] | Phase 4 | 60 participants (Actual) | Interventional | 2013-12-31 | Completed | ||
| The TRANSLATE-ACS Study: Treatment With ADP Receptor Inhibitors: Longitudinal Assessment of Treatment Patterns and Events After Acute Coronary Syndrome[NCT01088503] | 12,227 participants (Actual) | Observational | 2010-03-31 | Completed | |||
| Phase IV: A Comparison of Reduced-dose Prasugrel and Clopidogrel in Elderly Patients With Acute Coronary Syndrome Undergoing Early Percutaneous Coronary Intervention (PCI)[NCT01777503] | Phase 4 | 2,000 participants (Anticipated) | Interventional | 2012-11-30 | Recruiting | ||
| Future Revascularization Evaluation in Patients With Diabetes Mellitus: Optimal Management of Multivessel Disease (FREEDOM)[NCT00086450] | Phase 3 | 1,900 participants (Actual) | Interventional | 2004-04-30 | Active, not recruiting | ||
| Follow up of Ticagrelor Treatment Patterns in Chinese Acute Coronary Syndromes Patients- A Database Retrospective Study[NCT04861363] | 20,000 participants (Anticipated) | Observational | 2019-06-19 | Enrolling by invitation | |||
| Genotype Guided Versus Conventional Approach in Selection of Oral P2Y12 Receptor Blocker in Chinese Patients Suffering From Acute Coronary Syndrome[NCT01994941] | Phase 4 | 133 participants (Actual) | Interventional | 2013-08-31 | Completed | ||
| A Prospective, Multi-center, Randomized, Double-blind Trial to Assess the Effectiveness and Safety of 12 Versus 30 Months of Dual Antiplatelet Therapy in Subjects Undergoing Percutaneous Coronary Intervention With Either Drug-eluting Stent or Bare Metal S[NCT00977938] | Phase 4 | 25,682 participants (Actual) | Interventional | 2009-10-31 | Completed | ||
| [NCT01959191] | 859 participants (Actual) | Observational | 2008-01-31 | Completed | |||
| Effect of Tailored Use of Tirofiban in Patients With Non-ST-elevation Acute Coronary Syndrome Undergoing Percutaneous Coronary Intervention[NCT03114995] | Phase 4 | 140 participants (Actual) | Interventional | 2012-02-01 | Completed | ||
| Study of Optimal Clopidogrel Duration in Patients Receiving Drug Eluting Stents (SCORE Trial)[NCT00781573] | 167 participants (Actual) | Interventional | 2008-09-11 | Completed | |||
| Comparison of Platelet Inhibitory Effect With Adjunctive Cilostazol Versus High Maintenance-dose ClopidogrEL in Acute Myocardial Infarction Patients According to CYP2C19 Polymorphism[NCT00915733] | Phase 4 | 80 participants (Actual) | Interventional | 2009-05-31 | Completed | ||
| ReAssessment of Anti-Platelet Therapy Using an InDividualized Strategy in Patients With ST-segment Elevation Myocardial Infarction[NCT01452139] | Phase 2/Phase 3 | 102 participants (Actual) | Interventional | 2011-09-30 | Completed | ||
| A Multicenter Prospective observationaL Study to evAluate the effecT of Clopidogrel on the prEvention of Major vascuLar Events According to the gEnotype of Cytochrome P450 2C19 in Ischemic Stroke paTients; PLATELET Study[NCT04072705] | 2,927 participants (Actual) | Observational | 2019-09-20 | Completed | |||
| Genotype Guided Comparison of Clopidogrel and Prasugrel Outcomes Study[NCT00995514] | 4,471 participants (Actual) | Observational | 2009-10-31 | Terminated (stopped due to Administrative reasons) | |||
| Pharmacogenetics of Clopidogrel in Acute Coronary Syndromes[NCT03347435] | 889 participants (Actual) | Interventional | 2013-06-30 | Terminated (stopped due to Ethics Committe decision) | |||
| The Effect of Inducing the Cytochrome P450 System on the Pharmacodynamic Efficacy of Clopidogrel[NCT01330589] | 0 participants (Actual) | Interventional | 2011-04-30 | Withdrawn (stopped due to Inability to enroll subjects and changes in standard of care for PCI) | |||
| ReAssessment of Anti-Platelet Therapy Using an InDividualized Strategy Based on GENetic Evaluation (The RAPID GENE Study)[NCT01184300] | Phase 2/Phase 3 | 200 participants (Actual) | Interventional | 2010-08-31 | Completed | ||
| Cost-effectiveness of CYP2C19 Genotype Guided Treatment With Antiplatelet Drugs in Patients With ST-segment-elevation Myocardial Infarction Undergoing Immediate PCI With Stent Implantation: Optimization of Treatment (POPular Genetics).[NCT01761786] | Phase 4 | 2,700 participants (Actual) | Interventional | 2011-06-30 | Completed | ||
| Efficacy of H2 Receptor Antagonist in Prevention of Thienopyridine-related Peptic Ulcer[NCT02418312] | 228 participants (Actual) | Interventional | 2012-01-31 | Completed | |||
| Pantoprazole Versus Famotidine for the Prevention of Recurrent Peptic Ulcers in Thienopyridine Users - a Double-blind Randomized Controlled Trial[NCT02551744] | 101 participants (Actual) | Interventional | 2012-07-31 | Completed | |||
| The Role of Multiple Electrode Aggregometry in Detection of Clopidogrel Resistance in Diabetic Patients With Coronary Artery Disease and Prediction of Clinical Outcomes. A Comparative-method, Non Interventional, Single Center Study.[NCT01991093] | 280 participants (Actual) | Observational | 2014-06-30 | Completed | |||
| A Multicenter, Randomized, Controlled, Double-Blind Trial to Investigate the Clinical Efficacy and Tolerability of Early Treatment With Simvastatin 40 mg Daily for 30 Days, Followed by Simvastatin 80 mg Daily Thereafter in Tirofiban-Treated Acute Coronary[NCT00251576] | Phase 3 | 4,497 participants (Actual) | Interventional | 1999-11-01 | Completed | ||
| The ACUITY Trial: A Randomized Comparison of Angiomax (Bivalirudin) Versus Heparin (Unfractionated Heparin or Enoxaparin) in Patients Undergoing Early Invasive Management for Acute Coronary Syndromes Without ST-Segment Elevation[NCT00093158] | Phase 3 | 13,800 participants | Interventional | 2003-08-31 | Completed | ||
| A Phase 2, Placebo-Controlled, Randomized, Double Blind, Parallel Arm, Dose Ranging Study to Evaluate Safety and Efficacy of Apixaban in Patients With a Recent Acute Coronary Syndrome.[NCT00313300] | Phase 2 | 1,741 participants (Actual) | Interventional | 2006-05-31 | Completed | ||
| Prospective Multi-center Registry of Genotyping Related Clopidogrel in Percutaneous Coronary Intervention Patients[NCT02707445] | 5,000 participants (Actual) | Interventional | 2011-09-30 | Completed | |||
| The Effect of Ticagrelor on Acute Coronary Syndrome Patients With Clopidogrel Resistance Undergoing Percutaneous Coronary Intervention[NCT01812330] | Phase 3 | 180 participants (Anticipated) | Interventional | 2013-01-31 | Recruiting | ||
| Dual Antiplatelet Therapy to Inhibit Coronary Atherosclerosis and Myocardial Injury in Patients With Necrotic High-Risk Coronary Plaque Disease[NCT02110303] | Phase 2/Phase 3 | 220 participants (Actual) | Interventional | 2015-03-31 | Completed | ||
| Effects of Prolonged Dual Antiplatelet Therapy With Clopidogrel Plus Acetylsalicylic Acid (ASA) After Percutaneous Lower Extremity Revascularization in Patients With Peripheral Arterial Disease[NCT02798913] | Phase 3 | 300 participants (Anticipated) | Interventional | 2016-01-31 | Recruiting | ||
| MULTIcentric Study About RESistance to CLOpidogrel in Dual Antiplatelet Therapy for Carotid Stenting[NCT05566301] | 1,140 participants (Anticipated) | Observational | 2021-09-02 | Recruiting | |||
| Ticagrelor Compared to Clopidogrel in Acute Coronary Syndromes - the TC4 Comparative Effectiveness Study[NCT04057300] | Phase 4 | 1,038 participants (Actual) | Interventional | 2018-10-01 | Completed | ||
| Prospective, Randomized Study of the Platelet Inhibitory Efficacy of Ticagrelor Versus Prasugrel in Clopidogrel Low Responders After Percutaneous Coronary Intervention[NCT01456364] | Phase 4 | 70 participants (Anticipated) | Interventional | 2011-09-30 | Recruiting | ||
| CARDIOBASE Bern PCI Registry[NCT02241291] | 10,000 participants (Anticipated) | Observational | 2009-03-31 | Recruiting | |||
| A Non-interventional Study to Estimate the Rates of Outcomes in ACS Patients in Moscow[NCT03654157] | 1,576 participants (Actual) | Observational | 2018-03-25 | Completed | |||
| Efficacy and Safety of Tirofiban in Patients With Acute Branch Atheromatous Disease (BAD)- Related Stroke (BRANT)[NCT06037889] | Phase 3 | 516 participants (Anticipated) | Interventional | 2023-11-09 | Recruiting | ||
| Evaluation of a Strategy Guided by Imaging Versus Systematic Coronary Angiography in Elderly Patients With Ischemia: a Multicentric Randomized Non Inferiority Trial.[NCT03289728] | 1,756 participants (Anticipated) | Interventional | 2018-04-04 | Recruiting | |||
| Aspirin Impact on Platelet Reactivity in Acute Coronary Syndrome Patients on Novel P2Y12 Inhibitors Therapy[NCT02049762] | Phase 4 | 29 participants (Actual) | Interventional | 2015-06-30 | Completed | ||
| Antiplatelet Therapy in Elderly Patients Undergoing Percutaneous Coronary Intervention[NCT04999293] | 1,505 participants (Actual) | Observational | 2021-07-20 | Completed | |||
| A Multi-Centre, Prospective Cohort, Non-Interventional Study About Evaluation on the Safety of Ticagrelor Among Chinese ACS Patients[NCT02430493] | 1,066 participants (Actual) | Observational [Patient Registry] | 2015-05-28 | Completed | |||
| PercutaNEOus Coronary Intervention Followed by Monotherapy INstead of Dual Antiplatelet Therapy in the SETting of Acute Coronary Syndromes: The NEO-MINDSET Trial A Drug Reduction Study for Patients With Acute Coronary Syndrome in the Unified Health System[NCT04360720] | Phase 3 | 3,400 participants (Anticipated) | Interventional | 2020-10-15 | Recruiting | ||
| Evaluation of Platelet Aggregation and Adenosine Levels in Patients With Coronary Artery Disease and Chronic Kidney Dysfunction Taking Dual Antiplatelet Therapy With Aspirin and Clopidogrel or Ticagrelor[NCT03039205] | Phase 2 | 90 participants (Actual) | Interventional | 2017-11-07 | Completed | ||
| An Open Label, Randomized Study to Determine the Rate of Cardiovascular Events at 1 yr for Patients With Elevated Troponins Post Major Non-cardiac Surgery and the Impact of Ticagrelor vs Aspirin on the Occurrence of Cardiovascular Events[NCT02291419] | Phase 4 | 6 participants (Actual) | Interventional | 2015-07-31 | Terminated (stopped due to Enrollment expectations were not met) | ||
| "Evaluation of Antiplatelet Effects and Safety of Intraoperative Administration of Ticagrelor Versus Clopidogrel in Patients Undergoing One-stop Hybrid Coronary Revascularization"[NCT02513004] | Phase 4 | 60 participants (Anticipated) | Interventional | 2015-06-30 | Recruiting | ||
| Ticagrelor vs. Tirofiban, Comparison of Anti-platelet Effects in Patients With Non-ST Elevation Acute Coronary Syndrome(TE-CLOT Trial : Ticagrelor's Effect for CLOT Prevention) ; A Single Center, Open-label Randomized Controlled Study[NCT01660373] | Phase 3 | 100 participants (Anticipated) | Interventional | 2012-08-31 | Recruiting | ||
| Role of Innate and Adaptive Immunity After Acute Myocardial Infarction BATTLE-AMI Study (B And T Types of Lymphocytes Evaluation in Acute Myocardial Infarction)[NCT02428374] | Phase 4 | 300 participants (Anticipated) | Interventional | 2015-05-31 | Recruiting | ||
| Phase IV Study of Aspirin and Clopidogrel Therapy Tailored by Functional Thrombocyte Examination (PFA-100, LTA and VerifyNOW) in Acute Myocardial Infarction[NCT01381185] | Phase 4 | 154 participants (Actual) | Interventional | 2011-05-31 | Completed | ||
| Dual Arm Factorial Randomized Trial in Patients w/ST Segment Elevation AMI to Compare the Results of Using Anticoagulation With Either Unfractionated Heparin + Routine GP IIb/IIIa Inhibition or Bivalirudin + Bail-out GP IIb/IIIa Inhibition; and Primary An[NCT00433966] | Phase 3 | 3,602 participants (Actual) | Interventional | 2005-03-31 | Completed | ||
| A Clinical Trial Comparing Cangrelor to Clopidogrel in Subjects Who Require Percutaneous Coronary Intervention (PCI).[NCT00305162] | Phase 3 | 8,882 participants (Actual) | Interventional | 2006-04-30 | Terminated (stopped due to Insufficient evidence of the clinical effectiveness of cangrelor) | ||
| A Prospective, Multicentre, Randomized, Open Label, Blinded Endpoint, Phase 3 Trial to Assess the Safety and Efficacy of Prophylactic TicagrelOr With Acetylsalicylic Acid Versus CLopidogrel With Acetylsalicylic Acid in the Development of Cerebrovascular E[NCT02989558] | Phase 3 | 90 participants (Actual) | Interventional | 2016-12-31 | Completed | ||
| PPD Trial Pilot Study: Plavix, Prasugrel and Drug Eluting Stents[NCT01103843] | 1,000 participants (Anticipated) | Interventional | 2010-04-30 | Recruiting | |||
| Reversal of the Anti-platelet Effects of Ticagrelor in Healthy Persons and Patients With Coronary Artery Disease[NCT02383771] | Phase 4 | 64 participants (Actual) | Interventional | 2015-03-31 | Completed | ||
| Phase II Study of SCH 530348 in Subjects With Acute Coronary Syndrome[NCT00684203] | Phase 2 | 120 participants (Actual) | Interventional | 2006-12-01 | Completed | ||
| Secondary Prevention in Acute Coronary Syndromes: Long-term Survival in Relation to the Number and Combination of Evidence-based Therapies Prescribed Prior to Discharge (a CALIBER Study)[NCT01162187] | 400,000 participants (Anticipated) | Observational | 2003-07-31 | Active, not recruiting | |||
| A Randomized, Multicenter, Double-Blind, Study to Evaluate the Efficacy of Tirofiban HCl Versus Placebo in the Setting of Standard Therapies Among Subjects Undergoing Percutaneous Coronary Intervention[NCT01245725] | Phase 3 | 0 participants (Actual) | Interventional | Withdrawn (stopped due to Study was not initiated, change in clinical development) | |||
| Optimizing Therapy With Aspirin and Clopidogrel. The BOchum CLopidogrel and Aspirin Plan to Improve Dual Antiplatelet Therapy.[NCT01212302] | 500 participants (Actual) | Interventional | 2008-10-31 | Completed | |||
| CAOCT Study is a Prospective, Multi-centre, Single Cohort, Diagnostic Accuracy Study, Planned to Include 131 Patients in About 3 European Countries After Successful Return of Spontaneous Circulation After Out of Hospital Cardiac Arrest[NCT04431661] | 28 participants (Actual) | Observational | 2021-01-29 | Terminated (stopped due to Low patient recruitment rate and change of hopsital procedures for handling cardiac arrest patients during emergency) | |||
| A Randomized Controlled Trial of Influenza Vaccine to Prevent Adverse Vascular Events: A Pilot Study[NCT01945268] | Phase 4 | 107 participants (Actual) | Interventional | 2015-04-30 | Completed | ||
| A Randomized Controlled Trial of Influenza Vaccine to Prevent Adverse Vascular Events[NCT02762851] | Phase 4 | 5,000 participants (Anticipated) | Interventional | 2016-06-30 | Recruiting | ||
| A Pharmacodynamic Comparison of Prasugrel (LY640315) Versus Clopidogrel in Subjects With Acute Coronary Syndrome Who Are Receiving Clopidogrel[NCT00356135] | Phase 2 | 139 participants (Actual) | Interventional | 2006-07-31 | Completed | ||
| Evaluating Pharmacogenomic Variants for Cardiology Therapeutics: the Lighthouse Pilot (Association Between Genetic Variant Scores and P2Y12 Inhibitor Effects)[NCT04702113] | 300 participants (Actual) | Interventional | 2020-12-03 | Completed | |||
| A Parallel Randomized Controlled Evaluation of Clopidogrel Plus Aspirin, With Factorial Evaluation of Irbesartan, for the Prevention of Vascular Events, in Patients With Atrial Fibrillation[NCT00249873] | Phase 3 | 7,554 participants (Actual) | Interventional | 2003-06-30 | Completed | ||
| Chinese People's Liberation Army General Hospital[NCT02798874] | 240 participants (Anticipated) | Interventional | 2016-05-31 | Enrolling by invitation | |||
| Comparison of Ticagrelor and Clopidogrel on Reperfusion in Patients With AMI Undergoing PPCI Evaluated by SPECT[NCT02233790] | Phase 4 | 600 participants (Anticipated) | Interventional | 2014-12-31 | Not yet recruiting | ||
| Double Randomization of a Monitoring Adjusted Antiplatelet Treatment Versus a Common Antiplatelet Treatment for DES Implantation, and a Interruption Versus Continuation of Double Antiplatelet Therapy, One Year After Stenting[NCT00827411] | Phase 4 | 2,500 participants (Actual) | Interventional | 2009-01-31 | Completed | ||
| EValuation of REsidual Platelet REactivity After Acute Coronary Syndrome in HIV-infected Patients. The EVERE2ST-HIV Study.[NCT02380391] | 260 participants (Actual) | Observational | 2013-12-31 | Completed | |||
| Gender Differences in Prevention Strategies and Therapeutic Adherence After Acute Myocardial Infarction - GENAMI PREVENTION[NCT05619601] | 1,000 participants (Anticipated) | Observational [Patient Registry] | 2023-03-08 | Recruiting | |||
| Early Glycoprotein IIb/IIIa Inhibition in Non-ST-segment Elevation Acute Coronary Syndrome: A Randomized, Placebo-Controlled Trial Evaluating the Clinical Benefits of Early Front-loaded Eptifibatide in the Treatment of Patients With Non-ST-segment Elevati[NCT00089895] | Phase 3 | 9,406 participants (Actual) | Interventional | 2004-11-01 | Completed | ||
| CHoosing Triple or Double therApy in the Era of nOac for patientS Undergoing PCI: the CHAOS a Multicenter Study.[NCT03558295] | 1,000 participants (Anticipated) | Observational [Patient Registry] | 2018-05-01 | Recruiting | |||
| GRAVITAS: Gauging Responsiveness With A VerifyNow Assay-Impact On Thrombosis And Safety[NCT00645918] | 2,800 participants (Actual) | Interventional | 2008-06-30 | Completed | |||
| Effect of Modifying Anti-platelet Treatment to Ticagrelor in Patients With Diabetes and Low Response to Clopidogrel[NCT01643031] | Phase 4 | 500 participants (Anticipated) | Interventional | 2012-08-31 | Not yet recruiting | ||
| REsponsiveness to CLOpidogrel and Stent-related Events in Acute Coronary. Reclose 2-ACS Registry[NCT01231035] | 1,789 participants (Actual) | Observational | 2008-09-30 | Completed | |||
| Influence of Esomeprazole on Antiplatelet Action of Clopidogrel Associated With Aspirin[NCT01062516] | Phase 4 | 100 participants (Anticipated) | Interventional | 2010-01-31 | Completed | ||
| Famotidine Compared With Esomeprazole in the Prevention of Ulcer Complications in Patients With Acute Coronary Syndrome or Myocardial Infarction[NCT00683111] | Phase 4 | 500 participants (Anticipated) | Interventional | 2008-07-31 | Completed | ||
| Comparative Study of Clinical Efficacy and Safety of Different Clopidogrel Salts in Patients With Cardiovascular Disease. A Multi-center Non-interventional Clinical Trial.[NCT02126982] | 1,500 participants (Actual) | Observational | 2012-10-31 | Completed | |||
| Study of the Effect of Eicosapentaenoic Acid (EPA) on Markers of Atherothrombosis in Patients With Type-2 Diabetes[NCT06129526] | Phase 4 | 450 participants (Anticipated) | Interventional | 2023-12-31 | Not yet recruiting | ||
| GIFT: Genotype Information and Functional Testing Study[NCT00992420] | 2,000 participants (Anticipated) | Observational | 2009-10-01 | Completed | |||
| Brazilian Intervention to Increase Evidence Usage in Practice - Acute Coronary Syndromes[NCT00958958] | 1,150 participants (Actual) | Interventional | 2010-01-31 | Completed | |||
| Ticagrelor in Comparison to Prasugrel for Inhibition of Platelet Reactivity, in Patients With Acute Coronary Syndrome (ACS) Presenting Resistance to the Usual Clopidogrel Dose After PCI[NCT01360437] | Phase 3 | 44 participants (Actual) | Interventional | 2011-05-31 | Completed | ||
| Laboratory Implications of Non Obstructive Atherosclerotic Plaques Identified by Multiple Detector Coronary Angiotomography[NCT03632785] | 90 participants (Actual) | Observational | 2017-03-27 | Completed | |||
| Routine Or Selective Stress Testing After Revascularization: ROSSTAR Trial RCT Outline[NCT03067402] | 1,100 participants (Anticipated) | Interventional | 2017-03-20 | Not yet recruiting | |||
| Register of Cardiovascular Complications Among People Living With HIV[NCT02453919] | 800 participants (Anticipated) | Observational [Patient Registry] | 2010-02-28 | Recruiting | |||
| Prasugrel 5mg Versus High Dose Clopidogrel in Clopidogrel Resistant Patients Aged ≥75 Years and/or Weighing <60 kg Post Percutaneous Coronary Intervention (PCI)[NCT01463150] | Phase 4 | 27 participants (Actual) | Interventional | 2011-10-31 | Completed | ||
| Maintenance Of aNtiplatElet Therapy in Patients With Coronary Stenting Undergoing Surgery[NCT03445273] | 1,800 participants (Anticipated) | Observational [Patient Registry] | 2018-11-21 | Not yet recruiting | |||
| Platelet Inhibition With Ticagrelor 60 mg Versus Ticagrelor 90 mg Twice Daily in Elderly Patients With Acute Coronary Syndrome (ACS)[NCT04739384] | Phase 3 | 50 participants (Actual) | Interventional | 2021-04-01 | Completed | ||
| The Role of the P2Y12 Receptor in Tissue Factor Induced Coagulation[NCT01099566] | Phase 4 | 20 participants (Actual) | Interventional | 2009-11-30 | Completed | ||
| Correlation Between Bleeding Complication and Treatment Failure on P2Y12 Inhibitors and Its Predictions Based on Cipherome's Pharmacogenomic Technology[NCT04580602] | 200 participants (Actual) | Observational | 2020-10-07 | Completed | |||
| Beijing Tiantan Hospital,Capital Medical University.[NCT02317445] | 472 participants (Actual) | Observational | 2008-01-31 | Completed | |||
| Polypill Strategy for Evidence-Based Management of Patients With Acute Coronary Syndrome Undergoing Percutaneous Coronary Intervention in an Underserved Patient Population[NCT05514938] | Phase 2 | 60 participants (Anticipated) | Interventional | 2022-11-30 | Recruiting | ||
| Clopidogrel and Proton Pump Inhibitors: A Propensity Score Adjusted Cohort Study to Examine a Possible Interaction: A CALIBER Study[NCT01231867] | 24,471 participants (Actual) | Observational | 2010-12-31 | Completed | |||
| Phase 4 Study of Randomized Comparison Among Oral Rapamycin Plus Bare Metal Stents Versus Drug Eluting Stents in de Novo Coronary Lesions.[NCT00552669] | Phase 4 | 200 participants (Actual) | Interventional | 2006-01-31 | Completed | ||
| Platelet-Oriented Inhibition in New TIA and Minor Ischemic Stroke (POINT) Trial[NCT00991029] | Phase 3 | 4,881 participants (Actual) | Interventional | 2010-05-28 | Terminated (stopped due to The trial was halted by the DSMB.) | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
The mean change in the P2Y12 reaction unit value assessed from baseline to the end of the 4-week maintenance dose treatment period, after switching from clopidogrel maintenance dose to prasugrel maintenance dose was analyzed with a paired t-test model. Mean changes (including standard deviations) are presented. (NCT03672097)
Timeframe: Baseline up to Week 4 post-maintenance dose prasugrel treatment period
| Intervention | P2Y12 reaction unit (Mean) |
|---|---|
| Prasugrel | -18.2 |
The mean percentage change in platelet inhibition at the end of the 4-week maintenance dose prasugrel treatment period, after switching from clopidogrel maintenance dose to prasugrel maintenance dose is reported. (NCT03672097)
Timeframe: Baseline up to Week 4 post-maintenance dose prasugrel treatment period
| Intervention | percentage of platelet inhibition (Mean) |
|---|---|
| Prasugrel | 7.2 |
All safety events were assessed in the overall Safety Population, regardless of the study period. The incidence of major bleeding events (defined as non-coronary artery bypass grafting [CABG] thrombolysis in myocardial infarction (TIMI) major) after 28 maintenance dose treatment weeks (optional maximum 12-month P2Y12 inhibitor treatment after ACS participants underwent PCI) are reported. Non-CABG TIMI major bleeding was defined as any intracranial bleeding (excluding microhemorrhages less than 10 millimeter evident only on gradient-echo magnetic resonance imaging); clinically overt signs of hemorrhage associated with a drop in hemoglobin of greater than or equal to 5 g/dL; and fatal bleeding (bleeding that directly results in death within 7 days) (NCT03672097)
Timeframe: End of Week 4 up to Week 28 post-maintenance dose prasugrel treatment period
| Intervention | Participants (Count of Participants) |
|---|---|
| Prasugrel | 4 |
Adverse events of special interest were defined as major and minor bleeding events, clinically relevant bleeding events, and any major adverse cardiovascular events (MACE). Non-CABG TIMI major bleeding was defined as any intracranial bleeding (excluding microhemorrhages less than 10 millimeter evident only on gradient-echo magnetic resonance imaging); clinically overt signs of hemorrhage associated with a drop in hemoglobin of greater than or equal to 5 g/dL; and fatal bleeding (bleeding that directly results in death within 7 days). Non-CABG TIMI minor bleeding was defined as clinically overt (including imaging), resulting in hemoglobin drop of 3 to less than 5 g/dL. (NCT03672097)
Timeframe: Baseline up to Week 4 post-maintenance dose prasugrel treatment period
| Intervention | Participants (Count of Participants) | |||||||
|---|---|---|---|---|---|---|---|---|
| Any major bleeding adverse events (AE) | Any minor bleeding AE | Any clinically relevant bleeding AE | Any MACE, Cardiovascular death | Any MACE, Non-fatal myocardial infarction | Any MACE, Non-fatal stroke | Any MACE, Stent thrombosis | Any MACE, Revascularization | |
| Prasugrel | 0 | 1 | 2 | 0 | 0 | 0 | 0 | 0 |
All safety events were assessed in the overall Safety Population, regardless of the study period. Adverse events of special interest were defined as major and minor bleeding events, clinically relevant bleeding events, and any major adverse cardiovascular events (MACE). Non-CABG TIMI major bleeding was defined as any intracranial bleeding (excluding microhemorrhages less than 10 millimeter evident only on gradient-echo magnetic resonance imaging); clinically overt signs of hemorrhage associated with a drop in hemoglobin of greater than or equal to 5 g/dL; and fatal bleeding (bleeding that directly results in death within 7 days). Non-CABG TIMI minor bleeding was defined as clinically overt (including imaging), resulting in hemoglobin drop of 3 to less than 5 g/dL. (NCT03672097)
Timeframe: End of Week 4 up to Week 28 post-maintenance dose prasugrel treatment period
| Intervention | Participants (Count of Participants) | |||||||
|---|---|---|---|---|---|---|---|---|
| Any major bleeding AE | Any minor bleeding AE | Any clinically relevant bleeding AE | Any MACE, Cardiovascular death | Any MACE, Non-fatal myocardial infarction | Any MACE, Non-fatal stroke | Any MACE, Stent thrombosis | Any MACE, Revascularization | |
| Prasugrel | 4 | 12 | 4 | 0 | 2 | 0 | 0 | 0 |
High On-Treatment Platelet Reactivity (HTPR) was defined as PRU >235. (NCT03672097)
Timeframe: Baseline up to Week 4 post-maintenance dose prasugrel treatment period
| Intervention | Participants (Count of Participants) | |
|---|---|---|
| Baseline | Week 4 | |
| Prasugrel | 23 | 6 |
Participants with death from any cause, MI, or stroke. If no event, censoring occurs at the earliest of patient withdrawal of consent or date of scheduled withdrawal from therapy. ITT analysis of whole population. Events were adjudicated by an endpoint committee. (NCT00391872)
Timeframe: Randomization up to 12 months
| Intervention | Participants (Number) |
|---|---|
| TICAGRELOR | 901 |
| CLOPIDOGREL | 1065 |
Participants with death from vascular causes, MI, stroke, recurrent ischemia, or other thrombotic events. If no event, censoring occurs at the earliest of patient withdrawal consent or date of scheduled withdrawal from therapy. ITT analysis of whole population. Events were adjudicated. (NCT00391872)
Timeframe: Randomization up to 12 months
| Intervention | Participants (Number) |
|---|---|
| TICAGRELOR | 1290 |
| CLOPIDOGREL | 1456 |
Participants with death from vascular causes, MI, or stroke. If no event, censoring occurs at the earliest of patient withdrawal consent or date of scheduled withdrawal from therapy. ITT analysis of intent for invasive management population. Events were adjudicated by an endpoint committee. (NCT00391872)
Timeframe: Randomization up to 12 months
| Intervention | Participants (Number) |
|---|---|
| TICAGRELOR | 569 |
| CLOPIDOGREL | 668 |
Participants with death from vascular causes, MI, or stroke. If no event, censoring occurs at the earliest of patient withdrawal consent or date of scheduled withdrawal from therapy. Intention To Treat (ITT) analysis of whole population. Events were adjudicated by an endpoint committee. (NCT00391872)
Timeframe: Randomization up to 12 months
| Intervention | Participants (Number) |
|---|---|
| TICAGRELOR | 864 |
| CLOPIDOGREL | 1014 |
Participants with major (fatal/life-threatening or other) bleed by a study protocol scale based on need for treatment, number of transfusions, hemoglobin decrease, and other factors. Events were adjudicated by an endpoint committee. (NCT00391872)
Timeframe: First dosing up to 12 months
| Intervention | Participants (Number) |
|---|---|
| TICAGRELOR | 961 |
| CLOPIDOGREL | 929 |
Participants with a major CABG-related bleed by a study protocol scale based on need for treatment, number of transfusions, hemoglobin decrease, and other factors. All CABG surgeries were submitted for adjudication by an endpoint committee as potential bleeds. (NCT00391872)
Timeframe: First dosing up to 12 months
| Intervention | Participants (Number) |
|---|---|
| TICAGRELOR | 619 |
| CLOPIDOGREL | 654 |
Number of participants with a major fatal/life-threatening CABG-related bleed by a study protocol scale based on need for treatment, number of transfusions, hemoglobin decrease, and other factors. All CABG surgeries were submitted for adjudication by an endpoint committee as potential bleeds. (NCT00391872)
Timeframe: First dosing up to 12 months
| Intervention | Participants (Number) |
|---|---|
| TICAGRELOR | 329 |
| CLOPIDOGREL | 341 |
Participants with death from any cause. If no event, censoring occurs at the earliest of patient withdrawal consent or date of scheduled withdrawal from therapy. ITT (intention to treat) analysis of whole population. Events were adjudicated by an endpoint committee. (NCT00391872)
Timeframe: Randomization up to 12 months
| Intervention | Participants (Number) |
|---|---|
| TICAGRELOR | 399 |
| CLOPIDOGREL | 506 |
Participants with death from vascular causes. If no event, censoring occurs at the earliest of patient withdrawal consent or date of scheduled withdrawal from therapy. ITT (intention to treat) analysis of whole population. Events were adjudicated by an endpoint committee. (NCT00391872)
Timeframe: Randomization up to 12 months
| Intervention | Participants (Number) |
|---|---|
| TICAGRELOR | 353 |
| CLOPIDOGREL | 442 |
Participants with major (fatal/life-threatening or other) or minor bleed by a study protocol scale based on need for treatment, number of transfusions, hemoglobin decrease, and other factors. Events were adjudicated by an endpoint committee. (NCT00391872)
Timeframe: First dosing up to 12 months
| Intervention | Participants (Number) |
|---|---|
| TICAGRELOR | 1339 |
| CLOPIDOGREL | 1215 |
Participants with MI event. If no event, censoring occurs at the earliest of patient withdrawal consent or date of scheduled withdrawal from therapy. ITT (intention to treat) analysis of whole population. Events were adjudicated by an endpoint committee. (NCT00391872)
Timeframe: Randomization up to 12 months
| Intervention | Participants (Number) |
|---|---|
| TICAGRELOR | 504 |
| CLOPIDOGREL | 593 |
Participants with non CABG related major (fatal/life-threatening or other) bleed by a study protocol scale based on need for treatment, number of transfusions, hemoglobin decrease, and other factors. Events were adjudicated by an endpoint committee. (NCT00391872)
Timeframe: First dosing up to 12 months
| Intervention | Participants (Number) |
|---|---|
| TICAGRELOR | 362 |
| CLOPIDOGREL | 306 |
Participants with non-procedural major bleed by a study protocol scale based on need for treatment, number of transfusions, hemoglobin decrease, and other factors. Events were adjudicated by an endpoint committee. (NCT00391872)
Timeframe: First dosing up to 12 months
| Intervention | Participants (Number) |
|---|---|
| TICAGRELOR | 235 |
| CLOPIDOGREL | 180 |
Participants with stroke. If no event, censoring occurs at the earliest of patient withdrawal consent or date of scheduled withdrawal from therapy. ITT (intention to treat) analysis of whole population. Events were adjudicated by an endpoint committee. (NCT00391872)
Timeframe: Randomization up to 12 months
| Intervention | Participants (Number) |
|---|---|
| TICAGRELOR | 125 |
| CLOPIDOGREL | 106 |
Number of participants who were observed to have at least 1 ventricular pause of at least 3 seconds. Population is all patients who were observed over 2 week-long periods. Pauses were flagged algorithmically and confirmed by TIMI cardiologists. (NCT00391872)
Timeframe: 1-week period following randomization
| Intervention | Participants (Number) |
|---|---|
| TICAGRELOR | 21 |
| CLOPIDOGREL | 16 |
Number of participants who were observed to have at least 1 ventricular pause of at least 3 seconds. Population is all patients who were observed over 2 week-long periods. Pauses were flagged algorithmically and confirmed by Thrombolysis in Myocardial Infarction (TIMI) group cardiologists. (NCT00391872)
Timeframe: 1-week period following randomization
| Intervention | Participants (Number) |
|---|---|
| TICAGRELOR | 84 |
| CLOPIDOGREL | 51 |
Non CABG-related TIMI clinically significant bleeding events are sum of non CABG-related TIMI major bleeding events, TIMI minor bleeding events and TIMI bleeding events requiring medical attention. Major: any symptomatic intracranial bleeding: clinically overt signs of hemorrhage with hemoglobin (Hb) drop of greater than or equal to (>=)5 gram per deciliter (g/dl) (or absolute drop in hematocrit of >=15%) and fatal bleeding (results in death within 7 days); Minor: clinically overt sign of hemorrhage with Hb drop of 3 - <5 g/dl (or drop in hematocrit of 9 - <15%); requiring medical attention: bleeding event that required medical, surgical treatment/laboratory evaluation and did not meet criteria for major/minor bleeding event. (NCT02293395)
Timeframe: From start of study treatment until follow-up (up to 390 days)
| Intervention | participants (Number) |
|---|---|
| Rivaroxaban 2.5 mg Twice Daily (BID) | 80 |
| Acetylsalicylic Acid 100 mg Once Daily (OD) | 74 |
Participants with low (<150) baseline PRU values were excluded. (NCT01603082)
Timeframe: 2 hours after the loading dose
| Intervention | PRU (Mean) |
|---|---|
| Ticagrelor | 98.4 |
| Clopidogrel | 257.5 |
Participants with low (<150) baseline PRU values were excluded. (NCT01603082)
Timeframe: 0.5 hours, end of PCI, and 8 hours after the loading dose
| Intervention | PRU (Mean) | ||
|---|---|---|---|
| 0.5 hours | 8 hours | End of PCI (n=41 for ticagrelor) | |
| Clopidogrel | 297.7 | 202.3 | 307.8 |
| Ticagrelor | 277.3 | 43.8 | 264.2 |
The percentage of participants is the total number of participants experiencing an all-cause death, nonfatal MI, or nonfatal stroke divided by number of participants in the treatment arm. Endpoint events were adjudicated by the Clinical Endpoint Committee. (NCT00699998)
Timeframe: Randomization through end of study (30-month visit)
| Intervention | percentage of participants with an event (Number) |
|---|---|
| Prasugrel: <75 Years of Age | 10.61 |
| Prasugrel: 75 Years of Age or Older | 27.04 |
| Clopidogrel: <75 Years of Age | 11.12 |
| Clopidogrel: 75 Years of Age or Older | 26.83 |
The percentage of participants is the total number of participants experiencing a CV death, nonfatal MI, or nonfatal stroke divided by number of participants in the treatment arm multiplied by 100. Endpoint events were adjudicated by the Clinical Endpoint Committee. (NCT00699998)
Timeframe: Randomization through end of study (30-month visit)
| Intervention | percentage of participants with an event (Number) |
|---|---|
| Prasugrel: <75 Years of Age | 10.06 |
| Prasugrel: 75 Years of Age or Older | 24.64 |
| Clopidogrel: <75 Years of Age | 10.96 |
| Clopidogrel: 75 Years of Age or Older | 24.13 |
The percentage of participants is the total number of participants experiencing a CV death or nonfatal MI divided by number of participants in the treatment arm. Endpoint events were adjudicated by the Clinical Endpoint Committee. (NCT00699998)
Timeframe: Randomization through end of study (30-month visit)
| Intervention | percentage of participants with an event (Number) |
|---|---|
| Prasugrel: <75 Years of Age | 9.61 |
| Prasugrel: 75 Years of Age or Older | 22.53 |
| Clopidogrel: <75 Years of Age | 10.21 |
| Clopidogrel: 75 Years of Age or Older | 22.69 |
The percentage of participants is the total number of participants experiencing a CV death, nonfatal MI, nonfatal stroke or re-hospitalization for a recurrent UA divided by number of participants in the treatment arm. Endpoints events were adjudicated by the Clinical Endpoint Committee. (NCT00699998)
Timeframe: Randomization through end of study (30-month visit)
| Intervention | percentage of participants with an event (Number) |
|---|---|
| Prasugrel: <75 Years of Age | 12.13 |
| Prasugrel: 75 Years of Age or Older | 26.27 |
| Clopidogrel: <75 Years of Age | 12.83 |
| Clopidogrel: 75 Years of Age or Older | 25.67 |
Brain natriuretic peptide (BNP) is secreted by the ventricles of the heart in response to hemodynamic stress and is a biomarker associated with increased CV risk. Results are presented as geometric least squares means (Geometric LS means). Geometric LS means were adjusted for treatment + baseline value + clopidogrel status at randomization. (NCT00699998)
Timeframe: Day 30 and 6 Months
| Intervention | picograms per milliliter (pg/mL) (Geometric Mean) | |
|---|---|---|
| Day 30 | 6 Months (n=725, 125, 701, 174) | |
| Clopidogrel: <75 Years of Age | 319.345 | 250.982 |
| Clopidogrel: 75 Years of Age or Older | 951.359 | 722.750 |
| Prasugrel: <75 Years of Age | 313.494 | 253.434 |
| Prasugrel: 75 Years of Age or Older | 1082.396 | 770.132 |
C-Reactive Protein (CRP) is a biomarker associated with inflammation and increased CV risk. Results are presented as geometric least squares means (Geometric LS means). Geometric LS means were adjusted for treatment + baseline value + clopidogrel status at randomization. (NCT00699998)
Timeframe: Day 30 and Month 6
| Intervention | milligrams per liter (mg/L) (Geometric Mean) | |
|---|---|---|
| Day 30 | 6 Months (n=755, 143, 745, 178) | |
| Clopidogrel: <75 Years of Age | 2.287 | 2.149 |
| Clopidogrel: 75 Years of Age or Older | 2.226 | 1.543 |
| Prasugrel: <75 Years of Age | 2.330 | 2.272 |
| Prasugrel: 75 Years of Age or Older | 2.441 | 1.593 |
Seattle Angina Questionnaire (SAQ) is a validated, disease-specific questionnaire containing 11 questions (Q) yielding 5 summary scales related to angina: physical limitations, angina stability, angina frequency, treatment satisfaction and disease perception. In this study only angina frequency and the physical limitations scales were assessed. Anginal Frequency was assessed using Q3 and Q4 which consists of a Likert scale ranging from 1 to 6 (higher values equals better quality of life) to assess how often a patient is having symptoms now. Physical limitations was assessed using Q1 which contains 9 items each assessed via Likert scale ranging from 1 to 6 (higher values equals better quality of life) to assess how much a participant's condition is hampering their ability to do what they want to do. Scale scores are transformed to a 0-100 by subtracting the lowest possible score, dividing by the range of the scale, and multiplying by 100. Higher values equal better quality of life. (NCT00699998)
Timeframe: Baseline and follow-up (24 months)
| Intervention | units on a scale (Mean) | |||
|---|---|---|---|---|
| Baseline, physical limitations | Baseline, angina frequency | 24 Months, physical limitations (n=420, 412) | 24 Months, angina frequency (n=420, 412) | |
| Clopidogrel | 67.0 | 73.1 | 74.5 | 89.5 |
| Prasugrel | 67.8 | 73.6 | 75.1 | 89.7 |
Variation in the genes encoding the cytochrome P450 (CYP) enzymes (CYP2C19) can reduce the ability to metabolize clopidogrel and a reduced platelet response and have been associated with increased rates of CV events including CV death. Participants were classified as extensive metabolizers (EM); reduced metabolizers (RM); or unknown (UNK) metabolizers based on their CYP2C19 genotype. Possible extensive metabolizer (EM) phenotypes include EM=extensive metabolizer, UM=ultra-rapid metabolizer, and EM (non-UM) that are not UM. Possible reduced metabolizer (RM) phenotypes include IM=intermediate metabolizer and PM=poor metabolizer. Genotypes associated with each predicted phenotype are presented; predicted phenotype is presented first followed by the genotype. Percentage=(number of participants with the predicted phenotype and genotype divided by the total number of participants per arm) multiplied by 100. (NCT00699998)
Timeframe: Baseline
| Intervention | percentage participants with geneotype (Number) | ||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| UM, *1/*17 | UM, *17/*17 | EM (non-UM), *1/*1 | IM, *1/*2 | IM, *1/*3 | IM, *1/*4 | IM, *1/*6 | IM, *1/*8 | PM, *2/*2 | PM, *2/*3 | PM, *2/*4 | PM, *2/*6 | PM, *2/*8 | PM, *3/*3 | UNK, *1/*10 | UNK, *1/*13 | UNK, *1/*9 | UNK, *1/*9, *9/*17 | UNK, *13/*17 | UNK, *2/*13 | UNK, *2/*17 | UNK, *2/*9 | UNK, *3/*17 | UNK, *4/*17 | UNK, *4/*9 | UNK, *6/*17 | UNK, *8/*17 | UNK, *9/*17 | UNK, Undefined genotype | |
| Clopidogrel: <75 Years of Age | 25.1 | 5.4 | 35.7 | 19.8 | 0.5 | 0.1 | 0.0 | 0.4 | 4.3 | 0.3 | 0.2 | 0.0 | 0.0 | 0.2 | 0.1 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 6.8 | 0.1 | 0.0 | 0.2 | 0.0 | 0.0 | 0.1 | 0.0 | 0.5 |
| Clopidogrel: 75 Years of Age or Older | 21.8 | 4.3 | 41.2 | 19.7 | 0.6 | 0.3 | 0.2 | 0.3 | 3.8 | 0.3 | 0.2 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 6.2 | 0.0 | 0.3 | 0.0 | 0.0 | 0.2 | 0.0 | 0.0 | 0.6 |
| Prasugrel: <75 Years of Age | 24.0 | 5.1 | 38.8 | 18.6 | 0.8 | 0.4 | 0.0 | 0.1 | 3.9 | 0.3 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.1 | 0.0 | 0.0 | 0.0 | 6.3 | 0.0 | 0.1 | 0.2 | 0.0 | 0.0 | 0.2 | 0.0 | 0.7 |
| Prasugrel: 75 Years of Age or Older | 25.0 | 3.6 | 42.1 | 18.3 | 0.6 | 0.0 | 0.2 | 0.5 | 2.2 | 0.2 | 0.2 | 0.0 | 0.0 | 0.0 | 0.0 | 0.2 | 0.2 | 0.0 | 0.0 | 0.0 | 6.1 | 0.0 | 0.0 | 0.2 | 0.0 | 0.0 | 0.0 | 0.0 | 0.6 |
Platelet aggregation was measured by as measured by Accumetrics Verify Now™ P2Y12. Results were reported in P2Y12 Reaction Units (PRU). PRU represents the rate and extent of adenosine (ADP)-stimulated platelet aggregation. Lower values indicate greater P2Y12 platelet inhibition and lower platelet activity and aggregation. ANCOVA Model was used and values were corrected for treatment + baseline value + clopidogrel status at randomization. (NCT00699998)
Timeframe: Day 30 and 12 Months
| Intervention | P2Y12 Reaction Units (PRU) (Least Squares Mean) | |
|---|---|---|
| Day 30 | Month 12 (n=386, 76, 400, 103) | |
| Clopidogrel: <75 Years of Age | 193.489 | 199.003 |
| Clopidogrel: 75 Years of Age or Older | 200.285 | 181.360 |
| Prasugrel: <75 Years of Age | 93.280 | 94.529 |
| Prasugrel: 75 Years of Age or Older | 151.872 | 135.096 |
All deaths, regardless of possible relatedness, with the exception of 1 event, were adjudicated by the Clinical Endpoint Committee (CEC) and are reported in this table. The 1 event which was not adjudicated was a result of the revocation of consent by the participant prior to their death. Deaths possibly related to study drug in the opinion of the investigator are also contained in the Serious Adverse Event (SAE) module. (NCT00699998)
Timeframe: Randomization through end of study (30-month visit)
| Intervention | participants (Number) | |||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Congestive Heart Failure | Cardiogenic Shock | Cardiac Rupture | Myocardial Infarction | Dysrhythmia | Stent Thrombosis | Directly Related to Revascularization-CABG or PCI | Intracranial Hemorrhage | Non-Hemorrhagic Stroke | Sudden death due to cardiovascular event | Pulmonary Embolism | Stroke, unknown type | Other Cardiovascular Event | Cardiovascular event, unknown type | Accidental | Trauma | Hemorrhage, not intracranial | Infection | Malignancy | Suicide | Other Non-Cardiovascular event | Cause unknown (nonadjudicated event) | |
| Clopidogrel: <75 Years of Age | 13 | 10 | 0 | 24 | 6 | 0 | 1 | 4 | 4 | 70 | 2 | 0 | 0 | 45 | 1 | 0 | 0 | 16 | 14 | 0 | 8 | 0 |
| Clopidogrel: 75 Years of Age or Older | 23 | 9 | 0 | 21 | 3 | 0 | 1 | 1 | 3 | 43 | 1 | 0 | 1 | 45 | 1 | 1 | 4 | 17 | 11 | 0 | 6 | 0 |
| Prasugrel: <75 Years of Age | 10 | 8 | 0 | 16 | 5 | 0 | 1 | 2 | 4 | 75 | 0 | 0 | 6 | 40 | 1 | 2 | 1 | 14 | 14 | 1 | 8 | 0 |
| Prasugrel: 75 Years of Age or Older | 21 | 4 | 1 | 24 | 2 | 0 | 1 | 1 | 4 | 39 | 1 | 1 | 1 | 41 | 0 | 3 | 1 | 21 | 7 | 0 | 4 | 1 |
(NCT00335452)
Timeframe: 30 days
| Intervention | participants (Number) |
|---|---|
| Clopidogrel 300/75/75 mg + ASA Low Dose | 267 |
| Clopidogrel 300/75/75 mg + ASA High Dose | 290 |
| Clopidogrel 600/150/75 mg + ASA Low Dose | 282 |
| Clopidogrel 600/150/75 mg + ASA High Dose | 240 |
(NCT00335452)
Timeframe: 30 days
| Intervention | participants (Number) | |||
|---|---|---|---|---|
| CV death/MI/Stroke | - CV death | - MI (fatal or not) | - Stroke (fatal or not) | |
| Clopidogrel + ASA High Dose | 527 | 211 | 251 | 65 |
| Clopidogrel + ASA Low Dose | 546 | 231 | 260 | 55 |
"The primary endpoint is the first occurrence of any of the following events:~Cardiovascular death (any death with a clear cardiovascular or unknown cause),~Myocardial Infarction (diagnosis of new Myocardial Infarction (MI) - nonfatal or fatal)~Stroke (presence of a new focal neurologic deficit thought to be vascular in origin, with signs or symptoms lasting more than 24 hours - nonfatal or fatal)~reported between the randomization and Day 30 (inclusive), and validated by the blinded Event Adjudication Committee (EAC)." (NCT00335452)
Timeframe: 30 days
| Intervention | participants (Number) | |||
|---|---|---|---|---|
| CV death/MI/Stroke | - CV death | - MI (fatal or not) | - Stroke (fatal or not) | |
| Clopidogrel 300/75/75 mg + ASA | 557 | 222 | 274 | 61 |
| Clopidogrel 600/150/75 mg + ASA | 522 | 226 | 237 | 59 |
(NCT00335452)
Timeframe: 30 days
| Intervention | participants (Number) | |||
|---|---|---|---|---|
| CV death/MI/Stroke | - CV death | - MI (fatal or not) | - Stroke (fatal or not) | |
| Clopidogrel 300/75/75 mg + ASA | 392 | 132 | 225 | 35 |
| Clopidogrel 600/150/75 mg + ASA | 330 | 130 | 172 | 28 |
(NCT00335452)
Timeframe: 30 days
| Intervention | participants (Number) | ||
|---|---|---|---|
| Major bleeding | - Severe bleeding | - Major but not severe bleeding | |
| Clopidogrel + ASA High Dose | 282 | 216 | 73 |
| Clopidogrel + ASA Low Dose | 285 | 215 | 74 |
Major bleeding is defined as any severe bleeding (associated with any of the following: death, leading to a drop in hemoglobin ≥ 5 g/dl, significant hypotension with the need for inotropic agents, symptomatic intracranial hemorrhage, requirement for surgery or for a transfusion ≥ 4 units of red blood cells or equivalent whole blood) and other major bleeding (significantly disabling bleeding, or intraocular bleeding leading to significant loss of vision or bleeding requiring transfusion of 2-3 units of red blood cells or equivalent whole blood) after validation by the independent EAC. (NCT00335452)
Timeframe: 30 days
| Intervention | participants (Number) | ||
|---|---|---|---|
| Major bleeding | - Severe bleeding | - Major but not severe bleeding | |
| Clopidogrel 300/75/75 mg + ASA | 255 | 195 | 65 |
| Clopidogrel 600/150/75 mg + ASA | 313 | 236 | 83 |
This includes definite stent thrombosis (confirmed by angiography or evidence of recent thrombus determined at autopsy or by examination of tissue retrieved following thrombectomy) and probable stent thrombosis (unexplained death having occurred after intracoronary stenting or, MI related to acute ischemia in the territory of the implanted stent without angiographic confirmation and in the absence of any obvious cause) after validation by the EAC. (NCT00335452)
Timeframe: 30 days
| Intervention | participants (Number) | ||
|---|---|---|---|
| Stent trombosis | - Definite | - Probable | |
| Clopidogrel 300/75/75 mg + ASA | 200 | 111 | 89 |
| Clopidogrel 600/150/75 mg + ASA | 135 | 58 | 77 |
ADP-induced P2Y12 receptor mediated platelet aggregation serves as a biomarker of platelet function. It is measured in P2Y12 Reaction Units (PRU) with lower PRU reflecting stronger inhibition of P2Y12 and reduced platelet aggregation. Least Squares (LS) Mean values were controlled for treatment, visit, treatment and visit interaction, and country. (NCT01115738)
Timeframe: 6 hours after prasugrel loading dose
| Intervention | PRU (Least Squares Mean) |
|---|---|
| Placebo and 60-mg Prasugrel | 57.86 |
| 600-mg Clopidogrel and 60-mg Prasugrel | 35.61 |
| 600-mg Clopidogrel and 30-mg Prasugrel | 53.92 |
(NCT01115738)
Timeframe: Baseline, 72 hours
| Intervention | proportion of 1.0 (Mean) |
|---|---|
| Placebo and 60-mg Prasugrel | 0.0 |
| 600-mg Clopidogrel and 60-mg Prasugrel | 0.0 |
| 600-mg Clopidogrel and 30-mg Prasugrel | 0.0 |
(NCT01115738)
Timeframe: Baseline, 72 hours
| Intervention | gram per deciliter (g/dL) (Mean) |
|---|---|
| Placebo and 60-mg Prasugrel | -0.9 |
| 600-mg Clopidogrel and 60-mg Prasugrel | -0.6 |
| 600-mg Clopidogrel and 30-mg Prasugrel | -0.6 |
CYP2C19 is a drug metabolizing enzyme. CYP2C19 Extensive metabolizers (EM) are individuals with two fully active / normal function CYP2C19 alleles (*1/*1, *1/*17). CYP2C19 Reduced metabolizers (RM) are individuals with at least one reduced-function CYP2C19 allele (*2/*2, *1/*2). Least Squares (LS) Mean values were controlled for CYP2C19 genetic group. (NCT01115738)
Timeframe: 6 hours after prasugrel loading dose
| Intervention | PRU (Least Squares Mean) |
|---|---|
| Placebo and 60 mg Prasugrel-CYP2C19 EM | 39.036 |
| Placebo and 60 mg Prasugrel -CYP2C19 RM | 47.750 |
| 600 mg Clopidogrel and 60 mg Prasugrel - CYP2C19 EM | 20.190 |
| 600 mg Clopidogrel and 60 mg Prasugrel - CYP2C19 RM | 23.625 |
| 600 mg Clopidogrel and 30 mg Prasugrel - CYP2C19 EM | 36.478 |
| 600 mg Clopidogrel and 30 mg Prasugrel - CYP2C19 RM | 24.778 |
CYP2C19 is a drug metabolizing enzyme. CYP2C19 Extensive metabolizers (EM) are individuals with two fully active / normal function CYP2C19 alleles (*1/*1, *1/*17). CYP2C19 Reduced metabolizers (RM) are individuals with at least one reduced-function CYP2C19 allele (*2/*2, *1/*2). Least Squares (LS) Mean values were controlled for CYP2C19 genetic group. (NCT01115738)
Timeframe: Baseline
| Intervention | PRU (Least Squares Mean) |
|---|---|
| Clopidogrel at Baseline -CYP2C19 EM | 243.549 |
| Clopidogrel at Baseline - CYP2C19 RM | 240.100 |
ADP-induced P2Y12 receptor mediated platelet aggregation serves as a biomarker of platelet function. It is measured in P2Y12 Reaction Units (PRU) with lower PRU reflecting stronger inhibition of P2Y12 and reduced platelet aggregation. Least Squares (LS) Mean values were controlled for treatment, visit, treatment and visit interaction, and country. (NCT01115738)
Timeframe: Baseline and 2 hours and 24 hours and 72 hours after prasugrel loading dose
| Intervention | PRU (Least Squares Mean) | |||
|---|---|---|---|---|
| Baseline | 2 Hours after Prasugrel LD | 24 Hours after Prasugrel LD | 72 Hours after Prasugrel LD | |
| 600-mg Clopidogrel and 30-mg Prasugrel | 229.62 | 117.10 | 51.43 | 60.29 |
| 600-mg Clopidogrel and 60-mg Prasugrel | 248.58 | 113.10 | 34.05 | 48.08 |
| Placebo and 60-mg Prasugrel | 265.51 | 122.55 | 62.73 | 56.95 |
TEAE is a worsening or new occurrence of adverse event (AE) during treatment compared to baseline. A summary of serious adverse events (SAE) and other nonserious AE are located in the Reported Adverse Events section. (NCT01115738)
Timeframe: Baseline through 72 hours after prasugrel loading dose
| Intervention | participants (Number) | |
|---|---|---|
| Serious Adverse Events | Nonserious Adverse Events | |
| 600-mg Clopidogrel and 30-mg Prasugrel | 1 | 31 |
| 600-mg Clopidogrel and 60-mg Prasugrel | 8 | 31 |
| Placebo and 60-mg Prasugrel | 2 | 37 |
Adenosine Diphosphate (ADP)-induced P2Y12 receptor mediated platelet aggregation serves as a biomarker of platelet function. It is measured in P2Y12 Reaction Units (PRU) with lower PRU reflecting stronger inhibition of P2Y12 and reduced platelet aggregation. The internal BASE standard is an independent measurement and serves as an estimate of the participant's baseline platelet aggregation independent of P2Y12 receptor inhibition. Percent Inhibition of Platelet Aggregation=(1-[PRU/BASE) x 100%, high numbers represent increased platelet inhibition. Least Squares (LS) Mean values were controlled for treatment, visit, treatment and visit interaction, and country. (NCT01115738)
Timeframe: Baseline and 2 and 6 and 24 and 72 hours after loading dose
| Intervention | percentage of inhibition (Least Squares Mean) | ||||
|---|---|---|---|---|---|
| Baseline | 2 Hours after Prasugrel LD | 6 Hours after Prasugrel LD | 24 Hours after Prasugrel LD | 72 Hours after Prasugrel LD | |
| 600-mg Clopidogrel and 30-mg Prasugrel | 14.94 | 54.89 | 78.55 | 78.56 | 78.17 |
| 600-mg Clopidogrel and 60-mg Prasugrel | 13.02 | 58.75 | 86.77 | 87.64 | 83.51 |
| Placebo and 60-mg Prasugrel | 9.71 | 56.04 | 79.87 | 77.57 | 78.48 |
Poor responders are those who had P2Y12 Reaction Units (PRU)≥ 240. (NCT01115738)
Timeframe: Baseline and 2 and 6 and 24 and 72 hours after loading dose
| Intervention | percentage of participants (Number) | ||||
|---|---|---|---|---|---|
| Baseline | 2 Hours after Prasugrel LD | 6 Hours after Prasugrel LD | 24 Hours after Prasugrel LD | 72 Hours after Prasugrel LD | |
| 600-mg Clopidogrel and 30-mg Prasugrel | 51.2 | 21.4 | 4.4 | 8.8 | 0 |
| 600-mg Clopidogrel and 60-mg Prasugrel | 66.7 | 12.8 | 5.3 | 2.9 | 0 |
| Placebo and 60-mg Prasugrel | 68.1 | 23.3 | 11.6 | 9.5 | 0 |
The endpoint in this measure is a combination of all-cause death, nonfatal MI, or nonfatal stroke. Results are reported for the All ACS population. (NCT00097591)
Timeframe: Randomization up to 15 months
| Intervention | Participants (Number) |
|---|---|
| Prasugrel | 692 |
| Clopidogrel | 822 |
The endpoint in this measure is a combination of CV death, nonfatal MI, nonfatal stroke, or rehospitalization for cardiac ischemic events. Results are reported for the All ACS population. (NCT00097591)
Timeframe: Randomization up to 15 months
| Intervention | Participants (Number) |
|---|---|
| Prasugrel | 797 |
| Clopidogrel | 938 |
The endpoint in this measure is a combination of CV death, nonfatal MI, or nonfatal stroke. Results are reported for the All ACS population for the 30 and 90 day periods. (NCT00097591)
Timeframe: Randomization to 30 days; randomization to 90 days
| Intervention | Participants (Number) | |
|---|---|---|
| All ACS (Through 30 days) | All ACS (Through 90 days) | |
| Clopidogrel | 502 | 573 |
| Prasugrel | 389 | 462 |
The endpoint in this measure is a combination of CV death, nonfatal MI, or nonfatal stroke. The data is presented by the study population, which is represented as follows: 1) subjects who presented with unstable angina and non-ST-segment elevation myocardial infarction (UA/NSTEMI), 2) subjects who presented with ST segment elevation myocardial infarction (STEMI), and 3) all subjects with acute coronary syndromes (ACS) (i.e. all subjects with UA/NSTEMI or STEMI). (NCT00097591)
Timeframe: Randomization up to 15 months
| Intervention | Participants (Number) | ||
|---|---|---|---|
| UA/NSTEMI (n=5044, n=5030) | STEMI (n=1769, n=1765) | All ACS (n=6813, n=6795) | |
| Clopidogrel | 565 | 216 | 781 |
| Prasugrel | 469 | 174 | 643 |
The endpoint in this measure is a combination of CV death, nonfatal MI, or UTVR. Results are reported for the All ACS subject population for the 30 and 90 day periods. (NCT00097591)
Timeframe: Randomization to 30 days; randomization to 90 days
| Intervention | Participants (Number) | |
|---|---|---|
| All ACS (Through 30 days) | All ACS (Through 90 days) | |
| Clopidogrel | 504 | 588 |
| Prasugrel | 399 | 472 |
TIMI classification for major and minor bleeding in the subset of subjects who did not undergo a coronary artery bypass operation (CABG) were defined as follows: Major bleeding: any intracranial hemorrhage (ICH) OR any clinically overt bleeding (including bleeding evident on imaging studies) associated with a fall in hemoglobin (Hgb) of ≥5 grams/deciliter (gm/dL)from baseline. Minor Bleeding: any clinically overt bleeding associated with a fall in Hgb of ≥3 gm/dL but <5 gm/dL from baseline. Major bleeding events were further examined as events that were deemed life threatening and/or fatal. (NCT00097591)
Timeframe: First dose of study drug up to 15 months (while at risk)
| Intervention | Participants (Number) | ||||||||
|---|---|---|---|---|---|---|---|---|---|
| TIMI Major or Minor Bleeding | TIMI Major Bleeding | TIMI Major Bleeding - Life-threatening (LT) | LT - Fatal | LT - Symptomatic intracranial hemorrage (ICH) | LT - Requiring inotropes | LT - Requiring surgical intervention | LT - Requiring transfusion (>=4 units) | TIMI Minor Bleeding | |
| Clopidogrel | 231 | 111 | 56 | 5 | 17 | 8 | 19 | 30 | 125 |
| Prasugrel | 303 | 146 | 85 | 21 | 19 | 21 | 19 | 45 | 164 |
Number of participants with first occurrence of clinically relevant bleeding episode, defined as Bleeding Academic Research Consortium (BARC) Types 2, 3 or 5 bleeding. BARC bleeding types range from 0 (no bleeding) to 5 (fatal bleeding). (NCT02270242)
Timeframe: 12 months after randomization
| Intervention | Participants (Count of Participants) |
|---|---|
| Placebo + Ticagrelor | 141 |
| Aspirin + Ticagrelor | 250 |
Number of participants with first occurrence of confirmed all-cause death, non-fatal myocardial infarction or stroke. (NCT02270242)
Timeframe: 12 months after randomization
| Intervention | Participants (Count of Participants) |
|---|---|
| Placebo + Ticagrelor | 135 |
| Aspirin + Ticagrelor | 137 |
Alpha angle is measured using thromboelastography, measured by a tangent to the clotting curve through the 2mm point (NCT02578706)
Timeframe: baseline and 24 weeks
| Intervention | degree (Mean) |
|---|---|
| Aspirin and Placebo | 0.00 |
| Clopidogrel and Placebo | -0.60 |
| Placebo Only | -0.50 |
The classical monocyte is characterized by high level expression of the CD14 cell surface receptor (CD14++ CD16- monocyte) (NCT02578706)
Timeframe: baseline and 24 weeks
| Intervention | 10^3 cells/µl (Mean) |
|---|---|
| Aspirin and Placebo | -0.09 |
| Clopidogrel and Placebo | -0.12 |
| Placebo Only | -0.04 |
Clot formation time is measured using thromboelastography. time from 2 to 20 mm amplitude in seconds. (NCT02578706)
Timeframe: baseline and 24 weeks
| Intervention | seconds (Mean) |
|---|---|
| Aspirin and Placebo | -1.00 |
| Clopidogrel and Placebo | 2.00 |
| Placebo Only | 1.63 |
Clot formation kinetics, or coagulation time, is measured using thromboelastography. time to 2mm amplitude in seconds. (NCT02578706)
Timeframe: baseline and 24 weeks
| Intervention | seconds (Mean) |
|---|---|
| Aspirin and Placebo | 3.00 |
| Clopidogrel and Placebo | 1.00 |
| Placebo Only | -13.13 |
D-Dimer level looks at coagulation of blood. D-dimers are not normally present in blood except when coagulation has occurred. (NCT02578706)
Timeframe: Baseline and 24 weeks
| Intervention | mcg/L (Mean) |
|---|---|
| Aspirin and Placebo | -295.99 |
| Clopidogrel and Placebo | 151.96 |
| Placebo Only | 1109.38 |
Interleukin 6 gene encodes a cytokine that functions in inflammation and implicated in a variety of inflammatory-associated disease states. (NCT02578706)
Timeframe: baseline and 24 weeks
| Intervention | pg/mL (Mean) |
|---|---|
| Aspirin and Placebo | -0.36 |
| Clopidogrel and Placebo | 0.02 |
| Placebo Only | 0.85 |
The intermediate monocyte with high level expression of CD14 and low level expression of CD16 (CD14++CD16+ monocytes). (NCT02578706)
Timeframe: Baseline and 24 weeks
| Intervention | 10^3 cells/µl (Mean) |
|---|---|
| Aspirin and Placebo | 0.02 |
| Clopidogrel and Placebo | 0.06 |
| Placebo Only | 0.04 |
Maximum Clot Firmness (MCF) is measured using thromboelastography. maximum ampliture in mm (NCT02578706)
Timeframe: baseline and 24 weeks
| Intervention | mm (Mean) |
|---|---|
| Aspirin and Placebo | 1.38 |
| Clopidogrel and Placebo | 1.20 |
| Placebo Only | 0.38 |
Soluble CD163 is a specific macrophage activation marker, associated with morphological disease grade. A high sCD163 indicates more disease. (NCT02578706)
Timeframe: baseline and 24 weeks
| Intervention | 10^3 cells/µl (Mean) |
|---|---|
| Aspirin and Placebo | 26.88 |
| Clopidogrel and Placebo | 15.8 |
| Placebo Only | -63.38 |
Change in % platelet monocyte aggregates from baseline to week 24 (NCT02578706)
Timeframe: baseline and 24 weeks
| Intervention | % platelet monocyte aggregates (Mean) |
|---|---|
| Aspirin and Placebo | 10.55 |
| Clopidogrel and Placebo | 3.88 |
| Placebo Only | 8.96 |
The non-classical monocyte shows low level expression of CD14 and additional co-expression of the CD16 receptor (CD14+CD16++ monocyte).[ (NCT02578706)
Timeframe: baseline and 24 weeks
| Intervention | 10^3 cells/µl (Mean) |
|---|---|
| Aspirin and Placebo | 0.002 |
| Clopidogrel and Placebo | 0.03 |
| Placebo Only | -0.03 |
Change in % platelet aggregation in response to stimulation by Adenosine Diphosphate (ADP) from baseline to week 24 (NCT02578706)
Timeframe: baseline and 24 weeks
| Intervention | % platelet aggregation (Mean) |
|---|---|
| Aspirin and Placebo | -7.25 |
| Clopidogrel and Placebo | -32.40 |
| Placebo Only | -6.50 |
Change in % platelet aggregation in response to stimulation by arachidonic acid 1500µM from baseline to week 24 (NCT02578706)
Timeframe: baseline and 24 weeks
| Intervention | % platelet aggregation (Mean) |
|---|---|
| Aspirin and Placebo | -53.33 |
| Clopidogrel and Placebo | -31.00 |
| Placebo Only | -13.25 |
Change in % platelet aggregation in response to stimulation by Collagen 2µg/mL from baseline to week 24 (NCT02578706)
Timeframe: baseline and 24 weeks
| Intervention | % platelet aggregation (Mean) |
|---|---|
| Aspirin and Placebo | -40.37 |
| Clopidogrel and Placebo | -9.60 |
| Placebo Only | 8.62 |
Change in % platelet aggregation in response to stimulation by light transmission aggregometry as measured by epinephrine 5µM from baseline to week 24 (NCT02578706)
Timeframe: baseline and 24 weeks
| Intervention | % platelet aggregation (Mean) |
|---|---|
| Aspirin and Placebo | -35.25 |
| Clopidogrel and Placebo | -21.40 |
| Placebo Only | -10.63 |
Soluble CD14 (sCD14) levels in blood. sCD14 is a nonspecific maker of monocyte activation. (NCT02578706)
Timeframe: baseline and 24 weeks
| Intervention | pg/mL (Mean) |
|---|---|
| Aspirin and Placebo | 35.75 |
| Clopidogrel and Placebo | -251.40 |
| Placebo Only | -101.75 |
Soluble CD40-ligand levels (NCT02578706)
Timeframe: baseline and 24 weeks
| Intervention | pg/mL (Mean) |
|---|---|
| Aspirin and Placebo | -28.05 |
| Clopidogrel and Placebo | -25.68 |
| Placebo Only | 13.65 |
Change in spontaneous % platelet from baseline to week 24. Spontaneous platelet aggregation? (NCT02578706)
Timeframe: baseline and 24 weeks
| Intervention | % platelet (Mean) |
|---|---|
| Aspirin and Placebo | -0.75 |
| Clopidogrel and Placebo | -0.60 |
| Placebo Only | -0.88 |
Soluble tumor necrosis factor receptor (sTNFR) serum concentration (NCT02578706)
Timeframe: baseline and 24 weeks
| Intervention | pg/ml (Mean) |
|---|---|
| Aspirin and Placebo | 137.77 |
| Clopidogrel and Placebo | 59.46 |
| Placebo Only | 19.78 |
Soluble tumor necrosis factor receptor (sTNFR) serum concentration (NCT02578706)
Timeframe: baseline and 24 weeks
| Intervention | pg/ml (Mean) |
|---|---|
| Aspirin and Placebo | 283.13 |
| Clopidogrel and Placebo | 347.00 |
| Placebo Only | 4.25 |
substudy - Change in thrombus formation by Badimon chamber (high shear) from baseline to 24 weeks. Thrombus formation on a blood vessel measured by immunohistochemistry staining of tissue cross sections. The high shear chambers (inner lumen diameter 0.1 mm, Reynolds number 60, shear rate 1690 s- 1) mimic the rheologic conditions of a moderately stenosed coronary artery. (NCT02578706)
Timeframe: baseline and 24 weeks
| Intervention | μ(2)/mm (Mean) |
|---|---|
| Aspirin and Placebo | -3052.20 |
| Clopidogrel and Placebo | -2798.80 |
| Placebo Only | -753.00 |
substudy - Change in thrombus formation by Badimon chamber (low shear) from baseline to 24 weeks. Thrombus formation on a blood vessel measured by immunohistochemistry staining of tissue cross sections. μ(2)/mm is the area of thrombus. The low shear chamber (inner lumen diameter 0.2 mm, Reynolds number 30, shear rate 500 s- 1) simulates flow conditions of a normal coronary artery. (NCT02578706)
Timeframe: baseline and 24 weeks
| Intervention | μ(2)/mm (Mean) |
|---|---|
| Aspirin and Placebo | -1036 |
| Clopidogrel and Placebo | -899.20 |
| Placebo Only | -203.75 |
Safety as measured by a Summary of the number of subjects with at least one grade 3 or higher sign/symptom or laboratory abnormality. A grade 3 sign/symptom was defined as medically significant but not immediately life threatening. (NCT02578706)
Timeframe: 24 weeks
| Intervention | Participants (Count of Participants) |
|---|---|
| Aspirin and Placebo | 0 |
| Clopidogrel and Placebo | 1 |
| Placebo Only | 0 |
"Platelet activation by adenosine diphosphate (ADP) expressed in arbitrary aggregation units (U). P2Y12 inhibitors block ADP receptors and decrease platelet activation by ADP. Higher values mean less effect of P2Y12 inhibitors, lower values mean more effect of P2Y12 inhibitors on platelets.~High on-treatment platelet reactivity was defined as >46 U." (NCT02224274)
Timeframe: 12 hours after P2Y12 inhibitor loading
| Intervention | U (Mean) |
|---|---|
| Clopidogrel | 28 |
| Ticagrelor | 15 |
% inhibition reflects P2Y12 inhibitor effect regarding basal platelet reactivity (defined as: (1- (platelet reactivity/basal platelet reactivity)) x 100). Higher values mean better P2Y12 inhibition response. High on-treatment platelet reactivity was defined as <11% inhibition. (NCT02224274)
Timeframe: 12 hours after P2Y12 inhibitor loading
| Intervention | % inhibition (Mean) |
|---|---|
| Clopidogrel | 4 |
| Ticagrelor | 55 |
Platelet reactivity reflects P2Y12 inhibitor effect. Higher values mean normal platelet reactivity due to low P2Y12 inhibition response, while lower values mean decreased platelet reactivity due to the effect of a P2Y12 inhibitor. High on-treatment platelet reactivity was defined as >208 PRU. (NCT02224274)
Timeframe: 12 h after P2Y12 inhibitor loading
| Intervention | PRU (Mean) |
|---|---|
| Clopidogrel | 238 |
| Ticagrelor | 101 |
"Bleeding classified by the TIMI hemorrhage classification scheme:~Minor: any clinically overt sign of hemorrhage (including imaging) that is associated with a hemoglobin drop of 3 to < 5 g/dL~Major: (1) if it is intracranial, or (2) clinically significant overt signs of hemorrhage associated with a drop inhemoglobin of > 5 g/dL" (NCT01515345)
Timeframe: 30days
| Intervention | participants (Number) |
|---|---|
| Standard Therapy | 17 |
| Individualized Therapy | 9 |
"The angiographic or pathological confirmation of stent thrombosis is called definite stent thrombosis" (NCT01515345)
Timeframe: 30 days
| Intervention | participants (Number) |
|---|---|
| Standard Therapy | 1 |
| Individualized Therapy | 0 |
"Probable stent thrombosis is considered to have occurred in case of~any unexplained death within the first 30 days.~any MI that is related to documented acute ischemia in the territory of the implanted stent without angiographic confirmation of stent thrombosis and in the absence of any other obvious cause, irrespective of the time after the index procedure" (NCT01515345)
Timeframe: 30days
| Intervention | participants (Number) |
|---|---|
| Standard Therapy | 2 |
| Individualized Therapy | 0 |
Clinical Events Committee (CEC)-adjudicated results (modified intent-to-treat [mITT] population) (NCT01156571)
Timeframe: 48 hours after randomization
| Intervention | participants (Number) |
|---|---|
| Cangrelor Treatment Arm | 257 |
| Clopidogrel Treatment Arm | 322 |
GUSTO = Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Coronary Arteries trial (NCT01156571)
Timeframe: 48 hours after randomization
| Intervention | participants (Number) | ||||||
|---|---|---|---|---|---|---|---|
| GUSTO severe/life threatening | GUSTO moderate | GUSTO severe or moderate | TIMI major | TIMI minor | TIMI major or minor | Any blood transfusion | |
| Cangrelor Treatment Arm | 9 | 22 | 31 | 5 | 9 | 14 | 25 |
| Clopidogrel Treatment Arm | 6 | 13 | 19 | 5 | 3 | 8 | 16 |
CEC-adjudicated results (mITT population) (NCT01156571)
Timeframe: 48 hours after randomization
| Intervention | participants (Number) | |||
|---|---|---|---|---|
| Stent Thrombosis | Death | MI (myocardial infarction) | IDR (ischemia-driven revascularization) | |
| Cangrelor Treatment Arm | 46 | 18 | 207 | 28 |
| Clopidogrel Treatment Arm | 74 | 18 | 255 | 38 |
The Duke CAD Index is a validated composite measure of angiographic burden, which assigns prognostic weights 1 through 100. Higher scores indicate greater angiographic burden and are associated with poorer prognosis. (NCT01088503)
Timeframe: Day 0 (study enrollment)
| Intervention | units on a scale (Mean) |
|---|---|
| Prasugrel | 40.36 |
| Other | 41.87 |
(NCT01088503)
Timeframe: Day 0 (study enrollment)
| Intervention | grams/deciliter (g/dL) (Mean) |
|---|---|
| Prasugrel | 14.59 |
| Other | 14 |
Academic Research Consortium (ARC) criteria were used to define ST. Definite ST is angiographic or pathologic confirmation of partial or total thrombotic occlusion within the peri-stent region, and at least 1 of the following additional criteria: acute ischemic symptoms; ischemic electrocardiogram changes; elevated cardiac biomarkers. Probable ST is any unexplained death within 30 days of stent implantation; any MI, which is related to documented acute ischemia in the territory of the implanted stent without angiographic confirmation of ST and in the absence of any other obvious cause. Events that occurred more than 7 days after medication was switched or discontinued were excluded from the analysis. Observed (unadjusted) percentages of participants with ST events are presented. Kaplan-Meier analysis was used to estimate the percentage of participants with a definite or probable ST event. (NCT01088503)
Timeframe: Baseline through 15 months
| Intervention | percentage of participants (Number) |
|---|---|
| Prasugrel | 1.35 |
| Clopidogrel | 1.79 |
MACE is defined as a composite of all-cause death, MI, stroke, or unplanned coronary revascularization. Events that occurred more than 7 days after medication was switched or discontinued were excluded from the analysis. Observed (unadjusted) percentages of participants with MACE, as well as the statistical analyses adjusted for baseline cohort differences, are presented. Percentage of participant = (number of participants with events / number of participants treated) * 100. (NCT01088503)
Timeframe: Baseline through 12 months
| Intervention | percentage of participants (Number) |
|---|---|
| Prasugrel | 12.67 |
| Clopidogrel | 15.89 |
MACE is defined as a composite of all-cause death, myocardial infarction (MI), stroke, or unplanned coronary revascularization. Events that occurred more than 7 days after medication was switched or discontinued were excluded from the analysis. Observed (unadjusted) percentages of participants with MACE, as well as the statistical analyses adjusted for baseline cohort differences, are presented. Percentage of participants = (number of participants with events in 12 months/ number of participants treated) * 100. (NCT01088503)
Timeframe: Baseline through 12 months
| Intervention | percentage of participants (Number) |
|---|---|
| Prasugrel | 13.14 |
| Clopidogrel | 17.12 |
Factors are drug-eluting stent (DES) vs. bare metal stent (BMS) placement, other (no stent) vs. BMS, STEMI, other race, cardiogenic shock occurred within 24 hours, male, European Quality of Life Questionnaire-5 Dimension Health State Score (EQ-5D) - United States (US) Index =1 vs. <1, married, diabetes, and other vs. BMS placement. The EQ-5D US index is a participant-rated, health-related, quality-of-life instrument based on US population. Scores range from -0.11 to 1.0 with 1.0 = perfect health. (NCT01088503)
Timeframe: Day 0 (study enrollment)
| Intervention | participants (Number) | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Received DES | Received only BMS | STEMI | Other Race (Non-Caucasian) | Cardiogenic Shock on Presentation | Male Participants | EQ-5D US index = 1 vs. <1 | Married Participants | Participant has Diabetes | No BMS or DES | |
| Other | 6282 | 2491 | 4508 | 1049 | 176 | 6342 | 3873 | 5601 | 2472 | 331 |
| Prasugrel | 2365 | 672 | 1831 | 365 | 79 | 2451 | 1516 | 2044 | 767 | 86 |
Bleeding events were collected utilizing the Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Coronary Arteries (GUSTO) definition of bleeding. Non-coronary artery bypass grafting (CABG)-related GUSTO severe or life-threatening bleeding is any intracranial hemorrhage (ICH) OR any bleeding event resulting in substantial hemodynamic compromise requiring treatment. Non-CABG-related GUSTO moderate bleeding is any bleeding event resulting in the need for transfusion that is not considered a GUSTO severe or life-threatening bleed. Additional bleeding events are fatal bleeding or ICH, or any non -fatal surgical-related bleeding events leading to ≥4 units of red cell transfusion. Observed (unadjusted) percentages of participants with bleeding events, as well as the statistical analyses adjusted for baseline cohort differences, are presented. Percentage of participants = (number of participants with events / number of participants treated) * 100. (NCT01088503)
Timeframe: Baseline, 1, 6, 12 and 15 months
| Intervention | percentage of participants (Number) | ||||
|---|---|---|---|---|---|
| Baseline | 1 month | 6 months | 12 months | 15 months | |
| Clopidogrel | 0.45 | 1.62 | 2.77 | 3.86 | 4.21 |
| Prasugrel | 0.54 | 1.22 | 1.93 | 2.72 | 3.10 |
MACE is defined as a composite of all-cause death, MI, stroke, or unplanned coronary revascularization. Events that occurred more than 7 days after medication was switched or discontinued were excluded from the analysis. Observed (unadjusted) percentages of participants with MACE are presented. Kaplan-Meier analysis was used to estimate the percentage of participants with a MACE event. (NCT01088503)
Timeframe: Baseline through 1, 6 and 15 months
| Intervention | percentage of participants (Number) | ||
|---|---|---|---|
| 1 month | 6 months | 15 months | |
| Clopidogrel | 5.40 | 12.04 | 19.13 |
| Prasugrel | 4.63 | 9.64 | 14.26 |
median 3.8 years of follow-up (NCT00086450)
Timeframe: Measured at Year 5
| Intervention | percentage of participants (Number) |
|---|---|
| Percutaneous Coronary Intervention | 26.6 |
| Coronary Artery Bypass Graft | 18.7 |
(NCT00086450)
Timeframe: Measured at Year 5
| Intervention | percentage of participants (Number) |
|---|---|
| Percutaneous Coronary Intervention | 16.3 |
| Coronary Artery Bypass Graft | 10.9 |
(NCT00086450)
Timeframe: Measured at Year 1
| Intervention | percentage of participants (Number) |
|---|---|
| Percutaneous Coronary Intervention | 16.8 |
| Coronary Artery Bypass Graft | 11.8 |
Major adverse cardiovascular and cerebrovascular events (NCT00086450)
Timeframe: Measured at Day 30
| Intervention | percentage of participants (Number) |
|---|---|
| Percutaneous Coronary Intervention | 4.8 |
| Coronary Artery Bypass Graft | 5.2 |
Secondary powered endpoint (NCT00977938)
Timeframe: 33 months (0-33 months post-index procedure)
| Intervention | percentage of patients (Number) |
|---|---|
| Propensity-matched DES | 1.70 |
| Propensity-matched BMS | 2.61 |
ST was assessed according to the Academic Research Consortium (ARC) definitions. (NCT00977938)
Timeframe: 18 months (12-30 months post-index procedure)
| Intervention | percentage of patients (KM estimate) (Number) |
|---|---|
| BMS 30-month DAPT | 0.50 |
| BMS 12-month DAPT | 1.11 |
ST was assessed according to the Academic Research Consortium (ARC) definitions. (NCT00977938)
Timeframe: 21 months (12-33 months post-index procedure)
| Intervention | percentage of patients (KM estimate) (Number) |
|---|---|
| BMS 30-month DAPT | 0.50 |
| BMS 12-month DAPT | 1.11 |
ST was assessed according to the Academic Research Consortium (ARC) definitions. (NCT00977938)
Timeframe: 21 months (12-33 months post-index procedure)
| Intervention | percentage of patients (KM estimate) (Number) |
|---|---|
| DES 30-month DAPT | 0.69 |
| DES 12-month DAPT | 1.45 |
The coprimary efficacy endpoints were the cumulative incidence of MACCE and the cumulative incidence of definite or probable ST within randomized DES ITT patients between 12 and 30 months post procedure. ST was assessed according to the Academic Research Consortium (ARC) definitions. (NCT00977938)
Timeframe: 18 months (12-30 months post-index procedure)
| Intervention | percentage of patients (KM estimate) (Number) |
|---|---|
| DES 30-month DAPT | 0.40 |
| DES 12-month DAPT | 1.35 |
Bleeding was assessed according to the Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Arteries (GUSTO) criteria. (NCT00977938)
Timeframe: 18 months (12-30 months post-index procedure)
| Intervention | percentage of patients (Number) |
|---|---|
| BMS 30-month DAPT | 2.03 |
| BMS 12-month DAPT | 0.90 |
Bleeding was assessed according to the Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Arteries (GUSTO) criteria. (NCT00977938)
Timeframe: 21 months (12-33 months post-index procedure)
| Intervention | percentage of patients (Number) |
|---|---|
| BMS 30-month DAPT | 2.09 |
| BMS 12-month DAPT | 1.05 |
Bleeding was assessed according to the Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Arteries (GUSTO) criteria. (NCT00977938)
Timeframe: 21 months (12-33 months post-index procedure)
| Intervention | percentage of patients (Number) |
|---|---|
| DES 30-month DAPT | 2.74 |
| DES 12-month DAPT | 1.88 |
The primary safety endpoint was moderate or severe bleeding within randomized DES ITT patients between 12 and 30 months post procedure. Bleeding was assessed according to the Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Arteries (GUSTO) criteria. (NCT00977938)
Timeframe: 18 months (12-30 months post-index procedure)
| Intervention | percentage of patients (Number) |
|---|---|
| DES 30-month DAPT | 2.53 |
| DES 12-month DAPT | 1.57 |
Secondary powered endpoint (NCT00977938)
Timeframe: 33 months (0-33 months post-index procedure)
| Intervention | percentage of patients (Number) |
|---|---|
| Propensity-matched DES | 11.37 |
| Propensity-matched BMS | 13.24 |
(NCT00977938)
Timeframe: 18 months (12-30 months post-index procedure)
| Intervention | percentage of patients (KM estimate) (Number) |
|---|---|
| BMS 30-month DAPT | 4.04 |
| BMS 12-month DAPT | 4.69 |
(NCT00977938)
Timeframe: 21 months (12-33 months post-index procedure)
| Intervention | percentage of patients (KM estimate) (Number) |
|---|---|
| BMS 30-month DAPT | 4.68 |
| BMS 12-month DAPT | 5.48 |
(NCT00977938)
Timeframe: 21 months (12-33 months post-index procedure)
| Intervention | percentage of patients (KM estimate) (Number) |
|---|---|
| DES 30-month DAPT | 5.62 |
| DES 12-month DAPT | 6.49 |
The coprimary efficacy endpoints were the cumulative incidence of MACCE and the cumulative incidence of ARC definite or probable stent thrombosis within randomized DES ITT patients between 12 and 30 months post procedure. (NCT00977938)
Timeframe: 18 months (12-30 months post-index procedure)
| Intervention | percentage of patients (KM estimate) (Number) |
|---|---|
| DES 30-month DAPT | 4.34 |
| DES 12-month DAPT | 5.92 |
An area under the curve of serial levels of Troponin I and creatine kinase-MB isoenzyme during 36 hours (NCT03114995)
Timeframe: 0,6,12,18,24,30,36 hours
| Intervention | Hours*ng/ml (Median) | |
|---|---|---|
| Troponin I | creatine kinase-MB isoenzyme | |
| Control C1 (High Platelet Reactivity - no Tirofiban) | 38.0 | 92.7 |
| Control C2 (Low Platelet Reactivity - no Tirofiban) | 121.4 | 185.6 |
| Group A (High Platelet Reactivity - Tirofiban) | 197.2 | 252.5 |
"Percentage of participants with periprocedural myonecrosis under the criteria described below.~When the cardiac biomarkers before the procedure were within the 99th percentile upper reference limit (URL), more than a 5-fold elevation in the URL within 12 hours after percutaneous coronary intervention (PCI) was defined as periprocedural myonecrosis. If the cardiac biomarker level was already above the 99th percentile URL before the procedure and the trend was stationary or decreasing, a ≥20% increase compared to the previous level was considered periprocedural myonecrosis. If the trend was still increasing, the levels at the post-6 hour and 12-hour were compared to determine periprocedural myonecrosis." (NCT03114995)
Timeframe: 0,6,12,18,24,30,36 hours
| Intervention | Participants (Count of Participants) | |
|---|---|---|
| Troponin I | creatine kinase-MB isoenzyme | |
| Control C1 (High Platelet Reactivity - no Tirofiban) | 15 | 10 |
| Control C2 (Low Platelet Reactivity - no Tirofiban) | 26 | 25 |
| Group A (High Platelet Reactivity - Tirofiban) | 16 | 11 |
Follow-up endoscopy was performed at the end of the 6th month (NCT02418312)
Timeframe: 6 months
| Intervention | participants (Number) |
|---|---|
| Histamine-2 Receptor Antagonist Group | 106 |
| Placebo Group | 101 |
Follow-up endoscopy was performed at the end of the 6th month (NCT02551744)
Timeframe: six month
| Intervention | participants (Number) |
|---|---|
| Proton Pump Inhibitor Group | 1 |
| Histamine-2 Receptor Antagonist Group | 7 |
Bleeding was assessed using the ISTH guidelines. Events were adjudicated by the CEC. Event rate was number of participants with events divided by the number of participants treated (%). All bleeding events included major bleeding, clinically relevant non-major bleeding and minor bleeding. Phase B Adjusted Treatment Period=safety events occurring in the period from first dose through 2 days (or through 30 days for SAE tabulations) after the earliest of last dose date or 1-Oct-2007 (termination date for the 10 mg BID group). (NCT00313300)
Timeframe: From first dose (Day 1) to last dose, plus 2 days (plus 30 days for SAEs), up to high dose termination, 1 October 2007
| Intervention | percentage of participants (Number) |
|---|---|
| Placebo | 6.1 |
| Apixaban 2.5mg BID | 15.1 |
| Apixaban 10mg QD | 17.6 |
| Apixaban 10mg BID | 24.2 |
| Apixaban 20 mg QD | 23.9 |
Bleeding was assessed using the International Society on Thrombosis and Hemostasis (ISTH) guidelines. Events were adjudicated by the Clinical Events Committee (CEC). Event rate was number of participants with events divided by the number of participants treated (%). All bleeding events includes major bleeding, clinically relevant non-major bleeding and minor bleeding. Treatment Period refers to the period from first dose through 2 days, or through 30 days for Serious Adverse Event (SAE) tabulations, after discontinuation of study drug. Data in this outcome are combined across Phase A and Phase B. (NCT00313300)
Timeframe: first dose (Day 1) to last dose plus 2 days (or for SAEs, plus 30 days), up to Year 2 of the Study
| Intervention | percentage of participants (Number) |
|---|---|
| Placebo | 10.5 |
| Apixaban 2.5mg BID | 20.6 |
| Apixaban 10mg QD | 22.5 |
Bleeding was assessed using ISTH guidelines. Events were adjudicated by the CEC. Event rate was number of participants with events divided by the number of participants treated, measured as a percentage (%). The analyses of Phase B data across all doses of apixaban are secondary because of the premature termination of the apixaban high-dose groups and the lower duration of exposure. Phase B Adjusted Treatment Period=safety events occurring in the period from first dose through 2 days (or through 30 days for SAE tabulations) after the earliest of last dose date or 1-Oct-2007 (termination date for the 10 mg BID group). (NCT00313300)
Timeframe: From first dose (Day 1) to last dose, plus 2 days (plus 30 days for SAEs), up to high dose termination, 1 October 2007
| Intervention | percentage of participants (Number) |
|---|---|
| Placebo | 0.8 |
| Apixaban 2.5mg BID | 5.0 |
| Apixaban 10mg QD | 5.6 |
| Apixaban 10mg BID | 7.8 |
| Apixaban 20 mg QD | 7.3 |
Bleeding was assessed using the International Society on Thrombosis and Hemostasis (ISTH) guidelines. Events were adjudicated by the Clinical Events Committee (CEC). Event rate was number of participants with events divided by the number of participants treated, measured as a percentage (%). The primary outcome is based on data for the placebo and 2 apixaban low-dose groups (2.5 mg BID and 10 mg QD) combined across Phase A and Phase B. The analyses of Phase B data across all doses of apixaban are secondary because of the premature termination of the apixaban high-dose groups (10mg BID, 20mg QD) and the resulting lower duration of exposure for these groups. (NCT00313300)
Timeframe: From first dose of study drug (Day 1) to last dose plus 2 days, up to Year 2 of the Study
| Intervention | percentage of participants (Number) |
|---|---|
| Placebo | 3.0 |
| Apixaban 2.5mg BID | 5.7 |
| Apixaban 10mg QD | 7.9 |
Bleeding was assessed using the ISTH guidelines. Events were adjudicated by the CEC. Event rate was number of participants with events divided by the number of participants treated (%). (NCT00313300)
Timeframe: From first dose (Day 1) to last dose, plus 2 days (plus 30 days for SAEs), up to high dose termination, 1 October 2007
| Intervention | percentage of participants (Number) |
|---|---|
| Placebo | 0.0 |
| Apixaban 2.5mg BID | 0.8 |
| Apixaban 10mg QD | 0.0 |
| Apixaban 10mg BID | 2.9 |
| Apixaban 20 mg QD | 4.1 |
Bleeding was assessed using the ISTH guidelines. Events were adjudicated by the Clinical Events Committee. Event rate was number of participants with events divided by the number of participants treated, measured as a percentage (%). (NCT00313300)
Timeframe: from first dose (Day 1) to last dose plus 2 days, up to Year 2 of the Study
| Intervention | percentage of participants (Number) |
|---|---|
| Placebo | 0.8 |
| Apixaban 2.5mg BID | 1.6 |
| Apixaban 10mg QD | 1.9 |
Events were adjudicated by the Clinical Events Committee (CEC). Event rate was number of participants with events divided by the number of participants treated (%). Intended Treatment Period refers to the period starting on the day of randomization and ending 182 days after the day of randomization (for a total period duration of 183 days). Data in this outcome are combined across Phase A and Phase B (NCT00313300)
Timeframe: Day of randomization to 182 days after day of randomization (183 days)
| Intervention | participants (Number) |
|---|---|
| Placebo | 54 |
| Apixaban 2.5mg BID | 24 |
| Apixaban 10mg QD | 20 |
Events were adjudicated by the Clinical Events Committee (CEC). Intended Treatment Period refers to the period starting on the day of randomization and ending 182 days after the day of randomization (for a total period duration of 183 days). Data in this outcome are combined across Phase A and Phase B. (NCT00313300)
Timeframe: Randomization to 182 days after randomization (183 days)
| Intervention | participants (Number) |
|---|---|
| Placebo | 53 |
| Apixaban 2.5mg BID | 24 |
| Apixaban 10mg QD | 19 |
Phase B Adjusted Intended Treatment Period=day of randomization and ends on termination date of high dose apixaban, 1-Oct-2007. The analyses of Phase B data across all doses of apixaban are secondary due to the premature termination of the apixaban high dose groups and the lower duration of exposure. (NCT00313300)
Timeframe: Day of randomization and ends on high dose termination date, 1-Oct-2007
| Intervention | participants (Number) |
|---|---|
| Placebo | 16 |
| Apixaban 2.5mg BID | 6 |
| Apixaban 10mg QD | 4 |
| Apixaban 10mg BID | 8 |
| Apixaban 20 mg QD | 7 |
Phase B Adjusted Intended Treatment Period=day of randomization and ends on 1-Oct-2007. The analyses of Phase B data across all doses of apixaban are secondary due to the premature termination of the apixaban high dose groups and the lower duration of exposure. (NCT00313300)
Timeframe: Day of randomization up to high dose termination, 1-Oct-2007
| Intervention | participants (Number) |
|---|---|
| Placebo | 16 |
| Apixaban 2.5mg BID | 6 |
| Apixaban 10mg QD | 4 |
| Apixaban 10mg BID | 8 |
| Apixaban 20 mg QD | 7 |
Time to first occurence of All-cause death. The number of participants with events was reported. (NCT02291419)
Timeframe: up to 6 months. The planned duration of treatment was one year but the study was terminated after 6 months.
| Intervention | Participants (Count of Participants) |
|---|---|
| Ticagrelor | 0 |
| Aspirin | 0 |
Time to first occurence of Cardiovascular death. The number of patients with events was reported. (NCT02291419)
Timeframe: Up to 6 months. The planned duration of treatment was one year but the study was terminated after 6 months.
| Intervention | Participants (Count of Participants) |
|---|---|
| Ticagrelor | 0 |
| Aspirin | 0 |
Time to first occurence of the composite of Cardiovascular Death, Non-fatal Myocardial Infarction, Coronary Revascularization or Non-fatal Stroke. The number of patients with events is reported. (NCT02291419)
Timeframe: up to 6 months. The planned duration of treatment was one year but the study was terminated after 6 months.
| Intervention | Participants (Count of Participants) |
|---|---|
| Ticagrelor | 0 |
| Aspirin | 0 |
Time to first occurence of Non-fatal myocardial infarction or coronary revascularization. The number of participants with events was reported. (NCT02291419)
Timeframe: up to 6 months. The planned duration of treatment was one year but the study was terminated after 6 months.
| Intervention | Participants (Count of Participants) |
|---|---|
| Ticagrelor | 0 |
| Aspirin | 0 |
Time to first occurence of Non-fatal stroke. The number of participants with events was reported. (NCT02291419)
Timeframe: up to 6 months. The planned duration of treatment was one year but the study was terminated after 6 months.
| Intervention | Participants (Count of Participants) |
|---|---|
| Ticagrelor | 0 |
| Aspirin | 0 |
(NCT02291419)
Timeframe: up to 6 months. The planned duration of treatment was one year but the study was terminated after 6 months.
| Intervention | Participants (Count of Participants) |
|---|---|
| Ticagrelor | 0 |
| Aspirin | 0 |
Number of participants with major adverse cardiovascular events (death, reinfarction, target-vessel revascularization for ischemia, and stroke) (NCT00433966)
Timeframe: 3 years
| Intervention | Participants (Count of Participants) |
|---|---|
| Pharmacology Arm - Bivalirudin | 379 |
| Pharmacology Arm - Unfractionated Heparin | 377 |
Number of participants with major adverse cardiovascular events (death, reinfarction, target-vessel revascularization for ischemia, and stroke) (NCT00433966)
Timeframe: 30 days
| Intervention | Participants (Count of Participants) |
|---|---|
| Pharmacology Arm - Bivalirudin | 98 |
| Pharmacology Arm - Unfractionated Heparin | 99 |
Number of participants with major adverse cardiovascular events (death, reinfarction, target-vessel revascularization for ischemia, and stroke) and major bleeding (bleeding adjudicated as not related to coronary artery bypass grafting). (NCT00433966)
Timeframe: 30 Days
| Intervention | Participants (Count of Participants) |
|---|---|
| Pharmacology Arm - Bivalirudin | 166 |
| Pharmacology Arm - Unfractionated Heparin | 218 |
Number of participants with major bleeding (bleeding adjudicated as not related to coronary artery bypass grafting) (NCT00433966)
Timeframe: 30 days
| Intervention | Participants (Count of Participants) |
|---|---|
| Pharmacology Arm - Bivalirudin | 89 |
| Pharmacology Arm - Unfractionated Heparin | 149 |
Number of Participants With Death, Reinfarction, Stroke, or Stent Thrombosis (NCT00433966)
Timeframe: 1 year
| Intervention | Participants (Count of Participants) |
|---|---|
| Stent Arm - Paclitaxel-Eluting Stent | 181 |
| Stent Arm - Bare Metal Stent | 59 |
Number of Participants With Ischemic Target Lesion Revascularization (NCT00433966)
Timeframe: 1 year
| Intervention | Participants (Count of Participants) |
|---|---|
| Stent Arm - Paclitaxel-Eluting Stent | 98 |
| Stent Arm - Bare Metal Stent | 54 |
Number of Participants With Segment Binary Angiographic Restenosis (13-month Angiographic Subset). (NCT00433966)
Timeframe: 13 months
| Intervention | Participants (Count of Participants) |
|---|---|
| Stent Arm - Paclitaxel-Eluting Stent | 102 |
| Stent Arm - Bare Metal Stent | 76 |
(a patient could have multiple procedural events) (NCT00305162)
Timeframe: during index PCI
| Intervention | participants (Number) |
|---|---|
| Cangrelor Arm | 127 |
| Clopidogrel Arm | 141 |
Major bleeding (non-CABG-related) - Safety population (NCT00305162)
Timeframe: randomization through 48 hours after randomization
| Intervention | participants (Number) |
|---|---|
| Cangrelor Arm | 151 |
| Clopidogrel Arm | 120 |
excludes ACUITY major bleeding for which the only qualifying event was hematoma >/= 5 cm (NCT00305162)
Timeframe: randomization through 48 hours after randomization
| Intervention | participants (Number) |
|---|---|
| Cangrelor Arm | 78 |
| Clopidogrel Arm | 65 |
(excluding STEMI) (NCT00305162)
Timeframe: randomization through 1 year after randomization
| Intervention | participants (Number) |
|---|---|
| Cangrelor Arm | 116 |
| Clopidogrel Arm | 120 |
(NCT00305162)
Timeframe: randomization through 30 days after randomization
| Intervention | participants (Number) |
|---|---|
| Cangrelor Arm | 34 |
| Clopidogrel Arm | 29 |
(composite incidence) (NCT00305162)
Timeframe: randomization through 48 hours after randomization
| Intervention | participants (Number) |
|---|---|
| Cangrelor Arm | 285 |
| Clopidogrel Arm | 261 |
(composite incidence) (NCT00305162)
Timeframe: randomization through 30 days after randomization
| Intervention | participants (Number) |
|---|---|
| Cangrelor Arm | 321 |
| Clopidogrel Arm | 298 |
(composite incidence) (NCT00305162)
Timeframe: randomization through 30 days after randomization
| Intervention | participants (Number) |
|---|---|
| Cangrelor Arm | 343 |
| Clopidogrel Arm | 327 |
(composite incidence) (NCT00305162)
Timeframe: randomization through 48 hours after randomization
| Intervention | participants (Number) |
|---|---|
| Cangrelor Arm | 290 |
| Clopidogrel Arm | 276 |
Major bleeding (non-CABG-related) - Safety population (NCT00305162)
Timeframe: randomization through 48 hours after randomization
| Intervention | participants (Number) |
|---|---|
| Cangrelor Arm | 10 |
| Clopidogrel Arm | 11 |
(NCT00305162)
Timeframe: randomization through 30 days after randomization
| Intervention | participants (Number) |
|---|---|
| Cangrelor Arm | 44 |
| Clopidogrel Arm | 52 |
(NCT00305162)
Timeframe: randomization through 30 days after randomization
| Intervention | participants (Number) |
|---|---|
| Cangrelor Arm | 297 |
| Clopidogrel Arm | 276 |
(NCT00305162)
Timeframe: randomization through 30 days after randomization
| Intervention | participants (Number) |
|---|---|
| Cangrelor Arm | 5 |
| Clopidogrel Arm | 7 |
Major bleeding (non-CABG-related) - Safety population (NCT00305162)
Timeframe: randomization through 48 hours after randomization
| Intervention | participants (Number) |
|---|---|
| Cangrelor Arm | 19 |
| Clopidogrel Arm | 14 |
(NCT00305162)
Timeframe: randomization through 48 hours after randomization
| Intervention | participants (Number) |
|---|---|
| Cangrelor Arm | 8 |
| Clopidogrel Arm | 5 |
(NCT00305162)
Timeframe: randomization through 48 hours after randomization
| Intervention | participants (Number) |
|---|---|
| Cangrelor Arm | 13 |
| Clopidogrel Arm | 23 |
"Stroke is defined as a sudden, focal neurological defect resulting from a cerebrovascular cause that is not reversible within 24 hours and not due to a readily identifiable cause such as a tumor or trauma. All suspected strokes were reviewed and adjudicated by the Clinical Events Committee (CEC) who considered all clinically relevant information and imaging studies to classify all strokes as:~primary hemorrhagic - stroke with focal collections of intracranial blood~ischemic cerebral infarction - stroke without focal collections of intracranial blood~infarction with hemorrhagic conversion - cerebral infarction with blood thought to represent hemorrhagic conversion and not primary bleeding~uncertain - no imaging or autopsy data are available." (NCT00305162)
Timeframe: randomization through 48 hours after randomization
| Intervention | participants (Number) | |||
|---|---|---|---|---|
| primary hemorrhagic | infarction with hemorrhagic conversion | cerebral infarction | uncertain type | |
| Cangrelor Arm | 1 | 0 | 5 | 0 |
| Clopidogrel Arm | 0 | 0 | 7 | 0 |
An AE is any unfavorable and unintended change in the structure, function or chemistry of the body temporally associated with study drug administration, whether or not considered related to the study drug. (NCT00684203)
Timeframe: Up to Day 60
| Intervention | Participants (Number) |
|---|---|
| Vorapaxar 20 mg Loading Dose PCI | 40 |
| Vorapaxar 40 mg Loading Dose PCI | 30 |
| Placebo/Placebo PCI | 21 |
An AE is any unfavorable and unintended change in the structure, function or chemistry of the body temporally associated with study drug administration, whether or not considered related to the study drug. MACE events were defined as nonfatal MI, nonfatal stroke, hospitalization due to recurrent ischemia, or urgent coronary revascularization performed ≥ 30 days after administration of the loading dose (Day 1). All MACE events were excluded from this analysis. Analysis of data was by loading dose group. (NCT00684203)
Timeframe: Up to Day 121
| Intervention | Participants (Number) |
|---|---|
| Vorapaxar 20 mg Loading Dose Non-PCI | 6 |
| Vorapaxar 40 mg Loading Dose Non-PCI | 15 |
| Placebo/Placebo Non-PCI | 1 |
An AE is any unfavorable and unintended change in the structure, function or chemistry of the body temporally associated with study drug administration, whether or not considered related to the study drug. MACE events were defined as nonfatal myocardial infarction (MI), nonfatal stroke, hospitalization due to recurrent ischemia, or urgent coronary revascularization performed ≥ 30 days after administration of the loading dose (Day 1). All MACE events were excluded from this analysis. Analysis of data was by loading/maintenance dose group. (NCT00684203)
Timeframe: Up to Day 121
| Intervention | Participants (Number) |
|---|---|
| Vorapaxar 20 mg/1 mg PCI | 21 |
| Vorapaxar 20 mg/2.5 mg PCI | 19 |
| Vorapaxar 40 mg/1 mg PCI | 16 |
| Vorapaxar 40 mg/2.5 mg PCI | 14 |
| Placebo/Placebo PCI | 21 |
Bleeding events were evaluated among participants that did not undergo PCI to determine the number of participants who required a subsequent hospitalization. Analysis of data was by loading dose group. (NCT00684203)
Timeframe: Up to Day 30
| Intervention | Participants (Number) |
|---|---|
| Vorapaxar 20 mg Loading Dose Non-PCI | 0 |
| Vorapaxar 40 mg Loading Dose Non-PCI | 1 |
| Placebo/Placebo Non-PCI | 0 |
Bleeding events were evaluated among participants that did not undergo PCI to determine the number of participants that required blood transfusion. Analysis of data was by loading dose group. (NCT00684203)
Timeframe: Up to Day 60
| Intervention | Participants (Number) |
|---|---|
| Vorapaxar 20 mg Loading Dose Non-PCI | 1 |
| Vorapaxar 40 mg Loading Dose Non-PCI | 2 |
| Placebo/Placebo Non-PCI | 0 |
Participant blood samples were collected at baseline and at the time of hospital discharge to determine the mean serum level of CD40 ligand. Analysis of data was by loading dose group. (NCT00684203)
Timeframe: Baseline Up To Day 60
| Intervention | ng/mL (Mean) | |
|---|---|---|
| Baseline | Time of Hospital Discharge | |
| Placebo/Placebo Non-PCI | 11.1 | 12.9 |
| Vorapaxar 20 mg Loading Dose Non-PCI | 8.4 | 10.1 |
| Vorapaxar 40 mg Loading Dose Non-PCI | 4.6 | 7.1 |
Participant blood samples were collected at Baseline and Days 30 and 60 to evaluate the mean level of CD40 ligand present. CD40 ligand is a protein primarily found on activated T-cells, with higher levels indicating better immunological health. Analysis of data was by maintenance dose group. (NCT00684203)
Timeframe: Baseline, Day 30, Day 60
| Intervention | ng/mL (Mean) | ||
|---|---|---|---|
| Baseline (n=37, 34, 21) | Day 30 (n=35, 34, 31) | Day 60 (n=30, 25, 13) | |
| Placebo/Placebo PCI | 4.8 | 6.2 | 5.7 |
| Vorapaxar 1 mg Maintenance Dose PCI | 5.6 | 5.9 | 5.6 |
| Vorapaxar 2.5 mg Maintenance Dose PCI | 6.9 | 5.9 | 5.4 |
Participant blood samples were collected at Baseline and Days 30 and 60 to evaluate the mean level of membrane-bound P-selectin. Membrane-bound P-selectin was measured using flow cytometry and a monoclonal antibody to P-selectin. Intensity levels are reported in arbitrary units 0 (dark) to 1023 (bright). Higher values correspond to greater membrane-bound P-Selectin levels. Analysis of data was by maintenance dose group. (NCT00684203)
Timeframe: Baseline, Day 30, Day 60
| Intervention | Arbitrary Units (Mean) | ||
|---|---|---|---|
| Baseline (n=4, 4, 3) | Day 30 (n=3, 4, 3) | Day 60 (n=2, 3, 1) | |
| Placebo/Placebo PCI | 15.9 | 18.8 | 19.4 |
| Vorapaxar 1 mg Maintenance Dose PCI | 24.8 | 20.6 | 25.0 |
| Vorapaxar 2.5 mg Maintenance Dose PCI | 16.5 | 16.4 | 14.9 |
Participant blood samples were collected at Baseline and on Days 30 and 60 to evaluate the median level of hs-CRP. hs-CRP is a protein marker in the blood associated with inflammation with higher values indicating a greater degree of inflammation. Analysis of data was by maintenance dose group. (NCT00684203)
Timeframe: Baseline, Day 30, Day 60
| Intervention | mg/L (Median) | ||
|---|---|---|---|
| Baseline (n=37, 34, 21) | Day 30 (n=35, 34, 21) | Day 60 (n=30, 25, 13) | |
| Placebo/Placebo PCI | 1.78 | 2.99 | 1.27 |
| Vorapaxar 1 mg Maintenance Dose PCI | 1.30 | 1.28 | 1.20 |
| Vorapaxar 2.5 mg Maintenance Dose PCI | 2.00 | 1.01 | 0.79 |
Participant blood samples were collected at baseline and at the time of hospital discharge to determine the median serum level of hs-CRP. Analysis of data was by loading dose group. (NCT00684203)
Timeframe: Baseline Up To Day 60
| Intervention | mg/L (Median) | |
|---|---|---|
| Baseline | Time of Hospital Discharge | |
| Placebo/Placebo Non-PCI | 6.94 | 3.96 |
| Vorapaxar 20 mg Loading Dose Non-PCI | 2.57 | 3.56 |
| Vorapaxar 40 mg Loading Dose Non-PCI | 1.05 | 2.65 |
Clinically important bleeding events were defined as intracranial hemorrhage, bleeding requiring blood transfusion, bleeding requiring hospitalization, and TIMI major bleeding. Analysis of data was by loading dose group. (NCT00684203)
Timeframe: Baseline Up To Day 60
| Intervention | Participants (Number) | |||
|---|---|---|---|---|
| Intracranial hemorrhage | Bleeding requiring transfusion | Bleeding requiring hospitalization | Major TIMI bleeding | |
| Placebo/Placebo Non-PCI | 0 | 0 | 0 | 0 |
| Vorapaxar 20 mg Loading Dose Non-PCI | 0 | 1 | 0 | 1 |
| Vorapaxar 40 mg Loading Dose Non-PCI | 1 | 2 | 1 | 2 |
Clinically important bleeding events were defined as intracranial hemorrhage, bleeding requiring hospitalization, or TIMI major bleeding. Analysis of data was by loading/maintenance dose group. (NCT00684203)
Timeframe: Up to Day 121
| Intervention | Participants (Number) | |
|---|---|---|
| Treatment Phase | Post-Hospital Discharge | |
| Placebo/Placebo PCI | 0 | 0 |
| Vorapaxar 20 mg/1 mg PCI | 3 | 1 |
| Vorapaxar 20 mg/2.5 mg PCI | 0 | 0 |
| Vorapaxar 40 mg/1 mg PCI | 2 | 2 |
| Vorapaxar 40 mg/2.5 mg PCI | 0 | 0 |
Blood samples were collected from participants at Baseline and Days 30, 60, 74, 90, and 121 to determine the extent of inhibition of platelet aggregation induced by thrombin-receptor agonist peptide (TRAP). Analysis of data was by maintenance dose group. (NCT00684203)
Timeframe: Baseline, Day 30, Day 60, Day 74, Day 90, Day 121
| Intervention | Participants (Number) | |||||
|---|---|---|---|---|---|---|
| Baseline | Day 30 | Day 60 | Day 74 (follow-up period) | Day 90 (follow-up period) | Day 121 (follow-up period) | |
| Placebo/Placebo PCI | 3 | 3 | 1 | 3 | 3 | 3 |
| Vorapaxar 1 mg Maintenance Dose PCI | 5 | 5 | 3 | 5 | 5 | 5 |
| Vorapaxar 2.5 mg Maintenance Dose PCI | 4 | 4 | 3 | 4 | 4 | 4 |
Major TIMI bleeding was defined as any intracranial bleeding (excluding microhemorrhages <10 mm evident only on gradient-echo magnetic resonance imaging [MRI]), clinically overt signs of hemorrhage associated with a drop in hemoglobin of ≥5 g/dL, or fatal bleeding (bleeding that directly results in death within 7 days). Minor TIMI bleeding was defined as any clinically overt bleeding resulting in hemoglobin drop of 3 to <5 g/dL. Non-TIMI bleeding included all bleeding events not covered under Major TIMI bleeding or Minor TIMI bleeding. Analysis of data was by maintenance dose group. (NCT00684203)
Timeframe: Up to Day 60
| Intervention | Participants (Number) | ||
|---|---|---|---|
| Major TIMI Bleeding Events | Minor TIMI Bleeding Events | Non-TIMI Bleeding Events | |
| Placebo/Placebo PCI | 0 | 2 | 11 |
| Vorapaxar 1 mg Maintenance Dose PCI | 2 | 5 | 22 |
| Vorapaxar 2.5 mg Maintenance Dose PCI | 0 | 3 | 17 |
Major TIMI bleeding was defined as any intracranial bleeding (excluding microhemorrhages <10 mm evident only on gradient-echo MRI), clinically overt signs of hemorrhage associated with a drop in hemoglobin of ≥5 g/dL, or fatal bleeding (bleeding that directly results in death within 7 days). Minor TIMI bleeding was defined as any clinically overt bleeding resulting in hemoglobin drop of 3 to <5 g/dL. Non-TIMI bleeding included all bleeding events not covered under Major TIMI bleeding or Minor TIMI bleeding. Analysis of data was by loading dose group. (NCT00684203)
Timeframe: Up to Day 60
| Intervention | Participants (Number) | ||
|---|---|---|---|
| Major TIMI Events | Minor TIMI Events | Non-TIMI Bleeding Events | |
| Placebo/Placebo Non-PCI | 0 | 0 | 1 |
| Vorapaxar 20 mg Loading Dose Non-PCI | 1 | 0 | 1 |
| Vorapaxar 40 mg Loading Dose Non-PCI | 2 | 0 | 8 |
"In patients treated with aspirin and clopidogrel aggregometry was performed and depending on the results the patients were either responder or low-responder of antiplatelet therapy.~The following definitions were used for clopidogrel low response (CLR: >5 ohm when stimulated with adenosine diphosphate (ADP) 5 μM) and ASA low response (ALR: >0 ohm;stimulated with arachidonic acid 10 μM) with the ChronoLog 590 aggregometer. In the case of low-response alternative antiplatelet therapy was modified according to the study plan (see protocol section)." (NCT01212302)
Timeframe: 2 years
| Intervention | participants (Number) |
|---|---|
| Clopidogrel Low Response | 155 |
Maximum platelet aggregation (MPA) to 20 micromolar adenosine diphosphase (ADP) as measured with light transmittance aggregometry (LTA). (NCT00356135)
Timeframe: 1 week after first dose of randomized study drug
| Intervention | percent maximum platelet aggregation (%) (Least Squares Mean) |
|---|---|
| Prasugrel 10/10 mg | 41.1 |
| Clopidogrel 75/75 mg | 55.0 |
| Prasugrel 60/10 mg | 41.0 |
Data provided are the MPA to 20 micromolar ADP while taking clopidogrel (measurement taken at end of the 14 day open label phase) grouped by subjects who were taking clopidogrel at the time of the qualifying ACS event compared with subjects who were not taking clopidogrel at the time of the qualifying ACS event. (NCT00356135)
Timeframe: End of 14 day open label
| Intervention | percent maximum platelet aggregation (%) (Mean) |
|---|---|
| Clopidogrel Use | 60.73 |
| No Clopidogrel Use | 55.53 |
Correlation Coefficient comparing the Accumetrics VerifyNow™ P2Y12 device with light transmittance aggregometry (LTA) for monitoring platelet aggregation. (NCT00356135)
Timeframe: 1 week after randomized study drug
| Intervention | correlation coefficient (Number) | |
|---|---|---|
| MPA (20 uM ADP) at 1 week | RPA (20 uM ADP) at 1 week | |
| Clopidogrel 75/75 mg | 0.426 | 0.425 |
| Prasugrel 10/10 mg | 0.564 | 0.640 |
| Prasugrel 60/10 mg | 0.439 | 0.547 |
Maximum platelet aggregation (MPA) to 5 and 20 micromolar adenosine diphosphase (ADP) as measured with light transmittance aggregometry (LTA). (NCT00356135)
Timeframe: 2 hours, 24 hours, 1 week, 2 weeks after first dose of randomized study drug
| Intervention | percent maximum platelet aggregation (%) (Mean) | |||||||
|---|---|---|---|---|---|---|---|---|
| 2 Hour (20 uM ADP) | 24 Hour (20 uM ADP) | 1 Week (20 uM ADP) | 2 Week (20 uM ADP) | 2 Hour (5 uM ADP) | 24 Hour (5 uM ADP) | 1 Week (5 uM ADP) | 2 Week (5 uM ADP) | |
| Clopidogrel 75/75 mg | 48.07 | 53.80 | 53.80 | 52.25 | 37.25 | 40.88 | 41.94 | 41.05 |
| Prasugrel 10/10 mg | 49.46 | 52.29 | 42.95 | 40.84 | 37.87 | 38.84 | 32.44 | 30.18 |
| Prasugrel 60/10 mg | 26.65 | 27.36 | 40.64 | 38.61 | 19.97 | 20.94 | 31.45 | 28.64 |
Bleeding events were classified as Major Bleeding, Minor Bleeding, or Insignificant according to TIMI criteria. Major Bleeding: any intracranial hemorrhage OR any clinically overt bleeding (including bleeding evident on imaging studies) associated with a fall in hemoglobin (Hgb) of ≥5 gm/dL from baseline. Minor Bleeding: any clinically overt bleeding (including bleeding evident on imaging studies) associated with a fall in Hgb of ≥3 gm/dL but <5 gm/dL from baseline. Insignificant Bleeding: any bleeding event that does not meet criteria for a Major or Minor Bleed. (NCT00356135)
Timeframe: End of 14 day open label (baseline); 24 Hours, 7 days, 14 days after first dose of randomized drug
| Intervention | Participants (Number) | ||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Any Bleeding at Any Time During Randomized Period | Baseline: Any Bleeding | Baseline: Insignificant Bleeding | Baseline: Minor Bleeding | Baseline: Major Bleeding | Hour 24: Any Bleeding | Hour 24: Insignificant Bleeding | Hour 24: Minor Bleeding | Hour 24: Major Bleeding | Day 7: Any Bleeding | Day 7: Insignificant Bleeding | Day 7: Minor Bleeding | Day 7: Major Bleeding | Day 14: Any Bleeding | Day 14: Insignificant Bleeding | Day 14: Minor Bleeding | Day 14: Major Bleeding | |
| Clopidogrel 75/75 mg | 6 | 3 | 3 | 0 | 0 | 0 | 0 | 0 | 0 | 2 | 2 | 0 | 0 | 4 | 4 | 0 | 0 |
| Prasugrel 10/10 mg | 4 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 2 | 2 | 0 | 0 | 2 | 2 | 0 | 0 |
| Prasugrel 60/10 mg | 6 | 1 | 1 | 0 | 0 | 1 | 1 | 0 | 0 | 3 | 3 | 0 | 0 | 2 | 2 | 0 | 0 |
Residual platelet aggregation after the addition 5 and 20 micromolar ADP as measured with light transmittance aggregometry (LTA). (NCT00356135)
Timeframe: 2 hours, 24 hours, 1 week, 2 weeks after first dose of randomized study drug
| Intervention | percent residual platelet aggregation (Mean) | |||||||
|---|---|---|---|---|---|---|---|---|
| 2 Hour (20 uM ADP) | 24 Hour (20 uM ADP) | 1 Week (20 uM ADP) | 2 Week (20 uM ADP) | 2 Hour (5 uM ADP) | 24 Hour (5 uM ADP) | 1 Week (5 uM ADP) | 2 Week (5 uM ADP) | |
| Clopidogrel 75/75 mg | 28.21 | 35.16 | 34.45 | 34.56 | 14.84 | 19.66 | 21.57 | 19.28 |
| Prasugrel 10/10 mg | 32.06 | 32.97 | 22.92 | 18.89 | 18.83 | 19.18 | 11.11 | 10.03 |
| Prasugrel 60/10 mg | 5.10 | 4.70 | 17.94 | 15.17 | 4.17 | 4.45 | 9.94 | 9.43 |
The number of participants with at least one major bleeding, validated by the Event Adjudication Committee are counted over the duration of the follow-up (including after permanent discontinuation of the study drug). (NCT00249873)
Timeframe: expected median follow-up of approximately 3 years
| Intervention | participants (Number) |
|---|---|
| Clopidogrel + ASA | 251 |
| Placebo + ASA | 162 |
The considered event is death from any cause. The analysis is performed on the time from randomization to this event. Numbers of patients with the event over the duration of the follow-up are presented by arm group. (NCT00249873)
Timeframe: expected median follow-up of approximately 3 years
| Intervention | participants (Number) |
|---|---|
| Clopidogrel + ASA | 825 |
| Placebo + ASA | 841 |
The event is the occurence of stroke (nonfatal or fatal, ischemic, hemorrhagic or of uncertain type) after validation of the Event Adjudication Committee . The analysis is performed on the time from randomization to the occurrence of this event. Numbers of patients with the event over the duration of the follow-up are presented by arm group. (NCT00249873)
Timeframe: expected median follow-up of approximately 3 years
| Intervention | participants (Number) |
|---|---|
| Clopidogrel + ASA | 296 |
| Placebo + ASA | 408 |
"The primary event is the first occurence of any adjudicated component of the following cluster over the duration of follow-up :~stroke (nonfatal or fatal)~myocardial infarction (nonfatal or fatal)~non-CNS systemic embolism~vascular death~The primary efficacy analysis is performed on the time from randomization to this primary event. Numbers of patients with the composite event over the duration of the follow-up are presented by arm group." (NCT00249873)
Timeframe: expected median follow-up of approximately 3 years
| Intervention | participants (Number) | ||||
|---|---|---|---|---|---|
| All components | - Myocardial Infarction (fatal or not) | - Stroke (fatal or not) | - Non-CNS systemic embolism | - Vascular death | |
| Clopidogrel + ASA | 832 | 84 | 285 | 50 | 413 |
| Placebo + ASA | 924 | 105 | 391 | 48 | 380 |
(NCT00089895)
Timeframe: 96 hours after randomization
| Intervention | percentage of participants (Number) |
|---|---|
| Eptifibatide | 9.3 |
| Placebo | 10.0 |
(NCT00089895)
Timeframe: 30 days after randomization
| Intervention | percentage of participants (Number) |
|---|---|
| Eptifibatide | 11.2 |
| Placebo | 12.3 |
Overall costs expressed in US dollars at 18 months of follow up between Oral Sirolimus Plus BMS vs DES implantation in denovo coronary lesions. (NCT00552669)
Timeframe: Follow up will be conducted by the coordinating Center at 18 months of follow up
| Intervention | US dollars (Mean) |
|---|---|
| Oral Sirolimus + Bare Metal Stent | 5483 |
| Drug Eluting Stents | 7658.2 |
Efficacy end point was TVR as revasacularization of the treated vessel. (NCT00552669)
Timeframe: 18 months
| Intervention | vessels (Number) |
|---|---|
| Oral Sirolimus + Bare Metal Stent | 14 |
| Drug Eluting Stents | 15 |
Death from any cause, myocardial infarction and stroke. Safety was analyzed as MACCE (major adverse cardiovascular events) including death, MI and stroke. (NCT00552669)
Timeframe: 18 Months
| Intervention | participants (Number) | |||
|---|---|---|---|---|
| MACCE | Death | Acute Myocardial Infarction | Stroke | |
| Drug Eluting Stents | 15 | 7 | 9 | 1 |
| Oral Sirolimus + Bare Metal Stent | 9 | 3 | 6 | 0 |
Secondary efficacy outcome: Number of participants with ischemic stroke, myocardial infarction, death from ischemic vascular causes, or major hemorrhage (NCT00991029)
Timeframe: Up to 90 days
| Intervention | Participants (Count of Participants) |
|---|---|
| Clopidogrel | 141 |
| Placebo | 167 |
Primary efficacy outcome: Number of Participants with Ischemic Stroke, Myocardial Infarction, or Death From Ischemic Vascular Causes (NCT00991029)
Timeframe: Up to 90 days
| Intervention | Participants (Count of Participants) |
|---|---|
| Clopidogrel | 121 |
| Placebo | 160 |
Other safety outcome: Number of Participants with Death from any cause (NCT00991029)
Timeframe: up to 90 days
| Intervention | Participants (Count of Participants) |
|---|---|
| Clopidogrel | 18 |
| Placebo | 12 |
Secondary efficacy outcome: Number of participants with Death from ischemic vascular causes (NCT00991029)
Timeframe: Up to 90 days
| Intervention | Participants (Count of Participants) |
|---|---|
| Clopidogrel | 6 |
| Placebo | 4 |
Other safety outcome: Number of participants with Hemorrhagic stroke (NCT00991029)
Timeframe: up to 90 days
| Intervention | Participants (Count of Participants) |
|---|---|
| Clopidogrel | 5 |
| Placebo | 3 |
Secondary efficacy outcome: Number of participants with Ischemic or hemorrhagic stroke (NCT00991029)
Timeframe: Up to 90 days
| Intervention | Participants (Count of Participants) |
|---|---|
| Clopidogrel | 116 |
| Placebo | 156 |
Secondary efficacy outcome:Number of participants with Ischemic stroke (NCT00991029)
Timeframe: Up to 90 days
| Intervention | Participants (Count of Participants) |
|---|---|
| Clopidogrel | 112 |
| Placebo | 155 |
Primary safety outcome: Number of Participants with major hemorrhage (NCT00991029)
Timeframe: Up to 90 days
| Intervention | Participants (Count of Participants) |
|---|---|
| Clopidogrel | 23 |
| Placebo | 10 |
Other safety outcome: Number of Participants with Major hemorrhage other than intracranial hemorrhage (NCT00991029)
Timeframe: up to 90 days
| Intervention | Participants (Count of Participants) |
|---|---|
| Clopidogrel | 17 |
| Placebo | 7 |
Other safety outcome:Number of Participants with Minor hemorrhage (NCT00991029)
Timeframe: up to 90 days
| Intervention | Participants (Count of Participants) |
|---|---|
| Clopidogrel | 40 |
| Placebo | 13 |
Secondary efficacy outcome: Number of participants with Myocardial infarction (NCT00991029)
Timeframe: Up to 90 days
| Intervention | Participants (Count of Participants) |
|---|---|
| Clopidogrel | 10 |
| Placebo | 7 |
Other safety outcome: Number of participants with other symptomatic intracranial hemorrhage (NCT00991029)
Timeframe: up to 90 days
| Intervention | Participants (Count of Participants) |
|---|---|
| Clopidogrel | 2 |
| Placebo | 0 |
Other safety outcome: Number of participants with Symptomatic intracerebral hemorrhage (NCT00991029)
Timeframe: up to 90 days
| Intervention | Participants (Count of Participants) |
|---|---|
| Clopidogrel | 2 |
| Placebo | 2 |
293 reviews available for ticlopidine and Acute Coronary Syndrome
| Article | Year |
|---|---|
The role of platelet glycoprotein IIb / IIIa inhibitors in current treatment of acute coronary syndrome.
Topics: Acute Coronary Syndrome; Humans; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa C | 2022 |
Ideal P2Y12 Inhibitor in Acute Coronary Syndrome: A Review and Current Status.
Topics: Acute Coronary Syndrome; Clopidogrel; Humans; Platelet Aggregation Inhibitors; Prasugrel Hydrochlori | 2022 |
Pharmacokinetic and Pharmacodynamic Responses to Clopidogrel: Evidences and Perspectives.
Topics: Acute Coronary Syndrome; Clopidogrel; Comorbidity; Drug Interactions; Humans; Middle Aged; Platelet | 2017 |
Antiplatelet treatments: recent evidence from randomized controlled trials.
Topics: Acute Coronary Syndrome; Adenosine; Aspirin; Atherosclerosis; Blood Platelets; Humans; Platelet Aggr | 2017 |
Individualized dual antiplatelet therapy based on platelet function testing in patients undergoing percutaneous coronary intervention: a meta-analysis of randomized controlled trials.
Topics: Acute Coronary Syndrome; Blood Platelets; Chi-Square Distribution; Clopidogrel; Coronary Thrombosis; | 2017 |
Duration of dual antiplatelet therapy after coronary stent insertion: Does the benefit of extended therapy outweigh the risk?
Topics: Acute Coronary Syndrome; Aspirin; Clopidogrel; Drug Therapy, Combination; Drug-Eluting Stents; Human | 2016 |
Overcoming Clopidogrel Resistance: Three Promising Novel Antiplatelet Drugs Developed in China.
Topics: Acute Coronary Syndrome; China; Clopidogrel; Drug Discovery; Drug Resistance; Humans; Phenylacetates | 2017 |
The role of prasugrel in the management of acute coronary syndromes: a systematic review.
Topics: Acute Coronary Syndrome; Aspirin; Clopidogrel; Hemorrhage; Humans; Platelet Aggregation Inhibitors; | 2017 |
Role of CYP2C19 genotype testing in clinical use of clopidogrel: is it really useful?
Topics: Acute Coronary Syndrome; Clopidogrel; Coronary Artery Disease; Cytochrome P-450 CYP2C19; Genotype; H | 2018 |
Dual antiplatelet therapy with aspirin and clopidogrel: what is the risk in noncardiac surgery? A narrative review.
Topics: Acute Coronary Syndrome; Clopidogrel; Humans; Perioperative Care; Platelet Aggregation Inhibitors; P | 2013 |
The role of clopidogrel in the management of ischemic heart disease.
Topics: Acute Coronary Syndrome; Aryl Hydrocarbon Hydroxylases; Clopidogrel; Cytochrome P-450 CYP2C19; Human | 2013 |
A transition of P2Y12 antagonists for acute coronary syndrome: benefits, risks and costs.
Topics: Acute Coronary Syndrome; Adenosine; Clopidogrel; Hemorrhage; Humans; Piperazines; Prasugrel Hydrochl | 2014 |
Cigarette smoking and clopidogrel interaction.
Topics: Acute Coronary Syndrome; Blood Platelets; Clopidogrel; Humans; Platelet Aggregation Inhibitors; Puri | 2013 |
[Prominent features of management strategies in acute coronary syndromes with the new oral antiplatelet agents].
Topics: Acute Coronary Syndrome; Adenosine; Administration, Oral; Clopidogrel; Humans; Piperazines; Platelet | 2013 |
Aspirin, clopidogrel, and ticagrelor in acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aspirin; Clopidogrel; Dose-Response Relationship, Drug; Drug Int | 2013 |
Use of antiplatelet drugs in the treatment of acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Aged, 80 and over; Angina, Unstable; Aspirin; Clinical Trials as Topi | 2013 |
Clopidogrel, prasugrel, or ticagrelor? a practical guide to use of antiplatelet agents in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aspirin; Clopidogrel; Decision Support Techniques; Drug Therapy, | 2013 |
New antiplatelet agents and the role of platelet function testing in acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Adenosine Monophosphate; Blood Platelets; Clopidogrel; Drug Ther | 2013 |
Focused 2012 update of the Canadian Cardiovascular Society guidelines for the use of antiplatelet therapy.
Topics: Acute Coronary Syndrome; Adenosine; Anticoagulants; Aspirin; Clinical Trials as Topic; Clopidogrel; | 2013 |
Proton pump inhibitors and clopidogrel: an association to avoid?
Topics: Acute Coronary Syndrome; Clopidogrel; Cytochrome P-450 CYP2C19; Drug Interactions; Humans; Lansopraz | 2014 |
Triple versus dual antiplatelet therapy in acute coronary syndromes: adding cilostazol to aspirin and clopidogrel?
Topics: Acute Coronary Syndrome; Aspirin; Cilostazol; Clinical Trials as Topic; Clopidogrel; Drug Therapy, C | 2013 |
Use of antiplatelet agents in patients with atherosclerotic disease.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Aspirin; Atherosclerosis; Clopidogrel; Coronary Artery Dis | 2013 |
Dual antiplatelet therapy -- management in general practice.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Aspirin; Clopidogrel; Drug Interactions; Drug Therapy, Com | 2013 |
Platelet glycoprotein IIb/IIIa blockers during percutaneous coronary intervention and as the initial medical treatment of non-ST segment elevation acute coronary syndromes.
Topics: Acute Coronary Syndrome; Angioplasty, Balloon, Coronary; Aspirin; Cause of Death; Fibrinolytic Agent | 2013 |
Combination of a new oral anticoagulant, aspirin and clopidogrel after acute coronary syndrome: new therapeutic standard?
Topics: Acute Coronary Syndrome; Administration, Oral; Anticoagulants; Aspirin; Cardiovascular Diseases; Cli | 2013 |
Ticagrelor for acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Animals; Clinical Trials, Phase III as Topic; Clopidogrel; Human | 2013 |
Platelet glycoprotein IIb/IIIa blockers during percutaneous coronary intervention and as the initial medical treatment of non-ST segment elevation acute coronary syndromes.
Topics: Acute Coronary Syndrome; Angioplasty, Balloon, Coronary; Aspirin; Fibrinolytic Agents; Hemorrhage; H | 2013 |
What's new about clopidogrel.
Topics: Acute Coronary Syndrome; Aryl Hydrocarbon Hydroxylases; Clopidogrel; Cytochrome P-450 CYP2C19; Drug | 2013 |
Benefits from new ADP antagonists as compared with clopidogrel in patients with stable angina or acute coronary syndrome undergoing invasive management: a meta-analysis of randomized trials.
Topics: Acute Coronary Syndrome; Adenosine Diphosphate; Angina, Stable; Case Management; Clopidogrel; Endpoi | 2014 |
[Antiplatelet therapy: resistance to traditional antiaggregation drugs and role of new antiplatelet agents].
Topics: Acute Coronary Syndrome; Aspirin; Cardiovascular Diseases; Clinical Trials as Topic; Clopidogrel; Dr | 2014 |
Genetic and nongenetic factors influencing the response to clopidogrel.
Topics: Acute Coronary Syndrome; Aryl Hydrocarbon Hydroxylases; Clopidogrel; Cytochrome P-450 CYP2C19; Drug | 2013 |
Potential clinical utility of genetic and platelet function tests in patients on treatment with clopidogrel.
Topics: Acute Coronary Syndrome; Blood Platelets; Clopidogrel; Drug Administration Schedule; Drug Monitoring | 2013 |
Characteristics of new P2Y12 inhibitors: selection of P2Y12 inhibitors in clinical practice.
Topics: Acute Coronary Syndrome; Clopidogrel; Drug Administration Schedule; Humans; Platelet Aggregation Inh | 2013 |
Identifying responsiveness to oral P2Y12 receptor blockers: platelet function assays and genetic tests.
Topics: Acute Coronary Syndrome; Administration, Oral; Angioplasty, Balloon, Coronary; Blood Platelets; Clop | 2013 |
[Differentiated antiplatelet therapy for acute coronary syndromes].
Topics: Acute Coronary Syndrome; Adenosine; Angina, Unstable; Aspirin; Blood Platelets; Clopidogrel; Hemorrh | 2014 |
p2y12 receptor inhibitors in acute coronary syndromes: from the research laboratory to the clinic and vice versa.
Topics: Acute Coronary Syndrome; Aspirin; Clinical Trials as Topic; Clopidogrel; Diabetic Angiopathies; Huma | 2014 |
Anticoagulation and antiplatelet therapy in acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Anticoagulants; Aspirin; Benzimidazoles; beta-Alanine; Clopidogr | 2014 |
Unanswered questions in patients with concurrent atrial fibrillation and acute coronary syndrome.
Topics: Acute Coronary Syndrome; Anticoagulants; Aspirin; Atrial Fibrillation; Clopidogrel; Comorbidity; Dru | 2014 |
Impact of new oral or intravenous P2Y12 inhibitors and clopidogrel on major ischemic and bleeding events in patients with coronary artery disease: a meta-analysis of randomized trials.
Topics: Acute Coronary Syndrome; Adenosine; Adenosine Monophosphate; Administration, Oral; Clopidogrel; Coro | 2014 |
Pharmacokinetic evaluation of prasugrel for the treatment of myocardial infarction.
Topics: Acute Coronary Syndrome; Clopidogrel; Humans; Myocardial Infarction; Percutaneous Coronary Intervent | 2014 |
New antiplatelet agents in the treatment of acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Adenosine Monophosphate; Clinical Trials as Topic; Clopidogrel; | 2014 |
Efficacy and safety of prasugrel in acute coronary syndrome patients.
Topics: Acute Coronary Syndrome; Clopidogrel; Hemorrhage; Humans; Piperazines; Platelet Aggregation Inhibito | 2014 |
Should P2Y12 inhibitors be given for 12 months in acute coronary syndrome?
Topics: Acute Coronary Syndrome; Aspirin; Clopidogrel; Humans; Myocardial Ischemia; Percutaneous Coronary In | 2014 |
Update: Acute coronary syndromes (V). Personalized antiplatelet therapy.
Topics: Acute Coronary Syndrome; Clopidogrel; Humans; Platelet Aggregation Inhibitors; Precision Medicine; R | 2014 |
Role of phenotypic and genetic testing in managing clopidogrel therapy.
Topics: Acute Coronary Syndrome; Adenosine; Aryl Hydrocarbon Hydroxylases; Clopidogrel; Cytochrome P-450 CYP | 2014 |
Should clopidogrel be discontinued before coronary artery bypass grafting for patients with acute coronary syndrome? A systematic review and meta-analysis.
Topics: Acute Coronary Syndrome; Chi-Square Distribution; Clopidogrel; Coronary Artery Bypass; Drug Administ | 2014 |
[Dual platelet inhibitors in intensive care units].
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Germany; Guideline Adherence; Hemorrhage; Hum | 2014 |
[Antiplatelet drugs].
Topics: Acute Coronary Syndrome; Aspirin; Blood Platelets; Clopidogrel; Drug Therapy, Combination; Humans; P | 2014 |
[Antiplatelet therapy in atherosclerosis of various localizations: acute and stable States].
Topics: Acute Coronary Syndrome; Aspirin; Atherosclerosis; Drug Therapy, Combination; Drug-Related Side Effe | 2014 |
Decade in review--acute coronary syndromes: Successes and future objectives in acute coronary syndrome.
Topics: Acute Coronary Syndrome; Anticoagulants; Antithrombins; Aspirin; Clopidogrel; Hemorrhage; Humans; My | 2014 |
[Using ADP receptor antagonists in coronary heart disease and acute coronary syndrome].
Topics: Acute Coronary Syndrome; Adenosine; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary D | 2014 |
Management of acute coronary syndrome in the hospital: a focus on ACCF/AHA guideline updates to oral antiplatelet therapy.
Topics: Acute Coronary Syndrome; Adenosine; Age Factors; Aspirin; Body Weight; Clopidogrel; Humans; Myocardi | 2014 |
Pharmacodynamic and clinical implications of switching between P2Y12 receptor antagonists: considerations for practice.
Topics: Acute Coronary Syndrome; Clopidogrel; Drug Substitution; Humans; Platelet Aggregation Inhibitors; Pu | 2014 |
Pretreatment with P2Y12 inhibitors in non-ST-segment-elevation acute coronary syndrome is clinically justified.
Topics: Acute Coronary Syndrome; Clopidogrel; Humans; Purinergic P2Y Receptor Antagonists; Ticlopidine; Trea | 2014 |
[Added value of clopidogrel in cardiology and neurology].
Topics: Acute Coronary Syndrome; Aspirin; Clopidogrel; Hemorrhage; Humans; Platelet Aggregation Inhibitors; | 2014 |
Effect of addition of clopidogrel to aspirin on subdural hematoma: meta-analysis of randomized clinical trials.
Topics: Acute Coronary Syndrome; Aged; Aspirin; Atrial Fibrillation; Clopidogrel; Drug Therapy, Combination; | 2015 |
Clinical pharmacokinetics and pharmacodynamics of clopidogrel.
Topics: Acute Coronary Syndrome; Clopidogrel; Cytochrome P-450 CYP2C19; Dose-Response Relationship, Drug; Hu | 2015 |
Prasugrel hydrochloride for the treatment of acute coronary syndromes.
Topics: Acute Coronary Syndrome; Animals; Aspirin; Clinical Trials, Phase III as Topic; Clopidogrel; Drug Th | 2015 |
Review of pharmacoeconomic evaluation of genotype-guided antiplatelet therapy.
Topics: Acute Coronary Syndrome; Adenosine; Clopidogrel; Cost-Benefit Analysis; Cytochrome P-450 CYP2C19; Ge | 2015 |
Developments in Oral Antiplatelet Agents for the Treatment of Acute Coronary Syndromes: Clopidogrel, Prasugrel, and Ticagrelor.
Topics: Acute Coronary Syndrome; Adenosine; Administration, Oral; Clinical Trials as Topic; Clopidogrel; Hum | 2016 |
[Anticoagulant therapy in secondary prevention of coronary events].
Topics: Acute Coronary Syndrome; Administration, Oral; Anticoagulants; Aspirin; Benzimidazoles; beta-Alanine | 2014 |
Clinical evidence for oral antiplatelet therapy in acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Administration, Oral; Aspirin; Clopidogrel; Coronary Artery Bypa | 2015 |
Novel oral P2Y12 inhibitor prasugrel vs. clopidogrel in patients with acute coronary syndrome: evidence based on 6 studies.
Topics: Acute Coronary Syndrome; Administration, Oral; Clopidogrel; Evidence-Based Medicine; Hemorrhage; Hum | 2015 |
Thrombocytopenia in acute coronary syndromes: etiologies and proposed management.
Topics: Acute Coronary Syndrome; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Drug Therapy, Combina | 2015 |
Dual Antiplatelet Therapy After Coronary Artery Bypass Grafting in the Setting of Acute Coronary Syndrome.
Topics: Acute Coronary Syndrome; Aspirin; Clinical Trials as Topic; Clopidogrel; Coronary Artery Bypass; Dru | 2015 |
Antiplatelet therapy following transcatheter aortic valve implantation.
Topics: Acute Coronary Syndrome; Aged; Aged, 80 and over; Aortic Valve Stenosis; Aspirin; Cardiac Catheteriz | 2015 |
Switching from Clopidogrel to Prasugrel in patients undergoing PCI: A meta-analytic overview.
Topics: Acute Coronary Syndrome; Clopidogrel; Drug Substitution; Hemorrhage; Humans; Myocardial Infarction; | 2016 |
Practical experience with ticagrelor: an Australian and New Zealand perspective.
Topics: Acute Coronary Syndrome; Adenosine; Clopidogrel; Hemorrhage; Humans; Platelet Aggregation Inhibitors | 2015 |
Meta-Analysis of Comparison of the Newer Oral P2Y12 Inhibitors (Prasugrel or Ticagrelor) to Clopidogrel in Patients With Non-ST-Elevation Acute Coronary Syndrome.
Topics: Acute Coronary Syndrome; Adenosine; Administration, Oral; Clopidogrel; Dose-Response Relationship, D | 2015 |
Clopidogrel and Genotyping.
Topics: Acute Coronary Syndrome; Clopidogrel; Cytochrome P-450 CYP2C19; Drug Therapy, Combination; Gastroint | 2015 |
Current Evidence on Platelet P2Y12 Receptor Inhibitors: Is There Still a Role for Clopidogrel in 2015?
Topics: Acute Coronary Syndrome; Adenosine; Algorithms; Angioplasty, Balloon, Coronary; Clopidogrel; Humans; | 2015 |
Trends in pharmacological therapy following an acute coronary syndrome in Portugal: a systematic review.
Topics: Acute Coronary Syndrome; Angiotensin-Converting Enzyme Inhibitors; Aspirin; Cardiovascular Agents; C | 2016 |
Antiplatelet therapy in acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aspirin; Clopidogrel; Hemorrhage; Humans; Percutaneous Coronary | 2015 |
Ticagrelor: a safe and effective approach for overcoming clopidogrel resistance in patients with stent thrombosis?
Topics: Acute Coronary Syndrome; Adenosine; Angioplasty, Balloon, Coronary; Blood Platelets; Clopidogrel; Co | 2016 |
Recurrent acute coronary syndrome and restenosis after percutaneous coronary intervention in a patient with idiopathic thrombocytopenic purpura: a case report and literature review.
Topics: Acute Coronary Syndrome; Aged; Anticoagulants; Aspirin; Clopidogrel; Coronary Angiography; Drug-Elut | 2015 |
Efficacy and safety analysis of new P2Y12 inhibitors versus clopidogrel in patients with percutaneous coronary intervention: a meta-analysis.
Topics: Acute Coronary Syndrome; Clopidogrel; Hemorrhage; Humans; Myocardial Infarction; Percutaneous Corona | 2015 |
Comparing the effectiveness and safety between triple antiplatelet therapy and dual antiplatelet therapy in type 2 diabetes mellitus patients after coronary stents implantation: a systematic review and meta-analysis of randomized controlled trials.
Topics: Acute Coronary Syndrome; Aspirin; Cilostazol; Clopidogrel; Coronary Artery Disease; Diabetes Mellitu | 2015 |
Clopidogrel, prasugrel, ticagrelor or vorapaxar in patients with renal impairment: do we have a winner?
Topics: Acute Coronary Syndrome; Adenosine; Clinical Trials as Topic; Clopidogrel; Comparative Effectiveness | 2015 |
On-treatment platelet reactivity: State of the art and perspectives.
Topics: Acute Coronary Syndrome; Adenosine; Age Factors; Blood Platelets; Clopidogrel; Cytochrome P-450 CYP2 | 2016 |
PON1 Q192R genetic variant and response to clopidogrel and prasugrel: pharmacokinetics, pharmacodynamics, and a meta-analysis of clinical outcomes.
Topics: Acute Coronary Syndrome; Aged; Amino Acid Substitution; Aryldialkylphosphatase; Clopidogrel; Female; | 2016 |
Pre-treatment with P2Y12 inhibitors in ACS patients: who, when, why, and which agent?
Topics: Acute Coronary Syndrome; Humans; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors | 2016 |
Reviewing the controversy surrounding pre-treatment with P2Y12 inhibitors in acute coronary syndrome patients.
Topics: Acute Coronary Syndrome; Adenosine; Adenosine Monophosphate; Clopidogrel; Coronary Artery Disease; H | 2016 |
When is the Best Time for the Second Antiplatelet Agent in Non-St Elevation Acute Coronary Syndrome?
Topics: Acute Coronary Syndrome; Clinical Trials as Topic; Clopidogrel; Humans; Meta-Analysis as Topic; Plat | 2016 |
The pharmacodynamics of antiplatelet compounds in thrombosis treatment.
Topics: Acute Coronary Syndrome; Animals; Aspirin; Blood Platelets; Clopidogrel; Drug Design; Drug Therapy, | 2016 |
Oral P2Y12 Receptor Inhibitors in Hemodialysis Patients Undergoing Percutaneous Coronary Interventions: Current Knowledge and Future Directions.
Topics: Acute Coronary Syndrome; Adenosine; Clopidogrel; Humans; Percutaneous Coronary Intervention; Prasugr | 2016 |
Cytochrome allelic variants and clopidogrel metabolism in cardiovascular diseases therapy.
Topics: Acute Coronary Syndrome; Clopidogrel; Cytochrome P-450 Enzyme System; Drug Therapy, Combination; Gen | 2016 |
Systematic review of the clinical impact of dual antiplatelet therapy discontinuation after acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aspirin; Clopidogrel; Drug Therapy, Combination; Humans; Platelet Aggregati | 2017 |
Individualizing Duration of Dual Antiplatelet Therapy After Acute Coronary Syndrome or Percutaneous Coronary Intervention.
Topics: Acute Coronary Syndrome; Aged; Aged, 80 and over; Aspirin; Drug Administration Schedule; Female; Hem | 2016 |
[Subgroup analysis results of platelet inhibition trial in acute coronary syndrome patients (PLATO) who underwent intervention or medical treatment].
Topics: Acute Coronary Syndrome; Adenosine; Clopidogrel; Humans; Platelet Aggregation Inhibitors; Ticagrelor | 2013 |
Clopidogrel-Proton Pump Inhibitor Drug-Drug Interaction and Risk of Adverse Clinical Outcomes Among PCI-Treated ACS Patients: A Meta-analysis.
Topics: Acute Coronary Syndrome; Clopidogrel; Combined Modality Therapy; Drug Interactions; Humans; Percutan | 2016 |
Safety and efficacy of IIb/IIIa inhibitors in combination with highly active oral antiplatelet regimens in acute coronary syndromes: A meta-analysis of pivotal trials.
Topics: Acute Coronary Syndrome; Adenosine; Adult; Aged; Aged, 80 and over; Clinical Trials as Topic; Clopid | 2017 |
Immature Platelets: Clinical Relevance and Research Perspectives.
Topics: Acute Coronary Syndrome; Aspirin; Blood Platelets; Clopidogrel; Humans; Megakaryocytes; RNA, Messeng | 2016 |
Prasugrel hydrochloride for the treatment of acute coronary syndrome patients.
Topics: Acute Coronary Syndrome; Administration, Oral; Aspirin; Blood Platelets; Clopidogrel; Hemorrhage; Hu | 2016 |
Pharmacokinetics and pharmacodynamics of ticagrelor in the treatment of cardiac ischemia.
Topics: Acute Coronary Syndrome; Adenosine; Animals; Aspirin; Clopidogrel; Drug Therapy, Combination; Humans | 2016 |
Current controversies in the use of aspirin and ticagrelor for the treatment of thrombotic events.
Topics: Acute Coronary Syndrome; Adenosine; Aspirin; Clopidogrel; Humans; Platelet Aggregation Inhibitors; P | 2016 |
Genetic Determinants of P2Y
Topics: Acute Coronary Syndrome; Alleles; Clopidogrel; Cytochrome P-450 CYP2C19; Genotype; Humans; Percutane | 2017 |
Meta-analysis of clopidogrel pretreatment in acute coronary syndrome patients undergoing invasive strategy.
Topics: Acute Coronary Syndrome; Clopidogrel; Humans; Percutaneous Coronary Intervention; Platelet Aggregati | 2017 |
Meta-analysis of Comparison of the Newer P2Y12 Inhibitors (Oral Preparation or Intravenous) to Clopidogrel in Patients With Acute Coronary Syndrome.
Topics: Acute Coronary Syndrome; Administration, Intravenous; Administration, Oral; Clopidogrel; Humans; Pur | 2017 |
Spontaneous coronary artery dissection: Case report and review of the literature.
Topics: Acute Coronary Syndrome; Adrenergic beta-1 Receptor Antagonists; Adult; Aspirin; Atorvastatin; Clopi | 2016 |
Three, six, or twelve months of dual antiplatelet therapy after DES implantation in patients with or without acute coronary syndromes: an individual patient data pairwise and network meta-analysis of six randomized trials and 11 473 patients.
Topics: Acute Coronary Syndrome; Analysis of Variance; Aspirin; Blood Vessel Prosthesis Implantation; Clopid | 2017 |
Oral antiplatelet agents for the management of acute coronary syndromes: A review for nurses and allied healthcare professionals.
Topics: Acute Coronary Syndrome; Adenosine; Administration, Oral; Arylsulfonates; Aspirin; Clopidogrel; Dise | 2017 |
Antiplatelet and anticoagulant agents: key differences in mechanisms of action, clinical application, and therapeutic benefit in patients with non-ST-segment-elevation acute coronary syndromes.
Topics: Acute Coronary Syndrome; Angioplasty, Balloon, Coronary; Anticoagulants; Aspirin; Clopidogrel; Hirud | 2008 |
The year in interventional cardiology.
Topics: Acute Coronary Syndrome; American Heart Association; Angioplasty, Balloon, Coronary; Clopidogrel; Co | 2008 |
Antiplatelet treatment of cardiovascular disease: a translational research perspective.
Topics: Acute Coronary Syndrome; Aspirin; Clopidogrel; Coronary Thrombosis; Drug Resistance; Humans; Platele | 2008 |
Current antiplatelet therapies: benefits and limitations.
Topics: Acute Coronary Syndrome; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Disease; Dru | 2008 |
Treatment strategies in non-ST-elevation acute coronary syndromes in patients undergoing percutaneous coronary intervention: an evidence-based review of clinical trial results and treatment guidelines: report on a roundtable discussion.
Topics: Acute Coronary Syndrome; Algorithms; Angioplasty, Balloon, Coronary; Anticoagulants; Aspirin; Cardio | 2008 |
Intensity of antiplatelet therapy in patients with acute coronary syndromes and percutaneous coronary intervention: the promise of prasugrel?
Topics: Acute Coronary Syndrome; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Drug Therapy, Combina | 2008 |
Is prasugrel more effective than clopidogrel in patients with acute coronary syndrome scheduled for PCI?
Topics: Acute Coronary Syndrome; Angioplasty, Balloon, Coronary; Clopidogrel; Dose-Response Relationship, Dr | 2008 |
The rationale for and comparisons of different antiplatelet treatments in acute coronary syndrome.
Topics: Acute Coronary Syndrome; Aspirin; Blood Coagulation; Blood Platelets; Clopidogrel; Drug Therapy, Com | 2008 |
Contemporary issues on clopidogrel therapy.
Topics: Acute Coronary Syndrome; Clopidogrel; Dose-Response Relationship, Drug; Humans; Outcome Assessment, | 2009 |
Role of antiplatelet therapy across the spectrum of patients with coronary artery disease.
Topics: Acute Coronary Syndrome; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Artery Disea | 2009 |
Variability in responsiveness to oral antiplatelet therapy.
Topics: Acute Coronary Syndrome; Administration, Oral; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; | 2009 |
Monitoring platelet function to reduce the risk of ischemic and bleeding complications.
Topics: Acute Coronary Syndrome; Angioplasty, Balloon, Coronary; Aspirin; Blood Platelets; Clopidogrel; Hemo | 2009 |
Optimizing long-term dual aspirin/clopidogrel therapy in acute coronary syndromes: when does the risk outweigh the benefit?
Topics: Acute Coronary Syndrome; Administration, Oral; Aspirin; Clinical Trials as Topic; Clopidogrel; Drug | 2009 |
Clopidogrel resistance: pharmacokinetic or pharmacogenetic?
Topics: Acute Coronary Syndrome; Aryl Hydrocarbon Hydroxylases; Clopidogrel; Cytochrome P-450 CYP2C19; Cytoc | 2009 |
Antiplatelet therapy in percutaneous coronary intervention: integration of prasugrel into clinical practice.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Clopidogrel; Combined Modality Therap | 2009 |
Unmet needs in oral antiplatelet therapy with ADP receptor blocking agents.
Topics: Acute Coronary Syndrome; Adenosine; Adenosine Diphosphate; Administration, Oral; Clinical Trials as | 2009 |
Benefits and risks of clopidogrel use in patients with coronary artery disease: evidence from randomized studies and registries.
Topics: Acute Coronary Syndrome; Angioplasty, Balloon, Coronary; Clopidogrel; Coronary Artery Disease; Dose- | 2008 |
Does timing matter? Upstream or downstream administration of antiplatelet therapy.
Topics: Acute Coronary Syndrome; Algorithms; Aspirin; Clopidogrel; Coronary Angiography; Drug Administration | 2009 |
Percutaneous coronary intervention: assessing coronary vascular risk associated with bare-metal and drug-eluting stents.
Topics: Acute Coronary Syndrome; Angioplasty, Balloon; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; | 2009 |
Acute coronary syndrome and its antithrombotic treatment: focus on aspirin and clopidogrel resistance.
Topics: Acute Coronary Syndrome; Angioplasty, Balloon, Coronary; Aspirin; Clinical Trials as Topic; Clopidog | 2009 |
Clopidogrel in acute coronary syndromes.
Topics: Acute Coronary Syndrome; Clopidogrel; Drug-Eluting Stents; Hemorrhage; Humans; Myocardial Infarction | 2009 |
Prasugrel in acute coronary syndrome patients undergoing percutaneous coronary intervention.
Topics: Acute Coronary Syndrome; Angioplasty, Balloon, Coronary; Clinical Trials as Topic; Clopidogrel; Huma | 2009 |
Prasugrel for the treatment of patients with acute coronary syndrome.
Topics: Acute Coronary Syndrome; Administration, Oral; Angioplasty, Balloon, Coronary; Animals; Clinical Tri | 2009 |
[New approach to interventional cardiology treatment with personalized medicine].
Topics: Acute Coronary Syndrome; Adrenergic beta-Antagonists; Angiotensin-Converting Enzyme Inhibitors; Aspi | 2008 |
Prasugrel: newest antiplatelet agent and its emerging role in management of acute coronary syndrome and percutaneous coronary intervention.
Topics: Acute Coronary Syndrome; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Drug Resistance; Huma | 2009 |
Clopidogrel in the management of acute coronary syndromes: indications, results, obstacles.
Topics: Acute Coronary Syndrome; Clopidogrel; Humans; Platelet Aggregation Inhibitors; Ticlopidine; Treatmen | 2009 |
Review of prasugrel for the secondary prevention of atherothrombosis.
Topics: Acute Coronary Syndrome; Angioplasty, Balloon, Coronary; Atherosclerosis; Clopidogrel; Humans; Piper | 2009 |
Hospitals with and without percutaneous coronary intervention capability: considerations for treating acute coronary syndromes.
Topics: Acute Coronary Syndrome; Angioplasty, Balloon, Coronary; Anticoagulants; Aspirin; Clopidogrel; Emerg | 2009 |
A new generation of antiplatelet agents.
Topics: Acute Coronary Syndrome; Aspirin; Clopidogrel; Humans; Myocardial Infarction; Platelet Aggregation I | 2009 |
Diabetes and acute coronary syndromes.
Topics: Acute Coronary Syndrome; Anticoagulants; Aspirin; Blood Glucose; Clopidogrel; Diabetes Mellitus; Dia | 2009 |
The effect of different treatment durations of clopidogrel in patients with non-ST-segment elevation acute coronary syndromes: a systematic review and value of information analysis.
Topics: Acute Coronary Syndrome; Adolescent; Adult; Aged; Aspirin; Clopidogrel; Drug Therapy, Combination; F | 2009 |
Ticagrelor: the first reversibly binding oral P2Y12 receptor antagonist.
Topics: Acute Coronary Syndrome; Adenosine; Adenosine Diphosphate; Animals; Atherosclerosis; Clinical Trials | 2009 |
P2Y(12) inhibitors: differences in properties and mechanisms of action and potential consequences for clinical use.
Topics: Acute Coronary Syndrome; Clopidogrel; Cytochrome P-450 Enzyme System; Humans; Piperazines; Platelet | 2009 |
Prasugrel: a review of its use in patients with acute coronary syndromes undergoing percutaneous coronary intervention.
Topics: Acute Coronary Syndrome; Adult; Aged; Angioplasty, Balloon, Coronary; Blood Loss, Surgical; Clopidog | 2009 |
Coronary bypass surgery in patients treated with clopidogrel. Is it safe?
Topics: Acute Coronary Syndrome; Clopidogrel; Coronary Angiography; Coronary Artery Bypass; Hemorrhage; Huma | 2009 |
Pharmacodynamic effect and clinical efficacy of clopidogrel and prasugrel with or without a proton-pump inhibitor: an analysis of two randomised trials.
Topics: Acute Coronary Syndrome; Aged; Cardiovascular Diseases; Clopidogrel; Drug Interactions; Drug Therapy | 2009 |
Antiplatelet resistance--fact or myth?
Topics: Acute Coronary Syndrome; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Drug Resistance; Huma | 2009 |
Dual antiplatelet therapy in coronary artery disease: a case-based approach.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Artery | 2009 |
Comparison of prasugrel and clopidogrel in patients with acute coronary syndrome undergoing percutaneous coronary intervention.
Topics: Acute Coronary Syndrome; Angioplasty, Balloon, Coronary; Clopidogrel; Hemorrhage; Humans; Piperazine | 2009 |
Advances in antiplatelet treatment for acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Clopidogrel; Female; Forecasting; Humans; Male; Middle Aged; Pip | 2010 |
Ticagrelor--a new platelet aggregation inhibitor in patients with acute coronary syndromes. An improvement of other inhibitors?
Topics: Acute Coronary Syndrome; Adenosine; Adenosine Monophosphate; Biotransformation; Clinical Trials as T | 2009 |
Ticagrelor--a new platelet aggregation inhibitor in patients with acute coronary syndromes. An improvement of other inhibitors?
Topics: Acute Coronary Syndrome; Adenosine; Adenosine Monophosphate; Biotransformation; Clinical Trials as T | 2009 |
Ticagrelor--a new platelet aggregation inhibitor in patients with acute coronary syndromes. An improvement of other inhibitors?
Topics: Acute Coronary Syndrome; Adenosine; Adenosine Monophosphate; Biotransformation; Clinical Trials as T | 2009 |
Ticagrelor--a new platelet aggregation inhibitor in patients with acute coronary syndromes. An improvement of other inhibitors?
Topics: Acute Coronary Syndrome; Adenosine; Adenosine Monophosphate; Biotransformation; Clinical Trials as T | 2009 |
[Acute coronary syndrome in patients with carbohydrate metabolic disturbances (a review)].
Topics: Acute Coronary Syndrome; Blood Glucose; Cardiovascular Diseases; Clinical Trials as Topic; Clopidogr | 2009 |
Prasugrel: a critical comparison with clopidogrel.
Topics: Acute Coronary Syndrome; Angioplasty, Balloon, Coronary; Animals; Clinical Trials as Topic; Clopidog | 2009 |
Metabolism and disposition of the thienopyridine antiplatelet drugs ticlopidine, clopidogrel, and prasugrel in humans.
Topics: Acute Coronary Syndrome; Aryl Hydrocarbon Hydroxylases; Blood Platelets; Clopidogrel; Cytochrome P-4 | 2010 |
Update on antiplatelet therapy in acute coronary syndromes: what do new drugs bring into clinical practice?
Topics: Acute Coronary Syndrome; Adenosine; Adenosine Diphosphate; Adenosine Monophosphate; Clopidogrel; Hum | 2009 |
Prasugrel: Clinical development and therapeutic application.
Topics: Acute Coronary Syndrome; Angioplasty; Clopidogrel; Hemorrhage; Humans; Piperazines; Platelet Aggrega | 2009 |
Current standings of the proton pump inhibitor and clopidogrel co-therapy: review on an evolving field with the eyes of the gastroenterologist.
Topics: Acute Coronary Syndrome; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Drug Interactions; Dr | 2010 |
[Thienopyridines in the treatment and prevention of cardiovascular diseases. Part IV. therapeutic application of clopidogrel in combination with acetylsalicylic acid in acute coronary syndromes and percutaneous coronary interventions].
Topics: Acute Coronary Syndrome; American Heart Association; Angioplasty, Balloon; Aspirin; Clinical Trials | 2009 |
Unresolved issues associated with early initiation of antiplatelet therapy in acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aspirin; Clopidogrel; Dose-Response Relationship, Drug; Humans; Platelet Ag | 2010 |
Efficacy and safety of ticagrelor: a reversible P2Y12 receptor antagonist.
Topics: Acute Coronary Syndrome; Adenosine; Animals; Cardiovascular Diseases; Clopidogrel; Humans; Platelet | 2010 |
Preventing serious sequelae after an acute coronary syndrome: the consequences of thrombosis versus bleeding with antiplatelet therapy.
Topics: Acute Coronary Syndrome; Aspirin; Clinical Trials as Topic; Clopidogrel; Coronary Artery Bypass; Hem | 2010 |
Factors associated with clopidogrel nonresponsiveness.
Topics: Acute Coronary Syndrome; Angioplasty, Balloon, Coronary; Aryl Hydrocarbon Hydroxylases; Clopidogrel; | 2010 |
Antiplatelet therapy prasugrel: a novel platelet ADP P2Y12 receptor antagonist.
Topics: Acute Coronary Syndrome; Angioplasty, Balloon, Coronary; Aspirin; Clinical Trials, Phase III as Topi | 2010 |
Heterogeneity of efficacy and safety of antiplatelet therapy in cardiovascular and cerebrovascular disease.
Topics: Acute Coronary Syndrome; Aspirin; Cardiovascular Diseases; Cerebrovascular Disorders; Clinical Trial | 2010 |
Diabetes and the platelet: toward new therapeutic paradigms for diabetic atherothrombosis.
Topics: Acute Coronary Syndrome; Apoptosis; Aspirin; Blood Platelets; Clopidogrel; Diabetes Complications; D | 2010 |
[Extent of platelet aggregation inhibition and clinical events: new evidence with prasugrel].
Topics: Acute Coronary Syndrome; Angioplasty, Balloon, Coronary; Clinical Trials as Topic; Clopidogrel; Drug | 2010 |
Acute coronary syndrome in the patient with diabetes: is the management different?
Topics: Acute Coronary Syndrome; Angioplasty, Balloon, Coronary; Anticoagulants; Clopidogrel; Diabetes Melli | 2010 |
[The role of clopidogrel in the treatment and prevention of acute coronary syndrome and repetitive atherothrombotic events].
Topics: Acute Coronary Syndrome; Clopidogrel; Embolism, Cholesterol; Humans; Platelet Aggregation Inhibitors | 2010 |
What goes into a major acute coronary syndrome trial and what will future trials look like?
Topics: Acute Coronary Syndrome; Adenosine; Aspirin; Clinical Trials as Topic; Clopidogrel; Cyclic N-Oxides; | 2010 |
Prasugrel for the treatment of acute coronary artery syndromes with percutaneous coronary intervention.
Topics: Acute Coronary Syndrome; Angioplasty, Balloon, Coronary; Clopidogrel; Cost-Benefit Analysis; Humans; | 2010 |
Strategies and Therapies for Reducing Ischemic and Vascular Events (STRIVE): updated standing orders for ST-segment elevation myocardial infarction and unstable angina/non-ST-segment elevation myocardial infarction.
Topics: Acute Coronary Syndrome; Angina, Unstable; Angioplasty, Balloon, Coronary; Anticoagulants; Clopidogr | 2010 |
[Antiplatelet therapy in coronary heart disease. Some problems and achivements].
Topics: Acute Coronary Syndrome; Adenosine; Angioplasty, Balloon, Coronary; Aryl Hydrocarbon Hydroxylases; A | 2010 |
Prasugrel.
Topics: Acute Coronary Syndrome; Clinical Trials as Topic; Clopidogrel; Humans; Piperazines; Platelet Activa | 2010 |
[Platelet inhibition with prasugrel].
Topics: Acute Coronary Syndrome; Administration, Oral; Angina, Unstable; Biological Availability; Clopidogre | 2010 |
Safety evaluation of tirofiban.
Topics: Abciximab; Acute Coronary Syndrome; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Aspirin; | 2010 |
[Reduction of haemorrhagic risk in acute coronary syndromes].
Topics: Acute Coronary Syndrome; Anticoagulants; Aspirin; Clopidogrel; Fibrinolytic Agents; Hemorrhage; Huma | 2011 |
Pharmacologic therapy for non ST-segment elevation acute coronary syndromes: focus on antithrombotic therapy.
Topics: Acute Coronary Syndrome; Adenosine; Angioplasty, Balloon, Coronary; Anticoagulants; Aspirin; Clopido | 2010 |
Impact of clopidogrel loading dose on clinical outcome in patients undergoing percutaneous coronary intervention: a systematic review and meta-analysis.
Topics: Acute Coronary Syndrome; Angioplasty, Balloon, Coronary; Clopidogrel; Dose-Response Relationship, Dr | 2011 |
New P2Y12 inhibitors versus clopidogrel in percutaneous coronary intervention: a meta-analysis.
Topics: Acute Coronary Syndrome; Angioplasty, Balloon, Coronary; Clopidogrel; Humans; Postoperative Complica | 2010 |
Platelet glycoprotein IIb/IIIa blockers during percutaneous coronary intervention and as the initial medical treatment of non-ST segment elevation acute coronary syndromes.
Topics: Acute Coronary Syndrome; Angioplasty, Balloon, Coronary; Aspirin; Fibrinolytic Agents; Hemorrhage; H | 2010 |
Nonresponders to clopidogrel: pharmacokinetics and interactions involved.
Topics: Acute Coronary Syndrome; Biotransformation; Clopidogrel; Drug Interactions; Drug Resistance; Humans; | 2010 |
Clopidogrel in acute coronary syndrome: implications of recent study findings.
Topics: Acute Coronary Syndrome; Angioplasty, Balloon, Coronary; Clopidogrel; Humans; Platelet Aggregation I | 2010 |
[Thienopyridines in the treatment and prevention of cardiovascular diseases. Part V. Combination of clopidogrel and acetylsalicylic acid in the treatment of stable patients with atherothrombotic cardiovascular diseases].
Topics: Acute Coronary Syndrome; Angioplasty, Balloon, Coronary; Arteriosclerosis; Aspirin; Cardiovascular D | 2010 |
A comparison of the metabolism of clopidogrel and prasugrel.
Topics: Acute Coronary Syndrome; Angioplasty, Balloon, Coronary; Aspirin; Carboxylic Ester Hydrolases; Clopi | 2010 |
Antithrombotic strategies in patients undergoing percutaneous coronary intervention for acute coronary syndrome.
Topics: Acute Coronary Syndrome; Angioplasty, Balloon, Coronary; Aspirin; Clinical Trials as Topic; Clopidog | 2010 |
Prasugrel as antiplatelet therapy in patients with acute coronary syndromes or undergoing percutaneous coronary intervention.
Topics: Acute Coronary Syndrome; Angioplasty, Balloon, Coronary; Clinical Trials as Topic; Clopidogrel; Huma | 2010 |
Individual variability in the disposition of and response to clopidogrel: pharmacogenomics and beyond.
Topics: Acute Coronary Syndrome; Clopidogrel; Drug Evaluation; Humans; Individuality; Pharmacogenetics; Plat | 2011 |
Reduced-function CYP2C19 genotype and risk of adverse clinical outcomes among patients treated with clopidogrel predominantly for PCI: a meta-analysis.
Topics: Acute Coronary Syndrome; Angioplasty, Balloon, Coronary; Aryl Hydrocarbon Hydroxylases; Cardiovascul | 2010 |
Reduced-function CYP2C19 genotype and risk of adverse clinical outcomes among patients treated with clopidogrel predominantly for PCI: a meta-analysis.
Topics: Acute Coronary Syndrome; Angioplasty, Balloon, Coronary; Aryl Hydrocarbon Hydroxylases; Cardiovascul | 2010 |
Reduced-function CYP2C19 genotype and risk of adverse clinical outcomes among patients treated with clopidogrel predominantly for PCI: a meta-analysis.
Topics: Acute Coronary Syndrome; Angioplasty, Balloon, Coronary; Aryl Hydrocarbon Hydroxylases; Cardiovascul | 2010 |
Reduced-function CYP2C19 genotype and risk of adverse clinical outcomes among patients treated with clopidogrel predominantly for PCI: a meta-analysis.
Topics: Acute Coronary Syndrome; Angioplasty, Balloon, Coronary; Aryl Hydrocarbon Hydroxylases; Cardiovascul | 2010 |
Reduced-function CYP2C19 genotype and risk of adverse clinical outcomes among patients treated with clopidogrel predominantly for PCI: a meta-analysis.
Topics: Acute Coronary Syndrome; Angioplasty, Balloon, Coronary; Aryl Hydrocarbon Hydroxylases; Cardiovascul | 2010 |
Reduced-function CYP2C19 genotype and risk of adverse clinical outcomes among patients treated with clopidogrel predominantly for PCI: a meta-analysis.
Topics: Acute Coronary Syndrome; Angioplasty, Balloon, Coronary; Aryl Hydrocarbon Hydroxylases; Cardiovascul | 2010 |
Reduced-function CYP2C19 genotype and risk of adverse clinical outcomes among patients treated with clopidogrel predominantly for PCI: a meta-analysis.
Topics: Acute Coronary Syndrome; Angioplasty, Balloon, Coronary; Aryl Hydrocarbon Hydroxylases; Cardiovascul | 2010 |
Reduced-function CYP2C19 genotype and risk of adverse clinical outcomes among patients treated with clopidogrel predominantly for PCI: a meta-analysis.
Topics: Acute Coronary Syndrome; Angioplasty, Balloon, Coronary; Aryl Hydrocarbon Hydroxylases; Cardiovascul | 2010 |
Reduced-function CYP2C19 genotype and risk of adverse clinical outcomes among patients treated with clopidogrel predominantly for PCI: a meta-analysis.
Topics: Acute Coronary Syndrome; Angioplasty, Balloon, Coronary; Aryl Hydrocarbon Hydroxylases; Cardiovascul | 2010 |
Reduced-function CYP2C19 genotype and risk of adverse clinical outcomes among patients treated with clopidogrel predominantly for PCI: a meta-analysis.
Topics: Acute Coronary Syndrome; Angioplasty, Balloon, Coronary; Aryl Hydrocarbon Hydroxylases; Cardiovascul | 2010 |
Reduced-function CYP2C19 genotype and risk of adverse clinical outcomes among patients treated with clopidogrel predominantly for PCI: a meta-analysis.
Topics: Acute Coronary Syndrome; Angioplasty, Balloon, Coronary; Aryl Hydrocarbon Hydroxylases; Cardiovascul | 2010 |
Reduced-function CYP2C19 genotype and risk of adverse clinical outcomes among patients treated with clopidogrel predominantly for PCI: a meta-analysis.
Topics: Acute Coronary Syndrome; Angioplasty, Balloon, Coronary; Aryl Hydrocarbon Hydroxylases; Cardiovascul | 2010 |
Reduced-function CYP2C19 genotype and risk of adverse clinical outcomes among patients treated with clopidogrel predominantly for PCI: a meta-analysis.
Topics: Acute Coronary Syndrome; Angioplasty, Balloon, Coronary; Aryl Hydrocarbon Hydroxylases; Cardiovascul | 2010 |
Reduced-function CYP2C19 genotype and risk of adverse clinical outcomes among patients treated with clopidogrel predominantly for PCI: a meta-analysis.
Topics: Acute Coronary Syndrome; Angioplasty, Balloon, Coronary; Aryl Hydrocarbon Hydroxylases; Cardiovascul | 2010 |
Reduced-function CYP2C19 genotype and risk of adverse clinical outcomes among patients treated with clopidogrel predominantly for PCI: a meta-analysis.
Topics: Acute Coronary Syndrome; Angioplasty, Balloon, Coronary; Aryl Hydrocarbon Hydroxylases; Cardiovascul | 2010 |
Reduced-function CYP2C19 genotype and risk of adverse clinical outcomes among patients treated with clopidogrel predominantly for PCI: a meta-analysis.
Topics: Acute Coronary Syndrome; Angioplasty, Balloon, Coronary; Aryl Hydrocarbon Hydroxylases; Cardiovascul | 2010 |
Reduced-function CYP2C19 genotype and risk of adverse clinical outcomes among patients treated with clopidogrel predominantly for PCI: a meta-analysis.
Topics: Acute Coronary Syndrome; Angioplasty, Balloon, Coronary; Aryl Hydrocarbon Hydroxylases; Cardiovascul | 2010 |
Reduced-function CYP2C19 genotype and risk of adverse clinical outcomes among patients treated with clopidogrel predominantly for PCI: a meta-analysis.
Topics: Acute Coronary Syndrome; Angioplasty, Balloon, Coronary; Aryl Hydrocarbon Hydroxylases; Cardiovascul | 2010 |
Reduced-function CYP2C19 genotype and risk of adverse clinical outcomes among patients treated with clopidogrel predominantly for PCI: a meta-analysis.
Topics: Acute Coronary Syndrome; Angioplasty, Balloon, Coronary; Aryl Hydrocarbon Hydroxylases; Cardiovascul | 2010 |
Reduced-function CYP2C19 genotype and risk of adverse clinical outcomes among patients treated with clopidogrel predominantly for PCI: a meta-analysis.
Topics: Acute Coronary Syndrome; Angioplasty, Balloon, Coronary; Aryl Hydrocarbon Hydroxylases; Cardiovascul | 2010 |
Reduced-function CYP2C19 genotype and risk of adverse clinical outcomes among patients treated with clopidogrel predominantly for PCI: a meta-analysis.
Topics: Acute Coronary Syndrome; Angioplasty, Balloon, Coronary; Aryl Hydrocarbon Hydroxylases; Cardiovascul | 2010 |
Reduced-function CYP2C19 genotype and risk of adverse clinical outcomes among patients treated with clopidogrel predominantly for PCI: a meta-analysis.
Topics: Acute Coronary Syndrome; Angioplasty, Balloon, Coronary; Aryl Hydrocarbon Hydroxylases; Cardiovascul | 2010 |
Reduced-function CYP2C19 genotype and risk of adverse clinical outcomes among patients treated with clopidogrel predominantly for PCI: a meta-analysis.
Topics: Acute Coronary Syndrome; Angioplasty, Balloon, Coronary; Aryl Hydrocarbon Hydroxylases; Cardiovascul | 2010 |
Reduced-function CYP2C19 genotype and risk of adverse clinical outcomes among patients treated with clopidogrel predominantly for PCI: a meta-analysis.
Topics: Acute Coronary Syndrome; Angioplasty, Balloon, Coronary; Aryl Hydrocarbon Hydroxylases; Cardiovascul | 2010 |
Reduced-function CYP2C19 genotype and risk of adverse clinical outcomes among patients treated with clopidogrel predominantly for PCI: a meta-analysis.
Topics: Acute Coronary Syndrome; Angioplasty, Balloon, Coronary; Aryl Hydrocarbon Hydroxylases; Cardiovascul | 2010 |
Reduced-function CYP2C19 genotype and risk of adverse clinical outcomes among patients treated with clopidogrel predominantly for PCI: a meta-analysis.
Topics: Acute Coronary Syndrome; Angioplasty, Balloon, Coronary; Aryl Hydrocarbon Hydroxylases; Cardiovascul | 2010 |
Reduced-function CYP2C19 genotype and risk of adverse clinical outcomes among patients treated with clopidogrel predominantly for PCI: a meta-analysis.
Topics: Acute Coronary Syndrome; Angioplasty, Balloon, Coronary; Aryl Hydrocarbon Hydroxylases; Cardiovascul | 2010 |
Reduced-function CYP2C19 genotype and risk of adverse clinical outcomes among patients treated with clopidogrel predominantly for PCI: a meta-analysis.
Topics: Acute Coronary Syndrome; Angioplasty, Balloon, Coronary; Aryl Hydrocarbon Hydroxylases; Cardiovascul | 2010 |
Reduced-function CYP2C19 genotype and risk of adverse clinical outcomes among patients treated with clopidogrel predominantly for PCI: a meta-analysis.
Topics: Acute Coronary Syndrome; Angioplasty, Balloon, Coronary; Aryl Hydrocarbon Hydroxylases; Cardiovascul | 2010 |
Reduced-function CYP2C19 genotype and risk of adverse clinical outcomes among patients treated with clopidogrel predominantly for PCI: a meta-analysis.
Topics: Acute Coronary Syndrome; Angioplasty, Balloon, Coronary; Aryl Hydrocarbon Hydroxylases; Cardiovascul | 2010 |
Reduced-function CYP2C19 genotype and risk of adverse clinical outcomes among patients treated with clopidogrel predominantly for PCI: a meta-analysis.
Topics: Acute Coronary Syndrome; Angioplasty, Balloon, Coronary; Aryl Hydrocarbon Hydroxylases; Cardiovascul | 2010 |
Reduced-function CYP2C19 genotype and risk of adverse clinical outcomes among patients treated with clopidogrel predominantly for PCI: a meta-analysis.
Topics: Acute Coronary Syndrome; Angioplasty, Balloon, Coronary; Aryl Hydrocarbon Hydroxylases; Cardiovascul | 2010 |
Reduced-function CYP2C19 genotype and risk of adverse clinical outcomes among patients treated with clopidogrel predominantly for PCI: a meta-analysis.
Topics: Acute Coronary Syndrome; Angioplasty, Balloon, Coronary; Aryl Hydrocarbon Hydroxylases; Cardiovascul | 2010 |
Reduced-function CYP2C19 genotype and risk of adverse clinical outcomes among patients treated with clopidogrel predominantly for PCI: a meta-analysis.
Topics: Acute Coronary Syndrome; Angioplasty, Balloon, Coronary; Aryl Hydrocarbon Hydroxylases; Cardiovascul | 2010 |
Reduced-function CYP2C19 genotype and risk of adverse clinical outcomes among patients treated with clopidogrel predominantly for PCI: a meta-analysis.
Topics: Acute Coronary Syndrome; Angioplasty, Balloon, Coronary; Aryl Hydrocarbon Hydroxylases; Cardiovascul | 2010 |
Reduced-function CYP2C19 genotype and risk of adverse clinical outcomes among patients treated with clopidogrel predominantly for PCI: a meta-analysis.
Topics: Acute Coronary Syndrome; Angioplasty, Balloon, Coronary; Aryl Hydrocarbon Hydroxylases; Cardiovascul | 2010 |
Ticagrelor: an investigational oral antiplatelet treatment for reduction of major adverse cardiac events in patients with acute coronary syndrome.
Topics: Acute Coronary Syndrome; Adenosine; Aspirin; Blood Platelets; Clopidogrel; Dyspnea; Humans; Platelet | 2010 |
[New era in antiplatelet therapy based on results from recent clinical trials].
Topics: Acute Coronary Syndrome; Clopidogrel; Humans; Platelet Aggregation Inhibitors; Purinergic P2Y Recept | 2011 |
The safety of clopidogrel.
Topics: Acute Coronary Syndrome; Clopidogrel; Drug-Related Side Effects and Adverse Reactions; Hemorrhage; H | 2011 |
Controversy of proton pump inhibitor and clopidogrel interaction: a review.
Topics: Acute Coronary Syndrome; Clopidogrel; Drug Interactions; Humans; Platelet Aggregation Inhibitors; Pr | 2010 |
Clopidogrel withdrawal: is there a "rebound" phenomenon?
Topics: Acute Coronary Syndrome; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Drug Administration S | 2011 |
Inhibition of the antithrombotic effects of clopidogrel by proton pump inhibitors: facts or fancies?
Topics: Acute Coronary Syndrome; Clopidogrel; Drug Interactions; Gastrointestinal Hemorrhage; Humans; Platel | 2010 |
Prasugrel: an efficacy and safety review of a new antiplatelet therapy option.
Topics: Acute Coronary Syndrome; American Heart Association; Angioplasty, Balloon, Coronary; Clinical Trials | 2010 |
Contemporary management of coronary heart disease.
Topics: Acute Coronary Syndrome; Administration, Oral; Angina Pectoris; Angioplasty, Balloon, Coronary; Anti | 2010 |
Ticagrelor: from discovery to Phase III clinical trial.
Topics: Acute Coronary Syndrome; Adenosine; Adenosine Diphosphate; Clinical Trials, Phase III as Topic; Clop | 2010 |
[New approaches and indications for the analysis of platelet function in cardiology].
Topics: Acute Coronary Syndrome; Adenosine; Adenosine Monophosphate; Aspirin; Clopidogrel; Coronary Thrombos | 2011 |
[Novel agents in antiplatelet therapy].
Topics: Acute Coronary Syndrome; Adenosine; Adenosine Monophosphate; Aspirin; Clopidogrel; Humans; Lactones; | 2010 |
Antiplatelet therapy in the perioperative period.
Topics: Acute Coronary Syndrome; Aspirin; Clopidogrel; Drug Therapy, Combination; Evidence-Based Medicine; H | 2011 |
Beyond efficacy: pharmacokinetic differences between clopidogrel, prasugrel and ticagrelor.
Topics: Acute Coronary Syndrome; Adenosine; Clopidogrel; Humans; Piperazines; Prasugrel Hydrochloride; Purin | 2011 |
Review article: proton pump inhibitors with clopidogrel--evidence for and against a clinically-important interaction.
Topics: Acute Coronary Syndrome; Aspirin; Clopidogrel; Drug Interactions; Drug Therapy, Combination; Humans; | 2011 |
Thienopyridines in Acute Coronary Syndrome.
Topics: Acute Coronary Syndrome; Clopidogrel; Hemorrhage; Humans; Percutaneous Coronary Intervention; Platel | 2011 |
Antiplatelet resistance in stroke.
Topics: Acute Coronary Syndrome; Aspirin; Clopidogrel; Cyclooxygenase Inhibitors; Drug Resistance; Humans; P | 2011 |
[Current options to manage clopidogrel poor responsiveness].
Topics: Acute Coronary Syndrome; Adenosine; Angioplasty, Balloon, Coronary; Clopidogrel; Drug Interactions; | 2010 |
Triple therapy in hospitalized patients: facts and controversies.
Topics: Acute Coronary Syndrome; Angioplasty, Balloon, Coronary; Anticoagulants; Aspirin; Atrial Fibrillatio | 2011 |
[Prasugrel for acute and long-term treatment of patients with acute coronary syndromes: what is state-of-the-art?].
Topics: Acute Coronary Syndrome; Clinical Trials as Topic; Clopidogrel; Drug Therapy, Combination; Electroca | 2011 |
Triple therapy: boon or bane for high-risk CV patients?
Topics: Acute Coronary Syndrome; Anticoagulants; Aspirin; Clopidogrel; Drug Therapy, Combination; Humans; Pa | 2011 |
Clopidogrel in acute coronary syndromes: where are we now?
Topics: Acute Coronary Syndrome; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transpo | 2011 |
High platelet reactivity and clinical outcome - fact and fiction.
Topics: Acute Coronary Syndrome; Angioplasty, Balloon, Coronary; Aryl Hydrocarbon Hydroxylases; Blood Platel | 2011 |
Proton pump inhibitors, genetic polymorphisms and response to clopidogrel therapy.
Topics: Acute Coronary Syndrome; Aryl Hydrocarbon Hydroxylases; Blood Vessel Prosthesis Implantation; Clopid | 2011 |
Early clopidogrel use in non-ST elevation acute coronary syndrome and subsequent coronary artery bypass grafting.
Topics: Acute Coronary Syndrome; Clopidogrel; Coronary Artery Bypass; Humans; Platelet Aggregation Inhibitor | 2011 |
Ischaemic and bleeding complications with new, compared to standard, ADP-antagonist regimens in acute coronary syndromes: a meta-analysis of randomized trials.
Topics: Acute Coronary Syndrome; Adenosine; Administration, Oral; Clopidogrel; Hemorrhage; Humans; Ischemia; | 2011 |
[Recent advances on the studies of the platelet's inhibition and aggregation. State of the art of new P2Y12 antagonists].
Topics: Acute Coronary Syndrome; Adenosine; Adenosine Monophosphate; Catheter Ablation; Clinical Trials as T | 2011 |
Beyond aspirin and clopidogrel: is there a need for additional antiplatelet therapy in ACS?
Topics: Acute Coronary Syndrome; Adenosine; Adenosine Monophosphate; Aspirin; Cilostazol; Clopidogrel; Drug | 2011 |
Safety of clopidogrel being continued until the time of coronary artery bypass grafting in patients with acute coronary syndrome: a meta-analysis of 34 studies.
Topics: Acute Coronary Syndrome; Blood Transfusion; Clopidogrel; Coronary Artery Bypass; Critical Care; Fema | 2011 |
Implications of variability in definition and reporting of major bleeding in randomized trials of oral P2Y12 inhibitors for acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Clinical Trials, Phase III as Topic; Clopidogrel; Female; Hemorr | 2011 |
Ticagrelor for acute coronary syndrome?
Topics: Acute Coronary Syndrome; Adenosine; Clopidogrel; Contraindications; Drug Costs; Humans; Piperazines; | 2011 |
Emerging antiplatelet therapies in percutaneous coronary intervention: a focus on prasugrel.
Topics: Acute Coronary Syndrome; Angioplasty, Balloon, Coronary; Clinical Trials as Topic; Clopidogrel; Hemo | 2011 |
Clopidogrel response variability and the advent of personalised antiplatelet therapy. A bench to bedside journey.
Topics: Acute Coronary Syndrome; Angioplasty, Balloon, Coronary; Clinical Trials as Topic; Clopidogrel; Huma | 2011 |
[ADP receptor blockers: new insights in the therapy and prophylaxis of ischemic heart disease].
Topics: Acute Coronary Syndrome; Adenosine Monophosphate; Angioplasty, Balloon, Coronary; Aspirin; Clopidogr | 2011 |
Clinical Pharmacogenetics Implementation Consortium guidelines for cytochrome P450-2C19 (CYP2C19) genotype and clopidogrel therapy.
Topics: Acute Coronary Syndrome; Alleles; Angioplasty, Balloon, Coronary; Aryl Hydrocarbon Hydroxylases; Clo | 2011 |
Role of platelet function testing in clinical practice: current concepts and future perspectives.
Topics: Acute Coronary Syndrome; Biotransformation; Brain Ischemia; Clopidogrel; Drug Monitoring; Drug Resis | 2011 |
Association of genetic variants in CYP2C19 and adverse clinical outcomes after treatment with clopidogrel: an updated meta-analysis.
Topics: Acute Coronary Syndrome; Aryl Hydrocarbon Hydroxylases; Clopidogrel; Cytochrome P-450 CYP2C19; Human | 2011 |
Prasugrel vs. ticagrelor in acute coronary syndromes: which one to choose?
Topics: Acute Coronary Syndrome; Adenosine; Clopidogrel; Hemorrhage; Humans; Myocardial Infarction; Piperazi | 2011 |
Systematic review of thienopyridine discontinuation and its impact upon clinical outcomes.
Topics: Acute Coronary Syndrome; Angioplasty, Balloon, Coronary; Clopidogrel; Drug Administration Schedule; | 2011 |
[Ticagrelor: a novel antiplatelet agent for patients with acute coronary syndrome].
Topics: Acute Coronary Syndrome; Adenosine; Aspirin; Clopidogrel; Drug Interactions; Humans; Platelet Activa | 2011 |
Impact of CYP2C19 variant genotypes on clinical efficacy of antiplatelet treatment with clopidogrel: systematic review and meta-analysis.
Topics: Acute Coronary Syndrome; Angina Pectoris; Aryl Hydrocarbon Hydroxylases; Clopidogrel; Cytochrome P-4 | 2011 |
Antiplatelet function variability in clopidogrel-treated patients: need for new antiplatelet agents.
Topics: Acute Coronary Syndrome; Aspirin; Clopidogrel; Coronary Artery Disease; Drug Design; Drug Interactio | 2012 |
The future of platelet function testing to guide therapy in clopidogrel low and enhanced responders.
Topics: Acute Coronary Syndrome; Aspirin; Clopidogrel; Dose-Response Relationship, Drug; Drug Monitoring; Dr | 2011 |
A meta-analysis of impact of proton pump inhibitors on antiplatelet effect of clopidogrel.
Topics: Acute Coronary Syndrome; Clopidogrel; Data Interpretation, Statistical; Drug Interactions; Endpoint | 2012 |
Clinical effects and outcomes with new P2Y12 inhibitors in ACS.
Topics: Acute Coronary Syndrome; Angioplasty, Balloon, Coronary; Clopidogrel; Dose-Response Relationship, Dr | 2012 |
Treating acute coronary syndromes with new antiplatelet drugs: the mortality issue with prasugrel and ticagrelor.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Coronary Angiography; Diabetes Mellitus; Fema | 2011 |
Platelet function monitoring in patients on clopidogrel: What should we learn from GRAVITAS?
Topics: Acute Coronary Syndrome; Angioplasty, Balloon, Coronary; Aspirin; Blood Platelets; Clopidogrel; Huma | 2012 |
Anti-Platelet Therapy for Acute Coronary Syndrome: A Review of Currently Available Agents and What the Future Holds.
Topics: Acute Coronary Syndrome; Aspirin; Clopidogrel; Humans; Platelet Aggregation Inhibitors; Ticlopidine | 2011 |
Antiplatelet options for secondary prevention in acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aspirin; Clopidogrel; Drug Therapy, Combination; Hemorrhage; Hum | 2011 |
Clopidogrel and PPI interaction: clinically relevant or not?
Topics: Acute Coronary Syndrome; Aspirin; Clopidogrel; Drug Interactions; Drug Therapy, Combination; Female; | 2012 |
Safety and efficacy of antiplatelet and antithrombotic therapy in acute coronary syndrome patients with chronic kidney disease.
Topics: Acute Coronary Syndrome; Adenosine; Aspirin; Chronic Disease; Clinical Trials as Topic; Clopidogrel; | 2011 |
Evaluating the risk-benefit profile of the direct-acting P2Y(12) inhibitor ticagrelor in acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Clopidogrel; Cost-Benefit Analysis; Drug Interactions; Genotype; | 2011 |
Medical groups, researchers fine-tune clopidogrel therapy.
Topics: Acute Coronary Syndrome; Angioplasty, Balloon, Coronary; Clopidogrel; Humans; Randomized Controlled | 2011 |
[Clopidogrel resistance--clinical significance, pathogenesis and potential solutions].
Topics: Acute Coronary Syndrome; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Drug Resistance; Huma | 2011 |
Unstable angina and non-ST elevation myocardial infarction.
Topics: Acute Coronary Syndrome; Adenosine; Angina, Unstable; Anticoagulants; Aspirin; Clopidogrel; Coronary | 2012 |
ABCB1 C3435T polymorphism and risk of adverse clinical events in clopidogrel treated patients: a meta-analysis.
Topics: Acute Coronary Syndrome; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transpo | 2012 |
A comprehensive comparative review of adenosine diphosphate receptor antagonists.
Topics: Acute Coronary Syndrome; Adenosine; Clopidogrel; Drug Interactions; Humans; Piperazines; Platelet Ag | 2012 |
InforMatrix: ADP antagonists in acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Clopidogrel; Cost-Benefit Analysis; Decision Support Techniques; | 2012 |
Options to overcome clopidogrel response variability.
Topics: Acute Coronary Syndrome; Angioplasty, Balloon, Coronary; Clopidogrel; Combined Modality Therapy; Gen | 2012 |
Dual or mono antiplatelet therapy for patients with acute ischemic stroke or transient ischemic attack: systematic review and meta-analysis of randomized controlled trials.
Topics: Acute Coronary Syndrome; Adult; Aged; Aged, 80 and over; Aspirin; Brain Ischemia; Clopidogrel; Datab | 2012 |
Oral antiplatelet therapy in patients with diabetes mellitus and acute coronary syndromes.
Topics: Acute Coronary Syndrome; Administration, Oral; Aspirin; Cilostazol; Clopidogrel; Diabetes Complicati | 2010 |
Prasugrel versus clopidogrel antiplatelet therapy after acute coronary syndrome: matching treatments with patients.
Topics: Acute Coronary Syndrome; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Cl | 2012 |
Cilostazol and primary-PCI: mirage or good alternative?
Topics: Acute Coronary Syndrome; Angioplasty, Balloon, Coronary; Arrhythmias, Cardiac; Aspirin; Cilostazol; | 2012 |
Advances in antiplatelet therapy for acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Adenosine Monophosphate; Aspirin; Clopidogrel; Emergency Treatme | 2012 |
Acute coronary syndromes: identifying the appropriate patient for prasugrel.
Topics: Acute Coronary Syndrome; Clopidogrel; Hemorrhage; Humans; Patient Selection; Piperazines; Platelet A | 2012 |
Current antiplatelet options for NSTE-ACS patients.
Topics: Acute Coronary Syndrome; Adenosine; Aspirin; Biological Availability; Clopidogrel; Comparative Effec | 2012 |
Switching antiplatelet regimens: alternatives to clopidogrel in patients with acute coronary syndrome undergoing PCI: a review of the literature and practical considerations for the interventional cardiologist.
Topics: Acute Coronary Syndrome; Adenosine; Aspirin; Clopidogrel; Coronary Thrombosis; Drug Interactions; Dr | 2013 |
Latest evidence in personalized antiplatelet therapy in patients with acute coronary syndromes undergoing percutaneous coronary intervention.
Topics: Acute Coronary Syndrome; Aryl Hydrocarbon Hydroxylases; Aryldialkylphosphatase; Aspirin; Clopidogrel | 2012 |
Network meta-analysis of prasugrel, ticagrelor, high- and standard-dose clopidogrel in patients scheduled for percutaneous coronary interventions.
Topics: Acute Coronary Syndrome; Adenosine; Angioplasty; Cardiovascular Diseases; Clopidogrel; Hemorrhage; H | 2012 |
Ticagrelor: a P2Y12 antagonist for use in acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aspirin; Blood Platelets; Clinical Trials as Topic; Clopidogrel; | 2012 |
Development and clinical use of prasugrel and ticagrelor.
Topics: Acute Coronary Syndrome; Adenosine; Animals; Aspirin; Blood Platelets; Clopidogrel; Drug Design; Hem | 2012 |
Tailoring antiplatelet therapy: a step toward individualized therapy to improve clinical outcome?
Topics: Acute Coronary Syndrome; Adenosine; Aspirin; Blood Platelets; Clopidogrel; Coronary Thrombosis; Drug | 2012 |
Anticoagulants for the treatment of acute coronary syndrome in the era of new oral agents.
Topics: Acute Coronary Syndrome; Administration, Oral; Anticoagulants; Antithrombins; Aspirin; Benzimidazole | 2012 |
A brief review of the past and future of platelet P2Y12 antagonist.
Topics: Acute Coronary Syndrome; Adenosine; Adenosine Monophosphate; Clopidogrel; Coronary Artery Disease; H | 2012 |
Advances in platelet function testing assessing bleeding complications in patients with coronary artery disease.
Topics: Acute Coronary Syndrome; Aspirin; Blood Platelets; Clinical Trials as Topic; Clopidogrel; Coronary A | 2012 |
Cilostazol-based triple antiplatelet therapy compared to dual antiplatelet therapy in patients with coronary stent implantation: a meta-analysis of 5,821 patients.
Topics: Acute Coronary Syndrome; Aspirin; Blood Vessel Prosthesis; Blood Vessel Prosthesis Implantation; Cil | 2012 |
Impact of antiplatelet therapy in heart disease.
Topics: Acute Coronary Syndrome; Angioplasty, Balloon, Coronary; Anticoagulants; Aspirin; Atrial Fibrillatio | 2012 |
Genetic considerations.
Topics: Acute Coronary Syndrome; Aryl Hydrocarbon Hydroxylases; ATP Binding Cassette Transporter, Subfamily | 2012 |
Stents and antiplatelet therapy.
Topics: Acute Coronary Syndrome; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Drug-Eluting Stents; | 2012 |
Bleeding and the use of antiplatelet agents in the management of acute coronary syndromes and atrial fibrillation.
Topics: Acute Coronary Syndrome; Aspirin; Atrial Fibrillation; Clinical Trials as Topic; Clopidogrel; Hemorr | 2012 |
Review of ticagrelor in the management of acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Clopidogrel; Dyspnea; Hemorrhage; Humans; Platelet Aggregation I | 2012 |
Safety profile and bleeding risk of ticagrelor compared with clopidogrel.
Topics: Acute Coronary Syndrome; Adenosine; Clopidogrel; Dyspnea; Hemorrhage; Humans; Platelet Aggregation I | 2012 |
Clinical importance of antiplatelet drugs in cardiovascular diseases.
Topics: Acute Coronary Syndrome; Anti-Inflammatory Agents, Non-Steroidal; Blood Platelets; Cardiovascular Di | 2013 |
Clopidogrel: the data, the experience, and the controversies.
Topics: Acute Coronary Syndrome; Aspirin; Clopidogrel; Drug Therapy, Combination; Evidence-Based Medicine; H | 2012 |
Reloading patients chronically treated with P2Y12 inhibitors and presenting with ACS/PCI: facing a crossroad?
Topics: Acute Coronary Syndrome; Humans; Percutaneous Coronary Intervention; Purinergic P2Y Receptor Antagon | 2013 |
A critical overview on ticagrelor in acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aspirin; Clopidogrel; Double-Blind Method; Female; Humans; Male; | 2013 |
[Pharmacogenetics of clopidogrel and its clinical significance].
Topics: Acute Coronary Syndrome; Aryl Hydrocarbon Hydroxylases; Biotransformation; Clopidogrel; Cytochrome P | 2012 |
Dual antiplatelet therapy for primary and secondary prevention.
Topics: Acute Coronary Syndrome; Cardiovascular Diseases; Clinical Trials as Topic; Clopidogrel; Humans; Pla | 2012 |
Impact of clopidogrel and potent P2Y 12 -inhibitors on mortality and stroke in patients with acute coronary syndrome or undergoing percutaneous coronary intervention: a systematic review and meta-analysis.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Coronary Thrombosis; Female; Humans; Intracra | 2013 |
Association of clopidogrel pretreatment with mortality, cardiovascular events, and major bleeding among patients undergoing percutaneous coronary intervention: a systematic review and meta-analysis.
Topics: Acute Coronary Syndrome; Clopidogrel; Coronary Artery Disease; Endpoint Determination; Hemorrhage; H | 2012 |
Metabolic differences of current thienopyridine antiplatelet agents.
Topics: Acute Coronary Syndrome; Aryl Hydrocarbon Hydroxylases; Clopidogrel; Cytochrome P-450 CYP2C19; Drug | 2013 |
Antiplatelet drug use in patients with non-ST-segment elevation acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aspirin; Clopidogrel; Drug Therapy, Combination; Humans; Piperaz | 2013 |
Clinical use of clopidogrel in acute coronary syndrome.
Topics: Acute Coronary Syndrome; Aged; Clopidogrel; Female; Humans; Male; Middle Aged; Platelet Aggregation | 2007 |
Clopidogrel resistance.
Topics: Acute Coronary Syndrome; Adenosine Diphosphate; Clopidogrel; Cytochrome P-450 Enzyme System; Drug Re | 2007 |
[Management coronary syndrome in the acute phase].
Topics: Acute Coronary Syndrome; Angioplasty, Balloon, Coronary; Aspirin; Clinical Trials as Topic; Clopidog | 2007 |
[Long-term management of post acute coronary syndrome with oral antiplatelet therapy].
Topics: Acute Coronary Syndrome; Administration, Oral; Aspirin; Clinical Trials as Topic; Clopidogrel; Human | 2007 |
Coronary stents and noncardiac surgery.
Topics: Acute Coronary Syndrome; Aspirin; Clopidogrel; Drug-Eluting Stents; Humans; Male; Middle Aged; Plate | 2007 |
Management of an acute coronary syndrome in a patient with severe haemophilia A.
Topics: Acute Coronary Syndrome; Antifibrinolytic Agents; Aspirin; Clopidogrel; Fibrinolytic Agents; Hemophi | 2007 |
Platelet function monitoring in patients with coronary artery disease.
Topics: Acute Coronary Syndrome; Aspirin; Clopidogrel; Coronary Artery Disease; Coronary Disease; Drug Resis | 2007 |
Aspirin combined with clopidogrel (Plavix) decreases cardiovascular events in patients with acute coronary syndrome.
Topics: Acute Coronary Syndrome; Angina, Unstable; Aspirin; Clopidogrel; Coronary Artery Disease; Evidence-B | 2007 |
[Optimizing antithrombotic therapy in non-ST-elevation acute coronary syndrome].
Topics: Acute Coronary Syndrome; Anticoagulants; Clopidogrel; Fibrinolytic Agents; Fondaparinux; Hirudins; H | 2007 |
P2Y12 antagonism: promises and challenges.
Topics: Acute Coronary Syndrome; Angioplasty, Balloon, Coronary; Clinical Trials, Phase III as Topic; Clopid | 2008 |
[Gp IIb/IIIa receptor antagonists in acute coronary syndromes with no ST elevation].
Topics: Acute Coronary Syndrome; Angioplasty, Balloon, Coronary; Anticoagulants; Clopidogrel; Hirudins; Huma | 2007 |
Current update on glycoprotein IIb-IIIa and direct thrombin inhibition in percutaneous coronary intervention for non-ST elevation acute coronary syndromes: balancing bleeding risk and antiplatelet efficacy.
Topics: Acute Coronary Syndrome; Angioplasty, Balloon, Coronary; Angiotensin-Converting Enzyme Inhibitors; A | 2008 |
[Pharmacoeconomic evaluation of clopidogrel in acute coronary syndromes. Long-term treatment, secondary prophylaxis, and percutaneous coronary intervention].
Topics: Acute Coronary Syndrome; Angioplasty, Balloon, Coronary; Clopidogrel; Economics, Pharmaceutical; Hea | 2008 |
Indications for dual antiplatelet therapy with aspirin and clopidogrel: evidence-based recommendations for use.
Topics: Acute Coronary Syndrome; Angioplasty, Balloon, Coronary; Aspirin; Brain Ischemia; Clopidogrel; Coron | 2008 |
[Platelet aggregation inhibition in acute coronary syndrome. Facts and expectations].
Topics: Acute Coronary Syndrome; Aspirin; Clopidogrel; Drug Administration Schedule; Drug Resistance; Drugs, | 2008 |
Antiplatelet therapy in acute coronary syndromes: the emergency physician's perspective.
Topics: Acute Coronary Syndrome; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Artery Bypas | 2008 |
Antiplatelet drug nonresponsiveness.
Topics: Acute Coronary Syndrome; Aspirin; Clopidogrel; Coronary Disease; Drug Resistance; Humans; Platelet A | 2008 |
Will prasugrel supersede clopidogrel for acute coronary syndromes?
Topics: Acute Coronary Syndrome; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Clopidogrel; Coronary Art | 2008 |
Antiplatelet therapy in early management of non-ST-segment elevation acute coronary syndrome: the 2002 and 2007 guidelines from North America and Europe.
Topics: Acute Coronary Syndrome; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Clopidogrel; Contraindica | 2008 |
Aspirin and platelet adenosine diphosphate receptor antagonists in acute coronary syndromes and percutaneous coronary intervention: role in therapy and strategies to overcome resistance.
Topics: Acute Coronary Syndrome; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Drug Resistance; Huma | 2008 |
Managing antiplatelet therapy in the ACS patient: straight from the emergency department to you.
Topics: Acute Coronary Syndrome; Aspirin; Clinical Trials as Topic; Clopidogrel; Drug Therapy, Combination; | 2008 |
Antiplatelet strategies: evaluating their current role in the setting of acute coronary syndromes.
Topics: Abciximab; Acute Coronary Syndrome; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Aspirin; | 2008 |
Prasugrel: a novel antiplatelet agent.
Topics: Acute Coronary Syndrome; Animals; Clopidogrel; Hemorrhage; Humans; Piperazines; Platelet Aggregation | 2008 |
278 trials available for ticlopidine and Acute Coronary Syndrome
| Article | Year |
|---|---|
Impact of one-month DAPT followed by aspirin monotherapy in patients undergoing percutaneous coronary intervention according to clinical presentation: a post hoc analysis of the randomised One-Month DAPT trial.
Topics: Acute Coronary Syndrome; Aspirin; Clopidogrel; Coronary Artery Disease; Drug Therapy, Combination; D | 2022 |
Randomized, Double-Blind, Active Comparator Pharmacodynamic Study of Platelet Inhibition with Crushed and Integral Formulations of Clopidogrel and Ticagrelor in Acute Coronary Syndrome.
Topics: Acute Coronary Syndrome; Adenosine; Blood Platelets; Clopidogrel; Humans; Platelet Aggregation Inhib | 2023 |
Aspirin Dosing for Secondary Prevention of Atherosclerotic Cardiovascular Disease in Patients Treated With P2Y12 Inhibitors.
Topics: Acute Coronary Syndrome; Aspirin; Atherosclerosis; Cardiovascular Diseases; Clopidogrel; Hemorrhage; | 2023 |
Implementation of a Reference-Scaled Average Bioequivalence Approach for Highly Variable Acetylsalicylic Acid in Fixed-Dose Combination with Clopidogrel Versus Enteric Aspirin in Chinese Subjects Under Fasting Conditions: A Phase 1, Open-Label, Randomized
Topics: Acute Coronary Syndrome; Adult; Area Under Curve; Asian People; Aspirin; Clopidogrel; Cross-Over Stu | 2020 |
Effect of Ticagrelor Monotherapy vs Ticagrelor With Aspirin on Major Bleeding and Cardiovascular Events in Patients With Acute Coronary Syndrome: The TICO Randomized Clinical Trial.
Topics: Acute Coronary Syndrome; Aspirin; Cardiovascular Diseases; Drug Therapy, Combination; Drug-Eluting S | 2020 |
Comparison of one-month versus twelve-month dual antiplatelet therapy after implantation of drug-eluting stents guided by either intravascular ultrasound or angiography in patients with acute coronary syndrome: rationale and design of prospective, multice
Topics: Acute Coronary Syndrome; Adult; Aspirin; Coronary Angiography; Drug-Eluting Stents; Dual Anti-Platel | 2021 |
Clinically significant bleeding with low-dose rivaroxaban versus aspirin, in addition to P2Y12 inhibition, in acute coronary syndromes (GEMINI-ACS-1): a double-blind, multicentre, randomised trial.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Aspirin; Clopidogrel; Coronary Angiography; Double-Blind M | 2017 |
Predicting the risk of bleeding during dual antiplatelet therapy after acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Aged, 80 and over; Clopidogrel; Coronary Artery Bypass; Dose-Response | 2017 |
Pantoprazole Does Not Reduce the Antiplatelet Effect of Clopidogrel: A Randomized Controlled Trial in Korea.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Acute Coronary Syndrome; Aged; Clopidogrel; Cytochrome P-45 | 2017 |
Relationship Between Peak Troponin Values and Long-Term Ischemic Events Among Medically Managed Patients With Acute Coronary Syndromes.
Topics: Acute Coronary Syndrome; Aged; Biomarkers; Chi-Square Distribution; Clopidogrel; Double-Blind Method | 2017 |
Growth Differentiation Factor 15 at 1 Month After an Acute Coronary Syndrome Is Associated With Increased Risk of Major Bleeding.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Aspirin; Biomarkers; Clopidogrel; Double-Blind Method; Dru | 2017 |
Benefit of switching dual antiplatelet therapy after acute coronary syndrome: the TOPIC (timing of platelet inhibition after acute coronary syndrome) randomized study.
Topics: Acute Coronary Syndrome; Adenosine; Aspirin; Clopidogrel; Drug Administration Schedule; Drug Combina | 2017 |
[IMPACT OF ATORVASTATIN AND ROSUVASTATIN ON RESIDUAL ON-CLOPIDOGREL TREATMENT PLATELET REACTIVITY IN PATIENTS WITH ISCHEMIC HEART DISEASE AND TYPE 2 DIABETES MELLITUS AFTER ACUTE CORONARY SYNDROME].
Topics: Acute Coronary Syndrome; Aspirin; Atorvastatin; Blood Platelets; Clopidogrel; Diabetes Mellitus, Typ | 2017 |
Dual antiplatelet therapy in patients with diabetes and acute coronary syndromes managed without revascularization.
Topics: Acute Coronary Syndrome; Aged; Aspirin; Clopidogrel; Diabetes Mellitus; Dose-Response Relationship, | 2017 |
Relative efficacy and safety of ticagelor vs clopidogrel as a function of time to invasive management in non-ST-segment elevation acute coronary syndrome in the PLATO trial.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Coronary Angiography; Dose-Response Relations | 2017 |
Platelet-related biomarkers and their response to inhibition with aspirin and p2y
Topics: Acute Coronary Syndrome; Adenosine; Aged; Aspirin; Biomarkers; Blood Platelets; CD40 Ligand; Clopido | 2017 |
Dual Antiplatelet Therapy for 6 Versus 18 Months After Biodegradable Polymer Drug-Eluting Stent Implantation.
Topics: Absorbable Implants; Acute Coronary Syndrome; Aged; Aspirin; Clopidogrel; Coronary Artery Disease; D | 2017 |
Time course of the antiplatelet effect after switching to clopidogrel from initial prasugrel therapy in patients with acute coronary syndrome.
Topics: Acute Coronary Syndrome; Clopidogrel; Coronary Angiography; Dose-Response Relationship, Drug; Drug S | 2017 |
Prasugrel vs. clopidogrel in contemporary Western European patients with acute coronary syndromes receiving drug-eluting stents: Comparative cost-effectiveness analysis from the BASKET-PROVE cohorts.
Topics: Acute Coronary Syndrome; Aged; Clopidogrel; Cohort Studies; Cost-Benefit Analysis; Drug-Eluting Sten | 2017 |
Guided de-escalation of antiplatelet treatment in patients with acute coronary syndrome undergoing percutaneous coronary intervention (TROPICAL-ACS): a randomised, open-label, multicentre trial.
Topics: Acute Coronary Syndrome; Clopidogrel; Drug Administration Schedule; Drug Monitoring; Europe; Female; | 2017 |
Guided de-escalation of antiplatelet treatment in patients with acute coronary syndrome undergoing percutaneous coronary intervention (TROPICAL-ACS): a randomised, open-label, multicentre trial.
Topics: Acute Coronary Syndrome; Clopidogrel; Drug Administration Schedule; Drug Monitoring; Europe; Female; | 2017 |
Guided de-escalation of antiplatelet treatment in patients with acute coronary syndrome undergoing percutaneous coronary intervention (TROPICAL-ACS): a randomised, open-label, multicentre trial.
Topics: Acute Coronary Syndrome; Clopidogrel; Drug Administration Schedule; Drug Monitoring; Europe; Female; | 2017 |
Guided de-escalation of antiplatelet treatment in patients with acute coronary syndrome undergoing percutaneous coronary intervention (TROPICAL-ACS): a randomised, open-label, multicentre trial.
Topics: Acute Coronary Syndrome; Clopidogrel; Drug Administration Schedule; Drug Monitoring; Europe; Female; | 2017 |
Guided de-escalation of antiplatelet treatment in patients with acute coronary syndrome undergoing percutaneous coronary intervention (TROPICAL-ACS): a randomised, open-label, multicentre trial.
Topics: Acute Coronary Syndrome; Clopidogrel; Drug Administration Schedule; Drug Monitoring; Europe; Female; | 2017 |
Guided de-escalation of antiplatelet treatment in patients with acute coronary syndrome undergoing percutaneous coronary intervention (TROPICAL-ACS): a randomised, open-label, multicentre trial.
Topics: Acute Coronary Syndrome; Clopidogrel; Drug Administration Schedule; Drug Monitoring; Europe; Female; | 2017 |
Guided de-escalation of antiplatelet treatment in patients with acute coronary syndrome undergoing percutaneous coronary intervention (TROPICAL-ACS): a randomised, open-label, multicentre trial.
Topics: Acute Coronary Syndrome; Clopidogrel; Drug Administration Schedule; Drug Monitoring; Europe; Female; | 2017 |
Guided de-escalation of antiplatelet treatment in patients with acute coronary syndrome undergoing percutaneous coronary intervention (TROPICAL-ACS): a randomised, open-label, multicentre trial.
Topics: Acute Coronary Syndrome; Clopidogrel; Drug Administration Schedule; Drug Monitoring; Europe; Female; | 2017 |
Guided de-escalation of antiplatelet treatment in patients with acute coronary syndrome undergoing percutaneous coronary intervention (TROPICAL-ACS): a randomised, open-label, multicentre trial.
Topics: Acute Coronary Syndrome; Clopidogrel; Drug Administration Schedule; Drug Monitoring; Europe; Female; | 2017 |
Pharmacodynamics and pharmacokinetics of ticagrelor vs. clopidogrel in patients with acute coronary syndromes and chronic kidney disease.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Creatinine; Female; Glomerular Filtration Rat | 2018 |
Double-Dose Versus Standard-Dose Clopidogrel According to Smoking Status Among Patients With Acute Coronary Syndromes Undergoing Percutaneous Coronary Intervention.
Topics: Acute Coronary Syndrome; Aged; Chi-Square Distribution; Clopidogrel; Coronary Thrombosis; Female; He | 2017 |
Switching from clopidogrel to prasugrel to protect early invasive treatment in acute coronary syndromes: Results of the switch over trial.
Topics: Acute Coronary Syndrome; Aged; Clopidogrel; Drug Substitution; Female; Humans; Male; Middle Aged; Pl | 2018 |
A Multicenter, Randomized, Double-Blind, and Placebo-Controlled Study of the Effects of Tongxinluo Capsules in Acute Coronary Syndrome Patients with High On-Treatment Platelet Reactivity.
Topics: Acute Coronary Syndrome; Aged; Aspirin; Blood Platelets; Capsules; Clopidogrel; Double-Blind Method; | 2018 |
6-month versus 12-month or longer dual antiplatelet therapy after percutaneous coronary intervention in patients with acute coronary syndrome (SMART-DATE): a randomised, open-label, non-inferiority trial.
Topics: Acute Coronary Syndrome; Aged; Aspirin; Clopidogrel; Drug Administration Schedule; Drug Therapy, Com | 2018 |
[Duration and Timing of Initiation of Therapy With Platelet P2Y12 Inhibitors in the Treatment of Patients With Acute Coronary Syndrome].
Topics: Acute Coronary Syndrome; Adenosine; Humans; Percutaneous Coronary Intervention; Platelet Aggregation | 2018 |
Quantification of the effect of clopidogrel on enzymatic infarct size related to a percutaneous coronary intervention in patients with acute coronary syndromes: insights from the CHAMPION percutaneous coronary intervention trial.
Topics: Acute Coronary Syndrome; Aged; Clopidogrel; Creatine Kinase, MB Form; Female; Humans; Logistic Model | 2013 |
Cost-effectiveness of ticagrelor versus clopidogrel for the prevention of atherothrombotic events in adult patients with acute coronary syndrome in Germany.
Topics: Acute Coronary Syndrome; Adenosine; Adult; Atherosclerosis; Clopidogrel; Cost-Benefit Analysis; Deci | 2013 |
Randomized assessment of ticagrelor versus prasugrel antiplatelet effects in patients with diabetes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Diabetes Mellitus, Type 2; Female; Humans; Ma | 2013 |
Randomized assessment of ticagrelor versus prasugrel antiplatelet effects in patients with diabetes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Diabetes Mellitus, Type 2; Female; Humans; Ma | 2013 |
Randomized assessment of ticagrelor versus prasugrel antiplatelet effects in patients with diabetes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Diabetes Mellitus, Type 2; Female; Humans; Ma | 2013 |
Randomized assessment of ticagrelor versus prasugrel antiplatelet effects in patients with diabetes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Diabetes Mellitus, Type 2; Female; Humans; Ma | 2013 |
Ticagrelor in patients with acute coronary syndromes and stroke: interpretation of subgroups in clinical trials.
Topics: Acute Coronary Syndrome; Adenosine; Clopidogrel; Drug Therapy, Combination; Humans; Platelet Aggrega | 2013 |
Efficacy of clopidogrel reloading in patients with acute coronary syndrome undergoing percutaneous coronary intervention during chronic clopidogrel therapy (from the Antiplatelet therapy for Reduction of MYocardial Damage during Angioplasty [ARMYDA-8 RELO
Topics: Acute Coronary Syndrome; Aged; Clopidogrel; Female; Humans; Male; Middle Aged; Percutaneous Coronary | 2013 |
Incidence and outcome of high on-treatment platelet reactivity in patients with non-ST elevation acute coronary syndromes undergoing percutaneous coronary intervention (from the VIP [VerifyNow and Inhibition of Platelet Reactivity] study).
Topics: Acute Coronary Syndrome; Aged; Clopidogrel; Coronary Angiography; Death, Sudden, Cardiac; Electrocar | 2013 |
Platelet inhibition by abciximab bolus-only administration and oral ADP receptor antagonist loading in acute coronary syndrome patients: the blocking and bridging strategy.
Topics: Abciximab; Acute Coronary Syndrome; Administration, Oral; Adult; Aged; Antibodies, Monoclonal; Blood | 2013 |
Quantitative ST-depression in acute coronary syndromes: the PLATO electrocardiographic substudy.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Cardiovascular Diseases; Clopidogrel; Cohort Studies; Elec | 2013 |
Health-related quality of life of ticagrelor versus clopidogrel in patients with acute coronary syndromes-results from the PLATO trial.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Female; Follow-Up Studie | 2013 |
Elderly patients with acute coronary syndromes managed without revascularization: insights into the safety of long-term dual antiplatelet therapy with reduced-dose prasugrel versus standard-dose clopidogrel.
Topics: Acute Coronary Syndrome; Age Factors; Aged; Aged, 80 and over; Aspirin; Clopidogrel; Disease Managem | 2013 |
Angiographic outcomes in the PLATO Trial (Platelet Inhibition and Patient Outcomes).
Topics: Acute Coronary Syndrome; Adenosine; Administration, Oral; Aged; Clopidogrel; Coronary Angiography; C | 2013 |
Stent thrombosis with ticagrelor versus clopidogrel in patients with acute coronary syndromes: an analysis from the prospective, randomized PLATO trial.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Coronary Thrombosis; Double-Blind Method; Fem | 2013 |
Stent thrombosis with ticagrelor versus clopidogrel in patients with acute coronary syndromes: an analysis from the prospective, randomized PLATO trial.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Coronary Thrombosis; Double-Blind Method; Fem | 2013 |
Stent thrombosis with ticagrelor versus clopidogrel in patients with acute coronary syndromes: an analysis from the prospective, randomized PLATO trial.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Coronary Thrombosis; Double-Blind Method; Fem | 2013 |
Stent thrombosis with ticagrelor versus clopidogrel in patients with acute coronary syndromes: an analysis from the prospective, randomized PLATO trial.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Coronary Thrombosis; Double-Blind Method; Fem | 2013 |
Stent thrombosis with ticagrelor versus clopidogrel in patients with acute coronary syndromes: an analysis from the prospective, randomized PLATO trial.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Coronary Thrombosis; Double-Blind Method; Fem | 2013 |
Stent thrombosis with ticagrelor versus clopidogrel in patients with acute coronary syndromes: an analysis from the prospective, randomized PLATO trial.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Coronary Thrombosis; Double-Blind Method; Fem | 2013 |
Stent thrombosis with ticagrelor versus clopidogrel in patients with acute coronary syndromes: an analysis from the prospective, randomized PLATO trial.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Coronary Thrombosis; Double-Blind Method; Fem | 2013 |
Stent thrombosis with ticagrelor versus clopidogrel in patients with acute coronary syndromes: an analysis from the prospective, randomized PLATO trial.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Coronary Thrombosis; Double-Blind Method; Fem | 2013 |
Stent thrombosis with ticagrelor versus clopidogrel in patients with acute coronary syndromes: an analysis from the prospective, randomized PLATO trial.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Coronary Thrombosis; Double-Blind Method; Fem | 2013 |
Prasugrel versus clopidogrel for patients with unstable angina or non-ST-segment elevation myocardial infarction with or without angiography: a secondary, prespecified analysis of the TRILOGY ACS trial.
Topics: Acute Coronary Syndrome; Aged; Angina, Unstable; Clopidogrel; Coronary Angiography; Female; Humans; | 2013 |
Implementation of contemporary oral antiplatelet treatment guidelines in patients with acute coronary syndrome undergoing percutaneous coronary intervention: a report from the GReek AntiPlatelet rEgistry (GRAPE).
Topics: Acute Coronary Syndrome; Adenosine; Administration, Oral; Aged; Clopidogrel; Combined Modality Thera | 2013 |
Circadian variation of stent thrombosis and the effect of more robust platelet inhibition: a post hoc analysis of the TRITON-TIMI 38 trial.
Topics: Acute Coronary Syndrome; Aged; Circadian Rhythm; Clopidogrel; Double-Blind Method; Female; Humans; M | 2013 |
Effect on platelet reactivity from a prasugrel loading dose after a clopidogrel loading dose compared with a prasugrel loading dose alone: Transferring From Clopidogrel Loading Dose to Prasugrel Loading Dose in Acute Coronary Syndrome Patients (TRIPLET):
Topics: Acute Coronary Syndrome; Aged; Blood Platelets; Clopidogrel; Drug Dosage Calculations; Female; Human | 2013 |
Effect on platelet reactivity from a prasugrel loading dose after a clopidogrel loading dose compared with a prasugrel loading dose alone: Transferring From Clopidogrel Loading Dose to Prasugrel Loading Dose in Acute Coronary Syndrome Patients (TRIPLET):
Topics: Acute Coronary Syndrome; Aged; Blood Platelets; Clopidogrel; Drug Dosage Calculations; Female; Human | 2013 |
Effect on platelet reactivity from a prasugrel loading dose after a clopidogrel loading dose compared with a prasugrel loading dose alone: Transferring From Clopidogrel Loading Dose to Prasugrel Loading Dose in Acute Coronary Syndrome Patients (TRIPLET):
Topics: Acute Coronary Syndrome; Aged; Blood Platelets; Clopidogrel; Drug Dosage Calculations; Female; Human | 2013 |
Effect on platelet reactivity from a prasugrel loading dose after a clopidogrel loading dose compared with a prasugrel loading dose alone: Transferring From Clopidogrel Loading Dose to Prasugrel Loading Dose in Acute Coronary Syndrome Patients (TRIPLET):
Topics: Acute Coronary Syndrome; Aged; Blood Platelets; Clopidogrel; Drug Dosage Calculations; Female; Human | 2013 |
Cost-effectiveness of ticagrelor and generic clopidogrel in patients with acute coronary syndrome in Switzerland.
Topics: Acute Coronary Syndrome; Adenosine; Aspirin; Clopidogrel; Cost-Benefit Analysis; Decision Support Te | 2013 |
Evolving pattern of platelet P2Y12 inhibition in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Blood Platelets; Clopidogrel; Humans; Male; Middle Aged; Percuta | 2014 |
Discharge aspirin dose and clinical outcomes in patients with acute coronary syndromes treated with prasugrel versus clopidogrel: an analysis from the TRITON-TIMI 38 study (trial to assess improvement in therapeutic outcomes by optimizing platelet inhibit
Topics: Acute Coronary Syndrome; Aged; Aspirin; Clopidogrel; Dose-Response Relationship, Drug; Double-Blind | 2014 |
Treatment patterns and outcomes in patients undergoing percutaneous coronary intervention treated with prasugrel or clopidogrel (from the Swedish Coronary Angiography and Angioplasty Registry [SCAAR]).
Topics: Acute Coronary Syndrome; Aged; Cause of Death; Clopidogrel; Coronary Angiography; Dose-Response Rela | 2014 |
Biomarkers in relation to the effects of ticagrelor in comparison with clopidogrel in non-ST-elevation acute coronary syndrome patients managed with or without in-hospital revascularization: a substudy from the Prospective Randomized Platelet Inhibition a
Topics: Acute Coronary Syndrome; Adenosine; Biomarkers; Clopidogrel; Electrocardiography; Growth Differentia | 2014 |
Biomarkers in relation to the effects of ticagrelor in comparison with clopidogrel in non-ST-elevation acute coronary syndrome patients managed with or without in-hospital revascularization: a substudy from the Prospective Randomized Platelet Inhibition a
Topics: Acute Coronary Syndrome; Adenosine; Biomarkers; Clopidogrel; Electrocardiography; Growth Differentia | 2014 |
Biomarkers in relation to the effects of ticagrelor in comparison with clopidogrel in non-ST-elevation acute coronary syndrome patients managed with or without in-hospital revascularization: a substudy from the Prospective Randomized Platelet Inhibition a
Topics: Acute Coronary Syndrome; Adenosine; Biomarkers; Clopidogrel; Electrocardiography; Growth Differentia | 2014 |
Biomarkers in relation to the effects of ticagrelor in comparison with clopidogrel in non-ST-elevation acute coronary syndrome patients managed with or without in-hospital revascularization: a substudy from the Prospective Randomized Platelet Inhibition a
Topics: Acute Coronary Syndrome; Adenosine; Biomarkers; Clopidogrel; Electrocardiography; Growth Differentia | 2014 |
Three vs twelve months of dual antiplatelet therapy after zotarolimus-eluting stents: the OPTIMIZE randomized trial.
Topics: Acute Coronary Syndrome; Aged; Aspirin; Clopidogrel; Coronary Artery Disease; Drug Administration Sc | 2013 |
Three vs twelve months of dual antiplatelet therapy after zotarolimus-eluting stents: the OPTIMIZE randomized trial.
Topics: Acute Coronary Syndrome; Aged; Aspirin; Clopidogrel; Coronary Artery Disease; Drug Administration Sc | 2013 |
Three vs twelve months of dual antiplatelet therapy after zotarolimus-eluting stents: the OPTIMIZE randomized trial.
Topics: Acute Coronary Syndrome; Aged; Aspirin; Clopidogrel; Coronary Artery Disease; Drug Administration Sc | 2013 |
Three vs twelve months of dual antiplatelet therapy after zotarolimus-eluting stents: the OPTIMIZE randomized trial.
Topics: Acute Coronary Syndrome; Aged; Aspirin; Clopidogrel; Coronary Artery Disease; Drug Administration Sc | 2013 |
Decreased circulating microRNA-223 level predicts high on-treatment platelet reactivity in patients with troponin-negative non-ST elevation acute coronary syndrome.
Topics: Acute Coronary Syndrome; Aged; Aspirin; Biomarkers; Blood Platelets; Clopidogrel; Cytochrome P-450 C | 2014 |
Concomitant administration of clopidogrel with statins or calcium-channel blockers: insights from the TRITON-TIMI 38 (trial to assess improvement in therapeutic outcomes by optimizing platelet inhibition with prasugrel-thrombolysis in myocardial infarctio
Topics: Acute Coronary Syndrome; Aged; Calcium Channel Blockers; Clopidogrel; Double-Blind Method; Drug Inte | 2013 |
Ticagrelor increases adenosine plasma concentration in patients with an acute coronary syndrome.
Topics: Acute Coronary Syndrome; Adenosine; Adenosine Deaminase; Aged; C-Reactive Protein; Chromatography, L | 2014 |
Ticagrelor increases adenosine plasma concentration in patients with an acute coronary syndrome.
Topics: Acute Coronary Syndrome; Adenosine; Adenosine Deaminase; Aged; C-Reactive Protein; Chromatography, L | 2014 |
Ticagrelor increases adenosine plasma concentration in patients with an acute coronary syndrome.
Topics: Acute Coronary Syndrome; Adenosine; Adenosine Deaminase; Aged; C-Reactive Protein; Chromatography, L | 2014 |
Ticagrelor increases adenosine plasma concentration in patients with an acute coronary syndrome.
Topics: Acute Coronary Syndrome; Adenosine; Adenosine Deaminase; Aged; C-Reactive Protein; Chromatography, L | 2014 |
Ticagrelor increases adenosine plasma concentration in patients with an acute coronary syndrome.
Topics: Acute Coronary Syndrome; Adenosine; Adenosine Deaminase; Aged; C-Reactive Protein; Chromatography, L | 2014 |
Ticagrelor increases adenosine plasma concentration in patients with an acute coronary syndrome.
Topics: Acute Coronary Syndrome; Adenosine; Adenosine Deaminase; Aged; C-Reactive Protein; Chromatography, L | 2014 |
Ticagrelor increases adenosine plasma concentration in patients with an acute coronary syndrome.
Topics: Acute Coronary Syndrome; Adenosine; Adenosine Deaminase; Aged; C-Reactive Protein; Chromatography, L | 2014 |
Ticagrelor increases adenosine plasma concentration in patients with an acute coronary syndrome.
Topics: Acute Coronary Syndrome; Adenosine; Adenosine Deaminase; Aged; C-Reactive Protein; Chromatography, L | 2014 |
Ticagrelor increases adenosine plasma concentration in patients with an acute coronary syndrome.
Topics: Acute Coronary Syndrome; Adenosine; Adenosine Deaminase; Aged; C-Reactive Protein; Chromatography, L | 2014 |
Administration of a loading dose has no additive effect on platelet aggregation during the switch from ongoing clopidogrel treatment to ticagrelor in patients with acute coronary syndrome.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Drug Dosage Calculations; Drug Substitution; | 2014 |
Administration of a loading dose has no additive effect on platelet aggregation during the switch from ongoing clopidogrel treatment to ticagrelor in patients with acute coronary syndrome.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Drug Dosage Calculations; Drug Substitution; | 2014 |
Administration of a loading dose has no additive effect on platelet aggregation during the switch from ongoing clopidogrel treatment to ticagrelor in patients with acute coronary syndrome.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Drug Dosage Calculations; Drug Substitution; | 2014 |
Administration of a loading dose has no additive effect on platelet aggregation during the switch from ongoing clopidogrel treatment to ticagrelor in patients with acute coronary syndrome.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Drug Dosage Calculations; Drug Substitution; | 2014 |
A comparative evaluation of prasugrel and clopidogrel in patients with acute coronary syndrome undergoing percutaneous coronary intervention.
Topics: Acute Coronary Syndrome; Adult; Aged; Aspirin; Clopidogrel; Combined Modality Therapy; Double-Blind | 2013 |
Coronary artery bypass grafting-related bleeding complications in real-life acute coronary syndrome patients treated with clopidogrel or ticagrelor.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Coronary Artery Bypass; Coronary Thrombosis; | 2014 |
Randomised, double-blind trial on the value of tapered discontinuation of clopidogrel maintenance therapy after drug-eluting stent implantation. Intracoronary Stenting and Antithrombotic Regimen: CAUTION in Discontinuing Clopidogrel Therapy--ISAR-CAUTION.
Topics: Acute Coronary Syndrome; Aged; Clopidogrel; Double-Blind Method; Drug-Eluting Stents; Female; Fibrin | 2014 |
Ticagrelor treatment in patients with acute coronary syndrome is cost-effective in Sweden and Denmark.
Topics: Acute Coronary Syndrome; Adenosine; Clopidogrel; Cost-Benefit Analysis; Denmark; Humans; Purinergic | 2014 |
Switching from high-dose clopidogrel to prasugrel in ACS patients undergoing PCI: a single-center experience.
Topics: Acute Coronary Syndrome; Adult; Aged; Angioplasty, Balloon, Coronary; Clopidogrel; Drug Substitution | 2014 |
The efficacy of ticagrelor is maintained in women with acute coronary syndromes participating in the prospective, randomized, PLATelet inhibition and patient Outcomes (PLATO) trial.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Dose-Response Relationship, Drug; Double-Blin | 2014 |
Transferring from clopidogrel loading dose to prasugrel loading dose in acute coronary syndrome patients. High on-treatment platelet reactivity analysis of the TRIPLET trial.
Topics: Acute Coronary Syndrome; Aged; Blood Platelets; Clopidogrel; Cytochrome P-450 CYP2C19; Double-Blind | 2014 |
Ticagrelor vs. clopidogrel in patients with non-ST-elevation acute coronary syndrome with or without revascularization: results from the PLATO trial.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Female; Hemorrhage; Humans; Kaplan-Meier Esti | 2014 |
Efficacy and safety of adjusted-dose prasugrel compared with clopidogrel in Japanese patients with acute coronary syndrome: the PRASFIT-ACS study.
Topics: Acute Coronary Syndrome; Adult; Aged; Aged, 80 and over; Asian People; Aspirin; Clopidogrel; Drug Th | 2014 |
Effects of clopidogrel, prasugrel and ticagrelor on endothelial function, inflammatory and oxidative stress parameters and platelet function in patients undergoing coronary artery stenting for an acute coronary syndrome. A randomised, prospective, control
Topics: Acute Coronary Syndrome; Adenosine; Adolescent; Adult; Aged; Blood Platelets; Clopidogrel; Drug-Elut | 2014 |
Cardiovascular events in acute coronary syndrome patients with peripheral arterial disease treated with ticagrelor compared with clopidogrel: Data from the PLATO Trial.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Female; Hemorrhage; Huma | 2015 |
Serial clopidogrel dose adjustment after platelet function testing improves outcome of acute coronary syndrome patients undergoing percutaneous coronary intervention with high on-treatment platelet reactivity.
Topics: Acute Coronary Syndrome; Aged; Blood Platelets; Clopidogrel; Dose-Response Relationship, Drug; Femal | 2014 |
Comparing the effect of clopidogrel versus ticagrelor on coronary microvascular dysfunction in acute coronary syndrome patients (TIME trial): study protocol for a randomized controlled trial.
Topics: Acute Coronary Syndrome; Adenosine; Clinical Protocols; Clopidogrel; Coronary Circulation; Coronary | 2014 |
Impact of smoking status on platelet function and clinical outcomes with prasugrel vs. clopidogrel in patients with acute coronary syndromes managed without revascularization: Insights from the TRILOGY ACS trial.
Topics: Acute Coronary Syndrome; Aged; Clopidogrel; Dose-Response Relationship, Drug; Drug Therapy, Combinat | 2014 |
Causes of mortality with ticagrelor compared with clopidogrel in acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Age Factors; Aged; Cause of Death; Clopidogrel; Confidence Inter | 2014 |
Monitoring the efficacy of ADP inhibitor treatment in patients with acute STEMI post-PCI by VASP-P flow cytometry assay.
Topics: Acute Coronary Syndrome; Adenosine Diphosphate; Aged; Aged, 80 and over; Aspirin; Blood Platelets; C | 2015 |
An analysis of TRITON-TIMI 38, based on the 12 month recommended length of therapy in the European label for prasugrel.
Topics: Acute Coronary Syndrome; Aged; Aspirin; Clopidogrel; Cohort Studies; Coronary Artery Bypass; Drug Ad | 2014 |
Switching patients from clopidogrel to prasugrel in acute coronary syndrome: impact of the clopidogrel loading dose on platelet reactivity.
Topics: Acute Coronary Syndrome; Clopidogrel; Dose-Response Relationship, Drug; Female; Humans; Male; Middle | 2014 |
Platelet function in Takotsubo cardiomyopathy.
Topics: Acute Coronary Syndrome; Aged; Aged, 80 and over; Blood Platelets; Clopidogrel; Epinephrine; Female; | 2015 |
MULTInational non-interventional study of patients with ST-segment elevation myocardial infarction treated with PRimary Angioplasty and Concomitant use of upstream antiplatelet therapy with prasugrel or clopidogrel--the European MULTIPRAC Registry.
Topics: Acute Coronary Syndrome; Aged; Antithrombins; Clopidogrel; Drug Therapy, Combination; Europe; Female | 2015 |
Point-of-care measurements of platelet inhibition after clopidogrel loading in patients with acute coronary syndrome: comparison of generic and branded clopidogrel bisulfate.
Topics: Acute Coronary Syndrome; Aged; Blood Platelets; Clopidogrel; Drugs, Generic; Female; Humans; Male; M | 2014 |
Health economic analysis of ticagrelor in patients with acute coronary syndromes intended for non-invasive therapy.
Topics: Acute Coronary Syndrome; Adenosine; Brazil; Clopidogrel; Cost-Benefit Analysis; Disease Management; | 2015 |
Association of spontaneous and procedure-related bleeds with short- and long-term mortality after acute coronary syndromes: an analysis from the PLATO trial.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Coronary Angiography; Coronary Artery Bypass; | 2015 |
Early high-dose rosuvastatin and cardioprotection in the protective effect of rosuvastatin and antiplatelet therapy on contrast-induced acute kidney injury and myocardial damage in patients with acute coronary syndrome (PRATO-ACS) study.
Topics: Acute Coronary Syndrome; Acute Kidney Injury; Cardiotonic Agents; Clopidogrel; Contrast Media; Coron | 2014 |
Vorapaxar with or without clopidogrel after non-ST-segment elevation acute coronary syndromes: results from the thrombin receptor antagonist for clinical event reduction in acute coronary syndrome trial.
Topics: Acute Coronary Syndrome; Aged; Clopidogrel; Drug Monitoring; Drug Therapy, Combination; Electrocardi | 2014 |
Residual platelet reactivity to predict long-term clinical outcomes after clopidogrel loading in patients with acute coronary syndromes: comparison of different cutoff values by light transmission aggregometry from the responsiveness to clopidogrel and st
Topics: Acute Coronary Syndrome; Blood Platelets; Clopidogrel; Cohort Studies; Drug Administration Schedule; | 2015 |
Genetic polymorphisms of CYP2C19 2 and ABCB1 C3435T affect the pharmacokinetic and pharmacodynamic responses to clopidogrel in 401 patients with acute coronary syndrome.
Topics: Acute Coronary Syndrome; Aged; ATP Binding Cassette Transporter, Subfamily B; Clopidogrel; Cytochrom | 2015 |
Prasugrel and ticagrelor compared to clopidogrel in non-ST-segment elevation acute coronary syndromes undergoing percutaneous coronary interventions: Certainties and uncertainties.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Female; Humans; Male; Middle Aged; Percutaneo | 2015 |
Comparison of prasugrel and clopidogrel-treated patients with acute coronary syndrome undergoing percutaneous coronary intervention: A propensity score-matched analysis of the Acute Myocardial Infarction in Switzerland (AMIS)-Plus Registry.
Topics: Acute Coronary Syndrome; Acute Disease; Aged; Aged, 80 and over; Clopidogrel; Female; Humans; Male; | 2016 |
Economic analysis of ticagrelor therapy from a U.S. perspective: results from the PLATO study.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Cohort Studies; Cost-Benefit Analysis; Double | 2015 |
Impact of clinical presentation on ischaemic and bleeding outcomes in patients receiving 6- or 24-month duration of dual-antiplatelet therapy after stent implantation: a pre-specified analysis from the PRODIGY (Prolonging Dual-Antiplatelet Treatment After
Topics: Acute Coronary Syndrome; Aged; Aspirin; Clopidogrel; Coronary Artery Disease; Drug Therapy, Combinat | 2015 |
Ticagrelor increases endothelial progenitor cell level compared to clopidogrel in acute coronary syndromes: A prospective randomized study.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Antigens, CD34; Body Mass Index; Clopidogrel; Endothelial | 2015 |
Frailty is associated with worse outcomes in non-ST-segment elevation acute coronary syndromes: Insights from the TaRgeted platelet Inhibition to cLarify the Optimal strateGy to medicallY manage Acute Coronary Syndromes (TRILOGY ACS) trial.
Topics: Acute Coronary Syndrome; Age Factors; Aged; Aged, 80 and over; Clopidogrel; Double-Blind Method; Fem | 2016 |
Ticagrelor versus clopidogrel in Asian patients with acute coronary syndrome: A retrospective analysis from the Platelet Inhibition and Patient Outcomes (PLATO) Trial.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Asian People; Clopidogrel; Double-Blind Method; Female; He | 2015 |
Large early variation of residual platelet reactivity in Acute Coronary Syndrome patients treated with clopidogrel: results from Assessing Platelet Activity in Coronary Heart Disease (APACHE).
Topics: Acute Coronary Syndrome; Aged; Clopidogrel; Female; Humans; Male; Platelet Aggregation; Platelet Cou | 2015 |
Comparison of P2Y12 receptor inhibition by clopidogrel and prasugrel in patients undergoing percutaneous coronary intervention.
Topics: Acute Coronary Syndrome; Adult; Aged; Clopidogrel; Female; Humans; Male; Middle Aged; Percutaneous C | 2013 |
Impact of chronic kidney disease on long-term ischemic and bleeding outcomes in medically managed patients with acute coronary syndromes: Insights from the TRILOGY ACS Trial.
Topics: Acute Coronary Syndrome; Aged; Clopidogrel; Creatinine; Female; Hemorrhage; Humans; Kaplan-Meier Est | 2016 |
High Platelet Reactivity in Patients with Acute Coronary Syndromes Undergoing Percutaneous Coronary Intervention: Randomised Controlled Trial Comparing Prasugrel and Clopidogrel.
Topics: Acute Coronary Syndrome; Adenosine Diphosphate; Aged; Blood Platelets; Clopidogrel; Female; Follow-U | 2015 |
Ticagrelor versus clopidogrel in Chinese patients with acute coronary syndrome: A pharmacodynamic analysis.
Topics: Acute Coronary Syndrome; Adenosine; Aspirin; Clopidogrel; Follow-Up Studies; Humans; Platelet Aggreg | 2015 |
Stopping or continuing clopidogrel 12 months after drug-eluting stent placement: the OPTIDUAL randomized trial.
Topics: Acute Coronary Syndrome; Adult; Aftercare; Clopidogrel; Coronary Artery Disease; Drug Administration | 2016 |
Ticagrelor vs. clopidogrel in Japanese, Korean and Taiwanese patients with acute coronary syndrome -- randomized, double-blind, phase III PHILO study.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Asian People; Clopidogrel; Double-Blind Method; Female; He | 2015 |
Ticagrelor vs. clopidogrel in Japanese, Korean and Taiwanese patients with acute coronary syndrome -- randomized, double-blind, phase III PHILO study.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Asian People; Clopidogrel; Double-Blind Method; Female; He | 2015 |
Ticagrelor vs. clopidogrel in Japanese, Korean and Taiwanese patients with acute coronary syndrome -- randomized, double-blind, phase III PHILO study.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Asian People; Clopidogrel; Double-Blind Method; Female; He | 2015 |
Ticagrelor vs. clopidogrel in Japanese, Korean and Taiwanese patients with acute coronary syndrome -- randomized, double-blind, phase III PHILO study.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Asian People; Clopidogrel; Double-Blind Method; Female; He | 2015 |
Concomitant proton-pump inhibitor use, platelet activity, and clinical outcomes in patients with acute coronary syndromes treated with prasugrel versus clopidogrel and managed without revascularization: insights from the Targeted Platelet Inhibition to Cl
Topics: Acute Coronary Syndrome; Aged; Clopidogrel; Dose-Response Relationship, Drug; Double-Blind Method; D | 2015 |
Long-term outcomes for women versus men with unstable angina/non-ST-segment elevation myocardial infarction managed medically without revascularization: insights from the TaRgeted platelet Inhibition to cLarify the Optimal strateGy to medicallY manage Acu
Topics: Acute Coronary Syndrome; Aged; Angina, Unstable; Clopidogrel; Coronary Angiography; Double-Blind Met | 2015 |
Fixed and Modifiable Correlates of Drug-Eluting Stent Thrombosis From a Large All-Comers Registry: Insights From ADAPT-DES.
Topics: Acute Coronary Syndrome; Aged; Clopidogrel; Drug-Eluting Stents; Female; Follow-Up Studies; Humans; | 2015 |
Growth differentiation factor-15 level predicts major bleeding and cardiovascular events in patients with acute coronary syndromes: results from the PLATO study.
Topics: Acute Coronary Syndrome; C-Reactive Protein; Growth Differentiation Factor 15; Hemorrhage; Humans; N | 2016 |
Ticagrelor Versus Clopidogrel in Patients With Acute Coronary Syndromes and Chronic Obstructive Pulmonary Disease: An Analysis From the Platelet Inhibition and Patient Outcomes (PLATO) Trial.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Dyspnea; Female; Hemorrhage; Humans; Kaplan-M | 2015 |
Ticagrelor Versus Clopidogrel in Patients With Acute Coronary Syndromes and Chronic Obstructive Pulmonary Disease: An Analysis From the Platelet Inhibition and Patient Outcomes (PLATO) Trial.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Dyspnea; Female; Hemorrhage; Humans; Kaplan-M | 2015 |
Ticagrelor Versus Clopidogrel in Patients With Acute Coronary Syndromes and Chronic Obstructive Pulmonary Disease: An Analysis From the Platelet Inhibition and Patient Outcomes (PLATO) Trial.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Dyspnea; Female; Hemorrhage; Humans; Kaplan-M | 2015 |
Ticagrelor Versus Clopidogrel in Patients With Acute Coronary Syndromes and Chronic Obstructive Pulmonary Disease: An Analysis From the Platelet Inhibition and Patient Outcomes (PLATO) Trial.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Dyspnea; Female; Hemorrhage; Humans; Kaplan-M | 2015 |
Effects of CYP2C19 allelic variants on inhibition of platelet aggregation and major adverse cardiovascular events in Japanese patients with acute coronary syndrome: The PRASFIT-ACS study.
Topics: Acute Coronary Syndrome; Aged; Alleles; Aspirin; Clopidogrel; Cytochrome P-450 CYP2C19; Double-Blind | 2016 |
Ticagrelor or prasugrel versus clopidogrel in elderly patients with an acute coronary syndrome: Optimization of antiplatelet treatment in patients 70 years and older--rationale and design of the POPular AGE study.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Female; Follow-Up Studies; Humans; Male; Plat | 2015 |
Efficacy of ex vivo autologous and in vivo platelet transfusion in the reversal of P2Y12 inhibition by clopidogrel, prasugrel, and ticagrelor: the APTITUDE study.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Female; Humans; Male; Middle Aged; Percutaneo | 2015 |
Ascertainment, classification, and impact of neoplasm detection during prolonged treatment with dual antiplatelet therapy with prasugrel vs. clopidogrel following acute coronary syndrome.
Topics: Acute Coronary Syndrome; Aged; Clopidogrel; Drug Therapy, Combination; Female; Hemorrhage; Humans; L | 2016 |
Impact of Hemoglobin A1c Levels on Residual Platelet Reactivity and Outcomes After Insertion of Coronary Drug-Eluting Stents (from the ADAPT-DES Study).
Topics: Acute Coronary Syndrome; Blood Platelets; Clopidogrel; Diabetes Mellitus; Drug-Eluting Stents; Femal | 2016 |
Efficacy of Clopidogrel and Clinical Outcome When Clopidogrel Is Coadministered With Atorvastatin and Lansoprazole: A Prospective, Randomized, Controlled Trial.
Topics: Acute Coronary Syndrome; Adult; Aged; Atorvastatin; Clopidogrel; Drug Interactions; Drug-Eluting Ste | 2015 |
VERifyNow in DIabetes high-on-treatment platelet reactivity: a pharmacodynamic study on switching from clopidogrel to prasugrel.
Topics: Acute Coronary Syndrome; Aged; Blood Platelets; Clopidogrel; Diabetes Mellitus, Type 2; Dose-Respons | 2015 |
Relationship Between Early and Late Nonsustained Ventricular Tachycardia and Cardiovascular Death in Patients With Acute Coronary Syndrome in the Platelet Inhibition and Patient Outcomes (PLATO) Trial.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Biomarkers; Cause of Death; Clopidogrel; Death, Sudden, Ca | 2016 |
Effects of Ticagrelor Versus Clopidogrel in Troponin-Negative Patients With Low-Risk ACS Undergoing Ad Hoc PCI.
Topics: Acute Coronary Syndrome; Adenosine; Administration, Oral; Aged; Clopidogrel; Dose-Response Relations | 2016 |
Impact of CYP2C19 Metabolizer Status on Patients With ACS Treated With Prasugrel Versus Clopidogrel.
Topics: Acute Coronary Syndrome; Aged; Alleles; Clopidogrel; Cytochrome P-450 CYP2C19; DNA; Dose-Response Re | 2016 |
Spontaneous MI After Non-ST-Segment Elevation Acute Coronary Syndrome Managed Without Revascularization: The TRILOGY ACS Trial.
Topics: Acute Coronary Syndrome; Aged; Aspirin; Clopidogrel; Coronary Angiography; Dose-Response Relationshi | 2016 |
A randomized trial to compare the safety of rivaroxaban vs aspirin in addition to either clopidogrel or ticagrelor in acute coronary syndrome: The design of the GEMINI-ACS-1 phase II study.
Topics: Acute Coronary Syndrome; Adenosine; Adolescent; Adult; Aspirin; Clopidogrel; Dose-Response Relations | 2016 |
Effect of prior clopidogrel use on outcomes in medically managed acute coronary syndrome patients.
Topics: Acute Coronary Syndrome; Aged; Aspirin; Clopidogrel; Double-Blind Method; Drug Administration Schedu | 2016 |
Ticagrelor Improves Peripheral Arterial Function in Acute Coronary Syndrome Patients: Relationship With Adenosine Plasma Level.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Arteries; Aspirin; Biomarkers; Clopidogrel; Dose-Response | 2016 |
Inferiority of ticagrelor in the PHILO trial: Play of chance in East Asians or nightmare confirmation of PLATO-USA?
Topics: Acute Coronary Syndrome; Adenosine; Asian People; Aspirin; Black People; Clopidogrel; Hemorrhage; Hu | 2016 |
Efficacy and Safety of Proton-Pump Inhibitors in High-Risk Cardiovascular Subsets of the COGENT Trial.
Topics: Acute Coronary Syndrome; Aspirin; Clopidogrel; Double-Blind Method; Drug Therapy, Combination; Gastr | 2016 |
Prasugrel 5 mg inhibits platelet P-selectin and GPIIb-IIIa expression in very elderly and non elderly: results from the GENERATIONS trial, a pharmacodynamic study in stable CAD patients.
Topics: Acute Coronary Syndrome; Age Factors; Aged; Aged, 80 and over; Clopidogrel; Coronary Artery Disease; | 2016 |
Association Between Very Low Levels of High-Density Lipoprotein Cholesterol and Long-term Outcomes of Patients With Acute Coronary Syndrome Treated Without Revascularization: Insights From the TRILOGY ACS Trial.
Topics: Acute Coronary Syndrome; Aged; Angina, Unstable; Aspirin; Biomarkers; Cholesterol, HDL; Clopidogrel; | 2016 |
Impaired biological response to aspirin in therapeutic hypothermia comatose patients resuscitated from out-of-hospital cardiac arrest.
Topics: Acute Coronary Syndrome; Administration, Intravenous; Administration, Oral; Adult; Aged; Aspirin; Ca | 2016 |
Effect of Smoking Status on Clinical Outcome and Efficacy of Clopidogrel in Acute Coronary Syndrome.
Topics: Acute Coronary Syndrome; Aged; Aged, 80 and over; Clopidogrel; Disease-Free Survival; Female; Hospit | 2016 |
Risks and Benefits of Dual Antiplatelet Therapy Beyond 12 Months After Coronary Stenting: A Prospective Randomized Cohort Study.
Topics: Acute Coronary Syndrome; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Angiography; | 2016 |
Impact of glycoprotein IIb/IIIa inhibitors on the efficacy and safety of ticagrelor compared with clopidogrel in patients with acute coronary syndromes: Analysis from the Platelet Inhibition and Patient Outcomes (PLATO) Trial.
Topics: Abciximab; Acute Coronary Syndrome; Adenosine; Aged; Antibodies, Monoclonal; Aspirin; Cardiovascular | 2016 |
[The use of prasugrel in STEMI and NSTEMI: TRITON TIMI 38 study and subgroup analyses].
Topics: Acute Coronary Syndrome; Clopidogrel; Humans; Myocardial Infarction; Platelet Aggregation Inhibitors | 2015 |
[TRILOGY-ACS and ACCOAST trial from an expert's perspective].
Topics: Acute Coronary Syndrome; Clopidogrel; Hemorrhage; Humans; Myocardial Infarction; Prasugrel Hydrochlo | 2015 |
A randomized trial assessing the impact of three different glycoprotein IIb/IIIa antagonists on glycoprotein IIb/IIIa platelet receptor inhibition and clinical endpoints in patients with acute coronary syndromes.
Topics: Abciximab; Acute Coronary Syndrome; Adenosine; Aged; Antibodies, Monoclonal; Blood Platelets; Clopid | 2016 |
Safety and efficacy of policosanol in patients with high on-treatment platelet reactivity after drug-eluting stent implantation: two-year follow-up results.
Topics: Acute Coronary Syndrome; Aged; Aspirin; China; Clopidogrel; Drug Therapy, Combination; Drug-Eluting | 2016 |
Modulation of Circulating MicroRNAs Levels during the Switch from Clopidogrel to Ticagrelor.
Topics: Acute Coronary Syndrome; Adenosine; Clopidogrel; Drug Substitution; Female; Gene Expression Regulati | 2016 |
A Cost-Effectiveness Analysis of Clopidogrel for Patients with Non-ST-Segment Elevation Acute Coronary Syndrome in China.
Topics: Acute Coronary Syndrome; Aspirin; China; Clopidogrel; Cost-Benefit Analysis; Drug Costs; Drug Therap | 2016 |
The Prognostic Value of ADP-Induced Platelet Aggregation for Bleeding Complications in Low - Intermediate Risk Patients with Acute Coronary Syndrome Taking Clopidogrel After Percutaneous Coronary Intervention.
Topics: Acute Coronary Syndrome; Adenosine Diphosphate; Aged; Clopidogrel; Female; Follow-Up Studies; Hemorr | 2017 |
Dual Antiplatelet Therapy and Outcomes in Patients With Atrial Fibrillation and Acute Coronary Syndromes Managed Medically Without Revascularization: Insights From the TRILOGY ACS Trial.
Topics: Acute Coronary Syndrome; Aged; Aspirin; Atrial Fibrillation; Chi-Square Distribution; Clopidogrel; D | 2016 |
Implications of different criteria for percutaneous coronary intervention-related myocardial infarction on study results of three large phase III clinical trials: The CHAMPION experience.
Topics: Acute Coronary Syndrome; Adenosine Monophosphate; Aged; Dose-Response Relationship, Drug; Double-Bli | 2018 |
Changes in P2Y12 reaction units after switching treatments from prasugrel to clopidogrel in Japanese patients with acute coronary syndrome followed by elective coronary stenting.
Topics: Acute Coronary Syndrome; Aged; Aspirin; Clopidogrel; Cytochrome P-450 CYP2C19; Female; Humans; Japan | 2017 |
Randomized evaluation of short-term dual antiplatelet therapy in patients with acute coronary syndrome treated with the COMBO dual therapy stent: rationale and design of the REDUCE trial.
Topics: Acute Coronary Syndrome; Adenosine; Aspirin; Cause of Death; Clopidogrel; Coronary Artery Disease; D | 2016 |
Health-related quality of life outcomes with prasugrel among medically managed non-ST-segment elevation acute coronary syndrome patients: Insights from the Targeted Platelet Inhibition to Clarify the Optimal Strategy to Medically Manage Acute Coronary Syn
Topics: Acute Coronary Syndrome; Aged; Aspirin; Clopidogrel; Double-Blind Method; Drug Therapy, Combination; | 2016 |
Impact of Sex on 2-Year Clinical Outcomes in Patients Treated With 6-Month or 24-Month Dual-Antiplatelet Therapy Duration: A Pre-Specified Analysis From the PRODIGY Trial.
Topics: Acute Coronary Syndrome; Aged; Aspirin; Clopidogrel; Coronary Artery Disease; Coronary Restenosis; C | 2016 |
Pharmacodynamic effects of a new fixed-dose clopidogrel-aspirin combination compared with separate administration of clopidogrel and aspirin in patients treated with coronary stents: The ACCEL-COMBO trial.
Topics: Acute Coronary Syndrome; Aged; Aspirin; Clopidogrel; Comorbidity; Drug Therapy, Combination; Female; | 2017 |
Prasugrel versus clopidogrel in acute coronary syndromes treated with PCI: Effects on clinical outcome according to culprit artery location.
Topics: Acute Coronary Syndrome; Aged; Clopidogrel; Coronary Vessels; Double-Blind Method; Female; Humans; M | 2016 |
High-dose clopidogrel versus ticagrelor for treatment of acute coronary syndromes after percutaneous coronary intervention in CYP2C19 intermediate or poor metabolizers: a prospective, randomized, open-label, single-centre trial.
Topics: Acute Coronary Syndrome; Adenosine; Aged; China; Clopidogrel; Cytochrome P-450 CYP2C19; Dose-Respons | 2016 |
Studies of the interaction of ticagrelor with the P2Y
Topics: Acute Coronary Syndrome; Adenosine; Blood Platelets; HEK293 Cells; Humans; Megakaryocytes; Platelet | 2016 |
Six Versus Twelve Months Clopidogrel Therapy After Drug-Eluting Stenting in Patients With Acute Coronary Syndrome: An ISAR-SAFE Study Subgroup Analysis.
Topics: Acute Coronary Syndrome; Aged; Clopidogrel; Drug-Eluting Stents; Follow-Up Studies; Hemorrhage; Huma | 2016 |
A randomised trial on platelet function-guided de-escalation of antiplatelet treatment in ACS patients undergoing PCI. Rationale and design of the Testing Responsiveness to Platelet Inhibition on Chronic Antiplatelet Treatment for Acute Coronary Syndromes
Topics: Acute Coronary Syndrome; Adult; Aged; Blood Platelets; Clinical Protocols; Clopidogrel; Drug Adminis | 2017 |
Efficacy and Safety of Cangrelor in Preventing Periprocedural Complications in Patients With Stable Angina and Acute Coronary Syndromes Undergoing Percutaneous Coronary Intervention: The CHAMPION PHOENIX Trial.
Topics: Acute Coronary Syndrome; Adenosine Monophosphate; Aged; Angina, Stable; Chi-Square Distribution; Clo | 2016 |
A randomised study for optimising crossover from ticagrelor to clopidogrel in patients with acute coronary syndrome. The CAPITAL OPTI-CROSS Study.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Aged, 80 and over; Blood Platelets; Clopidogrel; Cross-Ove | 2017 |
Pharmacokinetics and relative bioavailability of fixed-dose combination of clopidogrel and aspirin versus coadministration of individual formulations in healthy Korean men.
Topics: Acute Coronary Syndrome; Administration, Oral; Adult; Area Under Curve; Aspirin; Biological Availabi | 2016 |
A comparison of reduced-dose prasugrel and standard-dose clopidogrel in elderly patients with acute coronary syndromes undergoing early percutaneous revascularization: Design and rationale of the randomized Elderly-ACS 2 study.
Topics: Acute Coronary Syndrome; Aged; Aged, 80 and over; Aspirin; Cause of Death; Clopidogrel; Drug Therapy | 2016 |
Safety of 6-month duration of dual antiplatelet therapy after percutaneous coronary intervention in patients with acute coronary syndromes: Rationale and design of the Smart Angioplasty Research Team-safety of 6-month duration of Dual Antiplatelet Therapy
Topics: Acute Coronary Syndrome; Adult; Aspirin; Clopidogrel; Drug Monitoring; Drug-Eluting Stents; Everolim | 2016 |
Genetic Polymorphism of CYP2C19 and Inhibitory Effects of Ticagrelor and Clopidogrel Towards Post-Percutaneous Coronary Intervention (PCI) Platelet Aggregation in Patients with Acute Coronary Syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Cytochrome P-450 CYP2C19; Female; Genetic Pre | 2016 |
Effect of Shexiang baoxin pills on clopidogrel resistance in patients with acute coronary syndrome.
Topics: Acute Coronary Syndrome; Aged; Biomarkers; China; Clopidogrel; Drug Resistance; Drugs, Chinese Herba | 2016 |
Genotyping-guided approach versus the conventional approach in selection of oral P2Y12 receptor blockers in Chinese patients suffering from acute coronary syndrome.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Alleles; Asian People; Blood Platelets; Clopidogrel; Cytoc | 2017 |
Myocardial Infarction Risk After Discontinuation of Thienopyridine Therapy in the Randomized DAPT Study (Dual Antiplatelet Therapy).
Topics: Acute Coronary Syndrome; Aged; Angina, Stable; Aspirin; Clopidogrel; Coronary Thrombosis; Double-Bli | 2017 |
Prasugrel in the poststroke cohort of the TRITON Trial: the clear and present danger.
Topics: Acute Coronary Syndrome; Angioplasty, Balloon, Coronary; Cardiovascular Diseases; Clopidogrel; Doubl | 2008 |
The antiplatelet effect of atorvastatin in patients with acute coronary syndrome depends on the hs-CRP level.
Topics: Acute Coronary Syndrome; Aged; Aspirin; Atorvastatin; C-Reactive Protein; Clopidogrel; Female; Hepta | 2008 |
Reduction in recurrent cardiovascular events with prasugrel compared with clopidogrel in patients with acute coronary syndromes from the TRITON-TIMI 38 trial.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Clopidogrel; Female; Hemorrhage; Huma | 2008 |
Point-of-care measurement of clopidogrel responsiveness predicts clinical outcome in patients undergoing percutaneous coronary intervention results of the ARMYDA-PRO (Antiplatelet therapy for Reduction of MYocardial Damage during Angioplasty-Platelet Reac
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Clopidogrel; Female; Humans; Logistic | 2008 |
Point-of-care measurement of clopidogrel responsiveness predicts clinical outcome in patients undergoing percutaneous coronary intervention results of the ARMYDA-PRO (Antiplatelet therapy for Reduction of MYocardial Damage during Angioplasty-Platelet Reac
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Clopidogrel; Female; Humans; Logistic | 2008 |
Point-of-care measurement of clopidogrel responsiveness predicts clinical outcome in patients undergoing percutaneous coronary intervention results of the ARMYDA-PRO (Antiplatelet therapy for Reduction of MYocardial Damage during Angioplasty-Platelet Reac
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Clopidogrel; Female; Humans; Logistic | 2008 |
Point-of-care measurement of clopidogrel responsiveness predicts clinical outcome in patients undergoing percutaneous coronary intervention results of the ARMYDA-PRO (Antiplatelet therapy for Reduction of MYocardial Damage during Angioplasty-Platelet Reac
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Clopidogrel; Female; Humans; Logistic | 2008 |
Comparison of the impact of short (<1 year) and long-term (> or =1 year) clopidogrel use following percutaneous coronary intervention on mortality.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Clopidogrel; Female; Humans; Male; Mi | 2008 |
Design and rationale of CURRENT-OASIS 7: a randomized, 2 x 2 factorial trial evaluating optimal dosing strategies for clopidogrel and aspirin in patients with ST and non-ST-elevation acute coronary syndromes managed with an early invasive strategy.
Topics: Acute Coronary Syndrome; Adult; Aged; Angioplasty, Balloon, Coronary; Aspirin; Cause of Death; Clopi | 2008 |
Randomized trial comparing 600- with 300-mg loading dose of clopidogrel in patients with non-ST elevation acute coronary syndrome undergoing percutaneous coronary intervention: results of the Platelet Responsiveness to Aspirin and Clopidogrel and Troponin
Topics: Acute Coronary Syndrome; Angioplasty, Balloon, Coronary; Aspirin; Blood Platelets; Clopidogrel; Fema | 2009 |
Immediate versus deferred coronary angioplasty in non-ST-segment elevation acute coronary syndromes.
Topics: Acute Coronary Syndrome; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Female; Humans; Incid | 2009 |
[Impact of statins on clopidogrel platelet inhibition in patients with acute coronary syndrome or stable angina].
Topics: Acute Coronary Syndrome; Adenosine Diphosphate; Aged; Angina Pectoris; Atorvastatin; Clopidogrel; Dr | 2008 |
Antiplatelet therapy in percutaneous coronary intervention: integration of prasugrel into clinical practice.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Clopidogrel; Combined Modality Therap | 2009 |
Comparison of ticagrelor, the first reversible oral P2Y(12) receptor antagonist, with clopidogrel in patients with acute coronary syndromes: Rationale, design, and baseline characteristics of the PLATelet inhibition and patient Outcomes (PLATO) trial.
Topics: Acute Coronary Syndrome; Adenosine; Administration, Oral; Angioplasty, Balloon, Coronary; Aspirin; C | 2009 |
Comparison of ticagrelor, the first reversible oral P2Y(12) receptor antagonist, with clopidogrel in patients with acute coronary syndromes: Rationale, design, and baseline characteristics of the PLATelet inhibition and patient Outcomes (PLATO) trial.
Topics: Acute Coronary Syndrome; Adenosine; Administration, Oral; Angioplasty, Balloon, Coronary; Aspirin; C | 2009 |
Comparison of ticagrelor, the first reversible oral P2Y(12) receptor antagonist, with clopidogrel in patients with acute coronary syndromes: Rationale, design, and baseline characteristics of the PLATelet inhibition and patient Outcomes (PLATO) trial.
Topics: Acute Coronary Syndrome; Adenosine; Administration, Oral; Angioplasty, Balloon, Coronary; Aspirin; C | 2009 |
Comparison of ticagrelor, the first reversible oral P2Y(12) receptor antagonist, with clopidogrel in patients with acute coronary syndromes: Rationale, design, and baseline characteristics of the PLATelet inhibition and patient Outcomes (PLATO) trial.
Topics: Acute Coronary Syndrome; Adenosine; Administration, Oral; Angioplasty, Balloon, Coronary; Aspirin; C | 2009 |
Comparison of ticagrelor, the first reversible oral P2Y(12) receptor antagonist, with clopidogrel in patients with acute coronary syndromes: Rationale, design, and baseline characteristics of the PLATelet inhibition and patient Outcomes (PLATO) trial.
Topics: Acute Coronary Syndrome; Adenosine; Administration, Oral; Angioplasty, Balloon, Coronary; Aspirin; C | 2009 |
Comparison of ticagrelor, the first reversible oral P2Y(12) receptor antagonist, with clopidogrel in patients with acute coronary syndromes: Rationale, design, and baseline characteristics of the PLATelet inhibition and patient Outcomes (PLATO) trial.
Topics: Acute Coronary Syndrome; Adenosine; Administration, Oral; Angioplasty, Balloon, Coronary; Aspirin; C | 2009 |
Comparison of ticagrelor, the first reversible oral P2Y(12) receptor antagonist, with clopidogrel in patients with acute coronary syndromes: Rationale, design, and baseline characteristics of the PLATelet inhibition and patient Outcomes (PLATO) trial.
Topics: Acute Coronary Syndrome; Adenosine; Administration, Oral; Angioplasty, Balloon, Coronary; Aspirin; C | 2009 |
Comparison of ticagrelor, the first reversible oral P2Y(12) receptor antagonist, with clopidogrel in patients with acute coronary syndromes: Rationale, design, and baseline characteristics of the PLATelet inhibition and patient Outcomes (PLATO) trial.
Topics: Acute Coronary Syndrome; Adenosine; Administration, Oral; Angioplasty, Balloon, Coronary; Aspirin; C | 2009 |
Comparison of ticagrelor, the first reversible oral P2Y(12) receptor antagonist, with clopidogrel in patients with acute coronary syndromes: Rationale, design, and baseline characteristics of the PLATelet inhibition and patient Outcomes (PLATO) trial.
Topics: Acute Coronary Syndrome; Adenosine; Administration, Oral; Angioplasty, Balloon, Coronary; Aspirin; C | 2009 |
Cilostazol in addition to aspirin and clopidogrel improves long-term outcomes after percutaneous coronary intervention in patients with acute coronary syndromes: a randomized, controlled study.
Topics: Acute Coronary Syndrome; Adult; Aged; Aged, 80 and over; Angioplasty, Balloon, Coronary; Aspirin; Ci | 2009 |
Frequency of CYP3A4, CYP3A5, CYP2C9, and CYP2C19 variant alleles in patients receiving clopidogrel that experience repeat acute coronary syndrome.
Topics: Acute Coronary Syndrome; Aged; Aged, 80 and over; Aryl Hydrocarbon Hydroxylases; Clopidogrel; Cytoch | 2009 |
Comparison of low vs moderate dose of atorvastatin in clopidogrel resistance after coronary stenting in Korean patients with acute coronary syndrome.
Topics: Acute Coronary Syndrome; Adult; Aged; Anticholesteremic Agents; Atorvastatin; Clopidogrel; Dose-Resp | 2009 |
Pharmacodynamic assessment of platelet inhibition by prasugrel vs. clopidogrel in the TRITON-TIMI 38 trial.
Topics: Acute Coronary Syndrome; Adenosine Diphosphate; Angioplasty, Balloon, Coronary; Cell Adhesion Molecu | 2009 |
Effect of the novel thienopyridine prasugrel compared with clopidogrel on spontaneous and procedural myocardial infarction in the Trial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet Inhibition with Prasugrel-Thrombolysis in Myocardi
Topics: Acute Coronary Syndrome; Angina, Unstable; Angioplasty, Balloon, Coronary; Biomarkers; Clopidogrel; | 2009 |
Outcomes following pre-operative clopidogrel administration in patients with acute coronary syndromes undergoing coronary artery bypass surgery: the ACUITY (Acute Catheterization and Urgent Intervention Triage strategY) trial.
Topics: Acute Coronary Syndrome; Adult; Aged; Aged, 80 and over; Cardiac Catheterization; Clopidogrel; Coron | 2009 |
Influence of timing of clopidogrel treatment on the efficacy and safety of bivalirudin in patients with non-ST-segment elevation acute coronary syndromes undergoing percutaneous coronary intervention: an analysis of the ACUITY (Acute Catheterization and U
Topics: Acute Coronary Syndrome; Adult; Aged; Aged, 80 and over; Angioplasty, Balloon, Coronary; Anticoagula | 2008 |
Apixaban, an oral, direct, selective factor Xa inhibitor, in combination with antiplatelet therapy after acute coronary syndrome: results of the Apixaban for Prevention of Acute Ischemic and Safety Events (APPRAISE) trial.
Topics: Acute Coronary Syndrome; Adolescent; Adult; Aged; Aged, 80 and over; Aspirin; Clopidogrel; Dose-Resp | 2009 |
A high maintenance dose of clopidogrel improves short-term clinical outcomes in patients with acute coronary syndrome undergoing drug-eluting stent implantation.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Clopidogrel; Coronary Angiography; Dr | 2009 |
The FDA prasugrel review: adjudication of myocardial infarction controversy.
Topics: Acute Coronary Syndrome; Clopidogrel; Dose-Response Relationship, Drug; Double-Blind Method; Drug Ad | 2009 |
[Effects of upstream tirofiban versus downstream tirofiban on platelet aggregation and clinical outcomes in patients with high-risk acute coronary syndromes undergoing percutaneous coronary interventions].
Topics: Acute Coronary Syndrome; Adult; Aged; Angioplasty, Balloon, Coronary; Cardiovascular Diseases; Clopi | 2009 |
The efficacy and safety of prasugrel with and without a glycoprotein IIb/IIIa inhibitor in patients with acute coronary syndromes undergoing percutaneous intervention: a TRITON-TIMI 38 (Trial to Assess Improvement in Therapeutic Outcomes by Optimizing Pla
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Clopidogrel; Drug Therapy, Combinatio | 2009 |
Effect of prasugrel versus clopidogrel on outcomes among patients with acute coronary syndrome undergoing percutaneous coronary intervention without stent implantation: a TRial to assess Improvement in Therapeutic Outcomes by optimizing platelet inhibitio
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Female; Humans; | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Electrocardiogr | 2009 |
A comparison of anticoagulation with bivalirudin and provisional GPIIb/IIIa inhibition with unfractionated heparin and mandatory GPIIb/IIIa inhibition during percutaneous coronary intervention in relation to platelet activation and the inhibition of coagu
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Anticoagulants; Aspirin; Biomarkers; | 2009 |
Comparison of omeprazole and pantoprazole influence on a high 150-mg clopidogrel maintenance dose the PACA (Proton Pump Inhibitors And Clopidogrel Association) prospective randomized study.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Corona | 2009 |
Gastrointestinal bleeding in patients with acute coronary syndromes: incidence, predictors, and clinical implications: analysis from the ACUITY (Acute Catheterization and Urgent Intervention Triage Strategy) trial.
Topics: Acute Coronary Syndrome; Age Factors; Aged; Angioplasty, Balloon, Coronary; Anticoagulants; Clopidog | 2009 |
Role of clopidogrel loading dose in patients with ST-segment elevation myocardial infarction undergoing primary angioplasty: results from the HORIZONS-AMI (harmonizing outcomes with revascularization and stents in acute myocardial infarction) trial.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon; Anticoagulants; Clopidogrel; Confidence Interva | 2009 |
Impact of final activated clotting time after transradial coronary stenting with maximal antiplatelet therapy.
Topics: Abciximab; Acute Coronary Syndrome; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Anticoag | 2009 |
Platelet inhibition with cangrelor in patients undergoing PCI.
Topics: Acute Coronary Syndrome; Adenosine Monophosphate; Administration, Oral; Aged; Angioplasty, Balloon, | 2009 |
Platelet inhibition with cangrelor in patients undergoing PCI.
Topics: Acute Coronary Syndrome; Adenosine Monophosphate; Administration, Oral; Aged; Angioplasty, Balloon, | 2009 |
Platelet inhibition with cangrelor in patients undergoing PCI.
Topics: Acute Coronary Syndrome; Adenosine Monophosphate; Administration, Oral; Aged; Angioplasty, Balloon, | 2009 |
Platelet inhibition with cangrelor in patients undergoing PCI.
Topics: Acute Coronary Syndrome; Adenosine Monophosphate; Administration, Oral; Aged; Angioplasty, Balloon, | 2009 |
Pantoprazole may enhance antiplatelet effect of enteric-coated aspirin in patients with acute coronary syndrome.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Corona | 2009 |
5-year clinical outcomes in the ICTUS (Invasive versus Conservative Treatment in Unstable coronary Syndromes) trial a randomized comparison of an early invasive versus selective invasive management in patients with non-ST-segment elevation acute coronary
Topics: Abciximab; Acute Coronary Syndrome; Adolescent; Adult; Aged; Aged, 80 and over; Angina, Unstable; An | 2010 |
Prasugrel compared with high-dose clopidogrel in acute coronary syndrome. The randomised, double-blind ACAPULCO study.
Topics: Acute Coronary Syndrome; Adenosine Diphosphate; Adult; Aged; Aged, 80 and over; Clopidogrel; Cross-O | 2010 |
Comparison of ticagrelor with clopidogrel in patients with a planned invasive strategy for acute coronary syndromes (PLATO): a randomised double-blind study.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Aged, 80 and over; Angioplasty, Balloon, Coronary; Clopido | 2010 |
Comparison of ticagrelor with clopidogrel in patients with a planned invasive strategy for acute coronary syndromes (PLATO): a randomised double-blind study.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Aged, 80 and over; Angioplasty, Balloon, Coronary; Clopido | 2010 |
Comparison of ticagrelor with clopidogrel in patients with a planned invasive strategy for acute coronary syndromes (PLATO): a randomised double-blind study.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Aged, 80 and over; Angioplasty, Balloon, Coronary; Clopido | 2010 |
Comparison of ticagrelor with clopidogrel in patients with a planned invasive strategy for acute coronary syndromes (PLATO): a randomised double-blind study.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Aged, 80 and over; Angioplasty, Balloon, Coronary; Clopido | 2010 |
Comparison of ticagrelor with clopidogrel in patients with a planned invasive strategy for acute coronary syndromes (PLATO): a randomised double-blind study.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Aged, 80 and over; Angioplasty, Balloon, Coronary; Clopido | 2010 |
Comparison of ticagrelor with clopidogrel in patients with a planned invasive strategy for acute coronary syndromes (PLATO): a randomised double-blind study.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Aged, 80 and over; Angioplasty, Balloon, Coronary; Clopido | 2010 |
Comparison of ticagrelor with clopidogrel in patients with a planned invasive strategy for acute coronary syndromes (PLATO): a randomised double-blind study.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Aged, 80 and over; Angioplasty, Balloon, Coronary; Clopido | 2010 |
Comparison of ticagrelor with clopidogrel in patients with a planned invasive strategy for acute coronary syndromes (PLATO): a randomised double-blind study.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Aged, 80 and over; Angioplasty, Balloon, Coronary; Clopido | 2010 |
Comparison of ticagrelor with clopidogrel in patients with a planned invasive strategy for acute coronary syndromes (PLATO): a randomised double-blind study.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Aged, 80 and over; Angioplasty, Balloon, Coronary; Clopido | 2010 |
Comparison of ticagrelor with clopidogrel in patients with a planned invasive strategy for acute coronary syndromes (PLATO): a randomised double-blind study.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Aged, 80 and over; Angioplasty, Balloon, Coronary; Clopido | 2010 |
Comparison of ticagrelor with clopidogrel in patients with a planned invasive strategy for acute coronary syndromes (PLATO): a randomised double-blind study.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Aged, 80 and over; Angioplasty, Balloon, Coronary; Clopido | 2010 |
Comparison of ticagrelor with clopidogrel in patients with a planned invasive strategy for acute coronary syndromes (PLATO): a randomised double-blind study.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Aged, 80 and over; Angioplasty, Balloon, Coronary; Clopido | 2010 |
Comparison of ticagrelor with clopidogrel in patients with a planned invasive strategy for acute coronary syndromes (PLATO): a randomised double-blind study.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Aged, 80 and over; Angioplasty, Balloon, Coronary; Clopido | 2010 |
Comparison of ticagrelor with clopidogrel in patients with a planned invasive strategy for acute coronary syndromes (PLATO): a randomised double-blind study.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Aged, 80 and over; Angioplasty, Balloon, Coronary; Clopido | 2010 |
Comparison of ticagrelor with clopidogrel in patients with a planned invasive strategy for acute coronary syndromes (PLATO): a randomised double-blind study.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Aged, 80 and over; Angioplasty, Balloon, Coronary; Clopido | 2010 |
Comparison of ticagrelor with clopidogrel in patients with a planned invasive strategy for acute coronary syndromes (PLATO): a randomised double-blind study.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Aged, 80 and over; Angioplasty, Balloon, Coronary; Clopido | 2010 |
Reducing cardiac ischemic events in patients with ACS: prasugrel versus clopidogrel. Commentary.
Topics: Acute Coronary Syndrome; Aspirin; Clopidogrel; Confidence Intervals; Double-Blind Method; Drug Thera | 2010 |
Safety and exploratory efficacy of the novel thrombin receptor (PAR-1) antagonist SCH530348 for non-ST-segment elevation acute coronary syndrome.
Topics: Acute Coronary Syndrome; Aged; Aspirin; Blood Platelets; Clopidogrel; Cohort Studies; Double-Blind M | 2010 |
Effect of cilostazol on platelet aggregation in patients with non-ST elevation acute coronary syndrome.
Topics: Acute Coronary Syndrome; Adult; Aged; Aspirin; Cilostazol; Clopidogrel; Double-Blind Method; Drug Th | 2010 |
Changes in inflammatory biomarkers in patients treated with ticagrelor or clopidogrel.
Topics: Acute Coronary Syndrome; Adenosine; Aspirin; Biomarkers; C-Reactive Protein; CD40 Ligand; Clopidogre | 2010 |
Impact of chronic antiplatelet therapy before hospitalization on ischemic and bleeding events in invasively managed patients with acute coronary syndromes: the ACUITY trial.
Topics: Acute Coronary Syndrome; Aged; Anticoagulants; Aspirin; Chi-Square Distribution; Clopidogrel; Drug A | 2011 |
Prasugrel versus clopidogrel in Asian patients with acute coronary syndromes: design and rationale of a multi-dose, pharmacodynamic, phase 3 clinical trial.
Topics: Acute Coronary Syndrome; Adolescent; Adult; Aged; Algorithms; Asian People; Clopidogrel; Dose-Respon | 2010 |
[Impact of application time of aspirin and clopidogrel on platelet aggregation in patients with acute coronary syndrome].
Topics: Acute Coronary Syndrome; Adult; Aged; Aspirin; Circadian Rhythm; Clopidogrel; Humans; Male; Middle A | 2010 |
[Glycoprotein IIb-IIIa antagonist Monafram in primary angioplasty of patients with acute coronary syndrome without st segment elevation].
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Aspirin; Clop | 2010 |
Randomised controlled trial evaluating the role of tirofiban in high-risk non-ST elevation acute coronary syndromes: an East Indian perspective.
Topics: Acute Coronary Syndrome; Aged; Aspirin; Clopidogrel; Dose-Response Relationship, Drug; Drug Administ | 2010 |
Ticagrelor vs. clopidogrel in patients with acute coronary syndromes and diabetes: a substudy from the PLATelet inhibition and patient Outcomes (PLATO) trial.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Blood Glucose; Clopidogrel; Diabetes Mellitus, Type 2; Dia | 2010 |
Ticagrelor versus clopidogrel in acute coronary syndromes in relation to renal function: results from the Platelet Inhibition and Patient Outcomes (PLATO) trial.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Cardiovascular Diseases; Chronic Disease; Clopidogrel; Fem | 2010 |
Ticagrelor versus clopidogrel in acute coronary syndromes in relation to renal function: results from the Platelet Inhibition and Patient Outcomes (PLATO) trial.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Cardiovascular Diseases; Chronic Disease; Clopidogrel; Fem | 2010 |
Ticagrelor versus clopidogrel in acute coronary syndromes in relation to renal function: results from the Platelet Inhibition and Patient Outcomes (PLATO) trial.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Cardiovascular Diseases; Chronic Disease; Clopidogrel; Fem | 2010 |
Ticagrelor versus clopidogrel in acute coronary syndromes in relation to renal function: results from the Platelet Inhibition and Patient Outcomes (PLATO) trial.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Cardiovascular Diseases; Chronic Disease; Clopidogrel; Fem | 2010 |
Double-dose versus standard-dose clopidogrel and high-dose versus low-dose aspirin in individuals undergoing percutaneous coronary intervention for acute coronary syndromes (CURRENT-OASIS 7): a randomised factorial trial.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Cardiovascular Diseases; Clo | 2010 |
Double-dose versus standard-dose clopidogrel and high-dose versus low-dose aspirin in individuals undergoing percutaneous coronary intervention for acute coronary syndromes (CURRENT-OASIS 7): a randomised factorial trial.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Cardiovascular Diseases; Clo | 2010 |
Double-dose versus standard-dose clopidogrel and high-dose versus low-dose aspirin in individuals undergoing percutaneous coronary intervention for acute coronary syndromes (CURRENT-OASIS 7): a randomised factorial trial.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Cardiovascular Diseases; Clo | 2010 |
Double-dose versus standard-dose clopidogrel and high-dose versus low-dose aspirin in individuals undergoing percutaneous coronary intervention for acute coronary syndromes (CURRENT-OASIS 7): a randomised factorial trial.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Cardiovascular Diseases; Clo | 2010 |
Double-dose versus standard-dose clopidogrel and high-dose versus low-dose aspirin in individuals undergoing percutaneous coronary intervention for acute coronary syndromes (CURRENT-OASIS 7): a randomised factorial trial.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Cardiovascular Diseases; Clo | 2010 |
Double-dose versus standard-dose clopidogrel and high-dose versus low-dose aspirin in individuals undergoing percutaneous coronary intervention for acute coronary syndromes (CURRENT-OASIS 7): a randomised factorial trial.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Cardiovascular Diseases; Clo | 2010 |
Double-dose versus standard-dose clopidogrel and high-dose versus low-dose aspirin in individuals undergoing percutaneous coronary intervention for acute coronary syndromes (CURRENT-OASIS 7): a randomised factorial trial.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Cardiovascular Diseases; Clo | 2010 |
Double-dose versus standard-dose clopidogrel and high-dose versus low-dose aspirin in individuals undergoing percutaneous coronary intervention for acute coronary syndromes (CURRENT-OASIS 7): a randomised factorial trial.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Cardiovascular Diseases; Clo | 2010 |
Double-dose versus standard-dose clopidogrel and high-dose versus low-dose aspirin in individuals undergoing percutaneous coronary intervention for acute coronary syndromes (CURRENT-OASIS 7): a randomised factorial trial.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Cardiovascular Diseases; Clo | 2010 |
Double-dose versus standard-dose clopidogrel and high-dose versus low-dose aspirin in individuals undergoing percutaneous coronary intervention for acute coronary syndromes (CURRENT-OASIS 7): a randomised factorial trial.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Cardiovascular Diseases; Clo | 2010 |
Double-dose versus standard-dose clopidogrel and high-dose versus low-dose aspirin in individuals undergoing percutaneous coronary intervention for acute coronary syndromes (CURRENT-OASIS 7): a randomised factorial trial.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Cardiovascular Diseases; Clo | 2010 |
Double-dose versus standard-dose clopidogrel and high-dose versus low-dose aspirin in individuals undergoing percutaneous coronary intervention for acute coronary syndromes (CURRENT-OASIS 7): a randomised factorial trial.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Cardiovascular Diseases; Clo | 2010 |
Double-dose versus standard-dose clopidogrel and high-dose versus low-dose aspirin in individuals undergoing percutaneous coronary intervention for acute coronary syndromes (CURRENT-OASIS 7): a randomised factorial trial.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Cardiovascular Diseases; Clo | 2010 |
Double-dose versus standard-dose clopidogrel and high-dose versus low-dose aspirin in individuals undergoing percutaneous coronary intervention for acute coronary syndromes (CURRENT-OASIS 7): a randomised factorial trial.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Cardiovascular Diseases; Clo | 2010 |
Double-dose versus standard-dose clopidogrel and high-dose versus low-dose aspirin in individuals undergoing percutaneous coronary intervention for acute coronary syndromes (CURRENT-OASIS 7): a randomised factorial trial.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Cardiovascular Diseases; Clo | 2010 |
Double-dose versus standard-dose clopidogrel and high-dose versus low-dose aspirin in individuals undergoing percutaneous coronary intervention for acute coronary syndromes (CURRENT-OASIS 7): a randomised factorial trial.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Cardiovascular Diseases; Clo | 2010 |
Dose comparisons of clopidogrel and aspirin in acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Cardiovascular Diseases; Clo | 2010 |
Dose comparisons of clopidogrel and aspirin in acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Cardiovascular Diseases; Clo | 2010 |
Dose comparisons of clopidogrel and aspirin in acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Cardiovascular Diseases; Clo | 2010 |
Dose comparisons of clopidogrel and aspirin in acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Cardiovascular Diseases; Clo | 2010 |
Dose comparisons of clopidogrel and aspirin in acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Cardiovascular Diseases; Clo | 2010 |
Dose comparisons of clopidogrel and aspirin in acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Cardiovascular Diseases; Clo | 2010 |
Dose comparisons of clopidogrel and aspirin in acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Cardiovascular Diseases; Clo | 2010 |
Dose comparisons of clopidogrel and aspirin in acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Cardiovascular Diseases; Clo | 2010 |
Dose comparisons of clopidogrel and aspirin in acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Cardiovascular Diseases; Clo | 2010 |
Dose comparisons of clopidogrel and aspirin in acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Cardiovascular Diseases; Clo | 2010 |
Dose comparisons of clopidogrel and aspirin in acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Cardiovascular Diseases; Clo | 2010 |
Dose comparisons of clopidogrel and aspirin in acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Cardiovascular Diseases; Clo | 2010 |
Dose comparisons of clopidogrel and aspirin in acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Cardiovascular Diseases; Clo | 2010 |
Dose comparisons of clopidogrel and aspirin in acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Cardiovascular Diseases; Clo | 2010 |
Dose comparisons of clopidogrel and aspirin in acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Cardiovascular Diseases; Clo | 2010 |
Dose comparisons of clopidogrel and aspirin in acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Cardiovascular Diseases; Clo | 2010 |
Comparison of rosuvastatin and atorvastatin on clopidogrel response and lipidic and inflammatory parameters after coronary stenting for acute coronary syndrome: the prospective, randomized OSCAR study (optimal statin therapy with clopidogrel after coronar
Topics: Acute Coronary Syndrome; Anticholesteremic Agents; Atorvastatin; Clopidogrel; Combined Modality Ther | 2010 |
Inhibitory effects of ticagrelor compared with clopidogrel on platelet function in patients with acute coronary syndromes: the PLATO (PLATelet inhibition and patient Outcomes) PLATELET substudy.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Blood Platelets; Clopidogrel; Cohort Studies; Female; Huma | 2010 |
Inhibitory effects of ticagrelor compared with clopidogrel on platelet function in patients with acute coronary syndromes: the PLATO (PLATelet inhibition and patient Outcomes) PLATELET substudy.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Blood Platelets; Clopidogrel; Cohort Studies; Female; Huma | 2010 |
Inhibitory effects of ticagrelor compared with clopidogrel on platelet function in patients with acute coronary syndromes: the PLATO (PLATelet inhibition and patient Outcomes) PLATELET substudy.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Blood Platelets; Clopidogrel; Cohort Studies; Female; Huma | 2010 |
Inhibitory effects of ticagrelor compared with clopidogrel on platelet function in patients with acute coronary syndromes: the PLATO (PLATelet inhibition and patient Outcomes) PLATELET substudy.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Blood Platelets; Clopidogrel; Cohort Studies; Female; Huma | 2010 |
Inhibitory effects of ticagrelor compared with clopidogrel on platelet function in patients with acute coronary syndromes: the PLATO (PLATelet inhibition and patient Outcomes) PLATELET substudy.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Blood Platelets; Clopidogrel; Cohort Studies; Female; Huma | 2010 |
Inhibitory effects of ticagrelor compared with clopidogrel on platelet function in patients with acute coronary syndromes: the PLATO (PLATelet inhibition and patient Outcomes) PLATELET substudy.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Blood Platelets; Clopidogrel; Cohort Studies; Female; Huma | 2010 |
Inhibitory effects of ticagrelor compared with clopidogrel on platelet function in patients with acute coronary syndromes: the PLATO (PLATelet inhibition and patient Outcomes) PLATELET substudy.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Blood Platelets; Clopidogrel; Cohort Studies; Female; Huma | 2010 |
Inhibitory effects of ticagrelor compared with clopidogrel on platelet function in patients with acute coronary syndromes: the PLATO (PLATelet inhibition and patient Outcomes) PLATELET substudy.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Blood Platelets; Clopidogrel; Cohort Studies; Female; Huma | 2010 |
Inhibitory effects of ticagrelor compared with clopidogrel on platelet function in patients with acute coronary syndromes: the PLATO (PLATelet inhibition and patient Outcomes) PLATELET substudy.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Blood Platelets; Clopidogrel; Cohort Studies; Female; Huma | 2010 |
Inhibitory effects of ticagrelor compared with clopidogrel on platelet function in patients with acute coronary syndromes: the PLATO (PLATelet inhibition and patient Outcomes) PLATELET substudy.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Blood Platelets; Clopidogrel; Cohort Studies; Female; Huma | 2010 |
Inhibitory effects of ticagrelor compared with clopidogrel on platelet function in patients with acute coronary syndromes: the PLATO (PLATelet inhibition and patient Outcomes) PLATELET substudy.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Blood Platelets; Clopidogrel; Cohort Studies; Female; Huma | 2010 |
Inhibitory effects of ticagrelor compared with clopidogrel on platelet function in patients with acute coronary syndromes: the PLATO (PLATelet inhibition and patient Outcomes) PLATELET substudy.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Blood Platelets; Clopidogrel; Cohort Studies; Female; Huma | 2010 |
Inhibitory effects of ticagrelor compared with clopidogrel on platelet function in patients with acute coronary syndromes: the PLATO (PLATelet inhibition and patient Outcomes) PLATELET substudy.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Blood Platelets; Clopidogrel; Cohort Studies; Female; Huma | 2010 |
Inhibitory effects of ticagrelor compared with clopidogrel on platelet function in patients with acute coronary syndromes: the PLATO (PLATelet inhibition and patient Outcomes) PLATELET substudy.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Blood Platelets; Clopidogrel; Cohort Studies; Female; Huma | 2010 |
Inhibitory effects of ticagrelor compared with clopidogrel on platelet function in patients with acute coronary syndromes: the PLATO (PLATelet inhibition and patient Outcomes) PLATELET substudy.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Blood Platelets; Clopidogrel; Cohort Studies; Female; Huma | 2010 |
Inhibitory effects of ticagrelor compared with clopidogrel on platelet function in patients with acute coronary syndromes: the PLATO (PLATelet inhibition and patient Outcomes) PLATELET substudy.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Blood Platelets; Clopidogrel; Cohort Studies; Female; Huma | 2010 |
Increased platelet inhibition after switching from maintenance clopidogrel to prasugrel in patients with acute coronary syndromes: results of the SWAP (SWitching Anti Platelet) study.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Blood Platelets; Clopidogrel; Double- | 2010 |
Effects of CYP2C19 genotype on outcomes of clopidogrel treatment.
Topics: Acute Coronary Syndrome; Aged; Aryl Hydrocarbon Hydroxylases; Atrial Fibrillation; Clopidogrel; Cyto | 2010 |
Ticagrelor versus clopidogrel in patients with ST-elevation acute coronary syndromes intended for reperfusion with primary percutaneous coronary intervention: A Platelet Inhibition and Patient Outcomes (PLATO) trial subgroup analysis.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Angioplasty, Balloon, Coronary; Clopidogrel; Coronary Thro | 2010 |
Ticagrelor versus clopidogrel in patients with ST-elevation acute coronary syndromes intended for reperfusion with primary percutaneous coronary intervention: A Platelet Inhibition and Patient Outcomes (PLATO) trial subgroup analysis.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Angioplasty, Balloon, Coronary; Clopidogrel; Coronary Thro | 2010 |
Ticagrelor versus clopidogrel in patients with ST-elevation acute coronary syndromes intended for reperfusion with primary percutaneous coronary intervention: A Platelet Inhibition and Patient Outcomes (PLATO) trial subgroup analysis.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Angioplasty, Balloon, Coronary; Clopidogrel; Coronary Thro | 2010 |
Ticagrelor versus clopidogrel in patients with ST-elevation acute coronary syndromes intended for reperfusion with primary percutaneous coronary intervention: A Platelet Inhibition and Patient Outcomes (PLATO) trial subgroup analysis.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Angioplasty, Balloon, Coronary; Clopidogrel; Coronary Thro | 2010 |
Ticagrelor versus clopidogrel in patients with ST-elevation acute coronary syndromes intended for reperfusion with primary percutaneous coronary intervention: A Platelet Inhibition and Patient Outcomes (PLATO) trial subgroup analysis.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Angioplasty, Balloon, Coronary; Clopidogrel; Coronary Thro | 2010 |
Ticagrelor versus clopidogrel in patients with ST-elevation acute coronary syndromes intended for reperfusion with primary percutaneous coronary intervention: A Platelet Inhibition and Patient Outcomes (PLATO) trial subgroup analysis.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Angioplasty, Balloon, Coronary; Clopidogrel; Coronary Thro | 2010 |
Ticagrelor versus clopidogrel in patients with ST-elevation acute coronary syndromes intended for reperfusion with primary percutaneous coronary intervention: A Platelet Inhibition and Patient Outcomes (PLATO) trial subgroup analysis.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Angioplasty, Balloon, Coronary; Clopidogrel; Coronary Thro | 2010 |
Ticagrelor versus clopidogrel in patients with ST-elevation acute coronary syndromes intended for reperfusion with primary percutaneous coronary intervention: A Platelet Inhibition and Patient Outcomes (PLATO) trial subgroup analysis.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Angioplasty, Balloon, Coronary; Clopidogrel; Coronary Thro | 2010 |
Ticagrelor versus clopidogrel in patients with ST-elevation acute coronary syndromes intended for reperfusion with primary percutaneous coronary intervention: A Platelet Inhibition and Patient Outcomes (PLATO) trial subgroup analysis.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Angioplasty, Balloon, Coronary; Clopidogrel; Coronary Thro | 2010 |
Ticagrelor versus clopidogrel in patients with ST-elevation acute coronary syndromes intended for reperfusion with primary percutaneous coronary intervention: A Platelet Inhibition and Patient Outcomes (PLATO) trial subgroup analysis.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Angioplasty, Balloon, Coronary; Clopidogrel; Coronary Thro | 2010 |
Ticagrelor versus clopidogrel in patients with ST-elevation acute coronary syndromes intended for reperfusion with primary percutaneous coronary intervention: A Platelet Inhibition and Patient Outcomes (PLATO) trial subgroup analysis.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Angioplasty, Balloon, Coronary; Clopidogrel; Coronary Thro | 2010 |
Ticagrelor versus clopidogrel in patients with ST-elevation acute coronary syndromes intended for reperfusion with primary percutaneous coronary intervention: A Platelet Inhibition and Patient Outcomes (PLATO) trial subgroup analysis.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Angioplasty, Balloon, Coronary; Clopidogrel; Coronary Thro | 2010 |
Ticagrelor versus clopidogrel in patients with ST-elevation acute coronary syndromes intended for reperfusion with primary percutaneous coronary intervention: A Platelet Inhibition and Patient Outcomes (PLATO) trial subgroup analysis.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Angioplasty, Balloon, Coronary; Clopidogrel; Coronary Thro | 2010 |
Ticagrelor versus clopidogrel in patients with ST-elevation acute coronary syndromes intended for reperfusion with primary percutaneous coronary intervention: A Platelet Inhibition and Patient Outcomes (PLATO) trial subgroup analysis.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Angioplasty, Balloon, Coronary; Clopidogrel; Coronary Thro | 2010 |
Ticagrelor versus clopidogrel in patients with ST-elevation acute coronary syndromes intended for reperfusion with primary percutaneous coronary intervention: A Platelet Inhibition and Patient Outcomes (PLATO) trial subgroup analysis.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Angioplasty, Balloon, Coronary; Clopidogrel; Coronary Thro | 2010 |
Ticagrelor versus clopidogrel in patients with ST-elevation acute coronary syndromes intended for reperfusion with primary percutaneous coronary intervention: A Platelet Inhibition and Patient Outcomes (PLATO) trial subgroup analysis.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Angioplasty, Balloon, Coronary; Clopidogrel; Coronary Thro | 2010 |
Safety and efficacy of prasugrel compared with clopidogrel in different regions of the world.
Topics: Acute Coronary Syndrome; Cause of Death; Clopidogrel; Dose-Response Relationship, Drug; Electrocardi | 2012 |
Comparison of adverse cardiovascular events and bleeding complications of loading dose of clopidogrel 300 mg versus 600 mg in stable patients undergoing elective percutaneous intervention (from the CADICE study).
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Clopidogrel; Double-Blind Method; Fem | 2011 |
Cilostazol reduces the progression of carotid intima-media thickness without increasing the risk of bleeding in patients with acute coronary syndrome during a 2-year follow-up.
Topics: Acute Coronary Syndrome; Aged; Aged, 80 and over; Analysis of Variance; Angioplasty, Balloon, Corona | 2011 |
Randomized comparison of platelet function monitoring to adjust antiplatelet therapy versus standard of care: rationale and design of the assessment with a double randomization of (1) a fixed dose versus a monitoring-guided dose of aspirin and clopidogrel
Topics: Acute Coronary Syndrome; Angioplasty, Balloon, Coronary; Aspirin; Blood Platelets; Clopidogrel; Dose | 2011 |
Randomized comparison of platelet function monitoring to adjust antiplatelet therapy versus standard of care: rationale and design of the assessment with a double randomization of (1) a fixed dose versus a monitoring-guided dose of aspirin and clopidogrel
Topics: Acute Coronary Syndrome; Angioplasty, Balloon, Coronary; Aspirin; Blood Platelets; Clopidogrel; Dose | 2011 |
Randomized comparison of platelet function monitoring to adjust antiplatelet therapy versus standard of care: rationale and design of the assessment with a double randomization of (1) a fixed dose versus a monitoring-guided dose of aspirin and clopidogrel
Topics: Acute Coronary Syndrome; Angioplasty, Balloon, Coronary; Aspirin; Blood Platelets; Clopidogrel; Dose | 2011 |
Randomized comparison of platelet function monitoring to adjust antiplatelet therapy versus standard of care: rationale and design of the assessment with a double randomization of (1) a fixed dose versus a monitoring-guided dose of aspirin and clopidogrel
Topics: Acute Coronary Syndrome; Angioplasty, Balloon, Coronary; Aspirin; Blood Platelets; Clopidogrel; Dose | 2011 |
Clopidogrel resistance is associated with long-term thrombotic events in patients implanted with drug-eluting stents.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Clopidogrel; Drug Resistance; Drug-El | 2010 |
Mortality benefit in PLATO cannot be explained by antiplatelet properties of ticagrelor.
Topics: Acute Coronary Syndrome; Adenosine; Clopidogrel; Humans; Purinergic P2Y Receptor Antagonists; Ticagr | 2010 |
Safety of clopidogrel in older patients: a nonrandomized, parallel-group, controlled, two-centre study.
Topics: Acute Coronary Syndrome; Administration, Cutaneous; Age Factors; Aged; Angioplasty, Balloon, Coronar | 2011 |
Upstream clopidogrel use and the efficacy and safety of early eptifibatide treatment in patients with acute coronary syndrome: an analysis from the Early Glycoprotein IIb/IIIa Inhibition in Patients with Non-ST-Segment Elevation Acute Coronary Syndrome (E
Topics: Acute Coronary Syndrome; Clopidogrel; Coronary Angiography; Drug Therapy, Combination; Electrocardio | 2011 |
Influence of abciximab on evolution of left ventricular function in patients with non-ST-segment elevation acute coronary syndromes undergoing PCI after clopidogrel pretreatment: lessons from the ISAR-REACT 2 trial.
Topics: Abciximab; Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Cl | 2011 |
Trans-radial approach for catheterisation in non-ST segment elevation acute coronary syndrome: an analysis of major bleeding complications in the ABOARD Study.
Topics: Abciximab; Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; As | 2011 |
Omeprazole affects clopidogrel efficacy but not ischemic events in patients with acute coronary syndrome undergoing elective percutaneous coronary intervention.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Female; Humans; | 2011 |
The incidence of bradyarrhythmias and clinical bradyarrhythmic events in patients with acute coronary syndromes treated with ticagrelor or clopidogrel in the PLATO (Platelet Inhibition and Patient Outcomes) trial: results of the continuous electrocardiogr
Topics: Acute Coronary Syndrome; Adenosine; Aged; Bradycardia; Clopidogrel; Electrocardiography; Female; Hum | 2011 |
The incidence of bradyarrhythmias and clinical bradyarrhythmic events in patients with acute coronary syndromes treated with ticagrelor or clopidogrel in the PLATO (Platelet Inhibition and Patient Outcomes) trial: results of the continuous electrocardiogr
Topics: Acute Coronary Syndrome; Adenosine; Aged; Bradycardia; Clopidogrel; Electrocardiography; Female; Hum | 2011 |
The incidence of bradyarrhythmias and clinical bradyarrhythmic events in patients with acute coronary syndromes treated with ticagrelor or clopidogrel in the PLATO (Platelet Inhibition and Patient Outcomes) trial: results of the continuous electrocardiogr
Topics: Acute Coronary Syndrome; Adenosine; Aged; Bradycardia; Clopidogrel; Electrocardiography; Female; Hum | 2011 |
The incidence of bradyarrhythmias and clinical bradyarrhythmic events in patients with acute coronary syndromes treated with ticagrelor or clopidogrel in the PLATO (Platelet Inhibition and Patient Outcomes) trial: results of the continuous electrocardiogr
Topics: Acute Coronary Syndrome; Adenosine; Aged; Bradycardia; Clopidogrel; Electrocardiography; Female; Hum | 2011 |
Dabigatran vs. placebo in patients with acute coronary syndromes on dual antiplatelet therapy: a randomized, double-blind, phase II trial.
Topics: Acute Coronary Syndrome; Aged; Aspirin; Benzimidazoles; beta-Alanine; Clopidogrel; Dabigatran; Dose- | 2011 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes intended for non-invasive management: substudy from prospective randomised PLATelet inhibition and patient Outcomes (PLATO) trial.
Topics: Acute Coronary Syndrome; Adenosine; Clopidogrel; Humans; Platelet Aggregation Inhibitors; Prospectiv | 2011 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes intended for non-invasive management: substudy from prospective randomised PLATelet inhibition and patient Outcomes (PLATO) trial.
Topics: Acute Coronary Syndrome; Adenosine; Clopidogrel; Humans; Platelet Aggregation Inhibitors; Prospectiv | 2011 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes intended for non-invasive management: substudy from prospective randomised PLATelet inhibition and patient Outcomes (PLATO) trial.
Topics: Acute Coronary Syndrome; Adenosine; Clopidogrel; Humans; Platelet Aggregation Inhibitors; Prospectiv | 2011 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes intended for non-invasive management: substudy from prospective randomised PLATelet inhibition and patient Outcomes (PLATO) trial.
Topics: Acute Coronary Syndrome; Adenosine; Clopidogrel; Humans; Platelet Aggregation Inhibitors; Prospectiv | 2011 |
Randomized double-blind placebo-controlled crossover study to determine the effects of esomeprazole on inhibition of platelet function by clopidogrel.
Topics: Acute Coronary Syndrome; Aged; Aryl Hydrocarbon Hydroxylases; Aspirin; Blood Platelets; Cell Adhesio | 2011 |
Residual platelet reactivity after clopidogrel loading in patients with ST-elevation myocardial infarction undergoing an unexpectedly delayed primary percutaneous coronary intervention. - Impact on intracoronary thrombus burden and myocardial perfusion-.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Clopidogrel; Coronary Circulation; Co | 2011 |
Characterization of dyspnoea in PLATO study patients treated with ticagrelor or clopidogrel and its association with clinical outcomes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Double-Blind Method; Dyspnea; Female; Humans; | 2011 |
The effect of the duration of clopidogrel use on hsCRP levels after stenting the target vessel in patients with acute coronary syndrome.
Topics: Acute Coronary Syndrome; C-Reactive Protein; Clopidogrel; Drug-Eluting Stents; Humans; Platelet Aggr | 2011 |
Relationship between clopidogrel-induced platelet P2Y12 inhibition and stent thrombosis or myocardial infarction after percutaneous coronary intervention-a case-control study.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Clopidogrel; Coronary Angiography; Co | 2011 |
Platelet reactivity and cardiovascular outcomes after percutaneous coronary intervention: a time-dependent analysis of the Gauging Responsiveness with a VerifyNow P2Y12 assay: Impact on Thrombosis and Safety (GRAVITAS) trial.
Topics: Acute Coronary Syndrome; Aged; Blood Platelets; Clopidogrel; Drug-Eluting Stents; Female; Follow-Up | 2011 |
Platelet reactivity and cardiovascular outcomes after percutaneous coronary intervention: a time-dependent analysis of the Gauging Responsiveness with a VerifyNow P2Y12 assay: Impact on Thrombosis and Safety (GRAVITAS) trial.
Topics: Acute Coronary Syndrome; Aged; Blood Platelets; Clopidogrel; Drug-Eluting Stents; Female; Follow-Up | 2011 |
Platelet reactivity and cardiovascular outcomes after percutaneous coronary intervention: a time-dependent analysis of the Gauging Responsiveness with a VerifyNow P2Y12 assay: Impact on Thrombosis and Safety (GRAVITAS) trial.
Topics: Acute Coronary Syndrome; Aged; Blood Platelets; Clopidogrel; Drug-Eluting Stents; Female; Follow-Up | 2011 |
Platelet reactivity and cardiovascular outcomes after percutaneous coronary intervention: a time-dependent analysis of the Gauging Responsiveness with a VerifyNow P2Y12 assay: Impact on Thrombosis and Safety (GRAVITAS) trial.
Topics: Acute Coronary Syndrome; Aged; Blood Platelets; Clopidogrel; Drug-Eluting Stents; Female; Follow-Up | 2011 |
Platelet reactivity and cardiovascular outcomes after percutaneous coronary intervention: a time-dependent analysis of the Gauging Responsiveness with a VerifyNow P2Y12 assay: Impact on Thrombosis and Safety (GRAVITAS) trial.
Topics: Acute Coronary Syndrome; Aged; Blood Platelets; Clopidogrel; Drug-Eluting Stents; Female; Follow-Up | 2011 |
Platelet reactivity and cardiovascular outcomes after percutaneous coronary intervention: a time-dependent analysis of the Gauging Responsiveness with a VerifyNow P2Y12 assay: Impact on Thrombosis and Safety (GRAVITAS) trial.
Topics: Acute Coronary Syndrome; Aged; Blood Platelets; Clopidogrel; Drug-Eluting Stents; Female; Follow-Up | 2011 |
Platelet reactivity and cardiovascular outcomes after percutaneous coronary intervention: a time-dependent analysis of the Gauging Responsiveness with a VerifyNow P2Y12 assay: Impact on Thrombosis and Safety (GRAVITAS) trial.
Topics: Acute Coronary Syndrome; Aged; Blood Platelets; Clopidogrel; Drug-Eluting Stents; Female; Follow-Up | 2011 |
Platelet reactivity and cardiovascular outcomes after percutaneous coronary intervention: a time-dependent analysis of the Gauging Responsiveness with a VerifyNow P2Y12 assay: Impact on Thrombosis and Safety (GRAVITAS) trial.
Topics: Acute Coronary Syndrome; Aged; Blood Platelets; Clopidogrel; Drug-Eluting Stents; Female; Follow-Up | 2011 |
Platelet reactivity and cardiovascular outcomes after percutaneous coronary intervention: a time-dependent analysis of the Gauging Responsiveness with a VerifyNow P2Y12 assay: Impact on Thrombosis and Safety (GRAVITAS) trial.
Topics: Acute Coronary Syndrome; Aged; Blood Platelets; Clopidogrel; Drug-Eluting Stents; Female; Follow-Up | 2011 |
Pulmonary function in patients with acute coronary syndrome treated with ticagrelor or clopidogrel (from the Platelet Inhibition and Patient Outcomes [PLATO] pulmonary function substudy).
Topics: Acute Coronary Syndrome; Adenosine; Administration, Oral; Clopidogrel; Dose-Response Relationship, D | 2011 |
Bleeding complications with the P2Y12 receptor antagonists clopidogrel and ticagrelor in the PLATelet inhibition and patient Outcomes (PLATO) trial.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Aspirin; Clopidogrel; Coronary Artery Bypass; Double-Blind | 2011 |
Effect of esomeprazole versus famotidine on platelet inhibition by clopidogrel: a double-blind, randomized trial.
Topics: Acute Coronary Syndrome; Anti-Ulcer Agents; Blood Platelets; Clopidogrel; Double-Blind Method; Esome | 2011 |
Esomeprazole compared with famotidine in the prevention of upper gastrointestinal bleeding in patients with acute coronary syndrome or myocardial infarction.
Topics: Acute Coronary Syndrome; Aged; Anti-Ulcer Agents; Aspirin; Chi-Square Distribution; Clopidogrel; Dou | 2012 |
Cystatin C and estimated glomerular filtration rate as predictors for adverse outcome in patients with ST-elevation and non-ST-elevation acute coronary syndromes: results from the Platelet Inhibition and Patient Outcomes study.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Biomarkers; C-Reactive Protein; Clopidogrel; Creatinine; C | 2012 |
Antiplatelet efficacy of long-term treatment with clopidogrel besylate in patients with a history of acute coronary syndrome: comparison with clopidogrel hydrogen sulfate.
Topics: Acute Coronary Syndrome; Clopidogrel; Drugs, Generic; Humans; Long-Term Care; Platelet Aggregation; | 2012 |
Antiplatelet efficacy of long-term treatment with clopidogrel besylate in patients with a history of acute coronary syndrome: comparison with clopidogrel hydrogen sulfate.
Topics: Acute Coronary Syndrome; Clopidogrel; Drugs, Generic; Humans; Long-Term Care; Platelet Aggregation; | 2012 |
Antiplatelet efficacy of long-term treatment with clopidogrel besylate in patients with a history of acute coronary syndrome: comparison with clopidogrel hydrogen sulfate.
Topics: Acute Coronary Syndrome; Clopidogrel; Drugs, Generic; Humans; Long-Term Care; Platelet Aggregation; | 2012 |
Antiplatelet efficacy of long-term treatment with clopidogrel besylate in patients with a history of acute coronary syndrome: comparison with clopidogrel hydrogen sulfate.
Topics: Acute Coronary Syndrome; Clopidogrel; Drugs, Generic; Humans; Long-Term Care; Platelet Aggregation; | 2012 |
[Tirofiban improved the prognosis of senior acute coronary syndrome patients received percutaneous coronary intervention].
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Female; Humans; | 2011 |
ST-elevation acute coronary syndromes in the Platelet Inhibition and Patient Outcomes (PLATO) trial: insights from the ECG substudy.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Angioplasty, Balloon, Coronary; Clopidogrel; Electrocardio | 2012 |
Effect of clopidogrel besylate on platelet reactivity in patients with acute coronary syndromes. Comparison with clopidogrel hydrogen sulfate.
Topics: Acute Coronary Syndrome; Aged; Clopidogrel; Female; Humans; Male; Middle Aged; Platelet Aggregation; | 2012 |
Effect of clopidogrel besylate on platelet reactivity in patients with acute coronary syndromes. Comparison with clopidogrel hydrogen sulfate.
Topics: Acute Coronary Syndrome; Aged; Clopidogrel; Female; Humans; Male; Middle Aged; Platelet Aggregation; | 2012 |
Effect of clopidogrel besylate on platelet reactivity in patients with acute coronary syndromes. Comparison with clopidogrel hydrogen sulfate.
Topics: Acute Coronary Syndrome; Aged; Clopidogrel; Female; Humans; Male; Middle Aged; Platelet Aggregation; | 2012 |
Effect of clopidogrel besylate on platelet reactivity in patients with acute coronary syndromes. Comparison with clopidogrel hydrogen sulfate.
Topics: Acute Coronary Syndrome; Aged; Clopidogrel; Female; Humans; Male; Middle Aged; Platelet Aggregation; | 2012 |
Tailoring clopidogrel dose according to multiple electrode aggregometry decreases the rate of ischemic complications after percutaneous coronary intervention.
Topics: Acute Coronary Syndrome; Aged; Angina Pectoris; Angioplasty, Balloon, Coronary; Clopidogrel; Disease | 2012 |
Factors associated with the failure of clopidogrel dose-adjustment according to platelet reactivity monitoring to optimize P2Y12-ADP receptor blockade.
Topics: Acute Coronary Syndrome; Aged; Aryl Hydrocarbon Hydroxylases; Aryldialkylphosphatase; ATP Binding Ca | 2012 |
Bleeding-associated outcomes with preoperative clopidogrel use in on- and off-pump coronary artery bypass.
Topics: Acute Coronary Syndrome; Aged; Clopidogrel; Coronary Artery Bypass, Off-Pump; Female; Hemorrhage; Hu | 2012 |
Point-of-care genetic testing for personalisation of antiplatelet treatment (RAPID GENE): a prospective, randomised, proof-of-concept trial.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aryl Hydrocarbon Hydroxylases; Clopid | 2012 |
[Effects of intensive antiplatelet therapy for patients with high on-treatment platelet reactivity after coronary stent implantation].
Topics: Acute Coronary Syndrome; Adult; Aged; Aspirin; Blood Platelets; Cilostazol; Clopidogrel; Drug Therap | 2012 |
Baseline Q waves as a prognostic modulator in patients with ST-segment elevation: insights from the PLATO trial.
Topics: Acute Coronary Syndrome; Adenosine; Angioplasty, Balloon, Coronary; Biomarkers; Clopidogrel; Creatin | 2012 |
Lessons from platelet inhibition and patient outcomes.
Topics: Acute Coronary Syndrome; Adenosine; Blood Platelets; Clopidogrel; Confidence Intervals; Humans; Myoc | 2012 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes and a history of stroke or transient ischemic attack.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Brain Ischemia; Clopidogrel; Female; Humans; Intracranial | 2012 |
Influence of genetic polymorphisms on the effect of high- and standard-dose clopidogrel after percutaneous coronary intervention: the GIFT (Genotype Information and Functional Testing) study.
Topics: Acute Coronary Syndrome; Alleles; Angioplasty, Balloon, Coronary; Aryl Hydrocarbon Hydroxylases; Blo | 2012 |
Mortality benefit with prasugrel in the TRITON-TIMI 38 coronary artery bypass grafting cohort: risk-adjusted retrospective data analysis.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Blood Loss, Surgical; Cause | 2012 |
Clopidogrel plus indobufen in acute coronary syndrome patients with hypersensitivity to aspirin undergoing percutaneous coronary intervention.
Topics: Acute Coronary Syndrome; Aged; Aspirin; Clopidogrel; Drug Hypersensitivity; Drug Therapy, Combinatio | 2013 |
Effect of a multifaceted intervention on use of evidence-based therapies in patients with acute coronary syndromes in Brazil: the BRIDGE-ACS randomized trial.
Topics: Acute Coronary Syndrome; Aged; Anticoagulants; Aspirin; Brazil; Case Management; Checklist; Clopidog | 2012 |
Cost-effectiveness of treating acute coronary syndrome patients with ticagrelor for 12 months: results from the PLATO study.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Cost-Benefit Analysis; Female; Humans; Life E | 2013 |
Ticagrelor versus prasugrel in acute coronary syndrome patients with high on-clopidogrel platelet reactivity following percutaneous coronary intervention: a pharmacodynamic study.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Angioplasty, Balloon, Coronary; Clopidogrel; Coronary Thro | 2012 |
Ticagrelor versus prasugrel in acute coronary syndrome patients with high on-clopidogrel platelet reactivity following percutaneous coronary intervention: a pharmacodynamic study.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Angioplasty, Balloon, Coronary; Clopidogrel; Coronary Thro | 2012 |
Ticagrelor versus prasugrel in acute coronary syndrome patients with high on-clopidogrel platelet reactivity following percutaneous coronary intervention: a pharmacodynamic study.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Angioplasty, Balloon, Coronary; Clopidogrel; Coronary Thro | 2012 |
Ticagrelor versus prasugrel in acute coronary syndrome patients with high on-clopidogrel platelet reactivity following percutaneous coronary intervention: a pharmacodynamic study.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Angioplasty, Balloon, Coronary; Clopidogrel; Coronary Thro | 2012 |
The impact of CYP3A5*1/*3, PIA1/A2 and T744C polymorphisms on clopidogrel and acetylsalicylic acid response variability in Mexican population.
Topics: Acute Coronary Syndrome; Aspirin; Clopidogrel; Comorbidity; Cytochrome P-450 CYP3A; Drug Resistance; | 2012 |
Influence of omeprazole and famotidine on the antiplatelet effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes: a prospective, randomized, multicenter study.
Topics: Acute Coronary Syndrome; Aged; Anti-Ulcer Agents; Aspirin; Blood Platelets; Clopidogrel; Drug Antago | 2012 |
Prasugrel versus clopidogrel for acute coronary syndromes without revascularization.
Topics: Acute Coronary Syndrome; Aged; Angina, Unstable; Aspirin; Cardiovascular Diseases; Clopidogrel; Doub | 2012 |
Aspirin plus clopidogrel for optimal platelet inhibition following off-pump coronary artery bypass surgery: results from the CRYSSA (prevention of Coronary arteRY bypaSS occlusion After off-pump procedures) randomised study.
Topics: Acute Coronary Syndrome; Aspirin; Clopidogrel; Coronary Angiography; Coronary Artery Bypass, Off-Pum | 2012 |
Prior smoking status, clinical outcomes, and the comparison of ticagrelor with clopidogrel in acute coronary syndromes-insights from the PLATelet inhibition and patient Outcomes (PLATO) trial.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Female; Humans; Male; Middle Aged; Platelet A | 2012 |
Ticagrelor versus clopidogrel in elderly patients with acute coronary syndromes: a substudy from the prospective randomized PLATelet inhibition and patient Outcomes (PLATO) trial.
Topics: Acute Coronary Syndrome; Adenosine; Age Factors; Aged; Cardiovascular Diseases; Chi-Square Distribut | 2012 |
Ticagrelor versus clopidogrel in elderly patients with acute coronary syndromes: a substudy from the prospective randomized PLATelet inhibition and patient Outcomes (PLATO) trial.
Topics: Acute Coronary Syndrome; Adenosine; Age Factors; Aged; Cardiovascular Diseases; Chi-Square Distribut | 2012 |
Ticagrelor versus clopidogrel in elderly patients with acute coronary syndromes: a substudy from the prospective randomized PLATelet inhibition and patient Outcomes (PLATO) trial.
Topics: Acute Coronary Syndrome; Adenosine; Age Factors; Aged; Cardiovascular Diseases; Chi-Square Distribut | 2012 |
Ticagrelor versus clopidogrel in elderly patients with acute coronary syndromes: a substudy from the prospective randomized PLATelet inhibition and patient Outcomes (PLATO) trial.
Topics: Acute Coronary Syndrome; Adenosine; Age Factors; Aged; Cardiovascular Diseases; Chi-Square Distribut | 2012 |
Ticagrelor versus clopidogrel in elderly patients with acute coronary syndromes: a substudy from the prospective randomized PLATelet inhibition and patient Outcomes (PLATO) trial.
Topics: Acute Coronary Syndrome; Adenosine; Age Factors; Aged; Cardiovascular Diseases; Chi-Square Distribut | 2012 |
Ticagrelor versus clopidogrel in elderly patients with acute coronary syndromes: a substudy from the prospective randomized PLATelet inhibition and patient Outcomes (PLATO) trial.
Topics: Acute Coronary Syndrome; Adenosine; Age Factors; Aged; Cardiovascular Diseases; Chi-Square Distribut | 2012 |
Ticagrelor versus clopidogrel in elderly patients with acute coronary syndromes: a substudy from the prospective randomized PLATelet inhibition and patient Outcomes (PLATO) trial.
Topics: Acute Coronary Syndrome; Adenosine; Age Factors; Aged; Cardiovascular Diseases; Chi-Square Distribut | 2012 |
Ticagrelor versus clopidogrel in elderly patients with acute coronary syndromes: a substudy from the prospective randomized PLATelet inhibition and patient Outcomes (PLATO) trial.
Topics: Acute Coronary Syndrome; Adenosine; Age Factors; Aged; Cardiovascular Diseases; Chi-Square Distribut | 2012 |
Ticagrelor versus clopidogrel in elderly patients with acute coronary syndromes: a substudy from the prospective randomized PLATelet inhibition and patient Outcomes (PLATO) trial.
Topics: Acute Coronary Syndrome; Adenosine; Age Factors; Aged; Cardiovascular Diseases; Chi-Square Distribut | 2012 |
Thrombus and antiplatelet therapy in type 2 diabetes mellitus. A prospective study after non-ST elevation acute coronary syndrome and a randomised, blinded, placebo-controlled study in stable angina.
Topics: Acute Coronary Syndrome; Aged; Angina, Stable; Aspirin; Clopidogrel; Diabetes Mellitus, Type 2; Fema | 2012 |
Factors contributing to the lower mortality with ticagrelor compared with clopidogrel in patients undergoing coronary artery bypass surgery.
Topics: Acute Coronary Syndrome; Adenosine; Clopidogrel; Coronary Artery Bypass; Dose-Response Relationship, | 2012 |
Factors contributing to the lower mortality with ticagrelor compared with clopidogrel in patients undergoing coronary artery bypass surgery.
Topics: Acute Coronary Syndrome; Adenosine; Clopidogrel; Coronary Artery Bypass; Dose-Response Relationship, | 2012 |
Factors contributing to the lower mortality with ticagrelor compared with clopidogrel in patients undergoing coronary artery bypass surgery.
Topics: Acute Coronary Syndrome; Adenosine; Clopidogrel; Coronary Artery Bypass; Dose-Response Relationship, | 2012 |
Factors contributing to the lower mortality with ticagrelor compared with clopidogrel in patients undergoing coronary artery bypass surgery.
Topics: Acute Coronary Syndrome; Adenosine; Clopidogrel; Coronary Artery Bypass; Dose-Response Relationship, | 2012 |
[Acute non ST-elevation coronary syndrome in real practice of hospitals in Russia. Comparative data from RECORD 2 and RECORD registries].
Topics: Acute Coronary Syndrome; Adult; Aged; Aged, 80 and over; Anticoagulants; Clopidogrel; Coronary Angio | 2012 |
Platelet function during extended prasugrel and clopidogrel therapy for patients with ACS treated without revascularization: the TRILOGY ACS platelet function substudy.
Topics: Acute Coronary Syndrome; Age Factors; Aged; Angina, Unstable; Aspirin; Body Weight; Clopidogrel; Fem | 2012 |
Platelet function during extended prasugrel and clopidogrel therapy for patients with ACS treated without revascularization: the TRILOGY ACS platelet function substudy.
Topics: Acute Coronary Syndrome; Age Factors; Aged; Angina, Unstable; Aspirin; Body Weight; Clopidogrel; Fem | 2012 |
Platelet function during extended prasugrel and clopidogrel therapy for patients with ACS treated without revascularization: the TRILOGY ACS platelet function substudy.
Topics: Acute Coronary Syndrome; Age Factors; Aged; Angina, Unstable; Aspirin; Body Weight; Clopidogrel; Fem | 2012 |
Platelet function during extended prasugrel and clopidogrel therapy for patients with ACS treated without revascularization: the TRILOGY ACS platelet function substudy.
Topics: Acute Coronary Syndrome; Age Factors; Aged; Angina, Unstable; Aspirin; Body Weight; Clopidogrel; Fem | 2012 |
Outcome and causes of renal deterioration evaluated by serial cystatin C measurements in acute coronary syndrome patients -- results from the PLATelet inhibition and patient Outcomes (PLATO) study.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Analysis of Variance; Biomarkers; Clopidogrel; Cystatin C; | 2012 |
Selecting antiplatelet therapy at the time of percutaneous intervention for an acute coronary syndrome: weighing the benefits and risks of prasugrel versus clopidogrel.
Topics: Acute Coronary Syndrome; Aged; Clopidogrel; Female; Follow-Up Studies; Hemorrhage; Humans; Male; Mid | 2013 |
Decrease in high on-treatment platelet reactivity (HPR) prevalence on switching from clopidogrel to prasugrel: insights from the switching anti-platelet (SWAP) study.
Topics: Acute Coronary Syndrome; Aged; Aryl Hydrocarbon Hydroxylases; Blood Platelets; Cell Adhesion Molecul | 2013 |
Pharmacodynamic effect of prasugrel 5 mg vs clopidogrel 150 mg in elderly patients with high on-clopidogrel platelet reactivity.
Topics: Acute Coronary Syndrome; Aged; Clopidogrel; Female; Humans; Male; Percutaneous Coronary Intervention | 2013 |
Reduction in first and recurrent cardiovascular events with ticagrelor compared with clopidogrel in the PLATO Study.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Aged, 80 and over; Clopidogrel; Female; Humans; Ischemic A | 2013 |
Relationship between platelet count and 30-day clinical outcomes after percutaneous coronary interventions. Pooled analysis of four ISAR trials.
Topics: Abciximab; Acute Coronary Syndrome; Aged; Angiography; Angioplasty, Balloon, Coronary; Antibodies, M | 2007 |
To adjust or not to adjust the platelet count in light transmission aggregometry in patients receiving dual aspirin/clopidogrel treatment.
Topics: Acute Coronary Syndrome; Aspirin; Clopidogrel; Humans; Platelet Aggregation; Platelet Aggregation In | 2007 |
Safety, tolerability, and initial efficacy of AZD6140, the first reversible oral adenosine diphosphate receptor antagonist, compared with clopidogrel, in patients with non-ST-segment elevation acute coronary syndrome: primary results of the DISPERSE-2 tri
Topics: Acute Coronary Syndrome; Adenosine; Administration, Oral; Adult; Aged; Aged, 80 and over; Aspirin; C | 2007 |
Safety, tolerability, and initial efficacy of AZD6140, the first reversible oral adenosine diphosphate receptor antagonist, compared with clopidogrel, in patients with non-ST-segment elevation acute coronary syndrome: primary results of the DISPERSE-2 tri
Topics: Acute Coronary Syndrome; Adenosine; Administration, Oral; Adult; Aged; Aged, 80 and over; Aspirin; C | 2007 |
Safety, tolerability, and initial efficacy of AZD6140, the first reversible oral adenosine diphosphate receptor antagonist, compared with clopidogrel, in patients with non-ST-segment elevation acute coronary syndrome: primary results of the DISPERSE-2 tri
Topics: Acute Coronary Syndrome; Adenosine; Administration, Oral; Adult; Aged; Aged, 80 and over; Aspirin; C | 2007 |
Safety, tolerability, and initial efficacy of AZD6140, the first reversible oral adenosine diphosphate receptor antagonist, compared with clopidogrel, in patients with non-ST-segment elevation acute coronary syndrome: primary results of the DISPERSE-2 tri
Topics: Acute Coronary Syndrome; Adenosine; Administration, Oral; Adult; Aged; Aged, 80 and over; Aspirin; C | 2007 |
Safety, tolerability, and initial efficacy of AZD6140, the first reversible oral adenosine diphosphate receptor antagonist, compared with clopidogrel, in patients with non-ST-segment elevation acute coronary syndrome: primary results of the DISPERSE-2 tri
Topics: Acute Coronary Syndrome; Adenosine; Administration, Oral; Adult; Aged; Aged, 80 and over; Aspirin; C | 2007 |
Safety, tolerability, and initial efficacy of AZD6140, the first reversible oral adenosine diphosphate receptor antagonist, compared with clopidogrel, in patients with non-ST-segment elevation acute coronary syndrome: primary results of the DISPERSE-2 tri
Topics: Acute Coronary Syndrome; Adenosine; Administration, Oral; Adult; Aged; Aged, 80 and over; Aspirin; C | 2007 |
Safety, tolerability, and initial efficacy of AZD6140, the first reversible oral adenosine diphosphate receptor antagonist, compared with clopidogrel, in patients with non-ST-segment elevation acute coronary syndrome: primary results of the DISPERSE-2 tri
Topics: Acute Coronary Syndrome; Adenosine; Administration, Oral; Adult; Aged; Aged, 80 and over; Aspirin; C | 2007 |
Safety, tolerability, and initial efficacy of AZD6140, the first reversible oral adenosine diphosphate receptor antagonist, compared with clopidogrel, in patients with non-ST-segment elevation acute coronary syndrome: primary results of the DISPERSE-2 tri
Topics: Acute Coronary Syndrome; Adenosine; Administration, Oral; Adult; Aged; Aged, 80 and over; Aspirin; C | 2007 |
Safety, tolerability, and initial efficacy of AZD6140, the first reversible oral adenosine diphosphate receptor antagonist, compared with clopidogrel, in patients with non-ST-segment elevation acute coronary syndrome: primary results of the DISPERSE-2 tri
Topics: Acute Coronary Syndrome; Adenosine; Administration, Oral; Adult; Aged; Aged, 80 and over; Aspirin; C | 2007 |
Inhibition of platelet aggregation by AZD6140, a reversible oral P2Y12 receptor antagonist, compared with clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Administration, Oral; Aged; Clopidogrel; Dose-Response Relationship, Drug; | 2007 |
Inhibition of platelet aggregation by AZD6140, a reversible oral P2Y12 receptor antagonist, compared with clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Administration, Oral; Aged; Clopidogrel; Dose-Response Relationship, Drug; | 2007 |
Inhibition of platelet aggregation by AZD6140, a reversible oral P2Y12 receptor antagonist, compared with clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Administration, Oral; Aged; Clopidogrel; Dose-Response Relationship, Drug; | 2007 |
Inhibition of platelet aggregation by AZD6140, a reversible oral P2Y12 receptor antagonist, compared with clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Administration, Oral; Aged; Clopidogrel; Dose-Response Relationship, Drug; | 2007 |
Inhibition of platelet aggregation by AZD6140, a reversible oral P2Y12 receptor antagonist, compared with clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Administration, Oral; Aged; Clopidogrel; Dose-Response Relationship, Drug; | 2007 |
Inhibition of platelet aggregation by AZD6140, a reversible oral P2Y12 receptor antagonist, compared with clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Administration, Oral; Aged; Clopidogrel; Dose-Response Relationship, Drug; | 2007 |
Inhibition of platelet aggregation by AZD6140, a reversible oral P2Y12 receptor antagonist, compared with clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Administration, Oral; Aged; Clopidogrel; Dose-Response Relationship, Drug; | 2007 |
Inhibition of platelet aggregation by AZD6140, a reversible oral P2Y12 receptor antagonist, compared with clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Administration, Oral; Aged; Clopidogrel; Dose-Response Relationship, Drug; | 2007 |
Inhibition of platelet aggregation by AZD6140, a reversible oral P2Y12 receptor antagonist, compared with clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Administration, Oral; Aged; Clopidogrel; Dose-Response Relationship, Drug; | 2007 |
Inhibition of platelet aggregation by AZD6140, a reversible oral P2Y12 receptor antagonist, compared with clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Administration, Oral; Aged; Clopidogrel; Dose-Response Relationship, Drug; | 2007 |
Inhibition of platelet aggregation by AZD6140, a reversible oral P2Y12 receptor antagonist, compared with clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Administration, Oral; Aged; Clopidogrel; Dose-Response Relationship, Drug; | 2007 |
Inhibition of platelet aggregation by AZD6140, a reversible oral P2Y12 receptor antagonist, compared with clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Administration, Oral; Aged; Clopidogrel; Dose-Response Relationship, Drug; | 2007 |
Inhibition of platelet aggregation by AZD6140, a reversible oral P2Y12 receptor antagonist, compared with clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Administration, Oral; Aged; Clopidogrel; Dose-Response Relationship, Drug; | 2007 |
Inhibition of platelet aggregation by AZD6140, a reversible oral P2Y12 receptor antagonist, compared with clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Administration, Oral; Aged; Clopidogrel; Dose-Response Relationship, Drug; | 2007 |
Inhibition of platelet aggregation by AZD6140, a reversible oral P2Y12 receptor antagonist, compared with clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Administration, Oral; Aged; Clopidogrel; Dose-Response Relationship, Drug; | 2007 |
Inhibition of platelet aggregation by AZD6140, a reversible oral P2Y12 receptor antagonist, compared with clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Administration, Oral; Aged; Clopidogrel; Dose-Response Relationship, Drug; | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Double-Blind Me | 2007 |
Cost-effectiveness of clopidogrel in acute coronary syndromes in Canada: a long-term analysis based on the CURE trial.
Topics: Acute Coronary Syndrome; Aged; Angina, Unstable; Angioplasty, Balloon, Coronary; Aspirin; Canada; Cl | 2007 |
Troponin level and efficacy of abciximab in patients with acute coronary syndromes undergoing early intervention after clopidogrel pretreatment.
Topics: Abciximab; Acute Coronary Syndrome; Aged; Antibodies, Monoclonal; Biomarkers; Cardiovascular Surgica | 2008 |
Comparison of the effects of pretreatment with tirofiban, clopidogrel or both on the inhibition of platelet aggregation and activation in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Animals; Clopidogrel; Drug Administration Schedule; Drug Synergism; F | 2009 |
[The antiplatelet effect of clopidogrel is not attenuated by statin treatment in patients with acute coronary syndromes undergone coronary stenting].
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Atorvastatin; Clopidogrel; Drug Inter | 2007 |
Evaluation of proton pump inhibitor use in patients with acute coronary syndromes based on risk factors for gastrointestinal bleed.
Topics: Acute Coronary Syndrome; Aged; Aspirin; Clopidogrel; Female; Fibrinolytic Agents; Gastrointestinal H | 2007 |
Variable responsiveness to clopidogrel and aspirin among patients with acute coronary syndrome as assessed by platelet function tests.
Topics: Acute Coronary Syndrome; Adenosine Diphosphate; Adult; Aged; Arachidonic Acid; Aspirin; Clopidogrel; | 2008 |
One-year clinical outcomes with abciximab vs. placebo in patients with non-ST-segment elevation acute coronary syndromes undergoing percutaneous coronary intervention after pre-treatment with clopidogrel: results of the ISAR-REACT 2 randomized trial.
Topics: Abciximab; Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Cl | 2008 |
Patients with non-ST-elevation acute coronary syndromes undergoing coronary artery bypass grafting in the modern era of antithrombotic therapy.
Topics: Acute Coronary Syndrome; Aged; Clopidogrel; Coronary Artery Bypass; Electrocardiography; Enoxaparin; | 2008 |
Residual prothrombotic status in low responder patients to clopidogrel identified by Vasodilator-Stimulated Phosphoprotein Phosphorylation (VASP) analysis?
Topics: Acute Coronary Syndrome; Adenosine Diphosphate; Aged; Aged, 80 and over; Biomarkers; Blood Platelets | 2008 |
Intensive oral antiplatelet therapy for reduction of ischaemic events including stent thrombosis in patients with acute coronary syndromes treated with percutaneous coronary intervention and stenting in the TRITON-TIMI 38 trial: a subanalysis of a randomi
Topics: Acute Coronary Syndrome; Administration, Oral; Aged; Angioplasty, Balloon, Coronary; Clopidogrel; Fe | 2008 |
[The TRITON-TIMI 38 trial].
Topics: Acute Coronary Syndrome; Angioplasty, Balloon, Coronary; Clopidogrel; Humans; Piperazines; Platelet | 2008 |
Effect of abciximab on clinical and angiographic restenosis in patients with non-ST-segment elevation acute coronary syndromes.
Topics: Abciximab; Acute Coronary Syndrome; Aged; Antibodies, Monoclonal; Chi-Square Distribution; Clopidogr | 2008 |
High-dose atorvastatin does not negatively influence clinical outcomes among clopidogrel treated acute coronary syndrome patients--a Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis in Myocardial Infarction 22 (PROVE IT-TIMI 22) a
Topics: Acute Coronary Syndrome; Aged; Atorvastatin; Clopidogrel; Cytochrome P-450 Enzyme System; Female; He | 2008 |
Early and late benefits of prasugrel in patients with acute coronary syndromes undergoing percutaneous coronary intervention: a TRITON-TIMI 38 (TRial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet InhibitioN with Prasugrel-Thrombolys
Topics: Acute Coronary Syndrome; Angina, Unstable; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Com | 2008 |
721 other studies available for ticlopidine and Acute Coronary Syndrome
| Article | Year |
|---|---|
Clinical Outcomes After Percutaneous Coronary Intervention Over Time on the Basis of CYP2C19 Polymorphisms.
Topics: Acute Coronary Syndrome; Clopidogrel; Cytochrome P-450 CYP2C19; Genotype; Humans; Percutaneous Coron | 2022 |
Clinical and Pharmacological Parameters Determine Relapse During Clopidogrel Treatment of Acute Coronary Syndrome.
Topics: Acute Coronary Syndrome; Aspirin; Calcium Channel Blockers; Clopidogrel; Coronary Artery Disease; Cy | 2022 |
Influence of Clinically Significant Genes on Antiplatelet Effect of Clopidogrel and Clinical Outcomes in Patients with Acute Coronary Syndrome and Atrial Fibrillation.
Topics: Acute Coronary Syndrome; Aryldialkylphosphatase; Atrial Fibrillation; Clopidogrel; Cytochrome P-450 | 2022 |
Clopidogrel or ticagrelor in elderly patients with acute coronary syndromes - Nihil nocere!
Topics: Acute Coronary Syndrome; Aged; Clopidogrel; Humans; Percutaneous Coronary Intervention; Platelet Agg | 2022 |
Effect of CYP2C19 status on platelet reactivity in Taiwanese acute coronary syndrome patients switching to prasugrel from clopidogrel: Switch Study.
Topics: Acute Coronary Syndrome; Clopidogrel; Cytochrome P-450 CYP2C19; Humans; Percutaneous Coronary Interv | 2022 |
Performance of the ABCD-GENE Score for Predicting Clinical Outcomes in Clopidogrel-Treated Patients with ACS.
Topics: Acute Coronary Syndrome; Blood Platelets; Clopidogrel; Humans; Percutaneous Coronary Intervention; P | 2022 |
The Cytochrome P450 2C19 Polymorphism Associated with Major Adverse Cardiovascular Events Risk in Kazak Patients Undergoing Percutaneous Coronary Intervention and Receiving Clopidogrel.
Topics: Acute Coronary Syndrome; China; Clopidogrel; Cytochrome P-450 CYP2C19; Genotype; Humans; Percutaneou | 2023 |
Cost-effectiveness of clopidogrel vs. ticagrelor in patients of 70 years or older with non-ST-elevation acute coronary syndrome.
Topics: Acute Coronary Syndrome; Aged; Clopidogrel; Cost-Benefit Analysis; Humans; Platelet Aggregation Inhi | 2022 |
Antiplatelet treatment of acute coronary syndromes: novel clinical and translational perspectives.
Topics: Acute Coronary Syndrome; Humans; Platelet Aggregation Inhibitors; Ticlopidine | 2022 |
One-month DAPT after acute coronary syndrome: too short or not too short?
Topics: Acute Coronary Syndrome; Drug Therapy, Combination; Humans; Percutaneous Coronary Intervention; Plat | 2022 |
The DNAm levels of CREB5 (cg11301281) were associated with clopidogrel resistance.
Topics: Acute Coronary Syndrome; Albumins; Blood Platelets; Clopidogrel; Cyclic AMP Response Element-Binding | 2022 |
Impact of renal failure and high-platelet reactivity on major cardiovascular ischemic events among patients with acute coronary syndrome receiving dual antiplatelet therapy with ticagrelor.
Topics: Acute Coronary Syndrome; Adenosine; Aftercare; Clopidogrel; Humans; Patient Discharge; Percutaneous | 2023 |
Oral P2Y12 inhibiting therapy in patients with acute coronary syndrome: finding the sweet spot.
Topics: Acute Coronary Syndrome; Clopidogrel; Humans; Platelet Aggregation Inhibitors; Ticlopidine | 2023 |
The Effectiveness of Antiplatelet Therapy and the Factors Influencing It in Patients with Acute Coronary Syndrome before and during the COVID-19 Pandemic.
Topics: Acute Coronary Syndrome; Adenosine; Aspirin; Clopidogrel; COVID-19; Drug Therapy, Combination; Human | 2022 |
Time Course of Death After Acute Coronary Syndrome Treated With Dual Antiplatelet Therapy for 1 Year.
Topics: Acute Coronary Syndrome; Aspirin; Clopidogrel; Drug Therapy, Combination; Hemorrhage; Humans; Percut | 2023 |
miR-6076 rs1463411 polymorphisms are associated with bleeding during clopidogrel treatment in patients with acute coronary syndrome.
Topics: Acute Coronary Syndrome; Clopidogrel; Cytochrome P-450 CYP2C19; Genotype; Hemorrhage; Humans; MicroR | 2023 |
Clinical Impact of CYP2C19 Genotype on Clopidogrel-Based Antiplatelet Therapy After Percutaneous Coronary Intervention.
Topics: Acute Coronary Syndrome; Clopidogrel; Cytochrome P-450 CYP2C19; Drug-Eluting Stents; Genotype; Human | 2023 |
De-escalation of oral P2Y
Topics: Acute Coronary Syndrome; Blood Platelets; Diabetes Mellitus; Drug Monitoring; Humans; Percutaneous C | 2019 |
Improving Adherence to Ticagrelor in Patients After Acute Coronary Syndrome: Talking Face to Face is Better than a Phone Call.
Topics: Acute Coronary Syndrome; Humans; Platelet Aggregation Inhibitors; Ticagrelor; Ticlopidine | 2020 |
[Relation of Functional Activity of Platelets to Prognosis of Unfavorable Cardiovascular Events in Patients with Acute Coronary Syndrome. Results of a Registry Study].
Topics: Acute Coronary Syndrome; Blood Platelets; Clopidogrel; Humans; Platelet Aggregation Inhibitors; Prog | 2019 |
Ticagrelor or Prasugrel in Acute Coronary Syndromes - The Winner Takes It All?
Topics: Acute Coronary Syndrome; Humans; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Ticag | 2019 |
Ticagrelor Compared to Clopidogrel in Acute Coronary Syndrome and Stable Coronary Artery Disease.
Topics: Acute Coronary Syndrome; Adult; Aged; Aged, 80 and over; Clopidogrel; Coronary Artery Disease; Femal | 2019 |
Distribution of polymorphisms in the CYP2C19 and ABCB1 genes among patients with acute coronary syndrome in Lower Silesian population.
Topics: Acute Coronary Syndrome; ATP Binding Cassette Transporter, Subfamily B; Clopidogrel; Cytochrome P-45 | 2019 |
Sex-specific differences in antithrombotic therapy and prognosis in patients with acute coronary syndrome treated with stent.
Topics: Acute Coronary Syndrome; Aged; Aged, 80 and over; Clopidogrel; Drug-Eluting Stents; Female; Hemorrha | 2019 |
Low-dose prasugrel versus clopidogrel in elderly patients with high clinical and PCI complexity.
Topics: Acute Coronary Syndrome; Aged; Clopidogrel; Humans; Percutaneous Coronary Intervention; Platelet Agg | 2020 |
Pharmacodynamic study of prasugrel or clopidogrel in non-ST-elevation acute coronary syndrome with CYP2C19 genetic variants undergoing percutaneous coronary intervention (PRAISE-GENE trial).
Topics: Acute Coronary Syndrome; Blood Platelets; Clopidogrel; Cytochrome P-450 CYP2C19; Humans; Percutaneou | 2020 |
Smoking and antiplatelet therapy after acute coronary syndromes.
Topics: Acute Coronary Syndrome; Clopidogrel; Humans; Platelet Aggregation Inhibitors; Smoking; Ticlopidine | 2020 |
Letter by Kim et al Regarding Article, "Clinically Significant Bleeding With Ticagrelor Versus Clopidogrel in Korean Patients With Acute Coronary Syndromes Intended for Invasive Management: A Randomized Clinical Trial".
Topics: Acute Coronary Syndrome; Clopidogrel; Humans; Purinergic P2Y Receptor Antagonists; Republic of Korea | 2020 |
Letter by Chen et al Regarding Article, "Clinically Significant Bleeding With Ticagrelor Versus Clopidogrel in Korean Patients With Acute Coronary Syndromes Intended for Invasive Management: A Randomized Clinical Trial".
Topics: Acute Coronary Syndrome; Clopidogrel; Humans; Purinergic P2Y Receptor Antagonists; Republic of Korea | 2020 |
Response by Park and Park to Letter Regarding Article, "Clinically Significant Bleeding With Ticagrelor Versus Clopidogrel in Korean Patients With Acute Coronary Syndromes Intended for Invasive Management: A Randomized Clinical Trial".
Topics: Acute Coronary Syndrome; Clopidogrel; Humans; Purinergic P2Y Receptor Antagonists; Republic of Korea | 2020 |
The Frequency of the Minor Polymorphisms in the
Topics: Acute Coronary Syndrome; Aged; Alleles; Asian People; Clopidogrel; Cytochrome P-450 CYP2C19; Ethnici | 2020 |
Clopidogrel is a favourable alternative to ticagrelor in older patients with NSTE-ACS.
Topics: Acute Coronary Syndrome; Aged; Clopidogrel; Humans; Platelet Aggregation Inhibitors; Prasugrel Hydro | 2020 |
Double Trouble: Reducing Gastrointestinal Bleeding due to DAPT Following Acute Coronary Syndromes.
Topics: Acute Coronary Syndrome; Clopidogrel; Gastrointestinal Hemorrhage; Humans; Platelet Aggregation Inhi | 2021 |
Decreased Platelet Inhibition by Thienopyridines in Hyperuricemia.
Topics: Acute Coronary Syndrome; Adenosine Diphosphate; Aged; Angioplasty; Clopidogrel; Comorbidity; Cytochr | 2021 |
Clopidogrel-induced sweet syndrome: severe dermatological complication after percutaneous coronary intervention.
Topics: Acute Coronary Syndrome; Clopidogrel; Humans; Percutaneous Coronary Intervention; Platelet Aggregati | 2021 |
Impact of the rs73598374 polymorphism of the adenosine deaminase gene on platelet reactivity and long-term outcomes among patients with acute coronary syndrome treated with ticagrelor.
Topics: Acute Coronary Syndrome; Adenosine Deaminase; Aftercare; Clopidogrel; Drug Therapy, Combination; Hum | 2020 |
Angiotensin-Converting Enzyme Inhibitors and Angiotensin Receptor Blockers in Acute Coronary Syndrome: Implications for Platelet Reactivity?
Topics: Acute Coronary Syndrome; Aged; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhib | 2021 |
Cost-effectiveness of CYP2C19-guided antiplatelet therapy for acute coronary syndromes in Singapore.
Topics: Acute Coronary Syndrome; Clopidogrel; Cost-Benefit Analysis; Cytochrome P-450 CYP2C19; Drug Costs; G | 2021 |
Is This a Good Time to Revisit the Tropics?: Platelet Function Testing in Patients With Acute Coronary Syndromes.
Topics: Acute Coronary Syndrome; Humans; Platelet Function Tests; Ticlopidine; Treatment Outcome | 2021 |
Low hemoglobin predicts high-platelet reactivity and major cardiovascular ischemic events at long-term follow-up among ACS patients receiving dual antiplatelet therapy with ticagrelor.
Topics: Acute Coronary Syndrome; Adenosine; Aftercare; Follow-Up Studies; Humans; Patient Discharge; Percuta | 2021 |
Letter by Alkhalil and Kuzemczak Regarding Article, "Comparative Efficacy and Safety of Oral P2Y12 Inhibitors in Acute Coronary Syndrome: Network Meta-Analysis of 52 816 Patients From 12 Randomized Trials".
Topics: Acute Coronary Syndrome; Humans; Network Meta-Analysis; Purinergic P2Y Receptor Antagonists; Randomi | 2021 |
Letter by Kessler et al Regarding Article, "Comparative Efficacy and Safety of Oral P2Y12 Inhibitors in Acute Coronary Syndrome: Network Meta-Analysis of 52 816 Patients From 12 Randomized Trials".
Topics: Acute Coronary Syndrome; Humans; Network Meta-Analysis; Purinergic P2Y Receptor Antagonists; Randomi | 2021 |
Letter by Ferracane et al Regarding Article, "Comparative Efficacy and Safety of Oral P2Y12 Inhibitors in Acute Coronary Syndrome: Network Meta-Analysis of 52 816 Patients From 12 Randomized Trials".
Topics: Acute Coronary Syndrome; Humans; Network Meta-Analysis; Purinergic P2Y Receptor Antagonists; Randomi | 2021 |
Ticagrelor vs Clopidogrel for Patients With Acute Coronary Syndrome Undergoing Percutaneous Intervention-Reply.
Topics: Acute Coronary Syndrome; Clopidogrel; Humans; Platelet Aggregation Inhibitors; Ticagrelor; Ticlopidi | 2021 |
The FDA and PLATO Investigators death lists: Call for a match.
Topics: Acute Coronary Syndrome; Adenosine; Humans; Platelet Aggregation Inhibitors; Purinergic P2Y Receptor | 2021 |
Prasugrel switching from clopidogrel after percutaneous coronary intervention for acute coronary syndrome in Taiwanese patients: an analysis of safety and efficacy.
Topics: Acute Coronary Syndrome; Aged; Clopidogrel; Female; Humans; Male; Percutaneous Coronary Intervention | 2022 |
Stronger inhibitory effects of Ticagrelor plus aspirin compared with Clopidogrel plus aspirin on arachidonic acid-induced platelet aggregation in patients with acute coronary syndrome with PCI.
Topics: Acute Coronary Syndrome; Adenosine; Arachidonic Acid; Aspirin; Clopidogrel; Humans; Percutaneous Cor | 2021 |
Cost-Effectiveness of Ticagrelor Compared with Clopidogrel in Patients with Acute Coronary Syndrome from Vietnamese Healthcare Payers' Perspective.
Topics: Acute Coronary Syndrome; Adenosine; Asian People; Clopidogrel; Cost-Benefit Analysis; Drug Costs; Hu | 2021 |
Pre-treatment with dual antiplatelet therapy in non-ST-segment elevation acute coronary syndromes: landing from guidelines recommendations to real-world ground.
Topics: Acute Coronary Syndrome; Clopidogrel; Dual Anti-Platelet Therapy; Humans; Platelet Aggregation Inhib | 2021 |
Clinical events beyond one year after an acute coronary syndrome: insights from the RECLOSE 2-ACS study.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Clopidogrel; Female; Humans; Male; Mi | 2017 |
Prediction of high on-treatment platelet reactivity in clopidogrel-treated patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Clopidogrel; Female; Gene Regulatory Networks; Humans; Machine Learni | 2017 |
Impact of Diabetes Mellitus on the Pharmacodynamic Effects of Ticagrelor Versus Clopidogrel in Troponin-Negative Acute Coronary Syndrome Patients Undergoing Ad Hoc Percutaneous Coronary Intervention.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Blood Platelets; Clopidogrel; Comorbidity; Diabetes Mellit | 2017 |
Incidence and outcome of switching of oral platelet P2Y12 receptor inhibitors in patients with acute coronary syndromes undergoing percutaneous coronary intervention: the SCOPE registry.
Topics: Acute Coronary Syndrome; Aged; Aged, 80 and over; Blood Platelets; Clopidogrel; Female; Hemorrhage; | 2017 |
Short Communication: Evaluation of nephrotoxicity by aspirin-clopidogrel combination therapy in patients with acute coronary syndrome.
Topics: Acute Coronary Syndrome; Aspirin; Biomarkers; Blood Urea Nitrogen; Clopidogrel; Creatinine; Drug The | 2016 |
Gene variants in responsiveness to clopidogrel have no impact on clinical outcomes in Chinese patients undergoing percutaneous coronary intervention - A multicenter study.
Topics: Acute Coronary Syndrome; Aged; Asian People; Clopidogrel; Cohort Studies; Female; Follow-Up Studies; | 2017 |
GPIIb-IIIa Receptor Inhibitors in Acute Coronary Syndrome Patients Presenting With Cardiogenic Shock and/or After Cardiopulmonary Resuscitation.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Cardiopulmonary Resuscitation; Cause of Death; Clopidogrel | 2018 |
Associations between P2RY12 gene polymorphisms and risks of clopidogrel resistance and adverse cardiovascular events after PCI in patients with acute coronary syndrome.
Topics: Acute Coronary Syndrome; Aged; Clopidogrel; Drug Resistance; Female; Humans; Male; Middle Aged; Perc | 2017 |
Authors' reply.
Topics: Acute Coronary Syndrome; Humans; Platelet Aggregation Inhibitors; Platelet Function Tests; Point-of- | 2017 |
Antiplatelet therapy suspension in patients undergoing coronary surgery for acute coronary syndrome: Is point-of-care guided strategy the best choice?
Topics: Acute Coronary Syndrome; Coronary Artery Bypass; Humans; Platelet Aggregation Inhibitors; Point-of-C | 2017 |
[Contemporary use of ticagrelor in patients with acute coronary syndrome after discharge].
Topics: Acute Coronary Syndrome; Adenosine; Humans; Myocardial Infarction; Patient Discharge; Platelet Aggre | 2017 |
Vitamin D Binding Protein rs7041 polymorphism and high-residual platelet reactivity in patients receiving dual antiplatelet therapy with clopidogrel or ticagrelor.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Aspirin; Chi-Square Distribution; Clopidogrel; Coronary Ar | 2017 |
Comparative Effectiveness and Safety Analysis of Dual Antiplatelet Therapies Within an Integrated Delivery System.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Delivery of Health Care, Integrated; Female; | 2017 |
Effects of four novel genetic polymorphisms on clopidogrel efficacy in Chinese acute coronary syndromes patients.
Topics: Acute Coronary Syndrome; Aged; Case-Control Studies; Clopidogrel; Female; Genetic Loci; Humans; Male | 2017 |
Letter--Prudent Formulary Management or Underutilization of the Novel P2Y12 Receptor Inhibitors in Patients with Acute Coronary Syndrome Who Received Percutaneous Coronary Intervention?
Topics: Acute Coronary Syndrome; Humans; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors | 2017 |
[A Case of Intramural Hematoma of the Esophagus Mimicking Acute Coronary Syndrome].
Topics: Acute Coronary Syndrome; Clopidogrel; Diagnosis, Differential; Endoscopy, Gastrointestinal; Esophage | 2017 |
Balancing the risk of spontaneous ischemic and major bleeding events in acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Female; Fibrinolytic Agents; Hemorrhage; Huma | 2017 |
Gender-related differences in antiplatelet treatment patterns and outcome: Insights from the GReekAntiPlatElet Registry.
Topics: Acute Coronary Syndrome; Aged; Cardiovascular Diseases; Clopidogrel; Cohort Studies; Female; Greece; | 2017 |
Predicting long-term bleeding risk after acute coronary syndrome: a step closer to optimising dual antiplatelet therapy duration?
Topics: Acute Coronary Syndrome; Aspirin; Drug Therapy, Combination; Humans; Platelet Aggregation Inhibitors | 2017 |
Comparative Effectiveness of Oral Antiplatelet Agents in Patients with Acute Coronary Syndrome.
Topics: Acute Coronary Syndrome; Adenosine; Administration, Oral; Adult; Aged; Clopidogrel; Cohort Studies; | 2017 |
Use of prasugrel vs clopidogrel and outcomes in patients with acute coronary syndrome undergoing percutaneous coronary intervention in contemporary clinical practice: Results from the PROMETHEUS study.
Topics: Acute Coronary Syndrome; Aged; Cause of Death; Clopidogrel; Dose-Response Relationship, Drug; Female | 2017 |
Management of diabetic patients hospitalized for acute coronary syndromes: a prospective multicenter registry.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Aged, 80 and over; Clopidogrel; Coronary Angiography; Diab | 2017 |
Contemporary use of P2Y12-inhibitors in patients with acute coronary syndrome undergoing percutaneous coronary intervention in Austria: A prospective, multi-centre registry.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Aspirin; Austria; Clopidogrel; Female; Hemorrhage; Hospita | 2017 |
Reversal of the platelet inhibitory effect of the P2Y
Topics: Acute Coronary Syndrome; Adenosine; Blood Platelets; Clopidogrel; Female; Humans; Male; Platelet Agg | 2017 |
Cost-effectiveness analysis of 30-month vs 12-month dual antiplatelet therapy with clopidogrel and aspirin after drug-eluting stents in patients with acute coronary syndrome.
Topics: Acute Coronary Syndrome; Aspirin; Clopidogrel; Computer Simulation; Coronary Thrombosis; Cost-Benefi | 2017 |
Interaction between platelet-derived microRNAs and CYP2C19*2 genotype on clopidogrel antiplatelet responsiveness in patients with ACS.
Topics: Acute Coronary Syndrome; Blood Platelets; Clopidogrel; Cytochrome P-450 CYP2C19; Female; Genotype; H | 2017 |
CYP2C19-guided antiplatelet therapy: a cost-effectiveness analysis of 30-day and 1-year outcomes following percutaneous coronary intervention.
Topics: Acute Coronary Syndrome; Clopidogrel; Cost-Benefit Analysis; Cytochrome P-450 CYP2C19; Drug Costs; G | 2017 |
Associations Between Chronic Kidney Disease and Outcomes With Use of Prasugrel Versus Clopidogrel in Patients With Acute Coronary Syndrome Undergoing Percutaneous Coronary Intervention: A Report From the PROMETHEUS Study.
Topics: Acute Coronary Syndrome; Aged; Aged, 80 and over; Chi-Square Distribution; Clopidogrel; Coronary Thr | 2017 |
Temporal Trends in the Use of Antiplatelet Therapy in Patients With Acute Coronary Syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Age Factors; Aged; Clopidogrel; Female; Hospitalization; Humans; | 2018 |
[Dual Antiplatelet Therapy in the Perioperative Period - To Continue or Discontinue Treatment?]
Topics: Acute Coronary Syndrome; Aspirin; Clopidogrel; Drug Therapy, Combination; Humans; Perioperative Peri | 2017 |
Contemporary Time Trends in Use of Antiplatelet Agents Among Patients with Acute Coronary Syndrome and Comorbid Diabetes Mellitus or Chronic Kidney Disease.
Topics: Acute Coronary Syndrome; Adenosine; Clopidogrel; Cohort Studies; Diabetes Mellitus; Drug Utilization | 2017 |
Antiplatelet treatment in diabetic patients with acute coronary syndrome undergoing percutaneous coronary intervention: a GReek AntiPlatElet registry substudy.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Case-Control Studies; Clopidogrel; Cohort Studies; Comorbi | 2018 |
High risk of stent thrombosis in the first 6 months after coronary stenting: Do not discontinue clopidogrel early after ACS.
Topics: Acute Coronary Syndrome; Aged; Clopidogrel; Drug Administration Schedule; Female; Graft Occlusion, V | 2017 |
Effects of statin therapy on platelet reactivity after percutaneous coronary revascularization in patients with acute coronary syndrome.
Topics: Acute Coronary Syndrome; Aged; Aged, 80 and over; Clopidogrel; Humans; Hydroxymethylglutaryl-CoA Red | 2017 |
Changes in Treatment Patterns and Incremental Health Care Utilization Due to P2Y12-Associated Complications in Patients with Acute Coronary Syndrome.
Topics: Acute Coronary Syndrome; Adenosine; Adult; Aged; Aged, 80 and over; Clopidogrel; Female; Humans; Mal | 2017 |
Contemporary antiplatelet therapy in acute coronary syndromes: are there differences in outcomes and discontinuation between clopidogrel and ticagrelor?
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Cohort Studies; Female; Hemorrhage; Humans; M | 2017 |
Author's reply.
Topics: Acute Coronary Syndrome; Humans; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Ticlopidi | 2018 |
Safety and efficacy of prasugrel in East Asian patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Clopidogrel; Humans; Myocardial Infarction; Platelet Aggregation Inhibitors | 2018 |
In PCI-treated ACS, switching from aspirin + a newer P2Y12 blocker to aspirin + clopidogrel reduced adverse events.
Topics: Acute Coronary Syndrome; Aspirin; Clopidogrel; Humans; Platelet Aggregation Inhibitors; Ticlopidine | 2017 |
Comparison of 4 different strategies of DAPT after PCI in ACS real world population from a Northern Italy registry.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Aged, 80 and over; Clopidogrel; Female; Humans; Italy; Mal | 2017 |
Dual Antiplatelet Therapy Duration in Conservatively Managed Patients with Acute Coronary Syndrome: Any News?
Topics: Acute Coronary Syndrome; Aspirin; Drug Therapy, Combination; Humans; Percutaneous Coronary Intervent | 2017 |
Ticagrelor versus prasugrel in patients with acute coronary syndrome undergoing percutaneous coronary intervention: An unresolved issue.
Topics: Acute Coronary Syndrome; Adenosine; Humans; Percutaneous Coronary Intervention; Platelet Aggregation | 2017 |
Real-world clopidogrel utilization in acute coronary syndromes: patients selection and outcomes in a single-center experience.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Aged, 80 and over; Chi-Square Distribution; Clopidogrel; D | 2017 |
Dual antiplatelet therapy after acute coronary syndromes: no time for a CHANGE.
Topics: Acute Coronary Syndrome; Aspirin; Drug Therapy, Combination; Humans; Platelet Aggregation Inhibitors | 2017 |
Clopidogrel or ticagrelor in acute coronary syndrome patients treated with newer-generation drug-eluting stents: CHANGE DAPT.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Aged, 80 and over; Aspirin; Clopidogrel; Coronary Artery D | 2017 |
Cost-effectiveness of prasugrel versus clopidogrel in acute coronary syndrome patients undergoing percutaneous coronary intervention.
Topics: Acute Coronary Syndrome; Clopidogrel; Cost-Benefit Analysis; Humans; Percutaneous Coronary Intervent | 2018 |
Prasugrel vs clopidogrel in contemporary Western European patients with acute coronary syndromes receiving drug-eluting stents: Comparative cost-effectiveness analysis from the BASKET-PROVE cohorts - Response to the letter to the Editor.
Topics: Acute Coronary Syndrome; Clopidogrel; Cost-Benefit Analysis; Drug-Eluting Stents; Humans; Platelet A | 2018 |
Cigarette smoking reduces platelet reactivity independently of clopidogrel treatment in patients with non-ST elevation acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Aged, 80 and over; Biomarkers; Blood Platelets; Cigarette Smoking; Cl | 2018 |
Platelet function monitoring for stent thrombosis in critically III patients with an acute Coronary syndrome.
Topics: Acute Coronary Syndrome; Aged; Aged, 80 and over; Aspirin; Blood Platelets; Female; Humans; Male; Mi | 2018 |
Effect of cytochrome P450 2C19 polymorphism on adverse cardiovascular events after drug-eluting stent implantation in a large Hakka population with acute coronary syndrome receiving clopidogrel in southern China.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Asian People; Chi-Square Distribution; China; Clinical Dec | 2018 |
Comparison of Single Nucleotide Polymorphism genotyping of CYP2C19 by Loop-mediated isothermal amplification and real-time PCR melting curve analysis.
Topics: Acute Coronary Syndrome; Clopidogrel; Cytochrome P-450 CYP2C19; Genotype; Genotyping Techniques; Hum | 2018 |
Guided early deescalation of antiplatelet treatment was noninferior to usual prasugrel care in PCI-treated ACS.
Topics: Acute Coronary Syndrome; Humans; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors | 2017 |
Dual Antiplatelet Therapy Guided by CYP2C19 Polymorphisms after Implantation of Second-Generation Drug-Eluting Stents for Management of Acute Coronary Syndrome.
Topics: Acute Coronary Syndrome; Aged; Clopidogrel; Cytochrome P-450 CYP2C19; DNA; Dose-Response Relationshi | 2018 |
A synergic effect between CYP2C19*2, CYP2C19*3 loss-of-function and CYP2C19*17 gain-of-function alleles is associated with Clopidogrel resistance among Moroccan Acute Coronary Syndromes patients.
Topics: Acute Coronary Syndrome; Aged; Alleles; Clopidogrel; Cytochrome P-450 CYP2C19; Drug Resistance; Fema | 2018 |
An Evaluation of the Cost-effectiveness of Comprehensive MTM Integrated with Point-of-Care Phenotypic and Genetic Testing for U.S. Elderly Patients After Percutaneous Coronary Intervention.
Topics: Acute Coronary Syndrome; Adenosine; Age Factors; Aged; Clopidogrel; Community Pharmacy Services; Com | 2018 |
Effect of Antiplatelet Therapy on Cardiac Outcomes in Patients With Acute Coronary Syndrome.
Topics: Acute Coronary Syndrome; Clopidogrel; Humans; Out-of-Hospital Cardiac Arrest; Platelet Aggregation I | 2018 |
Antiplatelet Therapy in ACS Patients: Comparing Appropriate P2Y12 Inhibition by Clopidogrel to the Use of New P2Y12 Inhibitors.
Topics: Acute Coronary Syndrome; Adenosine; Adult; Aged; Aged, 80 and over; Clopidogrel; Female; Follow-Up S | 2018 |
Associations Between Complex PCI and Prasugrel or Clopidogrel Use in Patients With Acute Coronary Syndrome Who Undergo PCI: From the PROMETHEUS Study.
Topics: Acute Coronary Syndrome; Angioplasty, Balloon, Coronary; Clopidogrel; Cohort Studies; Combined Modal | 2018 |
[Temporal evolution of antithrombotic therapy use in patients with acute coronary syndromes undergoing percutaneous coronary intervention in Italy: comparison between the EYESHOT and SCOPE registries].
Topics: Acute Coronary Syndrome; Adenosine; Clopidogrel; Fibrinolytic Agents; Humans; Italy; Percutaneous Co | 2018 |
12 months of DAPT after acute coronary syndrome still beats 6 months.
Topics: Acute Coronary Syndrome; Aspirin; Drug Therapy, Combination; Drug-Eluting Stents; Humans; Percutaneo | 2018 |
Moving towards personalised antiplatelet therapy after PCI using risk scores.
Topics: Acute Coronary Syndrome; Hemorrhage; Humans; Percutaneous Coronary Intervention; Platelet Aggregatio | 2018 |
Optimal antiplatelet therapy after an acute coronary syndrome in the elderly: An old issue.
Topics: Acute Coronary Syndrome; Aged; Aspirin; Drug Therapy, Combination; Humans; Platelet Aggregation Inhi | 2018 |
Acute myocardial infarction occurring while on chronic clopidogrel therapy ('clopidogrel failure') is associated with high incidence of clopidogrel poor responsiveness and stent thrombosis.
Topics: Acute Coronary Syndrome; Aged; Aged, 80 and over; Clopidogrel; Female; Humans; Male; Middle Aged; My | 2018 |
Detection of individual responses to clopidogrel: Validation of a novel, rapid analysis using thrombelastography 6s.
Topics: Acute Coronary Syndrome; Adolescent; Adult; Aged; Area Under Curve; Case-Control Studies; Clopidogre | 2018 |
Health Economic Analysis of Antiplatelet Therapy for Acute Coronary Syndromes in the Context of Five Eastern Asian Countries.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Asia; China; Clinical Trials as Topic; Clopidogrel; Cost-B | 2018 |
Platelet Function Analyzer-200 P2Y Results Are Predictive of the Risk of Major Adverse Cardiac Events in Korean Patients Receiving Clopidogrel Therapy Following Acute Coronary Syndrome.
Topics: Acute Coronary Syndrome; Aged; Blood Platelets; Clopidogrel; Female; Humans; Male; Middle Aged; Myoc | 2018 |
Equilibrative nucleoside transporter 1 gene polymorphisms and clinical outcomes following acute coronary syndromes: findings from the PLATelet inhibition and patient Outcomes (PLATO) study.
Topics: Acute Coronary Syndrome; Biomarkers; Blood Platelets; Cause of Death; Clopidogrel; Equilibrative Nuc | 2019 |
Prasugrel in the Elderly.
Topics: Acute Coronary Syndrome; Aged; Clopidogrel; Humans; Prasugrel Hydrochloride; Purinergic P2Y Receptor | 2018 |
Evidences about combination use of acetylsalicylic acid (aspirin) and clopidogrel in acute coronary syndrome.
Topics: Acute Coronary Syndrome; Aspirin; Clopidogrel; Drug Interactions; Drug Therapy, Combination; Fibrino | 2017 |
Cessation of dual antiplatelet therapy and cardiovascular events following acute coronary syndrome.
Topics: Acute Coronary Syndrome; Aged; Aspirin; Cardiovascular Diseases; Drug Therapy, Combination; Female; | 2019 |
Comparison of 6-Month Costs Between Oral Antiplatelet Agents Following Acute Coronary Syndrome.
Topics: Acute Coronary Syndrome; Adenosine; Administration, Oral; Aged; Clopidogrel; Costs and Cost Analysis | 2018 |
Impact of Baseline Bleeding Risk on Efficacy and Safety of Ticagrelor versus Clopidogrel in Chinese Patients with Acute Coronary Syndrome Undergoing Percutaneous Coronary Intervention.
Topics: Acute Coronary Syndrome; Adenosine; Clopidogrel; Female; Hemorrhage; Humans; Male; Middle Aged; Perc | 2018 |
How to select antiplatelet therapy in patients with acute coronary syndrome, according to platelet function testing or pharmacogenomic testing?
Topics: Acute Coronary Syndrome; Aspirin; Blood Platelets; Drug Therapy, Combination; Humans; Percutaneous C | 2018 |
Response to Letter of Li et al.: How to select antiplatelet therapy in patients with acute coronary syndrome, according to platelet function testing or pharmacogenomic testing?
Topics: Acute Coronary Syndrome; Aspirin; Blood Platelets; Drug Therapy, Combination; Humans; Pharmacogenomi | 2018 |
Laboratory monitoring of P2Y
Topics: Acute Coronary Syndrome; Anticoagulants; Aspirin; Blood Coagulation; Cardiology; Clopidogrel; Geneti | 2018 |
Dual antiplatelet therapy duration in patients with ACS undergoing PCI: The "12 months tenet" is soundly questioned.
Topics: Acute Coronary Syndrome; Humans; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors | 2019 |
The association of clopidogrel and 2-oxo-clopidogrel plasma levels and the 40 months clinical outcome after primary PCI.
Topics: Acute Coronary Syndrome; Adult; Aged; Aged, 80 and over; Chest Pain; Clopidogrel; Coronary Artery Di | 2018 |
Topics: Acute Coronary Syndrome; Hospitalization; Humans; Percutaneous Coronary Intervention; Platelet Aggre | 2018 |
"No Such Thing as a Free Lunch": Personalized P2Y
Topics: Acute Coronary Syndrome; Aged; Clopidogrel; Humans; Platelet Aggregation Inhibitors; Prasugrel Hydro | 2019 |
PURL: Should you switch the DAPT agent one month after ACS?
Topics: Acute Coronary Syndrome; Aspirin; Humans; Platelet Aggregation Inhibitors; Ticlopidine | 2019 |
Short-term Safety and Mid-term Efficacy of Prasugrel Versus Clopidogrel in Patients Undergoing Percutaneous Coronary Intervention.
Topics: Acute Coronary Syndrome; Aged; Aspirin; Clopidogrel; Female; Humans; Male; Middle Aged; Percutaneous | 2019 |
[Double antiplatelet therapy in patients with acute coronary syndrome after percutaneous coronary intervention: individual efficacy and hemorrhagic safety of P2Y12 blockers of ticagrelor and clopidogrel in actual clinical practice].
Topics: Acute Coronary Syndrome; Adenosine; Clopidogrel; Humans; Percutaneous Coronary Intervention; Platele | 2019 |
[Experience with Prasugrel in the Treatment of Patients with Acute Coronary Syndrome].
Topics: Acute Coronary Syndrome; Adenosine; Humans; Percutaneous Coronary Intervention; Platelet Aggregation | 2019 |
[Chinese experts consensus on antiplatelet therapy for medically managed acute coronary syndromes (2018)].
Topics: Acute Coronary Syndrome; Consensus; Drug Therapy, Combination; Humans; Platelet Aggregation Inhibito | 2019 |
Descriptive analysis of real-world medication use pattern of statins and antiplatelet agents among patients with acute coronary syndrome in Hong Kong and the USA.
Topics: Acute Coronary Syndrome; Administration, Oral; Aged; Clopidogrel; Databases, Factual; Drug Therapy, | 2019 |
Exploring the ticagrelor-statin interplay in the PLATO trial.
Topics: Acute Coronary Syndrome; Adenosine; Clinical Trials, Phase III as Topic; Clopidogrel; Cytochrome P-4 | 2013 |
Switching from prasugrel to clopidogrel: navigating in unknown waters.
Topics: Acute Coronary Syndrome; Blood Platelets; Clopidogrel; Drug Substitution; Female; Humans; Male; Pipe | 2013 |
Switching acute coronary syndrome patients from prasugrel to clopidogrel.
Topics: Acute Coronary Syndrome; Aged; Biomarkers; Blood Platelets; Cell Adhesion Molecules; Chi-Square Dist | 2013 |
[Gastrointestinal bleeding after treatment with ticagrelor].
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Coronary Artery Bypass; Female; Gastrointesti | 2013 |
Effects of coexisting polymorphisms of CYP2C19 and P2Y12 on clopidogrel responsiveness and clinical outcome in patients with acute coronary syndromes undergoing stent-based coronary intervention.
Topics: Acute Coronary Syndrome; Aged; Alleles; Aryl Hydrocarbon Hydroxylases; Clopidogrel; Cytochrome P-450 | 2013 |
Safety and efficacy of intense antithrombotic treatment and percutaneous coronary intervention deferral in patients with large intracoronary thrombus.
Topics: Acute Coronary Syndrome; Angiography; Angioplasty, Balloon, Coronary; Anticoagulants; Aspirin; Clopi | 2013 |
Correlation of platelet reactivity and C-reactive protein levels to occurrence of peri-procedural myocardial infarction in patients undergoing percutaneous coronary intervention (from the ARMYDA-CRP study).
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Biomarkers; C-Reactive Protein; Clopi | 2013 |
Lifetime cost-effectiveness analysis of ticagrelor in patients with acute coronary syndromes based on the PLATO trial: a Singapore healthcare perspective.
Topics: Acute Coronary Syndrome; Adenosine; Aspirin; Clinical Trials as Topic; Clopidogrel; Cost-Benefit Ana | 2013 |
[Effect of intracoronary and intravenous administration of tirofiban loading dose in patients underwent percutaneous coronary interventions because of acute coronary syndrome].
Topics: Acute Coronary Syndrome; Aged; Aspirin; Clopidogrel; Dose-Response Relationship, Drug; Drug Administ | 2013 |
Ticagrelor improves peripheral arterial function in patients with a previous acute coronary syndrome.
Topics: Acute Coronary Syndrome; Adenosine; Aspirin; Blood Pressure; Case-Control Studies; Clopidogrel; Endo | 2013 |
[Influence of the combination of antiplatelet agents on the occurrence of early left ventricular insufficiency in patients with acute coronary syndromes without persistent ST-segment elevation].
Topics: Acute Coronary Syndrome; Aged; Aged, 80 and over; Aspirin; Clopidogrel; Drug Therapy, Combination; F | 2014 |
Cost-effectiveness of universal and platelet reactivity assay-driven antiplatelet therapy in acute coronary syndrome.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Cohort Studies; Cost-Benefit Analysis; Decisi | 2013 |
Spontaneous platelet aggregation in patients with acute coronary syndrome.
Topics: Acute Coronary Syndrome; Alprostadil; Antibodies; Aspirin; Blood Platelets; Clopidogrel; Humans; Pla | 2013 |
[Interview with the Daiichi-Sankyo managing director Ralf Göddertz (interview by Dirk Einecke and Cornelius Heyer)].
Topics: Acute Coronary Syndrome; Adenosine; Clopidogrel; Cost Savings; Cost-Benefit Analysis; Drug Costs; Dr | 2013 |
Proton-pump inhibitors can decrease gastrointestinal bleeding after percutaneous coronary intervention.
Topics: Acute Coronary Syndrome; Age Factors; Aged; Alcohol Drinking; Angina, Stable; Aspirin; Case-Control | 2013 |
Chronic kidney disease is associated with adverse outcomes among elderly patients taking clopidogrel after hospitalization for acute coronary syndrome.
Topics: Acute Coronary Syndrome; Age Factors; Aged; Aged, 80 and over; Clopidogrel; Cohort Studies; Female; | 2013 |
Genetic determinants of high on-treatment platelet reactivity in clopidogrel treated Chinese patients.
Topics: Acute Coronary Syndrome; Aged; Aryl Hydrocarbon Hydroxylases; Aryldialkylphosphatase; Asian People; | 2013 |
Viewpoint: mismatch between the European and American guidelines on oral antiplatelet P2Y12 inhibitors after acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Administration, Oral; Clinical Trials as Topic; Clopidogrel; Eur | 2013 |
Differences between ACC/AHA and ESC Guidelines on antiplatelet therapy in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Clinical Trials as Topic; Clopidogrel; Europe; Evidence-Based Me | 2013 |
Is clopidogrel adequate in 2013?
Topics: Acute Coronary Syndrome; Adenosine; Administration, Oral; Clopidogrel; Hemorrhage; Humans; Platelet | 2013 |
P2Y12 receptor gene polymorphism and antiplatelet effect of clopidogrel in patients with coronary artery disease after coronary stenting.
Topics: Acute Coronary Syndrome; Adenosine Diphosphate; Adult; Aged; Blood Platelets; Clopidogrel; Female; G | 2013 |
Predictors of bleeding in acute coronary syndromes with clopidogrel and prasugrel.
Topics: Acute Coronary Syndrome; Angioplasty, Balloon, Coronary; Clopidogrel; Follow-Up Studies; Hemorrhage; | 2013 |
Predictors of myocardial infarction after an acute coronary syndrome with clopidogrel and prasugrel.
Topics: Acute Coronary Syndrome; Clopidogrel; Follow-Up Studies; Humans; Myocardial Infarction; Piperazines; | 2013 |
[Relevance of CYP2C19 2 regarding platelet reactivity in patients with acute coronary syndrome treated with clopidogrel].
Topics: Acute Coronary Syndrome; Aged; Alleles; Angina, Unstable; Aryldialkylphosphatase; Biotransformation; | 2014 |
Gastrointestinal adverse events after dual antiplatelet therapy: clopidogrel is safer than ticagrelor, but prasugrel data are lacking or inconclusive.
Topics: Acute Coronary Syndrome; Adenosine; Aspirin; Chemical and Drug Induced Liver Injury; Clinical Trials | 2013 |
P2Y12 Receptor Blockade and Myocardial Perfusion.
Topics: Acute Coronary Syndrome; Adenosine; Clopidogrel; Coronary Angiography; Coronary Stenosis; Coronary T | 2013 |
Personalised antiplatelet therapy: are we ready for prime time? Data from China.
Topics: Acute Coronary Syndrome; Aryl Hydrocarbon Hydroxylases; Clopidogrel; Cytochrome P-450 CYP2C19; Drug | 2013 |
Clinical assessment, platelet reactivity measurement or genetic testing after acute coronary syndrome? What benefits the patient?
Topics: Acute Coronary Syndrome; Aryl Hydrocarbon Hydroxylases; Clopidogrel; Cytochrome P-450 CYP2C19; Drug | 2013 |
The impact of gene polymorphism and high on-treatment platelet reactivity on clinical follow-up: outcomes in patients with acute coronary syndrome after drug-eluting stent implantation.
Topics: Acute Coronary Syndrome; Aged; Aryl Hydrocarbon Hydroxylases; ATP Binding Cassette Transporter, Subf | 2013 |
Long-term effect of dual antiplatelet treatment after off-pump coronary artery bypass grafting.
Topics: Acute Coronary Syndrome; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Cohort Studies; Corona | 2013 |
Platelet reactivity in the early and late phases of acute coronary syndromes according to cytochrome P450 2C19 phenotypes.
Topics: Acute Coronary Syndrome; Aged; Aged, 80 and over; Alleles; Aryl Hydrocarbon Hydroxylases; Asian Peop | 2013 |
Cost-effectiveness of 12-month treatment with ticagrelor compared with clopidogrel in the management of acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Australia; Clopidogrel; Coronary Artery Bypass; Cost-Benef | 2013 |
[The ARCTIC study].
Topics: Acute Coronary Syndrome; Aspirin; Clopidogrel; Drug-Eluting Stents; Heart Diseases; Humans; Myocardi | 2013 |
Provision of gastroprotective medication and bleeding risk following acute coronary syndrome.
Topics: Acute Coronary Syndrome; Aged; Aged, 80 and over; Clopidogrel; Female; Gastrointestinal Hemorrhage; | 2013 |
Effectiveness of switching 'hyper responders' from Prasugrel to Clopidogrel after acute coronary syndrome: the POBA (Predictor of Bleeding with Antiplatelet drugs) SWITCH study.
Topics: Acute Coronary Syndrome; Clopidogrel; Drug Substitution; Female; Humans; Male; Middle Aged; Percutan | 2013 |
Plasma and whole blood clot strength measured by thrombelastography in patients treated with clopidogrel during acute coronary syndromes.
Topics: Acute Coronary Syndrome; C-Reactive Protein; Clopidogrel; Female; Fibrinogen; Humans; Male; Middle A | 2013 |
Identification of poor response to P2Y12 inhibitors in ACS patients with a new ELISA-based vasodilator-associated stimulated phosphoprotein (VASP) phosphorylation assay.
Topics: Acute Coronary Syndrome; Aged; Anticoagulants; Cell Adhesion Molecules; Cell Separation; Clopidogrel | 2013 |
Pharmacodynamic effect of clopidogrel in patients undergoing transcatheter aortic valve implantation.
Topics: Acute Coronary Syndrome; Aged; Aged, 80 and over; Aortic Valve; Blood Platelets; Blood Vessel Prosth | 2013 |
Clinical implications of very low on-treatment platelet reactivity in patients treated with thienopyridine: the POBA study (predictor of bleedings with antiplatelet drugs).
Topics: Acute Coronary Syndrome; Aged; Aged, 80 and over; Area Under Curve; Biomarkers; Cell Adhesion Molecu | 2013 |
Bleeding and thrombosis risk matters: how long can we stick to the one-size-fits-all strategy of platelet inhibition?
Topics: Acute Coronary Syndrome; Clopidogrel; Female; Hemorrhage; Humans; Male; Percutaneous Coronary Interv | 2013 |
Effects of clopidogrel on mortality, cardiovascular and bleeding outcomes in patients with chronic kidney disease - data from Taiwan acute coronary syndrome full spectrum registry.
Topics: Acute Coronary Syndrome; Aged; Aged, 80 and over; Clopidogrel; Female; Hemorrhage; Humans; Kaplan-Me | 2013 |
Stratified reporting of high sensitivity troponin I assay is associated with suboptimal management of patients with acute coronary syndrome and intermediate troponin elevation.
Topics: Acute Coronary Syndrome; Aged; Anticoagulants; Clopidogrel; Cohort Studies; Coronary Angiography; Fe | 2013 |
Expert position paper on the role of platelet function testing in patients undergoing percutaneous coronary intervention.
Topics: Acute Coronary Syndrome; Aspirin; Clopidogrel; Dose-Response Relationship, Drug; Drug Substitution; | 2014 |
Impact of initial clinical presentation on clopidogrel low response.
Topics: Acute Coronary Syndrome; Aged; Blood Platelets; Chi-Square Distribution; Clopidogrel; Coronary Arter | 2013 |
Predictors of 1-year outcomes in the Taiwan Acute Coronary Syndrome Full Spectrum Registry.
Topics: Acute Coronary Syndrome; Aged; Aspirin; Clopidogrel; Drug-Eluting Stents; Female; Follow-Up Studies; | 2014 |
Duration of dual antiplatelet treatment with clopidogrel and aspirin in patients with acute coronary syndrome.
Topics: Acute Coronary Syndrome; Aged; Aspirin; Clopidogrel; Drug Therapy, Combination; Drug-Eluting Stents; | 2014 |
Value of high-sensitivity troponin in assessing the extent of benefit provided by ticagrelor versus clopidogrel in non-ST-segment elevation acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Clopidogrel; Humans; Myocardial Revascularization; Ticagrelor; T | 2014 |
Impact of CYP2C19 genetic testing on provider prescribing patterns for antiplatelet therapy after acute coronary syndromes and percutaneous coronary intervention.
Topics: Acute Coronary Syndrome; Aged; Alleles; Aryl Hydrocarbon Hydroxylases; Biotransformation; Clopidogre | 2013 |
Impact of -455G/a polymorphism of the β-fibrinogen gene on platelet aggregation in patients with acute coronary syndrome.
Topics: Acute Coronary Syndrome; Aspirin; Clopidogrel; Female; Fibrinogen; Genetic Predisposition to Disease | 2014 |
Predictors, cost, and outcomes of patients with acute coronary syndrome who receive optimal secondary prevention therapy: results from the antiplatelet treatment observational registries (APTOR).
Topics: Acute Coronary Syndrome; Adrenergic beta-Antagonists; Aged; Angiotensin-Converting Enzyme Inhibitors | 2013 |
Drug interactions with good old clopidogrel: case closed.
Topics: Acute Coronary Syndrome; Calcium Channel Blockers; Clopidogrel; Female; Humans; Hydroxymethylglutary | 2013 |
Antiplatelet therapy: DAPT for 3 months is sufficient.
Topics: Acute Coronary Syndrome; Aspirin; Coronary Artery Disease; Drug-Eluting Stents; Female; Humans; Male | 2014 |
The enigmatic search for optimal DAPT duration.
Topics: Acute Coronary Syndrome; Aspirin; Clopidogrel; Female; Humans; Male; Platelet Aggregation Inhibitors | 2014 |
Cost-effectiveness of using CYP2C19 genotype to guide selection of clopidogrel or ticagrelor in Australia.
Topics: Acute Coronary Syndrome; Adenosine; Alleles; Aryl Hydrocarbon Hydroxylases; Australia; Clopidogrel; | 2013 |
Sex differences in the treatment and outcome of patients with acute coronary syndrome after percutaneous coronary intervention: a population-based study.
Topics: Acute Coronary Syndrome; Aspirin; Clopidogrel; Female; Humans; Insurance, Health; Male; Odds Ratio; | 2014 |
Japanese postmarketing surveillance of clopidogrel for patients with non-ST-segment-elevation acute coronary syndrome indicated for percutaneous coronary intervention (J-PLACE NSTE-ACS).
Topics: Acute Coronary Syndrome; Adult; Aged; Clopidogrel; Female; Follow-Up Studies; Humans; Japan; Kaplan- | 2014 |
Health-related quality of life in patients with acute coronary syndromes and treated with ticagrelor or clopidogrel.
Topics: Acute Coronary Syndrome; Adenosine; Female; Humans; Male; Platelet Aggregation Inhibitors; Quality o | 2014 |
In-hospital switching of oral P2Y12 inhibitor treatment in patients with acute coronary syndrome undergoing percutaneous coronary intervention: prevalence, predictors and short-term outcome.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Female; Humans; Male; Middle Aged; Multivaria | 2014 |
Ticagrelor as an alternative in clopidogrel-associated neutropenia.
Topics: Acute Coronary Syndrome; Adenosine; Aged, 80 and over; Angioplasty, Balloon, Coronary; Clopidogrel; | 2015 |
A platelet P-selectin test predicts adverse cardiovascular events in patients with acute coronary syndromes treated with aspirin and clopidogrel.
Topics: Acute Coronary Syndrome; Aspirin; Clopidogrel; Female; Humans; Male; P-Selectin; Platelet Aggregatio | 2014 |
Variation in thromboxane B2 concentrations in serum and plasma in patients taking regular aspirin before and after clopidogrel therapy.
Topics: Acute Coronary Syndrome; Aged; Aspirin; Clopidogrel; Cross-Sectional Studies; Drug Therapy, Combinat | 2015 |
Fixed-dose aspirin-clopidogrel combination enhances compliance to aspirin after acute coronary syndrome.
Topics: Acute Coronary Syndrome; Aged; Aged, 80 and over; Aspirin; Clopidogrel; Coronary Thrombosis; Dose-Re | 2014 |
[The effects of cytochrome P450 2C19 genetic polymorphism on clopidogrel resistance and recent prognosis of patients with acute coronary syndrome].
Topics: Acute Coronary Syndrome; Clopidogrel; Cytochrome P-450 CYP2C19; Drug Resistance; Female; Genotype; H | 2013 |
Adenosine diphosphate-induced single-platelet count aggregation and bleeding in clopidogrel-treated patients undergoing coronary artery bypass grafting.
Topics: Acute Coronary Syndrome; Adenosine Diphosphate; Aged; Anesthesia; Aspirin; Blood Transfusion; Chest | 2014 |
Diagnostic accuracy of mean platelet volume in prediction of clopidogrel resistance in patients with acute coronary syndrome.
Topics: Acute Coronary Syndrome; Adenosine Diphosphate; Area Under Curve; Blood Platelets; Clopidogrel; Coho | 2014 |
P2Y12-based platelet function assays should be complemented with cyclooxygenase-dependent testing in framing the therapeutic windows for dual antiplatelet therapy.
Topics: Acute Coronary Syndrome; Female; Hemorrhage; Humans; Male; Percutaneous Coronary Intervention; Piper | 2014 |
Reply: P2Y12-Based platelet function assays should be complemented with cyclooxygenase-dependent testing in framing the therapeutic windows for dual antiplatelet therapy.
Topics: Acute Coronary Syndrome; Female; Hemorrhage; Humans; Male; Percutaneous Coronary Intervention; Piper | 2014 |
Discrepancies in the primary PLATO trial publication and the FDA reviews.
Topics: Acute Coronary Syndrome; Adenosine; Clinical Trials, Phase III as Topic; Clopidogrel; Congresses as | 2014 |
Angiographic outcomes contradict platelet data in the PLATO trial: confusion over official trial substudies.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Blood Platelets; Clopidogrel; Coronary Angiography; Corona | 2014 |
Smoking status and the effects of antiplatelet drugs.
Topics: Acute Coronary Syndrome; Adenosine; Aspirin; Clopidogrel; Female; Humans; Male; Piperazines; Platele | 2013 |
Optimizing P2Y12 receptor inhibition in patients with acute coronary syndrome on the basis of platelet function testing: impact of prasugrel and high-dose clopidogrel.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Cause of Death; Clopidogrel; Combined | 2014 |
Individualized strategy for clopidogrel suspension in patients undergoing off-pump coronary surgery for acute coronary syndrome: a case-control study.
Topics: Acute Coronary Syndrome; Case-Control Studies; Clopidogrel; Coronary Artery Bypass, Off-Pump; Female | 2014 |
Duration of dual antiplatelet therapy following percutaneous coronary intervention on re-hospitalization for acute coronary syndrome.
Topics: Acute Coronary Syndrome; Aged; Aspirin; Chi-Square Distribution; Clopidogrel; Drug Administration Sc | 2014 |
Clopidogrel and proton pump inhibitors.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Acute Coronary Syndrome; Clinical Trials as Topic; Clopidog | 2014 |
[Effect of drug interaction between clopidogrel and omeprazole in hospital readmision of patients by a recurrent acute coronary syndrome: a case-control study].
Topics: Acute Coronary Syndrome; Aged; Aged, 80 and over; Case-Control Studies; Clopidogrel; Drug Interactio | 2014 |
Differences in thrombus structure and kinetics in patients with type 2 diabetes mellitus after non ST elevation acute coronary syndrome.
Topics: Acute Coronary Syndrome; Aged; Aspirin; Clopidogrel; Diabetes Mellitus, Type 2; Female; Humans; Male | 2014 |
Association between the microarray-based CYP2C19 genotyping assay and the platelet function test in cardiovascular patients receiving clopidogrel.
Topics: Acute Coronary Syndrome; Adenosine Diphosphate; Alleles; Asian People; Aspirin; Blood Platelets; Clo | 2014 |
Evaluation of platelet response to different clopidogrel dosing regimens in patients with acute coronary syndrome in clinical practice.
Topics: Acute Coronary Syndrome; Aged; Blood Platelets; Clopidogrel; Electrocardiography; Female; Humans; Ma | 2015 |
"East asian paradox": challenge for the current antiplatelet strategy of "one-guideline-fits-all races" in acute coronary syndrome.
Topics: Acute Coronary Syndrome; Asia, Eastern; Asian People; Blood Platelets; Clopidogrel; Drug Administrat | 2014 |
Prasugrel overcomes high on-clopidogrel platelet reactivity in the acute phase of acute coronary syndrome and maintains its antiplatelet potency at 30-day follow-up.
Topics: Acute Coronary Syndrome; Adolescent; Adult; Aged; Blood Platelets; Clopidogrel; Coronary Angiography | 2014 |
Dual antiplatelet therapy after stent implantation.
Topics: Acute Coronary Syndrome; Aspirin; Coronary Artery Disease; Drug-Eluting Stents; Female; Humans; Male | 2014 |
Dual antiplatelet therapy after stent implantation--reply.
Topics: Acute Coronary Syndrome; Aspirin; Coronary Artery Disease; Drug-Eluting Stents; Female; Humans; Male | 2014 |
Cost-effectiveness of genotype-guided and dual antiplatelet therapies in acute coronary syndrome.
Topics: Acute Coronary Syndrome; Adenosine; Alleles; Aryl Hydrocarbon Hydroxylases; Clopidogrel; Coronary Th | 2014 |
Severe left ventricular systolic dysfunction is independently associated with high on-clopidogrel platelet reactivity.
Topics: Acute Coronary Syndrome; Aged; Blood Platelets; Cell Adhesion Molecules; Clopidogrel; Female; Humans | 2014 |
Letter by Grbel et al regarding article, "administration of a loading dose has no additive effect on platelet aggregation during the switch from ongoing clopidogrel treatment to ticagrelor in patients with acute coronary syndrome".
Topics: Acute Coronary Syndrome; Adenosine; Female; Humans; Male; Platelet Aggregation Inhibitors; Ticlopidi | 2014 |
Is it appropriate to compare the results from two clinical trials with one drug in common?
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Female; Humans; Male; Piperazines; Platelet A | 2013 |
Evaluation of comparative treatment effects using indirect comparisons.
Topics: Acute Coronary Syndrome; Adenosine; Female; Humans; Male; Piperazines; Platelet Aggregation Inhibito | 2013 |
Evaluation of comparative treatment effects using indirect comparisons. Response.
Topics: Acute Coronary Syndrome; Adenosine; Female; Humans; Male; Piperazines; Platelet Aggregation Inhibito | 2013 |
Platelet reactivity in comatose survivors of cardiac arrest undergoing percutaneous coronary intervention and hypothermia.
Topics: Acute Coronary Syndrome; Aged; Aged, 80 and over; Blood Platelets; Cardiopulmonary Resuscitation; Ca | 2015 |
Platelet reactivity in comatose survivors of cardiac arrest undergoing percutaneous coronary intervention and hypothermia.
Topics: Acute Coronary Syndrome; Aged; Aged, 80 and over; Blood Platelets; Cardiopulmonary Resuscitation; Ca | 2015 |
Platelet reactivity in comatose survivors of cardiac arrest undergoing percutaneous coronary intervention and hypothermia.
Topics: Acute Coronary Syndrome; Aged; Aged, 80 and over; Blood Platelets; Cardiopulmonary Resuscitation; Ca | 2015 |
Platelet reactivity in comatose survivors of cardiac arrest undergoing percutaneous coronary intervention and hypothermia.
Topics: Acute Coronary Syndrome; Aged; Aged, 80 and over; Blood Platelets; Cardiopulmonary Resuscitation; Ca | 2015 |
Viewpoint: "underutilisation of novel antiplatelet agents--myths, generics, and economics".
Topics: Acute Coronary Syndrome; Adenosine; Clinical Trials as Topic; Clopidogrel; Cost-Benefit Analysis; Dr | 2014 |
There's life in the old dog yet: clopidogrel competing with prasugrel and ticagrelor for treatment of ACS patients.
Topics: Acute Coronary Syndrome; Adenosine; Clinical Trials as Topic; Clopidogrel; Drug Substitution; Drug T | 2014 |
Utilisation of novel anti-platelet agents: evidence, guidelines and proven patients' value.
Topics: Acute Coronary Syndrome; Adenosine; Clinical Trials as Topic; Clopidogrel; Costs and Cost Analysis; | 2014 |
Mean platelet volume may not be related to clopidogrel resistance in patients with acute coronary syndrome.
Topics: Acute Coronary Syndrome; Adenosine Diphosphate; Blood Platelets; Female; Humans; Male; Ticlopidine | 2014 |
Switching patients from clopidogrel to novel P2Y12 receptor inhibitors in acute coronary syndrome: comparative effects of prasugrel and ticagrelor on platelet reactivity.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Blood Platelets; Clopidogrel; Drug Substitution; Female; H | 2014 |
Letter by Roguin and Musallam regarding article, "Stent thrombosis with ticagrelor versus clopidogrel in patients with acute coronary syndromes: an analysis from the prospective, randomized PLATO trial".
Topics: Acute Coronary Syndrome; Adenosine; Coronary Thrombosis; Female; Humans; Internationality; Male; Ste | 2014 |
Response to letter regarding article, "Stent thrombosis with ticagrelor versus clopidogrel in patients with acute coronary syndromes: an analysis from the prospective, randomized PLATO trial".
Topics: Acute Coronary Syndrome; Adenosine; Coronary Thrombosis; Female; Humans; Internationality; Male; Ste | 2014 |
Direct healthcare costs and cost-effectiveness of acute coronary syndrome secondary prevention with ticagrelor compared to clopidogrel: economic evaluation from the public payer's perspective in Poland based on the PLATO trial results.
Topics: Acute Coronary Syndrome; Adenosine; Adult; Aged; Aged, 80 and over; Clopidogrel; Cost-Benefit Analys | 2014 |
Projected inhibition of platelet aggregation with ticagrelor twice daily vs. clopidogrel once daily based on patient adherence data (the TWICE project).
Topics: Acute Coronary Syndrome; Adenosine; Clopidogrel; Drug Administration Schedule; Humans; Medication Ad | 2014 |
[Multination clinical trials: what is the relevance and what are the lessons from across-country differences?].
Topics: Acute Coronary Syndrome; Adenosine; Americas; Benzazepines; Cardiovascular Agents; Cardiovascular Di | 2014 |
Acute coronary syndrome antiplatelet alternatives in clopidogrel allergy.
Topics: Acute Coronary Syndrome; Adenosine; Adult; Aged; Clopidogrel; Drug Hypersensitivity; Female; Humans; | 2014 |
Pre-specified vs. post-hoc subgroup analyses: are we wiser before or after a trial has been performed?
Topics: Acute Coronary Syndrome; Adenosine; Clopidogrel; Female; Humans; Male; Platelet Aggregation Inhibito | 2014 |
No misrepresentation of vital status follow-up in PLATO: predefined analyses guarantee the integrity of the benefits of ticagrelor over clopidogrel in the PLATO trial: Commentary on: DiNicolantonio JJ, Tomek A, Misrepresentation of vital status follow-up:
Topics: Acute Coronary Syndrome; Adenosine; Advisory Committees; Clinical Trials as Topic; Clinical Trials, | 2014 |
The importance of genotype variation beyond different antiplatelet therapy in nonresponder patients.
Topics: Acute Coronary Syndrome; Cause of Death; Female; Humans; Male; Piperazines; Purinergic P2Y Receptor | 2014 |
Reply: The importance of genotype variation beyond different antiplatelet therapy in nonresponder patients.
Topics: Acute Coronary Syndrome; Cause of Death; Female; Humans; Male; Piperazines; Purinergic P2Y Receptor | 2014 |
Real-world observations with prasugrel compared to clopidogrel in acute coronary syndrome patients treated with percutaneous coronary intervention in the United States.
Topics: Acute Coronary Syndrome; Aged; Clopidogrel; Female; Hemorrhage; Hospitalization; Humans; Male; Middl | 2014 |
Ticagrelor and the prevention of cardiovascular mortality: more than just platelet inhibition?
Topics: Acute Coronary Syndrome; Adenosine; Cause of Death; Clopidogrel; Female; Humans; Male; Ticagrelor; T | 2014 |
Salvianolic acid B inhibits platelets as a P2Y12 antagonist and PDE inhibitor: evidence from clinic to laboratory.
Topics: Acute Coronary Syndrome; Aged; Aspirin; Benzofurans; Blood Platelets; Clopidogrel; Drugs, Chinese He | 2014 |
Mean platelet volume may not be related to clopidogrel resistance in patients with acute coronary syndrome. Author's reply.
Topics: Acute Coronary Syndrome; Adenosine Diphosphate; Blood Platelets; Female; Humans; Male; Ticlopidine | 2014 |
[Long-term cost-effectiveness of ticagrelor versus clopidogrel in acute coronary syndrome in Spain].
Topics: Acute Coronary Syndrome; Adenosine; Aspirin; Clopidogrel; Cost-Benefit Analysis; Female; Humans; Mal | 2014 |
Response to letter regarding, "administration of a loading dose has no additive effect on platelet aggregation during the switch from ongoing clopidogrel treatment to ticagrelor in patients with acute coronary syndrome".
Topics: Acute Coronary Syndrome; Adenosine; Female; Humans; Male; Platelet Aggregation Inhibitors; Ticlopidi | 2014 |
Comparison of the effect of CYP2C19 polymorphism on clinical outcome between acute coronary syndrome and stable angina.
Topics: Acute Coronary Syndrome; Aged; Alleles; Angina, Stable; Aspirin; Blood Platelets; Clopidogrel; Cytoc | 2015 |
Tailored antiplatelet therapy to improve prognosis in patients exhibiting clopidogrel low-response prior to percutaneous coronary intervention for stable angina or non-ST elevation acute coronary syndrome.
Topics: Acute Coronary Syndrome; Angina, Stable; Clopidogrel; Female; Humans; Male; Percutaneous Coronary In | 2015 |
Impact of gene polymorphisms, platelet reactivity, and the SYNTAX score on 1-year clinical outcomes in patients with non-ST-segment elevation acute coronary syndrome undergoing percutaneous coronary intervention: the GEPRESS study.
Topics: Acute Coronary Syndrome; Aged; Biotransformation; Blood Platelets; Clopidogrel; Coronary Angiography | 2014 |
Prasugrel vs. clopidogrel in acute coronary syndrome patients treated with prasugrel.
Topics: Acute Coronary Syndrome; Aged; Bayes Theorem; Clopidogrel; Cohort Studies; Female; Hospitalization; | 2014 |
How to optimize an individualized strategy for antiplatelet drug administration and discontinuation management using platelet function testing?
Topics: Acute Coronary Syndrome; Clopidogrel; Coronary Artery Bypass, Off-Pump; Female; Humans; Male; Platel | 2014 |
Reply to the editor.
Topics: Acute Coronary Syndrome; Clopidogrel; Coronary Artery Bypass, Off-Pump; Female; Humans; Male; Platel | 2014 |
Safety and efficacy of in-hospital clopidogrel-to-prasugrel switching in patients with acute coronary syndrome. An analysis from the 'real world'.
Topics: Acute Coronary Syndrome; Aged; Aged, 80 and over; Aspirin; Clopidogrel; Drug Substitution; Female; H | 2015 |
Individualising dual antiplatelet therapy after percutaneous coronary intervention: the IDEAL-PCI registry.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Angioplasty, Balloon, Coronary; Aspirin; Blood Platelets; | 2014 |
Kounis syndrome secondary to food allergy.
Topics: Acute Coronary Syndrome; Adrenal Cortex Hormones; Anti-Allergic Agents; Aspirin; Clopidogrel; Electr | 2014 |
Optimising pharmacotherapy for secondary prevention of non-invasively managed acute coronary syndrome.
Topics: Acute Coronary Syndrome; Adrenergic beta-Antagonists; Angiotensin-Converting Enzyme Inhibitors; Anti | 2014 |
A new mechanism of action of thienopyridine antiplatelet drugs - a role for gastric nitrosthiol metabolism?
Topics: Acute Coronary Syndrome; Blood Platelets; Clopidogrel; Gastric Mucosa; Humans; Hydrogen-Ion Concentr | 2014 |
Right here waiting...?
Topics: Acute Coronary Syndrome; Clopidogrel; Coronary Artery Bypass; Humans; Platelet Aggregation Inhibitor | 2014 |
Joint effects of CYP2C19*2 and smoking status on clopidogrel responsiveness in patients with acute coronary syndrome.
Topics: Acute Coronary Syndrome; Clopidogrel; Cytochrome P-450 CYP2C19; DNA; Female; Humans; Male; Middle Ag | 2015 |
Concomitant use of warfarin and ticagrelor as an alternative to triple antithrombotic therapy after an acute coronary syndrome.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Aged, 80 and over; Aspirin; Atrial Fibrillation; Clopidogr | 2015 |
Patterns of Antiplatelet Therapy in Patients Who Have Experienced an Acute Coronary Event: A Descriptive Study in UK Primary Care.
Topics: Acute Coronary Syndrome; Aged; Aged, 80 and over; Aspirin; Clopidogrel; Cohort Studies; Female; Foll | 2015 |
[Factors influencing platelet aggregation in patients with acute coronary syndrome].
Topics: Acute Coronary Syndrome; Aspirin; Blood Coagulation Tests; Clopidogrel; Cytochrome P-450 CYP2C19; Dr | 2014 |
[Population pharmacokinetics and pharmacodynamics of clopidogrel in patients with acute coronary syndrome].
Topics: Acute Coronary Syndrome; Clopidogrel; Humans; Polymorphism, Genetic; Ticlopidine | 2014 |
World heart federation expert consensus statement on antiplatelet therapy in east asian patients with ACS or undergoing PCI.
Topics: Acute Coronary Syndrome; Adenosine; Asia, Eastern; Cardiology; Clopidogrel; Humans; Percutaneous Cor | 2014 |
The relationship between on-clopidogrel platelet reactivity, genotype, and post-percutaneous coronary intervention outcomes in Chinese patients.
Topics: Acute Coronary Syndrome; Aged; Blood Platelets; China; Clopidogrel; Combined Modality Therapy; Cytoc | 2015 |
[Changes in the diagnosis and treatment of hospitalized patients with acute coronary syndrome from 2006 to 2012 in China].
Topics: Acute Coronary Syndrome; Aged; Aspirin; Cardiovascular Diseases; China; Clopidogrel; Female; Hospita | 2014 |
Balancing the risks of bleeding and stent thrombosis: a decision analytic model to compare durations of dual antiplatelet therapy after drug-eluting stents.
Topics: Acute Coronary Syndrome; Aspirin; Clopidogrel; Decision Support Techniques; Drug-Eluting Stents; Fem | 2015 |
A delicate balance: the cost effectiveness of new antiplatelet agents.
Topics: Acute Coronary Syndrome; Adenosine; Clopidogrel; Female; Humans; Male; Platelet Aggregation Inhibito | 2015 |
Optimal cutoff value of P2Y12 reaction units to prevent major adverse cardiovascular events in the acute periprocedural period: post-hoc analysis of the randomized PRASFIT-ACS study.
Topics: Acute Coronary Syndrome; Aged; Clopidogrel; Dose-Response Relationship, Drug; Double-Blind Method; D | 2015 |
Prognostic impact of clopidogrel pretreatment in patients with acute coronary syndrome managed invasively.
Topics: Acute Coronary Syndrome; Clopidogrel; Coronary Angiography; Dose-Response Relationship, Drug; Female | 2015 |
Close encounters with errors of the second kind: evaluating risks and benefits of long-term dual antiplatelet therapy.
Topics: Acute Coronary Syndrome; Aspirin; Coronary Artery Disease; Female; Humans; Male; Platelet Aggregatio | 2015 |
CYP2C19*2 genotype influence in acute coronary syndrome patients undergoing serial clopidogrel dose tailoring based on platelet function testing: Analysis from randomized controlled trial NCT02096419.
Topics: Acute Coronary Syndrome; Aged; Blood Platelets; Clopidogrel; Cytochrome P-450 CYP2C19; Dose-Response | 2015 |
Inflammatory and antioxidant pattern unbalance in "clopidogrel-resistant" patients during acute coronary syndrome.
Topics: Acute Coronary Syndrome; Aged; Aged, 80 and over; Antioxidants; Chemokine CCL4; Clopidogrel; Female; | 2015 |
CYP2C19 LOF alleles confer no risk for HTPR but higher risk for recurrent ischemic events in clopidogrel treated elderly ACS patients.
Topics: Acute Coronary Syndrome; Age Factors; Aged; Aged, 80 and over; Alleles; Blood Platelets; Clopidogrel | 2015 |
Selection of P2Y12 antagonist, treatment initiation, and predictors of high on-treatment platelet reactivity in a "Real World" registry.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Blood Platelets; Clinical Trials as Topic; Clopidogrel; Co | 2015 |
Dual antiplatelet therapy tailored on platelet function test after coronary stent implantation: a real-world experience.
Topics: Acute Coronary Syndrome; Aged; Aspirin; Blood Platelets; Clopidogrel; Drug Therapy, Combination; Fem | 2015 |
Ticagrelor-induced acute generalized exanthematous pustulosis.
Topics: Acute Coronary Syndrome; Acute Generalized Exanthematous Pustulosis; Adenosine; Aged; Biopsy; Clopid | 2015 |
Monitoring Residual Platelet Activity Among Patients With Acute Coronary Syndrome Post-PCI by Modified Impedance Whole Blood Platelet Aggregation and Release Method.
Topics: Acute Coronary Syndrome; Adult; Blood Platelets; Clopidogrel; Drug Monitoring; Electric Impedance; F | 2016 |
Pre-treatment with dual antiplatelet therapy in patients with non-ST-segment elevation acute coronary syndromes undergoing percutaneous coronary intervention.
Topics: Acute Coronary Syndrome; Aged; Aspirin; Australia; Clopidogrel; Female; Hemorrhage; Humans; Logistic | 2015 |
Body Mass Index and Platelet Reactivity During Dual Antiplatelet Therapy With Clopidogrel or Ticagrelor.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Aspirin; Blood Platelets; Body Mass Index; Clopidogrel; Co | 2015 |
Mean platelet volume and high-residual platelet reactivity in patients receiving dual antiplatelet therapy with clopidogrel or ticagrelor.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Aspirin; Blood Platelets; Clopidogrel; Coronary Artery Dis | 2015 |
Financial Analysis of CYP2C19 Genotyping in Patients Receiving Dual Antiplatelet Therapy Following Acute Coronary Syndrome and Percutaneous Coronary Intervention.
Topics: Acute Coronary Syndrome; Adenosine; Clopidogrel; Cytochrome P-450 CYP2C19; Drug Therapy, Combination | 2015 |
International central adjudication committee in the PLATO trial: independent body of experts or friendly family picnic?
Topics: Acute Coronary Syndrome; Adenosine; Biomedical Research; Clopidogrel; Conflict of Interest; Humans; | 2015 |
Redesigning TRACER trial after TRITON.
Topics: Acute Coronary Syndrome; Aspirin; Clinical Trials as Topic; Clopidogrel; Drug Evaluation; Drug Thera | 2015 |
An Extraordinary Case Associated with an Allergic Reaction to Clopidogrel: Coronary Artery Spasm or Kounis Syndrome?
Topics: Acute Coronary Syndrome; Clopidogrel; Coronary Vasospasm; Drug Hypersensitivity; Humans; Male; Middl | 2015 |
Cytochrome P450 CYP 2C19*2 Associated with Adverse 1-Year Cardiovascular Events in Patients with Acute Coronary Syndrome.
Topics: Activation, Metabolic; Acute Coronary Syndrome; Aged; Alleles; Angina Pectoris; Aspirin; Clopidogrel | 2015 |
Duration of clopidogrel-based dual antiplatelet therapy and clinical outcomes after endeavor sprint zotarolimus-eluting stent implantation in patients presenting with acute coronary syndrome.
Topics: Acute Coronary Syndrome; Aged; Cause of Death; Clopidogrel; Drug-Eluting Stents; Female; Humans; Kap | 2015 |
The change in platelet count in patients with acute coronary syndrome 6 months after coronary stent implantation.
Topics: Acute Coronary Syndrome; Adult; Aged; Clopidogrel; Female; Humans; Male; Middle Aged; Platelet Aggre | 2015 |
[SECONDARY PREVENTION IN PATIENTS WITH ACUTE CORONARY SYNDROME HOSPITALIZED IN INTERNAL MEDICINE DEPARTMENTS].
Topics: Acute Coronary Syndrome; Adrenergic beta-Antagonists; Aged; Angiotensin-Converting Enzyme Inhibitors | 2015 |
Implementation of Cell Samples as Controls in National Proficiency Testing for Clopidogrel Therapy-Related CYP2C19 Genotyping in China: A Novel Approach.
Topics: Acute Coronary Syndrome; Alleles; Cells, Cultured; China; Clopidogrel; Cytochrome P-450 CYP2C19; Gen | 2015 |
Predictors of high on-clopidogrel platelet reactivity in patients with acute coronary syndrome.
Topics: Acute Coronary Syndrome; Area Under Curve; Blood Platelets; C-Reactive Protein; Clopidogrel; Coronar | 2016 |
Management of Antiplatelet Therapy After Coronary Artery Bypass Grafting in the Setting of Acute Coronary Syndrome.
Topics: Acute Coronary Syndrome; Aspirin; Coronary Artery Bypass; Humans; Platelet Aggregation Inhibitors; T | 2015 |
CYP2C19*2 and Other Allelic Variants Affecting Platelet Response to Clopidogrel Tested by Thrombelastography in Patients with Acute Coronary Syndrome.
Topics: Acute Coronary Syndrome; Aged; Alleles; Asian People; Blood Platelets; Clopidogrel; Cytochrome P-450 | 2015 |
Independent Predictors of Major Adverse Events following Coronary Stenting over 28 Months of Follow-Up.
Topics: Acute Coronary Syndrome; Adult; Aged; Aspirin; Case-Control Studies; Clopidogrel; Coronary Angiograp | 2015 |
Effects of Clopidogrel and Proton Pump Inhibitors on Cardiovascular Events in Patients with Type 2 Diabetes Mellitus after Drug-Eluting Stent Implantation: A Nationwide Cohort Study.
Topics: Acute Coronary Syndrome; Aged; Clopidogrel; Coronary Artery Bypass; Diabetes Mellitus, Type 2; Drug- | 2015 |
Anti-platelet pre-treatment for atrial fibrillation patients on warfarin referred for coronary angiography/stenting because of non-ST-elevation acute coronary syndrome: An alternative proposal.
Topics: Acute Coronary Syndrome; Aged; Aged, 80 and over; Atrial Fibrillation; Clopidogrel; Coronary Angiogr | 2015 |
Ticagrelor shift from PLATO to PEGASUS: Vanished mortality benefit, excess cancer deaths, massive discontinuations, and overshooting target events.
Topics: Acute Coronary Syndrome; Adenosine; Aspirin; Clopidogrel; Follow-Up Studies; Hemorrhage; Humans; Mor | 2015 |
[Clopidogrel versus prasugrel in acute coronary syndrome treated with coronary angioplasty].
Topics: Acute Coronary Syndrome; Angioplasty; Clopidogrel; Female; Hemorrhage; Humans; Kaplan-Meier Estimate | 2015 |
Does "smoker's paradox" exist in clopidogrel-treated Turkish patients with acute coronary syndrome.
Topics: Acute Coronary Syndrome; Aged; Clopidogrel; Drug Resistance; Female; Humans; Male; Middle Aged; Plat | 2016 |
CYP2C19 genotype plus platelet reactivity-guided antiplatelet therapy in acute coronary syndrome patients: a decision analysis.
Topics: Acute Coronary Syndrome; Adenosine; Alleles; Blood Platelets; Clopidogrel; Cost-Benefit Analysis; Cy | 2015 |
Economic outcomes with prasugrel versus clopidogrel in acute coronary syndrome patients: observations from prasugrel users and matched clopidogrel users.
Topics: Acute Coronary Syndrome; Aged; Bayes Theorem; Clopidogrel; Costs and Cost Analysis; Female; Health C | 2015 |
Point-of-care genetic profiling and/or platelet function testing in acute coronary syndrome.
Topics: Acute Coronary Syndrome; Aged; Alleles; Blood Platelets; Clopidogrel; Cytochrome P-450 CYP2C19; Fema | 2016 |
Changes in platelet function independent of pharmacotherapy following coronary intervention in non-ST-elevation myocardial infarction patients.
Topics: 12-Hydroxy-5,8,10,14-eicosatetraenoic Acid; Acute Coronary Syndrome; Adenosine Diphosphate; Aged; Bl | 2015 |
Prior chronic clopidogrel therapy is associated with increased adverse events and early stent thrombosis.
Topics: Acute Coronary Syndrome; Aged; Cardiovascular Diseases; Clopidogrel; Comorbidity; Coronary Artery By | 2016 |
Japanese postmarketing surveillance of clopidogrel in patients with non-ST-segment elevation acute coronary syndrome, stable angina, old myocardial infarction, and ST-segment elevation myocardial infarction after percutaneous coronary intervention in a re
Topics: Acute Coronary Syndrome; Adolescent; Adult; Aged; Angina, Stable; Asian People; Clopidogrel; Female; | 2016 |
Rapid and portable, lab-on-chip, point-of-care genotyping for evaluating clopidogrel metabolism.
Topics: Acute Coronary Syndrome; Alleles; ATP Binding Cassette Transporter, Subfamily B; Clopidogrel; Cytoch | 2015 |
PHILO -- ensuring trial results are not lost in translation.
Topics: Acute Coronary Syndrome; Adenosine; Clopidogrel; Female; Humans; Male; Percutaneous Coronary Interve | 2015 |
A new approach: Left atrial appendage occlusion, as an alternative to anticoagulant, to treat patient who suffered of atrial fibrillation, acute coronary syndrome and clopidogrel resistance.
Topics: Acute Coronary Syndrome; Aged; Anticoagulants; Atrial Appendage; Atrial Fibrillation; Clopidogrel; D | 2016 |
Ticagrelor vs. clopidogrel in non-ST-elevation acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Bradycardia; Clopidogrel; Comorbidity; Electrocardiography; Fema | 2016 |
Deciding about prolonged ticagrelor therapy in coronary clot formers: an ongoing dilemma.
Topics: Acute Coronary Syndrome; Humans; Platelet Aggregation Inhibitors; Purinergic P2Y Receptor Antagonist | 2016 |
The evolution of dual antiplatelet therapy in the setting of acute coronary syndrome: ticagrelor versus clopidogrel.
Topics: Acute Coronary Syndrome; Adenosine; Female; Humans; Male; Platelet Aggregation Inhibitors; Purinergi | 2016 |
Impact of Cytochrome P450 2C19*2 and *3 on Clopidogrel Loading Dose in Saudi Patients with Acute Coronary Syndrome.
Topics: Acute Coronary Syndrome; Aged; Clopidogrel; Coronary Thrombosis; Cytochrome P-450 CYP2C19; Drug Dosa | 2016 |
Relationship between pharmacokinetics and pharmacodynamics of clopidogrel in patients undergoing percutaneous coronary intervention: comparison between vasodilator-stimulated phosphoprotein phosphorylation assay and multiple electrode aggregometry.
Topics: Acute Coronary Syndrome; Adult; ATP Binding Cassette Transporter, Subfamily B; Biological Availabili | 2016 |
Current Antiplatelet Agents in Acute Coronary Syndrome.
Topics: Acute Coronary Syndrome; Adenosine; Clopidogrel; Humans; Platelet Aggregation Inhibitors; Prasugrel | 2015 |
Acute Coronary Syndromes, Gastrointestinal Protection, and Recommendations Regarding Concomitant Administration of Proton-Pump Inhibitors (Omeprazol/Esomeprazole) and Clopidogrel.
Topics: Acute Coronary Syndrome; Aged; Clopidogrel; Dose-Response Relationship, Drug; Drug Therapy, Combinat | 2016 |
Do Not Use Novel Antiplatelet Agents in Patients on Oral Anticoagulants After Stenting.
Topics: Acute Coronary Syndrome; Administration, Oral; Anticoagulants; Aspirin; Drug Therapy, Combination; H | 2015 |
Factors influencing platelet reactivity in patients undergoing coronary artery bypass surgery.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Aspirin; Blood Platelets; Clopidogrel; Coronary Artery Byp | 2016 |
High on-aspirin platelet reactivity predicts cardiac death in acute coronary syndrome patients undergoing PCI.
Topics: Acute Coronary Syndrome; Aged; Aged, 80 and over; Aspirin; Blood Platelets; Clopidogrel; Death; Drug | 2016 |
Defining a Role for Prasugrel in Patients With Stable Coronary Artery Disease Undergoing Ad Hoc Percutaneous Coronary Intervention.
Topics: Acute Coronary Syndrome; Coronary Artery Disease; Humans; Percutaneous Coronary Intervention; Platel | 2016 |
Resource use and costs in high-risk symptomatic peripheral artery disease patients with diabetes and prior acute coronary syndrome: a retrospective analysis.
Topics: Acute Coronary Syndrome; Adrenergic beta-Antagonists; Aged; Angiotensin-Converting Enzyme Inhibitors | 2016 |
[Advantages of Ticagrelor outweigh also in COPD patients].
Topics: Acute Coronary Syndrome; Adenosine; Female; Humans; Male; Platelet Aggregation Inhibitors; Pulmonary | 2016 |
Usefulness of Intravascular Ultrasound for Predicting Risk of Intraprocedural Stent Thrombosis.
Topics: Acute Coronary Syndrome; Adult; Aged; Aged, 80 and over; Aspirin; Clopidogrel; Humans; Japan; Male; | 2016 |
Gender Differences in Platelet Reactivity in Patients Receiving Dual Antiplatelet Therapy.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Blood Platelets; Clopidogrel; Drug Therapy, Combination; F | 2016 |
Potent P2Y12 Inhibitors in Low-Risk Patients: Is There a Medical Need?
Topics: Acute Coronary Syndrome; Adenosine; Female; Humans; Male; Percutaneous Coronary Intervention; Preope | 2016 |
The Impact of CYP2C19 Loss-of-Function Polymorphisms, Clinical, and Demographic Variables on Platelet Response to Clopidogrel Evaluated Using Impedance Aggregometry.
Topics: Acute Coronary Syndrome; Aspirin; Blood Platelets; Cardiography, Impedance; Clopidogrel; Cytochrome | 2017 |
Time-Varying Effects of Prasugrel Versus Clopidogrel on the Long-Term Risks of Stroke After Acute Coronary Syndromes: Results From the TRILOGY ACS Trial.
Topics: Acute Coronary Syndrome; Aged; Brain Ischemia; Clopidogrel; Female; Follow-Up Studies; Humans; Male; | 2016 |
Clopidogrel, prasugrel or ticagrelor in patients with acute coronary syndromes undergoing percutaneous coronary intervention.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Aged, 80 and over; Australia; Clopidogrel; Comorbidity; Fe | 2016 |
CYP2C19 in ACS Patients: Could Genotyping Have a Role in Medically Managed Patients or Beyond?
Topics: Acute Coronary Syndrome; Cytochrome P-450 CYP2C19; DNA; Female; Humans; Male; Polymorphism, Genetic; | 2016 |
Clopidogrel pharmacokinetics and pharmacodynamics in out-of-hospital cardiac arrest patients with acute coronary syndrome undergoing target temperature management.
Topics: Acute Coronary Syndrome; Aged; Cardiopulmonary Resuscitation; Clopidogrel; Female; Follow-Up Studies | 2016 |
[Impact of novel P2Y12 receptor inhibitors on platelet reactivity in acute coronary syndrome patients undergoing percutaneous coronary intervention].
Topics: Acute Coronary Syndrome; Adenosine; Aged; Aspirin; Blood Platelets; Clopidogrel; Female; Humans; Mal | 2016 |
Impact of diabetes on immature platelets fraction and its relationship with platelet reactivity in patients receiving dual antiplatelet therapy.
Topics: Acute Coronary Syndrome; Adenosine; Aspirin; Clopidogrel; Diabetes Mellitus; Drug Therapy, Combinati | 2016 |
Comparative resource utilization and costs for patients with acute coronary syndrome managed with percutaneous coronary intervention and treated with clopidogrel or prasugrel.
Topics: Acute Coronary Syndrome; Aged; Clopidogrel; Databases, Factual; Disease Management; Female; Health R | 2016 |
Impact of preoperative dual antiplatelet therapy on bleeding complications in patients with acute coronary syndromes who undergo urgent coronary artery bypass grafting.
Topics: Acute Coronary Syndrome; Aged; Aspirin; Blood Transfusion; Clopidogrel; Coronary Angiography; Corona | 2017 |
Save the Unlucky Unrevascularized Acute Coronary Syndrome Patient.
Topics: Acute Coronary Syndrome; Aspirin; Electrocardiography; Female; Humans; Male; Myocardial Infarction; | 2016 |
Contemporary antiplatelet treatment in acute coronary syndrome patients undergoing percutaneous coronary intervention: 1-year outcomes from the GReek AntiPlatElet (GRAPE) Registry.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Female; Follow-Up Studies; Greece; Humans; Ma | 2016 |
Comparison of Modified Impedance Whole Blood Platelet Aggregation Method Detecting Platelet Function in ACS Patients with Different CYP2C19 Genotypes.
Topics: Acute Coronary Syndrome; Adenosine Triphosphate; Adult; Aged; Automation, Laboratory; Biomarkers; Bi | 2016 |
Dual Antiplatelet Therapy Beyond 1 Year Postinfarction: The Time Has Come and We're Beginning to Know Who Will Benefit.
Topics: Acute Coronary Syndrome; Adenosine; Aspirin; Clopidogrel; Drug Therapy, Combination; Humans; Myocard | 2016 |
Occurrence, causes, and outcome after switching from ticagrelor to clopidogrel in a real-life scenario: data from a prospective registry.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Aged, 80 and over; Angiography; Cause of Death; Clopidogre | 2016 |
Coronary Thrombosis and Major Bleeding After PCI With Drug-Eluting Stents: Risk Scores From PARIS.
Topics: Acute Coronary Syndrome; Age Factors; Aged; Anemia; Aspirin; Body Mass Index; Clopidogrel; Cohort St | 2016 |
Parathyroid Hormone Levels and High-Residual Platelet Reactivity in Patients Receiving Dual Antiplatelet Therapy With Acetylsalicylic Acid and Clopidogrel or Ticagrelor.
Topics: Acute Coronary Syndrome; Adenosine; Adenosine Diphosphate; Aged; Aspirin; Biomarkers; Clopidogrel; C | 2016 |
Antiplatelet therapy: Ticagrelor reduces cardiac events in patients with PAD or diabetes.
Topics: Acute Coronary Syndrome; Adenosine; Diabetes Mellitus; Humans; Platelet Aggregation Inhibitors; Tica | 2016 |
ATP-binding cassette, sub-family B (MDR/TAP), member 1 (ABCB1) polymorphism and clopidogrel concentration in acute coronary syndrome: molecular change can explain the observed therapeutic concentration.
Topics: Acute Coronary Syndrome; Adenosine Triphosphate; ATP Binding Cassette Transporter, Subfamily B; Clop | 2016 |
[Relationship between ATP-binding cassette subfamily B member 1 and cytochrome P450 2C19 polymorphisms and the effect of clopidogrel post percutaneous coronary intervention in patients with acute coronary syndrome].
Topics: Acute Coronary Syndrome; Alleles; Angina Pectoris; ATP Binding Cassette Transporter, Subfamily B; Cl | 2016 |
Serum uric acid levels during dual antiplatelet therapy with ticagrelor or clopidogrel: Results from a single-centre study.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Aspirin; Biomarkers; Chi-Square Distribution; Clopidogrel; | 2016 |
Sex-related differences in outcomes among men and women under 55 years of age with acute coronary syndrome undergoing percutaneous coronary intervention: Results from the PROMETHEUS study.
Topics: Acute Coronary Syndrome; Age Factors; Clopidogrel; Drug Therapy, Combination; Female; Follow-Up Stud | 2017 |
Cost-effectiveness analysis of personalized antiplatelet therapy in patients with acute coronary syndrome.
Topics: Acute Coronary Syndrome; Adenosine; Clopidogrel; Cost-Benefit Analysis; Cytochrome P-450 CYP2C19; De | 2016 |
Platelet reactivity in patients receiving a maintenance dose of P2Y12-ADP receptor antagonists undergoing elective percutaneous coronary intervention.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Elective Surgical Procedures; Female; Humans; | 2016 |
Switching from clopidogrel to prasugrel or ticagrelor: tips and tricks.
Topics: Acute Coronary Syndrome; Adenosine; Clopidogrel; Percutaneous Coronary Intervention; Platelet Aggreg | 2016 |
[THE FIRST RESULTS OF THE PREVALENCE OF CYP2C19 GENEPOLYMORPHISM IN PATIENTS WITH ACUTE CORONARY SYNDROME IN THE AKTYUBINSK POPULATION].
Topics: Acute Coronary Syndrome; Adult; Aged; Asian People; Aspirin; Clopidogrel; Cytochrome P-450 CYP2C19; | 2016 |
Incidence and Clinical Features of Early Stent Thrombosis in the Era of New P2y12 Inhibitors (PLATIS-2).
Topics: Acute Coronary Syndrome; Adenosine; Aged; Aspirin; Clopidogrel; Early Diagnosis; Female; Humans; Isr | 2016 |
[ANMCO/SIC/SICI-GISE/SICCH Consensus document: Clinical approach to pharmacological pretreatment for patients undergoing myocardial revascularization].
Topics: Acute Coronary Syndrome; Angioplasty, Balloon, Coronary; Anticoagulants; Aspirin; Clopidogrel; Drug | 2016 |
Relationship between diabetes, platelet reactivity, and the SYNTAX score to one-year clinical outcome in patients with non-ST-segment elevation acute coronary syndrome undergoing percutaneous coronary intervention.
Topics: Acute Coronary Syndrome; Aged; Aged, 80 and over; Angioplasty, Balloon, Coronary; Blood Platelets; C | 2016 |
CYP2C19 polymorphisms in acute coronary syndrome patients undergoing clopidogrel therapy in Zhengzhou population.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Alleles; Clopidogrel; Cytochrome P-450 CYP2C19; Drug Resis | 2016 |
Dynamic platelet adhesion in patients with an acute coronary syndrome: The effect of antiplatelet therapy.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Aspirin; Biomarkers; Blood Platelets; Case-Control Studies | 2016 |
Efficacy and safety of ticagrelor versus clopidogrel in acute coronary syndrome in Taiwan: A multicenter retrospective pilot study.
Topics: Acute Coronary Syndrome; Adenosine; Adult; Aged; Aged, 80 and over; Clopidogrel; Female; Humans; Mal | 2016 |
Effect of genetic and coexisting polymorphisms on platelet response to clopidogrel in Chinese Han patients with acute coronary syndrome.
Topics: Acute Coronary Syndrome; Aged; Alleles; Aryldialkylphosphatase; Asian People; ATP Binding Cassette T | 2016 |
CYP2C19 loss-of-function alleles are not associated with clinical outcome of clopidogrel therapy in patients treated with newer-generation drug-eluting stents.
Topics: Acute Coronary Syndrome; Alleles; Clopidogrel; Cytochrome P-450 CYP2C19; Drug-Eluting Stents; Female | 2016 |
Optimizing prevention and guideline-concordant care in Montenegro.
Topics: Acute Coronary Syndrome; Adrenergic beta-Antagonists; Aged; Angiotensin Receptor Antagonists; Angiot | 2016 |
Safety and effectiveness of the new P2Y12r inhibitor agents vs clopidogrel in ACS patients according to the geographic area: East Asia vs Europe.
Topics: Acute Coronary Syndrome; Aged; Asia, Eastern; Clopidogrel; Europe; Female; Follow-Up Studies; Hemorr | 2016 |
Treating Acute Coronary Syndrome.
Topics: Acute Coronary Syndrome; Adenosine; Age Factors; Aged; Clopidogrel; Humans; Platelet Aggregation Inh | 2015 |
Are Immature Platelets Growing Up?: Toward a New Marker of Antiplatelet Drug Resistance.
Topics: Acute Coronary Syndrome; Blood Platelets; Percutaneous Coronary Intervention; Platelet Aggregation I | 2016 |
Outcomes in patients treated with ticagrelor or clopidogrel after acute myocardial infarction: experiences from SWEDEHEART registry.
Topics: Acute Coronary Syndrome; Adenosine; Clopidogrel; Humans; Myocardial Infarction; Platelet Aggregation | 2016 |
Understanding the Adverse Effects of Ticagrelor in Practice.
Topics: Acute Coronary Syndrome; Adenosine; Platelet Aggregation Inhibitors; Purinergic P2Y Receptor Antagon | 2016 |
Successful multivessel percutaneous coronary intervention for acute coronary syndrome in a HIV-positive severe haemophiliac.
Topics: Acute Coronary Syndrome; Clopidogrel; Hematuria; Hemophilia A; Hemorrhage; HIV Infections; Humans; M | 2016 |
Assessment of P2Y12 inhibitor usage and switching in acute coronary syndrome patients undergoing percutaneous coronary revascularization.
Topics: Acute Coronary Syndrome; Adenosine; Aftercare; Clopidogrel; Dose-Response Relationship, Drug; Drug S | 2016 |
Ticagrelor for patients with acute coronary syndromes: PLATOnic affair or lasting SWEDEHEART?
Topics: Acute Coronary Syndrome; Adenosine; Humans; Platelet Aggregation Inhibitors; Purinergic P2Y Receptor | 2016 |
Choices for Potent Platelet Inhibition in Patients With Diabetes Mellitus.
Topics: Acute Coronary Syndrome; Adenosine; Blood Platelets; Diabetes Mellitus; Humans; Percutaneous Coronar | 2016 |
The Diagnostic Utility of the Point-of-Care CYP2C19 Genotyping Assay in Patients with Acute Coronary Syndrome Dosing Clopidogrel: Comparison with Platelet Function Test and SNP Genotyping.
Topics: Acute Coronary Syndrome; Clopidogrel; Cytochrome P-450 CYP2C19; Dose-Response Relationship, Drug; Fe | 2016 |
Antiplatelet therapy: What have we learned from the ANTARCTIC trial?
Topics: Acute Coronary Syndrome; Aged; Aspirin; Humans; Platelet Aggregation Inhibitors; Ticlopidine | 2016 |
Letter by Petrie Regarding Article, "Individualizing Duration of Dual Antiplatelet Therapy After Acute Coronary Syndrome or Percutaneous Coronary Intervention".
Topics: Acute Coronary Syndrome; Aspirin; Drug Therapy, Combination; Humans; Percutaneous Coronary Intervent | 2016 |
Response by Bagai et al to Letter Regarding Article, "Individualizing Duration of Dual Antiplatelet Therapy After Acute Coronary Syndrome or Percutaneous Coronary Intervention".
Topics: Acute Coronary Syndrome; Aspirin; Drug Therapy, Combination; Humans; Percutaneous Coronary Intervent | 2016 |
Early Cessation of Adenosine Diphosphate Receptor Inhibitors Among Acute Myocardial Infarction Patients Treated With Percutaneous Coronary Intervention: Insights From the TRANSLATE-ACS Study (Treatment With Adenosine Diphosphate Receptor Inhibitors: Longi
Topics: Acute Coronary Syndrome; Aged; Clopidogrel; Drug Administration Schedule; Drug Costs; Female; Health | 2016 |
Impact of Proton Pump Inhibitor Use on the Comparative Effectiveness and Safety of Prasugrel Versus Clopidogrel: Insights From the Treatment With Adenosine Diphosphate Receptor Inhibitors: Longitudinal Assessment of Treatment Patterns and Events After Acu
Topics: Acute Coronary Syndrome; Aftercare; Aged; Cardiovascular Diseases; Clopidogrel; Comparative Effectiv | 2016 |
Relationship of Platelet Reactivity With Bleeding Outcomes During Long-Term Treatment With Dual Antiplatelet Therapy for Medically Managed Patients With Non-ST-Segment Elevation Acute Coronary Syndromes.
Topics: Acute Coronary Syndrome; Aged; Angina, Unstable; Aspirin; Blood Platelets; Clopidogrel; Drug Therapy | 2016 |
Time-To-Treatment of Acute Coronary Syndrome and Unit of First Contact in the ERICO Study.
Topics: Acute Coronary Syndrome; Aged; Anticoagulants; Aspirin; Brazil; Clopidogrel; Educational Status; Fem | 2016 |
Long-term outcomes in patients with acute coronary syndromes related to prolonging dual antiplatelet therapy more than 12 months after coronary stenting.
Topics: Acute Coronary Syndrome; Aged; Aspirin; Clopidogrel; Databases, Factual; Drug Administration Schedul | 2017 |
ABCC3 Polymorphisms and mRNA Expression Influence the Concentration of a Carboxylic Acid Metabolite in Patients on Clopidogrel and Aspirin Therapy.
Topics: Acute Coronary Syndrome; Aged; Aspirin; Carboxylic Acids; Chromatography, Liquid; Clopidogrel; Cytoc | 2017 |
Efficacy and safety of ticagrelor versus clopidogrel with different dosage in high-risk patients with acute coronary syndrome.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Cohort Studies; Dose-Response Relationship, D | 2017 |
Long-term versus short-term dual antiplatelet therapy was similarly associated with a lower risk of death, stroke, or infarction in patients with acute coronary syndrome regardless of underlying kidney disease.
Topics: Acute Coronary Syndrome; Aged; Aged, 80 and over; Aspirin; Clopidogrel; Creatinine; Drug Therapy, Co | 2017 |
Prasugrel Versus Ticagrelor: Uncertainty Remains.
Topics: Acute Coronary Syndrome; Adenosine; Percutaneous Coronary Intervention; Platelet Aggregation Inhibit | 2016 |
Platelet aggregation and risk of stent thrombosis or bleeding in interventionally treated diabetic patients with acute coronary syndrome.
Topics: Acute Coronary Syndrome; Aged; Clopidogrel; Diabetes Mellitus; Female; Follow-Up Studies; Graft Occl | 2016 |
Latin American Clinical Epidemiology Network Series - Paper 8: Ticagrelor was cost-effective vs. clopidogrel in acute coronary syndrome in Chile.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Cost-Benefit Analysis; Epidemiologic Studies; | 2017 |
Contemporary Trends in Oral Antiplatelet Agent Use in Patients Treated with Percutaneous Coronary Intervention for Acute Coronary Syndrome.
Topics: Acute Coronary Syndrome; Adenosine; Administration, Oral; Aged; Clopidogrel; Drug Therapy, Combinati | 2017 |
Ticagrelor Compared with Clopidogrel Increased Adenosine and Cyclic Adenosine Monophosphate Plasma Concentration in Acute Coronary Syndrome Patients.
Topics: Acute Coronary Syndrome; Adenosine; Adenosine Deaminase; Aged; Clopidogrel; Cyclic AMP; Female; Huma | 2017 |
Platelet reactivity in human immunodeficiency virus infected patients on dual antiplatelet therapy for an acute coronary syndrome: the EVERE2ST-HIV study.
Topics: Acute Coronary Syndrome; Adenosine; Anti-HIV Agents; Aspirin; Blood Platelets; Clopidogrel; Cross-Se | 2017 |
Concomitant use of calcium channel blockers with dual antiplatelet therapy and re-hospitalization for acute coronary syndrome.
Topics: Acute Coronary Syndrome; Aged; Aged, 80 and over; Calcium Channel Blockers; Clopidogrel; Databases, | 2017 |
Dual Antiplatelet Therapy Versus Aspirin Monotherapy in Diabetics With Multivessel Disease Undergoing CABG: FREEDOM Insights.
Topics: Acute Coronary Syndrome; Aged; Aspirin; Cause of Death; Clopidogrel; Diabetic Angiopathies; Drug The | 2017 |
Drug-Drug Interactions When Switching Between Intravenous and Oral P2Y
Topics: Acute Coronary Syndrome; Adenosine; Drug Interactions; Platelet Aggregation Inhibitors; Prasugrel Hy | 2017 |
Validation of a New ELISA-Based Vasodilator-Associated Stimulated Phosphoprotein Phosphorylation Assay to Assess Platelet Reactivity Index in a Chinese Population.
Topics: Acute Coronary Syndrome; Adenosine; Adult; Aged; Asian People; Cell Adhesion Molecules; Clopidogrel; | 2018 |
Dyspnea in patients treated with P2Y
Topics: Acute Coronary Syndrome; Adenosine; Dyspnea; Female; Greece; Hematocrit; Hemorrhage; Humans; Male; M | 2017 |
Angiotensin-Converting Enzyme Inhibitors' Influence on Antiplatelet Therapy of Clopidogrel in ACS.
Topics: Acute Coronary Syndrome; Adult; Aged; Angiotensin-Converting Enzyme Inhibitors; Carboxylic Ester Hyd | 2016 |
Conundrums of Platelet Function Testing: Does Sex Matter?
Topics: Acute Coronary Syndrome; Blood Platelets; Platelet Aggregation; Platelet Aggregation Inhibitors; Pla | 2017 |
Comparison of Platelet Reactivity in Black Versus White Patients With Acute Coronary Syndromes After Treatment With Ticagrelor.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Black People; Blood Platelets; Clopidogrel; Female; Humans | 2017 |
Ticagrelor safety profile in real-life setting of acute coronary syndrome patients.
Topics: Acute Coronary Syndrome; Adenosine; Humans; Platelet Aggregation Inhibitors; Ticagrelor; Ticlopidine | 2017 |
Poor adherence to P2Y12 antagonists increased cardiovascular risks in Chinese PCI-treated patients.
Topics: Acute Coronary Syndrome; Adenosine; Aged; China; Clopidogrel; Coronary Artery Bypass; Female; Follow | 2017 |
[Correlation between cytochrome 3A4+894C>T P450 gene polymorphism and outcomes of coronary intervention in patients with acute coronary syndrome].
Topics: Acute Coronary Syndrome; Alleles; Blood Platelets; Clopidogrel; Cytochrome P-450 CYP3A; Humans; Perc | 2016 |
Clopidogrel, prasugrel, or ticagrelor use and clinical outcome in patients with acute coronary syndrome: A nationwide long-term registry analysis from 2009 to 2014.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Aspirin; Austria; Clopidogrel; Drug Therapy, Combination; | 2017 |
A randomized clinical trial comparing long-term clopidogrel vs aspirin monotherapy beyond dual antiplatelet therapy after drug-eluting coronary stent implantation: Design and rationale of the Harmonizing Optimal Strategy for Treatment of coronary artery s
Topics: Acute Coronary Syndrome; Aspirin; Cause of Death; Clopidogrel; Coronary Stenosis; Drug Therapy, Comb | 2017 |
Antithrombotic therapy for non-ST-segment elevation acute coronary syndromes: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition).
Topics: Acute Coronary Syndrome; Aspirin; Clopidogrel; Electrocardiography; Fibrinolytic Agents; Fondaparinu | 2008 |
Coexisting polymorphisms of P2Y12 and CYP2C19 genes as a risk factor for persistent platelet activation with clopidogrel.
Topics: Acute Coronary Syndrome; Aged; Aryl Hydrocarbon Hydroxylases; Clopidogrel; Cytochrome P-450 CYP2C19; | 2008 |
Benefit of clopidogrel for acute coronary syndrome and percutaneous coronary interventions in doubt due to rebound adverse events.
Topics: Acute Coronary Syndrome; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Drug Therapy, Combina | 2008 |
Antiplatelet therapy in acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Adenosine Monophosphate; Aspirin; Clopidogrel; Drug Therapy, Com | 2008 |
[Commentary to the article: Wiviott S D, Braunwald E, McCabe C H et al. Prasugrel versus clopidogrel in patients with acute coronary syndrome. N Engl J Med 2007; 357: 2001-15].
Topics: Acute Coronary Syndrome; Clopidogrel; Humans; Piperazines; Platelet Aggregation Inhibitors; Prasugre | 2008 |
Increased major bleeding complications related to triple antithrombotic therapy usage in patients with atrial fibrillation undergoing percutaneous coronary artery stenting.
Topics: Acute Coronary Syndrome; Aged; Aged, 80 and over; Angioplasty, Balloon, Coronary; Anticoagulants; As | 2008 |
Evaluation of triple anti-platelet therapy by modified thrombelastography in patients with acute coronary syndrome.
Topics: Acute Coronary Syndrome; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Humans; Platelet Aggr | 2008 |
Post-PCI fatal bleeding in aspirin and clopidogrel hyper responder: shifting from antiplatelet resistance to bleeding risk assessment?
Topics: Acute Coronary Syndrome; Aspirin; Blood Platelets; Clopidogrel; Fatal Outcome; Female; Humans; Intra | 2010 |
[Prasugrel versus Clopidogrel in patients with acute coronary syndromes. Results of the TRITON-TIMI 38 trial].
Topics: Acute Coronary Syndrome; Clopidogrel; Double-Blind Method; Humans; Piperazines; Platelet Aggregation | 2008 |
Late outcomes after drug-eluting stent implantation in "real-world" clinical practice.
Topics: Acute Coronary Syndrome; Adult; Aged; Aged, 80 and over; Angina Pectoris; Angioplasty, Balloon, Coro | 2008 |
Repeated high doses of clopidogrel in 2 cases of pharmacological resistance.
Topics: Acute Coronary Syndrome; Angioplasty, Balloon, Coronary; Blood Platelets; Cell Adhesion Molecules; C | 2008 |
Outcomes after percutaneous coronary intervention in contemporary Australian practice: insights from a large multicentre registry.
Topics: Acute Coronary Syndrome; Adult; Aged; Angioplasty, Balloon, Coronary; Clopidogrel; Comorbidity; Drug | 2008 |
[Acute coronary syndrome -- long term protection by dual thrombocyte aggregation inhibition during twelve months].
Topics: Acute Coronary Syndrome; Angina, Unstable; Angioplasty, Balloon, Coronary; Aspirin; Clinical Trials | 2008 |
Pro: 'Antithrombotic therapy with warfarin, aspirin and clopidogrel is the recommended regime in anticoagulated patients who present with an acute coronary syndrome and/or undergo percutaneous coronary interventions'.
Topics: Acute Coronary Syndrome; Angioplasty, Balloon, Coronary; Anticoagulants; Aspirin; Clopidogrel; Drug | 2008 |
Contra: 'Antithrombotic therapy with warfarin, aspirin and clopidogrel is the recommended regimen in anticoagulated patients who present with an acute coronary syndrome and/or undergo percutaneous coronary interventions'. Not for everybody.
Topics: Acute Coronary Syndrome; Angioplasty, Balloon, Coronary; Anticoagulants; Aspirin; Clopidogrel; Drug | 2008 |
Impact of clopidogrel in patients with acute coronary syndromes requiring coronary artery bypass surgery: a multicenter analysis.
Topics: Acute Coronary Syndrome; Age Distribution; Aged; Analysis of Variance; Clopidogrel; Cohort Studies; | 2008 |
Efficacy and safety of optimized antithrombotic therapy with aspirin, clopidogrel and enoxaparin in patients with non-ST segment elevation acute coronary syndromes in clinical practice.
Topics: Acute Coronary Syndrome; Aged; Aspirin; Clopidogrel; Drug Evaluation; Drug Therapy, Combination; Dru | 2009 |
Efficacy and safety of prasugrel compared with clopidogrel in patients with acute coronary syndromes: results of TRITON-TIMI 38 trials.
Topics: Acute Coronary Syndrome; Administration, Oral; Aged; Angioplasty, Balloon, Coronary; Clinical Trials | 2009 |
Cytochrome p-450 polymorphisms and response to clopidogrel.
Topics: Acute Coronary Syndrome; Adult; Angioplasty, Balloon, Coronary; Area Under Curve; Aryl Hydrocarbon H | 2009 |
Cytochrome p-450 polymorphisms and response to clopidogrel.
Topics: Acute Coronary Syndrome; Adult; Angioplasty, Balloon, Coronary; Area Under Curve; Aryl Hydrocarbon H | 2009 |
Cytochrome p-450 polymorphisms and response to clopidogrel.
Topics: Acute Coronary Syndrome; Adult; Angioplasty, Balloon, Coronary; Area Under Curve; Aryl Hydrocarbon H | 2009 |
Cytochrome p-450 polymorphisms and response to clopidogrel.
Topics: Acute Coronary Syndrome; Adult; Angioplasty, Balloon, Coronary; Area Under Curve; Aryl Hydrocarbon H | 2009 |
Cytochrome p-450 polymorphisms and response to clopidogrel.
Topics: Acute Coronary Syndrome; Adult; Angioplasty, Balloon, Coronary; Area Under Curve; Aryl Hydrocarbon H | 2009 |
Cytochrome p-450 polymorphisms and response to clopidogrel.
Topics: Acute Coronary Syndrome; Adult; Angioplasty, Balloon, Coronary; Area Under Curve; Aryl Hydrocarbon H | 2009 |
Cytochrome p-450 polymorphisms and response to clopidogrel.
Topics: Acute Coronary Syndrome; Adult; Angioplasty, Balloon, Coronary; Area Under Curve; Aryl Hydrocarbon H | 2009 |
Cytochrome p-450 polymorphisms and response to clopidogrel.
Topics: Acute Coronary Syndrome; Adult; Angioplasty, Balloon, Coronary; Area Under Curve; Aryl Hydrocarbon H | 2009 |
Cytochrome p-450 polymorphisms and response to clopidogrel.
Topics: Acute Coronary Syndrome; Adult; Angioplasty, Balloon, Coronary; Area Under Curve; Aryl Hydrocarbon H | 2009 |
Cytochrome p-450 polymorphisms and response to clopidogrel.
Topics: Acute Coronary Syndrome; Adult; Angioplasty, Balloon, Coronary; Area Under Curve; Aryl Hydrocarbon H | 2009 |
Cytochrome p-450 polymorphisms and response to clopidogrel.
Topics: Acute Coronary Syndrome; Adult; Angioplasty, Balloon, Coronary; Area Under Curve; Aryl Hydrocarbon H | 2009 |
Cytochrome p-450 polymorphisms and response to clopidogrel.
Topics: Acute Coronary Syndrome; Adult; Angioplasty, Balloon, Coronary; Area Under Curve; Aryl Hydrocarbon H | 2009 |
Cytochrome p-450 polymorphisms and response to clopidogrel.
Topics: Acute Coronary Syndrome; Adult; Angioplasty, Balloon, Coronary; Area Under Curve; Aryl Hydrocarbon H | 2009 |
Cytochrome p-450 polymorphisms and response to clopidogrel.
Topics: Acute Coronary Syndrome; Adult; Angioplasty, Balloon, Coronary; Area Under Curve; Aryl Hydrocarbon H | 2009 |
Cytochrome p-450 polymorphisms and response to clopidogrel.
Topics: Acute Coronary Syndrome; Adult; Angioplasty, Balloon, Coronary; Area Under Curve; Aryl Hydrocarbon H | 2009 |
Cytochrome p-450 polymorphisms and response to clopidogrel.
Topics: Acute Coronary Syndrome; Adult; Angioplasty, Balloon, Coronary; Area Under Curve; Aryl Hydrocarbon H | 2009 |
Cytochrome p-450 polymorphisms and response to clopidogrel.
Topics: Acute Coronary Syndrome; Adult; Angioplasty, Balloon, Coronary; Area Under Curve; Aryl Hydrocarbon H | 2009 |
Cytochrome p-450 polymorphisms and response to clopidogrel.
Topics: Acute Coronary Syndrome; Adult; Angioplasty, Balloon, Coronary; Area Under Curve; Aryl Hydrocarbon H | 2009 |
Cytochrome p-450 polymorphisms and response to clopidogrel.
Topics: Acute Coronary Syndrome; Adult; Angioplasty, Balloon, Coronary; Area Under Curve; Aryl Hydrocarbon H | 2009 |
Cytochrome p-450 polymorphisms and response to clopidogrel.
Topics: Acute Coronary Syndrome; Adult; Angioplasty, Balloon, Coronary; Area Under Curve; Aryl Hydrocarbon H | 2009 |
Cytochrome p-450 polymorphisms and response to clopidogrel.
Topics: Acute Coronary Syndrome; Adult; Angioplasty, Balloon, Coronary; Area Under Curve; Aryl Hydrocarbon H | 2009 |
Cytochrome p-450 polymorphisms and response to clopidogrel.
Topics: Acute Coronary Syndrome; Adult; Angioplasty, Balloon, Coronary; Area Under Curve; Aryl Hydrocarbon H | 2009 |
Cytochrome p-450 polymorphisms and response to clopidogrel.
Topics: Acute Coronary Syndrome; Adult; Angioplasty, Balloon, Coronary; Area Under Curve; Aryl Hydrocarbon H | 2009 |
Cytochrome p-450 polymorphisms and response to clopidogrel.
Topics: Acute Coronary Syndrome; Adult; Angioplasty, Balloon, Coronary; Area Under Curve; Aryl Hydrocarbon H | 2009 |
Cytochrome p-450 polymorphisms and response to clopidogrel.
Topics: Acute Coronary Syndrome; Adult; Angioplasty, Balloon, Coronary; Area Under Curve; Aryl Hydrocarbon H | 2009 |
Cytochrome p-450 polymorphisms and response to clopidogrel.
Topics: Acute Coronary Syndrome; Adult; Angioplasty, Balloon, Coronary; Area Under Curve; Aryl Hydrocarbon H | 2009 |
Cytochrome p-450 polymorphisms and response to clopidogrel.
Topics: Acute Coronary Syndrome; Adult; Angioplasty, Balloon, Coronary; Area Under Curve; Aryl Hydrocarbon H | 2009 |
Cytochrome p-450 polymorphisms and response to clopidogrel.
Topics: Acute Coronary Syndrome; Adult; Angioplasty, Balloon, Coronary; Area Under Curve; Aryl Hydrocarbon H | 2009 |
Cytochrome p-450 polymorphisms and response to clopidogrel.
Topics: Acute Coronary Syndrome; Adult; Angioplasty, Balloon, Coronary; Area Under Curve; Aryl Hydrocarbon H | 2009 |
Cytochrome p-450 polymorphisms and response to clopidogrel.
Topics: Acute Coronary Syndrome; Adult; Angioplasty, Balloon, Coronary; Area Under Curve; Aryl Hydrocarbon H | 2009 |
Cytochrome p-450 polymorphisms and response to clopidogrel.
Topics: Acute Coronary Syndrome; Adult; Angioplasty, Balloon, Coronary; Area Under Curve; Aryl Hydrocarbon H | 2009 |
Cytochrome p-450 polymorphisms and response to clopidogrel.
Topics: Acute Coronary Syndrome; Adult; Angioplasty, Balloon, Coronary; Area Under Curve; Aryl Hydrocarbon H | 2009 |
Cytochrome p-450 polymorphisms and response to clopidogrel.
Topics: Acute Coronary Syndrome; Adult; Angioplasty, Balloon, Coronary; Area Under Curve; Aryl Hydrocarbon H | 2009 |
Cytochrome p-450 polymorphisms and response to clopidogrel.
Topics: Acute Coronary Syndrome; Adult; Angioplasty, Balloon, Coronary; Area Under Curve; Aryl Hydrocarbon H | 2009 |
Cytochrome p-450 polymorphisms and response to clopidogrel.
Topics: Acute Coronary Syndrome; Adult; Angioplasty, Balloon, Coronary; Area Under Curve; Aryl Hydrocarbon H | 2009 |
Cytochrome p-450 polymorphisms and response to clopidogrel.
Topics: Acute Coronary Syndrome; Adult; Angioplasty, Balloon, Coronary; Area Under Curve; Aryl Hydrocarbon H | 2009 |
Cytochrome p-450 polymorphisms and response to clopidogrel.
Topics: Acute Coronary Syndrome; Adult; Angioplasty, Balloon, Coronary; Area Under Curve; Aryl Hydrocarbon H | 2009 |
Cytochrome p-450 polymorphisms and response to clopidogrel.
Topics: Acute Coronary Syndrome; Adult; Angioplasty, Balloon, Coronary; Area Under Curve; Aryl Hydrocarbon H | 2009 |
Cytochrome p-450 polymorphisms and response to clopidogrel.
Topics: Acute Coronary Syndrome; Adult; Angioplasty, Balloon, Coronary; Area Under Curve; Aryl Hydrocarbon H | 2009 |
Cytochrome p-450 polymorphisms and response to clopidogrel.
Topics: Acute Coronary Syndrome; Adult; Angioplasty, Balloon, Coronary; Area Under Curve; Aryl Hydrocarbon H | 2009 |
Cytochrome p-450 polymorphisms and response to clopidogrel.
Topics: Acute Coronary Syndrome; Adult; Angioplasty, Balloon, Coronary; Area Under Curve; Aryl Hydrocarbon H | 2009 |
Cytochrome p-450 polymorphisms and response to clopidogrel.
Topics: Acute Coronary Syndrome; Adult; Angioplasty, Balloon, Coronary; Area Under Curve; Aryl Hydrocarbon H | 2009 |
Cytochrome p-450 polymorphisms and response to clopidogrel.
Topics: Acute Coronary Syndrome; Adult; Angioplasty, Balloon, Coronary; Area Under Curve; Aryl Hydrocarbon H | 2009 |
Cytochrome p-450 polymorphisms and response to clopidogrel.
Topics: Acute Coronary Syndrome; Adult; Angioplasty, Balloon, Coronary; Area Under Curve; Aryl Hydrocarbon H | 2009 |
Cytochrome p-450 polymorphisms and response to clopidogrel.
Topics: Acute Coronary Syndrome; Adult; Angioplasty, Balloon, Coronary; Area Under Curve; Aryl Hydrocarbon H | 2009 |
Cytochrome p-450 polymorphisms and response to clopidogrel.
Topics: Acute Coronary Syndrome; Adult; Angioplasty, Balloon, Coronary; Area Under Curve; Aryl Hydrocarbon H | 2009 |
Cytochrome p-450 polymorphisms and response to clopidogrel.
Topics: Acute Coronary Syndrome; Adult; Angioplasty, Balloon, Coronary; Area Under Curve; Aryl Hydrocarbon H | 2009 |
Cytochrome p-450 polymorphisms and response to clopidogrel.
Topics: Acute Coronary Syndrome; Adult; Angioplasty, Balloon, Coronary; Area Under Curve; Aryl Hydrocarbon H | 2009 |
Cytochrome p-450 polymorphisms and response to clopidogrel.
Topics: Acute Coronary Syndrome; Adult; Angioplasty, Balloon, Coronary; Area Under Curve; Aryl Hydrocarbon H | 2009 |
Cytochrome p-450 polymorphisms and response to clopidogrel.
Topics: Acute Coronary Syndrome; Adult; Angioplasty, Balloon, Coronary; Area Under Curve; Aryl Hydrocarbon H | 2009 |
Cytochrome p-450 polymorphisms and response to clopidogrel.
Topics: Acute Coronary Syndrome; Adult; Angioplasty, Balloon, Coronary; Area Under Curve; Aryl Hydrocarbon H | 2009 |
Cytochrome p-450 polymorphisms and response to clopidogrel.
Topics: Acute Coronary Syndrome; Adult; Angioplasty, Balloon, Coronary; Area Under Curve; Aryl Hydrocarbon H | 2009 |
Cytochrome p-450 polymorphisms and response to clopidogrel.
Topics: Acute Coronary Syndrome; Adult; Angioplasty, Balloon, Coronary; Area Under Curve; Aryl Hydrocarbon H | 2009 |
Cytochrome p-450 polymorphisms and response to clopidogrel.
Topics: Acute Coronary Syndrome; Adult; Angioplasty, Balloon, Coronary; Area Under Curve; Aryl Hydrocarbon H | 2009 |
Cytochrome p-450 polymorphisms and response to clopidogrel.
Topics: Acute Coronary Syndrome; Adult; Angioplasty, Balloon, Coronary; Area Under Curve; Aryl Hydrocarbon H | 2009 |
Cytochrome p-450 polymorphisms and response to clopidogrel.
Topics: Acute Coronary Syndrome; Adult; Angioplasty, Balloon, Coronary; Area Under Curve; Aryl Hydrocarbon H | 2009 |
Cytochrome p-450 polymorphisms and response to clopidogrel.
Topics: Acute Coronary Syndrome; Adult; Angioplasty, Balloon, Coronary; Area Under Curve; Aryl Hydrocarbon H | 2009 |
Cytochrome p-450 polymorphisms and response to clopidogrel.
Topics: Acute Coronary Syndrome; Adult; Angioplasty, Balloon, Coronary; Area Under Curve; Aryl Hydrocarbon H | 2009 |
Cytochrome p-450 polymorphisms and response to clopidogrel.
Topics: Acute Coronary Syndrome; Adult; Angioplasty, Balloon, Coronary; Area Under Curve; Aryl Hydrocarbon H | 2009 |
Cytochrome p-450 polymorphisms and response to clopidogrel.
Topics: Acute Coronary Syndrome; Adult; Angioplasty, Balloon, Coronary; Area Under Curve; Aryl Hydrocarbon H | 2009 |
Cytochrome p-450 polymorphisms and response to clopidogrel.
Topics: Acute Coronary Syndrome; Adult; Angioplasty, Balloon, Coronary; Area Under Curve; Aryl Hydrocarbon H | 2009 |
Cytochrome p-450 polymorphisms and response to clopidogrel.
Topics: Acute Coronary Syndrome; Adult; Angioplasty, Balloon, Coronary; Area Under Curve; Aryl Hydrocarbon H | 2009 |
Cytochrome p-450 polymorphisms and response to clopidogrel.
Topics: Acute Coronary Syndrome; Adult; Angioplasty, Balloon, Coronary; Area Under Curve; Aryl Hydrocarbon H | 2009 |
Cytochrome p-450 polymorphisms and response to clopidogrel.
Topics: Acute Coronary Syndrome; Adult; Angioplasty, Balloon, Coronary; Area Under Curve; Aryl Hydrocarbon H | 2009 |
Cytochrome p-450 polymorphisms and response to clopidogrel.
Topics: Acute Coronary Syndrome; Adult; Angioplasty, Balloon, Coronary; Area Under Curve; Aryl Hydrocarbon H | 2009 |
Cytochrome p-450 polymorphisms and response to clopidogrel.
Topics: Acute Coronary Syndrome; Adult; Angioplasty, Balloon, Coronary; Area Under Curve; Aryl Hydrocarbon H | 2009 |
Cytochrome p-450 polymorphisms and response to clopidogrel.
Topics: Acute Coronary Syndrome; Adult; Angioplasty, Balloon, Coronary; Area Under Curve; Aryl Hydrocarbon H | 2009 |
Cytochrome p-450 polymorphisms and response to clopidogrel.
Topics: Acute Coronary Syndrome; Adult; Angioplasty, Balloon, Coronary; Area Under Curve; Aryl Hydrocarbon H | 2009 |
Cytochrome p-450 polymorphisms and response to clopidogrel.
Topics: Acute Coronary Syndrome; Adult; Angioplasty, Balloon, Coronary; Area Under Curve; Aryl Hydrocarbon H | 2009 |
Cytochrome p-450 polymorphisms and response to clopidogrel.
Topics: Acute Coronary Syndrome; Adult; Angioplasty, Balloon, Coronary; Area Under Curve; Aryl Hydrocarbon H | 2009 |
Cytochrome p-450 polymorphisms and response to clopidogrel.
Topics: Acute Coronary Syndrome; Adult; Angioplasty, Balloon, Coronary; Area Under Curve; Aryl Hydrocarbon H | 2009 |
Cytochrome p-450 polymorphisms and response to clopidogrel.
Topics: Acute Coronary Syndrome; Adult; Angioplasty, Balloon, Coronary; Area Under Curve; Aryl Hydrocarbon H | 2009 |
Cytochrome p-450 polymorphisms and response to clopidogrel.
Topics: Acute Coronary Syndrome; Adult; Angioplasty, Balloon, Coronary; Area Under Curve; Aryl Hydrocarbon H | 2009 |
Cytochrome p-450 polymorphisms and response to clopidogrel.
Topics: Acute Coronary Syndrome; Adult; Angioplasty, Balloon, Coronary; Area Under Curve; Aryl Hydrocarbon H | 2009 |
Cytochrome p-450 polymorphisms and response to clopidogrel.
Topics: Acute Coronary Syndrome; Adult; Angioplasty, Balloon, Coronary; Area Under Curve; Aryl Hydrocarbon H | 2009 |
Cytochrome p-450 polymorphisms and response to clopidogrel.
Topics: Acute Coronary Syndrome; Adult; Angioplasty, Balloon, Coronary; Area Under Curve; Aryl Hydrocarbon H | 2009 |
Cytochrome p-450 polymorphisms and response to clopidogrel.
Topics: Acute Coronary Syndrome; Adult; Angioplasty, Balloon, Coronary; Area Under Curve; Aryl Hydrocarbon H | 2009 |
Cytochrome p-450 polymorphisms and response to clopidogrel.
Topics: Acute Coronary Syndrome; Adult; Angioplasty, Balloon, Coronary; Area Under Curve; Aryl Hydrocarbon H | 2009 |
Cytochrome p-450 polymorphisms and response to clopidogrel.
Topics: Acute Coronary Syndrome; Adult; Angioplasty, Balloon, Coronary; Area Under Curve; Aryl Hydrocarbon H | 2009 |
Cytochrome p-450 polymorphisms and response to clopidogrel.
Topics: Acute Coronary Syndrome; Adult; Angioplasty, Balloon, Coronary; Area Under Curve; Aryl Hydrocarbon H | 2009 |
Cytochrome p-450 polymorphisms and response to clopidogrel.
Topics: Acute Coronary Syndrome; Adult; Angioplasty, Balloon, Coronary; Area Under Curve; Aryl Hydrocarbon H | 2009 |
Clopidogrel in acute coronary syndrome: to genotype or not?
Topics: Acute Coronary Syndrome; Adenosine Diphosphate; Aryl Hydrocarbon Hydroxylases; Clopidogrel; Cytochro | 2009 |
Utilization of evidence-based therapy for the secondary prevention of acute coronary syndromes in Australian practice.
Topics: Acute Coronary Syndrome; Adrenergic beta-Antagonists; Adult; Aged; Aged, 80 and over; Angiotensin-Co | 2008 |
Clopidogrel, genetics, and drug responsiveness.
Topics: Acute Coronary Syndrome; Aryl Hydrocarbon Hydroxylases; Cardiovascular Diseases; Clopidogrel; Cytoch | 2009 |
Prognosis of patients suffering an acute coronary syndrome while already under chronic clopidogrel therapy.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Cardiovascular Diseases; Clo | 2009 |
Post-treatment platelet reactivity predicts long-term adverse events better than the response to clopidogrel in patients with non-ST-segment elevation acute coronary syndrome.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Blood Platelets; Clopidogrel; Coronar | 2009 |
Facts and controversies of aspirin and clopidogrel therapy.
Topics: Acute Coronary Syndrome; Aspirin; Atherosclerosis; Blood Platelets; Brain Ischemia; Clopidogrel; Dos | 2009 |
Risk of adverse outcomes associated with concomitant use of clopidogrel and proton pump inhibitors following acute coronary syndrome.
Topics: Acute Coronary Syndrome; Aged; Clopidogrel; Cohort Studies; Drug Interactions; Female; Hospitalizati | 2009 |
Risk of adverse outcomes associated with concomitant use of clopidogrel and proton pump inhibitors following acute coronary syndrome.
Topics: Acute Coronary Syndrome; Aged; Clopidogrel; Cohort Studies; Drug Interactions; Female; Hospitalizati | 2009 |
Risk of adverse outcomes associated with concomitant use of clopidogrel and proton pump inhibitors following acute coronary syndrome.
Topics: Acute Coronary Syndrome; Aged; Clopidogrel; Cohort Studies; Drug Interactions; Female; Hospitalizati | 2009 |
Risk of adverse outcomes associated with concomitant use of clopidogrel and proton pump inhibitors following acute coronary syndrome.
Topics: Acute Coronary Syndrome; Aged; Clopidogrel; Cohort Studies; Drug Interactions; Female; Hospitalizati | 2009 |
Temporal trends and patterns of early clopidogrel use across the spectrum of acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Cardiac Catheterization; Clopidogrel; Drug Utilization; Electrocardio | 2009 |
Novel antiplatelet strategies in acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Blood Platelets; Clinical Trials, Phase III as Topic; Clopidogrel; Hu | 2009 |
Bleeding risk with AZD6140, a reversible P2Y12 receptor antagonist, vs. clopidogrel in patients undergoing coronary artery bypass grafting in the DISPERSE2 trial.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clinical Trials as Topic; Clopidogrel; Coronary Artery Byp | 2009 |
Spontaneous coronary artery dissection and severe hypothyroidism.
Topics: Acute Coronary Syndrome; Adrenergic beta-Antagonists; Adult; Antihypertensive Agents; Aspirin; Clopi | 2009 |
Early, accurate, non-invasive predictors of left main or 3-vessel disease in patients with non-ST-segment elevation acute coronary syndrome.
Topics: Acute Coronary Syndrome; Adult; Aged; Aged, 80 and over; Clopidogrel; Coronary Artery Bypass; Corona | 2009 |
Cytochrome p-450 polymorphisms and response to clopidogrel.
Topics: Acute Coronary Syndrome; Adult; Clopidogrel; Cytochrome P-450 Enzyme System; Female; Humans; Male; P | 2009 |
Incidence and prognostic significance of thrombocytopenia developed during acute coronary syndrome in contemporary clinical practice.
Topics: Acute Coronary Syndrome; Aged; Aged, 80 and over; Angina, Unstable; Anticoagulants; Aspirin; Clopido | 2009 |
Influence of platelet reactivity and response to clopidogrel on myocardial damage following percutaneous coronary intervention in patients with non-ST-segment elevation acute coronary syndrome.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Blood Platelets; Clopidogrel | 2009 |
Platelet reactivity on aspirin, clopidogrel and abciximab in patients with acute coronary syndromes and reduced estimated glomerular filtration rate.
Topics: Abciximab; Acute Coronary Syndrome; Aged; Aged, 80 and over; Antibodies, Monoclonal; Aspirin; Blood | 2010 |
Acknowledging a failed strategy.
Topics: Acute Coronary Syndrome; Angioplasty, Balloon, Coronary; Aspirin; Cardiovascular Diseases; Clopidogr | 2009 |
Clopidogrel. Bleeding and resistance.
Topics: Acute Coronary Syndrome; Clopidogrel; Drug Resistance; Hemorrhage; Humans; Platelet Aggregation Inhi | 2009 |
Clopidogrel. Increasing concordance.
Topics: Acute Coronary Syndrome; Clinical Trials as Topic; Clopidogrel; Humans; Platelet Aggregation Inhibit | 2009 |
Acute coronary syndromes: don't bypass the clopidogrel.
Topics: Acute Coronary Syndrome; Clopidogrel; Coronary Artery Bypass; Dose-Response Relationship, Drug; Huma | 2009 |
Impact of combining proton pump inhibitors and clopidogrel.
Topics: Acute Coronary Syndrome; Angioplasty, Balloon, Coronary; Clopidogrel; Drug Interactions; Drug Therap | 2009 |
Antiplatelet therapy: Clopidogrel plus PPIs-a dangerous combination?
Topics: Acute Coronary Syndrome; Clopidogrel; Drug Interactions; Gastrointestinal Hemorrhage; Humans; Platel | 2009 |
Aprotinin reduces the antiplatelet effect of clopidogrel.
Topics: Acute Coronary Syndrome; Adenosine Diphosphate; Aged; Aprotinin; Aspirin; Clopidogrel; Coronary Arte | 2009 |
The CYP2C19*17 allele is associated with better platelet response to clopidogrel in patients admitted for non-ST acute coronary syndrome.
Topics: Acute Coronary Syndrome; Aged; Alleles; Aryl Hydrocarbon Hydroxylases; Blood Platelets; Clopidogrel; | 2009 |
Rethinking loading dose clopidogrel in light of increased bleeding complications in bypass patients.
Topics: Acute Coronary Syndrome; Clopidogrel; Coronary Artery Bypass; Humans; Platelet Aggregation Inhibitor | 2009 |
Adverse outcomes associated with use of proton pump inhibitors and clopidogrel.
Topics: Acute Coronary Syndrome; Clopidogrel; Humans; Platelet Aggregation Inhibitors; Proton Pump Inhibitor | 2009 |
Adverse outcomes associated with use of proton pump inhibitors and clopidogrel.
Topics: Acute Coronary Syndrome; Clopidogrel; Drug Interactions; Humans; Platelet Aggregation Inhibitors; Pr | 2009 |
Adverse outcomes associated with use of proton pump inhibitors and clopidogrel.
Topics: Acute Coronary Syndrome; Clopidogrel; Humans; Platelet Aggregation Inhibitors; Proton Pump Inhibitor | 2009 |
Adverse outcomes associated with use of proton pump inhibitors and clopidogrel.
Topics: Acute Coronary Syndrome; Clopidogrel; Gastrointestinal Hemorrhage; Humans; Platelet Aggregation Inhi | 2009 |
Clopidogrel in ESRD patients with acute coronary syndrome.
Topics: Acute Coronary Syndrome; Aspirin; Clopidogrel; Hemorrhage; Humans; Kidney Failure, Chronic; Platelet | 2009 |
Impact of loading dose adjustment on platelet reactivity in homozygotes of the 2C19 2* loss of function polymorphism.
Topics: Acute Coronary Syndrome; Aryl Hydrocarbon Hydroxylases; Clopidogrel; Cytochrome P-450 CYP2C19; Homoz | 2010 |
Ticagrelor--is there need for a new player in the antiplatelet-therapy field?
Topics: Acute Coronary Syndrome; Adenosine; Clopidogrel; Humans; Piperazines; Platelet Aggregation Inhibitor | 2009 |
Effect of blood hematocrit and erythrocyte deformability on adenosine 5'-diphosphate platelet reactivity in patients with acute coronary syndromes on dual antiplatelet therapy.
Topics: Acute Coronary Syndrome; Adenosine Diphosphate; Adult; Aged; Aged, 80 and over; Angioplasty, Balloon | 2009 |
Predictive value of post-treatment platelet reactivity for occurrence of post-discharge bleeding after non-ST elevation acute coronary syndrome. Shifting from antiplatelet resistance to bleeding risk assessment?
Topics: Acute Coronary Syndrome; Adenosine Diphosphate; Aged; Arachidonic Acid; Aspirin; Biomarkers; Cell Ad | 2009 |
Early treatment for non-ST-segment elevation acute coronary syndrome is associated with appropriate discharge care.
Topics: Acute Coronary Syndrome; Adrenergic beta-Antagonists; Aged; Aspirin; Clopidogrel; Drug Administratio | 2009 |
Antiplatelet agents used for early intervention in acute coronary syndrome: myocardial salvage versus bleeding complications.
Topics: Acute Coronary Syndrome; Aspirin; Clopidogrel; Coronary Artery Bypass; Hemorrhage; Humans; Platelet | 2009 |
Significantly lower incidence of early definite stent thrombosis of drug-eluting stents after unrestricted use in Japan using ticlopidine compared to western countries using clopidogrel: a retrospective comparison with western mega-studies.
Topics: Acute Coronary Syndrome; Angina, Unstable; Clinical Trials as Topic; Drug-Eluting Stents; Europe; Hu | 2009 |
Influence of C3435T multidrug resistance gene-1 (MDR-1) polymorphism on platelet reactivity and prognosis in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Acute Disease; Aged; Angioplasty, Balloon, Coronary; ATP Binding Cassette T | 2009 |
Predictive values of post-treatment adenosine diphosphate-induced aggregation and vasodilator-stimulated phosphoprotein index for stent thrombosis after acute coronary syndrome in clopidogrel-treated patients.
Topics: Acute Coronary Syndrome; Adenosine Diphosphate; Aged; Angioplasty, Balloon, Coronary; Blood Proteins | 2009 |
[New thrombocyte inhibitor. Fewer ischemic complications in acute coronary syndrome].
Topics: Acute Coronary Syndrome; Clopidogrel; Double-Blind Method; Humans; Myocardial Ischemia; Piperazines; | 2009 |
Potential unrecognised costs of clopidogrel pretreatment in acute coronary syndrome.
Topics: Acute Coronary Syndrome; Aged; American Heart Association; Blood Transfusion; Clopidogrel; Coronary | 2009 |
Evaluation of hospitalization and follow-up care costs among patients hospitalized with ACS treated with a stent and clopidogrel.
Topics: Acute Coronary Syndrome; Cardiovascular Surgical Procedures; Clopidogrel; Female; Follow-Up Studies; | 2009 |
Patient characteristics associated with the choice of triple antithrombotic therapy in acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Anemia; Angioplasty, Balloon, Coronary; Anticoagulants; Aspirin; Atri | 2009 |
Platelet-bound P-selectin expression in patients with coronary artery disease: impact on clinical presentation and myocardial necrosis, and effect of diabetes mellitus and anti-platelet medication.
Topics: Acute Coronary Syndrome; Angina Pectoris; Aspirin; Biomarkers; Blood Platelets; Clopidogrel; Coronar | 2010 |
Prasugrel: new drug. After angioplasty and stenting: continue to use aspirin + clopidogrel.
Topics: Acute Coronary Syndrome; Angioplasty, Balloon, Coronary; Aspirin; Cardiovascular Diseases; Clopidogr | 2009 |
Risk and benefit of proton pump inhibitor for patients undergoing anti-platelet therapy including clopidogrel.
Topics: Acute Coronary Syndrome; Angioplasty, Balloon, Coronary; Clopidogrel; Coronary Restenosis; Drug Ther | 2009 |
Glycoprotein IIb/IIIa antagonists: new developments.
Topics: Abciximab; Acute Coronary Syndrome; Antibodies, Monoclonal; Atherectomy; Clinical Trials as Topic; C | 2009 |
Platelet monitoring for PCI: which test is the one to choose?
Topics: Acute Coronary Syndrome; Aspirin; Blood Platelets; Clopidogrel; Electric Impedance; Humans; Platelet | 2009 |
Potential Interaction between clopidogrel and proton pump inhibitors.
Topics: Acute Coronary Syndrome; Clopidogrel; Coronary Thrombosis; Drug Interactions; Drug Therapy, Combinat | 2009 |
Is it possible to safely administer early a loading dose of clopidogrel before coronary angiography to patients who are candidates for percutaneous coronary intervention?
Topics: Acute Coronary Syndrome; Adult; Aged, 80 and over; Angioplasty, Balloon, Coronary; Clopidogrel; Coho | 2009 |
Cardiovascular outcomes and mortality in patients using clopidogrel with proton pump inhibitors after percutaneous coronary intervention or acute coronary syndrome.
Topics: Acute Coronary Syndrome; Aged; Aged, 80 and over; Angioplasty, Balloon, Coronary; Cardiovascular Dis | 2009 |
Antiplatelet therapy: Ticagrelor in ACS-what does PLATO teach us?
Topics: Acute Coronary Syndrome; Adenosine; Angioplasty, Balloon, Coronary; Clinical Trials, Phase III as To | 2009 |
Clopidogrel versus prasugrel: times are changing, but not for everyone.
Topics: Acute Coronary Syndrome; Clinical Trials as Topic; Clopidogrel; Humans; Piperazines; Platelet Aggreg | 2009 |
Prasugrel for acute coronary syndromes: faster, more potent, but higher bleeding risk.
Topics: Acute Coronary Syndrome; Angioplasty, Balloon, Coronary; Clopidogrel; Hemorrhage; Humans; Patient Se | 2009 |
Underutilization of clopidogrel and glycoprotein IIb/IIIa inhibitors in non-ST-elevation acute coronary syndrome patients: the Canadian global registry of acute coronary events (GRACE) experience.
Topics: Acute Coronary Syndrome; Aged; Canada; Clopidogrel; Drug Utilization; Female; Guideline Adherence; H | 2009 |
Dual antiplatelet therapy in patients requiring urgent coronary artery bypass grafting surgery: a position statement of the Canadian Cardiovascular Society.
Topics: Acute Coronary Syndrome; Aspirin; Canada; Clopidogrel; Coronary Artery Bypass; Drug Therapy, Combina | 2009 |
Clinical trial update II: TRITON-TIMI 38 provides reassurance on concomitant use of proton pump inhibitors and thienopyridines.
Topics: Acute Coronary Syndrome; Angioplasty, Balloon, Coronary; Clopidogrel; Drug Interactions; Gastrointes | 2009 |
The right oral antithrombotics in acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aspirin; Cardiovascular Diseases; Clinical Trials as Topic; Clopidogrel; He | 2009 |
Ticagrelor versus clopidogrel in acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Clopidogrel; Dyspnea; Humans; Platelet Aggregation Inhibitors; P | 2009 |
The PLATO trial: do you believe in magic?
Topics: Acute Coronary Syndrome; Adenosine; Clinical Trials, Phase III as Topic; Clopidogrel; Humans; Intrac | 2010 |
The TRITON versus PLATO trials: differences beyond platelet inhibition.
Topics: Acute Coronary Syndrome; Adenosine; Clinical Trials as Topic; Clopidogrel; Drug Evaluation; Humans; | 2010 |
Cost-effectiveness of prasugrel versus clopidogrel in patients with acute coronary syndromes and planned percutaneous coronary intervention: results from the trial to assess improvement in therapeutic outcomes by optimizing platelet inhibition with Prasug
Topics: Acute Coronary Syndrome; Angioplasty, Balloon, Coronary; Clopidogrel; Combined Modality Therapy; Cos | 2010 |
Should dual antiplatelet therapy after drug-eluting stents be continued for more than 1 year?: Dual antiplatelet therapy after drug-eluting stents should be continued for more than one year and preferably indefinitely.
Topics: Acute Coronary Syndrome; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Restenosis; | 2008 |
Acute coronary syndrome.
Topics: Acute Coronary Syndrome; Aspirin; Clopidogrel; Critical Pathways; Electrocardiography; Emergency Tre | 2009 |
Ticagrelor versus clopidogrel in acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Clopidogrel; Humans; Platelet Aggregation Inhibitors; Purinergic | 2009 |
Ticagrelor versus clopidogrel in acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Clopidogrel; Coronary Artery Bypass; Hemorrhage; Humans; Myocard | 2009 |
Ticagrelor versus clopidogrel in acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Clopidogrel; Hemorrhage; Humans; Platelet Aggregation Inhibitors | 2009 |
Ticagrelor in ACS: redefining a new standard of care?
Topics: Acute Coronary Syndrome; Adenosine; Clopidogrel; Humans; Piperazines; Platelet Aggregation Inhibitor | 2010 |
Efficacy of high-dose clopidogrel treatment (600 mg) less than two hours before percutaneous coronary intervention in patients with non-ST-segment elevation acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Clopidogrel; Electrocardiography; Fem | 2010 |
Highlights from Transcatheter Cardiovascular Therapeutics 2009: San Francisco, California, September 21 to 25, 2009.
Topics: Acute Coronary Syndrome; Angioplasty, Balloon, Coronary; Cardiac Surgical Procedures; Clinical Trial | 2010 |
Clinical outcome after acute coronary syndrome in Japanese patients: an observational cohort study.
Topics: Acute Coronary Syndrome; Adrenergic beta-Antagonists; Age Factors; Aged; Angioplasty, Balloon, Coron | 2010 |
Lack of outcome benefit and clopidogrel "resistance." The TRITON trial challenge.
Topics: Acute Coronary Syndrome; Clopidogrel; Drug Approval; Drug Resistance; Humans; Myocardial Infarction; | 2010 |
Adrenergic receptor polymorphisms and platelet reactivity after treatment with dual antiplatelet therapy with aspirin and clopidogrel in acute coronary syndrome.
Topics: Acute Coronary Syndrome; Adenosine Diphosphate; Aged; Aspirin; Cell Adhesion Molecules; Chi-Square D | 2010 |
Clopidogrel response: head-to-head comparison of different platelet assays to identify clopidogrel non responder patients after coronary stenting.
Topics: Acute Coronary Syndrome; Adenosine Diphosphate; Aged; Angioplasty, Balloon, Coronary; Blood Platelet | 2010 |
[Ticagrelor versus clopidogrel in patients with acute coronary syndromes: results of the PLATO study].
Topics: Acute Coronary Syndrome; Adenosine; Clopidogrel; Dose-Response Relationship, Drug; Humans; Multicent | 2010 |
Slow response to clopidogrel predicts low response.
Topics: Acute Coronary Syndrome; Adenosine Diphosphate; Aged; Biomarkers, Pharmacological; Clopidogrel; Dose | 2010 |
Antiplatelet therapy: cangrelor for ACS-lessons from the CHAMPION trials.
Topics: Acute Coronary Syndrome; Adenosine Monophosphate; Angioplasty, Balloon, Coronary; Blood Platelets; C | 2010 |
[The effect of different dosage of aspirin on inflammatory biomarkers and prognosis in acute coronary syndrome.].
Topics: Acute Coronary Syndrome; Aspirin; Biomarkers; Humans; Platelet Aggregation Inhibitors; Prognosis; Ri | 2009 |
The loading dose of clopidogrel in patients with ST-segment elevation myocardial infarction undergoing primary angioplasty.
Topics: Acute Coronary Syndrome; Angioplasty, Balloon; Aspirin; Clopidogrel; Humans; Myocardial Infarction; | 2010 |
Delays of event adjudication in the TRITON trial.
Topics: Acute Coronary Syndrome; Angioplasty, Balloon, Coronary; Cerebral Infarction; Clopidogrel; Coronary | 2010 |
Acute coronary syndrome and severe haemophilia: an unusual association with challenging treatment.
Topics: Acute Coronary Syndrome; Anticoagulants; Clopidogrel; Coagulants; Comorbidity; Coronary Angiography; | 2010 |
Adverse events after stopping clopidogrel in post-acute coronary syndrome patients: Insights from a large integrated healthcare delivery system.
Topics: Acute Coronary Syndrome; Aged; Aged, 80 and over; Angiotensin-Converting Enzyme Inhibitors; Clopidog | 2010 |
A comparison of the VerifyNow P2Y12 point-of-care device and light transmission aggregometry to monitor platelet function with prasugrel and clopidogrel: an integrated analysis.
Topics: Acute Coronary Syndrome; Adenosine Diphosphate; Adult; Aged; Clinical Trials as Topic; Clopidogrel; | 2010 |
Pharmacy cost sharing, antiplatelet therapy utilization, and health outcomes for patients with acute coronary syndrome.
Topics: Acute Coronary Syndrome; Aged; Aged, 80 and over; Clopidogrel; Cost Sharing; Cost-Benefit Analysis; | 2010 |
Individualised assessment of response to clopidogrel in patients presenting with acute coronary syndromes: a role for short thrombelastography?
Topics: Acute Coronary Syndrome; Adult; Aged; Aged, 80 and over; Angioplasty, Balloon, Coronary; Biomarkers; | 2010 |
[Recurrent stent thrombosis in a patient with non-ST-segment elevation acute coronary syndrome].
Topics: Acute Coronary Syndrome; Clopidogrel; Coronary Angiography; Coronary Thrombosis; Drug Resistance; El | 2010 |
Dual low response to acetylsalicylic acid and clopidogrel is associated with myonecrosis and stent thrombosis after coronary stent implantation.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Artery | 2010 |
[Interview with Prof. Franz-Joseph Krozingen: Interventional cardiology on the success course].
Topics: Acute Coronary Syndrome; Angioplasty, Balloon, Coronary; Cardiology; Clinical Trials as Topic; Clopi | 2010 |
Six-month survival benefits associated with clinical guideline recommendations in acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adult; Aged; Aged, 80 and over; Case-Control Studies; Clopidogrel; Drug Uti | 2010 |
Antiplatelet therapy and percutaneous coronary intervention in patients with acute coronary syndrome and thrombocytopenia.
Topics: Acute Coronary Syndrome; Aged; Aged, 80 and over; Angioplasty, Balloon, Coronary; Aspirin; Clopidogr | 2010 |
The evidence base for platelet function testing in patients undergoing percutaneous coronary intervention.
Topics: Acute Coronary Syndrome; Atherectomy; Clopidogrel; Coronary Thrombosis; Coronary Vessels; Diagnostic | 2010 |
Routine platelet testing should not be performed on all patients undergoing percutaneous coronary intervention.
Topics: Acute Coronary Syndrome; Atherectomy; Blood Platelets; Clopidogrel; Diagnostic Tests, Routine; Human | 2010 |
The causes and outcomes of inadequate implementation of existing guidelines for antiplatelet treatment in patients with acute coronary syndrome: the experience from Taiwan Acute Coronary Syndrome Descriptive Registry (T-ACCORD Registry).
Topics: Acute Coronary Syndrome; Aged; Aged, 80 and over; Aspirin; Chi-Square Distribution; Clopidogrel; Dru | 2010 |
[Standard therapy of acute coronary syndrome becomes easier. Dual platelet inhibition with only 1 tablet].
Topics: Acute Coronary Syndrome; Aspirin; Clinical Trials as Topic; Clopidogrel; Drug Combinations; Germany; | 2010 |
Histamine2-receptor antagonists are an alternative to proton pump inhibitor in patients receiving clopidogrel.
Topics: Acute Coronary Syndrome; Aged; Aryl Hydrocarbon Hydroxylases; Clopidogrel; Cohort Studies; Cytochrom | 2010 |
[Managing myocardial infarct in general practice].
Topics: Acute Coronary Syndrome; Algorithms; Angina, Unstable; Anticoagulants; Atorvastatin; Blood Chemical | 2010 |
Ad hoc percutaneous coronary intervention after in-laboratory high dose clopidogrel loading for clopidogrel-naive patients: safe for all?
Topics: Acute Coronary Syndrome; Angioplasty, Balloon, Coronary; Clopidogrel; Female; Humans; Male; Platelet | 2010 |
Clopidogrel and proton pump inhibitors: between a rock and a hard place.
Topics: Acute Coronary Syndrome; Clopidogrel; Drug Interactions; Humans; Prodrugs; Proton Pump Inhibitors; R | 2010 |
[Comparison of effects of prasugrel and clopidogrel in patients with acute coronary syndrome, subjected to percutaneous coronary intervention: TRITON-TIMI 38 trial].
Topics: Acute Coronary Syndrome; Angioplasty, Balloon, Coronary; Clopidogrel; Drug-Eluting Stents; Hemorrhag | 2010 |
Letter by Potter and Le Lorier regarding article, "Cardiovascular outcomes and mortality in patients using clopidogrel with proton pump inhibitors after percutaneous coronary intervention or acute coronary syndrome".
Topics: Acute Coronary Syndrome; Angioplasty, Balloon, Coronary; Clopidogrel; Drug Interactions; Humans; Pla | 2010 |
Clopidogrel loading dose adjustment according to platelet reactivity monitoring in patients carrying the 2C19*2 loss of function polymorphism.
Topics: Acute Coronary Syndrome; Alleles; Angioplasty, Balloon, Coronary; Aryl Hydrocarbon Hydroxylases; Blo | 2010 |
Pattern of clopidogrel use in hospitalized patients receiving percutaneous coronary interventions.
Topics: Acute Coronary Syndrome; Adult; Aged; Aged, 80 and over; Angina Pectoris; Angioplasty, Balloon, Coro | 2010 |
Pre-procedural platelet reactivity after clopidogrel loading in korean patients undergoing scheduled percutaneous coronary intervention.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aryl Hydrocarbon Hydroxylases; Clopid | 2010 |
Antiplatelet effect of clopidogrel is reduced in patients treated with therapeutic hypothermia after cardiac arrest.
Topics: Acute Coronary Syndrome; Clopidogrel; Female; Heart Arrest; Humans; Hypothermia, Induced; Male; Midd | 2010 |
Antiplatelet effect of clopidogrel is reduced in patients treated with therapeutic hypothermia after cardiac arrest.
Topics: Acute Coronary Syndrome; Clopidogrel; Female; Heart Arrest; Humans; Hypothermia, Induced; Male; Midd | 2010 |
Antiplatelet effect of clopidogrel is reduced in patients treated with therapeutic hypothermia after cardiac arrest.
Topics: Acute Coronary Syndrome; Clopidogrel; Female; Heart Arrest; Humans; Hypothermia, Induced; Male; Midd | 2010 |
Antiplatelet effect of clopidogrel is reduced in patients treated with therapeutic hypothermia after cardiac arrest.
Topics: Acute Coronary Syndrome; Clopidogrel; Female; Heart Arrest; Humans; Hypothermia, Induced; Male; Midd | 2010 |
Impact of inflammatory markers on platelet inhibition and cardiovascular outcome including stent thrombosis in patients with symptomatic coronary artery disease.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon; Aspirin; Blood Platelets; C-Reactive Protein; C | 2010 |
Letter by Serebruany regarding article, "Cost-effectiveness of prasugrel versus clopidogrel in patients with acute coronary syndromes and planned percutaneous coronary intervention: results from the Trial to Assess Improvement in Therapeutic Outcomes by O
Topics: Acute Coronary Syndrome; Angioplasty, Balloon, Coronary; Clopidogrel; Cost-Benefit Analysis; Humans; | 2010 |
Genetic variants in ABCB1 and CYP2C19 and cardiovascular outcomes after treatment with clopidogrel and prasugrel in the TRITON-TIMI 38 trial: a pharmacogenetic analysis.
Topics: Acute Coronary Syndrome; Angioplasty, Balloon, Coronary; Aryl Hydrocarbon Hydroxylases; ATP Binding | 2010 |
Genetic variants in ABCB1 and CYP2C19 and cardiovascular outcomes after treatment with clopidogrel and prasugrel in the TRITON-TIMI 38 trial: a pharmacogenetic analysis.
Topics: Acute Coronary Syndrome; Angioplasty, Balloon, Coronary; Aryl Hydrocarbon Hydroxylases; ATP Binding | 2010 |
Genetic variants in ABCB1 and CYP2C19 and cardiovascular outcomes after treatment with clopidogrel and prasugrel in the TRITON-TIMI 38 trial: a pharmacogenetic analysis.
Topics: Acute Coronary Syndrome; Angioplasty, Balloon, Coronary; Aryl Hydrocarbon Hydroxylases; ATP Binding | 2010 |
Genetic variants in ABCB1 and CYP2C19 and cardiovascular outcomes after treatment with clopidogrel and prasugrel in the TRITON-TIMI 38 trial: a pharmacogenetic analysis.
Topics: Acute Coronary Syndrome; Angioplasty, Balloon, Coronary; Aryl Hydrocarbon Hydroxylases; ATP Binding | 2010 |
Response to antiplatelet treatment: from genes to outcome.
Topics: Acute Coronary Syndrome; Angioplasty, Balloon, Coronary; Aryl Hydrocarbon Hydroxylases; Aspirin; ATP | 2010 |
Effect of CYP2C19 and ABCB1 single nucleotide polymorphisms on outcomes of treatment with ticagrelor versus clopidogrel for acute coronary syndromes: a genetic substudy of the PLATO trial.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Aryl Hydrocarbon Hydroxylases; ATP Binding Cassette Transp | 2010 |
Effect of CYP2C19 and ABCB1 single nucleotide polymorphisms on outcomes of treatment with ticagrelor versus clopidogrel for acute coronary syndromes: a genetic substudy of the PLATO trial.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Aryl Hydrocarbon Hydroxylases; ATP Binding Cassette Transp | 2010 |
Effect of CYP2C19 and ABCB1 single nucleotide polymorphisms on outcomes of treatment with ticagrelor versus clopidogrel for acute coronary syndromes: a genetic substudy of the PLATO trial.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Aryl Hydrocarbon Hydroxylases; ATP Binding Cassette Transp | 2010 |
Effect of CYP2C19 and ABCB1 single nucleotide polymorphisms on outcomes of treatment with ticagrelor versus clopidogrel for acute coronary syndromes: a genetic substudy of the PLATO trial.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Aryl Hydrocarbon Hydroxylases; ATP Binding Cassette Transp | 2010 |
Cardiovascular and gastrointestinal events of three antiplatelet therapies: clopidogrel, clopidogrel plus proton-pump inhibitors, and aspirin plus proton-pump inhibitors in patients with previous gastrointestinal bleeding.
Topics: Acute Coronary Syndrome; Aged; Aged, 80 and over; Aspirin; Cardiovascular Diseases; Clopidogrel; Dru | 2011 |
Atorvastatin for reduction of myocardial damage during angioplasty trials.
Topics: Acute Coronary Syndrome; Angioplasty, Balloon, Coronary; Anti-Inflammatory Agents; Atorvastatin; Clo | 2010 |
Acute coronary syndromes: finding meaning in OASIS 7.
Topics: Acute Coronary Syndrome; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Humans; Platelet Aggr | 2010 |
Fine-tuning therapy for acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aspirin; Cardiovascular Diseases; Clopidogrel; Coronary Angiography; Hemorr | 2010 |
Lack of effect of chronic kidney disease on clopidogrel response with high loading and maintenance doses of clopidogrel after Acute Coronary Syndrome.
Topics: Acute Coronary Syndrome; Aged; Clopidogrel; Dose-Response Relationship, Drug; Female; Humans; Male; | 2010 |
[The PLATO study].
Topics: Acute Coronary Syndrome; Adenosine; Cardiovascular Diseases; Clopidogrel; Humans; Multicenter Studie | 2010 |
Recent research on antithrombotics. News on the treatment of patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Biomedical Research; Clopidogrel; Cyclic N-Oxides; Factor Xa Inh | 2010 |
[Clopidogrel resistance in patients with acute coronary syndrome].
Topics: Acute Coronary Syndrome; C-Reactive Protein; Clopidogrel; Drug Resistance; Electrocardiography; Fema | 2010 |
Efficacy and safety of bivalirudin in patients receiving clopidogrel therapy after diagnostic angiography for percutaneous coronary intervention in acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Aged, 80 and over; Angioplasty, Balloon, Coronary; Antithrombins; Chi | 2010 |
It is standard practice, but is it really best practice or clinical biocreep?
Topics: Acute Coronary Syndrome; Angioplasty, Balloon, Coronary; Antithrombins; Clopidogrel; Coronary Angiog | 2010 |
[Does dual antiplatelet therapy always require gastroprotection? Tailored medical therapy should prevail over the generalized prescription of proton pump inhibitors in patients on dual antiplatelet therapy].
Topics: Acute Coronary Syndrome; Aspirin; Clopidogrel; Drug Therapy, Combination; Drug-Eluting Stents; Elect | 2010 |
Impact of concomitant treatment with proton pump inhibitors and clopidogrel on clinical outcome in patients after coronary stent implantation.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Cardiovascular Diseases; Chi | 2010 |
Diabetics with acute coronary syndrome: advances, challenges, and uncertainties.
Topics: Acute Coronary Syndrome; Adenosine; Clopidogrel; Diabetic Angiopathies; Humans; Purinergic P2Y Recep | 2010 |
Clopidogrel and the reduced-function CYP2C19 genetic variant: a limited piece of the overall therapeutic puzzle.
Topics: Acute Coronary Syndrome; Angioplasty, Balloon, Coronary; Aryl Hydrocarbon Hydroxylases; Cardiovascul | 2010 |
Emerging oral antiplatelet therapies for acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Administration, Oral; Aspirin; Cardiology; Clopidogrel; Drug The | 2010 |
Association between smoking, outcomes, and early clopidogrel use in patients with acute coronary syndrome: insights from the Global Registry of Acute Coronary Events.
Topics: Acute Coronary Syndrome; Aged; Aged, 80 and over; Clopidogrel; Coronary Angiography; Electrocardiogr | 2010 |
Dosing of clopidogrel and aspirin in acute coronary syndromes.
Topics: Acute Coronary Syndrome; Algorithms; Angina, Unstable; Angioplasty, Balloon, Coronary; Aspirin; Clop | 2010 |
Dosing of clopidogrel and aspirin in acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aspirin; Clopidogrel; Drug Antagonism; Humans; Platelet Aggregation Inhibit | 2010 |
Dosing of clopidogrel and aspirin in acute coronary syndromes.
Topics: Acute Coronary Syndrome; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Combined Modality The | 2010 |
An early and simple predictor of severe left main and/or three-vessel disease in patients with non-ST-segment elevation acute coronary syndrome.
Topics: Acute Coronary Syndrome; Adult; Aged; Aged, 80 and over; Biomarkers; Clopidogrel; Coronary Angiograp | 2011 |
Frequency and location of yellow and disrupted coronary plaques in patients as detected by angioscopy.
Topics: Acute Coronary Syndrome; Aged; Angioscopy; Aspirin; Clopidogrel; Coronary Artery Disease; Disease Pr | 2011 |
Ticagrelor versus clopidogrel in patients with acute coronary syndromes undergoing coronary artery bypass surgery: results from the PLATO (Platelet Inhibition and Patient Outcomes) trial.
Topics: Acute Coronary Syndrome; Adenosine; Aged; Clopidogrel; Coronary Artery Bypass; Double-Blind Method; | 2011 |
Mechanisms potentially contributing to the reduction in mortality associated with ticagrelor therapy.
Topics: Acute Coronary Syndrome; Adenosine; Clopidogrel; Coronary Artery Bypass; Female; Humans; Male; Posto | 2011 |
[Antiplatelet agents in acute coronary syndromes. Data from the main clinical trials].
Topics: Acute Coronary Syndrome; Adenosine; Aspirin; Clinical Trials as Topic; Clopidogrel; Humans; Platelet | 2010 |
Factors associated with clopidogrel use, adherence, and persistence in patients with acute coronary syndromes undergoing percutaneous coronary intervention.
Topics: Acute Coronary Syndrome; Adult; Aged; Angioplasty, Balloon, Coronary; Clopidogrel; Cohort Studies; C | 2011 |
Overview of the 2010 Food and Drug Administration Cardiovascular and Renal Drugs Advisory Committee meeting regarding ticagrelor.
Topics: Acute Coronary Syndrome; Adenosine; Advisory Committees; Aspirin; Clinical Trials, Phase II as Topic | 2011 |
Cardiovascular mortality in chronic kidney disease patients undergoing percutaneous coronary intervention is mainly related to impaired P2Y12 inhibition by clopidogrel.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Blood Platelets; Cause of Death; Clop | 2011 |
One-year clinical outcome in patients with acute coronary syndrome treated with concomitant use of clopidogrel and proton pump inhibitors: results from a regional cohort study.
Topics: Acute Coronary Syndrome; Aged; Aged, 80 and over; Chi-Square Distribution; Clopidogrel; Drug Interac | 2012 |
Clopidogrel differentially affects platelet-mediated thrombosis and inflammatory response in patients with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Blood Platelets; Clopidogrel; Female; Humans; Inflammation; Male; Mid | 2011 |
Double-dose clopidogrel in patients undergoing PCI for ACS.
Topics: Acute Coronary Syndrome; Angioplasty, Balloon, Coronary; Aspirin; Cardiovascular Diseases; Clopidogr | 2011 |
Double-dose clopidogrel in patients undergoing PCI for ACS.
Topics: Acute Coronary Syndrome; Angioplasty, Balloon, Coronary; Aspirin; Cardiovascular Diseases; Clopidogr | 2011 |
Usefulness of platelet response to clopidogrel by point-of-care testing to predict bleeding outcomes in patients undergoing percutaneous coronary intervention (from the Antiplatelet Therapy for Reduction of Myocardial Damage During Angioplasty-Bleeding St
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Clopidogrel; Coronary Thrombosis; Dos | 2011 |
Proton pump inhibitors in patients treated with aspirin and clopidogrel after acute coronary syndrome.
Topics: Acute Coronary Syndrome; Aged; Aspirin; Clopidogrel; Drug Interactions; Drug Therapy, Combination; F | 2010 |
CYP2C19 genotype and outcomes of clopidogrel treatment.
Topics: Acute Coronary Syndrome; Aryl Hydrocarbon Hydroxylases; Clopidogrel; Cytochrome P-450 CYP2C19; Cytoc | 2011 |
CYP2C19 genotype and outcomes of clopidogrel treatment.
Topics: Acute Coronary Syndrome; Aryl Hydrocarbon Hydroxylases; Atrial Fibrillation; Clopidogrel; Cytochrome | 2011 |
Relationship between peripheral arterial reactive hyperemia and residual platelet reactivity after 600 mg clopidogrel.
Topics: Acute Coronary Syndrome; Aged; Clopidogrel; Coronary Artery Disease; Endothelium, Vascular; Female; | 2011 |
Has the ClOpidogrel and Metoprolol in Myocardial Infarction Trial (COMMIT) of early β-blocker use in acute coronary syndromes impacted on clinical practice in Canada? Insights from the Global Registry of Acute Coronary Events (GRACE).
Topics: Acute Coronary Syndrome; Adrenergic beta-Antagonists; Aged; Aged, 80 and over; Canada; Clopidogrel; | 2011 |
Treatment patterns in acute coronary syndrome patients in the United Kingdom undergoing PCI.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Thromb | 2011 |
CYP2C19 and ABCB1 genes and individualized treatment with clopidogrel.
Topics: Acute Coronary Syndrome; Aryl Hydrocarbon Hydroxylases; ATP Binding Cassette Transporter, Subfamily | 2011 |
Genetic substudy of the PLATO trial.
Topics: Acute Coronary Syndrome; Alleles; Angioplasty, Balloon, Coronary; Anticoagulants; Aryl Hydrocarbon H | 2011 |
Safety of clopidogrel and proton pump inhibitors in patients undergoing drug-eluting stent implantation.
Topics: Acute Coronary Syndrome; Aged; Blood Vessel Prosthesis Implantation; Clopidogrel; Cohort Studies; Co | 2011 |
Impact of concomitant use of proton-pump inhibitors and thienopyridine derivatives on the antiplatelet effects.
Topics: Acute Coronary Syndrome; Aged; Clopidogrel; Coronary Disease; Drug Interactions; Female; Humans; Mal | 2011 |
Viewpoint: paradoxical excess mortality in the PLATO trial should be independently verified.
Topics: Acute Coronary Syndrome; Adenosine; Bias; Clinical Trials as Topic; Clopidogrel; Europe; Humans; Mor | 2011 |
Oral antiplatelet therapy for atherothrombotic disease: current evidence and new directions.
Topics: Acute Coronary Syndrome; Adenosine; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary A | 2011 |
Explaining the unexpected: insights from the PLATelet inhibition and clinical Outcomes (PLATO) trial comparing ticagrelor and clopidogrel. Editorial on Serebruany "Viewpoint: Paradoxical excess mortality in the PLATO trial should be independently verified
Topics: Acute Coronary Syndrome; Adenosine; Clinical Trials as Topic; Clopidogrel; Epidemiologic Research De | 2011 |
The PLATO trial reveals further opportunities to improve outcomes in patients with acute coronary syndrome. Editorial on Serebruany. "Viewpoint: Paradoxical excess mortality in the PLATO trial should be independently verified" (Thromb Haemost 2011; 105.5)
Topics: Acute Coronary Syndrome; Adenosine; Clinical Trials as Topic; Clinical Trials Data Monitoring Commit | 2011 |
Incidence of death and recurring acute coronary syndrome after stopping clopidogrel therapy in a large commercially-insured population in the US.
Topics: Acute Coronary Syndrome; Aged; Clopidogrel; Female; Humans; Incidence; Insurance Coverage; Insurance | 2011 |
Influence of updated guidelines on short- and long-term mortality in patients with non-ST-segment elevation acute coronary syndrome (NSTE-ACS).
Topics: Acute Coronary Syndrome; Aged; Aged, 80 and over; Angina, Unstable; Clopidogrel; Female; Follow-Up S | 2012 |
Use of the oral platelet inhibitors dipyridamole and acetylsalicylic acid is associated with increased risk of fracture.
Topics: Acute Coronary Syndrome; Adult; Aged; Aspirin; Case-Control Studies; Clopidogrel; Dipyridamole; Drug | 2012 |
Clinical, pharmacokinetic, and pharmacogenetic determinants of clopidogrel resistance in Korean patients with acute coronary syndrome.
Topics: Acute Coronary Syndrome; Adult; Aged; Aged, 80 and over; Aryl Hydrocarbon Hydroxylases; Asian People | 2011 |
[Antiplatelet therapy in acute coronary syndromes: state of the art and new perspectives].
Topics: Acute Coronary Syndrome; Clopidogrel; Humans; Platelet Aggregation Inhibitors; Ticlopidine | 2010 |
Age-related differences in antithrombotic therapy, success rate and in-hospital mortality in patients undergoing percutaneous coronary intervention: results of the quality control registry of the Arbeitsgemeinschaft Leitende Kardiologische Krankenhausärzt
Topics: Acute Coronary Syndrome; Age Factors; Aged; Aged, 80 and over; Angioplasty, Balloon, Coronary; Aspir | 2011 |
Efficacy and safety of clopidogrel after PCI with stenting in patients on oral anticoagulants with acute coronary syndrome.
Topics: Acute Coronary Syndrome; Administration, Oral; Aged; Angioplasty, Balloon, Coronary; Anticoagulants; | 2011 |
[ACC/AHA warning on effectiveness of clopidogrel].
Topics: Acute Coronary Syndrome; Clopidogrel; Drug Resistance; Genetic Testing; Humans; Purinergic P2Y Recep | 2010 |
[The CURRENT-OASIS 7 study].
Topics: Acute Coronary Syndrome; Angioplasty, Balloon, Coronary; Aspirin; Cardiovascular Diseases; Clopidogr | 2011 |
Effect of early clopidogrel discontinuation on rehospitalization in acute coronary syndrome: results from two distinct patient populations.
Topics: Acute Coronary Syndrome; Adolescent; Adult; Aged; Angioplasty, Balloon, Coronary; Clopidogrel; Cohor | 2011 |
Relationship between plasma inflammatory markers and platelet aggregation in patients with clopidogrel resistance after angioplasty.
Topics: Acute Coronary Syndrome; Adult; Angioplasty, Balloon, Coronary; Blood Vessel Prosthesis Implantation | 2012 |
Multiple electrode aggregometry and vasodilator stimulated phosphoprotein-phosphorylation assay in clinical routine for prediction of postprocedural major adverse cardiovascular events.
Topics: Acute Coronary Syndrome; Adult; Aged; Angioplasty, Balloon, Coronary; Cell Adhesion Molecules; Clopi | 2011 |
Effect of clopidogrel pretreatment on ischemic complications of percutaneous coronary intervention among bivalirudin-treated patients (from the EVENT registry).
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Antithrombins; Clopidogrel; Female; H | 2011 |
Safety and efficacy of clopidogrel reloading in patients on chronic clopidogrel therapy who present with an acute coronary syndrome and undergo percutaneous coronary intervention.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Clopidogrel; Coronary Angiography; Fe | 2011 |
Unraveling myths of platelet function and genetic testing the road to making tailored antiplatelet therapy a reality.
Topics: Acute Coronary Syndrome; Blood Platelets; Clopidogrel; Humans; Platelet Aggregation Inhibitors; Poly | 2011 |
Non-interventional management of acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Clopidogrel; Humans; Platelet Aggregation Inhibitors; Ticagrelor | 2011 |
[Specificities of diabetes in acute coronary syndromes].
Topics: Acute Coronary Syndrome; Algorithms; Angioplasty; Anti-Inflammatory Agents, Non-Steroidal; Clopidogr | 2011 |
Usefulness of high clopidogrel maintenance dose according to CYP2C19 genotypes in clopidogrel low responders undergoing coronary stenting for non ST elevation acute coronary syndrome.
Topics: Acute Coronary Syndrome; Alleles; Analysis of Variance; Aryl Hydrocarbon Hydroxylases; Chi-Square Di | 2011 |
The platelet hyporesponsiveness to clopidogrel in acute coronary syndrome patients treated with 75 mg/day clopidogrel may be overcome within 1 month of treatment.
Topics: Acute Coronary Syndrome; Adenosine Diphosphate; Blood Platelets; Clopidogrel; Drug Administration Sc | 2012 |
Malaysia-ACute CORonary syndromes Descriptive study (ACCORD): evaluation of compliance with existing guidelines in patients with acute coronary syndrome.
Topics: Acute Coronary Syndrome; Adult; Aspirin; Clopidogrel; Drug Therapy, Combination; Female; Guideline A | 2011 |
Sensitive troponin I assay in patients with suspected acute coronary syndrome.
Topics: Acute Coronary Syndrome; Clopidogrel; Creatinine; Humans; Myocardial Infarction; Myocardial Ischemia | 2011 |
Clinical and prognostic implications of the initial response to aspirin in patients with acute coronary syndrome.
Topics: Acute Coronary Syndrome; Administration, Oral; Aspirin; Clopidogrel; Electrocardiography; Female; Fo | 2011 |
Relationship between cardiovascular outcomes and proton pump inhibitor use in patients receiving dual antiplatelet therapy after acute coronary syndrome.
Topics: Acute Coronary Syndrome; Aged; Aryl Hydrocarbon Hydroxylases; Aspirin; Cardiovascular Diseases; Clop | 2011 |
Comparison of platelet reactivity and clopidogrel response in patients ≤ 75 Years Versus > 75 years undergoing percutaneous coronary intervention for non-ST-segment elevation acute coronary syndrome.
Topics: Acute Coronary Syndrome; Adenosine Diphosphate; Age Factors; Aged; Aged, 80 and over; Angioplasty, B | 2011 |
Clopidogrel discontinuation after acute coronary syndromes: frequency, predictors and associations with death and myocardial infarction--a hospital registry-primary care linked cohort (MINAP-GPRD).
Topics: Acute Coronary Syndrome; Adult; Aged; Aged, 80 and over; Clopidogrel; Cohort Studies; Death, Sudden, | 2011 |
[Platelet aggregation upon acetylsalicylic acid and clopidogrel treatment and glycoprotein IIb/IIIa content in patients with acute coronary syndrome].
Topics: Acute Coronary Syndrome; Aspirin; Blood Platelets; Clopidogrel; Drug Administration Schedule; Drug D | 2011 |
Comparison of characteristics, management practices, and outcomes of patients between the global registry and the gulf registry of acute coronary events.
Topics: Acute Coronary Syndrome; Adrenergic beta-Antagonists; Aged; Angiotensin Receptor Antagonists; Aspiri | 2011 |
Impact of dyspnea on medical utilization and affiliated costs in patients with acute coronary syndrome.
Topics: Acute Coronary Syndrome; Aged; Aged, 80 and over; Aspirin; Clopidogrel; Costs and Cost Analysis; Dia | 2011 |
High residual platelet reactivity after clopidogrel loading and long-term cardiovascular events among patients with acute coronary syndromes undergoing PCI.
Topics: Acute Coronary Syndrome; Adenosine Diphosphate; Aged; Angioplasty; Aspirin; Clopidogrel; Death; Fema | 2011 |
High residual platelet reactivity after clopidogrel loading and long-term cardiovascular events among patients with acute coronary syndromes undergoing PCI.
Topics: Acute Coronary Syndrome; Adenosine Diphosphate; Aged; Angioplasty; Aspirin; Clopidogrel; Death; Fema | 2011 |
High residual platelet reactivity after clopidogrel loading and long-term cardiovascular events among patients with acute coronary syndromes undergoing PCI.
Topics: Acute Coronary Syndrome; Adenosine Diphosphate; Aged; Angioplasty; Aspirin; Clopidogrel; Death; Fema | 2011 |
High residual platelet reactivity after clopidogrel loading and long-term cardiovascular events among patients with acute coronary syndromes undergoing PCI.
Topics: Acute Coronary Syndrome; Adenosine Diphosphate; Aged; Angioplasty; Aspirin; Clopidogrel; Death; Fema | 2011 |
Applying platelet function testing in clinical practice: what are the unmet needs?
Topics: Acute Coronary Syndrome; Clopidogrel; Cohort Studies; Death; Humans; Myocardial Infarction; Platelet | 2011 |
Clopidogrel and CYP2C19 testing: ready for clinical prime time?
Topics: Acute Coronary Syndrome; Aryl Hydrocarbon Hydroxylases; Clopidogrel; Cytochrome P-450 CYP2C19; Genet | 2012 |
[Stent thrombosis and clopidogrel response variability: is the genetic test useful in clinical practice?].
Topics: Acute Coronary Syndrome; Aged, 80 and over; Angioplasty, Balloon, Coronary; Clopidogrel; Drug-Elutin | 2011 |
Perioperative management of clopidogrel therapy: the effects on in-hospital cardiac morbidity in older patients with hip fractures.
Topics: Acute Coronary Syndrome; Aged; Aged, 80 and over; Blood Transfusion; Clopidogrel; Female; Hip Fractu | 2011 |
Influence of high-density lipoprotein and paraoxonase-1 on platelet reactivity in patients with acute coronary syndromes receiving clopidogrel therapy.
Topics: Acute Coronary Syndrome; Aged; Aryldialkylphosphatase; Base Sequence; Cell Adhesion Molecules; Clopi | 2011 |
Cost-effectiveness of prasugrel in a US managed care population.
Topics: Acute Coronary Syndrome; Aged; Aspirin; Clopidogrel; Cost Control; Cost-Benefit Analysis; Drug Thera | 2012 |
High on-thienopyridine platelet reactivity in elderly coronary patients: the SENIOR-PLATELET study.
Topics: Acute Coronary Syndrome; Adult; Age Factors; Aged; Aged, 80 and over; Clopidogrel; Cross-Sectional S | 2012 |
No free lunches: balancing bleeding and efficacy with ticagrelor.
Topics: Acute Coronary Syndrome; Adenosine; Clopidogrel; Female; Hemorrhage; Humans; Male; Platelet Aggregat | 2011 |
Influence of CYP2C19 polymorphisms in platelet reactivity and prognosis in an unselected population of non ST elevation acute coronary syndrome.
Topics: Acute Coronary Syndrome; Aged; Aryl Hydrocarbon Hydroxylases; Clopidogrel; Cohort Studies; Cytochrom | 2012 |
[Acute coronary syndromes in hospitalized patients with diabetes. Data from the RECORD registry].
Topics: Acute Coronary Syndrome; Aged; Aged, 80 and over; Clinical Protocols; Clopidogrel; Coronary Angiogra | 2011 |
Managing antiplatelet therapy during ophthalmic procedures: communication is the key.
Topics: Acute Coronary Syndrome; Angioplasty, Balloon, Coronary; Aspirin; Cardiology; Clopidogrel; Humans; I | 2011 |
No one-size-fits-all: A tailored approach to antithrombotic therapy after stent implantation.
Topics: Acute Coronary Syndrome; Adenosine; Aspirin; Clopidogrel; Coronary Disease; Coronary Restenosis; Dru | 2012 |
Low mean corpuscular hemoglobin level is a predictor of discontinuation of antiplatelet therapy in patients with acute coronary syndrome.
Topics: Acute Coronary Syndrome; Adult; Aged; Aged, 80 and over; Angioplasty, Balloon, Coronary; Aspirin; Cl | 2011 |
High residual platelet reactivity and thrombotic events.
Topics: Acute Coronary Syndrome; Female; Humans; Male; Myocardial Infarction; Platelet Adhesiveness; Platele | 2011 |
Effect size of ticagrelor over clopidogrel in the Platelet Inhibition and Patient Outcomes (PLATO) trial: from statistics to clinical judgment.
Topics: Acute Coronary Syndrome; Adenosine; Angioplasty, Balloon, Coronary; Clinical Trials as Topic; Clopid | 2012 |
Pharmacogenetics of clopidogrel: comparison between a standard and a rapid genetic testing.
Topics: Acute Coronary Syndrome; Aryl Hydrocarbon Hydroxylases; Clopidogrel; Cytochrome P-450 CYP2C19; Genet | 2012 |
Prior antiplatelet use and cardiovascular outcomes in patients presenting with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adult; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Drug The | 2012 |
Toward a therapeutic window for antiplatelet therapy in the elderly.
Topics: Acute Coronary Syndrome; Clopidogrel; Female; Humans; Male; Myocardial Infarction; Piperazines; Plat | 2012 |
Bare metal stent thrombosis in patients with acute coronary syndrome.
Topics: Acute Coronary Syndrome; Adult; Aged; Clopidogrel; Female; Humans; Incidence; Male; Middle Aged; Ris | 2012 |
Value of CYP2C19 *2 and *17 genotyping in clinical practice. Promising but not ready yet.
Topics: Acute Coronary Syndrome; Aryl Hydrocarbon Hydroxylases; Clopidogrel; Cytochrome P-450 CYP2C19; Femal | 2012 |
[Aspirin response and related factors in aged patients].
Topics: Acute Coronary Syndrome; Aged; Aged, 80 and over; Arachidonic Acid; Aspirin; Coronary Artery Disease | 2011 |
Cardiovascular outcomes associated with concomitant use of clopidogrel and proton pump inhibitors in patients with acute coronary syndrome in Taiwan.
Topics: Acute Coronary Syndrome; Aged; Aged, 80 and over; Angioplasty, Balloon, Coronary; Aryl Hydrocarbon H | 2012 |
High on-treatment platelet reactivity by ADP and increased risk of MACE in good clopidogrel metabolizers.
Topics: Acute Coronary Syndrome; Adenosine Diphosphate; Adult; Aged; Aged, 80 and over; Alleles; Aryl Hydroc | 2012 |
Coronary artery bypass graft surgery in acute coronary syndrome: incidence, cost impact, and acute clopidogrel interruption.
Topics: Acute Coronary Syndrome; Aged; Clopidogrel; Coronary Artery Bypass; Female; Hemorrhage; Hospital Cos | 2012 |
The FDA outlook of events reporting after ticagrelor or clopidogrel in the PLATO Trial: impact of sponsor censoring dates, drug discontinuation, and withdrawal of consent.
Topics: Acute Coronary Syndrome; Adenosine; Clinical Trials, Phase III as Topic; Clopidogrel; Data Interpret | 2011 |
Reducing co-administration of clopidogrel and proton pump inhibitors in acute coronary syndromes.
Topics: Acute Coronary Syndrome; Algorithms; Clopidogrel; Drug Interactions; Drug Therapy, Combination; Guid | 2012 |
Cost-effectiveness of cytochrome P450 2C19 genotype screening for selection of antiplatelet therapy with clopidogrel or prasugrel.
Topics: Acute Coronary Syndrome; Aryl Hydrocarbon Hydroxylases; Cardiovascular Diseases; Clopidogrel; Comput | 2012 |
Suboptimal response to clopidogrel and the effect of prasugrel in acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Clopidogrel; Cohort Studies; Female; Humans; Male; Middle Aged; New Z | 2013 |
Individualised PPI prescription in patients on combination antiplatelet therapy and upper gastrointestinal events after percutaneous coronary intervention: a cohort study.
Topics: Acute Coronary Syndrome; Adrenal Cortex Hormones; Adverse Drug Reaction Reporting Systems; Aged; Ang | 2012 |
Erratum for Fernandez et al. “Comparison of adverse cardiovascular events and bleeding complications of loading dose of clopidogrel 300 mg versus 600 mg in stable patients undergoing elective percutaneous intervention (from the CADICE Study)” Am J Cardiol
Topics: Acute Coronary Syndrome; Angioplasty, Balloon, Coronary; Clopidogrel; Dose-Response Relationship, Dr | 2012 |
Biological efficacy of a 600 mg loading dose of clopidogrel in ST-elevation myocardial infarction.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Animals; Clinical Protocols; Clopidog | 2012 |
Beware of novel antiplatelet therapy in acute coronary syndrome patients with previous stroke.
Topics: Acute Coronary Syndrome; Adenosine; Clopidogrel; Female; Humans; Ischemic Attack, Transient; Male; S | 2012 |
Dramatic effect of early clopidogrel administration in reducing mortality and MACE rates in ACS patients. Data from the Swiss registry AMIS-Plus.
Topics: Acute Coronary Syndrome; Adult; Aged; Aged, 80 and over; Aspirin; Cardiac Catheterization; Clopidogr | 2012 |
Prasugrel: a guide to its use in patients with acute coronary syndromes undergoing percutaneous coronary intervention in the US.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Clinical Trials as Topic; Clopidogrel | 2012 |
How to prevent bleeding events in on- and off-pump coronary artery bypass patients exposed to clopidogrel preoperatively.
Topics: Acute Coronary Syndrome; Coronary Artery Bypass, Off-Pump; Female; Hemorrhage; Humans; Male; Platele | 2012 |
Evaluation of the role of the new INNOVANCE PFA P2Y test cartridge in detection of clopidogrel resistance.
Topics: Acute Coronary Syndrome; Aged; Aspirin; Blood Platelets; Case-Control Studies; Cell Adhesion Molecul | 2012 |
Economic evaluation of clopidogrel in acute coronary syndrome patients without ST-segment elevation in Greece: a cost-utility analysis.
Topics: Acute Coronary Syndrome; Aged; Angina, Unstable; Aspirin; Clopidogrel; Computer Simulation; Cost-Ben | 2012 |
The extent of P2Y12 inhibition by clopidogrel in diabetes mellitus patients with acute coronary syndrome is not related to glycaemic control: roles of white blood cell count and body weight.
Topics: Acute Coronary Syndrome; Aged; Body Weight; Clopidogrel; Diabetes Complications; Diabetes Mellitus; | 2012 |
Effect of the clopidogrel-proton pump inhibitor drug interaction on adverse cardiovascular events in patients with acute coronary syndrome.
Topics: Acute Coronary Syndrome; Aged; Cardiovascular Diseases; Clopidogrel; Cohort Studies; Drug Interactio | 2012 |
Rehospitalization following percutaneous coronary intervention for commercially insured patients with acute coronary syndrome: a retrospective analysis.
Topics: Acute Coronary Syndrome; Aged; Clopidogrel; Drug-Eluting Stents; Female; Hospital Costs; Humans; Len | 2012 |
Switching patients from clopidogrel to prasugrel in acute coronary syndrome: effects of prasugrel loading dose on residual platelet reactivity.
Topics: Acute Coronary Syndrome; Aged; Blood Platelets; Clopidogrel; Female; Humans; Male; Middle Aged; Pipe | 2012 |
Antiplatelet therapy in acute coronary syndromes: beyond aspirin and clopidogrel.
Topics: Acute Coronary Syndrome; Aspirin; Clopidogrel; Cyclooxygenase Inhibitors; Humans; Platelet Aggregati | 2012 |
Double interruption of antiplatelet therapy and tirofiban "bridging" for lung cancer resection.
Topics: Acute Coronary Syndrome; Aged; Biopsy, Needle; Clopidogrel; Coronary Restenosis; Drug Administration | 2012 |
A potent alternative to clopidogrel emerges. Prasugrel appears to lower heart attack risk for patients with acute coronary syndrome.
Topics: Acute Coronary Syndrome; Clopidogrel; Drug Dosage Calculations; Hemorrhage; Humans; Myocardial Infar | 2010 |
[Residual platelet activity in patients managed with clopidogrel: clinical implications for the management of patients with acute coronary syndrome].
Topics: Acute Coronary Syndrome; Clopidogrel; Humans; Platelet Activation; Platelet Aggregation Inhibitors; | 2012 |
Ticagrelor FDA approval issues revisited.
Topics: Acute Coronary Syndrome; Adenosine; Clinical Trials, Phase III as Topic; Clopidogrel; Dose-Response | 2012 |
[Removal of epidural catheter under dual antiplatelet therapy following acute coronary syndrome : scenario without special consideration to the current guidelines on epidural regional anesthesia].
Topics: Acute Coronary Syndrome; Analgesia, Epidural; Aspirin; Catheterization; Clopidogrel; Digestive Syste | 2012 |
Platelet aggregation at discharge: a useful tool in acute coronary syndromes?
Topics: Acute Coronary Syndrome; Clopidogrel; Female; Humans; Longitudinal Studies; Male; Middle Aged; Patie | 2012 |
[Three case reports of the use of herbal combinations resulted in stent thrombosis: herbal combinations; friend or foe?].
Topics: Acute Coronary Syndrome; Angioplasty, Balloon, Coronary; Aspirin; Avena; Chest Pain; Clopidogrel; Co | 2012 |
Bleeding after initiation of multiple antithrombotic drugs, including triple therapy, in atrial fibrillation patients following myocardial infarction and coronary intervention: a nationwide cohort study.
Topics: Acute Coronary Syndrome; Aged; Aged, 80 and over; Angioplasty, Balloon, Coronary; Aspirin; Atrial Fi | 2012 |
Atopaxar: a review of its mechanism of action and role in patients with coronary artery disease.
Topics: Acute Coronary Syndrome; Animals; Clopidogrel; Coronary Artery Disease; Coronary Thrombosis; Humans; | 2012 |
Mortality in the TRACER and ATLAS ACS 2 trials: two more reasons to audit vital records in PLATO.
Topics: Acute Coronary Syndrome; Clinical Trials as Topic; Clopidogrel; Humans; Medical Audit; Platelet Aggr | 2012 |
Association of CYP2C19 genotype with periprocedural myocardial infarction after uneventful stent implantation in Chinese patients receiving clopidogrel pretreatment.
Topics: Acute Coronary Syndrome; Adenosine Diphosphate; Aged; Aryl Hydrocarbon Hydroxylases; Asian People; B | 2012 |
The cost effectiveness of genetic testing for CYP2C19 variants to guide thienopyridine treatment in patients with acute coronary syndromes: a New Zealand evaluation.
Topics: Acute Coronary Syndrome; Aged; Aged, 80 and over; Alleles; Aryl Hydrocarbon Hydroxylases; Clopidogre | 2012 |
Besides CYP2C19, PON1 genetic variant influences post-clopidogrel platelet reactivity in Chinese patients.
Topics: Acute Coronary Syndrome; Aged; Alleles; Aryl Hydrocarbon Hydroxylases; Aryldialkylphosphatase; Asian | 2013 |
Comparison between initial and chronic response to clopidogrel therapy after coronary stenting for acute coronary syndrome and influence on clinical outcomes.
Topics: Acute Coronary Syndrome; Aged; Cell Adhesion Molecules; Clopidogrel; Dose-Response Relationship, Dru | 2012 |
Transfusion outcomes in patients undergoing coronary artery bypass grafting treated with prasugrel or clopidogrel: TRITON-TIMI 38 retrospective data analysis.
Topics: Acute Coronary Syndrome; Clopidogrel; Coronary Artery Bypass; Humans; Piperazines; Platelet Aggregat | 2013 |
[Surgery shortly after stent implantation?].
Topics: Acute Coronary Syndrome; Angioplasty, Balloon, Coronary; Anticoagulants; Aspirin; Clopidogrel; Contr | 2012 |
Proton-pump inhibitors could be innocent when used concomitantly with clopidogrel.
Topics: Acute Coronary Syndrome; Anti-Ulcer Agents; Aspirin; Blood Platelets; Clopidogrel; Famotidine; Femal | 2012 |
Clopidogrel and cardiac surgery: enemy or friend?
Topics: Acute Coronary Syndrome; Aspirin; Clopidogrel; Coronary Artery Bypass, Off-Pump; Coronary Occlusion; | 2012 |
Platelet reactivity in diabetic patients undergoing coronary stenting for acute coronary syndrome treated with clopidogrel loading dose followed by prasugrel maintenance therapy.
Topics: Acute Coronary Syndrome; Aged; Blood Platelets; Clopidogrel; Diabetes Mellitus; Female; Follow-Up St | 2013 |
Triple antithrombotic therapy following an acute coronary syndrome: prevalence, outcomes and prognostic utility of the HAS-BLED score.
Topics: Acute Coronary Syndrome; Aged; Anticoagulants; Aspirin; Chi-Square Distribution; Clopidogrel; Comorb | 2012 |
Monitoring residual platelet activity among patients with acute coronary syndrome.
Topics: Acute Coronary Syndrome; Adult; Aged; Aged, 80 and over; Aspirin; Blood Platelets; Clopidogrel; Fema | 2014 |
Measured drug effect and cardiovascular outcomes in patients receiving platelet P2Y12 receptor antagonists: clarifying the time and place for intensive inhibition.
Topics: Acute Coronary Syndrome; Clopidogrel; Female; Humans; Male; Piperazines; Platelet Activation; Platel | 2012 |
Short-term effects of aspirin and clopidogrel on mean platelet volume among patients with acute coronary syndromes. A single-center prospective study.
Topics: Acute Coronary Syndrome; Aged; Aspirin; Blood Platelets; Cell Size; Clopidogrel; Female; Humans; Mal | 2012 |
Genetic testing in patients with acute coronary syndrome undergoing percutaneous coronary intervention: a cost-effectiveness analysis.
Topics: Acute Coronary Syndrome; Aryl Hydrocarbon Hydroxylases; Cerebrovascular Disorders; Clopidogrel; Comp | 2013 |
Near patient anti-platelet response testing over time and gene analysis in patients admitted with acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adult; Aged; Aged, 80 and over; Alleles; Aryl Hydrocarbon Hydroxylases; ATP | 2013 |
Current status of clopidogrel pharmacogenomics.
Topics: Acute Coronary Syndrome; Aryl Hydrocarbon Hydroxylases; Clopidogrel; Cytochrome P-450 CYP2C19; Human | 2012 |
2012 ACCF/AHA/ACP/AATS/PCNA/SCAI/STS Guideline for the diagnosis and management of patients with stable ischemic heart disease: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines, and the
Topics: Acute Coronary Syndrome; Adrenergic beta-Antagonists; Alcohol Drinking; Angina Pectoris; Body Weight | 2012 |
2012 ACCF/AHA/ACP/AATS/PCNA/SCAI/STS Guideline for the diagnosis and management of patients with stable ischemic heart disease: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines, and the
Topics: Acute Coronary Syndrome; Adrenergic beta-Antagonists; Alcohol Drinking; Angina Pectoris; Body Weight | 2012 |
2012 ACCF/AHA/ACP/AATS/PCNA/SCAI/STS Guideline for the diagnosis and management of patients with stable ischemic heart disease: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines, and the
Topics: Acute Coronary Syndrome; Adrenergic beta-Antagonists; Alcohol Drinking; Angina Pectoris; Body Weight | 2012 |
2012 ACCF/AHA/ACP/AATS/PCNA/SCAI/STS Guideline for the diagnosis and management of patients with stable ischemic heart disease: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines, and the
Topics: Acute Coronary Syndrome; Adrenergic beta-Antagonists; Alcohol Drinking; Angina Pectoris; Body Weight | 2012 |
Trilogy: in search of the lost ring.
Topics: Acute Coronary Syndrome; Aged; Aged, 80 and over; Clinical Trials as Topic; Clopidogrel; Female; Hum | 2013 |
Differential prognostic impact of high on-treatment platelet reactivity among patients with acute coronary syndromes versus stable coronary artery disease undergoing percutaneous coronary intervention.
Topics: Acute Coronary Syndrome; Aged; Clopidogrel; Coronary Artery Disease; Female; Follow-Up Studies; Hemo | 2013 |
Therapeutic momentum: a concept opposite to therapeutic inertia.
Topics: Acute Coronary Syndrome; Aspirin; Clopidogrel; Cross-Sectional Studies; Humans; Platelet Aggregation | 2013 |
Safety of reloading prasugrel in addition to clopidogrel loading in patients with acute coronary syndrome undergoing percutaneous coronary intervention.
Topics: Acute Coronary Syndrome; Aspirin; Chi-Square Distribution; Clopidogrel; Endpoint Determination; Fema | 2013 |
Clopidogrel has no effect on mortality from hip fracture.
Topics: Acute Coronary Syndrome; Adult; Aged; Aged, 80 and over; Arthroplasty, Replacement, Hip; Aspirin; Bl | 2013 |
Prasugrel versus clopidogrel for acute coronary syndromes.
Topics: Acute Coronary Syndrome; Angina, Unstable; Female; Humans; Male; Myocardial Infarction; Piperazines; | 2013 |
Prasugrel versus clopidogrel for acute coronary syndromes.
Topics: Acute Coronary Syndrome; Angina, Unstable; Female; Humans; Male; Myocardial Infarction; Piperazines; | 2013 |
Hirudin anticoagulation allows more rapid determination of P2Y₁₂ inhibition by the VerifyNow P2Y12 assay.
Topics: Acute Coronary Syndrome; Aged; Anticoagulants; Antithrombins; Area Under Curve; Cations; Citrates; C | 2013 |
High on-treatment platelet reactivity (HPR): what does it mean, and does it matter?
Topics: Acute Coronary Syndrome; Clopidogrel; Drug Substitution; Female; Humans; Male; Piperazines; Platelet | 2013 |
Promise and peril of clinical decision support: translating medical evidence to the individual patient.
Topics: Acute Coronary Syndrome; Clopidogrel; Female; Humans; Male; Percutaneous Coronary Intervention; Pipe | 2013 |
Predictors of long-term high on-treatment platelet reactivity in clopidogrel-treated patients undergoing coronary stenting for acute coronary syndrome.
Topics: Acute Coronary Syndrome; Aged; Blood Platelets; Clopidogrel; Female; Humans; Male; Middle Aged; Perc | 2013 |
Prasugrel vs clopidogrel in patients with acute coronary syndrome undergoing percutaneous coronary intervention: a model-based cost-effectiveness analysis for Germany, Sweden, the Netherlands, and Turkey.
Topics: Acute Coronary Syndrome; Age Factors; Clopidogrel; Comorbidity; Cost-Benefit Analysis; Europe; Human | 2013 |
Effect of CYP2C19*2 and *17 genetic variants on platelet response to clopidogrel and prasugrel maintenance dose and relation to bleeding complications.
Topics: Acute Coronary Syndrome; Alleles; Aryl Hydrocarbon Hydroxylases; Blood Platelets; Cell Adhesion Mole | 2013 |
Establishment of a CYP2C19 genotyping assay for clinical use.
Topics: Acute Coronary Syndrome; Aryl Hydrocarbon Hydroxylases; Clopidogrel; Cytochrome P-450 CYP2C19; DNA; | 2013 |
[Analysis of the risk factors of patients with acute coronary syndrome suffering hemorrhage during hospitalization].
Topics: Acute Coronary Syndrome; Age of Onset; Aged; Clopidogrel; Female; Hemorrhage; Hospitalization; Human | 2012 |
[Clopidogrel metabolism related gene polymorphisms in Chinese patients with acute coronary syndrome].
Topics: Acute Coronary Syndrome; Aged; Alleles; Aryl Hydrocarbon Hydroxylases; Aryldialkylphosphatase; Asian | 2012 |
The power of more than one.
Topics: Acute Coronary Syndrome; Adenosine; Clopidogrel; Female; Humans; Male; Platelet Aggregation Inhibito | 2013 |
Long-term cost-effectiveness of clopidogrel in patients with acute coronary syndrome without ST-segment elevation in Germany.
Topics: Acute Coronary Syndrome; Adult; Age Factors; Aged; Aspirin; Clopidogrel; Cost-Benefit Analysis; Elec | 2007 |
Utilisation review of clopidogrel: are they used under the FDA-approved indications?
Topics: Acute Coronary Syndrome; Adverse Drug Reaction Reporting Systems; Aged; Aged, 80 and over; Aspirin; | 2007 |
Residual platelet reactivity is associated with clinical and laboratory characteristics in patients with ischemic heart disease undergoing PCI on dual antiplatelet therapy.
Topics: Acute Coronary Syndrome; Adenosine Diphosphate; Aged; Angioplasty, Balloon, Coronary; Arachidonic Ac | 2007 |
Residual platelet activity is increased in clopidogrel- and ASA-treated patients with coronary stenting for acute coronary syndromes compared with stable coronary artery disease.
Topics: Acute Coronary Syndrome; Aged; Aspirin; Clopidogrel; Cohort Studies; Coronary Artery Disease; Corona | 2008 |
Clopidogrel loading doses and outcomes of patients undergoing percutaneous coronary intervention for acute coronary syndromes.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Clopidogrel; Combined Modality Therap | 2007 |
Of Swiss alchemists and road hazards.
Topics: Acute Coronary Syndrome; Cardiology; Clopidogrel; Humans; Platelet Aggregation Inhibitors; Ticlopidi | 2007 |
Safety of the cardiac triple therapy: the experience of the Quebec Heart Institute.
Topics: Acute Coronary Syndrome; Aged; Anticoagulants; Aspirin; Clopidogrel; Drug Therapy, Combination; Fema | 2007 |
ADP-induced platelet aggregation and platelet reactivity index VASP are good predictive markers for clinical outcomes in non-ST elevation acute coronary syndrome.
Topics: Acute Coronary Syndrome; Acute Disease; Adenosine Diphosphate; Aged; Blood Platelets; Cell Adhesion | 2007 |
The Residual Platelet Aggregation after Deployment of Intracoronary Stent (PREDICT) score.
Topics: Acute Coronary Syndrome; Adenosine Diphosphate; Aged; Angina Pectoris; Clopidogrel; Cohort Studies; | 2008 |
Temporal trends in antiplatelet/antithrombotic use in acute coronary syndromes and in-hospital major bleeding complications.
Topics: Acute Coronary Syndrome; Aged; Angina, Unstable; Angioplasty, Balloon, Coronary; Cardiac Catheteriza | 2007 |
Effectiveness and safety of reduced-dose enoxaparin in non-ST-segment elevation acute coronary syndrome followed by antiplatelet therapy alone for percutaneous coronary intervention.
Topics: Acute Coronary Syndrome; Aged; Anticoagulants; Aspirin; Atherectomy, Coronary; Clopidogrel; Coronary | 2007 |
Intensifying platelet inhibition--navigating between Scylla and Charybdis.
Topics: Acute Coronary Syndrome; Aspirin; Clopidogrel; Drug Therapy, Combination; Hemorrhage; Humans; Ischem | 2007 |
Clinical trials update from the European Society of Cardiology Congress in Vienna, 2007: PROSPECT, EVEREST, ARISE, ALOFT, FINESSE, Prague-8, CARESS in MI and ACUITY.
Topics: Abciximab; Acute Coronary Syndrome; Amides; Antibodies, Monoclonal; Benzazepines; Clinical Trials as | 2007 |
Cytochrome P450 2C19 loss-of-function polymorphism, but not CYP3A4 IVS10 + 12G/A and P2Y12 T744C polymorphisms, is associated with response variability to dual antiplatelet treatment in high-risk vascular patients.
Topics: Acute Coronary Syndrome; Adult; Aged; Aged, 80 and over; Alleles; Aryl Hydrocarbon Hydroxylases; Asp | 2007 |
2007 Focused update of the ACC/AHA/SCAI 2005 guideline update for percutaneous coronary intervention. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines.
Topics: Acute Coronary Syndrome; Angina, Unstable; Angioplasty, Balloon, Coronary; Anticoagulants; Aspirin; | 2008 |
Aspirin + clopidogrel therapy: how does your care compare to the evidence?
Topics: Acute Coronary Syndrome; Aspirin; Clinical Trials as Topic; Clopidogrel; Drug Therapy, Combination; | 2008 |
Gastrointestinal bleeding in patients receiving a combination of aspirin, clopidogrel, and enoxaparin in acute coronary syndrome.
Topics: Acute Coronary Syndrome; Adult; Aged; Aged, 80 and over; Anticoagulants; Aspirin; Clopidogrel; Drug | 2008 |
Incidence of death and acute myocardial infarction associated with stopping clopidogrel after acute coronary syndrome.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Cause of Death; Clopidogrel; Cluster | 2008 |
Incidence of death and acute myocardial infarction associated with stopping clopidogrel after acute coronary syndrome.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Cause of Death; Clopidogrel; Cluster | 2008 |
Incidence of death and acute myocardial infarction associated with stopping clopidogrel after acute coronary syndrome.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Cause of Death; Clopidogrel; Cluster | 2008 |
Incidence of death and acute myocardial infarction associated with stopping clopidogrel after acute coronary syndrome.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Cause of Death; Clopidogrel; Cluster | 2008 |
Incidence of death and acute myocardial infarction associated with stopping clopidogrel after acute coronary syndrome.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Cause of Death; Clopidogrel; Cluster | 2008 |
Incidence of death and acute myocardial infarction associated with stopping clopidogrel after acute coronary syndrome.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Cause of Death; Clopidogrel; Cluster | 2008 |
Incidence of death and acute myocardial infarction associated with stopping clopidogrel after acute coronary syndrome.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Cause of Death; Clopidogrel; Cluster | 2008 |
Incidence of death and acute myocardial infarction associated with stopping clopidogrel after acute coronary syndrome.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Cause of Death; Clopidogrel; Cluster | 2008 |
Incidence of death and acute myocardial infarction associated with stopping clopidogrel after acute coronary syndrome.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Cause of Death; Clopidogrel; Cluster | 2008 |
Incidence of death and acute myocardial infarction associated with stopping clopidogrel after acute coronary syndrome.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Cause of Death; Clopidogrel; Cluster | 2008 |
Incidence of death and acute myocardial infarction associated with stopping clopidogrel after acute coronary syndrome.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Cause of Death; Clopidogrel; Cluster | 2008 |
Incidence of death and acute myocardial infarction associated with stopping clopidogrel after acute coronary syndrome.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Cause of Death; Clopidogrel; Cluster | 2008 |
Incidence of death and acute myocardial infarction associated with stopping clopidogrel after acute coronary syndrome.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Cause of Death; Clopidogrel; Cluster | 2008 |
Incidence of death and acute myocardial infarction associated with stopping clopidogrel after acute coronary syndrome.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Cause of Death; Clopidogrel; Cluster | 2008 |
Incidence of death and acute myocardial infarction associated with stopping clopidogrel after acute coronary syndrome.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Cause of Death; Clopidogrel; Cluster | 2008 |
Incidence of death and acute myocardial infarction associated with stopping clopidogrel after acute coronary syndrome.
Topics: Acute Coronary Syndrome; Aged; Angioplasty, Balloon, Coronary; Cause of Death; Clopidogrel; Cluster | 2008 |
Platelet glycoprotein IIb/IIIa receptor inhibitors--end of an era?
Topics: Abciximab; Acute Coronary Syndrome; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Clopidog | 2008 |
Antiplatelet therapy in acute coronary syndrome: not as confusing as you think.
Topics: Acute Coronary Syndrome; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Artery Bypas | 2008 |
Glycoprotein IIb-IIIa inhibitors in the emergency department for patients with non-ST-elevation acute coronary syndromes: principles and practices.
Topics: Acute Coronary Syndrome; Atherectomy; Clopidogrel; Emergency Service, Hospital; Hemorrhage; Humans; | 2009 |
Prasugrel versus clopidogrel.
Topics: Acute Coronary Syndrome; Clopidogrel; Hemorrhage; Humans; Myocardial Infarction; Piperazines; Platel | 2008 |
Prasugrel versus clopidogrel.
Topics: Acute Coronary Syndrome; Angioplasty, Balloon, Coronary; Clopidogrel; Hemorrhage; Humans; Myocardial | 2008 |
Prasugrel versus clopidogrel.
Topics: Acute Coronary Syndrome; Aspirin; Clopidogrel; Humans; Monitoring, Physiologic; Myocardial Infarctio | 2008 |
Effects of continuous administration of clopidogrel before off-pump coronary artery bypass grafting in patients with acute coronary syndrome.
Topics: Acute Coronary Syndrome; Aged; Blood Transfusion; Clopidogrel; Coronary Artery Bypass, Off-Pump; Fem | 2008 |
Current challenges and directions in antithrombotic therapy.
Topics: Acute Coronary Syndrome; Aspirin; Clopidogrel; Drug Therapy, Combination; Fibrinolytic Agents; Human | 2008 |
Effect of cytochrome p450 polymorphisms on platelet reactivity after treatment with clopidogrel in acute coronary syndrome.
Topics: Acute Coronary Syndrome; Adenosine Diphosphate; Alleles; Body Mass Index; Cell Adhesion Molecules; C | 2008 |
Platelet activation and atherothrombosis.
Topics: Acute Coronary Syndrome; Aspirin; Atherosclerosis; Clopidogrel; Drug Therapy, Combination; Humans; M | 2008 |
[Antiplatelet treatment after acute and chronic ischemic heart and brain events is insufficient according to recommendations].
Topics: Acute Coronary Syndrome; Adult; Aged; Aged, 80 and over; Angina Pectoris; Angina, Unstable; Aspirin; | 2008 |
Bleeding risks with prasugrel in the TRITON trial: good news ... bad news.
Topics: Acute Coronary Syndrome; Angioplasty, Balloon, Coronary; Clopidogrel; Drug Therapy, Combination; Hem | 2008 |
Clopidogrel resistance: more grist for the mill.
Topics: Acute Coronary Syndrome; Angioplasty, Balloon, Coronary; Clopidogrel; Humans; Platelet Aggregation I | 2008 |
Pharmacoeconomic concepts in antiplatelet therapy: understanding cost-effectiveness analyses using clopidogrel as an example.
Topics: Acute Coronary Syndrome; Clopidogrel; Cost-Benefit Analysis; Costs and Cost Analysis; Economics, Pha | 2008 |
Relationship between aspirin and clopidogrel responses in acute coronary syndrome and clinical predictors of non response.
Topics: Acute Coronary Syndrome; Age Factors; Aged; Arachidonic Acid; Aspirin; Body Mass Index; Cell Adhesio | 2009 |
For better or for worse: the future of antiplatelet therapy.
Topics: Acute Coronary Syndrome; Clopidogrel; Coronary Disease; Forecasting; Hemorrhage; Humans; Myocardial | 2008 |
Adverse events associated with stopping clopidogrel after acute coronary syndrome.
Topics: Acute Coronary Syndrome; Clopidogrel; Humans; Platelet Aggregation Inhibitors; Risk; Ticlopidine | 2008 |
Adverse events associated with stopping clopidogrel after acute coronary syndrome.
Topics: Acute Coronary Syndrome; Aspirin; Clopidogrel; Humans; Platelet Aggregation Inhibitors; Risk; Ticlop | 2008 |